data_2kdg_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kdg _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo . . . . . 0 CA--C 1.542 0.914 0 N-CA-C 113.258 0.446 . . . . 10.0 113.258 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -66.96 152.08 80.99 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.859 2.373 . . . . 10.0 111.427 168.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 68.9 ttt180 -142.52 162.68 34.84 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 125.764 1.626 . . . . 10.0 111.542 -177.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -71.33 141.29 50.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.321 1.449 . . . . 10.0 112.224 173.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.1 mp -135.47 -66.14 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.544 1.538 . . . . 10.0 109.724 171.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 -149.56 140.3 22.67 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.34 1.456 . . . . 10.0 111.105 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 24.7 m -127.26 152.59 76.32 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 126.207 1.803 . . . . 10.0 110.287 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.3 156.91 50.49 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.87 2.38 . . . . 10.0 112.016 176.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.63 167.28 22.12 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.114 0.966 . . . . 10.0 112.67 172.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -60.2 106.9 0.57 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 124.839 1.256 . . . . 10.0 111.698 173.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 26.4 mtm -79.4 154.57 28.88 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 123.653 0.781 . . . . 10.0 112.467 -175.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.7 p -138.43 110.13 7.11 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 125.306 1.442 . . . . 10.0 110.539 170.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.8 mm -126.85 131.12 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.314 1.446 . . . . 10.0 110.391 -163.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -59.43 131.92 52.42 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.646 1.178 . . . . 10.0 112.558 173.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -51.97 129.83 28.05 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 125.159 1.384 . . . . 10.0 112.674 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.75 -8.91 76.37 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 125.497 1.522 . . . . 10.0 115.278 177.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -70.87 161.61 30.71 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 119.321 1.56 . . . . 10.0 113.051 175.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -73.47 138.48 45.14 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.55 1.14 . . . . 10.0 110.043 155.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.1 p -149.42 169.4 20.95 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.468 0.707 . . . . 10.0 112.348 164.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -147.45 155.56 42.04 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.855 1.262 . . . . 10.0 112.975 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -122.39 143.36 49.71 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 128.028 2.531 . . . . 10.0 108.925 173.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -139.5 114.56 9.57 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.187 0.995 . . . . 10.0 111.936 -170.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -115.85 113.79 23.84 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.222 2.209 . . . . 10.0 110.42 -173.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.3 mtpp -67.99 133.85 49.74 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.473 -0.767 . . . . 10.0 110.015 170.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -140.94 125.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.521 1.528 . . . . 10.0 111.139 -174.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 50.6 m -136.03 103.34 5.32 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.798 1.239 . . . . 10.0 111.467 -176.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -154.9 165.08 32.04 Favored Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.983 2.23 . . . . 10.0 110.662 169.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.6 tp -141.91 125.85 9.97 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.129 0.971 . . . . 10.0 110.847 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -65.43 167.16 49.53 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.63 1.261 . . . . 10.0 112.511 -2.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.09 121.84 44.01 Favored Pre-proline 0 CA--C 1.549 0.915 0 C-N-CA 124.483 1.113 . . . . 10.0 111.202 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.77 150.79 68.64 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.492 2.128 . . . . 10.0 113.076 -172.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -73.62 143.77 46.2 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.146 0.979 . . . . 10.0 109.666 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.61 136.23 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.796 0.839 . . . . 10.0 111.858 -174.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -126.99 157.71 38.81 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.897 1.679 . . . . 10.0 111.68 173.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 51.0 m95 -125.97 154.88 42.25 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 125.533 1.533 . . . . 10.0 113.666 -173.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -144.49 161.12 39.88 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.26 2.224 . . . . 10.0 111.96 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.1 tp -146.56 124.35 11.91 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.748 2.419 . . . . 10.0 109.69 173.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.01 14.28 0.68 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 126.775 2.03 . . . . 10.0 116.064 175.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.36 0.55 24.99 Favored Glycine 0 CA--C 1.539 1.552 0 C-N-CA 125.693 1.616 . . . . 10.0 116.043 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.0 ptp85 -123.93 163.19 21.82 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 125.679 1.592 . . . . 10.0 112.177 173.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.4 p -69.65 159.59 33.17 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.596 1.158 . . . . 10.0 113.616 -175.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 92.7 t -134.92 108.1 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 126.93 2.092 . . . . 10.0 108.939 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -77.01 159.66 29.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 123.724 0.81 . . . . 10.0 111.365 170.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 81.3 p -76.91 155.48 32.77 Favored 'General case' 0 N--CA 1.473 0.683 0 O-C-N 121.645 -0.659 . . . . 10.0 112.144 168.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -155.71 -176.39 5.93 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.578 1.551 . . . . 10.0 111.576 168.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -62.08 -18.18 59.92 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -177.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 68.7 mt -107.37 -26.67 10.88 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.845 1.658 . . . . 10.0 112.266 175.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -108.74 68.78 0.69 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.828 2.051 . . . . 10.0 110.711 177.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -74.25 146.09 43.55 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.346 1.058 . . . . 10.0 111.839 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 65.7 mtt -138.89 114.69 9.99 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.533 1.933 . . . . 10.0 110.184 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.55 155.82 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.928 1.291 . . . . 10.0 111.776 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.1 p -141.21 122.02 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.595 1.158 . . . . 10.0 111.238 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 38.7 t -74.87 141.8 44.17 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.485 1.114 . . . . 10.0 111.65 175.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.78 -17.68 37.39 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.769 1.228 . . . . 10.0 113.688 170.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -76.47 -4.2 41.32 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.936 1.694 . . . . 10.0 113.917 174.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.68 39.43 4.15 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.979 1.275 . . . . 10.0 114.867 172.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.2 tp -136.55 114.78 11.61 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 125.109 1.364 . . . . 10.0 111.122 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 5.1 t60 -98.35 132.88 43.46 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.21 1.404 . . . . 10.0 110.994 174.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 37.9 m -121.89 138.07 54.54 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.558 1.543 . . . . 10.0 111.487 -178.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -128.06 117.84 22.38 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 127.713 2.405 . . . . 10.0 107.85 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 85.3 mt -118.63 148.45 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.471 1.108 . . . . 10.0 111.064 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -123.07 106.31 10.69 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 127.355 2.262 . . . . 10.0 109.014 171.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -63.59 -38.3 90.61 Favored 'General case' 0 N--CA 1.475 0.781 0 O-C-N 121.296 -0.878 . . . . 10.0 113.09 176.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.2 p -150.76 90.1 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.889 1.676 . . . . 10.0 110.248 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -68.48 144.75 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 O-C-N 121.27 -0.894 . . . . 10.0 112.101 -178.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -129.21 162.17 28.45 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.03 1.732 . . . . 10.0 112.005 174.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.54 -34.38 64.65 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 113.642 0.979 . . . . 10.0 113.642 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.1 m -64.87 -17.15 64.03 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.387 1.475 . . . . 10.0 114.509 175.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -81.7 -8.28 59.68 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.513 1.125 . . . . 10.0 113.328 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.72 150.64 43.99 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 119.219 0.918 . . . . 10.0 112.933 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.9 -172.2 22.71 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.563 1.078 . . . . 10.0 114.789 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.87 101.95 13.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.963 1.705 . . . . 10.0 111.209 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -76.15 150.85 37.11 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.225 1.01 . . . . 10.0 111.501 167.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.5 161.97 38.49 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.906 0.883 . . . . 10.0 111.545 169.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 30.8 p -144.88 161.87 38.25 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.186 0.994 . . . . 10.0 112.044 171.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.98 131.25 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.273 1.429 . . . . 10.0 110.072 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.47 126.8 54.77 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.651 1.98 . . . . 10.0 110.044 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -133.93 129.06 35.75 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.644 1.577 . . . . 10.0 112.012 -169.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.5 p30 -132.21 -179.46 5.44 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.448 1.099 . . . . 10.0 111.832 166.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -60.51 -14.68 21.07 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.657 1.725 . . . . 10.0 115.657 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.84 -16.38 14.48 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.288 1.435 . . . . 10.0 114.276 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.93 -170.17 40.55 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 115.876 1.11 . . . . 10.0 115.876 177.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -134.68 146.72 49.75 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.852 2.061 . . . . 10.0 111.7 -172.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.81 153.11 49.68 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.753 1.621 . . . . 10.0 110.982 169.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 25.2 m -137.55 136.78 37.93 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.832 1.253 . . . . 10.0 110.552 -172.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -134.89 153.72 51.95 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.964 1.306 . . . . 10.0 111.524 -173.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.0 m -142.33 144.5 33.24 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 125.251 1.42 . . . . 10.0 111.456 -173.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.9 p -151.8 156.72 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 C-N-CA 125.695 1.598 . . . . 10.0 111.271 170.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -107.89 148.89 29.0 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 124.349 1.06 . . . . 10.0 111.746 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.29 114.96 18.29 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.469 1.907 . . . . 10.0 110.222 174.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -103.46 84.74 2.35 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.719 1.608 . . . . 10.0 110.685 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.8 t -67.23 110.96 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.708 0.803 . . . . 10.0 110.871 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 75.7 mt -75.95 101.03 5.05 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.731 2.012 . . . . 10.0 110.567 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.872 0 C-N-CA 124.058 0.943 . . . . 10.0 112.87 175.655 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo . . . . . 0 CA--C 1.543 0.949 0 N-CA-C 113.29 0.458 . . . . 10.0 113.29 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -67.33 148.31 79.59 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.825 2.35 . . . . 10.0 111.435 173.477 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 32.7 ttp-105 -138.09 136.9 37.22 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.855 1.262 . . . . 10.0 113.208 -173.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -63.58 117.26 6.54 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 127.274 2.23 . . . . 10.0 110.997 170.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 35.8 mm -108.35 -54.26 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.735 0.814 . . . . 10.0 110.328 171.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -153.18 142.68 21.76 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.412 1.085 . . . . 10.0 111.433 172.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.53 148.48 53.06 Favored Pre-proline 0 N--CA 1.476 0.862 0 C-N-CA 125.247 1.419 . . . . 10.0 110.073 169.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -77.13 163.69 30.29 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.965 2.443 . . . . 10.0 112.117 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -73.1 166.74 22.54 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.593 0.757 . . . . 10.0 111.43 166.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -62.44 160.9 12.64 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.364 -0.835 . . . . 10.0 112.081 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 51.0 mtm -133.49 161.25 35.1 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.181 0.992 . . . . 10.0 112.939 -178.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 55.2 p -137.88 115.64 11.43 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 125.907 1.683 . . . . 10.0 109.854 168.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.6 mm -124.51 132.9 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.306 1.442 . . . . 10.0 110.05 -166.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -59.56 126.51 27.91 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.402 1.481 . . . . 10.0 112.475 173.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -50.23 126.75 15.5 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.599 1.56 . . . . 10.0 112.679 176.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.99 -11.75 58.91 Favored Glycine 0 CA--C 1.537 1.468 0 C-N-CA 126.182 1.849 . . . . 10.0 115.088 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -75.53 162.39 28.34 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 119.2 1.5 . . . . 10.0 113.418 177.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -76.69 143.3 40.13 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.076 1.351 . . . . 10.0 110.328 157.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 28.6 p -150.82 168.97 22.83 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.608 0.763 . . . . 10.0 112.621 162.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.8 ptm85 -144.12 168.93 18.86 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.426 1.49 . . . . 10.0 112.966 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.7 mtt -131.81 158.82 40.27 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.974 2.11 . . . . 10.0 110.867 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -136.15 92.61 2.81 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.144 1.378 . . . . 10.0 112.139 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -108.41 104.02 13.29 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.456 1.502 . . . . 10.0 111.319 -176.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.1 mtpp -81.7 122.98 28.33 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 121.077 -1.014 . . . . 10.0 110.322 173.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.43 151.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.803 2.041 . . . . 10.0 110.633 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.9 t -131.1 175.7 8.88 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.18 1.392 . . . . 10.0 111.419 172.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 136.7 167.53 11.17 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 127.418 2.437 . . . . 10.0 112.445 -175.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.33 119.79 5.16 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 123.878 0.871 . . . . 10.0 111.707 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.8 169.44 59.05 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 CA-C-N 120.459 1.2 . . . . 10.0 112.473 -1.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.85 127.79 75.31 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.059 0.943 . . . . 10.0 110.838 175.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.69 148.32 65.28 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 122.298 1.999 . . . . 10.0 113.062 -172.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -71.01 142.02 50.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.353 1.061 . . . . 10.0 109.583 160.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 10.8 m -127.02 137.67 57.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 124.618 1.167 . . . . 10.0 112.583 -170.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.1 m -137.57 112.55 9.05 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.109 1.764 . . . . 10.0 110.758 -174.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -85.87 152.76 22.73 Favored 'General case' 0 CA--C 1.536 0.417 0 N-CA-C 113.475 0.917 . . . . 10.0 113.475 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.41 158.89 43.21 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.386 2.274 . . . . 10.0 111.129 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.15 117.78 8.62 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 127.153 2.181 . . . . 10.0 110.109 177.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 55.14 10.98 0.47 Allowed 'General case' 0 CA--C 1.555 1.172 0 C-N-CA 126.747 2.019 . . . . 10.0 115.573 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.27 -15.63 17.97 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 126.832 2.158 . . . . 10.0 115.047 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -84.09 157.45 21.74 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 118.988 1.394 . . . . 10.0 111.088 169.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.9 p -71.71 157.91 37.09 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.281 1.033 . . . . 10.0 112.137 170.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.8 105.77 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 126.303 1.841 . . . . 10.0 108.676 173.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 23.0 mm100 -76.26 159.83 30.23 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.218 0.607 . . . . 10.0 111.495 173.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 36.7 p -67.06 150.8 48.7 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.692 0.797 . . . . 10.0 111.928 169.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -150.76 166.01 31.77 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.179 1.392 . . . . 10.0 111.128 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -54.86 -36.56 65.21 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.147 -0.97 . . . . 10.0 113.1 170.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.0 mt -84.22 -13.77 51.79 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.434 1.094 . . . . 10.0 113.863 174.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -135.04 70.95 1.43 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.93 1.692 . . . . 10.0 111.322 -173.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.08 143.12 49.17 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.049 1.339 . . . . 10.0 111.73 -175.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -139.6 101.99 4.35 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.644 1.978 . . . . 10.0 110.055 -174.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.14 162.73 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.254 1.422 . . . . 10.0 111.557 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.86 118.15 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.899 1.279 . . . . 10.0 110.994 177.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 63.3 m -68.56 158.44 33.91 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.328 1.051 . . . . 10.0 112.218 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -61.24 -21.26 63.71 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 114.243 1.201 . . . . 10.0 114.243 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.1 mptt -77.06 -5.4 48.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.299 1.84 . . . . 10.0 113.865 173.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.05 3.43 65.59 Favored Glycine 0 CA--C 1.536 1.394 0 C-N-CA 125.6 1.572 . . . . 10.0 115.181 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.8 tp -77.44 101.81 6.58 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 118.686 1.243 . . . . 10.0 111.318 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -78.96 113.55 17.16 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.185 1.394 . . . . 10.0 110.925 170.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 75.0 m -84.98 139.44 31.79 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 125.524 1.53 . . . . 10.0 111.986 171.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -131.92 121.24 23.68 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 126.704 2.002 . . . . 10.0 107.688 168.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 61.0 mt -122.18 152.57 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.855 1.262 . . . . 10.0 111.357 -166.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -129.4 109.85 11.42 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 127.519 2.328 . . . . 10.0 109.142 170.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -66.15 -40.22 90.4 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.359 -0.838 . . . . 10.0 113.168 176.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -149.96 88.92 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.838 1.655 . . . . 10.0 110.104 -178.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -68.53 140.29 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 O-C-N 121.378 -0.826 . . . . 10.0 112.045 -176.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -124.78 160.64 28.21 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.463 1.905 . . . . 10.0 111.841 177.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.14 -34.32 63.66 Favored 'General case' 0 CA--C 1.547 0.828 0 N-CA-C 113.509 0.929 . . . . 10.0 113.509 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.4 m -65.05 -17.46 64.47 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.499 1.52 . . . . 10.0 114.62 175.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -80.99 -6.53 58.88 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.446 1.098 . . . . 10.0 113.324 177.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.88 148.44 51.4 Favored 'General case' 0 CA--C 1.547 0.843 0 O-C-N 121.017 -1.052 . . . . 10.0 112.77 177.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 139.75 -174.75 22.19 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.844 1.211 . . . . 10.0 114.815 177.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.81 108.68 17.6 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.971 1.708 . . . . 10.0 110.932 175.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.5 m-85 -86.12 151.96 23.25 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.208 1.003 . . . . 10.0 111.869 172.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.97 160.68 39.88 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.933 0.893 . . . . 10.0 112.006 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.0 t -137.57 107.47 6.3 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.753 1.621 . . . . 10.0 110.586 177.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.5 t -76.05 132.9 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.294 1.037 . . . . 10.0 108.937 169.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -128.3 121.79 30.08 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 126.372 1.869 . . . . 10.0 110.494 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -134.4 139.45 45.59 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.941 1.297 . . . . 10.0 112.604 -171.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.3 p30 -133.74 -178.31 4.95 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.609 1.164 . . . . 10.0 111.259 165.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -61.9 -7.79 4.2 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 115.667 1.729 . . . . 10.0 115.667 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -117.7 -12.7 10.24 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 126.135 1.774 . . . . 10.0 114.578 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.01 -172.66 44.48 Favored Glycine 0 CA--C 1.535 1.308 0 CA-C-N 119.776 1.171 . . . . 10.0 115.924 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -137.8 144.23 41.44 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.992 2.117 . . . . 10.0 111.625 -174.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.64 162.96 33.3 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.594 1.957 . . . . 10.0 110.626 168.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -141.99 124.5 15.77 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.389 1.076 . . . . 10.0 110.736 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -105.14 154.39 20.25 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.33 1.452 . . . . 10.0 110.898 178.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.7 m -144.03 145.12 31.98 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 124.271 1.028 . . . . 10.0 112.035 -170.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.8 p -154.11 171.64 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 C-N-CA 126.595 1.958 . . . . 10.0 110.976 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -131.92 147.88 52.49 Favored 'General case' 0 N--CA 1.471 0.614 0 O-C-N 120.77 -1.206 . . . . 10.0 111.622 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.7 tp -131.14 117.04 18.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 126.283 1.833 . . . . 10.0 110.2 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -106.4 77.68 1.23 Allowed 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.681 1.592 . . . . 10.0 110.481 178.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -58.37 114.31 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.414 1.086 . . . . 10.0 111.014 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.5 mt -76.25 99.58 4.8 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.477 1.911 . . . . 10.0 109.831 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.838 0 C-N-CA 123.975 0.91 . . . . 10.0 113.117 -177.656 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo . . . . . 0 CA--C 1.543 0.944 0 N-CA-C 113.027 0.357 . . . . 10.0 113.027 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -68.24 143.19 57.9 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.133 2.555 . . . . 10.0 111.497 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -131.24 149.45 52.57 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.96 1.304 . . . . 10.0 113.757 -174.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -77.76 111.13 13.24 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.019 2.527 . . . . 10.0 110.939 176.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.5 mm -109.34 -44.66 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.772 0.829 . . . . 10.0 111.104 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -149.51 142.18 24.53 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.708 1.203 . . . . 10.0 111.494 170.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -122.91 135.69 26.08 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 124.873 1.269 . . . . 10.0 109.278 158.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -75.47 159.88 39.18 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.003 2.468 . . . . 10.0 112.206 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -67.44 164.84 17.86 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.92 1.288 . . . . 10.0 112.111 171.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -62.49 113.77 3.15 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.216 -0.928 . . . . 10.0 111.332 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 29.0 mtm -76.22 148.87 37.37 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.736 -0.603 . . . . 10.0 111.69 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 24.0 p -128.08 102.76 6.87 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 125.705 1.602 . . . . 10.0 110.468 176.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.7 mm -121.8 123.61 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.931 1.293 . . . . 10.0 110.63 -163.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -58.86 126.23 26.83 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.134 1.374 . . . . 10.0 111.893 170.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -53.22 136.37 36.58 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.126 1.371 . . . . 10.0 113.468 -176.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 94.93 -10.92 70.09 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 125.97 1.747 . . . . 10.0 114.808 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 73.8 mtp180 -72.5 158.92 34.81 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 118.877 1.339 . . . . 10.0 113.479 177.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -75.31 141.04 43.45 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.373 1.069 . . . . 10.0 110.265 154.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 32.0 p -150.76 170.87 18.18 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.583 0.753 . . . . 10.0 112.269 160.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . 0.892 HH21 ' HG ' ' A' ' 307' ' ' SER . 14.7 ptm180 -145.83 144.06 30.02 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.195 1.398 . . . . 10.0 111.74 172.113 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.7 mtt -91.75 159.33 15.88 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.084 1.354 . . . . 10.0 110.665 169.028 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -138.15 109.83 7.09 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.231 1.412 . . . . 10.0 112.557 -177.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -116.56 98.47 6.56 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.646 1.978 . . . . 10.0 110.383 -176.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 29.5 mtpp -67.87 137.88 55.62 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.148 -0.97 . . . . 10.0 110.196 171.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.28 152.83 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.486 1.514 . . . . 10.0 111.27 -172.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -136.5 174.87 10.14 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.28 1.432 . . . . 10.0 111.164 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 121.07 164.34 12.31 Favored Glycine 0 CA--C 1.538 1.478 0 C-N-CA 127.288 2.375 . . . . 10.0 112.878 -174.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.0 tp -153.04 135.04 8.87 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.752 1.221 . . . . 10.0 110.978 -179.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -68.38 172.11 44.74 Favored 'Cis proline' 0 CA--C 1.54 0.794 0 CA-C-N 120.815 1.327 . . . . 10.0 112.722 -4.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.69 122.58 52.33 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.777 1.231 . . . . 10.0 111.777 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -72.17 155.43 56.54 Favored 'Trans proline' 0 CA--C 1.538 0.713 0 C-N-CA 122.618 2.212 . . . . 10.0 113.542 -172.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -79.13 74.41 5.69 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.316 1.846 . . . . 10.0 111.517 177.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 15.3 m -56.69 122.46 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 125.526 1.53 . . . . 10.0 113.194 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 66.3 m -133.69 111.56 10.68 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 126.334 1.853 . . . . 10.0 111.145 -172.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.4 m95 -87.59 149.77 24.11 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 114.43 1.271 . . . . 10.0 114.43 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -141.6 160.43 40.17 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.606 2.363 . . . . 10.0 111.463 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.4 tp -148.19 123.5 10.26 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 127.733 2.413 . . . . 10.0 109.989 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 53.58 16.03 0.87 Allowed 'General case' 0 CA--C 1.556 1.196 0 C-N-CA 126.498 1.919 . . . . 10.0 115.844 175.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.25 0.04 33.22 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.679 1.609 . . . . 10.0 115.824 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -117.11 162.4 17.89 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 126.031 1.732 . . . . 10.0 111.376 173.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.1 p -69.28 158.69 34.52 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.499 1.119 . . . . 10.0 113.017 178.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 43.6 t -130.82 106.91 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 126.011 1.724 . . . . 10.0 108.607 170.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -72.92 153.25 41.06 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.48 0.712 . . . . 10.0 111.377 172.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 32.2 p -68.25 150.29 48.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.615 0.766 . . . . 10.0 112.026 171.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -151.89 169.65 21.76 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.148 1.379 . . . . 10.0 110.798 175.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -62.52 -31.55 72.34 Favored 'General case' 0 N--CA 1.471 0.625 0 O-C-N 120.464 -1.398 . . . . 10.0 112.549 169.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 97.8 mt -73.99 -22.31 59.65 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.012 0.925 . . . . 10.0 113.468 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -136.75 67.91 1.44 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.152 1.781 . . . . 10.0 111.108 -171.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 63.8 mttm -69.78 142.73 53.15 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.183 0.993 . . . . 10.0 111.336 -177.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -135.51 102.9 5.27 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 126.724 2.01 . . . . 10.0 109.423 -173.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.55 155.71 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 124.165 0.986 . . . . 10.0 112.546 -173.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.66 165.51 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 126.484 1.914 . . . . 10.0 111.188 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 39.0 t -137.72 146.83 44.2 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.797 1.239 . . . . 10.0 112.642 -178.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -56.98 -20.47 24.06 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.244 1.818 . . . . 10.0 113.837 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -74.71 -1.51 22.23 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.745 1.618 . . . . 10.0 114.014 176.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.2 48.01 5.27 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.072 1.32 . . . . 10.0 112.987 178.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.0 tp -140.28 146.96 39.24 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.475 1.51 . . . . 10.0 111.625 -175.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -129.43 132.86 47.08 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.085 2.154 . . . . 10.0 109.678 170.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 307' ' ' SER . . . . . 0.892 ' HG ' HH21 ' A' ' 268' ' ' ARG . 67.6 m -119.28 149.2 42.17 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.844 1.258 . . . . 10.0 112.319 178.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -136.21 110.19 8.24 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.045 2.138 . . . . 10.0 108.478 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -95.18 153.34 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.641 1.576 . . . . 10.0 111.151 -171.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -129.54 107.64 9.63 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.92 2.088 . . . . 10.0 108.761 161.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -63.75 -43.25 96.99 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 121.447 -0.783 . . . . 10.0 113.077 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 2.8 p -150.08 87.08 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 126.156 1.782 . . . . 10.0 109.333 -178.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.8 p -66.99 141.13 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 O-C-N 121.525 -0.734 . . . . 10.0 111.8 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -127.07 160.12 32.13 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 126.429 1.892 . . . . 10.0 111.046 177.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.24 -33.79 59.23 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.009 1.114 . . . . 10.0 114.009 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.41 -17.77 64.09 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.287 1.435 . . . . 10.0 114.547 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -81.4 -8.17 59.69 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.656 1.182 . . . . 10.0 113.413 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -62.97 146.28 53.46 Favored 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.136 -0.977 . . . . 10.0 112.622 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.64 -175.37 23.64 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.024 0.821 . . . . 10.0 114.936 178.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.71 105.5 16.99 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 126.196 1.798 . . . . 10.0 111.257 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -84.94 150.76 24.72 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.714 1.206 . . . . 10.0 111.932 173.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.64 160.74 40.67 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 123.865 0.866 . . . . 10.0 112.249 170.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 47.3 t -138.21 109.12 6.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.58 1.552 . . . . 10.0 110.753 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 93.9 t -76.98 134.86 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.638 1.175 . . . . 10.0 109.146 169.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -132.37 114.5 14.44 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.245 1.818 . . . . 10.0 110.13 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.6 mtpp -129.8 136.61 49.79 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.409 1.484 . . . . 10.0 111.722 -174.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 28.3 p30 -133.26 -179.41 5.49 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.893 1.277 . . . . 10.0 111.371 168.295 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -62.2 -9.93 9.17 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 115.662 1.726 . . . . 10.0 115.662 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.72 -16.12 13.27 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.744 1.618 . . . . 10.0 114.471 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.29 -168.06 40.96 Favored Glycine 0 CA--C 1.536 1.36 0 CA-C-N 119.992 1.269 . . . . 10.0 116.241 176.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -136.24 143.93 44.58 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.995 2.118 . . . . 10.0 112.21 -171.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.25 160.19 40.51 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.774 2.03 . . . . 10.0 110.476 166.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 53.1 m -144.2 116.16 8.33 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.445 1.098 . . . . 10.0 110.61 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -98.0 151.07 20.69 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.16 1.384 . . . . 10.0 110.979 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.5 m -142.32 146.3 34.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 124.613 1.165 . . . . 10.0 111.819 -174.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . 0.405 HG21 ' H ' ' A' ' 337' ' ' GLN . 7.5 p -153.06 174.58 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 126.721 2.008 . . . . 10.0 110.916 173.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . 0.405 ' H ' HG21 ' A' ' 336' ' ' VAL . 49.5 tt0 -130.47 150.58 51.62 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.176 1.39 . . . . 10.0 111.118 173.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.5 tp -125.16 108.36 11.7 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 110.846 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -90.4 81.07 6.03 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.258 1.823 . . . . 10.0 110.473 176.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.9 t -68.44 109.5 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 121.119 -0.988 . . . . 10.0 110.472 177.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.7 mt -77.55 97.64 5.11 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.774 1.63 . . . . 10.0 109.548 177.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.867 0 C-N-CA 124.592 1.157 . . . . 10.0 113.957 -172.728 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 CA--C 1.542 0.918 0 N-CA-C 113.116 0.391 . . . . 10.0 113.116 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.76 161.71 44.28 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.934 2.423 . . . . 10.0 111.072 166.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.86 166.47 24.37 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.471 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -85.93 71.95 10.55 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.355 1.862 . . . . 10.0 111.543 -173.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . 0.549 HG21 ' H ' ' A' ' 254' ' ' GLN . 0.5 OUTLIER -73.55 179.78 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 125.031 1.333 . . . . 10.0 111.137 176.889 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.549 ' H ' HG21 ' A' ' 253' ' ' ILE . 35.3 tt0 -50.06 140.02 13.2 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.152 2.181 . . . . 10.0 114.336 -175.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.4 m -127.12 152.11 75.36 Favored Pre-proline 0 N--CA 1.477 0.915 0 C-N-CA 126.696 1.998 . . . . 10.0 110.982 172.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -77.2 159.22 33.46 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.249 2.632 . . . . 10.0 112.429 174.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -69.47 172.39 7.31 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.19 1.396 . . . . 10.0 112.263 169.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -55.65 111.74 0.98 Allowed 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 124.578 1.151 . . . . 10.0 112.854 173.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.7 mtp -82.58 155.63 24.36 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.769 1.628 . . . . 10.0 112.121 -177.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -147.22 109.38 4.49 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.249 1.419 . . . . 10.0 111.062 175.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.2 mm -123.01 133.37 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.248 1.419 . . . . 10.0 110.464 -168.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.74 130.98 47.36 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.096 1.359 . . . . 10.0 112.562 174.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -52.78 133.63 37.01 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.254 1.421 . . . . 10.0 112.862 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 93.22 -9.84 74.22 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.784 1.659 . . . . 10.0 115.276 177.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.1 mtp-105 -75.79 161.15 29.27 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 119.179 1.489 . . . . 10.0 113.018 176.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -72.46 147.33 46.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.442 1.097 . . . . 10.0 110.605 157.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 9.0 t -149.67 164.8 34.21 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.569 1.148 . . . . 10.0 111.582 165.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.7 ptm180 -149.54 155.41 40.29 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.645 1.578 . . . . 10.0 111.62 163.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 40.6 mtt -102.43 166.85 10.31 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.614 1.566 . . . . 10.0 112.071 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -132.73 110.9 10.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.331 1.852 . . . . 10.0 111.099 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -127.31 101.74 6.61 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 125.322 1.449 . . . . 10.0 111.172 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -60.36 142.76 54.41 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.513 -0.742 . . . . 10.0 110.296 172.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.0 p -148.98 146.3 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 124.597 1.159 . . . . 10.0 111.753 -175.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 51.8 m -139.19 178.59 7.07 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 126.341 1.856 . . . . 10.0 111.454 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 112.64 161.27 15.22 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 126.349 1.928 . . . . 10.0 113.092 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.15 129.93 7.43 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 125.145 1.378 . . . . 10.0 110.638 -179.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -66.39 168.86 48.14 Favored 'Cis proline' 0 CA--C 1.54 0.798 0 CA-C-N 120.806 1.324 . . . . 10.0 112.546 -2.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.63 120.62 33.43 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 124.673 1.189 . . . . 10.0 111.658 -177.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.0 159.5 52.3 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.597 2.198 . . . . 10.0 113.265 -174.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -68.7 169.41 11.28 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.336 1.454 . . . . 10.0 111.923 171.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 87.1 t -131.95 112.99 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.302 1.841 . . . . 10.0 110.165 -176.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 70.8 m -131.54 100.3 5.09 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.238 1.415 . . . . 10.0 110.91 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -84.02 154.64 23.15 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 122.035 0.921 . . . . 10.0 113.29 176.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -142.53 160.35 40.45 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.749 2.419 . . . . 10.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -148.83 124.06 10.18 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.104 2.161 . . . . 10.0 109.98 176.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.54 10.99 0.38 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 126.996 2.118 . . . . 10.0 116.378 174.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.51 -0.96 22.02 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.847 1.689 . . . . 10.0 115.852 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -117.36 163.99 15.52 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.795 1.638 . . . . 10.0 111.929 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.0 p -71.63 160.31 32.89 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.626 1.17 . . . . 10.0 112.948 178.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 64.5 t -136.24 111.29 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 126.632 1.973 . . . . 10.0 108.903 173.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -85.02 159.18 20.28 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.831 0.853 . . . . 10.0 111.199 170.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.9 p -69.61 151.06 46.38 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.725 0.81 . . . . 10.0 112.426 171.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -151.36 179.27 8.47 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.492 1.517 . . . . 10.0 110.79 166.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -56.71 -30.74 63.79 Favored 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 114.327 1.232 . . . . 10.0 114.327 -177.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 55.7 mt -87.63 -13.31 43.06 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.912 1.285 . . . . 10.0 113.514 175.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -135.64 68.12 1.46 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.158 1.783 . . . . 10.0 111.226 -172.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -67.86 145.13 54.92 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.089 1.356 . . . . 10.0 111.167 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.2 mtt -135.21 102.68 5.26 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 126.774 2.029 . . . . 10.0 109.726 -175.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.97 158.54 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.822 1.249 . . . . 10.0 112.212 -175.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 38.7 t -133.64 113.97 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 125.778 1.631 . . . . 10.0 109.73 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 46.6 t -64.89 141.15 58.87 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.917 0.887 . . . . 10.0 111.518 172.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -57.76 -19.48 28.18 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.72 1.208 . . . . 10.0 113.946 173.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.5 -3.45 40.59 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.454 1.502 . . . . 10.0 113.697 176.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.66 43.05 4.32 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.293 1.425 . . . . 10.0 113.883 176.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 61.9 tp -137.13 107.03 6.26 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.077 1.351 . . . . 10.0 111.578 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -80.43 138.61 36.63 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 125.379 1.471 . . . . 10.0 111.227 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 60.6 m -122.19 146.51 47.18 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 125.917 1.687 . . . . 10.0 111.807 174.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -134.13 112.54 11.22 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.214 2.206 . . . . 10.0 108.211 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -94.13 154.69 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.399 1.48 . . . . 10.0 111.55 -170.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -131.96 99.05 4.62 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.381 2.272 . . . . 10.0 108.96 163.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -62.11 -39.23 91.82 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 120.943 -1.098 . . . . 10.0 113.125 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.6 p -150.52 90.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.998 1.719 . . . . 10.0 109.839 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.1 p -68.54 140.23 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 121.39 -0.819 . . . . 10.0 112.148 -175.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 27.2 mmt180 -126.13 162.09 26.16 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.463 1.905 . . . . 10.0 111.834 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.98 -33.4 64.78 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.431 0.9 . . . . 10.0 113.431 -177.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 m -64.11 -18.01 64.0 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.386 1.474 . . . . 10.0 114.472 175.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -83.33 -5.99 59.32 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.609 1.164 . . . . 10.0 113.32 177.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.06 152.29 44.99 Favored 'General case' 0 CA--C 1.547 0.852 0 O-C-N 121.039 -1.038 . . . . 10.0 113.191 179.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 137.08 -173.32 22.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 124.689 1.138 . . . . 10.0 115.161 175.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.08 102.05 13.5 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.143 1.777 . . . . 10.0 111.234 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -80.91 153.6 27.48 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.624 1.17 . . . . 10.0 112.169 170.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.21 162.7 36.5 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.238 1.015 . . . . 10.0 111.795 166.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.3 t -139.64 125.52 19.65 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 125.446 1.499 . . . . 10.0 110.827 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 96.2 t -97.63 134.82 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 125.436 1.495 . . . . 10.0 109.7 174.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.19 117.33 22.13 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.224 1.809 . . . . 10.0 110.794 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -132.96 140.35 47.76 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.197 1.399 . . . . 10.0 112.196 -172.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.4 p30 -135.04 -177.83 4.81 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.234 1.414 . . . . 10.0 111.209 166.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -62.23 -13.26 26.03 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 115.624 1.713 . . . . 10.0 115.624 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -104.15 -22.54 13.39 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.33 1.452 . . . . 10.0 114.183 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.79 -166.24 39.44 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 116.098 1.199 . . . . 10.0 116.098 179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.91 146.13 47.02 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.93 2.092 . . . . 10.0 112.098 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.71 167.0 23.21 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.553 1.941 . . . . 10.0 111.037 166.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 10.8 m -145.2 148.68 33.81 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.338 1.055 . . . . 10.0 111.071 -177.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -132.17 151.15 51.95 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.039 1.736 . . . . 10.0 110.647 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.3 m -143.45 145.98 33.05 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 125.034 1.334 . . . . 10.0 111.642 -174.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.9 p -154.2 156.42 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 126.016 1.727 . . . . 10.0 110.99 170.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -110.91 141.42 44.34 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.353 1.061 . . . . 10.0 110.485 169.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.4 tp -124.14 106.8 10.62 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.07 1.748 . . . . 10.0 110.321 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -94.54 83.22 4.08 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.435 1.494 . . . . 10.0 110.824 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.0 t -64.05 113.56 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 O-C-N 121.372 -0.83 . . . . 10.0 110.704 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.45 97.49 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.1 1.76 . . . . 10.0 110.073 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.83 0 C-N-CA 124.384 1.074 . . . . 10.0 113.429 -177.405 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_endo . . . . . 0 CA--C 1.544 1.001 0 N-CA-C 113.549 0.557 . . . . 10.0 113.549 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -70.53 148.0 59.1 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.204 2.603 . . . . 10.0 112.054 173.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -136.46 158.59 44.07 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 125.576 1.551 . . . . 10.0 112.758 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -84.41 79.41 9.57 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.293 2.237 . . . . 10.0 112.261 -174.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 44.4 mm -73.41 -55.31 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.529 -0.732 . . . . 10.0 111.21 178.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.22 129.52 10.53 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.5 1.12 . . . . 10.0 111.705 176.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.1 m -104.09 148.17 35.48 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 124.669 1.188 . . . . 10.0 110.196 158.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.32 162.4 36.36 Favored 'Trans proline' 0 CA--C 1.542 0.882 0 C-N-CA 122.99 2.46 . . . . 10.0 111.155 171.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -73.66 168.29 19.65 Favored 'General case' 0 CA--C 1.545 0.783 0 O-C-N 121.389 -0.82 . . . . 10.0 111.655 169.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.5 p30 -61.79 160.22 12.28 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.422 -0.799 . . . . 10.0 112.405 172.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.2 mtm -132.56 160.4 36.66 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.079 0.952 . . . . 10.0 113.073 -178.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 p -136.07 103.14 5.24 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 126.192 1.797 . . . . 10.0 110.527 175.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.5 mm -119.37 131.27 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.247 1.419 . . . . 10.0 110.723 -165.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -60.91 129.07 39.62 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.804 1.242 . . . . 10.0 112.558 173.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -54.21 127.8 28.43 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.825 1.25 . . . . 10.0 112.596 -178.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.13 -10.27 61.71 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 126.187 1.851 . . . . 10.0 115.036 178.16 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 27.1 mtp-105 -73.84 163.93 27.3 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.116 1.458 . . . . 10.0 113.099 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -75.37 141.18 43.34 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.895 1.278 . . . . 10.0 110.506 158.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.46 170.32 19.89 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.756 0.822 . . . . 10.0 112.343 162.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -146.84 163.32 36.44 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.37 1.468 . . . . 10.0 112.757 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -134.97 140.3 45.59 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.215 2.206 . . . . 10.0 109.137 175.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -131.97 125.7 32.21 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.795 1.238 . . . . 10.0 111.974 -168.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -129.17 111.81 13.3 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 126.789 2.035 . . . . 10.0 111.624 -167.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -73.65 120.55 19.4 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 121.587 -0.696 . . . . 10.0 109.808 171.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -130.11 108.92 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.792 2.037 . . . . 10.0 110.831 -171.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.8 t -76.79 -174.77 3.17 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.336 1.054 . . . . 10.0 112.301 174.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 100.27 160.58 28.25 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 126.92 2.2 . . . . 10.0 113.795 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -151.17 135.26 9.53 Favored Pre-proline 0 CA--C 1.548 0.889 0 C-N-CA 126.044 1.738 . . . . 10.0 109.531 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.18 169.94 37.76 Favored 'Cis proline' 0 CA--C 1.539 0.76 0 CA-C-N 121.15 1.447 . . . . 10.0 112.373 -6.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 123.18 51.65 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 124.581 1.153 . . . . 10.0 111.278 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -70.88 161.57 45.61 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 122.501 2.134 . . . . 10.0 113.333 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 40.2 m-20 -65.66 170.56 5.02 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.826 1.25 . . . . 10.0 111.761 165.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 5.6 p -138.37 122.96 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.219 1.408 . . . . 10.0 111.471 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.0 m -137.36 106.25 5.94 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.818 1.647 . . . . 10.0 110.563 174.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.8 m95 -85.86 153.54 22.17 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 123.953 0.901 . . . . 10.0 113.223 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.19 159.0 43.1 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.979 2.112 . . . . 10.0 111.295 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -143.93 117.07 8.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 127.072 2.149 . . . . 10.0 110.281 175.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 54.07 18.86 1.85 Allowed 'General case' 0 CA--C 1.554 1.116 0 C-N-CA 126.375 1.87 . . . . 10.0 114.558 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.97 -9.35 46.86 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.422 1.963 . . . . 10.0 115.476 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.18 155.13 19.61 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.044 1.422 . . . . 10.0 110.166 171.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.6 p -69.34 155.24 40.75 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.801 0.84 . . . . 10.0 112.585 173.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 57.4 t -133.12 105.04 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.332 1.853 . . . . 10.0 108.766 173.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 95.4 mm-40 -72.62 159.59 33.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.498 0.719 . . . . 10.0 111.701 173.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.3 p -70.11 154.9 41.36 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.35 0.66 . . . . 10.0 111.67 166.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -154.15 168.95 24.78 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.404 1.482 . . . . 10.0 111.025 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -57.83 -34.55 69.8 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.792 -1.193 . . . . 10.0 112.658 168.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.3 mt -82.79 -15.16 52.77 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.556 1.142 . . . . 10.0 113.9 173.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -134.61 69.41 1.46 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.011 1.724 . . . . 10.0 111.324 -173.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -70.61 144.4 51.18 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.086 1.354 . . . . 10.0 111.666 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.3 mtt -141.14 103.36 4.43 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 126.835 2.054 . . . . 10.0 109.723 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.75 162.03 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 C-N-CA 124.617 1.167 . . . . 10.0 112.66 -176.683 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 t -133.83 113.91 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.632 1.573 . . . . 10.0 109.698 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 66.8 m -69.04 144.46 54.03 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.47 0.708 . . . . 10.0 111.053 171.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.03 -17.1 56.24 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.487 1.515 . . . . 10.0 114.579 -176.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -74.44 -4.88 39.3 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 126.155 1.782 . . . . 10.0 114.107 173.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.17 38.35 5.71 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 125.139 1.352 . . . . 10.0 113.644 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 44.4 tp -125.68 102.54 7.38 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.424 1.489 . . . . 10.0 110.646 -177.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -78.25 145.26 35.56 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.009 0.924 . . . . 10.0 110.926 169.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 32.6 t -134.53 145.52 48.83 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.943 1.297 . . . . 10.0 111.985 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -130.63 120.53 24.1 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.434 2.694 . . . . 10.0 108.115 -178.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.4 152.33 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.605 1.162 . . . . 10.0 111.424 -170.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -125.96 108.84 11.79 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 127.273 2.229 . . . . 10.0 108.892 168.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -65.98 -38.45 88.56 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.323 -0.861 . . . . 10.0 112.715 175.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.2 p -150.28 86.82 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 126.098 1.759 . . . . 10.0 110.043 -178.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.5 p -66.64 139.6 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 O-C-N 121.3 -0.875 . . . . 10.0 111.827 -177.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -119.69 160.82 21.8 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.964 1.705 . . . . 10.0 112.069 176.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.29 -31.62 65.81 Favored 'General case' 0 CA--C 1.548 0.891 0 N-CA-C 113.709 1.003 . . . . 10.0 113.709 -176.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -65.3 -21.13 66.68 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.125 1.37 . . . . 10.0 113.891 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -77.66 -6.16 52.91 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.68 1.192 . . . . 10.0 113.591 178.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.2 147.79 52.82 Favored 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.874 -1.141 . . . . 10.0 112.695 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.76 -172.6 22.49 Favored Glycine 0 CA--C 1.532 1.155 0 C-N-CA 124.767 1.175 . . . . 10.0 114.894 177.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.92 109.83 18.43 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.981 1.712 . . . . 10.0 111.06 175.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -85.15 153.72 22.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.473 1.109 . . . . 10.0 112.213 171.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.17 159.34 42.42 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.172 0.989 . . . . 10.0 112.069 167.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -139.03 104.26 4.99 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.76 1.624 . . . . 10.0 110.827 -178.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.8 t -76.39 129.61 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.316 1.046 . . . . 10.0 109.692 171.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.68 117.91 20.16 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.668 1.987 . . . . 10.0 110.681 178.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -132.11 139.63 48.53 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.299 1.44 . . . . 10.0 112.017 -172.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 26.8 p30 -134.27 -177.98 4.83 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.903 1.281 . . . . 10.0 111.411 167.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -61.29 -11.22 8.91 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.778 1.77 . . . . 10.0 115.778 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.97 -19.78 12.23 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.409 1.484 . . . . 10.0 114.443 -178.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.44 -170.39 43.51 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 116.149 1.22 . . . . 10.0 116.149 178.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -136.8 144.17 43.56 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.968 2.107 . . . . 10.0 111.819 -170.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.68 157.1 47.2 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 126.482 1.913 . . . . 10.0 110.534 166.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -140.12 98.03 3.36 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.64 1.176 . . . . 10.0 110.206 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -75.35 156.97 34.96 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.107 0.963 . . . . 10.0 111.467 177.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 33.0 m -144.87 143.47 30.61 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.058 1.343 . . . . 10.0 111.348 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.5 p -153.95 170.74 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 C-N-CA 126.215 1.806 . . . . 10.0 110.867 173.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 -131.15 146.81 52.48 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.756 1.222 . . . . 10.0 111.88 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.5 tp -131.76 119.41 21.25 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.057 1.743 . . . . 10.0 111.018 -178.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -104.35 83.02 2.01 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.79 1.636 . . . . 10.0 110.857 176.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.05 110.89 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 O-C-N 121.531 -0.731 . . . . 10.0 110.692 -179.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 67.4 mt -73.01 97.95 2.42 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.305 1.842 . . . . 10.0 109.87 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.823 0 C-N-CA 124.644 1.177 . . . . 10.0 113.661 -173.488 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo . . . . . 0 CA--C 1.543 0.963 0 N-CA-C 112.943 0.324 . . . . 10.0 112.943 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -70.23 166.07 29.41 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.144 2.562 . . . . 10.0 112.428 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 21.3 tpp180 -140.77 147.18 38.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.462 1.105 . . . . 10.0 112.436 -174.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -76.8 58.06 1.38 Allowed 'General case' 0 CA--C 1.55 0.977 0 C-N-CA 128.564 2.746 . . . . 10.0 112.409 -177.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.3 mm -60.64 -58.5 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.964 -1.085 . . . . 10.0 112.63 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -154.35 153.34 31.45 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 119.006 0.821 . . . . 10.0 113.172 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 17.8 m -131.05 155.57 81.37 Favored Pre-proline 0 N--CA 1.479 0.997 0 C-N-CA 127.371 2.269 . . . . 10.0 110.382 167.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -74.8 166.14 29.93 Favored 'Trans proline' 0 CA--C 1.542 0.921 0 C-N-CA 122.771 2.314 . . . . 10.0 111.499 168.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -73.05 176.45 5.77 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.446 -0.784 . . . . 10.0 111.194 163.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -59.18 152.83 19.62 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.911 -1.118 . . . . 10.0 112.128 171.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.7 mtp -132.46 157.19 45.24 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 125.526 1.531 . . . . 10.0 111.946 -172.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 76.4 p -145.93 136.79 24.43 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 125.26 1.424 . . . . 10.0 110.856 169.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 24.9 mm -138.4 133.08 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.581 1.552 . . . . 10.0 109.531 -170.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -63.85 131.12 46.8 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.639 1.175 . . . . 10.0 112.302 173.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -51.54 130.59 28.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.515 1.526 . . . . 10.0 113.305 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.4 -10.25 67.13 Favored Glycine 0 CA--C 1.537 1.426 0 C-N-CA 126.185 1.85 . . . . 10.0 115.175 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.3 mtp180 -72.3 161.33 30.99 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.037 1.418 . . . . 10.0 113.356 177.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -71.49 148.6 46.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.678 1.191 . . . . 10.0 110.637 156.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.8 t -147.06 154.62 41.39 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.941 1.296 . . . . 10.0 111.019 168.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -145.53 166.18 26.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.747 1.219 . . . . 10.0 112.547 165.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 49.5 mtt -133.07 166.9 21.35 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.471 1.908 . . . . 10.0 111.815 -176.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -134.39 117.65 16.56 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.082 1.753 . . . . 10.0 111.694 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -127.83 99.55 5.58 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.551 1.54 . . . . 10.0 111.358 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -66.41 123.31 19.64 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.862 0.865 . . . . 10.0 110.115 172.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 5.9 p -142.45 102.63 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.311 1.845 . . . . 10.0 110.684 -176.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.7 t -75.68 -177.25 3.63 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.003 0.921 . . . . 10.0 111.855 172.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 117.32 160.3 11.73 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 127.356 2.408 . . . . 10.0 113.319 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -149.47 128.38 6.15 Favored Pre-proline 0 CA--C 1.548 0.871 0 C-N-CA 124.797 1.239 . . . . 10.0 110.414 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -66.86 169.61 47.63 Favored 'Cis proline' 0 CA--C 1.54 0.809 0 CA-C-N 121.06 1.414 . . . . 10.0 112.507 -3.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.18 122.59 55.06 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.616 1.166 . . . . 10.0 111.429 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.57 151.39 64.42 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 122.55 2.167 . . . . 10.0 113.284 -173.098 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.99 145.66 46.54 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.337 1.055 . . . . 10.0 109.963 160.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.68 86.37 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.091 1.356 . . . . 10.0 112.103 -165.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.4 m -78.5 116.1 18.66 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.866 1.267 . . . . 10.0 111.506 177.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.1 m95 -90.27 155.77 18.76 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.704 1.001 . . . . 10.0 113.704 177.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.34 160.54 41.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.476 2.311 . . . . 10.0 111.495 -177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.9 tp -147.23 119.76 8.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.392 2.277 . . . . 10.0 110.024 174.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 54.9 15.0 1.01 Allowed 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 126.645 1.978 . . . . 10.0 115.145 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.58 -13.23 35.8 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 126.631 2.063 . . . . 10.0 115.19 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -86.84 159.55 19.04 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 118.971 1.385 . . . . 10.0 110.833 169.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.7 p -73.21 159.15 33.91 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.098 0.959 . . . . 10.0 112.729 174.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 90.5 t -137.12 145.71 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 127.008 2.123 . . . . 10.0 108.775 171.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 80.4 mt-30 -128.1 163.21 25.13 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.295 1.438 . . . . 10.0 111.285 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.5 p -68.35 152.61 45.19 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.657 0.783 . . . . 10.0 112.613 176.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -152.17 168.18 26.16 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.978 1.711 . . . . 10.0 110.641 175.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.45 -35.12 67.53 Favored 'General case' 0 CA--C 1.544 0.741 0 O-C-N 120.906 -1.121 . . . . 10.0 112.76 169.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.0 mt -84.84 -12.99 52.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.608 1.163 . . . . 10.0 113.979 173.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.9 m80 -136.59 71.18 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.633 1.573 . . . . 10.0 111.453 -173.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -71.89 147.45 47.07 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.797 1.239 . . . . 10.0 111.898 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.6 mtt -141.54 107.28 5.11 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 126.846 2.058 . . . . 10.0 109.908 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.0 157.93 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.641 1.176 . . . . 10.0 112.398 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.1 t -133.81 113.93 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.893 1.677 . . . . 10.0 109.928 -177.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 68.7 m -70.38 151.27 45.4 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.954 0.902 . . . . 10.0 112.132 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -57.45 -32.18 66.67 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 125.766 1.627 . . . . 10.0 113.856 -175.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . 0.441 ' HE2' ' HA ' ' A' ' 303' ' ' LYS . 11.3 mmpt? -70.82 -3.39 18.71 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 126.174 1.79 . . . . 10.0 114.425 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.83 49.92 3.91 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 125.006 1.289 . . . . 10.0 112.897 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 65.1 tp -130.72 104.15 7.01 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.455 1.502 . . . . 10.0 110.469 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -83.7 125.9 32.35 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 125.145 1.378 . . . . 10.0 111.229 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.8 m -102.86 142.67 33.58 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.243 1.417 . . . . 10.0 111.739 169.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -130.55 126.07 35.84 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 127.469 2.308 . . . . 10.0 107.884 175.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 44.1 mt -122.1 152.68 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.237 1.415 . . . . 10.0 111.722 -167.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.93 109.98 10.93 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 128.059 2.544 . . . . 10.0 109.064 169.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.33 -38.87 85.59 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.02 -1.05 . . . . 10.0 113.069 177.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.04 88.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 125.723 1.609 . . . . 10.0 110.286 -178.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -70.66 141.81 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 O-C-N 121.235 -0.915 . . . . 10.0 112.313 -175.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -126.18 163.21 23.63 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 126.631 1.972 . . . . 10.0 111.958 177.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.1 -31.56 65.4 Favored 'General case' 0 CA--C 1.548 0.875 0 N-CA-C 113.899 1.074 . . . . 10.0 113.899 -177.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.5 m -68.28 -15.91 63.75 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 114.216 1.191 . . . . 10.0 114.216 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -82.83 -5.16 58.84 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.432 1.093 . . . . 10.0 113.308 177.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 150.22 48.84 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.933 -1.104 . . . . 10.0 113.143 178.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.17 -175.19 21.06 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.905 1.241 . . . . 10.0 115.279 174.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.12 98.05 7.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.801 1.64 . . . . 10.0 111.246 175.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -74.5 150.96 39.61 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 123.556 0.742 . . . . 10.0 111.479 167.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.01 161.9 38.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 123.966 0.906 . . . . 10.0 111.997 168.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.1 t -137.31 139.01 40.6 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.737 1.615 . . . . 10.0 110.487 176.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.9 t -117.17 104.7 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.289 1.835 . . . . 10.0 108.862 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -89.64 118.06 28.98 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 126.283 1.833 . . . . 10.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -129.84 132.61 46.53 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.085 1.354 . . . . 10.0 112.598 -176.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -129.44 -179.02 4.92 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.834 1.253 . . . . 10.0 111.513 166.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -61.64 -12.28 15.36 Favored 'General case' 0 N--CA 1.482 1.129 0 N-CA-C 115.726 1.75 . . . . 10.0 115.726 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.18 -20.03 12.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 125.383 1.473 . . . . 10.0 114.424 -178.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 172.92 -169.26 42.42 Favored Glycine 0 CA--C 1.534 1.232 0 N-CA-C 116.101 1.2 . . . . 10.0 116.101 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -134.19 143.8 48.09 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 126.939 2.095 . . . . 10.0 111.909 -171.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.25 165.92 25.0 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.281 1.833 . . . . 10.0 111.076 168.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 19.0 m -141.57 141.59 33.5 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.203 1.001 . . . . 10.0 111.569 -173.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -134.47 150.93 50.87 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.797 1.639 . . . . 10.0 110.556 -178.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -146.4 146.81 30.76 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 124.454 1.102 . . . . 10.0 111.786 -169.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.7 p -152.97 146.68 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 125.251 1.42 . . . . 10.0 112.026 170.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 9.2 tp-100 -100.14 127.47 46.39 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 125.667 1.587 . . . . 10.0 110.245 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -121.18 105.56 10.7 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.542 1.537 . . . . 10.0 111.261 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -93.62 85.79 4.99 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.268 1.427 . . . . 10.0 111.319 175.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.6 t -66.14 115.35 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 121.301 -0.874 . . . . 10.0 110.826 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.3 mt -78.91 100.0 7.04 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.437 1.895 . . . . 10.0 110.356 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.805 0 C-N-CA 123.947 0.899 . . . . 10.0 112.821 179.46 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 CA--C 1.543 0.935 0 N-CA-C 112.943 0.324 . . . . 10.0 112.943 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -65.39 133.59 35.44 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.351 2.701 . . . . 10.0 111.324 171.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -130.64 134.66 47.14 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 126.698 1.999 . . . . 10.0 110.654 -176.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -48.87 120.39 3.82 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 127.09 2.156 . . . . 10.0 112.58 173.587 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 49.7 mm -113.85 -59.29 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.232 1.013 . . . . 10.0 110.413 171.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.5 tt0 -150.47 136.04 18.12 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.013 0.925 . . . . 10.0 111.531 177.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 21.9 m -117.88 149.75 45.89 Favored Pre-proline 0 N--CA 1.474 0.749 0 C-N-CA 125.367 1.467 . . . . 10.0 109.579 167.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.78 155.96 53.38 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 122.485 2.123 . . . . 10.0 111.92 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -69.98 168.35 15.58 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.74 0.816 . . . . 10.0 111.091 166.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.21 152.19 21.22 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 121.211 -0.931 . . . . 10.0 112.334 173.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 86.1 mtp -127.05 152.44 47.26 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.222 1.409 . . . . 10.0 111.87 -167.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 p -144.15 104.94 4.18 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.265 1.426 . . . . 10.0 111.094 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.9 mm -122.6 130.95 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.401 1.481 . . . . 10.0 110.405 -166.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -65.15 129.97 41.64 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.51 1.124 . . . . 10.0 112.518 175.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -52.57 123.5 11.27 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 125.656 1.582 . . . . 10.0 113.132 -176.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 101.45 -10.25 57.76 Favored Glycine 0 CA--C 1.534 1.269 0 C-N-CA 125.975 1.75 . . . . 10.0 115.551 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -70.77 160.64 32.33 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-N 119.248 1.524 . . . . 10.0 113.086 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -73.43 147.73 43.93 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.663 1.185 . . . . 10.0 110.571 159.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 7.1 t -153.4 168.26 26.69 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.075 0.95 . . . . 10.0 112.607 169.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.1 ptm85 -145.61 166.68 25.05 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.95 1.7 . . . . 10.0 112.82 167.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.3 mtt -121.06 159.82 24.9 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 126.964 2.106 . . . . 10.0 111.241 173.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -140.27 93.21 2.6 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.076 1.35 . . . . 10.0 111.961 -166.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -114.07 106.9 14.94 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.733 1.613 . . . . 10.0 111.651 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -85.88 129.73 34.75 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.027 -1.045 . . . . 10.0 111.513 176.521 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.6 p -132.63 153.68 38.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.072 1.749 . . . . 10.0 110.351 170.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 58.4 m -127.24 126.67 43.13 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.766 1.226 . . . . 10.0 110.889 172.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.1 168.01 40.66 Favored Glycine 0 CA--C 1.534 1.28 0 C-N-CA 126.615 2.055 . . . . 10.0 111.236 175.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.9 tp -146.56 131.39 8.9 Favored Pre-proline 0 CA--C 1.546 0.825 0 C-N-CA 124.474 1.11 . . . . 10.0 110.73 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.13 170.59 45.23 Favored 'Cis proline' 0 CA--C 1.541 0.825 0 CA-C-N 120.414 1.184 . . . . 10.0 112.665 -3.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.13 122.05 45.59 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 124.662 1.185 . . . . 10.0 111.29 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -73.82 164.31 34.98 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.572 2.181 . . . . 10.0 113.845 -170.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -61.58 165.77 4.7 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.114 1.766 . . . . 10.0 111.961 165.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.2 p -139.23 113.6 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.097 1.359 . . . . 10.0 111.455 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -128.92 147.61 50.85 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.945 1.698 . . . . 10.0 110.821 173.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -128.44 153.29 47.27 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.355 1.062 . . . . 10.0 113.545 -174.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -143.3 162.65 35.13 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.324 2.25 . . . . 10.0 111.227 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.5 tp -147.86 123.59 10.54 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 126.905 2.082 . . . . 10.0 110.012 176.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 55.02 10.15 0.37 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.739 2.016 . . . . 10.0 116.049 176.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.01 -5.09 25.58 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.08 1.8 . . . . 10.0 115.607 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -105.58 161.65 14.18 Favored 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 119.176 1.488 . . . . 10.0 111.922 171.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.9 p -70.08 154.94 41.31 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.427 1.091 . . . . 10.0 112.791 176.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.33 101.76 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.791 2.036 . . . . 10.0 108.401 170.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -74.3 157.58 35.54 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.529 0.731 . . . . 10.0 111.319 172.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.2 p -70.61 149.5 47.0 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.691 0.796 . . . . 10.0 112.388 172.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -152.29 179.54 8.45 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.419 1.487 . . . . 10.0 111.063 167.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -57.24 -28.66 63.12 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.425 1.269 . . . . 10.0 114.425 -177.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 48.7 mt -92.41 -11.82 33.83 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.272 1.429 . . . . 10.0 113.391 176.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -134.25 70.91 1.45 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.397 1.879 . . . . 10.0 111.153 -174.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -71.87 143.32 49.44 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.171 1.388 . . . . 10.0 111.052 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -138.9 106.47 5.58 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 126.318 1.847 . . . . 10.0 110.455 -172.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.92 171.79 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.315 1.446 . . . . 10.0 112.229 -177.179 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -135.55 134.23 51.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.807 1.643 . . . . 10.0 109.275 174.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 24.9 p -67.95 172.14 5.89 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.838 1.051 . . . . 10.0 113.838 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -59.37 -20.3 53.68 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.237 1.415 . . . . 10.0 113.436 170.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -117.43 5.64 12.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.278 1.831 . . . . 10.0 114.243 -171.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.78 15.71 36.02 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 124.623 1.106 . . . . 10.0 115.777 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 28.4 tp -80.13 98.0 7.11 Favored 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 118.864 1.332 . . . . 10.0 110.3 171.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -63.5 132.24 50.68 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.926 0.89 . . . . 10.0 110.002 166.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -129.71 126.26 37.84 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 126.33 1.852 . . . . 10.0 111.167 -171.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -126.21 123.35 37.99 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 127.043 2.137 . . . . 10.0 108.027 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 50.9 mt -114.54 153.55 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 125.177 1.391 . . . . 10.0 110.968 -171.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -127.78 109.39 11.59 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.353 2.261 . . . . 10.0 108.897 170.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -68.14 -41.66 81.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.188 -0.945 . . . . 10.0 112.606 174.587 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.83 90.2 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.764 1.625 . . . . 10.0 110.388 -176.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -69.89 151.91 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 O-C-N 121.31 -0.869 . . . . 10.0 112.898 -175.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 86.7 mmt-85 -132.31 159.83 38.0 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 127.019 2.128 . . . . 10.0 111.836 174.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.84 -30.83 64.17 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.386 1.074 . . . . 10.0 113.721 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.9 t -62.99 -23.46 67.46 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.966 1.306 . . . . 10.0 113.646 174.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -78.6 -8.46 58.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.556 1.142 . . . . 10.0 113.64 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 152.58 42.84 Favored 'General case' 0 CA--C 1.547 0.839 0 CA-C-N 119.543 1.065 . . . . 10.0 113.406 -179.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.27 -170.88 22.42 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.928 1.252 . . . . 10.0 114.891 176.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.62 97.67 7.99 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.939 1.696 . . . . 10.0 111.454 176.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -71.55 150.41 44.78 Favored 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 123.948 0.899 . . . . 10.0 111.793 168.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.31 158.08 44.36 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.799 0.84 . . . . 10.0 112.406 168.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.8 t -130.62 141.9 50.44 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 127.162 2.185 . . . . 10.0 109.601 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 28.6 t -124.66 131.74 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.255 1.422 . . . . 10.0 109.489 177.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.43 124.03 40.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.189 1.795 . . . . 10.0 110.705 -177.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 1.9 mppt? -129.04 135.94 49.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.241 1.416 . . . . 10.0 111.602 -176.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -134.77 179.39 6.33 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.269 1.028 . . . . 10.0 111.534 163.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 14.9 ptp180 -62.62 -11.08 14.67 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.551 1.685 . . . . 10.0 115.551 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.17 -18.6 13.96 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.507 1.523 . . . . 10.0 114.167 178.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.04 -171.1 42.85 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 119.854 1.206 . . . . 10.0 115.849 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -135.26 147.09 49.16 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.586 1.955 . . . . 10.0 111.835 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.94 159.08 42.99 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.882 1.673 . . . . 10.0 111.861 170.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 86.9 m -138.75 138.26 37.48 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.76 1.624 . . . . 10.0 110.49 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -131.69 156.06 46.55 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.002 1.721 . . . . 10.0 111.25 -175.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -143.93 147.03 33.4 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.427 1.091 . . . . 10.0 112.392 -170.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.1 p -150.98 158.93 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 126.201 1.8 . . . . 10.0 111.277 168.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.6 tt0 -109.16 135.1 50.83 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.848 1.259 . . . . 10.0 111.538 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.4 tp -119.09 110.16 16.75 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.349 1.86 . . . . 10.0 110.639 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -96.5 83.98 3.61 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 125.825 1.65 . . . . 10.0 111.017 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -65.02 112.28 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 121.405 -0.809 . . . . 10.0 110.649 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.0 mt -74.11 101.37 3.9 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.169 1.788 . . . . 10.0 109.862 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.859 0 C-N-CA 124.436 1.094 . . . . 10.0 113.895 -174.03 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 CA--C 1.542 0.895 0 N-CA-C 112.511 0.158 . . . . 10.0 112.511 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -67.91 158.85 55.49 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 122.631 2.22 . . . . 10.0 111.794 171.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 41.6 ttt-85 -142.31 150.69 41.14 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.008 1.323 . . . . 10.0 111.538 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 8.9 m-30 -63.84 133.92 54.27 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.073 0.949 . . . . 10.0 110.161 162.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 32.0 mm -130.83 -59.64 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.095 1.358 . . . . 10.0 109.547 173.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -152.51 141.67 21.38 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.739 1.216 . . . . 10.0 111.21 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -127.5 152.77 77.03 Favored Pre-proline 0 N--CA 1.476 0.853 0 C-N-CA 125.736 1.614 . . . . 10.0 110.522 170.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.74 152.8 59.04 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 122.676 2.251 . . . . 10.0 111.553 171.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -72.76 174.17 8.04 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 123.904 0.882 . . . . 10.0 111.833 164.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -60.45 152.99 24.23 Favored 'General case' 0 CA--C 1.547 0.829 0 O-C-N 121.178 -0.951 . . . . 10.0 112.303 175.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.5 mtp -131.02 158.24 40.86 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 125.121 1.368 . . . . 10.0 112.292 -171.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 46.9 p -143.36 120.43 11.41 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.537 1.535 . . . . 10.0 110.49 172.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.5 mm -129.91 134.46 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.475 1.51 . . . . 10.0 109.796 -169.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.54 130.02 43.22 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.275 1.43 . . . . 10.0 112.39 175.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -51.47 127.21 19.41 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.227 1.411 . . . . 10.0 112.618 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.73 -10.61 60.81 Favored Glycine 0 CA--C 1.537 1.412 0 C-N-CA 126.125 1.821 . . . . 10.0 115.196 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -74.65 160.78 30.37 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 119.28 1.54 . . . . 10.0 113.302 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -74.61 142.65 44.59 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.63 1.172 . . . . 10.0 110.044 155.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.7 p -150.75 170.47 19.15 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 123.575 0.75 . . . . 10.0 112.254 163.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -146.61 162.77 37.72 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.156 1.382 . . . . 10.0 112.669 177.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -137.2 139.73 41.27 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 127.508 2.323 . . . . 10.0 109.151 176.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -134.22 124.05 25.33 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.048 0.939 . . . . 10.0 111.453 -171.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -123.82 110.11 14.48 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 126.517 1.927 . . . . 10.0 110.678 -168.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -72.14 119.63 16.6 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.6 0.76 . . . . 10.0 110.002 173.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.9 p -137.94 110.18 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.762 2.025 . . . . 10.0 110.3 -175.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 5.6 t -75.81 -170.88 1.44 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.378 1.071 . . . . 10.0 112.441 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 103.64 164.25 25.23 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 126.886 2.184 . . . . 10.0 114.039 176.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.8 tp -150.8 133.53 8.46 Favored Pre-proline 0 CA--C 1.548 0.895 0 C-N-CA 125.433 1.493 . . . . 10.0 110.335 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -67.02 168.79 51.76 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 CA-C-N 120.783 1.315 . . . . 10.0 112.528 -3.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.03 124.76 60.78 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.418 1.087 . . . . 10.0 110.846 177.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 155.35 64.46 Favored 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 122.434 2.089 . . . . 10.0 113.375 -170.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -72.8 114.24 10.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.458 1.503 . . . . 10.0 109.327 161.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.53 131.34 56.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.682 1.193 . . . . 10.0 111.289 -175.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.5 m -129.44 156.06 44.7 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 126.073 1.749 . . . . 10.0 111.405 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 63.4 m95 -124.88 156.4 37.97 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.85 1.26 . . . . 10.0 113.194 -176.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -144.4 159.78 42.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 127.119 2.168 . . . . 10.0 111.098 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.8 tp -145.74 119.21 9.05 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 126.887 2.075 . . . . 10.0 110.118 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 54.47 15.69 1.09 Allowed 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.449 1.9 . . . . 10.0 115.019 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.55 -11.87 39.16 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.663 2.078 . . . . 10.0 115.254 -177.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -87.43 158.03 19.08 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.948 1.374 . . . . 10.0 111.125 171.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.1 p -71.54 153.37 42.22 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.395 1.078 . . . . 10.0 112.674 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 53.9 t -132.76 100.85 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.367 1.867 . . . . 10.0 108.715 172.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 59.2 mt-30 -73.23 160.77 31.4 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.554 0.742 . . . . 10.0 111.359 171.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.2 p -68.49 155.67 39.46 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.383 0.673 . . . . 10.0 112.012 168.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -153.07 168.91 24.3 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.484 1.513 . . . . 10.0 110.917 177.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -56.9 -35.37 68.89 Favored 'General case' 0 CA--C 1.545 0.775 0 O-C-N 120.942 -1.098 . . . . 10.0 112.779 169.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.7 mt -84.48 -14.19 49.86 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.48 1.112 . . . . 10.0 113.9 173.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -133.62 70.27 1.46 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.837 1.655 . . . . 10.0 111.264 -174.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -71.29 144.09 50.11 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.834 1.254 . . . . 10.0 111.518 -176.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -141.54 106.06 4.86 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.654 1.982 . . . . 10.0 109.811 -175.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.01 164.99 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.643 1.177 . . . . 10.0 112.37 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 62.3 t -131.58 116.05 30.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 125.992 1.717 . . . . 10.0 109.63 178.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -72.54 143.51 48.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.369 0.667 . . . . 10.0 111.105 170.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.18 -20.33 40.21 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 115.308 1.596 . . . . 10.0 115.308 -174.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -75.45 -5.18 43.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.574 1.55 . . . . 10.0 113.867 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.64 50.75 2.28 Favored Glycine 0 CA--C 1.531 1.064 0 C-N-CA 125.436 1.493 . . . . 10.0 112.855 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 17.9 tp -136.46 106.17 6.2 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.332 1.453 . . . . 10.0 110.511 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -76.51 144.41 39.79 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.582 0.353 . . . . 10.0 110.864 168.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.5 m -130.62 114.76 15.82 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 126.427 1.891 . . . . 10.0 110.603 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -108.59 121.06 44.2 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 127.656 2.383 . . . . 10.0 108.715 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 71.3 mt -121.57 152.17 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.514 1.126 . . . . 10.0 111.304 -168.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.74 110.73 12.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.532 2.333 . . . . 10.0 109.43 171.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -66.11 -39.95 90.33 Favored 'General case' 0 N--CA 1.474 0.749 0 O-C-N 121.285 -0.884 . . . . 10.0 113.038 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -151.22 90.22 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.747 1.619 . . . . 10.0 110.277 -178.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.3 p -69.98 140.96 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 O-C-N 121.287 -0.883 . . . . 10.0 111.995 -177.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.3 mmt180 -124.22 161.81 24.98 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.421 1.888 . . . . 10.0 112.043 177.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.74 -33.89 64.68 Favored 'General case' 0 CA--C 1.546 0.82 0 N-CA-C 113.434 0.902 . . . . 10.0 113.434 -178.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.4 m -65.24 -17.68 64.69 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.355 1.462 . . . . 10.0 114.512 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -82.53 -5.47 58.76 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.685 1.194 . . . . 10.0 113.228 177.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.98 151.98 45.59 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.084 -1.01 . . . . 10.0 113.067 178.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.78 -171.27 22.44 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.746 1.165 . . . . 10.0 114.801 175.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.91 103.87 14.35 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.972 1.709 . . . . 10.0 111.055 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -78.15 152.02 32.98 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.009 0.924 . . . . 10.0 111.839 169.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -139.04 156.34 47.27 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.068 0.947 . . . . 10.0 111.687 168.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.0 t -134.06 136.74 44.2 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.525 1.93 . . . . 10.0 109.472 -175.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 67.8 t -128.25 126.53 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.488 1.515 . . . . 10.0 109.143 -178.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.83 117.4 23.29 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.258 1.823 . . . . 10.0 110.77 -174.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 23.0 mtpp -124.49 133.71 53.26 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.482 1.513 . . . . 10.0 111.536 -174.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 14.4 p30 -131.43 178.81 6.44 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.145 0.978 . . . . 10.0 111.7 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -63.57 -10.04 16.37 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 115.636 1.717 . . . . 10.0 115.636 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.12 -20.33 12.73 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.645 1.578 . . . . 10.0 114.246 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.05 -169.2 42.21 Favored Glycine 0 CA--C 1.535 1.291 0 CA-C-N 119.788 1.176 . . . . 10.0 115.769 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -138.54 147.09 42.69 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.357 1.863 . . . . 10.0 112.013 -173.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.66 153.61 50.86 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.033 1.733 . . . . 10.0 111.242 169.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.7 m -136.67 140.07 42.46 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.566 1.546 . . . . 10.0 110.646 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -133.55 159.28 40.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.966 1.706 . . . . 10.0 111.247 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.6 m -143.43 144.14 31.9 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 124.949 1.3 . . . . 10.0 111.341 -174.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.39 161.4 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.938 1.695 . . . . 10.0 110.563 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.8 tt0 -123.72 138.44 54.52 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 124.484 1.114 . . . . 10.0 111.196 176.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.3 tp -125.24 108.94 12.25 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.035 1.734 . . . . 10.0 110.711 -178.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -93.8 83.15 4.36 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.432 1.493 . . . . 10.0 110.682 174.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.34 114.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 O-C-N 121.452 -0.78 . . . . 10.0 110.418 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.9 mt -75.25 94.09 2.95 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.193 1.797 . . . . 10.0 110.015 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.78 0 C-N-CA 124.43 1.092 . . . . 10.0 112.98 -179.586 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo . . . . . 0 CA--C 1.544 0.976 0 N-CA-C 113.528 0.549 . . . . 10.0 113.528 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.71 139.09 56.38 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.02 2.48 . . . . 10.0 111.006 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 53.1 ttt85 -128.78 151.64 49.35 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.457 1.503 . . . . 10.0 112.617 -174.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -76.44 88.72 3.21 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.041 2.137 . . . . 10.0 111.708 177.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.2 mm -82.92 -58.78 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 O-C-N 121.605 -0.684 . . . . 10.0 110.264 171.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 24.8 tt0 -154.29 146.62 23.89 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.735 1.214 . . . . 10.0 111.776 175.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.79 152.29 74.86 Favored Pre-proline 0 N--CA 1.477 0.881 0 C-N-CA 126.452 1.901 . . . . 10.0 110.004 169.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.83 157.45 35.12 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.567 2.178 . . . . 10.0 112.247 -178.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -73.88 168.15 20.02 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.833 0.853 . . . . 10.0 111.326 166.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -60.14 158.14 11.85 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 121.419 -0.8 . . . . 10.0 112.801 176.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -128.47 152.75 47.88 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.714 1.606 . . . . 10.0 111.742 -171.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 39.5 p -141.77 116.85 9.98 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 125.385 1.474 . . . . 10.0 110.416 170.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.9 mm -129.3 129.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.29 1.436 . . . . 10.0 109.995 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -60.66 127.17 30.35 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.173 1.389 . . . . 10.0 112.12 173.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -53.22 134.38 39.2 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.202 1.401 . . . . 10.0 113.161 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.85 -12.02 67.55 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.346 1.927 . . . . 10.0 114.79 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -74.24 161.56 29.81 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 118.972 1.386 . . . . 10.0 113.268 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -75.9 141.16 42.4 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.885 1.274 . . . . 10.0 110.276 156.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.79 172.03 15.29 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.678 0.791 . . . . 10.0 112.065 161.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -152.43 170.21 20.68 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.145 1.378 . . . . 10.0 112.923 174.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.9 mtt -121.8 164.7 17.03 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 126.587 1.955 . . . . 10.0 112.526 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -138.23 103.42 4.92 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 126.353 1.861 . . . . 10.0 111.738 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -115.37 109.61 18.15 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.5 1.52 . . . . 10.0 111.178 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -80.03 74.72 6.79 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 121.302 -0.874 . . . . 10.0 111.496 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -79.84 128.14 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.913 1.285 . . . . 10.0 109.945 163.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 68.6 m -135.28 115.35 13.19 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.787 1.235 . . . . 10.0 111.343 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -158.41 169.85 34.99 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 126.695 2.093 . . . . 10.0 111.55 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 21.8 tp -142.14 120.04 7.47 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.504 1.122 . . . . 10.0 110.449 -177.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -68.05 167.54 63.18 Favored 'Cis proline' 0 CA--C 1.54 0.79 0 CA-C-N 121.018 1.399 . . . . 10.0 112.906 0.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 124.39 62.23 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.791 1.236 . . . . 10.0 111.189 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.49 151.33 59.02 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.41 2.073 . . . . 10.0 113.82 -169.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -69.94 130.45 42.26 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.611 1.564 . . . . 10.0 109.543 159.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.3 m -124.54 134.74 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.891 1.276 . . . . 10.0 112.253 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.6 m -136.47 114.56 11.48 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.673 1.589 . . . . 10.0 111.418 -173.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -87.44 151.98 22.61 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 114.016 1.117 . . . . 10.0 114.016 -178.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -141.61 160.57 39.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.975 2.51 . . . . 10.0 111.017 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -146.97 120.92 9.34 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.541 2.337 . . . . 10.0 109.833 176.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 54.93 14.71 0.97 Allowed 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.494 1.918 . . . . 10.0 115.341 178.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.28 -7.31 34.76 Favored Glycine 0 CA--C 1.539 1.582 0 C-N-CA 126.351 1.929 . . . . 10.0 115.487 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -99.55 159.75 14.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.587 1.555 . . . . 10.0 110.921 171.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.9 p -71.69 158.99 35.17 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.12 0.968 . . . . 10.0 112.788 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 39.0 t -135.71 102.47 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.984 1.714 . . . . 10.0 109.354 173.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.9 mt-30 -70.18 155.21 40.96 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.239 0.615 . . . . 10.0 111.251 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 67.6 p -69.63 160.23 31.96 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 123.562 0.745 . . . . 10.0 112.164 170.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -152.66 169.66 22.16 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.383 1.473 . . . . 10.0 111.024 178.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.9 -35.01 68.47 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 120.867 -1.146 . . . . 10.0 112.749 168.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 77.1 mt -82.65 -14.08 55.33 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.506 1.122 . . . . 10.0 113.889 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -135.25 69.53 1.44 Allowed 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.782 1.633 . . . . 10.0 111.501 -173.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 77.9 mttt -71.34 134.22 46.56 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.037 1.335 . . . . 10.0 110.547 -179.008 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 60.4 mtt -131.75 101.04 5.3 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 126.22 1.808 . . . . 10.0 109.524 -174.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.19 159.15 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 124.839 1.256 . . . . 10.0 112.562 -170.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.53 167.9 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 126.007 1.723 . . . . 10.0 111.992 -177.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 34.2 t -131.14 147.39 52.6 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 125.545 1.538 . . . . 10.0 112.128 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -57.82 -20.37 35.44 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.831 1.652 . . . . 10.0 113.87 168.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -78.0 -1.36 31.74 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.788 1.635 . . . . 10.0 114.355 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 79.87 60.94 2.34 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 124.677 1.132 . . . . 10.0 111.935 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 42.9 tp -150.97 148.53 28.5 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.96 1.704 . . . . 10.0 110.862 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -132.84 129.24 38.21 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.897 2.079 . . . . 10.0 110.097 174.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.1 m -108.81 147.1 32.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.475 1.51 . . . . 10.0 112.146 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.91 108.57 9.48 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 126.623 1.969 . . . . 10.0 108.333 171.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -89.89 151.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 125.268 1.427 . . . . 10.0 110.329 -178.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -130.61 99.69 5.06 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.94 2.096 . . . . 10.0 108.38 167.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -62.4 -38.4 89.49 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 113.225 0.824 . . . . 10.0 113.225 -176.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.8 p -149.65 87.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 125.897 1.679 . . . . 10.0 110.133 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.1 p -70.07 139.53 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 121.347 -0.846 . . . . 10.0 112.029 -176.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.4 mmm180 -128.42 161.68 28.92 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.466 1.907 . . . . 10.0 111.26 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -52.21 -35.95 50.78 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 114.195 1.183 . . . . 10.0 114.195 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.7 -17.72 64.36 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.242 1.417 . . . . 10.0 114.673 176.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -82.52 -5.92 59.02 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.74 1.216 . . . . 10.0 113.473 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 151.01 47.6 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.988 -1.07 . . . . 10.0 113.187 179.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.49 -172.63 22.4 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.872 1.225 . . . . 10.0 115.069 175.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.72 102.54 13.07 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.075 1.75 . . . . 10.0 111.538 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -79.67 149.02 31.37 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 124.291 1.037 . . . . 10.0 111.932 171.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.9 159.26 43.18 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.906 0.882 . . . . 10.0 112.271 170.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 49.8 t -137.68 118.2 13.87 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 125.139 1.375 . . . . 10.0 111.391 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 42.3 t -87.75 124.85 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 125.169 1.388 . . . . 10.0 109.268 172.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -117.65 128.16 54.65 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.456 1.903 . . . . 10.0 111.075 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.0 mtmt -133.83 130.12 37.47 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 126.116 1.767 . . . . 10.0 112.159 -167.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -136.4 -179.56 5.75 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 118.879 0.763 . . . . 10.0 112.305 162.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -59.33 -14.68 12.48 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 115.823 1.786 . . . . 10.0 115.823 -177.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.6 -12.28 15.0 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.452 1.501 . . . . 10.0 114.357 -178.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 162.98 -172.39 38.99 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.443 1.02 . . . . 10.0 115.457 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -134.6 147.76 50.28 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.239 1.816 . . . . 10.0 111.57 -173.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.08 163.26 30.74 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.537 1.935 . . . . 10.0 110.785 169.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 96.4 m -144.29 124.28 13.57 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.514 1.126 . . . . 10.0 110.649 177.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -113.54 155.5 25.27 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.523 1.529 . . . . 10.0 111.17 -176.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.5 m -141.77 148.51 39.05 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.621 1.168 . . . . 10.0 112.41 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.79 171.01 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 127.024 2.13 . . . . 10.0 110.603 168.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -128.78 140.63 51.62 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.924 1.29 . . . . 10.0 111.12 172.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.3 tp -125.41 111.81 15.56 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.4 1.88 . . . . 10.0 110.642 -178.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -97.38 85.85 3.75 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.8 1.64 . . . . 10.0 110.864 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.5 t -67.08 112.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.364 -0.835 . . . . 10.0 110.599 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.51 94.16 3.66 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.037 1.735 . . . . 10.0 110.1 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.77 0 C-N-CA 124.519 1.127 . . . . 10.0 112.764 -179.953 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo . . . . . 0 CA--C 1.544 0.991 0 N-CA-C 113.31 0.466 . . . . 10.0 113.31 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -69.73 168.26 22.02 Favored 'Trans proline' 0 CA--C 1.541 0.867 0 C-N-CA 123.249 2.632 . . . . 10.0 112.361 171.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 58.2 ttp85 -134.44 156.42 48.6 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.322 1.449 . . . . 10.0 112.22 -174.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -93.94 64.6 3.4 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 126.816 2.047 . . . . 10.0 111.086 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.48 -66.08 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.095 -1.003 . . . . 10.0 112.679 -170.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -155.24 165.03 37.94 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.0 m -132.92 161.99 60.32 Favored Pre-proline 0 N--CA 1.476 0.829 0 C-N-CA 127.871 2.468 . . . . 10.0 110.492 170.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.67 164.02 32.86 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.832 2.355 . . . . 10.0 111.228 164.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -72.59 169.43 16.55 Favored 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.251 -0.906 . . . . 10.0 112.523 169.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.31 148.79 40.09 Favored 'General case' 0 CA--C 1.546 0.789 0 O-C-N 121.346 -0.846 . . . . 10.0 112.652 173.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 75.8 mtp -130.81 154.07 48.42 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.882 1.273 . . . . 10.0 112.48 -170.117 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 64.6 m -140.48 101.03 4.01 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.302 1.841 . . . . 10.0 110.107 -176.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 37.6 mm -117.8 134.31 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 124.528 1.131 . . . . 10.0 111.292 -166.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -64.11 130.06 42.46 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.816 1.246 . . . . 10.0 112.445 173.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -53.24 129.8 32.64 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.112 1.365 . . . . 10.0 112.925 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.74 -11.5 62.73 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 126.305 1.907 . . . . 10.0 115.041 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -75.72 161.18 29.28 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.001 1.401 . . . . 10.0 113.276 177.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.9 149.22 46.96 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.665 1.186 . . . . 10.0 110.71 157.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 10.7 t -150.39 160.43 43.75 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.755 1.222 . . . . 10.0 111.903 168.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -151.65 167.41 28.23 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.342 1.457 . . . . 10.0 112.883 167.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -132.91 167.03 20.98 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.646 1.978 . . . . 10.0 112.119 -176.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -134.55 108.35 8.03 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.258 1.823 . . . . 10.0 111.775 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -117.67 112.17 20.14 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.448 1.499 . . . . 10.0 111.42 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -71.96 108.5 5.24 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.4 1.08 . . . . 10.0 110.31 174.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 18.0 t -117.59 149.32 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.684 1.594 . . . . 10.0 109.819 177.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.4 t -148.15 -177.58 5.82 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.254 1.422 . . . . 10.0 111.112 175.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 122.77 162.14 11.44 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 127.65 2.548 . . . . 10.0 111.795 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.1 tp -144.61 122.73 6.68 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-O 118.083 -0.96 . . . . 10.0 110.571 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -66.56 167.89 53.29 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.689 1.282 . . . . 10.0 112.627 -1.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.24 126.02 72.72 Favored Pre-proline 0 CA--C 1.549 0.935 0 C-N-CA 124.454 1.102 . . . . 10.0 111.291 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.51 149.9 62.79 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.406 2.071 . . . . 10.0 113.321 -173.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -74.66 151.05 39.33 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.61 1.164 . . . . 10.0 109.918 159.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 59.1 t -131.56 138.46 52.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.963 0.905 . . . . 10.0 112.125 -169.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 63.2 m -132.73 115.27 15.14 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 126.767 2.027 . . . . 10.0 110.61 177.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 53.4 m95 -86.44 158.83 19.5 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 122.001 0.905 . . . . 10.0 112.85 176.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -144.69 159.88 42.11 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 127.063 2.145 . . . . 10.0 111.235 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.6 tp -145.65 118.12 8.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.146 2.178 . . . . 10.0 110.062 175.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 54.87 14.95 0.99 Allowed 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 126.479 1.912 . . . . 10.0 115.092 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.82 -14.02 34.78 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 126.747 2.118 . . . . 10.0 115.165 -177.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -83.41 155.53 23.42 Favored 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 118.981 1.39 . . . . 10.0 110.929 169.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.7 p -71.46 155.14 40.94 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.27 1.028 . . . . 10.0 112.602 173.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 59.5 t -136.63 135.96 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 126.678 1.991 . . . . 10.0 108.976 172.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -119.09 164.01 16.17 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 125.267 1.427 . . . . 10.0 111.344 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 98.1 p -66.89 152.76 45.05 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.655 0.741 . . . . 10.0 112.441 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -151.95 167.96 26.71 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.827 1.651 . . . . 10.0 110.656 176.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.65 -34.92 67.78 Favored 'General case' 0 CA--C 1.545 0.772 0 O-C-N 120.97 -1.081 . . . . 10.0 112.832 169.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.4 mt -85.39 -13.55 49.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.55 1.14 . . . . 10.0 114.001 174.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.3 m80 -136.08 70.35 1.42 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.658 1.583 . . . . 10.0 111.184 -174.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -69.91 145.28 52.06 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.713 1.205 . . . . 10.0 111.636 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.4 mtt -139.41 101.74 4.31 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.785 2.034 . . . . 10.0 109.736 -176.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.37 162.24 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.851 1.26 . . . . 10.0 111.818 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 13.8 p -136.83 134.61 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.631 1.172 . . . . 10.0 111.269 -179.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 40.7 t -65.21 159.89 22.65 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.923 1.289 . . . . 10.0 112.505 177.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -52.19 -33.15 39.53 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.538 1.535 . . . . 10.0 111.965 164.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -81.72 -3.63 54.19 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.405 1.882 . . . . 10.0 113.735 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.25 -3.48 82.23 Favored Glycine 0 CA--C 1.538 1.494 0 C-N-CA 125.75 1.643 . . . . 10.0 115.468 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 48.2 tp -67.97 107.59 2.74 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.846 1.259 . . . . 10.0 111.165 174.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.6 t60 -84.86 124.57 31.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.781 1.632 . . . . 10.0 111.514 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.8 m -97.74 134.1 41.37 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.638 1.575 . . . . 10.0 111.793 171.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -123.07 123.55 41.1 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 127.154 2.182 . . . . 10.0 107.94 171.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 47.4 mt -121.79 153.63 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 125.124 1.37 . . . . 10.0 111.517 -166.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -132.18 108.23 9.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 128.044 2.538 . . . . 10.0 109.224 172.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -66.73 -38.79 87.37 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.846 -1.159 . . . . 10.0 112.914 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.5 p -151.78 89.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.684 1.593 . . . . 10.0 110.441 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.35 140.56 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 121.212 -0.93 . . . . 10.0 111.883 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -129.34 162.3 28.3 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 126.385 1.874 . . . . 10.0 111.267 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -53.11 -35.11 59.28 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.128 1.158 . . . . 10.0 114.128 -175.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.4 m -65.09 -17.83 64.79 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.32 1.448 . . . . 10.0 114.644 176.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -82.9 -7.0 59.7 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.754 1.222 . . . . 10.0 113.518 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.97 147.9 52.64 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.096 -1.003 . . . . 10.0 113.218 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.74 -171.99 24.19 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.507 1.051 . . . . 10.0 115.448 173.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.69 104.15 11.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.846 1.658 . . . . 10.0 110.893 173.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -80.79 151.1 28.93 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.985 0.914 . . . . 10.0 111.751 170.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.93 161.19 38.42 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.093 0.957 . . . . 10.0 112.132 168.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 29.6 t -141.49 104.79 4.64 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.549 1.94 . . . . 10.0 109.766 -172.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.69 131.1 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.576 1.15 . . . . 10.0 109.386 174.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.15 126.15 44.81 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.304 1.842 . . . . 10.0 110.721 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -134.35 135.42 42.69 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.479 1.512 . . . . 10.0 112.435 -169.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -130.04 -178.2 4.63 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.577 1.151 . . . . 10.0 111.712 166.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -59.88 -12.41 7.55 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 115.841 1.793 . . . . 10.0 115.841 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.7 -14.31 12.02 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.448 1.499 . . . . 10.0 114.589 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.32 -170.3 42.88 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-N 119.978 1.263 . . . . 10.0 116.165 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -134.74 144.35 47.67 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.104 2.162 . . . . 10.0 111.674 -172.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.98 163.13 31.44 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.039 1.735 . . . . 10.0 111.043 168.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -142.26 140.44 32.24 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.16 0.984 . . . . 10.0 111.492 -175.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -126.93 156.69 41.09 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 126.097 1.759 . . . . 10.0 110.841 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.8 m -145.3 146.62 31.71 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 124.761 1.224 . . . . 10.0 111.682 -171.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.59 161.65 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 125.894 1.678 . . . . 10.0 110.848 169.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.2 tt0 -116.75 128.52 55.39 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.583 1.153 . . . . 10.0 110.466 170.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.9 tp -118.55 104.15 10.39 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 126.003 1.721 . . . . 10.0 109.831 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -77.99 138.74 38.99 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.23 0.612 . . . . 10.0 110.108 163.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 27.8 t -117.01 105.16 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.051 0.94 . . . . 10.0 109.157 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.8 mt -67.62 97.71 0.63 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.535 1.934 . . . . 10.0 109.869 179.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.769 0 C-N-CA 124.382 1.073 . . . . 10.0 112.683 -179.385 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 N-CA-C 113.101 0.385 . . . . 10.0 113.101 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -66.86 150.84 83.12 Favored 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 122.784 2.322 . . . . 10.0 111.064 168.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 64.2 ttt-85 -138.54 153.74 48.73 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.317 1.447 . . . . 10.0 111.62 -177.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.95 117.2 9.5 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.614 1.166 . . . . 10.0 111.052 169.29 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.32 -57.78 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.102 1.361 . . . . 10.0 110.368 176.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -149.53 137.15 20.17 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.847 1.259 . . . . 10.0 111.547 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -131.96 153.82 81.52 Favored Pre-proline 0 N--CA 1.474 0.736 0 C-N-CA 126.488 1.915 . . . . 10.0 110.028 170.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.75 162.91 36.8 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.627 2.218 . . . . 10.0 111.433 171.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.13 179.92 2.61 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.629 0.772 . . . . 10.0 110.738 161.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -58.11 142.68 46.32 Favored 'General case' 0 CA--C 1.546 0.82 0 O-C-N 120.506 -1.372 . . . . 10.0 111.156 166.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 89.9 mtp -122.53 157.33 32.27 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 125.484 1.513 . . . . 10.0 111.937 -172.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 57.8 p -144.38 129.62 18.73 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.295 1.438 . . . . 10.0 110.691 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.9 mm -134.51 133.97 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.7 1.6 . . . . 10.0 109.288 -170.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -63.94 130.83 45.67 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.616 1.166 . . . . 10.0 112.171 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -52.28 126.69 19.74 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.01 1.324 . . . . 10.0 112.509 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.0 61.46 Favored Glycine 0 CA--C 1.537 1.423 0 C-N-CA 125.842 1.687 . . . . 10.0 115.22 179.033 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -72.72 160.59 31.96 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.379 1.59 . . . . 10.0 113.105 175.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -72.67 149.38 43.9 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 124.488 1.115 . . . . 10.0 110.513 157.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 34.6 t -148.78 157.0 43.13 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.461 1.104 . . . . 10.0 111.272 167.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . 0.808 HH21 ' HG ' ' A' ' 307' ' ' SER . 9.6 ptm180 -144.73 154.47 42.77 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.003 1.321 . . . . 10.0 111.503 164.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.3 mtt -125.61 113.25 17.14 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 125.718 1.607 . . . . 10.0 111.107 -173.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -69.65 127.53 33.27 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.426 1.49 . . . . 10.0 112.766 174.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -137.97 93.82 2.81 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.105 1.362 . . . . 10.0 110.976 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -67.38 121.25 15.34 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.551 0.741 . . . . 10.0 110.124 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.8 p -135.17 115.59 18.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 126.859 2.064 . . . . 10.0 110.189 -173.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 66.2 m -126.98 107.25 9.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.892 1.277 . . . . 10.0 111.59 -173.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -156.15 167.58 33.38 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 127.166 2.317 . . . . 10.0 110.927 169.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -142.14 125.58 9.63 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 124.417 1.087 . . . . 10.0 110.686 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -66.06 168.06 49.72 Favored 'Cis proline' 0 CA--C 1.539 0.763 0 CA-C-N 120.622 1.258 . . . . 10.0 112.453 -2.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 123.45 57.07 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 124.348 1.059 . . . . 10.0 111.264 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.83 149.21 66.14 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.428 2.085 . . . . 10.0 112.999 -172.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -72.1 139.19 48.27 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.263 1.025 . . . . 10.0 109.535 161.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.36 142.05 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.266 1.027 . . . . 10.0 113.136 -172.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.7 m -141.39 115.34 9.2 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 125.841 1.657 . . . . 10.0 111.195 -176.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 71.1 m95 -84.07 151.22 25.08 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 122.2 1.0 . . . . 10.0 113.43 176.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -141.3 161.3 38.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 128.249 2.619 . . . . 10.0 110.776 -179.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.1 tp -147.09 119.78 8.59 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.431 2.292 . . . . 10.0 110.041 176.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 55.02 15.29 1.14 Allowed 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 126.581 1.952 . . . . 10.0 115.045 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.33 -12.53 40.01 Favored Glycine 0 CA--C 1.539 1.564 0 C-N-CA 126.607 2.051 . . . . 10.0 115.104 -177.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -87.67 158.33 18.86 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 119.008 1.404 . . . . 10.0 110.824 170.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.8 p -71.25 158.32 36.59 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.99 0.916 . . . . 10.0 112.345 173.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 40.1 t -134.62 100.82 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.844 1.658 . . . . 10.0 108.779 171.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -71.43 156.22 39.72 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.346 0.658 . . . . 10.0 110.693 170.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.0 p -70.08 151.96 44.9 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 121.559 -0.713 . . . . 10.0 111.908 170.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -152.74 -177.49 6.29 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.051 1.34 . . . . 10.0 111.949 171.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -60.3 -22.75 63.54 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 114.64 1.348 . . . . 10.0 114.64 -177.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 52.9 mt -104.19 -26.19 12.63 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.866 1.666 . . . . 10.0 112.67 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -110.9 74.14 0.86 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.416 1.886 . . . . 10.0 111.052 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 92.2 mttt -77.21 146.31 37.07 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.691 1.196 . . . . 10.0 111.175 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.1 mtt -145.34 102.51 3.73 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 126.06 1.744 . . . . 10.0 110.281 -170.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.91 163.25 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 124.505 1.122 . . . . 10.0 112.468 178.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 54.7 t -121.38 112.58 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.536 1.934 . . . . 10.0 109.266 174.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 74.7 m -69.25 151.51 46.18 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.76 0.824 . . . . 10.0 111.552 173.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -57.96 -19.68 32.2 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 115.346 1.61 . . . . 10.0 115.346 -174.366 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -75.97 -4.0 38.72 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.763 1.625 . . . . 10.0 113.994 178.104 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.09 48.92 4.43 Favored Glycine 0 CA--C 1.531 1.071 0 C-N-CA 125.161 1.363 . . . . 10.0 112.139 -175.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 51.5 tp -136.82 103.56 5.22 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.571 1.549 . . . . 10.0 110.642 -171.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 23.7 t60 -70.45 147.27 49.64 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 122.032 -0.418 . . . . 10.0 110.46 166.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 307' ' ' SER . . . . . 0.808 ' HG ' HH21 ' A' ' 268' ' ' ARG . 5.5 t -135.94 99.53 4.18 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.016 1.326 . . . . 10.0 111.204 176.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -81.86 120.28 24.99 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.485 1.514 . . . . 10.0 108.884 173.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 42.6 mt -115.55 151.6 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 125.125 1.37 . . . . 10.0 111.514 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -129.25 108.04 10.02 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.954 2.502 . . . . 10.0 109.258 170.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -63.94 -42.0 97.47 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.194 -0.942 . . . . 10.0 112.845 175.015 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.47 90.88 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.863 1.665 . . . . 10.0 110.121 -179.226 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.7 140.89 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.296 -0.878 . . . . 10.0 112.212 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -120.86 160.76 22.77 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.454 1.901 . . . . 10.0 112.057 176.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.86 -30.81 66.1 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 113.617 0.969 . . . . 10.0 113.617 -177.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.6 p -67.85 -15.62 63.71 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.921 1.689 . . . . 10.0 114.788 173.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -83.05 -5.08 58.97 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.599 1.16 . . . . 10.0 113.486 176.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.66 151.75 44.07 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.012 -1.055 . . . . 10.0 113.063 177.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.31 -173.07 22.67 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.915 1.245 . . . . 10.0 114.837 176.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -87.6 101.28 13.48 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.9 1.68 . . . . 10.0 111.274 176.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -78.37 151.78 32.65 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.295 1.038 . . . . 10.0 111.972 169.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.8 157.31 43.93 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.246 1.018 . . . . 10.0 112.109 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.6 t -134.97 104.89 6.14 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.645 1.578 . . . . 10.0 110.925 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.1 t -71.42 134.53 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 123.916 0.886 . . . . 10.0 109.131 168.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -133.51 119.46 19.56 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.756 2.023 . . . . 10.0 110.27 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.3 mtpt -134.4 136.06 43.05 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.79 1.236 . . . . 10.0 113.018 -170.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 24.9 p30 -132.51 -178.36 4.89 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.061 1.344 . . . . 10.0 111.547 167.093 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.1 ptm180 -60.97 -14.84 25.45 Favored 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 115.482 1.66 . . . . 10.0 115.482 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.03 -19.65 13.66 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.443 1.497 . . . . 10.0 114.208 -177.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.28 -169.98 42.63 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 116.142 1.217 . . . . 10.0 116.142 177.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -134.54 144.64 48.12 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 127.262 2.225 . . . . 10.0 111.664 -170.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.88 159.91 40.71 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 126.214 1.806 . . . . 10.0 110.794 167.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 32.8 m -140.35 101.14 4.05 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 124.457 1.103 . . . . 10.0 110.733 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -77.66 155.56 31.3 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.777 1.231 . . . . 10.0 111.254 175.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 28.3 m -146.98 146.35 30.05 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.728 1.211 . . . . 10.0 112.057 -174.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.3 p -154.3 145.99 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 125.819 1.648 . . . . 10.0 111.934 170.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -100.45 135.46 41.85 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.611 1.165 . . . . 10.0 110.929 170.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.1 tp -122.39 112.4 18.04 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.98 1.712 . . . . 10.0 111.026 177.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -100.0 85.22 3.01 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.942 1.697 . . . . 10.0 110.834 175.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -64.94 114.49 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.954 0.902 . . . . 10.0 110.684 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.6 mt -75.81 99.78 4.55 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.154 1.781 . . . . 10.0 110.042 179.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.861 0 C-N-CA 124.304 1.042 . . . . 10.0 113.525 -175.682 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo . . . . . 0 CA--C 1.543 0.932 0 N-CA-C 113.161 0.408 . . . . 10.0 113.161 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -67.05 158.78 55.17 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.861 2.374 . . . . 10.0 111.32 168.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.7 tpt85 -135.1 151.44 50.72 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.007 1.323 . . . . 10.0 111.772 -174.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -79.01 65.4 4.17 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 127.251 2.22 . . . . 10.0 111.812 -176.356 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 39.8 mm -63.16 -62.35 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 O-C-N 121.225 -0.922 . . . . 10.0 112.635 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -153.16 149.67 28.27 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.822 0.849 . . . . 10.0 112.59 -178.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.2 m -134.44 151.11 75.56 Favored Pre-proline 0 N--CA 1.477 0.925 0 C-N-CA 126.405 1.882 . . . . 10.0 110.558 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -74.65 159.77 42.06 Favored 'Trans proline' 0 CA--C 1.542 0.916 0 C-N-CA 123.049 2.499 . . . . 10.0 111.596 168.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -77.24 172.61 13.0 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 123.942 0.897 . . . . 10.0 111.542 167.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -49.61 108.86 0.23 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.416 1.486 . . . . 10.0 113.594 178.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.3 mtp -82.41 155.66 24.56 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.349 1.46 . . . . 10.0 112.008 -177.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 71.2 p -140.36 131.81 26.91 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.964 1.306 . . . . 10.0 111.023 170.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.2 mm -137.08 129.46 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.385 1.474 . . . . 10.0 109.94 -170.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -62.26 127.61 32.17 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.785 1.234 . . . . 10.0 112.169 172.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -52.82 135.02 36.59 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.289 1.435 . . . . 10.0 113.171 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.12 -11.27 69.45 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.046 1.784 . . . . 10.0 114.952 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.9 mtp-105 -77.63 162.73 26.82 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 118.989 1.394 . . . . 10.0 113.162 177.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -71.71 151.98 43.17 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.884 1.273 . . . . 10.0 110.763 158.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 36.0 t -148.41 156.83 42.98 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.496 1.118 . . . . 10.0 111.474 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -135.76 139.98 43.97 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 125.516 1.526 . . . . 10.0 110.858 162.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 43.9 mtt -100.77 155.39 17.94 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.801 1.641 . . . . 10.0 109.818 167.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -139.57 118.32 12.37 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.157 1.383 . . . . 10.0 110.984 -170.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -130.52 106.84 8.78 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 125.992 1.717 . . . . 10.0 111.952 -170.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -65.93 127.64 32.84 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.902 0.881 . . . . 10.0 110.52 173.126 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.1 125.34 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.642 1.577 . . . . 10.0 110.769 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 69.4 m -133.21 115.3 14.84 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.674 1.19 . . . . 10.0 111.907 -173.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -161.69 169.76 37.23 Favored Glycine 0 CA--C 1.536 1.393 0 C-N-CA 127.161 2.315 . . . . 10.0 111.381 172.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -143.7 125.3 8.24 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.09 0.956 . . . . 10.0 111.194 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.01 167.64 51.14 Favored 'Cis proline' 0 CA--C 1.539 0.744 0 CA-C-N 120.866 1.345 . . . . 10.0 112.476 -2.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.11 122.32 47.31 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.404 1.081 . . . . 10.0 111.231 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -69.34 148.59 68.16 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.42 2.08 . . . . 10.0 112.922 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -72.06 145.73 48.06 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.143 0.977 . . . . 10.0 109.736 161.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.98 139.72 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.556 1.142 . . . . 10.0 112.575 -172.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 73.2 m -136.81 142.12 42.91 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 126.024 1.729 . . . . 10.0 110.672 177.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -111.86 158.05 19.88 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.474 1.11 . . . . 10.0 113.278 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -145.69 159.57 42.96 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 127.256 2.222 . . . . 10.0 111.329 -174.15 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.4 tp -147.19 119.52 8.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.054 2.142 . . . . 10.0 110.0 175.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 55.26 14.05 0.98 Allowed 'General case' 0 CA--C 1.554 1.106 0 C-N-CA 126.537 1.935 . . . . 10.0 115.376 179.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.17 -12.22 31.4 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.564 2.031 . . . . 10.0 115.182 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -89.9 160.68 16.32 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 118.924 1.362 . . . . 10.0 110.978 169.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.5 p -73.99 158.92 33.48 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.369 1.067 . . . . 10.0 112.752 175.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 87.6 t -136.82 104.98 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 127.097 2.159 . . . . 10.0 108.623 173.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -79.68 161.54 25.77 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.417 0.687 . . . . 10.0 111.131 170.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.9 p -70.27 148.02 49.03 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.564 0.746 . . . . 10.0 112.211 171.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -152.61 -179.93 8.04 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 125.365 1.466 . . . . 10.0 111.328 168.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -57.97 -27.53 63.53 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.698 1.37 . . . . 10.0 114.698 -176.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 57.2 mt -93.11 -13.97 27.84 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.23 1.412 . . . . 10.0 113.084 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -131.97 68.82 1.49 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.545 1.938 . . . . 10.0 111.204 -172.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -72.9 146.61 46.02 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.092 1.357 . . . . 10.0 111.321 -179.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -139.2 110.35 6.89 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 126.547 1.939 . . . . 10.0 110.278 -172.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.26 162.78 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 125.079 1.351 . . . . 10.0 112.212 -177.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.4 t -129.8 104.09 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.518 1.527 . . . . 10.0 109.491 177.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 70.8 m -73.05 166.32 23.33 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 125.063 1.345 . . . . 10.0 112.804 177.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.07 158.52 6.73 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.292 1.437 . . . . 10.0 112.323 175.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt 64.8 9.64 5.45 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 127.392 2.277 . . . . 10.0 114.782 -172.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.2 62.74 1.86 Allowed Glycine 0 CA--C 1.53 1.027 0 C-N-CA 125.178 1.371 . . . . 10.0 113.491 173.235 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 43.2 tp -131.03 99.86 5.04 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.027 1.331 . . . . 10.0 111.09 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -76.68 133.95 39.39 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.923 0.889 . . . . 10.0 110.739 172.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 49.4 m -121.01 141.23 50.92 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.574 1.55 . . . . 10.0 111.434 178.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -133.2 115.78 15.43 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 126.788 2.035 . . . . 10.0 108.641 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 49.5 mt -105.35 154.36 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 124.83 1.252 . . . . 10.0 111.836 -168.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -130.4 107.51 9.3 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.496 2.318 . . . . 10.0 109.019 167.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 -63.77 -42.83 97.72 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.256 -0.902 . . . . 10.0 113.049 178.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 3.5 p -151.66 91.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 125.845 1.658 . . . . 10.0 110.233 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -74.63 142.47 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 O-C-N 121.368 -0.833 . . . . 10.0 112.123 -177.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -129.02 163.26 25.77 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 126.408 1.883 . . . . 10.0 111.394 177.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.5 -31.72 62.28 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -174.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.0 m -67.75 -16.31 64.06 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 114.166 1.173 . . . . 10.0 114.166 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -83.87 -5.98 59.33 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.732 1.213 . . . . 10.0 113.48 178.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.04 151.69 42.31 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 120.985 -1.072 . . . . 10.0 113.1 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 140.11 -174.0 22.68 Favored Glycine 0 CA--C 1.533 1.161 0 C-N-CA 124.317 0.96 . . . . 10.0 114.993 176.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 98.53 9.24 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.888 1.675 . . . . 10.0 111.367 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -76.37 146.92 38.41 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.016 0.926 . . . . 10.0 111.386 168.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.4 160.32 41.25 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.595 0.758 . . . . 10.0 112.425 169.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.0 t -133.39 142.28 48.29 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.091 2.156 . . . . 10.0 109.841 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.29 124.5 71.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.536 1.534 . . . . 10.0 108.72 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.39 124.48 51.3 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.374 1.87 . . . . 10.0 110.451 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -134.16 134.95 42.74 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.01 1.324 . . . . 10.0 112.543 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -130.87 -178.24 4.72 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 124.624 1.17 . . . . 10.0 111.55 166.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 -60.14 -12.61 8.92 Favored 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 115.804 1.779 . . . . 10.0 115.804 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.45 -16.19 13.38 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.381 1.472 . . . . 10.0 114.525 -178.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.78 -168.83 40.92 Favored Glycine 0 CA--C 1.533 1.217 0 CA-C-N 119.884 1.22 . . . . 10.0 116.124 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -134.11 145.78 49.65 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 127.117 2.167 . . . . 10.0 111.878 -170.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.75 161.02 37.12 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.133 1.773 . . . . 10.0 111.205 168.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 60.8 m -137.11 141.92 42.3 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.084 1.354 . . . . 10.0 110.966 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -135.98 137.04 40.86 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.595 1.558 . . . . 10.0 110.056 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.5 m -141.65 143.7 33.76 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.797 0.839 . . . . 10.0 112.049 -167.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.6 p -152.36 142.51 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 125.279 1.431 . . . . 10.0 111.947 171.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -90.34 136.25 33.17 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.996 0.918 . . . . 10.0 110.751 168.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.6 tp -118.82 104.22 10.36 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.879 1.672 . . . . 10.0 110.909 178.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -84.63 88.3 7.33 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.036 1.334 . . . . 10.0 110.846 170.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.78 108.04 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.228 -0.92 . . . . 10.0 109.84 174.055 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.9 mt -73.96 97.03 2.74 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.072 1.749 . . . . 10.0 109.852 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.796 0 C-N-CA 124.65 1.18 . . . . 10.0 113.754 -174.825 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 CA--C 1.543 0.953 0 N-CA-C 113.228 0.434 . . . . 10.0 113.228 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -63.99 139.13 66.02 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.963 2.442 . . . . 10.0 110.795 172.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 76.4 ttt-85 -139.41 141.41 37.52 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.39 1.076 . . . . 10.0 113.568 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -59.19 118.88 6.4 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.352 2.261 . . . . 10.0 111.912 171.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.6 -52.75 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.262 1.025 . . . . 10.0 110.001 165.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 40.1 tt0 -150.57 134.86 17.06 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.649 1.18 . . . . 10.0 111.145 176.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 31.7 m -119.35 152.78 53.12 Favored Pre-proline 0 N--CA 1.475 0.791 0 C-N-CA 126.0 1.72 . . . . 10.0 109.266 168.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -75.73 163.77 33.17 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.599 2.2 . . . . 10.0 112.211 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.52 170.77 14.47 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.484 -0.76 . . . . 10.0 110.79 163.091 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.6 p30 -61.18 157.69 15.58 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.167 -0.958 . . . . 10.0 111.867 169.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -127.2 151.92 48.05 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.592 1.557 . . . . 10.0 111.664 -170.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -143.67 84.64 1.8 Allowed 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.304 1.442 . . . . 10.0 111.183 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 40.4 mm -102.41 136.56 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.304 1.441 . . . . 10.0 110.593 -170.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -66.92 129.15 38.96 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.441 1.096 . . . . 10.0 112.414 175.126 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -53.92 128.09 28.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.169 1.388 . . . . 10.0 112.704 178.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 104.7 -13.19 50.38 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 126.564 2.031 . . . . 10.0 114.651 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -77.43 161.86 27.65 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 118.775 1.288 . . . . 10.0 113.577 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -75.32 144.08 42.58 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.683 1.193 . . . . 10.0 110.433 155.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.72 172.36 16.23 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 123.686 0.794 . . . . 10.0 112.394 159.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . 0.89 HH21 ' HG ' ' A' ' 307' ' ' SER . 16.4 ptm180 -147.18 168.3 22.01 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.397 1.479 . . . . 10.0 112.516 173.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 45.8 mtt -118.03 165.88 13.2 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 126.508 1.923 . . . . 10.0 111.7 176.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -142.62 107.95 5.02 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.586 1.555 . . . . 10.0 112.448 -171.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -125.7 101.44 6.88 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 126.489 1.916 . . . . 10.0 111.128 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -76.59 111.2 11.82 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.118 -0.989 . . . . 10.0 109.685 172.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -123.76 102.16 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 125.666 1.586 . . . . 10.0 110.481 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 12.3 t -73.76 173.08 10.35 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.725 0.81 . . . . 10.0 111.357 171.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 124.16 162.89 11.56 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 127.076 2.274 . . . . 10.0 112.431 -176.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -152.52 130.84 6.28 Favored Pre-proline 0 CA--C 1.547 0.835 0 C-N-CA 124.393 1.077 . . . . 10.0 110.828 -177.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -67.89 169.25 54.77 Favored 'Cis proline' 0 CA--C 1.539 0.762 0 CA-C-N 120.891 1.354 . . . . 10.0 112.735 -2.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.04 122.19 46.05 Favored Pre-proline 0 CA--C 1.549 0.917 0 C-N-CA 124.658 1.183 . . . . 10.0 111.038 178.043 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.1 151.0 61.0 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 122.483 2.122 . . . . 10.0 113.295 -170.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 150.45 47.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.158 0.983 . . . . 10.0 109.531 157.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 p -138.48 143.85 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 113.269 0.84 . . . . 10.0 113.269 -174.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 21.6 m -127.12 151.7 48.3 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.901 2.081 . . . . 10.0 110.353 173.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 34.9 m95 -125.51 157.59 36.65 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.282 1.033 . . . . 10.0 112.865 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 74.9 m-85 -147.16 160.13 42.8 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 126.309 1.844 . . . . 10.0 111.553 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.8 tp -148.45 124.77 10.88 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 127.38 2.272 . . . . 10.0 110.121 176.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 53.42 14.18 0.53 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.845 2.058 . . . . 10.0 116.202 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.2 0.49 25.23 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.732 1.634 . . . . 10.0 115.962 -179.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.4 ptp85 -122.21 166.55 14.44 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 125.769 1.628 . . . . 10.0 112.319 173.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 20.1 p -71.58 158.85 35.47 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.835 1.254 . . . . 10.0 113.674 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 97.1 t -136.84 142.52 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 128.069 2.547 . . . . 10.0 108.299 171.037 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.2 mt-30 -128.93 163.67 24.8 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.151 1.38 . . . . 10.0 111.344 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 52.9 p -66.67 148.54 51.77 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.616 0.766 . . . . 10.0 112.383 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -152.44 167.27 29.3 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.727 1.611 . . . . 10.0 110.824 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -56.63 -34.93 67.75 Favored 'General case' 0 CA--C 1.546 0.796 0 O-C-N 121.005 -1.06 . . . . 10.0 112.963 170.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 82.9 mt -84.84 -14.74 47.04 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.527 1.131 . . . . 10.0 113.902 174.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.83 70.52 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.546 1.538 . . . . 10.0 111.371 -172.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.57 147.7 48.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.591 1.156 . . . . 10.0 111.517 -176.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -134.36 107.09 7.42 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 126.927 2.091 . . . . 10.0 109.467 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.31 161.32 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.429 -176.113 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 19.7 t -135.75 120.19 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 125.882 1.673 . . . . 10.0 109.509 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 22.6 t -64.33 160.32 19.12 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.439 1.096 . . . . 10.0 112.341 175.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -51.8 -35.48 44.32 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.781 1.633 . . . . 10.0 112.579 173.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 44.8 mmtm -82.15 -0.7 46.09 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.022 1.729 . . . . 10.0 114.704 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.52 8.65 65.65 Favored Glycine 0 CA--C 1.538 1.479 0 C-N-CA 124.987 1.28 . . . . 10.0 115.345 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 50.3 tp -76.7 102.01 6.03 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.71 1.204 . . . . 10.0 110.699 171.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -78.29 144.21 36.33 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.36 1.064 . . . . 10.0 111.085 168.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 307' ' ' SER . . . . . 0.89 ' HG ' HH21 ' A' ' 268' ' ' ARG . 17.2 m -135.37 155.14 51.07 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.174 1.39 . . . . 10.0 112.833 173.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.05 116.09 15.07 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 128.122 2.569 . . . . 10.0 107.949 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -98.61 154.79 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.405 1.482 . . . . 10.0 111.26 -171.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -130.6 104.91 7.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.127 2.171 . . . . 10.0 108.831 164.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.8 mm-40 -64.0 -37.09 86.15 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.287 -0.883 . . . . 10.0 113.023 178.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.0 p -150.61 91.66 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 125.816 1.646 . . . . 10.0 110.3 177.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.29 139.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 121.3 -0.875 . . . . 10.0 112.194 -176.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -125.9 161.05 28.33 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 126.853 2.061 . . . . 10.0 111.112 176.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.37 -29.64 64.21 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.716 1.206 . . . . 10.0 113.74 -177.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 39.5 p -67.08 -17.07 64.72 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 125.477 1.511 . . . . 10.0 114.597 173.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -82.27 -6.49 59.27 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.7 1.2 . . . . 10.0 113.256 174.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.56 152.45 45.25 Favored 'General case' 0 CA--C 1.546 0.806 0 O-C-N 120.912 -1.117 . . . . 10.0 113.403 -178.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 133.14 -170.21 22.3 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.79 1.186 . . . . 10.0 115.147 174.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.66 105.64 16.37 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.052 1.741 . . . . 10.0 111.197 177.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -81.38 153.75 26.81 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.378 1.071 . . . . 10.0 111.769 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.01 159.09 42.96 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.016 0.927 . . . . 10.0 112.006 167.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 37.6 t -138.81 127.19 22.96 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 127.052 2.141 . . . . 10.0 109.248 -173.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.8 t -122.68 113.09 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.26 1.424 . . . . 10.0 109.49 -175.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -108.44 135.17 50.18 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.64 1.576 . . . . 10.0 111.231 -177.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.28 133.71 37.25 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.735 1.614 . . . . 10.0 111.763 -171.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -135.1 179.99 5.98 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.148 0.979 . . . . 10.0 111.99 166.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -61.32 -9.37 5.1 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 115.83 1.789 . . . . 10.0 115.83 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.84 -12.62 13.29 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 125.823 1.649 . . . . 10.0 114.332 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.77 -170.49 40.59 Favored Glycine 0 CA--C 1.535 1.343 0 CA-C-N 120.02 1.282 . . . . 10.0 115.949 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -135.43 147.56 49.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.858 2.063 . . . . 10.0 111.487 -176.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -141.06 158.36 44.04 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.629 1.572 . . . . 10.0 111.93 172.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 85.4 m -136.71 130.59 32.29 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.096 1.358 . . . . 10.0 111.148 -176.354 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -123.87 156.35 36.4 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.496 1.918 . . . . 10.0 110.815 -178.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.2 m -142.85 145.6 33.3 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 124.463 1.105 . . . . 10.0 111.559 -169.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.0 p -151.59 159.1 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 125.894 1.678 . . . . 10.0 110.85 172.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -121.83 137.17 54.88 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.808 1.243 . . . . 10.0 111.015 176.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.2 tp -124.65 105.3 9.22 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 126.359 1.864 . . . . 10.0 110.277 -178.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -93.97 80.35 4.12 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.676 1.59 . . . . 10.0 110.809 176.342 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -62.3 115.27 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.701 0.8 . . . . 10.0 110.95 -178.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.1 mt -76.03 97.38 4.02 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.702 1.601 . . . . 10.0 109.792 178.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.856 0 C-N-CA 124.731 1.212 . . . . 10.0 113.962 -173.185 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo . . . . . 0 CA--C 1.543 0.949 0 N-CA-C 113.045 0.363 . . . . 10.0 113.045 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -70.92 167.56 25.59 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.231 2.62 . . . . 10.0 112.58 173.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -135.42 156.75 48.41 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.223 1.409 . . . . 10.0 112.703 -171.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -96.94 74.37 2.62 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.161 2.185 . . . . 10.0 110.695 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.5 mp -76.05 -71.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.134 -0.979 . . . . 10.0 112.322 -173.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -152.13 143.47 23.34 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.983 0.913 . . . . 10.0 112.281 -174.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.91 152.55 54.1 Favored Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 126.295 1.838 . . . . 10.0 110.57 172.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -74.29 160.84 41.57 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.768 2.312 . . . . 10.0 111.348 172.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -72.16 165.7 23.83 Favored 'General case' 0 CA--C 1.543 0.711 0 O-C-N 121.452 -0.78 . . . . 10.0 111.551 169.217 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -62.19 158.05 17.87 Favored 'General case' 0 CA--C 1.546 0.792 0 O-C-N 121.453 -0.779 . . . . 10.0 112.433 174.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 46.5 mtm -130.15 162.32 29.13 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.318 1.047 . . . . 10.0 112.912 -178.013 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -139.83 96.37 3.06 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.862 2.065 . . . . 10.0 110.482 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.1 mm -112.74 133.29 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 124.594 1.158 . . . . 10.0 111.214 -166.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -60.15 126.93 29.42 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.439 1.496 . . . . 10.0 112.456 172.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -55.18 127.13 27.76 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.273 1.029 . . . . 10.0 112.18 -178.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.92 -10.43 58.67 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 126.004 1.764 . . . . 10.0 114.955 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -73.93 161.19 30.37 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 119.362 1.581 . . . . 10.0 113.333 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -75.98 140.32 41.96 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.328 1.451 . . . . 10.0 110.264 157.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.48 166.3 31.54 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.702 0.801 . . . . 10.0 112.598 165.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm85 -141.69 168.0 20.81 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.88 1.272 . . . . 10.0 113.744 175.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 52.3 mtt -131.76 160.29 35.97 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 127.317 2.247 . . . . 10.0 111.01 175.231 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -140.96 103.52 4.49 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.442 1.497 . . . . 10.0 111.932 -168.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 -113.85 121.59 44.47 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.849 1.66 . . . . 10.0 111.677 -176.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.7 mtpp -77.48 127.35 32.37 Favored 'General case' 0 N--CA 1.478 0.955 0 O-C-N 121.382 -0.824 . . . . 10.0 110.887 173.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.7 p -138.96 145.12 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.596 1.558 . . . . 10.0 111.053 -179.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.9 t -142.99 -176.06 4.76 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.63 1.572 . . . . 10.0 110.886 178.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 118.42 164.49 13.0 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 127.519 2.485 . . . . 10.0 112.005 -172.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.5 tp -147.27 129.08 7.44 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 123.975 0.91 . . . . 10.0 110.785 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.4 169.15 47.01 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 CA-C-N 120.784 1.316 . . . . 10.0 112.373 -3.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.76 53.23 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 124.498 1.119 . . . . 10.0 111.102 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -69.33 150.44 70.82 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.398 2.065 . . . . 10.0 113.049 -172.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -70.4 140.71 52.14 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.129 0.972 . . . . 10.0 109.456 159.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 m -129.01 137.9 55.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.323 1.049 . . . . 10.0 112.521 -170.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 72.2 m -132.92 152.8 51.85 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.165 1.786 . . . . 10.0 110.861 177.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -128.15 152.86 47.52 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.85 1.26 . . . . 10.0 112.765 -175.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -145.48 158.32 43.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 126.08 1.752 . . . . 10.0 111.68 -171.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.8 tp -148.16 123.33 10.17 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.187 2.195 . . . . 10.0 109.875 177.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 54.22 11.0 0.34 Allowed 'General case' 0 CA--C 1.556 1.192 0 N-CA-C 116.571 2.063 . . . . 10.0 116.571 173.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 116.05 -0.64 21.11 Favored Glycine 0 CA--C 1.54 1.608 0 C-N-CA 125.802 1.668 . . . . 10.0 115.875 -178.239 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -119.41 166.45 13.05 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 125.865 1.666 . . . . 10.0 112.108 172.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.1 p -72.49 161.17 31.15 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.756 1.222 . . . . 10.0 113.131 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.92 91.97 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.878 2.071 . . . . 10.0 108.703 173.207 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -69.31 145.34 53.11 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 123.254 0.622 . . . . 10.0 110.661 171.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 44.1 p -73.77 153.93 39.79 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.453 0.701 . . . . 10.0 112.542 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.69 -172.91 4.24 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.527 1.931 . . . . 10.0 111.676 175.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -61.55 -17.76 56.3 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.984 1.475 . . . . 10.0 114.984 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.4 mt -113.26 -18.84 11.98 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 126.285 1.834 . . . . 10.0 113.423 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.9 m80 -121.0 93.38 4.01 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.947 2.099 . . . . 10.0 109.923 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.9 mttt -106.7 121.33 44.14 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.444 1.098 . . . . 10.0 110.79 -169.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -128.71 100.57 5.77 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.258 1.423 . . . . 10.0 110.375 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.18 161.65 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 125.888 1.675 . . . . 10.0 111.934 -174.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.93 167.04 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 125.686 1.594 . . . . 10.0 112.12 -178.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.8 t -133.85 149.55 51.36 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.648 1.579 . . . . 10.0 112.046 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.86 -19.54 42.81 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.904 1.682 . . . . 10.0 114.156 175.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -76.74 -2.23 31.97 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 125.622 1.569 . . . . 10.0 114.142 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.0 46.27 6.0 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.816 1.198 . . . . 10.0 112.703 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 11.6 tp -137.94 150.59 47.18 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.257 1.423 . . . . 10.0 111.265 -174.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -130.81 123.84 29.99 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.767 2.027 . . . . 10.0 109.893 174.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 48.3 m -94.49 156.02 16.66 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.339 1.056 . . . . 10.0 112.506 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.92 116.46 15.62 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.368 1.867 . . . . 10.0 107.205 162.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.36 133.86 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.819 1.248 . . . . 10.0 110.636 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -109.69 108.77 19.28 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.975 2.11 . . . . 10.0 108.916 171.742 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -64.19 -37.74 88.54 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 121.489 -0.757 . . . . 10.0 112.817 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.4 p -151.07 89.45 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.154 1.782 . . . . 10.0 109.918 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -66.32 138.29 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 O-C-N 121.232 -0.918 . . . . 10.0 111.742 -178.081 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.7 mmt180 -121.32 160.35 24.16 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 126.021 1.728 . . . . 10.0 112.208 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.97 -34.37 65.65 Favored 'General case' 0 CA--C 1.546 0.81 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -176.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 19.9 m -65.51 -16.47 63.7 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.498 1.519 . . . . 10.0 114.555 175.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -82.18 -7.48 59.62 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.649 1.179 . . . . 10.0 113.311 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.52 147.33 53.03 Favored 'General case' 0 CA--C 1.546 0.815 0 O-C-N 121.185 -0.947 . . . . 10.0 112.926 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.94 -170.79 23.02 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 124.512 1.053 . . . . 10.0 115.347 175.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.97 107.03 15.28 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.994 1.718 . . . . 10.0 111.326 177.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -83.3 151.13 25.73 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.386 1.075 . . . . 10.0 111.776 170.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.27 160.38 40.59 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 10.0 112.309 169.115 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -133.02 145.84 51.2 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 126.416 1.886 . . . . 10.0 110.027 175.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 66.6 t -127.73 129.15 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 125.624 1.569 . . . . 10.0 108.882 175.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -122.4 120.79 35.0 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.574 1.95 . . . . 10.0 110.469 -175.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -131.56 134.48 46.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.305 1.442 . . . . 10.0 112.11 -171.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -130.63 -178.23 4.69 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.472 1.109 . . . . 10.0 111.645 168.182 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -60.03 -11.3 5.53 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 115.788 1.773 . . . . 10.0 115.788 -179.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.97 -18.48 11.24 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.417 1.487 . . . . 10.0 114.654 -177.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.53 -170.13 43.2 Favored Glycine 0 CA--C 1.534 1.22 0 CA-C-N 120.034 1.288 . . . . 10.0 116.314 179.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.12 143.6 46.66 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.172 2.189 . . . . 10.0 111.764 -172.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.75 160.18 38.99 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.167 1.787 . . . . 10.0 111.173 168.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.4 m -138.89 145.26 39.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 125.229 1.412 . . . . 10.0 110.871 -175.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -136.48 152.92 51.08 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.33 1.452 . . . . 10.0 111.102 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.8 m -145.16 145.88 31.55 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.567 1.147 . . . . 10.0 111.762 -172.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -152.79 171.82 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 126.36 1.864 . . . . 10.0 110.734 171.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -128.53 142.98 50.9 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.755 1.222 . . . . 10.0 111.404 173.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.0 tp -127.36 109.13 11.47 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.04 1.736 . . . . 10.0 110.128 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -78.88 141.89 37.27 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.935 -0.478 . . . . 10.0 110.035 160.091 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 40.0 t -120.5 106.53 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.458 1.103 . . . . 10.0 108.752 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.5 mt -69.37 96.78 0.9 Allowed 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.222 1.809 . . . . 10.0 109.288 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.792 0 C-N-CA 124.954 1.302 . . . . 10.0 114.259 -167.554 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 CA--C 1.543 0.947 0 N-CA-C 112.934 0.321 . . . . 10.0 112.934 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -65.85 145.0 79.27 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 123.017 2.478 . . . . 10.0 111.228 169.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -136.28 147.82 47.68 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.569 1.548 . . . . 10.0 112.384 -175.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -61.22 110.07 1.29 Allowed 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.814 2.046 . . . . 10.0 111.502 171.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 46.9 mm -105.46 -63.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.995 0.918 . . . . 10.0 110.285 172.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -153.36 101.88 2.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.311 1.044 . . . . 10.0 111.456 176.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 25.3 m -72.27 150.07 91.84 Favored Pre-proline 0 N--CA 1.476 0.834 0 C-N-CA 123.019 0.528 . . . . 10.0 110.22 161.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -75.72 161.0 37.25 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 122.859 2.373 . . . . 10.0 112.089 177.179 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -73.2 166.66 22.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 123.912 0.885 . . . . 10.0 111.517 168.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -62.01 157.79 17.93 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 121.34 -0.85 . . . . 10.0 112.644 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.0 mtp -132.6 153.41 51.06 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.349 1.459 . . . . 10.0 112.118 -166.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 16.9 p -147.27 100.95 3.34 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.8 1.64 . . . . 10.0 110.947 178.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.3 mm -117.32 138.95 46.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.044 1.337 . . . . 10.0 110.911 -167.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -67.75 132.18 46.95 Favored 'General case' 0 CA--C 1.543 0.688 0 O-C-N 121.359 -0.838 . . . . 10.0 112.311 176.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -54.63 119.49 5.37 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.564 1.545 . . . . 10.0 112.132 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 108.52 -10.8 35.83 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 126.216 1.865 . . . . 10.0 115.191 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -74.01 162.31 29.17 Favored 'General case' 0 N--CA 1.479 0.985 0 CA-C-N 119.224 1.512 . . . . 10.0 113.577 178.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -73.97 147.18 43.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.565 1.146 . . . . 10.0 110.558 158.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 4.3 t -153.72 173.29 16.03 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.212 1.005 . . . . 10.0 112.541 167.373 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -148.57 166.83 27.07 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 126.039 1.736 . . . . 10.0 112.436 166.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.0 mtt -118.15 157.41 26.97 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.617 1.967 . . . . 10.0 111.333 172.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -140.02 95.01 2.83 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.275 1.43 . . . . 10.0 111.579 -167.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -113.1 100.74 8.83 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.426 1.49 . . . . 10.0 111.609 -175.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -73.4 128.97 36.98 Favored 'General case' 0 N--CA 1.477 0.889 0 O-C-N 121.356 -0.84 . . . . 10.0 111.311 175.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.4 p -146.99 138.52 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.632 1.973 . . . . 10.0 110.501 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 70.4 m -125.68 126.33 44.49 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.641 1.176 . . . . 10.0 111.596 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -172.02 169.02 42.16 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 127.12 2.295 . . . . 10.0 111.338 175.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.6 tp -146.69 131.36 8.81 Favored Pre-proline 0 CA--C 1.548 0.901 0 C-N-CA 124.47 1.108 . . . . 10.0 111.105 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -66.91 169.86 46.94 Favored 'Cis proline' 0 CA--C 1.54 0.797 0 CA-C-N 120.533 1.226 . . . . 10.0 112.546 -3.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.17 120.78 32.36 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 124.605 1.162 . . . . 10.0 111.255 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.41 161.49 45.39 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 122.585 2.19 . . . . 10.0 113.221 -172.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -63.85 163.05 12.51 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.844 1.258 . . . . 10.0 111.692 166.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.4 p -139.31 114.97 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.139 1.375 . . . . 10.0 111.525 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 53.2 m -137.1 158.91 43.38 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.948 1.699 . . . . 10.0 110.876 171.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -133.94 160.86 36.42 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.576 1.151 . . . . 10.0 113.604 -170.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -143.5 161.64 37.92 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.872 2.069 . . . . 10.0 111.529 -177.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.7 tp -146.12 119.26 8.85 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 127.027 2.131 . . . . 10.0 110.188 176.052 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.4 m-20 54.78 16.65 1.48 Allowed 'General case' 0 CA--C 1.554 1.132 0 C-N-CA 126.469 1.908 . . . . 10.0 114.964 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.37 -11.86 47.51 Favored Glycine 0 CA--C 1.538 1.531 0 C-N-CA 126.52 2.01 . . . . 10.0 115.164 -177.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -86.17 156.34 20.37 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 118.932 1.366 . . . . 10.0 110.976 170.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.4 p -70.88 154.14 42.09 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.345 1.058 . . . . 10.0 112.51 173.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -132.89 107.38 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.099 1.76 . . . . 10.0 108.78 173.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -78.68 163.47 25.41 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.027 0.931 . . . . 10.0 111.37 171.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.7 p -72.59 157.13 38.15 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.709 0.803 . . . . 10.0 112.615 173.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -146.95 171.09 15.77 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 126.538 1.935 . . . . 10.0 110.322 170.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -59.97 -31.54 69.99 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.039 -1.038 . . . . 10.0 112.292 167.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 80.2 mt -81.95 -17.2 47.86 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.191 1.396 . . . . 10.0 113.949 173.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.2 m80 -136.28 69.77 1.42 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.985 1.714 . . . . 10.0 110.895 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -68.07 142.72 55.76 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.952 1.301 . . . . 10.0 111.005 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.3 mtt -133.63 102.49 5.51 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 126.494 1.917 . . . . 10.0 110.049 -175.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.84 171.54 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.371 1.468 . . . . 10.0 111.874 -176.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 23.8 m -131.45 134.55 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.021 1.328 . . . . 10.0 110.983 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 23.7 t -77.53 151.0 34.75 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.272 0.629 . . . . 10.0 111.91 173.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -60.74 -20.88 62.26 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.835 1.254 . . . . 10.0 113.224 168.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -75.96 -5.37 45.9 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.718 1.607 . . . . 10.0 113.86 173.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.9 56.54 2.72 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.792 1.186 . . . . 10.0 112.571 -177.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.5 tp -133.58 105.51 6.91 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.619 1.567 . . . . 10.0 110.629 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 9.3 m170 -65.79 129.08 38.52 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.45 0.7 . . . . 10.0 110.101 166.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 66.2 m -125.1 131.56 53.27 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.899 1.679 . . . . 10.0 111.681 -173.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.17 115.87 14.71 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.657 1.983 . . . . 10.0 108.927 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.94 154.36 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 125.187 1.395 . . . . 10.0 110.696 -174.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -127.08 102.8 7.12 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.032 2.133 . . . . 10.0 108.952 164.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.9 mm-40 -65.67 -36.01 82.42 Favored 'General case' 0 N--CA 1.476 0.83 0 O-C-N 121.044 -1.035 . . . . 10.0 112.675 176.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.2 p -151.58 90.23 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.188 1.795 . . . . 10.0 110.012 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.82 131.52 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 O-C-N 121.199 -0.938 . . . . 10.0 111.392 -179.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -110.8 161.07 16.16 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.508 1.523 . . . . 10.0 111.555 177.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.43 -34.45 66.83 Favored 'General case' 0 CA--C 1.546 0.808 0 N-CA-C 113.355 0.872 . . . . 10.0 113.355 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 23.5 m -66.44 -16.59 64.22 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.522 1.529 . . . . 10.0 114.57 176.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -81.32 -7.92 59.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.302 1.041 . . . . 10.0 113.469 179.022 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.12 148.14 48.8 Favored 'General case' 0 CA--C 1.548 0.88 0 CA-C-N 119.428 1.013 . . . . 10.0 113.099 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.24 -172.65 25.26 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.655 1.121 . . . . 10.0 115.079 176.121 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.34 101.92 10.11 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.834 1.654 . . . . 10.0 111.02 174.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -78.83 151.51 31.84 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 124.119 0.968 . . . . 10.0 111.886 171.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.47 161.47 37.97 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.667 0.787 . . . . 10.0 112.179 168.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.1 t -135.28 149.98 49.92 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 126.627 1.971 . . . . 10.0 110.079 177.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -124.05 141.47 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.898 1.279 . . . . 10.0 110.844 174.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.11 120.63 24.93 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.686 1.994 . . . . 10.0 110.095 -178.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -135.11 132.89 38.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 125.176 1.39 . . . . 10.0 111.672 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.2 p30 -134.03 -179.58 5.64 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.744 1.218 . . . . 10.0 111.332 166.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -61.97 -11.78 15.15 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 115.576 1.695 . . . . 10.0 115.576 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.18 -15.28 14.9 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.552 1.541 . . . . 10.0 114.246 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.46 -167.94 37.9 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.839 1.2 . . . . 10.0 116.023 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.85 146.48 47.5 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.84 2.056 . . . . 10.0 112.221 -170.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.79 157.01 46.01 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.317 1.847 . . . . 10.0 111.294 167.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -139.56 135.35 33.3 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.487 1.515 . . . . 10.0 110.069 -179.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -128.43 156.19 43.58 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.47 1.508 . . . . 10.0 111.791 -173.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.9 m -142.39 147.42 36.19 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 124.632 1.173 . . . . 10.0 112.139 -171.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.11 165.9 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 126.484 1.914 . . . . 10.0 110.852 168.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -119.25 131.75 55.83 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.981 1.313 . . . . 10.0 110.827 173.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.5 tp -120.44 108.62 14.33 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 126.206 1.802 . . . . 10.0 110.253 177.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -78.66 146.18 34.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 121.951 -0.468 . . . . 10.0 110.569 160.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.1 t -124.84 104.91 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 124.287 1.035 . . . . 10.0 109.152 174.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.95 98.98 1.7 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.674 1.989 . . . . 10.0 110.253 -175.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.745 0 C-N-CA 124.878 1.271 . . . . 10.0 112.47 -178.319 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 N-CA-C 113.021 0.354 . . . . 10.0 113.021 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -69.17 162.38 42.03 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.044 2.496 . . . . 10.0 112.152 175.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.14 162.73 31.3 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.753 1.221 . . . . 10.0 113.561 -171.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -106.55 83.8 1.92 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.654 1.982 . . . . 10.0 110.76 -171.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.4 mm -83.04 -67.94 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.526 0.73 . . . . 10.0 111.7 -173.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 -155.59 148.8 24.68 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.386 1.074 . . . . 10.0 111.955 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 20.8 m -126.02 150.75 70.22 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 125.724 1.61 . . . . 10.0 110.654 172.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -74.63 159.39 42.63 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 123.016 2.478 . . . . 10.0 111.861 174.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -75.6 167.43 21.9 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.745 0.818 . . . . 10.0 112.344 168.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -59.7 152.14 23.36 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.688 0.795 . . . . 10.0 113.027 175.347 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 58.4 mtm -130.16 160.74 32.87 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.207 1.003 . . . . 10.0 112.908 -176.339 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -138.04 108.21 6.42 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 126.2 1.8 . . . . 10.0 110.642 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.7 mm -123.93 132.41 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.267 1.427 . . . . 10.0 110.409 -165.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -63.49 133.69 54.33 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.44 1.096 . . . . 10.0 112.456 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -52.51 132.46 35.2 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.465 1.506 . . . . 10.0 112.981 -179.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 91.4 -9.24 77.83 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.782 1.658 . . . . 10.0 115.394 177.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.44 160.72 32.25 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.206 1.503 . . . . 10.0 113.201 176.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 57.8 t80 -71.96 145.87 48.12 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.836 1.254 . . . . 10.0 110.488 158.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.8 t -150.44 163.48 38.29 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.454 1.102 . . . . 10.0 111.686 170.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.6 ptm85 -144.64 166.82 24.09 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.256 1.422 . . . . 10.0 112.769 169.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.0 mtt -130.87 159.14 38.26 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.956 2.102 . . . . 10.0 110.84 173.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -138.15 95.03 2.95 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.486 1.514 . . . . 10.0 111.34 -167.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -108.89 103.36 12.4 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.794 1.638 . . . . 10.0 111.103 -175.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -68.01 137.37 55.03 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 121.188 -0.945 . . . . 10.0 110.54 174.309 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.09 155.29 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.508 1.523 . . . . 10.0 111.396 -173.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -142.63 170.45 15.68 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.136 1.375 . . . . 10.0 110.992 171.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 137.71 160.47 8.54 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 127.613 2.53 . . . . 10.0 112.573 -176.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.7 tp -150.46 127.01 5.23 Favored Pre-proline 0 CA--C 1.547 0.846 0 C-N-CA 124.396 1.079 . . . . 10.0 110.711 178.495 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -66.78 169.13 49.01 Favored 'Cis proline' 0 CA--C 1.538 0.709 0 CA-C-N 121.346 1.517 . . . . 10.0 112.31 -2.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.58 121.11 36.66 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.708 1.203 . . . . 10.0 111.335 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -70.36 160.23 50.24 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.538 2.158 . . . . 10.0 113.274 -173.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -66.7 169.65 7.55 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 125.481 1.512 . . . . 10.0 111.736 169.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.5 p -133.33 115.71 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 125.708 1.603 . . . . 10.0 111.624 -175.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.9 m -133.84 99.16 4.37 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.515 1.526 . . . . 10.0 110.622 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -84.38 156.06 22.01 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 121.873 0.844 . . . . 10.0 112.798 175.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -143.0 159.58 41.97 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.126 2.17 . . . . 10.0 111.208 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -146.35 118.35 8.23 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.956 2.102 . . . . 10.0 109.892 176.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.2 m-20 55.4 12.26 0.71 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.578 1.951 . . . . 10.0 115.487 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.48 -13.05 23.25 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 126.662 2.077 . . . . 10.0 115.343 -178.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -91.14 161.77 14.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 125.233 1.413 . . . . 10.0 110.923 170.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 289' ' ' THR . . . . . 0.557 ' HG1' HE21 ' A' ' 291' ' ' GLN . 70.5 p -70.92 160.5 32.73 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.61 0.719 . . . . 10.0 112.34 174.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 98.5 t -129.85 113.43 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 126.53 1.932 . . . . 10.0 107.308 166.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . 0.557 HE21 ' HG1' ' A' ' 289' ' ' THR . 68.5 mt-30 -107.59 139.0 42.79 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.014 1.326 . . . . 10.0 109.832 -174.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 51.1 p -63.6 144.5 56.96 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.283 0.846 . . . . 10.0 113.283 -174.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -154.21 -177.77 6.66 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.9 1.68 . . . . 10.0 111.342 172.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -58.95 -18.84 37.4 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.227 1.411 . . . . 10.0 114.721 -177.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.7 mt -107.44 -11.42 15.52 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.74 1.616 . . . . 10.0 113.205 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -130.21 70.85 1.44 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.973 2.109 . . . . 10.0 110.285 -175.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -80.12 144.54 32.99 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.897 1.279 . . . . 10.0 111.706 -173.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -141.65 107.37 5.1 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.418 1.887 . . . . 10.0 110.535 -171.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 164.62 25.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.781 1.232 . . . . 10.0 112.232 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 22.1 t -133.69 116.37 24.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 125.334 1.453 . . . . 10.0 110.012 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 44.6 t -65.37 143.98 57.39 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.097 0.959 . . . . 10.0 111.755 173.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.26 -18.88 41.17 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.926 1.29 . . . . 10.0 113.888 173.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -77.11 -3.7 40.67 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.005 1.722 . . . . 10.0 114.014 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 88.33 45.94 4.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.971 1.272 . . . . 10.0 113.414 178.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.5 tp -135.18 105.6 6.38 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 125.293 1.437 . . . . 10.0 111.005 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -77.34 116.4 17.92 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.501 1.121 . . . . 10.0 110.984 171.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.9 m -93.33 137.14 32.93 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 125.495 1.518 . . . . 10.0 111.672 171.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.37 124.84 31.2 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.13 2.172 . . . . 10.0 107.639 174.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.4 mp -123.37 147.71 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.518 1.127 . . . . 10.0 111.536 -170.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -121.45 107.39 12.41 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 127.707 2.403 . . . . 10.0 109.175 170.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.4 mm-40 -66.68 -37.3 84.47 Favored 'General case' 0 N--CA 1.474 0.775 0 O-C-N 121.076 -1.015 . . . . 10.0 112.924 177.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.15 90.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 125.865 1.666 . . . . 10.0 110.284 -178.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -69.45 147.28 12.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 O-C-N 121.175 -0.953 . . . . 10.0 112.305 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -136.27 156.5 48.58 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.722 1.609 . . . . 10.0 112.721 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.54 -34.91 71.54 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.679 1.192 . . . . 10.0 113.663 -177.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.4 m -64.63 -13.08 52.1 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.453 1.501 . . . . 10.0 114.389 176.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -108.8 8.09 26.53 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.255 1.822 . . . . 10.0 113.009 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.38 158.0 30.41 Favored 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.94 -1.1 . . . . 10.0 112.616 168.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.37 -167.55 21.91 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.549 1.071 . . . . 10.0 115.134 173.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.63 103.25 10.35 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.174 1.79 . . . . 10.0 111.544 178.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -80.72 150.26 29.39 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.711 1.205 . . . . 10.0 111.919 171.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 162.96 35.0 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.113 0.965 . . . . 10.0 112.066 168.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 41.8 t -140.38 127.51 20.96 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.653 1.581 . . . . 10.0 110.768 176.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 89.7 t -102.55 132.78 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 125.666 1.586 . . . . 10.0 109.401 173.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.47 117.55 22.33 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.527 1.931 . . . . 10.0 110.659 -178.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -131.05 139.5 49.93 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.249 1.42 . . . . 10.0 112.056 -172.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -132.92 -177.87 4.7 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.8 1.24 . . . . 10.0 111.355 167.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -61.72 -8.8 5.1 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 115.888 1.81 . . . . 10.0 115.888 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -116.36 -17.44 10.72 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.587 1.555 . . . . 10.0 114.736 -178.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 175.4 -170.36 43.37 Favored Glycine 0 CA--C 1.534 1.232 0 CA-C-N 120.0 1.273 . . . . 10.0 116.257 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -136.58 141.99 43.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.222 2.209 . . . . 10.0 111.68 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.5 158.56 44.14 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.209 1.804 . . . . 10.0 110.953 168.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -143.52 141.32 30.69 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.517 1.127 . . . . 10.0 111.072 -175.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -132.4 154.2 50.04 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.694 1.598 . . . . 10.0 111.349 -176.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.0 m -145.39 145.3 31.1 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 124.672 1.189 . . . . 10.0 112.003 -171.036 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -154.0 172.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 126.572 1.949 . . . . 10.0 110.984 172.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 39.5 tt0 -130.1 143.13 50.62 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 120.665 -1.272 . . . . 10.0 111.557 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.9 tp -129.39 106.58 8.88 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.088 1.755 . . . . 10.0 111.14 -177.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -91.96 85.62 5.61 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.815 1.646 . . . . 10.0 111.307 177.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.9 t -70.15 110.06 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.256 -0.902 . . . . 10.0 110.997 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.8 mt -75.47 98.74 4.0 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 126.454 1.902 . . . . 10.0 110.503 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.811 0 C-N-CA 124.255 1.022 . . . . 10.0 112.743 178.38 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo . . . . . 0 CA--C 1.542 0.892 0 N-CA-C 113.08 0.377 . . . . 10.0 113.08 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -69.04 164.59 33.25 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.146 2.564 . . . . 10.0 111.52 168.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -141.12 155.32 46.13 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.717 1.207 . . . . 10.0 112.0 -174.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -74.6 102.66 4.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.19 2.196 . . . . 10.0 111.452 178.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . 0.522 HG21 ' H ' ' A' ' 254' ' ' GLN . 0.2 OUTLIER -115.0 -176.69 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 126.026 1.73 . . . . 10.0 110.483 175.76 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.522 ' H ' HG21 ' A' ' 253' ' ' ILE . 0.0 OUTLIER -46.35 102.43 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 128.458 2.703 . . . . 10.0 115.024 -175.033 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.91 151.59 92.99 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 124.385 1.074 . . . . 10.0 111.061 158.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.4 162.65 33.29 Favored 'Trans proline' 0 CA--C 1.541 0.852 0 C-N-CA 123.023 2.482 . . . . 10.0 111.269 170.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -73.3 159.97 32.56 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 121.36 -0.838 . . . . 10.0 111.478 170.395 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -59.45 129.93 44.42 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 121.564 -0.71 . . . . 10.0 111.529 175.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 31.1 mtm -100.09 155.04 17.95 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.928 0.891 . . . . 10.0 112.162 -174.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 23.6 p -134.81 105.76 6.59 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.852 1.661 . . . . 10.0 110.269 175.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.0 mm -125.44 127.06 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.12 1.368 . . . . 10.0 110.206 -164.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -62.91 134.3 56.0 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.157 0.983 . . . . 10.0 112.189 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -53.03 130.16 33.02 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.813 1.245 . . . . 10.0 112.751 -178.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.74 -8.87 76.4 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 125.9 1.714 . . . . 10.0 115.284 177.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -70.15 160.29 32.35 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 119.272 1.536 . . . . 10.0 113.004 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 43.8 t80 -76.95 139.62 40.21 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.818 1.247 . . . . 10.0 110.222 156.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.6 p -149.32 169.71 20.18 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.754 0.822 . . . . 10.0 111.892 162.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 35.5 ptt-85 -145.27 137.78 25.96 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.217 1.007 . . . . 10.0 112.525 172.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.2 mtt -87.47 159.31 18.71 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.888 1.275 . . . . 10.0 110.906 169.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -136.7 132.29 34.69 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.014 1.326 . . . . 10.0 112.025 173.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -134.43 113.92 12.36 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 126.715 2.006 . . . . 10.0 109.645 -176.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.71 146.69 53.53 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 121.067 -1.021 . . . . 10.0 110.206 171.178 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.7 p -149.21 156.51 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.063 1.345 . . . . 10.0 111.492 -174.016 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.1 t -144.53 -176.62 5.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.712 1.605 . . . . 10.0 111.668 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 104.92 162.77 23.98 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.125 2.297 . . . . 10.0 113.54 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -148.74 131.05 7.7 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 125.234 1.414 . . . . 10.0 110.48 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -67.33 170.97 44.65 Favored 'Cis proline' 0 CA--C 1.54 0.778 0 CA-C-N 120.917 1.363 . . . . 10.0 112.615 -3.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.01 120.96 32.83 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.022 1.329 . . . . 10.0 111.437 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.53 152.42 59.86 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 122.481 2.121 . . . . 10.0 113.466 -171.273 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -72.31 141.6 48.84 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.81 1.244 . . . . 10.0 109.899 160.316 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.1 m -128.15 89.23 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.699 1.199 . . . . 10.0 112.233 -166.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.5 m -74.93 115.76 14.9 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.762 1.225 . . . . 10.0 111.251 175.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -96.89 148.77 22.61 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.475 1.11 . . . . 10.0 113.349 177.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 83.1 m-85 -143.21 160.19 40.92 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 126.562 1.945 . . . . 10.0 112.427 -174.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.2 tp -147.13 120.78 9.17 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.721 2.408 . . . . 10.0 109.799 174.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 54.93 15.1 1.05 Allowed 'General case' 0 CA--C 1.556 1.192 0 C-N-CA 126.584 1.954 . . . . 10.0 115.43 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 106.82 -11.01 41.53 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.207 1.86 . . . . 10.0 115.176 -177.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -90.55 159.81 16.28 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.207 1.403 . . . . 10.0 110.677 169.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 25.2 p -74.28 160.49 31.03 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.018 0.927 . . . . 10.0 112.6 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 41.2 t -135.54 104.77 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.979 1.712 . . . . 10.0 109.563 174.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -70.32 148.88 47.95 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.135 0.574 . . . . 10.0 111.209 170.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 34.7 p -73.55 149.5 42.15 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.497 0.719 . . . . 10.0 111.611 166.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -155.04 -177.67 6.7 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.171 1.388 . . . . 10.0 111.977 172.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -59.29 -19.95 50.38 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -177.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.7 mt -105.16 -9.35 17.8 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.501 1.52 . . . . 10.0 113.112 175.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.3 m80 -132.95 65.91 1.58 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 127.22 2.208 . . . . 10.0 110.261 -174.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -76.42 130.74 38.45 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.771 1.229 . . . . 10.0 110.668 -174.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 62.3 mtt -129.32 103.1 6.73 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.241 1.817 . . . . 10.0 109.776 -174.23 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.32 163.46 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.703 1.201 . . . . 10.0 112.763 -172.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.4 m -124.01 166.75 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 126.308 1.843 . . . . 10.0 111.649 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 35.6 t -136.88 149.04 47.43 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.487 1.515 . . . . 10.0 112.365 -178.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -58.72 -19.59 41.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.895 1.678 . . . . 10.0 114.075 174.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.2 mmtt -75.06 -2.17 26.23 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.565 1.546 . . . . 10.0 113.949 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.86 41.7 7.08 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.008 1.29 . . . . 10.0 112.903 -178.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.2 tp -133.51 150.02 51.7 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.276 1.43 . . . . 10.0 111.641 -175.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -132.93 137.78 46.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.02 2.528 . . . . 10.0 108.952 173.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 50.9 m -131.72 153.1 50.38 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.812 0.845 . . . . 10.0 112.471 -175.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.91 102.18 5.95 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.151 1.78 . . . . 10.0 109.059 178.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -86.68 142.32 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 124.841 1.256 . . . . 10.0 109.35 179.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -120.62 104.68 10.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.608 1.963 . . . . 10.0 108.459 167.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -64.85 -39.73 94.03 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.16 85.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.969 1.708 . . . . 10.0 110.111 -178.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.3 p -67.54 142.9 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 O-C-N 121.255 -0.903 . . . . 10.0 112.327 -176.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -124.77 161.07 27.23 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.286 1.834 . . . . 10.0 112.255 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.12 -30.87 64.76 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 113.839 1.051 . . . . 10.0 113.839 -176.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.7 p -67.53 -16.34 64.14 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 125.658 1.583 . . . . 10.0 114.803 173.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -82.18 -7.63 59.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.635 1.174 . . . . 10.0 113.433 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 151.61 45.35 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.136 -0.977 . . . . 10.0 113.021 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.96 -170.97 21.11 Favored Glycine 0 CA--C 1.532 1.141 0 C-N-CA 124.664 1.126 . . . . 10.0 114.935 176.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.41 104.08 14.12 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.067 1.747 . . . . 10.0 111.724 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -78.97 150.39 32.03 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.377 1.071 . . . . 10.0 112.016 170.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.43 160.28 41.82 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 123.778 0.831 . . . . 10.0 112.427 169.097 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.35 142.36 43.8 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.747 1.619 . . . . 10.0 110.414 174.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.2 t -123.14 104.92 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.798 1.639 . . . . 10.0 109.102 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.75 120.54 27.28 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 126.277 1.831 . . . . 10.0 110.835 177.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.64 135.45 51.21 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 125.21 1.404 . . . . 10.0 111.9 -178.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -133.85 -179.16 5.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.05 0.94 . . . . 10.0 111.744 164.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.7 ptp180 -60.53 -12.58 10.27 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 115.797 1.777 . . . . 10.0 115.797 -179.249 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.44 -17.99 13.33 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 125.521 1.528 . . . . 10.0 114.356 -178.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.44 -169.72 42.5 Favored Glycine 0 CA--C 1.535 1.298 0 CA-C-N 119.846 1.203 . . . . 10.0 115.809 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -137.94 145.6 42.22 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.352 1.861 . . . . 10.0 111.958 -173.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.18 162.34 35.5 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.072 1.749 . . . . 10.0 111.385 170.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 64.2 m -135.83 145.94 46.96 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.316 1.046 . . . . 10.0 111.736 -171.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -136.2 149.52 48.6 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.391 1.876 . . . . 10.0 110.63 -177.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -146.42 145.2 30.16 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.597 1.159 . . . . 10.0 111.79 -172.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . 0.406 HG21 ' H ' ' A' ' 337' ' ' GLN . 9.8 p -152.4 172.78 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 126.042 1.737 . . . . 10.0 110.856 168.008 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . 0.406 ' H ' HG21 ' A' ' 336' ' ' VAL . 49.4 tt0 -126.62 147.16 49.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.17 1.388 . . . . 10.0 111.334 172.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 63.6 tp -127.86 113.0 15.34 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 126.09 1.756 . . . . 10.0 111.024 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -92.88 91.57 7.49 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.584 1.554 . . . . 10.0 110.606 171.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.4 t -74.62 106.84 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 O-C-N 121.158 -0.964 . . . . 10.0 110.157 175.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.1 mt -76.64 97.95 4.57 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.846 1.658 . . . . 10.0 110.5 -179.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.786 0 C-N-CA 124.077 0.951 . . . . 10.0 112.542 177.656 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo . . . . . 0 CA--C 1.542 0.905 0 N-CA-C 112.85 0.289 . . . . 10.0 112.85 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.4 143.12 62.37 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.756 2.304 . . . . 10.0 110.766 169.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 38.1 ttp-105 -111.02 152.59 26.67 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.472 1.509 . . . . 10.0 111.429 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -77.64 75.63 4.18 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 126.32 1.848 . . . . 10.0 111.712 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . 0.576 HG21 ' H ' ' A' ' 254' ' ' GLN . 0.7 OUTLIER -75.15 177.45 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.034 0 C-N-CA 124.739 1.216 . . . . 10.0 111.312 175.969 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.576 ' H ' HG21 ' A' ' 253' ' ' ILE . 32.9 tt0 -49.94 113.01 0.75 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.79 2.436 . . . . 10.0 114.439 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 23.6 m -76.41 154.13 83.95 Favored Pre-proline 0 N--CA 1.477 0.905 0 C-N-CA 125.008 1.323 . . . . 10.0 111.19 159.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.45 167.53 25.48 Favored 'Trans proline' 0 CA--C 1.543 0.956 0 C-N-CA 123.265 2.644 . . . . 10.0 111.779 171.259 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.39 167.31 20.77 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.334 -0.854 . . . . 10.0 111.66 166.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -61.88 160.15 12.66 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.345 -0.847 . . . . 10.0 112.767 174.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 91.5 mtp -127.74 154.02 45.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.8 1.64 . . . . 10.0 111.793 -171.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 59.1 p -144.23 120.17 10.65 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 125.061 1.344 . . . . 10.0 110.367 166.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.0 mm -129.02 130.2 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.16 1.384 . . . . 10.0 109.89 -166.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -60.28 126.22 26.66 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.895 1.278 . . . . 10.0 112.238 173.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -52.33 130.71 31.78 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.48 1.512 . . . . 10.0 113.222 -177.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.33 -10.73 67.34 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.077 1.798 . . . . 10.0 115.106 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -71.69 162.06 30.03 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.144 1.472 . . . . 10.0 113.395 176.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -74.03 139.45 44.73 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.494 1.118 . . . . 10.0 110.466 155.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.3 p -148.78 172.66 14.27 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.596 0.758 . . . . 10.0 112.255 159.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . 0.552 HH21 ' HG ' ' A' ' 307' ' ' SER . 8.5 ptm180 -151.77 175.46 12.4 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 126.029 1.732 . . . . 10.0 112.1 175.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.7 mtt -129.14 162.32 28.04 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 126.042 1.737 . . . . 10.0 112.078 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -136.6 108.94 7.31 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.758 1.623 . . . . 10.0 111.525 -177.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -124.71 113.38 17.9 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.482 1.513 . . . . 10.0 111.155 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -67.48 146.38 54.03 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.542 -0.724 . . . . 10.0 111.099 173.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 9.3 p -149.21 139.8 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.444 1.498 . . . . 10.0 111.551 177.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 24.6 m -142.21 115.11 8.69 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.985 1.314 . . . . 10.0 111.19 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.32 166.79 38.9 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 127.086 2.279 . . . . 10.0 111.723 174.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.44 129.81 7.23 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.311 1.045 . . . . 10.0 111.242 -178.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -67.13 169.57 49.18 Favored 'Cis proline' 0 CA--C 1.539 0.739 0 CA-C-N 121.022 1.401 . . . . 10.0 112.686 -2.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.83 120.66 34.67 Favored Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 124.845 1.258 . . . . 10.0 111.478 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.51 159.85 50.14 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.593 2.196 . . . . 10.0 113.45 -173.31 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -66.86 167.49 11.41 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.514 1.526 . . . . 10.0 111.748 167.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.72 107.02 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.708 1.603 . . . . 10.0 110.48 -171.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.0 m -124.62 99.53 6.22 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.418 1.487 . . . . 10.0 111.339 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -81.82 151.83 27.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.051 0.94 . . . . 10.0 113.093 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -140.72 160.24 40.47 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.155 2.182 . . . . 10.0 111.416 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.9 tp -146.56 116.73 7.37 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 127.257 2.223 . . . . 10.0 110.128 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 55.76 12.46 0.85 Allowed 'General case' 0 CA--C 1.556 1.179 0 C-N-CA 126.503 1.921 . . . . 10.0 115.234 -179.556 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.25 -14.76 30.69 Favored Glycine 0 CA--C 1.54 1.611 0 C-N-CA 126.778 2.132 . . . . 10.0 114.959 -176.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -80.9 158.09 25.41 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.996 1.318 . . . . 10.0 110.524 168.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 65.8 p -74.4 162.93 28.37 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.408 0.683 . . . . 10.0 111.855 170.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 16.7 t -136.01 137.43 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.378 1.471 . . . . 10.0 109.44 171.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 25.6 mp0 -107.9 156.53 19.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.321 1.449 . . . . 10.0 111.032 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 63.7 p -71.14 155.68 40.47 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.757 0.823 . . . . 10.0 112.316 173.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -153.48 168.91 24.53 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.476 1.51 . . . . 10.0 110.92 177.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.66 -35.69 70.89 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 120.832 -1.168 . . . . 10.0 112.655 169.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 76.7 mt -81.2 -15.45 55.65 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.527 1.131 . . . . 10.0 113.803 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -135.28 70.41 1.43 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.723 1.609 . . . . 10.0 111.561 -173.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -69.12 136.56 52.41 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.776 1.23 . . . . 10.0 110.478 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 55.6 mtt -134.06 102.46 5.41 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 126.477 1.911 . . . . 10.0 109.357 -173.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.57 162.51 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 125.02 1.328 . . . . 10.0 112.985 -169.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 17.7 t -132.42 113.02 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 126.964 2.106 . . . . 10.0 109.538 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.3 t -68.93 146.41 52.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 124.545 1.138 . . . . 10.0 111.937 173.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -59.0 -19.59 45.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.803 1.241 . . . . 10.0 113.89 172.084 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -77.7 -3.29 40.37 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.381 1.472 . . . . 10.0 113.99 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.94 49.36 4.31 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.942 1.258 . . . . 10.0 113.014 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -144.74 121.39 11.14 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.863 1.665 . . . . 10.0 109.496 -175.034 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -114.14 157.22 22.9 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.424 0.898 . . . . 10.0 113.424 173.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 307' ' ' SER . . . . . 0.552 ' HG ' HH21 ' A' ' 268' ' ' ARG . 74.4 m -143.36 158.58 43.52 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.766 1.226 . . . . 10.0 113.291 -169.517 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.96 104.96 7.43 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.962 2.105 . . . . 10.0 108.549 171.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -79.4 151.01 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.445 1.098 . . . . 10.0 109.736 177.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -131.6 98.84 4.61 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 126.69 1.996 . . . . 10.0 108.195 167.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -62.85 -36.2 82.47 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -178.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.34 83.93 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.142 1.777 . . . . 10.0 109.747 178.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.5 p -66.5 141.45 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.246 -0.909 . . . . 10.0 112.014 -175.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 10.6 mmt180 -127.33 160.91 29.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.028 1.731 . . . . 10.0 112.503 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.9 -33.24 61.86 Favored 'General case' 0 CA--C 1.547 0.865 0 N-CA-C 114.131 1.16 . . . . 10.0 114.131 -177.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 73.6 m -68.62 -15.62 63.59 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.328 1.233 . . . . 10.0 114.328 175.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -81.47 -6.79 59.31 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.386 1.074 . . . . 10.0 113.236 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.06 149.69 49.43 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 120.931 -1.106 . . . . 10.0 113.017 179.014 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.75 -173.87 22.36 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.812 1.196 . . . . 10.0 114.976 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.21 103.16 13.92 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.069 1.748 . . . . 10.0 111.297 176.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 62.7 m-85 -81.04 151.5 28.36 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.0 0.92 . . . . 10.0 112.11 172.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 164.86 29.47 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.223 1.009 . . . . 10.0 112.283 168.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 34.0 t -140.83 117.26 10.77 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.64 1.576 . . . . 10.0 110.643 175.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.8 t -88.3 132.16 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.834 1.253 . . . . 10.0 109.373 170.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -126.58 119.7 27.75 Favored 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 126.459 1.904 . . . . 10.0 110.876 -177.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -131.76 137.11 48.05 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 125.408 1.483 . . . . 10.0 112.32 -170.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.5 p30 -132.53 -177.24 4.39 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.806 1.243 . . . . 10.0 111.572 166.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -59.83 -15.78 23.51 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 115.652 1.723 . . . . 10.0 115.652 -179.28 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -107.97 -20.65 13.11 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.262 1.425 . . . . 10.0 114.192 -176.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.15 -169.7 42.84 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 116.104 1.201 . . . . 10.0 116.104 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -134.67 143.33 47.18 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 127.041 2.136 . . . . 10.0 111.647 -172.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -135.93 164.28 28.33 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.013 1.725 . . . . 10.0 111.153 166.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.5 m -140.75 140.22 34.78 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.479 1.111 . . . . 10.0 110.931 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -124.92 153.09 43.21 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.212 1.805 . . . . 10.0 110.437 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 16.1 m -148.41 146.25 28.38 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 124.197 0.999 . . . . 10.0 112.274 -169.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.2 p -151.36 171.74 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.538 1.935 . . . . 10.0 110.601 171.102 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -130.95 140.03 50.11 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.841 1.256 . . . . 10.0 110.758 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.9 tp -126.2 110.58 13.62 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.321 1.849 . . . . 10.0 110.695 -176.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -97.64 82.56 3.08 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.682 1.593 . . . . 10.0 110.86 175.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.3 114.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.897 0.879 . . . . 10.0 110.779 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 78.3 mt -78.35 93.33 4.66 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 126.279 1.831 . . . . 10.0 110.366 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.874 0 C-N-CA 124.893 1.277 . . . . 10.0 113.486 -179.424 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo . . . . . 0 CA--C 1.544 1.006 0 N-CA-C 113.578 0.569 . . . . 10.0 113.578 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -67.56 161.15 44.78 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.116 2.544 . . . . 10.0 112.094 169.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 50.6 ttp180 -144.7 155.55 43.63 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 124.911 1.284 . . . . 10.0 112.649 -173.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -75.15 83.02 2.34 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.915 2.086 . . . . 10.0 111.831 176.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.3 mm -79.12 -66.33 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 O-C-N 121.543 -0.723 . . . . 10.0 110.778 177.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -156.24 145.84 20.92 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 124.833 1.253 . . . . 10.0 111.347 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.5 150.93 74.18 Favored Pre-proline 0 N--CA 1.477 0.882 0 C-N-CA 125.77 1.628 . . . . 10.0 110.331 171.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_endo -73.38 158.08 48.73 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.817 2.345 . . . . 10.0 112.198 176.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -73.81 170.69 14.8 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.928 0.891 . . . . 10.0 111.275 165.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.96 155.18 17.21 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.258 -0.901 . . . . 10.0 112.577 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.4 mtp -132.72 159.45 39.65 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.435 1.494 . . . . 10.0 112.341 -171.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 58.2 p -142.54 128.0 18.96 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 125.657 1.583 . . . . 10.0 110.288 168.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.9 mm -133.73 132.04 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.306 1.442 . . . . 10.0 109.826 -169.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -61.79 128.86 38.23 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.12 1.368 . . . . 10.0 112.347 173.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.32 132.94 29.34 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.717 1.607 . . . . 10.0 113.268 -177.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.62 -9.18 78.41 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 125.767 1.651 . . . . 10.0 115.277 177.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.5 mtp85 -70.22 160.25 32.51 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.185 1.492 . . . . 10.0 113.112 175.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.9 t80 -73.26 138.82 45.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.203 1.001 . . . . 10.0 110.267 154.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.28 172.39 15.95 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.797 0.839 . . . . 10.0 112.103 162.278 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -148.43 171.95 15.23 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.857 1.263 . . . . 10.0 113.005 173.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 55.2 mtt -132.08 154.93 48.94 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 127.72 2.408 . . . . 10.0 110.105 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -134.98 102.09 5.1 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.655 1.582 . . . . 10.0 112.041 -170.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -107.95 106.68 17.04 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 125.651 1.581 . . . . 10.0 110.126 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -65.54 131.9 47.54 Favored 'General case' 0 N--CA 1.474 0.773 0 O-C-N 121.348 -0.845 . . . . 10.0 109.978 172.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.9 p -137.16 155.95 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 125.771 1.628 . . . . 10.0 111.051 -171.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.4 t -142.84 -170.83 3.32 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.464 1.506 . . . . 10.0 111.737 -176.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 93.86 165.44 37.0 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 126.717 2.103 . . . . 10.0 113.301 -176.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.81 130.98 8.55 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 125.818 1.647 . . . . 10.0 109.363 178.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -67.11 169.95 47.65 Favored 'Cis proline' 0 CA--C 1.541 0.847 0 CA-C-N 120.788 1.317 . . . . 10.0 112.635 -3.215 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.0 123.54 54.06 Favored Pre-proline 0 CA--C 1.55 0.952 0 C-N-CA 124.832 1.253 . . . . 10.0 111.209 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.4 150.6 58.53 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 122.324 2.016 . . . . 10.0 114.081 -168.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -68.99 117.28 10.44 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.09 1.756 . . . . 10.0 109.485 160.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -114.71 86.74 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.654 1.582 . . . . 10.0 111.917 -169.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.8 m -72.3 157.48 37.61 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.913 0.885 . . . . 10.0 111.742 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 62.0 m95 -131.24 155.33 47.3 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.914 1.286 . . . . 10.0 112.828 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -146.29 159.52 43.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.435 1.894 . . . . 10.0 111.488 -175.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.4 tp -147.59 121.58 9.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.15 2.18 . . . . 10.0 110.047 176.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 54.18 17.35 1.44 Allowed 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 126.466 1.906 . . . . 10.0 115.241 178.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.46 -7.09 42.57 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 126.181 1.848 . . . . 10.0 115.416 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.8 mtt85 -98.2 161.45 13.7 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.458 1.503 . . . . 10.0 111.219 171.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.7 p -71.56 156.74 39.07 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.535 1.134 . . . . 10.0 113.003 176.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 80.5 t -134.33 141.84 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 127.101 2.16 . . . . 10.0 108.551 170.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -126.18 161.9 26.62 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.228 1.411 . . . . 10.0 111.354 -177.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 55.6 p -68.36 150.14 48.54 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.548 0.739 . . . . 10.0 112.304 174.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -152.68 167.68 28.14 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.826 1.65 . . . . 10.0 110.723 176.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.34 -34.53 66.66 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 121.003 -1.06 . . . . 10.0 112.883 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.3 mt -86.39 -12.94 47.8 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.671 1.188 . . . . 10.0 113.91 174.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.9 m80 -136.39 71.02 1.41 Allowed 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.579 1.551 . . . . 10.0 111.271 -173.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.9 mttt -71.55 144.83 49.42 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.684 1.194 . . . . 10.0 111.574 -176.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 64.6 mtt -137.75 104.93 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.897 2.079 . . . . 10.0 109.602 -176.016 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.3 157.14 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 124.175 0.99 . . . . 10.0 112.616 -177.653 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.58 108.17 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 126.54 1.936 . . . . 10.0 110.752 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 41.7 t -64.8 142.17 58.52 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.75 0.82 . . . . 10.0 111.573 174.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -60.11 -18.44 47.29 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.752 1.221 . . . . 10.0 113.705 172.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -77.51 -3.6 41.38 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.935 1.694 . . . . 10.0 113.849 173.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.0 45.64 4.73 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.155 1.359 . . . . 10.0 113.694 177.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.4 108.28 8.07 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 125.306 1.443 . . . . 10.0 110.478 -177.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.4 t60 -83.31 108.68 16.68 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.141 0.977 . . . . 10.0 111.155 170.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 23.8 m -85.02 136.18 33.7 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.52 1.128 . . . . 10.0 111.585 169.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -128.56 119.33 24.59 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 127.096 2.158 . . . . 10.0 107.918 174.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.6 mt -116.68 152.4 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.762 1.225 . . . . 10.0 111.576 -166.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -129.4 107.97 9.92 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.5 2.32 . . . . 10.0 109.187 169.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.04 -37.99 85.06 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.219 -0.925 . . . . 10.0 112.961 176.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.3 p -151.88 83.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.68 1.592 . . . . 10.0 110.353 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -68.48 143.9 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 O-C-N 121.178 -0.951 . . . . 10.0 112.291 -176.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -126.13 163.33 23.34 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 126.222 1.809 . . . . 10.0 112.276 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.3 -30.8 65.05 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.715 1.006 . . . . 10.0 113.715 -178.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.9 p -67.96 -16.63 64.14 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.673 1.589 . . . . 10.0 114.707 173.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -82.73 -5.97 59.16 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 124.691 1.196 . . . . 10.0 113.354 175.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.33 152.09 45.73 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.035 -1.041 . . . . 10.0 113.082 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.77 -170.56 22.01 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.881 1.229 . . . . 10.0 114.937 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.0 104.56 14.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.025 1.73 . . . . 10.0 111.402 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -80.06 153.11 28.99 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.415 1.086 . . . . 10.0 112.029 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.93 159.9 41.35 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.947 0.899 . . . . 10.0 112.207 167.26 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -132.51 145.15 50.93 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.346 1.858 . . . . 10.0 110.031 176.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 45.3 t -130.14 102.1 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.119 1.368 . . . . 10.0 109.812 -179.657 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.46 125.41 33.01 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 126.649 1.98 . . . . 10.0 111.245 176.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 22.7 mtmt -131.63 131.72 43.43 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.181 1.792 . . . . 10.0 111.996 -175.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.5 p30 -137.15 -179.1 5.51 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 123.461 0.704 . . . . 10.0 112.078 162.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.1 ptp180 -59.6 -14.41 13.36 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 115.763 1.764 . . . . 10.0 115.763 -177.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.3 -15.08 14.56 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.207 1.403 . . . . 10.0 114.402 -178.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.34 -173.5 42.48 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 119.587 1.085 . . . . 10.0 115.709 178.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -134.86 146.99 49.76 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.515 1.926 . . . . 10.0 111.455 -174.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.25 155.94 48.16 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.795 1.638 . . . . 10.0 111.12 170.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.7 m -135.36 131.45 36.37 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.769 1.228 . . . . 10.0 110.753 -173.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -126.17 157.25 38.63 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.364 1.466 . . . . 10.0 111.219 -176.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 20.5 m -146.13 146.34 30.83 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.37 1.068 . . . . 10.0 111.931 -169.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.4 p -152.32 165.81 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 C-N-CA 126.245 1.818 . . . . 10.0 110.629 170.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -126.29 139.17 53.52 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.82 1.248 . . . . 10.0 110.956 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 54.5 tp -126.74 113.12 16.23 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.979 1.712 . . . . 10.0 110.969 -177.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -98.9 85.21 3.23 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.638 1.575 . . . . 10.0 110.964 175.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.0 t -66.96 114.23 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.899 0.88 . . . . 10.0 110.82 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.4 mt -78.33 98.29 5.9 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.387 1.875 . . . . 10.0 110.516 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.871 0 C-N-CA 124.354 1.061 . . . . 10.0 113.577 -179.78 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo . . . . . 0 CA--C 1.541 0.833 0 N-CA-C 112.633 0.205 . . . . 10.0 112.633 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.01 159.99 51.71 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.619 2.212 . . . . 10.0 112.218 176.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -112.35 169.05 9.15 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.752 1.621 . . . . 10.0 112.989 -172.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -108.7 97.55 7.18 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.798 2.039 . . . . 10.0 109.417 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . 0.544 HG21 ' H ' ' A' ' 254' ' ' GLN . 1.1 mp -115.37 171.41 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 126.245 1.818 . . . . 10.0 109.868 -174.133 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.544 ' H ' HG21 ' A' ' 253' ' ' ILE . 6.5 tm0? -44.34 122.08 2.85 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.692 2.397 . . . . 10.0 114.655 -173.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.7 m -107.69 158.86 32.29 Favored Pre-proline 0 N--CA 1.476 0.867 0 C-N-CA 127.508 2.323 . . . . 10.0 110.461 172.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -73.6 159.0 46.78 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.456 2.104 . . . . 10.0 111.697 173.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -71.41 172.5 9.34 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 123.71 0.804 . . . . 10.0 111.125 165.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.3 p30 -59.0 151.62 21.67 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 121.109 -0.994 . . . . 10.0 112.067 173.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.8 mtp -134.11 158.18 44.28 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.184 1.394 . . . . 10.0 111.961 -171.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 61.3 p -141.86 131.28 23.74 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 125.483 1.513 . . . . 10.0 110.823 173.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.3 mm -136.57 133.82 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.54 1.536 . . . . 10.0 109.557 -169.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -65.11 131.33 46.25 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.408 1.083 . . . . 10.0 112.428 175.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -51.61 123.44 9.99 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.607 1.563 . . . . 10.0 113.045 -179.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 102.9 -10.39 55.63 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 126.285 1.898 . . . . 10.0 115.106 178.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.7 mtp180 -72.94 160.93 31.34 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 119.127 1.464 . . . . 10.0 113.398 177.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -72.3 148.94 44.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.866 1.266 . . . . 10.0 110.632 157.647 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 45.4 t -149.48 156.05 41.38 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.763 1.225 . . . . 10.0 111.087 169.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -146.35 163.14 36.52 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.605 1.162 . . . . 10.0 112.675 165.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 59.0 mtt -137.51 121.72 18.04 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.784 1.634 . . . . 10.0 111.661 -173.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 26.1 m-20 -80.73 117.9 21.8 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 126.363 1.865 . . . . 10.0 112.353 175.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -128.13 105.46 8.39 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 125.373 1.469 . . . . 10.0 111.448 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -65.78 131.73 47.02 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 121.253 -0.904 . . . . 10.0 111.131 175.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.39 133.2 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.157 1.783 . . . . 10.0 110.73 -177.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -146.86 157.15 43.58 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.599 1.159 . . . . 10.0 111.536 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 149.13 165.52 12.37 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 128.178 2.799 . . . . 10.0 111.332 -173.671 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.0 tp -146.69 125.33 6.31 Favored Pre-proline 0 CA--C 1.546 0.816 0 CA-C-O 118.106 -0.949 . . . . 10.0 111.137 179.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -66.46 167.87 52.77 Favored 'Cis proline' 0 CA--C 1.538 0.708 0 CA-C-N 120.937 1.37 . . . . 10.0 112.669 -1.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.17 121.46 41.9 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.787 1.235 . . . . 10.0 111.341 -178.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -70.52 153.56 65.33 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 122.474 2.116 . . . . 10.0 113.196 -172.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -74.54 141.87 44.79 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.378 1.071 . . . . 10.0 109.55 159.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 47.8 t -130.94 131.7 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.262 1.025 . . . . 10.0 111.475 -170.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.1 m -131.73 156.7 45.46 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.865 1.666 . . . . 10.0 111.966 177.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -123.56 155.45 37.6 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.214 1.405 . . . . 10.0 113.177 -177.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -145.01 160.74 40.89 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 127.142 2.177 . . . . 10.0 111.572 -173.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -145.64 118.08 8.5 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 127.346 2.258 . . . . 10.0 109.905 176.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 54.72 16.24 1.33 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 126.318 1.847 . . . . 10.0 114.793 -179.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.96 -12.65 45.41 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.689 2.09 . . . . 10.0 115.24 -177.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -84.99 158.11 20.59 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 125.088 1.355 . . . . 10.0 110.698 170.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.4 p -72.1 157.11 38.38 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.882 0.873 . . . . 10.0 112.611 174.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 55.0 t -133.86 93.29 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.446 1.898 . . . . 10.0 108.74 173.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 60.8 mt-30 -68.51 155.09 40.61 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.615 0.766 . . . . 10.0 111.223 172.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.2 p -71.12 155.94 40.18 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-O 121.832 0.825 . . . . 10.0 112.327 171.525 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -155.07 170.16 22.44 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 126.68 1.992 . . . . 10.0 110.668 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.95 -34.5 65.72 Favored 'General case' 0 CA--C 1.546 0.805 0 O-C-N 120.568 -1.333 . . . . 10.0 112.828 169.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 66.8 mt -86.08 -13.25 47.87 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.755 1.222 . . . . 10.0 114.289 176.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -138.56 91.84 2.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.509 1.524 . . . . 10.0 111.122 -173.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.4 mttt -95.66 145.06 25.56 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.466 1.106 . . . . 10.0 111.494 -174.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -139.74 104.01 4.8 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 127.031 2.133 . . . . 10.0 109.621 -178.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.58 162.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.119 1.368 . . . . 10.0 111.728 177.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.13 133.68 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 126.147 1.779 . . . . 10.0 109.664 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 60.3 p -66.22 170.59 5.64 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.265 1.026 . . . . 10.0 113.561 176.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -68.99 -4.44 16.81 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.455 1.102 . . . . 10.0 113.886 166.65 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -109.07 -3.64 17.23 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 126.488 1.915 . . . . 10.0 114.134 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 87.55 40.75 6.7 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 124.509 1.052 . . . . 10.0 114.048 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 41.7 tp -124.52 106.81 10.45 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.313 1.445 . . . . 10.0 110.395 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 13.7 t60 -72.75 142.81 48.14 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.633 0.773 . . . . 10.0 111.19 173.122 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 55.1 m -123.55 97.06 5.22 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 126.865 2.066 . . . . 10.0 110.552 175.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -83.03 123.06 29.11 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 125.112 1.365 . . . . 10.0 108.662 169.161 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 37.1 mt -124.94 149.26 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 125.129 1.371 . . . . 10.0 111.705 -169.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -127.1 113.85 16.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 128.362 2.665 . . . . 10.0 109.481 171.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -69.21 -41.52 76.97 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.033 -1.042 . . . . 10.0 112.913 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.57 88.91 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.72 1.608 . . . . 10.0 110.345 -176.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.7 p -70.59 141.49 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.219 -0.925 . . . . 10.0 112.252 -176.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -123.18 162.54 22.34 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.556 1.942 . . . . 10.0 112.045 176.282 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.69 -34.41 65.04 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.463 0.912 . . . . 10.0 113.463 -178.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 24.9 m -64.59 -17.71 64.22 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.386 1.474 . . . . 10.0 114.508 175.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -83.46 -6.16 59.37 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.637 1.175 . . . . 10.0 113.383 178.398 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.84 151.21 46.06 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 121.057 -1.027 . . . . 10.0 112.986 178.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.51 -171.55 22.87 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.746 1.165 . . . . 10.0 114.881 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.78 101.33 11.52 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.858 1.663 . . . . 10.0 111.314 176.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -75.96 148.65 37.99 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.807 0.843 . . . . 10.0 111.661 169.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.83 156.84 46.05 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.852 0.861 . . . . 10.0 112.074 170.282 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.2 t -132.18 140.56 48.78 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 126.865 2.066 . . . . 10.0 109.411 -179.056 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 61.2 t -130.6 125.41 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 125.147 1.379 . . . . 10.0 109.311 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -118.55 125.02 48.92 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.149 1.78 . . . . 10.0 110.542 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -133.03 133.27 42.84 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 125.568 1.547 . . . . 10.0 112.215 -170.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -131.06 -177.74 4.52 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.693 1.197 . . . . 10.0 111.737 168.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.9 ptm180 -59.52 -14.82 14.41 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 115.702 1.742 . . . . 10.0 115.702 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.96 -17.88 13.19 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.524 1.53 . . . . 10.0 114.331 -176.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.75 -169.22 42.32 Favored Glycine 0 CA--C 1.534 1.243 0 N-CA-C 116.175 1.23 . . . . 10.0 116.175 178.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -133.65 144.42 49.19 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 127.331 2.252 . . . . 10.0 111.498 -173.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.94 157.71 46.19 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.009 1.724 . . . . 10.0 111.278 170.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 62.1 m -137.88 145.06 41.7 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.996 1.318 . . . . 10.0 111.408 -173.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -136.63 152.89 50.93 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.191 1.796 . . . . 10.0 110.478 -179.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 22.6 m -145.36 147.35 32.19 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.042 0.937 . . . . 10.0 112.252 -170.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.5 p -151.98 160.87 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 126.308 1.843 . . . . 10.0 111.039 169.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.2 tt0 -116.96 134.96 54.09 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 124.972 1.309 . . . . 10.0 110.912 173.103 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.8 tp -121.02 111.21 17.2 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.022 1.729 . . . . 10.0 110.875 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -97.32 85.88 3.77 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 125.777 1.631 . . . . 10.0 110.968 175.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.1 t -67.04 112.97 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.764 0.826 . . . . 10.0 110.736 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.0 mt -76.03 99.53 4.63 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.214 1.806 . . . . 10.0 110.101 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.836 0 C-N-CA 124.109 0.964 . . . . 10.0 112.976 -179.307 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo . . . . . 0 CA--C 1.544 1.017 0 N-CA-C 113.366 0.487 . . . . 10.0 113.366 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.45 164.82 32.77 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.32 2.68 . . . . 10.0 111.787 169.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.6 ttt180 -143.4 158.02 43.98 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.4 1.08 . . . . 10.0 112.366 -173.233 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -82.77 69.7 9.61 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.681 1.992 . . . . 10.0 112.516 -171.258 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . 0.608 HG21 ' H ' ' A' ' 254' ' ' GLN . 2.7 mm -77.88 175.34 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.231 0 C-N-CA 124.338 1.055 . . . . 10.0 110.865 175.624 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.608 ' H ' HG21 ' A' ' 253' ' ' ILE . 47.4 tt0 -48.72 115.42 1.25 Allowed 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 128.302 2.641 . . . . 10.0 115.259 -173.651 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.7 m -78.4 153.7 79.1 Favored Pre-proline 0 N--CA 1.479 0.999 0 C-N-CA 124.927 1.291 . . . . 10.0 111.552 162.439 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -76.31 166.85 26.87 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 123.267 2.645 . . . . 10.0 111.714 169.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.42 164.91 26.03 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.311 -0.868 . . . . 10.0 111.887 169.097 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -63.46 162.22 12.98 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.601 0.76 . . . . 10.0 112.634 172.625 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.6 mtm -134.11 161.43 34.9 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.373 1.069 . . . . 10.0 113.228 -178.234 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -140.15 90.14 2.35 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.887 2.075 . . . . 10.0 110.477 177.411 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . 0.405 HG13 ' HG ' ' A' ' 267' ' ' CYS . 41.7 mm -103.87 138.23 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 124.697 1.199 . . . . 10.0 111.184 -166.797 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -68.83 130.06 41.71 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.108 0.963 . . . . 10.0 112.355 174.613 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -53.23 125.79 18.78 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.448 1.499 . . . . 10.0 112.824 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.95 -8.74 61.38 Favored Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.185 1.85 . . . . 10.0 115.115 -179.234 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.7 mtp85 -74.35 159.79 31.91 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 119.489 1.644 . . . . 10.0 113.102 175.103 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -76.75 141.01 40.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.453 1.101 . . . . 10.0 110.207 156.368 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . 0.405 ' HG ' HG13 ' A' ' 261' ' ' ILE . 31.1 p -150.22 173.61 13.74 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.733 0.813 . . . . 10.0 112.353 162.436 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -145.95 167.89 22.21 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 125.682 1.593 . . . . 10.0 112.356 175.342 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -126.48 159.78 32.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.531 1.933 . . . . 10.0 110.772 172.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -137.43 96.87 3.34 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.448 1.499 . . . . 10.0 111.504 -167.862 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.13 111.39 22.71 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.678 1.591 . . . . 10.0 111.126 -177.037 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 90.7 mttt -66.38 147.35 53.43 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 121.111 -0.993 . . . . 10.0 110.272 169.438 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -150.78 159.95 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.232 1.413 . . . . 10.0 111.458 -175.669 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -143.53 -176.88 5.13 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.648 1.579 . . . . 10.0 111.854 178.102 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.22 161.43 23.53 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.251 2.358 . . . . 10.0 113.481 -178.161 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.9 tp -149.7 130.87 7.25 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 125.124 1.37 . . . . 10.0 110.282 179.823 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -66.0 168.97 45.62 Favored 'Cis proline' 0 CA--C 1.539 0.742 0 CA-C-N 121.194 1.462 . . . . 10.0 112.56 -2.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 121.54 41.15 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 124.783 1.233 . . . . 10.0 111.403 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 151.49 66.55 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.517 2.144 . . . . 10.0 113.102 -173.152 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -71.68 143.57 49.66 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.157 0.983 . . . . 10.0 109.783 160.357 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.64 87.53 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.081 1.353 . . . . 10.0 111.83 -166.073 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 62.5 m -77.08 113.72 15.12 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.549 1.14 . . . . 10.0 111.177 176.318 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -91.17 153.12 20.26 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.19 0.996 . . . . 10.0 113.186 176.481 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -144.11 159.92 41.79 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.658 1.983 . . . . 10.0 111.995 -176.512 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.2 tp -146.02 119.25 8.9 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 127.511 2.325 . . . . 10.0 110.022 176.236 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 54.9 14.14 0.86 Allowed 'General case' 0 CA--C 1.555 1.148 0 C-N-CA 126.419 1.887 . . . . 10.0 115.309 179.221 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.44 -12.19 36.27 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.602 2.049 . . . . 10.0 115.165 -177.345 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -87.95 158.07 18.77 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.974 1.387 . . . . 10.0 110.976 170.097 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.6 p -71.6 156.78 39.01 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.357 1.063 . . . . 10.0 112.656 173.627 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.85 105.94 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 126.373 1.869 . . . . 10.0 108.866 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 63.0 mt-30 -74.31 159.36 32.52 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.458 0.703 . . . . 10.0 111.394 171.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.0 p -69.07 155.92 39.54 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.514 0.726 . . . . 10.0 112.036 169.647 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -153.13 168.55 25.56 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.26 1.424 . . . . 10.0 110.891 175.634 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -57.23 -35.98 70.36 Favored 'General case' 0 CA--C 1.546 0.797 0 O-C-N 120.857 -1.152 . . . . 10.0 112.548 168.692 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.9 mt -80.19 -17.79 51.4 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 124.537 1.135 . . . . 10.0 113.804 173.886 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -134.46 70.51 1.45 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.18 1.792 . . . . 10.0 111.205 -172.186 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -73.16 142.43 47.43 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.4 1.48 . . . . 10.0 111.046 -173.199 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.8 mtt -136.48 98.7 3.89 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.249 1.82 . . . . 10.0 110.074 -174.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.09 159.86 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.363 1.465 . . . . 10.0 111.636 -177.034 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.38 122.57 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.753 1.221 . . . . 10.0 111.504 -177.85 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 67.6 m -69.63 148.6 49.12 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.508 1.123 . . . . 10.0 112.016 177.293 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 19.4 tp10 -55.8 -34.78 65.62 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.656 1.583 . . . . 10.0 113.396 -177.663 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -78.41 0.38 25.95 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 126.082 1.753 . . . . 10.0 114.574 179.369 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.49 50.23 1.88 Allowed Glycine 0 CA--C 1.532 1.133 0 C-N-CA 124.833 1.206 . . . . 10.0 114.841 170.19 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 54.4 tp -133.51 106.5 7.48 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.155 1.382 . . . . 10.0 111.056 176.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -86.45 118.37 25.84 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.954 1.701 . . . . 10.0 111.365 177.484 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -91.71 144.93 25.01 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.903 1.681 . . . . 10.0 112.224 173.658 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -138.21 115.73 11.26 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 126.439 1.896 . . . . 10.0 108.669 173.569 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 154.19 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 C-N-CA 125.36 1.464 . . . . 10.0 111.42 -170.832 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -131.74 108.36 9.41 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 127.007 2.123 . . . . 10.0 109.599 163.565 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 36.5 mm-40 -65.06 -45.32 85.82 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 113.898 1.073 . . . . 10.0 113.898 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.61 70.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 CA-C-O 122.614 1.197 . . . . 10.0 111.344 -172.506 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.96 142.23 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.025 1.33 . . . . 10.0 113.502 -170.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.2 mmt-85 -120.64 162.07 20.29 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 126.5 1.92 . . . . 10.0 112.323 177.04 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.11 -31.32 61.15 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.265 1.026 . . . . 10.0 113.613 177.239 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 43.2 p -67.8 -17.12 64.42 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.539 1.536 . . . . 10.0 114.806 174.287 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -83.31 -7.39 59.59 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.54 1.136 . . . . 10.0 113.409 175.823 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 149.68 49.71 Favored 'General case' 0 CA--C 1.547 0.85 0 O-C-N 120.958 -1.089 . . . . 10.0 112.988 179.38 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.1 -173.44 23.27 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.806 1.193 . . . . 10.0 115.076 176.077 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 106.53 14.8 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.855 1.662 . . . . 10.0 111.094 175.063 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -84.01 150.43 25.62 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 124.347 1.059 . . . . 10.0 111.921 172.902 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.56 162.18 37.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.946 0.898 . . . . 10.0 112.268 170.516 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.3 t -139.01 140.42 38.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.581 1.552 . . . . 10.0 110.487 175.065 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 43.6 t -121.38 104.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.837 1.655 . . . . 10.0 109.07 179.395 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -86.3 122.0 29.67 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.278 1.831 . . . . 10.0 111.078 178.396 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -132.35 132.58 43.04 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.421 1.488 . . . . 10.0 112.224 -177.184 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.2 p30 -130.97 -177.95 4.6 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.488 1.115 . . . . 10.0 111.646 167.085 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.8 ptp180 -59.47 -12.71 6.71 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 115.922 1.823 . . . . 10.0 115.922 -179.37 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -113.52 -16.82 12.34 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 125.382 1.473 . . . . 10.0 114.557 -177.048 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.17 -169.27 42.34 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 120.022 1.283 . . . . 10.0 116.224 178.876 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -135.96 144.06 45.2 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.093 2.157 . . . . 10.0 111.997 -172.311 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.78 161.96 36.3 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.111 1.764 . . . . 10.0 111.151 168.587 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -137.65 144.17 41.74 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.319 1.048 . . . . 10.0 111.599 -172.31 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -134.52 152.38 51.75 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.189 1.796 . . . . 10.0 110.86 -178.214 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 15.4 m -147.85 146.18 29.0 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.525 1.13 . . . . 10.0 111.942 -173.027 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.9 p -153.45 174.21 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 126.49 1.916 . . . . 10.0 110.781 171.838 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -129.63 144.31 51.22 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.689 1.196 . . . . 10.0 111.51 172.773 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.0 tp -128.77 109.12 11.02 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.304 1.842 . . . . 10.0 109.997 179.386 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -79.4 147.0 32.51 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 121.938 -0.477 . . . . 10.0 110.029 158.406 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 30.1 t -128.43 106.83 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.124 0.97 . . . . 10.0 109.344 175.352 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.8 101.99 2.24 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.282 1.833 . . . . 10.0 109.659 -178.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.828 0 C-N-CA 124.191 0.996 . . . . 10.0 113.22 -175.75 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 CA--C 1.542 0.88 0 N-CA-C 113.483 0.532 . . . . 10.0 113.483 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -66.88 156.23 67.11 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 C-N-CA 122.933 2.422 . . . . 10.0 112.021 170.888 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.2 ttt85 -146.43 150.48 35.71 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.554 1.142 . . . . 10.0 112.568 -173.374 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -77.59 82.49 4.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.058 2.143 . . . . 10.0 111.65 178.098 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.0 mm -74.89 -56.94 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.613 -0.679 . . . . 10.0 110.502 173.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -154.9 143.49 20.61 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.819 1.248 . . . . 10.0 111.44 176.711 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.39 151.84 79.48 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 126.053 1.741 . . . . 10.0 110.112 171.068 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.01 154.9 47.9 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.929 2.419 . . . . 10.0 112.132 175.736 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -75.63 171.15 14.81 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.353 1.061 . . . . 10.0 112.318 167.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -62.5 153.3 32.08 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 121.269 -0.894 . . . . 10.0 112.607 176.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 73.8 mtp -133.16 157.45 45.31 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.042 1.337 . . . . 10.0 112.408 -169.701 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -141.27 112.79 7.56 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.524 1.53 . . . . 10.0 111.036 178.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 33.2 mm -129.94 128.3 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 125.049 1.339 . . . . 10.0 110.949 -164.68 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -60.37 131.5 50.98 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.083 1.353 . . . . 10.0 112.661 173.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -54.44 136.2 44.52 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.886 1.275 . . . . 10.0 113.001 -177.768 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.76 -6.7 81.95 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.649 1.595 . . . . 10.0 115.312 177.683 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -71.87 158.31 36.28 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 118.944 1.372 . . . . 10.0 112.892 175.783 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -70.65 143.37 51.43 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.316 1.046 . . . . 10.0 109.968 155.1 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.6 t -147.62 165.58 29.96 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.245 1.018 . . . . 10.0 111.634 172.7 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -148.04 159.06 44.3 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.721 1.208 . . . . 10.0 112.868 168.544 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -130.1 151.12 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 126.678 1.991 . . . . 10.0 109.431 170.405 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -143.41 125.6 15.49 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.254 1.021 . . . . 10.0 111.442 -173.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -121.72 156.72 32.5 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.55 2.34 . . . . 10.0 110.196 -175.634 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -114.11 104.06 11.75 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.773 1.229 . . . . 10.0 110.198 175.836 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 43.8 t -109.38 99.15 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.462 1.905 . . . . 10.0 110.021 -170.316 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.5 t -73.44 -175.24 1.89 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.093 0.957 . . . . 10.0 112.527 174.106 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 109.79 155.88 15.91 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 127.312 2.386 . . . . 10.0 113.592 176.379 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 19.2 tp -147.48 125.31 5.92 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.531 . . . . 10.0 109.664 178.513 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.47 169.05 47.71 Favored 'Cis proline' 0 CA--C 1.541 0.834 0 CA-C-N 120.8 1.322 . . . . 10.0 112.567 -2.602 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.36 68.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 C-N-CA 124.205 1.002 . . . . 10.0 111.387 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.81 150.68 68.24 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.476 2.117 . . . . 10.0 113.14 -173.57 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -69.65 142.03 53.51 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.032 1.333 . . . . 10.0 110.431 165.113 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 55.9 t -117.16 126.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.723 1.609 . . . . 10.0 111.269 -167.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.3 m -134.31 106.47 7.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.635 1.574 . . . . 10.0 111.004 175.337 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -82.25 153.59 25.82 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.913 0.885 . . . . 10.0 113.044 176.064 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -142.86 160.44 40.33 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 127.286 2.235 . . . . 10.0 111.378 179.718 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.1 tp -146.4 119.08 8.57 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 127.223 2.209 . . . . 10.0 109.974 175.196 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 54.76 17.15 1.64 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 126.442 1.897 . . . . 10.0 115.014 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.94 -12.87 49.63 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.518 2.009 . . . . 10.0 115.117 -178.236 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.7 mtt85 -84.94 155.72 21.52 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.923 1.362 . . . . 10.0 110.78 169.077 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.5 p -69.84 157.67 36.96 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.02 0.928 . . . . 10.0 112.52 173.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 81.9 t -132.34 143.39 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.667 1.987 . . . . 10.0 108.875 172.442 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -132.85 155.3 49.24 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.629 1.572 . . . . 10.0 110.541 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.0 p -72.43 149.09 44.55 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 123.67 0.788 . . . . 10.0 112.851 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -154.62 -173.11 4.44 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.529 1.932 . . . . 10.0 111.322 175.312 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -60.53 -18.72 53.97 Favored 'General case' 0 CA--C 1.549 0.932 0 N-CA-C 114.84 1.422 . . . . 10.0 114.84 -178.693 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 59.9 mt -113.64 -16.82 12.27 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.556 1.943 . . . . 10.0 113.541 -179.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -122.25 98.34 5.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 126.798 2.039 . . . . 10.0 110.339 -178.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.96 109.77 19.41 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 124.536 1.134 . . . . 10.0 110.857 -168.384 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 5.1 mpp? -116.31 110.22 18.44 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.992 1.717 . . . . 10.0 110.718 -175.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.09 161.46 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.975 1.71 . . . . 10.0 112.096 -172.642 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.1 t -131.22 118.57 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 125.568 1.547 . . . . 10.0 110.238 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 14.5 t -67.55 163.18 21.74 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 124.793 1.237 . . . . 10.0 112.551 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -57.53 -30.52 65.24 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.635 1.574 . . . . 10.0 113.139 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 11.3 mmpt? -86.02 0.11 54.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.922 1.689 . . . . 10.0 114.604 178.356 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.01 6.36 71.98 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 124.896 1.236 . . . . 10.0 114.894 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.54 105.67 1.92 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.579 1.152 . . . . 10.0 109.453 170.329 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.0 t60 -95.8 114.44 26.17 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.612 1.565 . . . . 10.0 111.061 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 41.2 m -101.57 151.02 22.48 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.847 1.259 . . . . 10.0 112.477 -179.782 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -135.81 103.24 5.33 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.439 2.296 . . . . 10.0 108.368 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.32 139.65 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.57 1.148 . . . . 10.0 110.263 -179.524 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -115.14 105.61 13.12 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 127.922 2.489 . . . . 10.0 109.152 171.444 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -64.61 -40.4 95.43 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 120.995 -1.066 . . . . 10.0 113.339 -179.789 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.04 93.22 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.635 1.574 . . . . 10.0 110.402 179.951 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.88 142.47 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.354 -0.842 . . . . 10.0 112.118 -177.548 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -123.08 160.21 26.88 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.145 1.778 . . . . 10.0 112.038 175.393 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.74 -31.87 64.98 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.989 1.107 . . . . 10.0 113.989 -175.2 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.2 t -65.9 -20.85 66.36 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.005 1.322 . . . . 10.0 113.958 175.582 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -78.41 -4.22 47.16 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.908 1.283 . . . . 10.0 113.685 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 155.3 36.61 Favored 'General case' 0 CA--C 1.547 0.84 0 N-CA-C 113.669 0.988 . . . . 10.0 113.669 178.362 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.6 -167.52 17.96 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.933 1.254 . . . . 10.0 114.909 174.312 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.05 105.3 14.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.91 1.684 . . . . 10.0 111.686 179.463 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.6 m-85 -79.58 151.15 30.81 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.311 1.044 . . . . 10.0 111.576 168.633 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.68 159.96 41.54 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.837 0.855 . . . . 10.0 112.226 169.084 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.6 t -137.49 103.95 5.21 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.806 1.642 . . . . 10.0 110.596 -179.501 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 90.0 t -74.95 130.03 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.432 1.093 . . . . 10.0 109.402 170.093 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.93 118.76 24.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.7 2.0 . . . . 10.0 110.259 178.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.9 mtpp -131.76 133.48 44.81 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.969 1.307 . . . . 10.0 112.553 -173.112 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.5 p30 -131.55 -178.91 5.07 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.497 1.119 . . . . 10.0 111.73 167.182 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -60.63 -11.84 8.45 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 115.798 1.777 . . . . 10.0 115.798 -179.101 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.1 -15.11 13.32 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.296 1.438 . . . . 10.0 114.547 -178.378 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.21 -169.57 41.06 Favored Glycine 0 CA--C 1.534 1.256 0 N-CA-C 116.025 1.17 . . . . 10.0 116.025 177.479 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -135.83 145.79 46.83 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.917 2.087 . . . . 10.0 112.002 -169.383 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.91 158.98 43.21 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.393 1.877 . . . . 10.0 110.632 166.017 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.9 m -140.03 100.23 3.87 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.781 1.232 . . . . 10.0 110.414 176.697 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -79.78 154.67 28.32 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.604 1.162 . . . . 10.0 111.187 177.289 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 32.0 m -144.64 145.41 31.74 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 124.456 1.102 . . . . 10.0 111.748 -172.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.92 165.77 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 126.324 1.85 . . . . 10.0 110.559 171.86 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -128.84 140.44 51.7 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.729 1.211 . . . . 10.0 111.549 177.255 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 53.1 tp -128.63 110.45 12.24 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.02 1.728 . . . . 10.0 111.951 -176.905 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -87.78 89.88 8.16 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.155 1.382 . . . . 10.0 110.843 169.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.58 106.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.031 -1.043 . . . . 10.0 109.614 174.131 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.3 mt -72.56 97.91 2.21 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.116 1.766 . . . . 10.0 109.873 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.828 0 C-N-CA 124.522 1.129 . . . . 10.0 113.399 -175.918 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo . . . . . 0 CA--C 1.543 0.941 0 N-CA-C 113.258 0.446 . . . . 10.0 113.258 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.55 158.2 58.66 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.961 2.441 . . . . 10.0 112.337 173.667 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -145.18 161.44 39.51 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 125.018 1.327 . . . . 10.0 113.556 -171.533 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -83.45 98.84 9.73 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.022 1.729 . . . . 10.0 111.869 -178.602 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 36.5 mm -90.64 -68.27 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.445 0.698 . . . . 10.0 110.723 177.01 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 37.2 tt0 -155.49 143.78 20.16 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.306 1.042 . . . . 10.0 111.679 177.104 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.1 m -126.07 153.77 74.05 Favored Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 125.85 1.66 . . . . 10.0 110.659 171.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -70.65 155.03 63.83 Favored 'Trans proline' 0 CA--C 1.542 0.876 0 C-N-CA 122.61 2.207 . . . . 10.0 111.834 171.594 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -72.95 174.3 8.02 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.006 0.922 . . . . 10.0 111.311 166.405 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -59.03 152.24 20.39 Favored 'General case' 0 CA--C 1.548 0.886 0 O-C-N 121.051 -1.031 . . . . 10.0 112.371 174.671 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.0 mtp -134.87 159.3 41.85 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 125.59 1.556 . . . . 10.0 111.887 -171.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 67.2 p -142.12 134.25 27.55 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 125.11 1.364 . . . . 10.0 111.242 172.258 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 27.8 mm -139.41 132.83 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 125.62 1.568 . . . . 10.0 109.629 -170.197 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -63.44 132.63 52.02 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.624 1.169 . . . . 10.0 112.4 173.741 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -52.58 128.12 25.07 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.697 1.199 . . . . 10.0 112.786 -179.311 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.21 -9.29 63.13 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 126.017 1.77 . . . . 10.0 115.298 178.412 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -74.47 162.14 29.11 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 119.227 1.514 . . . . 10.0 113.342 176.668 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -72.75 150.97 42.38 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.199 1.4 . . . . 10.0 110.725 159.159 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.9 t -149.97 156.4 41.65 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.663 1.185 . . . . 10.0 111.437 170.425 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm85 -140.87 164.62 29.75 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.558 1.143 . . . . 10.0 112.99 163.372 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.4 mtt -131.73 161.03 33.79 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.801 2.04 . . . . 10.0 111.142 176.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -137.12 94.25 2.93 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.131 1.372 . . . . 10.0 111.612 -167.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 41.7 m-85 -104.04 116.27 31.94 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.313 1.445 . . . . 10.0 110.831 -178.881 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -78.68 131.14 36.52 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.406 -0.809 . . . . 10.0 110.141 172.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 56.9 t -133.25 148.82 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.135 1.774 . . . . 10.0 110.192 -174.107 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.0 t -136.82 -174.32 3.69 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.542 1.537 . . . . 10.0 111.474 173.77 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 110.06 162.0 18.78 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 127.401 2.429 . . . . 10.0 112.549 -173.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -148.04 128.78 6.94 Favored Pre-proline 0 CA--C 1.546 0.826 0 C-N-CA 124.661 1.184 . . . . 10.0 110.591 -179.587 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -66.56 170.01 44.55 Favored 'Cis proline' 0 CA--C 1.54 0.783 0 CA-C-N 120.786 1.316 . . . . 10.0 112.453 -4.225 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.55 123.42 56.8 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.512 1.125 . . . . 10.0 111.375 179.572 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.55 151.09 64.35 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.543 2.162 . . . . 10.0 113.168 -173.371 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -72.96 146.55 45.97 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.248 1.019 . . . . 10.0 109.831 160.158 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.8 m -130.97 135.98 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.662 1.185 . . . . 10.0 112.541 -170.23 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 64.1 m -135.51 119.3 17.25 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.234 1.814 . . . . 10.0 111.037 -178.834 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 62.2 m95 -91.02 156.22 18.11 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.598 0.962 . . . . 10.0 113.598 -179.43 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -143.45 160.25 40.93 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.796 2.438 . . . . 10.0 111.1 -176.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.6 tp -146.18 117.72 8.03 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 127.189 2.196 . . . . 10.0 109.997 176.237 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 55.54 13.33 0.94 Allowed 'General case' 0 CA--C 1.555 1.145 0 C-N-CA 126.467 1.907 . . . . 10.0 115.208 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 109.83 -14.62 31.82 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 126.731 2.11 . . . . 10.0 115.02 -177.313 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -82.09 157.42 24.1 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 118.9 1.35 . . . . 10.0 110.687 168.896 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.8 p -72.91 158.25 35.85 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.936 0.894 . . . . 10.0 112.339 172.358 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.6 t -133.98 90.83 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 126.278 1.831 . . . . 10.0 108.898 172.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -68.77 143.48 54.63 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.254 0.622 . . . . 10.0 110.412 169.815 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.3 p -69.39 149.53 48.28 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.374 0.67 . . . . 10.0 112.163 173.098 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.18 -172.68 4.3 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.186 1.794 . . . . 10.0 111.983 178.103 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.09 -18.34 46.26 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 114.774 1.398 . . . . 10.0 114.774 -178.472 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.8 mt -113.12 -15.07 12.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.915 1.686 . . . . 10.0 113.531 179.479 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -126.43 96.81 4.81 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.82 2.048 . . . . 10.0 109.755 -177.206 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -110.61 126.17 54.19 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.25 1.02 . . . . 10.0 111.207 -168.323 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -128.89 109.06 10.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.427 1.891 . . . . 10.0 110.033 -173.044 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.22 164.83 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 125.615 1.566 . . . . 10.0 111.858 -178.172 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.5 t -125.6 106.82 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 125.513 1.525 . . . . 10.0 109.688 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -74.31 164.93 26.01 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.525 1.13 . . . . 10.0 112.536 176.515 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -57.12 156.61 6.93 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.945 1.298 . . . . 10.0 112.018 173.199 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt 64.68 6.47 3.26 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 127.392 2.277 . . . . 10.0 114.642 -170.431 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 83.77 55.68 2.78 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.307 1.432 . . . . 10.0 114.041 171.854 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.31 101.36 7.92 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.892 1.277 . . . . 10.0 110.11 177.16 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -79.64 112.55 17.01 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.91 1.284 . . . . 10.0 111.197 174.733 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.8 m -83.34 146.78 28.31 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 124.753 1.221 . . . . 10.0 112.197 172.146 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.82 120.1 24.44 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.401 1.88 . . . . 10.0 107.088 161.756 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.7 mt -121.31 139.06 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.494 1.518 . . . . 10.0 110.453 -174.166 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -120.42 110.74 16.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 127.584 2.354 . . . . 10.0 109.522 176.746 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.83 -42.89 85.07 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 121.343 -0.848 . . . . 10.0 113.202 179.465 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.0 89.42 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.806 1.642 . . . . 10.0 110.161 -177.361 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.6 p -70.37 140.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.284 -0.885 . . . . 10.0 112.203 -176.239 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -119.93 160.79 22.03 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.358 1.863 . . . . 10.0 112.157 176.717 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.11 -32.56 66.46 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 113.726 1.01 . . . . 10.0 113.726 -177.45 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.4 t -65.13 -21.75 66.84 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.106 1.362 . . . . 10.0 113.776 175.209 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -79.48 -5.32 54.55 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.779 1.231 . . . . 10.0 113.611 -179.832 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.65 152.17 44.81 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.168 -0.957 . . . . 10.0 113.236 178.624 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.59 -168.98 22.53 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.633 1.111 . . . . 10.0 115.043 174.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.67 103.03 11.88 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.909 1.684 . . . . 10.0 111.551 177.856 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 -78.82 149.7 32.48 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.037 0.935 . . . . 10.0 111.678 169.714 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.94 160.93 40.55 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.901 0.881 . . . . 10.0 112.265 170.413 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.45 120.53 17.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.543 1.537 . . . . 10.0 110.858 177.12 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 59.1 t -92.36 126.39 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.757 1.223 . . . . 10.0 108.996 171.204 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -119.27 126.11 50.7 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 126.428 1.891 . . . . 10.0 110.747 -178.957 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -134.47 133.33 40.31 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 125.259 1.423 . . . . 10.0 112.516 -170.698 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.7 p30 -130.55 -179.1 5.08 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.741 1.216 . . . . 10.0 111.533 166.535 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -60.89 -12.77 12.14 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 115.618 1.71 . . . . 10.0 115.618 -179.465 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -109.44 -17.63 13.73 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.521 1.528 . . . . 10.0 114.392 -178.282 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 168.64 -169.2 41.55 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 115.972 1.149 . . . . 10.0 115.972 177.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -133.77 146.56 50.84 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.986 2.114 . . . . 10.0 111.745 -172.088 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.2 160.1 40.31 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.317 1.847 . . . . 10.0 110.974 169.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.3 m -136.33 130.56 33.06 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.722 1.209 . . . . 10.0 111.379 177.759 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -113.65 153.65 28.56 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.204 1.801 . . . . 10.0 110.659 177.81 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.7 m -143.09 148.19 36.25 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.598 1.159 . . . . 10.0 112.37 -173.13 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.41 169.15 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 C-N-CA 126.994 2.117 . . . . 10.0 110.763 169.468 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 52.4 tt0 -128.04 137.04 52.03 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.196 1.399 . . . . 10.0 111.088 174.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.5 tp -125.65 107.14 10.28 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.958 1.703 . . . . 10.0 111.077 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -88.96 87.47 7.23 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.259 1.424 . . . . 10.0 110.869 172.773 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -67.36 112.35 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.242 -0.911 . . . . 10.0 110.061 175.45 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.6 mt -75.3 94.65 3.05 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 126.104 1.762 . . . . 10.0 109.875 -179.747 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 124.765 1.226 . . . . 10.0 113.53 -175.769 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo . . . . . 0 CA--C 1.544 0.991 0 N-CA-C 113.134 0.398 . . . . 10.0 113.134 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -68.07 167.67 21.14 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 123.303 2.668 . . . . 10.0 111.634 169.191 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 2.1 tpt180 -139.42 175.22 9.75 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.664 1.186 . . . . 10.0 112.803 -172.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -103.92 95.48 6.04 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 126.394 1.878 . . . . 10.0 110.326 -175.643 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . 0.59 HG21 ' H ' ' A' ' 254' ' ' GLN . 0.4 OUTLIER -115.61 -179.28 1.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.99 0 C-N-CA 126.298 1.839 . . . . 10.0 109.779 -179.655 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.59 ' H ' HG21 ' A' ' 253' ' ' ILE . 41.8 tt0 -46.15 123.37 4.61 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.507 2.323 . . . . 10.0 115.026 -166.535 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 19.1 m -106.84 153.83 40.56 Favored Pre-proline 0 N--CA 1.474 0.769 0 C-N-CA 126.425 1.89 . . . . 10.0 110.365 167.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.25 158.49 44.94 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.759 2.306 . . . . 10.0 111.705 169.902 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -66.29 172.4 3.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 124.606 1.162 . . . . 10.0 111.841 167.342 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -60.32 153.72 21.93 Favored 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.99 -1.068 . . . . 10.0 111.857 170.311 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 84.8 mtp -133.01 155.9 48.33 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.994 1.318 . . . . 10.0 112.179 -169.647 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 47.6 p -141.81 122.86 14.6 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 125.505 1.522 . . . . 10.0 110.903 175.091 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.5 mm -134.18 132.38 55.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.546 1.538 . . . . 10.0 109.901 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -63.99 129.12 38.78 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.235 1.014 . . . . 10.0 112.101 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -54.31 131.82 42.6 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.201 1.4 . . . . 10.0 112.683 -177.736 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.76 -10.11 66.34 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 126.042 1.782 . . . . 10.0 115.07 179.11 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 78.3 mtp85 -71.47 160.98 31.76 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 119.005 1.402 . . . . 10.0 113.061 175.91 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -71.18 145.8 49.49 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 124.014 0.926 . . . . 10.0 110.368 155.684 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 16.6 t -147.45 163.79 35.4 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.7 1.2 . . . . 10.0 111.405 168.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -143.85 157.52 44.31 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.589 1.556 . . . . 10.0 111.806 167.706 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 53.2 mtt -129.22 150.42 50.61 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 127.117 2.167 . . . . 10.0 109.187 171.454 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -142.12 126.08 17.23 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.317 1.047 . . . . 10.0 111.479 -169.85 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -130.86 123.69 29.59 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 126.745 2.018 . . . . 10.0 111.151 -168.718 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -70.27 130.81 43.02 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.493 -0.754 . . . . 10.0 110.301 171.472 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.77 149.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 126.109 1.763 . . . . 10.0 111.138 -175.592 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 6.1 t -147.24 -174.08 4.42 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 125.144 1.377 . . . . 10.0 112.113 -176.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.18 162.47 23.7 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 127.319 2.39 . . . . 10.0 112.864 -174.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -146.48 128.07 7.48 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.874 1.27 . . . . 10.0 110.567 -179.698 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -66.7 169.4 47.55 Favored 'Cis proline' 0 CA--C 1.539 0.743 0 CA-C-N 120.88 1.35 . . . . 10.0 112.658 -2.149 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.72 122.77 48.04 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.752 1.221 . . . . 10.0 111.575 -178.463 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -71.11 159.95 50.66 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 122.597 2.198 . . . . 10.0 113.359 -174.292 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.7 168.94 10.36 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.799 1.24 . . . . 10.0 111.851 166.426 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 71.5 t -130.24 123.76 56.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.691 1.597 . . . . 10.0 110.397 -178.366 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.2 m -134.82 150.35 50.49 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.68 1.592 . . . . 10.0 110.661 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 47.6 m95 -130.06 157.82 41.34 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 124.884 1.274 . . . . 10.0 112.593 179.151 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -143.91 159.19 43.0 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.674 1.99 . . . . 10.0 111.413 -177.292 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.1 tp -144.99 118.24 8.95 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 127.128 2.171 . . . . 10.0 109.943 175.844 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 54.91 14.79 0.97 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.508 1.923 . . . . 10.0 115.177 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.8 -13.23 35.06 Favored Glycine 0 CA--C 1.539 1.556 0 C-N-CA 126.709 2.1 . . . . 10.0 115.182 -178.061 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.9 mtp180 -85.89 157.11 20.26 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.971 1.385 . . . . 10.0 110.961 170.134 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.6 p -71.41 155.25 40.84 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.358 1.063 . . . . 10.0 112.765 174.432 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 61.1 t -134.0 102.65 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.729 2.012 . . . . 10.0 108.597 172.834 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -74.61 161.4 29.75 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.463 0.705 . . . . 10.0 111.4 172.547 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 58.4 p -67.99 154.41 41.68 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.363 0.665 . . . . 10.0 111.785 168.163 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -153.6 168.68 25.4 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.144 1.377 . . . . 10.0 111.03 177.799 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.8 -35.18 68.43 Favored 'General case' 0 CA--C 1.544 0.749 0 O-C-N 120.933 -1.105 . . . . 10.0 112.696 168.84 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 69.8 mt -82.83 -14.25 54.69 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.553 1.141 . . . . 10.0 113.916 173.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.4 m80 -136.16 69.91 1.42 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.954 1.701 . . . . 10.0 111.216 -173.427 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.53 143.02 51.77 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.786 1.235 . . . . 10.0 111.134 -177.671 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -136.85 103.58 5.22 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.649 1.98 . . . . 10.0 109.718 -174.695 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.45 158.99 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.823 1.249 . . . . 10.0 112.18 -175.389 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -134.5 111.42 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 125.31 1.444 . . . . 10.0 110.035 -178.614 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 58.6 m -66.53 145.83 55.19 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.904 0.882 . . . . 10.0 111.401 173.269 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.47 -17.52 59.71 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.526 1.53 . . . . 10.0 114.622 -176.237 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -75.36 -4.82 41.51 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.058 1.743 . . . . 10.0 114.108 173.621 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.82 47.38 3.68 Favored Glycine 0 CA--C 1.532 1.098 0 C-N-CA 125.134 1.35 . . . . 10.0 113.219 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.94 105.71 6.51 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.085 1.354 . . . . 10.0 110.224 -176.129 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -85.45 124.94 32.61 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.073 1.349 . . . . 10.0 111.447 174.751 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 38.0 m -109.0 142.94 38.95 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.398 1.479 . . . . 10.0 111.915 175.695 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -132.79 115.85 15.83 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.538 2.335 . . . . 10.0 108.887 -178.306 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 153.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.785 1.234 . . . . 10.0 111.44 -171.402 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -128.49 103.65 7.25 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.398 2.279 . . . . 10.0 109.05 164.663 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -65.34 -38.96 91.73 Favored 'General case' 0 N--CA 1.475 0.825 0 O-C-N 120.872 -1.143 . . . . 10.0 113.072 178.738 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.56 87.71 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.838 1.655 . . . . 10.0 110.245 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.58 137.39 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 O-C-N 121.241 -0.912 . . . . 10.0 111.928 -177.555 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -117.34 161.15 19.99 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.091 1.757 . . . . 10.0 112.094 176.57 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.91 -34.12 65.29 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -177.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.0 m -65.37 -16.6 63.77 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 125.515 1.526 . . . . 10.0 114.565 175.468 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -81.95 -5.33 58.21 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.695 1.198 . . . . 10.0 113.348 178.33 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.49 151.44 46.37 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.025 -1.047 . . . . 10.0 112.773 175.908 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.96 -171.89 21.59 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 124.97 1.271 . . . . 10.0 114.846 176.892 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.01 105.74 14.25 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.891 1.676 . . . . 10.0 111.252 176.518 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -80.6 152.7 28.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.206 1.002 . . . . 10.0 111.963 169.479 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.92 44.52 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.905 0.882 . . . . 10.0 111.933 166.231 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 51.3 t -130.66 143.61 50.86 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.666 1.987 . . . . 10.0 109.789 177.018 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 99.0 t -126.38 129.66 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 125.57 1.548 . . . . 10.0 109.673 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -123.58 118.81 28.18 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.404 1.881 . . . . 10.0 110.433 -178.529 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -131.95 138.23 48.24 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 125.373 1.469 . . . . 10.0 111.822 -173.467 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -134.14 -177.48 4.6 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.936 1.295 . . . . 10.0 111.358 168.174 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -60.91 -11.63 8.56 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 115.727 1.751 . . . . 10.0 115.727 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.49 -19.82 12.42 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 125.569 1.548 . . . . 10.0 114.503 -178.107 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.4 -168.92 41.99 Favored Glycine 0 CA--C 1.534 1.252 0 N-CA-C 116.371 1.308 . . . . 10.0 116.371 178.984 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -135.71 142.41 45.05 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.29 2.236 . . . . 10.0 111.683 -172.059 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.05 162.53 33.9 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.052 1.741 . . . . 10.0 111.309 169.011 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -141.4 146.09 36.14 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.023 1.329 . . . . 10.0 110.753 -172.511 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -133.45 154.22 50.97 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.349 1.46 . . . . 10.0 110.774 177.263 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.7 m -144.27 144.71 31.62 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.489 1.116 . . . . 10.0 111.615 -171.491 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.8 p -153.23 164.02 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 126.126 1.77 . . . . 10.0 110.698 172.414 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -125.17 138.71 54.14 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 124.79 1.236 . . . . 10.0 111.13 174.888 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -124.61 120.04 30.77 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.997 1.719 . . . . 10.0 111.068 -177.829 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -105.69 86.24 2.36 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.064 1.746 . . . . 10.0 110.723 176.694 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 23.8 t -67.47 109.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 123.992 0.917 . . . . 10.0 110.607 -179.581 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 66.1 mt -72.98 103.11 3.66 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 126.324 1.85 . . . . 10.0 109.853 178.798 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 113.887 1.069 . . . . 10.0 113.887 -172.069 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 CA--C 1.544 1.007 0 N-CA-C 113.077 0.376 . . . . 10.0 113.077 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.54 160.49 49.1 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 123.146 2.564 . . . . 10.0 112.083 171.013 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.27 168.96 23.69 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.266 1.426 . . . . 10.0 112.539 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -72.98 146.47 45.98 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.517 1.527 . . . . 10.0 111.988 173.269 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.2 mp -136.4 -64.08 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 125.699 1.6 . . . . 10.0 109.054 168.539 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -151.7 138.39 18.8 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.716 1.606 . . . . 10.0 110.521 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.6 m -133.37 151.99 78.5 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.773 1.629 . . . . 10.0 110.404 173.688 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.24 148.03 67.56 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 122.652 2.234 . . . . 10.0 112.348 175.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -74.53 176.5 6.79 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.489 1.115 . . . . 10.0 111.253 166.273 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -54.37 122.86 11.32 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.04 -1.037 . . . . 10.0 112.508 176.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.6 mtp -101.31 159.02 15.62 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.01 1.724 . . . . 10.0 111.872 -177.2 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 p -146.82 115.28 6.71 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.178 1.391 . . . . 10.0 111.259 177.708 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.0 mm -127.01 134.22 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.595 1.558 . . . . 10.0 110.166 -169.221 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -63.98 131.85 48.89 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.683 1.193 . . . . 10.0 112.666 176.202 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -52.74 121.54 7.4 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.758 1.623 . . . . 10.0 112.962 -178.941 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 103.81 -9.31 51.56 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 126.2 1.857 . . . . 10.0 115.106 177.829 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.8 mtp180 -72.05 159.51 34.07 Favored 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 119.173 1.486 . . . . 10.0 113.398 177.449 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -72.55 147.7 45.67 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.54 1.136 . . . . 10.0 110.412 156.513 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 15.0 t -149.49 162.82 39.39 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.329 1.052 . . . . 10.0 111.941 170.199 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.0 ptm85 -143.08 164.26 30.59 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.67 1.588 . . . . 10.0 112.107 165.541 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.0 mtt -126.11 159.97 31.42 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 126.802 2.041 . . . . 10.0 110.654 173.883 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -136.72 89.95 2.5 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.416 1.486 . . . . 10.0 111.025 -169.369 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -100.72 106.06 17.46 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.24 1.416 . . . . 10.0 111.029 -178.329 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -67.05 133.07 49.17 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 121.62 -0.675 . . . . 10.0 110.117 171.17 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.7 p -143.71 146.43 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 125.467 1.507 . . . . 10.0 111.392 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 93.6 p -128.6 -165.7 1.54 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.974 1.71 . . . . 10.0 112.733 -174.687 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 98.99 163.45 29.88 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 126.298 1.904 . . . . 10.0 112.813 -178.264 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -142.68 127.09 9.83 Favored Pre-proline 0 CA--C 1.546 0.797 0 C-N-CA 125.507 1.523 . . . . 10.0 109.555 177.781 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -66.26 169.16 46.24 Favored 'Cis proline' 0 CA--C 1.54 0.825 0 CA-C-N 120.312 1.147 . . . . 10.0 112.584 -4.193 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.96 70.01 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.386 1.075 . . . . 10.0 111.046 178.479 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.63 148.53 59.67 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 122.284 1.989 . . . . 10.0 113.834 -169.155 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -67.43 132.83 48.42 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.384 1.474 . . . . 10.0 109.561 158.43 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.1 m -124.0 138.64 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.514 1.126 . . . . 10.0 112.155 -173.276 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 48.1 m -135.25 154.08 51.7 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.975 1.71 . . . . 10.0 110.755 178.221 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -124.93 153.21 43.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.536 1.135 . . . . 10.0 113.389 -176.469 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.3 m-85 -145.1 160.29 41.64 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.088 2.155 . . . . 10.0 111.15 -172.372 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 58.3 tp -149.87 122.34 8.5 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 126.695 1.998 . . . . 10.0 110.332 178.171 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 54.98 6.97 0.14 Allowed 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 126.995 2.118 . . . . 10.0 116.595 174.864 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 121.21 -6.18 10.92 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.2 1.857 . . . . 10.0 115.725 -177.189 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.0 ptm180 -108.09 165.44 11.47 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 119.254 1.527 . . . . 10.0 112.227 171.637 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.8 p -72.47 158.1 36.37 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.861 1.264 . . . . 10.0 112.437 172.302 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 44.4 t -131.09 101.72 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 126.076 1.751 . . . . 10.0 108.372 171.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 11.5 mp0 -67.04 149.95 49.9 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.573 1.149 . . . . 10.0 111.295 176.818 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.4 p -65.54 138.98 58.42 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.45 0.7 . . . . 10.0 110.922 167.698 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -146.8 167.96 22.58 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.721 1.208 . . . . 10.0 111.819 -176.479 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -56.79 -35.07 68.29 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.162 -0.961 . . . . 10.0 113.105 171.023 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 70.4 mt -85.76 -15.17 42.96 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.996 1.11 . . . . 10.0 113.996 174.834 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.5 m80 -135.72 73.03 1.45 Allowed 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.975 1.71 . . . . 10.0 111.088 -174.35 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -73.02 143.66 47.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 125.144 1.377 . . . . 10.0 111.329 -178.173 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 58.8 mtt -142.44 105.25 4.54 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.864 1.666 . . . . 10.0 110.214 -172.338 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.92 144.77 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.161 0.984 . . . . 10.0 112.46 -178.667 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 48.0 t -95.16 100.52 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 125.154 1.382 . . . . 10.0 108.757 175.484 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 15.2 m -64.3 168.76 5.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.693 1.997 . . . . 10.0 112.741 176.307 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -62.01 165.45 5.54 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.541 1.136 . . . . 10.0 113.793 174.705 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 96.6 mttt 56.76 20.69 5.31 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 126.874 2.07 . . . . 10.0 115.794 173.129 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.42 53.83 2.98 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.816 1.198 . . . . 10.0 114.131 173.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 52.0 tp -137.16 146.56 45.11 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.726 1.61 . . . . 10.0 110.517 179.505 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -126.84 115.72 19.76 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.997 1.319 . . . . 10.0 111.359 -179.784 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.0 m -80.83 129.19 34.4 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.834 1.654 . . . . 10.0 111.819 172.366 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -128.35 119.43 25.04 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.088 2.155 . . . . 10.0 107.645 170.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 54.4 mt -119.68 154.06 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.808 1.243 . . . . 10.0 111.662 -164.464 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -131.57 108.65 9.69 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 127.848 2.459 . . . . 10.0 109.35 173.468 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -66.36 -43.21 86.65 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 120.985 -1.072 . . . . 10.0 113.031 177.432 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.71 89.12 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.791 1.637 . . . . 10.0 110.16 -177.685 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -70.09 139.48 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.353 -0.842 . . . . 10.0 112.26 -176.322 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -121.91 163.53 19.1 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.312 1.845 . . . . 10.0 112.045 175.408 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.06 -30.33 66.1 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.574 0.953 . . . . 10.0 113.574 -178.686 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.7 p -67.82 -16.9 64.32 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.657 1.583 . . . . 10.0 114.681 173.648 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -83.66 -5.63 59.23 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.633 1.173 . . . . 10.0 113.356 175.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.83 154.43 39.16 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.027 -1.046 . . . . 10.0 113.352 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.01 -169.72 21.99 Favored Glycine 0 CA--C 1.532 1.123 0 C-N-CA 124.67 1.128 . . . . 10.0 115.043 174.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.81 100.19 10.79 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.966 1.706 . . . . 10.0 111.392 177.626 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -75.11 151.57 38.6 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.214 1.006 . . . . 10.0 111.679 167.432 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.36 159.01 43.15 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.94 0.896 . . . . 10.0 112.157 168.71 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -130.69 144.47 51.46 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.545 1.938 . . . . 10.0 110.223 177.272 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.3 t -126.57 116.11 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 125.49 1.516 . . . . 10.0 109.347 179.229 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -106.3 126.58 52.41 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.452 1.901 . . . . 10.0 110.806 -178.255 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -132.47 127.58 35.58 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 126.439 1.896 . . . . 10.0 111.774 -168.058 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -134.33 177.73 7.53 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.864 0.757 . . . . 10.0 112.238 164.211 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 -62.47 -11.13 14.25 Favored 'General case' 0 N--CA 1.48 1.072 0 N-CA-C 115.536 1.68 . . . . 10.0 115.536 -178.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.49 -15.37 14.81 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.569 1.548 . . . . 10.0 114.088 178.138 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.18 -170.39 38.61 Favored Glycine 0 CA--C 1.536 1.369 0 CA-C-N 119.659 1.118 . . . . 10.0 115.423 176.365 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -134.06 149.59 51.15 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 126.059 1.744 . . . . 10.0 111.892 -172.775 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.42 162.73 33.71 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.237 1.815 . . . . 10.0 111.501 171.144 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 30.1 m -140.28 135.97 32.81 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.938 1.295 . . . . 10.0 110.758 -175.7 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -129.72 154.02 47.58 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.669 1.588 . . . . 10.0 110.976 -178.059 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -144.84 145.61 31.7 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.236 1.014 . . . . 10.0 112.017 -169.421 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.6 p -152.27 150.46 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 125.661 1.584 . . . . 10.0 111.696 170.46 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.3 tt0 -100.91 139.2 36.94 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.531 1.133 . . . . 10.0 111.004 171.655 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.9 tp -123.25 103.86 8.79 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.89 1.676 . . . . 10.0 110.566 175.898 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -90.73 82.9 5.71 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.63 1.572 . . . . 10.0 110.981 175.861 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.9 t -63.69 112.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.844 0.858 . . . . 10.0 110.621 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.7 mt -75.34 98.54 3.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.288 1.835 . . . . 10.0 110.184 -179.22 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.758 0 C-N-CA 124.062 0.945 . . . . 10.0 112.72 179.351 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.522 0 N-CA-C 111.192 -0.763 . . . . 10.0 111.192 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.32 162.01 15.67 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.232 1.013 . . . . 10.0 112.794 175.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.99 174.09 11.84 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.901 1.681 . . . . 10.0 111.823 -176.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -179.06 173.05 45.27 Favored Glycine 0 CA--C 1.542 1.777 0 N-CA-C 116.858 1.503 . . . . 10.0 116.858 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -70.84 162.18 43.5 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.722 2.948 . . . . 10.0 113.258 -172.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -66.96 152.08 80.99 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.859 2.373 . . . . 10.0 111.427 168.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 68.9 ttt180 -142.52 162.68 34.84 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 125.764 1.626 . . . . 10.0 111.542 -177.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -71.33 141.29 50.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.321 1.449 . . . . 10.0 112.224 173.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.1 mp -135.47 -66.14 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.544 1.538 . . . . 10.0 109.724 171.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 -149.56 140.3 22.67 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.34 1.456 . . . . 10.0 111.105 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 24.7 m -127.26 152.59 76.32 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 126.207 1.803 . . . . 10.0 110.287 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.3 156.91 50.49 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.87 2.38 . . . . 10.0 112.016 176.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.63 167.28 22.12 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.114 0.966 . . . . 10.0 112.67 172.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -60.2 106.9 0.57 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 124.839 1.256 . . . . 10.0 111.698 173.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 26.4 mtm -79.4 154.57 28.88 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 123.653 0.781 . . . . 10.0 112.467 -175.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.7 p -138.43 110.13 7.11 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 125.306 1.442 . . . . 10.0 110.539 170.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.8 mm -126.85 131.12 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.314 1.446 . . . . 10.0 110.391 -163.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -59.43 131.92 52.42 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.646 1.178 . . . . 10.0 112.558 173.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -51.97 129.83 28.05 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 125.159 1.384 . . . . 10.0 112.674 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.75 -8.91 76.37 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 125.497 1.522 . . . . 10.0 115.278 177.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -70.87 161.61 30.71 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 119.321 1.56 . . . . 10.0 113.051 175.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -73.47 138.48 45.14 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.55 1.14 . . . . 10.0 110.043 155.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.1 p -149.42 169.4 20.95 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.468 0.707 . . . . 10.0 112.348 164.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -147.45 155.56 42.04 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.855 1.262 . . . . 10.0 112.975 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -122.39 143.36 49.71 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 128.028 2.531 . . . . 10.0 108.925 173.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -139.5 114.56 9.57 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.187 0.995 . . . . 10.0 111.936 -170.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -115.85 113.79 23.84 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.222 2.209 . . . . 10.0 110.42 -173.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.3 mtpp -67.99 133.85 49.74 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.473 -0.767 . . . . 10.0 110.015 170.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -140.94 125.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.521 1.528 . . . . 10.0 111.139 -174.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 50.6 m -136.03 103.34 5.32 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.798 1.239 . . . . 10.0 111.467 -176.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -154.9 165.08 32.04 Favored Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.983 2.23 . . . . 10.0 110.662 169.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.6 tp -141.91 125.85 9.97 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.129 0.971 . . . . 10.0 110.847 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -65.43 167.16 49.53 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.63 1.261 . . . . 10.0 112.511 -2.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.09 121.84 44.01 Favored Pre-proline 0 CA--C 1.549 0.915 0 C-N-CA 124.483 1.113 . . . . 10.0 111.202 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.77 150.79 68.64 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.492 2.128 . . . . 10.0 113.076 -172.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -73.62 143.77 46.2 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.146 0.979 . . . . 10.0 109.666 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.61 136.23 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.796 0.839 . . . . 10.0 111.858 -174.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -126.99 157.71 38.81 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.897 1.679 . . . . 10.0 111.68 173.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 51.0 m95 -125.97 154.88 42.25 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 125.533 1.533 . . . . 10.0 113.666 -173.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -144.49 161.12 39.88 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.26 2.224 . . . . 10.0 111.96 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.1 tp -146.56 124.35 11.91 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.748 2.419 . . . . 10.0 109.69 173.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.01 14.28 0.68 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 126.775 2.03 . . . . 10.0 116.064 175.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.36 0.55 24.99 Favored Glycine 0 CA--C 1.539 1.552 0 C-N-CA 125.693 1.616 . . . . 10.0 116.043 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.0 ptp85 -123.93 163.19 21.82 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 125.679 1.592 . . . . 10.0 112.177 173.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.4 p -69.65 159.59 33.17 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.596 1.158 . . . . 10.0 113.616 -175.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 92.7 t -134.92 108.1 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 126.93 2.092 . . . . 10.0 108.939 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -77.01 159.66 29.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 123.724 0.81 . . . . 10.0 111.365 170.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 81.3 p -76.91 155.48 32.77 Favored 'General case' 0 N--CA 1.473 0.683 0 O-C-N 121.645 -0.659 . . . . 10.0 112.144 168.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -155.71 -176.39 5.93 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.578 1.551 . . . . 10.0 111.576 168.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -62.08 -18.18 59.92 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -177.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 68.7 mt -107.37 -26.67 10.88 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.845 1.658 . . . . 10.0 112.266 175.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -108.74 68.78 0.69 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.828 2.051 . . . . 10.0 110.711 177.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -74.25 146.09 43.55 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.346 1.058 . . . . 10.0 111.839 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 65.7 mtt -138.89 114.69 9.99 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.533 1.933 . . . . 10.0 110.184 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.55 155.82 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.928 1.291 . . . . 10.0 111.776 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.1 p -141.21 122.02 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.595 1.158 . . . . 10.0 111.238 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 38.7 t -74.87 141.8 44.17 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.485 1.114 . . . . 10.0 111.65 175.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.78 -17.68 37.39 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.769 1.228 . . . . 10.0 113.688 170.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -76.47 -4.2 41.32 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.936 1.694 . . . . 10.0 113.917 174.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.68 39.43 4.15 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.979 1.275 . . . . 10.0 114.867 172.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.2 tp -136.55 114.78 11.61 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 125.109 1.364 . . . . 10.0 111.122 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 5.1 t60 -98.35 132.88 43.46 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.21 1.404 . . . . 10.0 110.994 174.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 37.9 m -121.89 138.07 54.54 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.558 1.543 . . . . 10.0 111.487 -178.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -128.06 117.84 22.38 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 127.713 2.405 . . . . 10.0 107.85 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 85.3 mt -118.63 148.45 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.471 1.108 . . . . 10.0 111.064 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -123.07 106.31 10.69 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 127.355 2.262 . . . . 10.0 109.014 171.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -63.59 -38.3 90.61 Favored 'General case' 0 N--CA 1.475 0.781 0 O-C-N 121.296 -0.878 . . . . 10.0 113.09 176.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.2 p -150.76 90.1 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.889 1.676 . . . . 10.0 110.248 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -68.48 144.75 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 O-C-N 121.27 -0.894 . . . . 10.0 112.101 -178.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -129.21 162.17 28.45 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.03 1.732 . . . . 10.0 112.005 174.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.54 -34.38 64.65 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 113.642 0.979 . . . . 10.0 113.642 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.1 m -64.87 -17.15 64.03 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.387 1.475 . . . . 10.0 114.509 175.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -81.7 -8.28 59.68 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.513 1.125 . . . . 10.0 113.328 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.72 150.64 43.99 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 119.219 0.918 . . . . 10.0 112.933 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.9 -172.2 22.71 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.563 1.078 . . . . 10.0 114.789 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.87 101.95 13.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.963 1.705 . . . . 10.0 111.209 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -76.15 150.85 37.11 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.225 1.01 . . . . 10.0 111.501 167.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.5 161.97 38.49 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.906 0.883 . . . . 10.0 111.545 169.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 30.8 p -144.88 161.87 38.25 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.186 0.994 . . . . 10.0 112.044 171.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.98 131.25 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.273 1.429 . . . . 10.0 110.072 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.47 126.8 54.77 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.651 1.98 . . . . 10.0 110.044 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -133.93 129.06 35.75 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.644 1.577 . . . . 10.0 112.012 -169.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.5 p30 -132.21 -179.46 5.44 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.448 1.099 . . . . 10.0 111.832 166.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -60.51 -14.68 21.07 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.657 1.725 . . . . 10.0 115.657 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.84 -16.38 14.48 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.288 1.435 . . . . 10.0 114.276 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.93 -170.17 40.55 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 115.876 1.11 . . . . 10.0 115.876 177.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -134.68 146.72 49.75 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.852 2.061 . . . . 10.0 111.7 -172.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.81 153.11 49.68 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.753 1.621 . . . . 10.0 110.982 169.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 25.2 m -137.55 136.78 37.93 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.832 1.253 . . . . 10.0 110.552 -172.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -134.89 153.72 51.95 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.964 1.306 . . . . 10.0 111.524 -173.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.0 m -142.33 144.5 33.24 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 125.251 1.42 . . . . 10.0 111.456 -173.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.9 p -151.8 156.72 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 C-N-CA 125.695 1.598 . . . . 10.0 111.271 170.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -107.89 148.89 29.0 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 124.349 1.06 . . . . 10.0 111.746 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.29 114.96 18.29 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.469 1.907 . . . . 10.0 110.222 174.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -103.46 84.74 2.35 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.719 1.608 . . . . 10.0 110.685 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.8 t -67.23 110.96 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.708 0.803 . . . . 10.0 110.871 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 75.7 mt -75.95 101.03 5.05 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.731 2.012 . . . . 10.0 110.567 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -64.21 161.91 15.57 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.058 0.943 . . . . 10.0 112.87 175.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -127.79 16.04 6.91 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 125.69 1.596 . . . . 10.0 114.889 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? . . . . . 0 C--O 1.253 1.241 0 C-N-CA 126.463 1.905 . . . . 10.0 114.656 172.834 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.577 0 N-CA-C 112.0 -0.44 . . . . 10.0 112.0 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -62.94 143.69 57.47 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.268 1.027 . . . . 10.0 113.013 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -64.62 166.4 8.71 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.666 1.586 . . . . 10.0 113.8 174.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.52 160.6 34.24 Favored Glycine 0 CA--C 1.541 1.69 0 C-N-CA 125.707 1.622 . . . . 10.0 113.166 174.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.1 163.72 36.67 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.865 3.043 . . . . 10.0 113.29 -171.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -67.33 148.31 79.59 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.825 2.35 . . . . 10.0 111.435 173.477 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 32.7 ttp-105 -138.09 136.9 37.22 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.855 1.262 . . . . 10.0 113.208 -173.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -63.58 117.26 6.54 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 127.274 2.23 . . . . 10.0 110.997 170.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 35.8 mm -108.35 -54.26 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.735 0.814 . . . . 10.0 110.328 171.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -153.18 142.68 21.76 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.412 1.085 . . . . 10.0 111.433 172.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.53 148.48 53.06 Favored Pre-proline 0 N--CA 1.476 0.862 0 C-N-CA 125.247 1.419 . . . . 10.0 110.073 169.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -77.13 163.69 30.29 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.965 2.443 . . . . 10.0 112.117 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -73.1 166.74 22.54 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.593 0.757 . . . . 10.0 111.43 166.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -62.44 160.9 12.64 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.364 -0.835 . . . . 10.0 112.081 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 51.0 mtm -133.49 161.25 35.1 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.181 0.992 . . . . 10.0 112.939 -178.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 55.2 p -137.88 115.64 11.43 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 125.907 1.683 . . . . 10.0 109.854 168.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.6 mm -124.51 132.9 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.306 1.442 . . . . 10.0 110.05 -166.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -59.56 126.51 27.91 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.402 1.481 . . . . 10.0 112.475 173.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -50.23 126.75 15.5 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.599 1.56 . . . . 10.0 112.679 176.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.99 -11.75 58.91 Favored Glycine 0 CA--C 1.537 1.468 0 C-N-CA 126.182 1.849 . . . . 10.0 115.088 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -75.53 162.39 28.34 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 119.2 1.5 . . . . 10.0 113.418 177.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -76.69 143.3 40.13 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.076 1.351 . . . . 10.0 110.328 157.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 28.6 p -150.82 168.97 22.83 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.608 0.763 . . . . 10.0 112.621 162.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.8 ptm85 -144.12 168.93 18.86 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.426 1.49 . . . . 10.0 112.966 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.7 mtt -131.81 158.82 40.27 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.974 2.11 . . . . 10.0 110.867 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -136.15 92.61 2.81 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.144 1.378 . . . . 10.0 112.139 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -108.41 104.02 13.29 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.456 1.502 . . . . 10.0 111.319 -176.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.1 mtpp -81.7 122.98 28.33 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 121.077 -1.014 . . . . 10.0 110.322 173.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.43 151.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.803 2.041 . . . . 10.0 110.633 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.9 t -131.1 175.7 8.88 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.18 1.392 . . . . 10.0 111.419 172.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 136.7 167.53 11.17 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 127.418 2.437 . . . . 10.0 112.445 -175.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.33 119.79 5.16 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 123.878 0.871 . . . . 10.0 111.707 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.8 169.44 59.05 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 CA-C-N 120.459 1.2 . . . . 10.0 112.473 -1.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.85 127.79 75.31 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.059 0.943 . . . . 10.0 110.838 175.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.69 148.32 65.28 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 122.298 1.999 . . . . 10.0 113.062 -172.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -71.01 142.02 50.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.353 1.061 . . . . 10.0 109.583 160.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 10.8 m -127.02 137.67 57.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 124.618 1.167 . . . . 10.0 112.583 -170.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.1 m -137.57 112.55 9.05 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.109 1.764 . . . . 10.0 110.758 -174.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -85.87 152.76 22.73 Favored 'General case' 0 CA--C 1.536 0.417 0 N-CA-C 113.475 0.917 . . . . 10.0 113.475 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.41 158.89 43.21 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.386 2.274 . . . . 10.0 111.129 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.15 117.78 8.62 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 127.153 2.181 . . . . 10.0 110.109 177.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 55.14 10.98 0.47 Allowed 'General case' 0 CA--C 1.555 1.172 0 C-N-CA 126.747 2.019 . . . . 10.0 115.573 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.27 -15.63 17.97 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 126.832 2.158 . . . . 10.0 115.047 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -84.09 157.45 21.74 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 118.988 1.394 . . . . 10.0 111.088 169.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.9 p -71.71 157.91 37.09 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.281 1.033 . . . . 10.0 112.137 170.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.8 105.77 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 126.303 1.841 . . . . 10.0 108.676 173.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 23.0 mm100 -76.26 159.83 30.23 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.218 0.607 . . . . 10.0 111.495 173.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 36.7 p -67.06 150.8 48.7 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.692 0.797 . . . . 10.0 111.928 169.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -150.76 166.01 31.77 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.179 1.392 . . . . 10.0 111.128 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -54.86 -36.56 65.21 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.147 -0.97 . . . . 10.0 113.1 170.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.0 mt -84.22 -13.77 51.79 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.434 1.094 . . . . 10.0 113.863 174.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -135.04 70.95 1.43 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.93 1.692 . . . . 10.0 111.322 -173.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.08 143.12 49.17 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.049 1.339 . . . . 10.0 111.73 -175.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -139.6 101.99 4.35 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.644 1.978 . . . . 10.0 110.055 -174.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.14 162.73 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.254 1.422 . . . . 10.0 111.557 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.86 118.15 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.899 1.279 . . . . 10.0 110.994 177.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 63.3 m -68.56 158.44 33.91 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.328 1.051 . . . . 10.0 112.218 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -61.24 -21.26 63.71 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 114.243 1.201 . . . . 10.0 114.243 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.1 mptt -77.06 -5.4 48.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.299 1.84 . . . . 10.0 113.865 173.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.05 3.43 65.59 Favored Glycine 0 CA--C 1.536 1.394 0 C-N-CA 125.6 1.572 . . . . 10.0 115.181 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.8 tp -77.44 101.81 6.58 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 118.686 1.243 . . . . 10.0 111.318 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -78.96 113.55 17.16 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.185 1.394 . . . . 10.0 110.925 170.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 75.0 m -84.98 139.44 31.79 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 125.524 1.53 . . . . 10.0 111.986 171.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -131.92 121.24 23.68 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 126.704 2.002 . . . . 10.0 107.688 168.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 61.0 mt -122.18 152.57 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.855 1.262 . . . . 10.0 111.357 -166.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -129.4 109.85 11.42 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 127.519 2.328 . . . . 10.0 109.142 170.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -66.15 -40.22 90.4 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.359 -0.838 . . . . 10.0 113.168 176.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -149.96 88.92 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.838 1.655 . . . . 10.0 110.104 -178.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -68.53 140.29 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 O-C-N 121.378 -0.826 . . . . 10.0 112.045 -176.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -124.78 160.64 28.21 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.463 1.905 . . . . 10.0 111.841 177.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.14 -34.32 63.66 Favored 'General case' 0 CA--C 1.547 0.828 0 N-CA-C 113.509 0.929 . . . . 10.0 113.509 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.4 m -65.05 -17.46 64.47 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.499 1.52 . . . . 10.0 114.62 175.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -80.99 -6.53 58.88 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.446 1.098 . . . . 10.0 113.324 177.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.88 148.44 51.4 Favored 'General case' 0 CA--C 1.547 0.843 0 O-C-N 121.017 -1.052 . . . . 10.0 112.77 177.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 139.75 -174.75 22.19 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.844 1.211 . . . . 10.0 114.815 177.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.81 108.68 17.6 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.971 1.708 . . . . 10.0 110.932 175.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.5 m-85 -86.12 151.96 23.25 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.208 1.003 . . . . 10.0 111.869 172.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.97 160.68 39.88 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.933 0.893 . . . . 10.0 112.006 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.0 t -137.57 107.47 6.3 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.753 1.621 . . . . 10.0 110.586 177.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.5 t -76.05 132.9 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.294 1.037 . . . . 10.0 108.937 169.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -128.3 121.79 30.08 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 126.372 1.869 . . . . 10.0 110.494 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -134.4 139.45 45.59 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.941 1.297 . . . . 10.0 112.604 -171.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.3 p30 -133.74 -178.31 4.95 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.609 1.164 . . . . 10.0 111.259 165.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -61.9 -7.79 4.2 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 115.667 1.729 . . . . 10.0 115.667 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -117.7 -12.7 10.24 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 126.135 1.774 . . . . 10.0 114.578 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.01 -172.66 44.48 Favored Glycine 0 CA--C 1.535 1.308 0 CA-C-N 119.776 1.171 . . . . 10.0 115.924 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -137.8 144.23 41.44 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.992 2.117 . . . . 10.0 111.625 -174.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.64 162.96 33.3 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.594 1.957 . . . . 10.0 110.626 168.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -141.99 124.5 15.77 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.389 1.076 . . . . 10.0 110.736 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -105.14 154.39 20.25 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.33 1.452 . . . . 10.0 110.898 178.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.7 m -144.03 145.12 31.98 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 124.271 1.028 . . . . 10.0 112.035 -170.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.8 p -154.11 171.64 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 C-N-CA 126.595 1.958 . . . . 10.0 110.976 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -131.92 147.88 52.49 Favored 'General case' 0 N--CA 1.471 0.614 0 O-C-N 120.77 -1.206 . . . . 10.0 111.622 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.7 tp -131.14 117.04 18.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 126.283 1.833 . . . . 10.0 110.2 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -106.4 77.68 1.23 Allowed 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.681 1.592 . . . . 10.0 110.481 178.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -58.37 114.31 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.414 1.086 . . . . 10.0 111.014 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.5 mt -76.25 99.58 4.8 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.477 1.911 . . . . 10.0 109.831 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.49 150.39 31.43 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.975 0.91 . . . . 10.0 113.117 -177.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -77.28 -9.45 58.82 Favored 'General case' 0 N--CA 1.48 1.069 0 N-CA-C 115.104 1.52 . . . . 10.0 115.104 -178.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 . . . . . 0 C--O 1.253 1.248 0 C-N-CA 126.829 2.052 . . . . 10.0 114.06 -178.482 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.597 0 N-CA-C 112.154 -0.378 . . . . 10.0 112.154 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.65 166.09 11.34 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 124.449 1.1 . . . . 10.0 112.872 174.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.3 ptt? -133.98 177.19 7.93 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 125.614 1.565 . . . . 10.0 112.57 -176.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 179.03 172.34 43.22 Favored Glycine 0 CA--C 1.541 1.668 0 N-CA-C 116.708 1.443 . . . . 10.0 116.708 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.16 159.9 47.42 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 123.901 3.068 . . . . 10.0 113.027 -173.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -68.24 143.19 57.9 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.133 2.555 . . . . 10.0 111.497 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -131.24 149.45 52.57 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.96 1.304 . . . . 10.0 113.757 -174.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -77.76 111.13 13.24 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.019 2.527 . . . . 10.0 110.939 176.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.5 mm -109.34 -44.66 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.772 0.829 . . . . 10.0 111.104 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -149.51 142.18 24.53 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.708 1.203 . . . . 10.0 111.494 170.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -122.91 135.69 26.08 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 124.873 1.269 . . . . 10.0 109.278 158.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -75.47 159.88 39.18 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.003 2.468 . . . . 10.0 112.206 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -67.44 164.84 17.86 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.92 1.288 . . . . 10.0 112.111 171.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -62.49 113.77 3.15 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.216 -0.928 . . . . 10.0 111.332 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 29.0 mtm -76.22 148.87 37.37 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.736 -0.603 . . . . 10.0 111.69 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 24.0 p -128.08 102.76 6.87 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 125.705 1.602 . . . . 10.0 110.468 176.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.7 mm -121.8 123.61 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.931 1.293 . . . . 10.0 110.63 -163.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -58.86 126.23 26.83 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.134 1.374 . . . . 10.0 111.893 170.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -53.22 136.37 36.58 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.126 1.371 . . . . 10.0 113.468 -176.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 94.93 -10.92 70.09 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 125.97 1.747 . . . . 10.0 114.808 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 73.8 mtp180 -72.5 158.92 34.81 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 118.877 1.339 . . . . 10.0 113.479 177.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -75.31 141.04 43.45 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.373 1.069 . . . . 10.0 110.265 154.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 32.0 p -150.76 170.87 18.18 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.583 0.753 . . . . 10.0 112.269 160.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.892 HH21 ' HG ' ' A' ' 307' ' ' SER . 14.7 ptm180 -145.83 144.06 30.02 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.195 1.398 . . . . 10.0 111.74 172.113 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.7 mtt -91.75 159.33 15.88 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.084 1.354 . . . . 10.0 110.665 169.028 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -138.15 109.83 7.09 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.231 1.412 . . . . 10.0 112.557 -177.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -116.56 98.47 6.56 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.646 1.978 . . . . 10.0 110.383 -176.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 29.5 mtpp -67.87 137.88 55.62 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.148 -0.97 . . . . 10.0 110.196 171.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.28 152.83 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.486 1.514 . . . . 10.0 111.27 -172.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -136.5 174.87 10.14 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.28 1.432 . . . . 10.0 111.164 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 121.07 164.34 12.31 Favored Glycine 0 CA--C 1.538 1.478 0 C-N-CA 127.288 2.375 . . . . 10.0 112.878 -174.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.0 tp -153.04 135.04 8.87 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.752 1.221 . . . . 10.0 110.978 -179.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -68.38 172.11 44.74 Favored 'Cis proline' 0 CA--C 1.54 0.794 0 CA-C-N 120.815 1.327 . . . . 10.0 112.722 -4.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.69 122.58 52.33 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.777 1.231 . . . . 10.0 111.777 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -72.17 155.43 56.54 Favored 'Trans proline' 0 CA--C 1.538 0.713 0 C-N-CA 122.618 2.212 . . . . 10.0 113.542 -172.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -79.13 74.41 5.69 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.316 1.846 . . . . 10.0 111.517 177.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 15.3 m -56.69 122.46 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 125.526 1.53 . . . . 10.0 113.194 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 66.3 m -133.69 111.56 10.68 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 126.334 1.853 . . . . 10.0 111.145 -172.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.4 m95 -87.59 149.77 24.11 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 114.43 1.271 . . . . 10.0 114.43 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -141.6 160.43 40.17 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.606 2.363 . . . . 10.0 111.463 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.4 tp -148.19 123.5 10.26 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 127.733 2.413 . . . . 10.0 109.989 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 53.58 16.03 0.87 Allowed 'General case' 0 CA--C 1.556 1.196 0 C-N-CA 126.498 1.919 . . . . 10.0 115.844 175.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.25 0.04 33.22 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.679 1.609 . . . . 10.0 115.824 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -117.11 162.4 17.89 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 126.031 1.732 . . . . 10.0 111.376 173.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.1 p -69.28 158.69 34.52 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.499 1.119 . . . . 10.0 113.017 178.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 43.6 t -130.82 106.91 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 126.011 1.724 . . . . 10.0 108.607 170.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -72.92 153.25 41.06 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.48 0.712 . . . . 10.0 111.377 172.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 32.2 p -68.25 150.29 48.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.615 0.766 . . . . 10.0 112.026 171.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -151.89 169.65 21.76 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.148 1.379 . . . . 10.0 110.798 175.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -62.52 -31.55 72.34 Favored 'General case' 0 N--CA 1.471 0.625 0 O-C-N 120.464 -1.398 . . . . 10.0 112.549 169.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 97.8 mt -73.99 -22.31 59.65 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.012 0.925 . . . . 10.0 113.468 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -136.75 67.91 1.44 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.152 1.781 . . . . 10.0 111.108 -171.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 63.8 mttm -69.78 142.73 53.15 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.183 0.993 . . . . 10.0 111.336 -177.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -135.51 102.9 5.27 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 126.724 2.01 . . . . 10.0 109.423 -173.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.55 155.71 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 124.165 0.986 . . . . 10.0 112.546 -173.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.66 165.51 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 126.484 1.914 . . . . 10.0 111.188 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 39.0 t -137.72 146.83 44.2 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.797 1.239 . . . . 10.0 112.642 -178.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -56.98 -20.47 24.06 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.244 1.818 . . . . 10.0 113.837 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -74.71 -1.51 22.23 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.745 1.618 . . . . 10.0 114.014 176.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.2 48.01 5.27 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.072 1.32 . . . . 10.0 112.987 178.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.0 tp -140.28 146.96 39.24 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.475 1.51 . . . . 10.0 111.625 -175.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -129.43 132.86 47.08 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.085 2.154 . . . . 10.0 109.678 170.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' SER . . . . . 0.892 ' HG ' HH21 ' A' ' 268' ' ' ARG . 67.6 m -119.28 149.2 42.17 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.844 1.258 . . . . 10.0 112.319 178.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -136.21 110.19 8.24 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.045 2.138 . . . . 10.0 108.478 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -95.18 153.34 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.641 1.576 . . . . 10.0 111.151 -171.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -129.54 107.64 9.63 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.92 2.088 . . . . 10.0 108.761 161.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -63.75 -43.25 96.99 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 121.447 -0.783 . . . . 10.0 113.077 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 2.8 p -150.08 87.08 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 126.156 1.782 . . . . 10.0 109.333 -178.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.8 p -66.99 141.13 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 O-C-N 121.525 -0.734 . . . . 10.0 111.8 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -127.07 160.12 32.13 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 126.429 1.892 . . . . 10.0 111.046 177.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.24 -33.79 59.23 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.009 1.114 . . . . 10.0 114.009 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.41 -17.77 64.09 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.287 1.435 . . . . 10.0 114.547 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -81.4 -8.17 59.69 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.656 1.182 . . . . 10.0 113.413 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -62.97 146.28 53.46 Favored 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.136 -0.977 . . . . 10.0 112.622 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.64 -175.37 23.64 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.024 0.821 . . . . 10.0 114.936 178.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.71 105.5 16.99 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 126.196 1.798 . . . . 10.0 111.257 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -84.94 150.76 24.72 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.714 1.206 . . . . 10.0 111.932 173.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.64 160.74 40.67 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 123.865 0.866 . . . . 10.0 112.249 170.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 47.3 t -138.21 109.12 6.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.58 1.552 . . . . 10.0 110.753 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 93.9 t -76.98 134.86 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.638 1.175 . . . . 10.0 109.146 169.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -132.37 114.5 14.44 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.245 1.818 . . . . 10.0 110.13 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.6 mtpp -129.8 136.61 49.79 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.409 1.484 . . . . 10.0 111.722 -174.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 28.3 p30 -133.26 -179.41 5.49 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.893 1.277 . . . . 10.0 111.371 168.295 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -62.2 -9.93 9.17 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 115.662 1.726 . . . . 10.0 115.662 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.72 -16.12 13.27 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.744 1.618 . . . . 10.0 114.471 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.29 -168.06 40.96 Favored Glycine 0 CA--C 1.536 1.36 0 CA-C-N 119.992 1.269 . . . . 10.0 116.241 176.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -136.24 143.93 44.58 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.995 2.118 . . . . 10.0 112.21 -171.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.25 160.19 40.51 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.774 2.03 . . . . 10.0 110.476 166.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 53.1 m -144.2 116.16 8.33 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.445 1.098 . . . . 10.0 110.61 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -98.0 151.07 20.69 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.16 1.384 . . . . 10.0 110.979 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.5 m -142.32 146.3 34.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 124.613 1.165 . . . . 10.0 111.819 -174.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . 0.405 HG21 ' H ' ' A' ' 337' ' ' GLN . 7.5 p -153.06 174.58 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 126.721 2.008 . . . . 10.0 110.916 173.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . 0.405 ' H ' HG21 ' A' ' 336' ' ' VAL . 49.5 tt0 -130.47 150.58 51.62 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.176 1.39 . . . . 10.0 111.118 173.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.5 tp -125.16 108.36 11.7 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 110.846 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -90.4 81.07 6.03 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.258 1.823 . . . . 10.0 110.473 176.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.9 t -68.44 109.5 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 121.119 -0.988 . . . . 10.0 110.472 177.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.7 mt -77.55 97.64 5.11 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.774 1.63 . . . . 10.0 109.548 177.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.45 150.51 26.43 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.592 1.157 . . . . 10.0 113.957 -172.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -67.57 -47.29 70.19 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.078 1.751 . . . . 10.0 112.592 179.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 . . . . . 0 C--O 1.253 1.266 0 C-N-CA 126.193 1.797 . . . . 10.0 113.433 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.549 0 N-CA-C 111.793 -0.523 . . . . 10.0 111.793 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.43 160.91 21.0 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.366 1.067 . . . . 10.0 112.983 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.86 178.39 8.72 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 126.026 1.73 . . . . 10.0 112.034 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.83 170.84 43.7 Favored Glycine 0 CA--C 1.541 1.717 0 N-CA-C 116.513 1.365 . . . . 10.0 116.513 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.94 159.58 52.09 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.391 2.727 . . . . 10.0 113.116 -173.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.76 161.71 44.28 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.934 2.423 . . . . 10.0 111.072 166.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.86 166.47 24.37 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.471 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -85.93 71.95 10.55 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.355 1.862 . . . . 10.0 111.543 -173.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . 0.549 HG21 ' H ' ' A' ' 254' ' ' GLN . 0.5 OUTLIER -73.55 179.78 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 125.031 1.333 . . . . 10.0 111.137 176.889 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.549 ' H ' HG21 ' A' ' 253' ' ' ILE . 35.3 tt0 -50.06 140.02 13.2 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.152 2.181 . . . . 10.0 114.336 -175.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.4 m -127.12 152.11 75.36 Favored Pre-proline 0 N--CA 1.477 0.915 0 C-N-CA 126.696 1.998 . . . . 10.0 110.982 172.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -77.2 159.22 33.46 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.249 2.632 . . . . 10.0 112.429 174.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -69.47 172.39 7.31 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.19 1.396 . . . . 10.0 112.263 169.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -55.65 111.74 0.98 Allowed 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 124.578 1.151 . . . . 10.0 112.854 173.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.7 mtp -82.58 155.63 24.36 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.769 1.628 . . . . 10.0 112.121 -177.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -147.22 109.38 4.49 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.249 1.419 . . . . 10.0 111.062 175.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.2 mm -123.01 133.37 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.248 1.419 . . . . 10.0 110.464 -168.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.74 130.98 47.36 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.096 1.359 . . . . 10.0 112.562 174.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -52.78 133.63 37.01 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.254 1.421 . . . . 10.0 112.862 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 93.22 -9.84 74.22 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.784 1.659 . . . . 10.0 115.276 177.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.1 mtp-105 -75.79 161.15 29.27 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 119.179 1.489 . . . . 10.0 113.018 176.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -72.46 147.33 46.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.442 1.097 . . . . 10.0 110.605 157.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 9.0 t -149.67 164.8 34.21 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.569 1.148 . . . . 10.0 111.582 165.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.7 ptm180 -149.54 155.41 40.29 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.645 1.578 . . . . 10.0 111.62 163.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 40.6 mtt -102.43 166.85 10.31 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.614 1.566 . . . . 10.0 112.071 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -132.73 110.9 10.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.331 1.852 . . . . 10.0 111.099 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -127.31 101.74 6.61 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 125.322 1.449 . . . . 10.0 111.172 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -60.36 142.76 54.41 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.513 -0.742 . . . . 10.0 110.296 172.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.0 p -148.98 146.3 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 124.597 1.159 . . . . 10.0 111.753 -175.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 51.8 m -139.19 178.59 7.07 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 126.341 1.856 . . . . 10.0 111.454 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 112.64 161.27 15.22 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 126.349 1.928 . . . . 10.0 113.092 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.15 129.93 7.43 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 125.145 1.378 . . . . 10.0 110.638 -179.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -66.39 168.86 48.14 Favored 'Cis proline' 0 CA--C 1.54 0.798 0 CA-C-N 120.806 1.324 . . . . 10.0 112.546 -2.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.63 120.62 33.43 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 124.673 1.189 . . . . 10.0 111.658 -177.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.0 159.5 52.3 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.597 2.198 . . . . 10.0 113.265 -174.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -68.7 169.41 11.28 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.336 1.454 . . . . 10.0 111.923 171.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 87.1 t -131.95 112.99 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.302 1.841 . . . . 10.0 110.165 -176.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 70.8 m -131.54 100.3 5.09 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.238 1.415 . . . . 10.0 110.91 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -84.02 154.64 23.15 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 122.035 0.921 . . . . 10.0 113.29 176.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -142.53 160.35 40.45 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.749 2.419 . . . . 10.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -148.83 124.06 10.18 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.104 2.161 . . . . 10.0 109.98 176.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.54 10.99 0.38 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 126.996 2.118 . . . . 10.0 116.378 174.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.51 -0.96 22.02 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.847 1.689 . . . . 10.0 115.852 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -117.36 163.99 15.52 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.795 1.638 . . . . 10.0 111.929 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.0 p -71.63 160.31 32.89 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.626 1.17 . . . . 10.0 112.948 178.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 64.5 t -136.24 111.29 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 126.632 1.973 . . . . 10.0 108.903 173.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -85.02 159.18 20.28 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.831 0.853 . . . . 10.0 111.199 170.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.9 p -69.61 151.06 46.38 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.725 0.81 . . . . 10.0 112.426 171.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -151.36 179.27 8.47 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.492 1.517 . . . . 10.0 110.79 166.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -56.71 -30.74 63.79 Favored 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 114.327 1.232 . . . . 10.0 114.327 -177.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 55.7 mt -87.63 -13.31 43.06 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.912 1.285 . . . . 10.0 113.514 175.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -135.64 68.12 1.46 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.158 1.783 . . . . 10.0 111.226 -172.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -67.86 145.13 54.92 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.089 1.356 . . . . 10.0 111.167 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.2 mtt -135.21 102.68 5.26 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 126.774 2.029 . . . . 10.0 109.726 -175.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.97 158.54 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.822 1.249 . . . . 10.0 112.212 -175.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 38.7 t -133.64 113.97 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 125.778 1.631 . . . . 10.0 109.73 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 46.6 t -64.89 141.15 58.87 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.917 0.887 . . . . 10.0 111.518 172.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -57.76 -19.48 28.18 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.72 1.208 . . . . 10.0 113.946 173.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.5 -3.45 40.59 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.454 1.502 . . . . 10.0 113.697 176.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.66 43.05 4.32 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.293 1.425 . . . . 10.0 113.883 176.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 61.9 tp -137.13 107.03 6.26 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.077 1.351 . . . . 10.0 111.578 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -80.43 138.61 36.63 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 125.379 1.471 . . . . 10.0 111.227 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 60.6 m -122.19 146.51 47.18 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 125.917 1.687 . . . . 10.0 111.807 174.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -134.13 112.54 11.22 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.214 2.206 . . . . 10.0 108.211 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -94.13 154.69 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.399 1.48 . . . . 10.0 111.55 -170.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -131.96 99.05 4.62 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.381 2.272 . . . . 10.0 108.96 163.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -62.11 -39.23 91.82 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 120.943 -1.098 . . . . 10.0 113.125 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.6 p -150.52 90.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.998 1.719 . . . . 10.0 109.839 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.1 p -68.54 140.23 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 121.39 -0.819 . . . . 10.0 112.148 -175.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 27.2 mmt180 -126.13 162.09 26.16 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.463 1.905 . . . . 10.0 111.834 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.98 -33.4 64.78 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.431 0.9 . . . . 10.0 113.431 -177.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 m -64.11 -18.01 64.0 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.386 1.474 . . . . 10.0 114.472 175.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -83.33 -5.99 59.32 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.609 1.164 . . . . 10.0 113.32 177.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.06 152.29 44.99 Favored 'General case' 0 CA--C 1.547 0.852 0 O-C-N 121.039 -1.038 . . . . 10.0 113.191 179.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 137.08 -173.32 22.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 124.689 1.138 . . . . 10.0 115.161 175.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.08 102.05 13.5 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.143 1.777 . . . . 10.0 111.234 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -80.91 153.6 27.48 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.624 1.17 . . . . 10.0 112.169 170.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.21 162.7 36.5 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.238 1.015 . . . . 10.0 111.795 166.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.3 t -139.64 125.52 19.65 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 125.446 1.499 . . . . 10.0 110.827 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 96.2 t -97.63 134.82 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 125.436 1.495 . . . . 10.0 109.7 174.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.19 117.33 22.13 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.224 1.809 . . . . 10.0 110.794 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -132.96 140.35 47.76 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.197 1.399 . . . . 10.0 112.196 -172.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.4 p30 -135.04 -177.83 4.81 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.234 1.414 . . . . 10.0 111.209 166.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -62.23 -13.26 26.03 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 115.624 1.713 . . . . 10.0 115.624 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -104.15 -22.54 13.39 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.33 1.452 . . . . 10.0 114.183 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.79 -166.24 39.44 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 116.098 1.199 . . . . 10.0 116.098 179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.91 146.13 47.02 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.93 2.092 . . . . 10.0 112.098 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.71 167.0 23.21 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.553 1.941 . . . . 10.0 111.037 166.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 10.8 m -145.2 148.68 33.81 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.338 1.055 . . . . 10.0 111.071 -177.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -132.17 151.15 51.95 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.039 1.736 . . . . 10.0 110.647 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.3 m -143.45 145.98 33.05 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 125.034 1.334 . . . . 10.0 111.642 -174.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.9 p -154.2 156.42 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 126.016 1.727 . . . . 10.0 110.99 170.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -110.91 141.42 44.34 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.353 1.061 . . . . 10.0 110.485 169.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.4 tp -124.14 106.8 10.62 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.07 1.748 . . . . 10.0 110.321 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -94.54 83.22 4.08 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.435 1.494 . . . . 10.0 110.824 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.0 t -64.05 113.56 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 O-C-N 121.372 -0.83 . . . . 10.0 110.704 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.45 97.49 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.1 1.76 . . . . 10.0 110.073 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.23 151.61 35.72 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 124.384 1.074 . . . . 10.0 113.429 -177.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -142.9 79.2 1.64 Allowed 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 126.462 1.905 . . . . 10.0 110.455 176.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 . . . . . 0 C--O 1.254 1.303 0 C-N-CA 125.623 1.569 . . . . 10.0 114.353 175.672 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.594 0 N-CA-C 111.659 -0.576 . . . . 10.0 111.659 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.61 159.5 21.77 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.302 1.041 . . . . 10.0 112.783 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.64 175.15 11.81 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.168 1.787 . . . . 10.0 111.616 -176.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.79 172.45 45.1 Favored Glycine 0 CA--C 1.543 1.784 0 N-CA-C 117.473 1.749 . . . . 10.0 117.473 -175.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_endo -72.71 159.54 48.37 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 124.128 3.219 . . . . 10.0 113.549 -171.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -70.53 148.0 59.1 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.204 2.603 . . . . 10.0 112.054 173.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -136.46 158.59 44.07 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 125.576 1.551 . . . . 10.0 112.758 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -84.41 79.41 9.57 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.293 2.237 . . . . 10.0 112.261 -174.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 44.4 mm -73.41 -55.31 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.529 -0.732 . . . . 10.0 111.21 178.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.22 129.52 10.53 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.5 1.12 . . . . 10.0 111.705 176.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.1 m -104.09 148.17 35.48 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 124.669 1.188 . . . . 10.0 110.196 158.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.32 162.4 36.36 Favored 'Trans proline' 0 CA--C 1.542 0.882 0 C-N-CA 122.99 2.46 . . . . 10.0 111.155 171.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -73.66 168.29 19.65 Favored 'General case' 0 CA--C 1.545 0.783 0 O-C-N 121.389 -0.82 . . . . 10.0 111.655 169.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.5 p30 -61.79 160.22 12.28 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.422 -0.799 . . . . 10.0 112.405 172.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.2 mtm -132.56 160.4 36.66 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.079 0.952 . . . . 10.0 113.073 -178.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 p -136.07 103.14 5.24 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 126.192 1.797 . . . . 10.0 110.527 175.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.5 mm -119.37 131.27 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.247 1.419 . . . . 10.0 110.723 -165.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -60.91 129.07 39.62 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.804 1.242 . . . . 10.0 112.558 173.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -54.21 127.8 28.43 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.825 1.25 . . . . 10.0 112.596 -178.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.13 -10.27 61.71 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 126.187 1.851 . . . . 10.0 115.036 178.16 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 27.1 mtp-105 -73.84 163.93 27.3 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.116 1.458 . . . . 10.0 113.099 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -75.37 141.18 43.34 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.895 1.278 . . . . 10.0 110.506 158.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.46 170.32 19.89 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.756 0.822 . . . . 10.0 112.343 162.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -146.84 163.32 36.44 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.37 1.468 . . . . 10.0 112.757 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -134.97 140.3 45.59 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.215 2.206 . . . . 10.0 109.137 175.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -131.97 125.7 32.21 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.795 1.238 . . . . 10.0 111.974 -168.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -129.17 111.81 13.3 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 126.789 2.035 . . . . 10.0 111.624 -167.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -73.65 120.55 19.4 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 121.587 -0.696 . . . . 10.0 109.808 171.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -130.11 108.92 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.792 2.037 . . . . 10.0 110.831 -171.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.8 t -76.79 -174.77 3.17 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.336 1.054 . . . . 10.0 112.301 174.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 100.27 160.58 28.25 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 126.92 2.2 . . . . 10.0 113.795 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -151.17 135.26 9.53 Favored Pre-proline 0 CA--C 1.548 0.889 0 C-N-CA 126.044 1.738 . . . . 10.0 109.531 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.18 169.94 37.76 Favored 'Cis proline' 0 CA--C 1.539 0.76 0 CA-C-N 121.15 1.447 . . . . 10.0 112.373 -6.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 123.18 51.65 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 124.581 1.153 . . . . 10.0 111.278 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -70.88 161.57 45.61 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 122.501 2.134 . . . . 10.0 113.333 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 40.2 m-20 -65.66 170.56 5.02 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.826 1.25 . . . . 10.0 111.761 165.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 5.6 p -138.37 122.96 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.219 1.408 . . . . 10.0 111.471 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.0 m -137.36 106.25 5.94 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.818 1.647 . . . . 10.0 110.563 174.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.8 m95 -85.86 153.54 22.17 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 123.953 0.901 . . . . 10.0 113.223 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.19 159.0 43.1 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.979 2.112 . . . . 10.0 111.295 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -143.93 117.07 8.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 127.072 2.149 . . . . 10.0 110.281 175.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 54.07 18.86 1.85 Allowed 'General case' 0 CA--C 1.554 1.116 0 C-N-CA 126.375 1.87 . . . . 10.0 114.558 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.97 -9.35 46.86 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.422 1.963 . . . . 10.0 115.476 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.18 155.13 19.61 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.044 1.422 . . . . 10.0 110.166 171.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.6 p -69.34 155.24 40.75 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.801 0.84 . . . . 10.0 112.585 173.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 57.4 t -133.12 105.04 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.332 1.853 . . . . 10.0 108.766 173.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 95.4 mm-40 -72.62 159.59 33.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.498 0.719 . . . . 10.0 111.701 173.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.3 p -70.11 154.9 41.36 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.35 0.66 . . . . 10.0 111.67 166.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -154.15 168.95 24.78 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.404 1.482 . . . . 10.0 111.025 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -57.83 -34.55 69.8 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.792 -1.193 . . . . 10.0 112.658 168.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.3 mt -82.79 -15.16 52.77 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.556 1.142 . . . . 10.0 113.9 173.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -134.61 69.41 1.46 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.011 1.724 . . . . 10.0 111.324 -173.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -70.61 144.4 51.18 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.086 1.354 . . . . 10.0 111.666 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.3 mtt -141.14 103.36 4.43 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 126.835 2.054 . . . . 10.0 109.723 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.75 162.03 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 C-N-CA 124.617 1.167 . . . . 10.0 112.66 -176.683 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 t -133.83 113.91 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.632 1.573 . . . . 10.0 109.698 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 66.8 m -69.04 144.46 54.03 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.47 0.708 . . . . 10.0 111.053 171.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.03 -17.1 56.24 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.487 1.515 . . . . 10.0 114.579 -176.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -74.44 -4.88 39.3 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 126.155 1.782 . . . . 10.0 114.107 173.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.17 38.35 5.71 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 125.139 1.352 . . . . 10.0 113.644 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 44.4 tp -125.68 102.54 7.38 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.424 1.489 . . . . 10.0 110.646 -177.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -78.25 145.26 35.56 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.009 0.924 . . . . 10.0 110.926 169.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 32.6 t -134.53 145.52 48.83 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.943 1.297 . . . . 10.0 111.985 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -130.63 120.53 24.1 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.434 2.694 . . . . 10.0 108.115 -178.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.4 152.33 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.605 1.162 . . . . 10.0 111.424 -170.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -125.96 108.84 11.79 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 127.273 2.229 . . . . 10.0 108.892 168.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -65.98 -38.45 88.56 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.323 -0.861 . . . . 10.0 112.715 175.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.2 p -150.28 86.82 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 126.098 1.759 . . . . 10.0 110.043 -178.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.5 p -66.64 139.6 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 O-C-N 121.3 -0.875 . . . . 10.0 111.827 -177.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -119.69 160.82 21.8 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.964 1.705 . . . . 10.0 112.069 176.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.29 -31.62 65.81 Favored 'General case' 0 CA--C 1.548 0.891 0 N-CA-C 113.709 1.003 . . . . 10.0 113.709 -176.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -65.3 -21.13 66.68 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.125 1.37 . . . . 10.0 113.891 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -77.66 -6.16 52.91 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.68 1.192 . . . . 10.0 113.591 178.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.2 147.79 52.82 Favored 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.874 -1.141 . . . . 10.0 112.695 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.76 -172.6 22.49 Favored Glycine 0 CA--C 1.532 1.155 0 C-N-CA 124.767 1.175 . . . . 10.0 114.894 177.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.92 109.83 18.43 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.981 1.712 . . . . 10.0 111.06 175.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -85.15 153.72 22.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.473 1.109 . . . . 10.0 112.213 171.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.17 159.34 42.42 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.172 0.989 . . . . 10.0 112.069 167.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -139.03 104.26 4.99 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.76 1.624 . . . . 10.0 110.827 -178.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.8 t -76.39 129.61 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.316 1.046 . . . . 10.0 109.692 171.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.68 117.91 20.16 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.668 1.987 . . . . 10.0 110.681 178.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -132.11 139.63 48.53 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.299 1.44 . . . . 10.0 112.017 -172.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 26.8 p30 -134.27 -177.98 4.83 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.903 1.281 . . . . 10.0 111.411 167.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -61.29 -11.22 8.91 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.778 1.77 . . . . 10.0 115.778 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.97 -19.78 12.23 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.409 1.484 . . . . 10.0 114.443 -178.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.44 -170.39 43.51 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 116.149 1.22 . . . . 10.0 116.149 178.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -136.8 144.17 43.56 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.968 2.107 . . . . 10.0 111.819 -170.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.68 157.1 47.2 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 126.482 1.913 . . . . 10.0 110.534 166.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -140.12 98.03 3.36 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.64 1.176 . . . . 10.0 110.206 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -75.35 156.97 34.96 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.107 0.963 . . . . 10.0 111.467 177.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 33.0 m -144.87 143.47 30.61 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.058 1.343 . . . . 10.0 111.348 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.5 p -153.95 170.74 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 C-N-CA 126.215 1.806 . . . . 10.0 110.867 173.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 -131.15 146.81 52.48 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.756 1.222 . . . . 10.0 111.88 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.5 tp -131.76 119.41 21.25 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.057 1.743 . . . . 10.0 111.018 -178.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -104.35 83.02 2.01 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.79 1.636 . . . . 10.0 110.857 176.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.05 110.89 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 O-C-N 121.531 -0.731 . . . . 10.0 110.692 -179.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 67.4 mt -73.01 97.95 2.42 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.305 1.842 . . . . 10.0 109.87 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.5 147.0 46.78 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.644 1.177 . . . . 10.0 113.661 -173.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -89.25 -26.0 21.42 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 125.932 1.693 . . . . 10.0 113.782 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 . . . . . 0 C--O 1.252 1.236 0 C-N-CA 125.619 1.568 . . . . 10.0 114.619 177.411 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.583 0 N-CA-C 111.928 -0.469 . . . . 10.0 111.928 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.67 158.15 25.34 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.239 1.015 . . . . 10.0 112.961 176.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.67 176.78 10.69 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.235 1.814 . . . . 10.0 111.522 -177.215 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.91 172.44 45.38 Favored Glycine 0 CA--C 1.542 1.744 0 N-CA-C 117.5 1.76 . . . . 10.0 117.5 -176.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -69.11 159.52 53.56 Favored 'Trans proline' 0 CA--C 1.543 0.963 0 C-N-CA 123.761 2.974 . . . . 10.0 112.943 -173.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -70.23 166.07 29.41 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.144 2.562 . . . . 10.0 112.428 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 21.3 tpp180 -140.77 147.18 38.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.462 1.105 . . . . 10.0 112.436 -174.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -76.8 58.06 1.38 Allowed 'General case' 0 CA--C 1.55 0.977 0 C-N-CA 128.564 2.746 . . . . 10.0 112.409 -177.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.3 mm -60.64 -58.5 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.964 -1.085 . . . . 10.0 112.63 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -154.35 153.34 31.45 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 119.006 0.821 . . . . 10.0 113.172 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 17.8 m -131.05 155.57 81.37 Favored Pre-proline 0 N--CA 1.479 0.997 0 C-N-CA 127.371 2.269 . . . . 10.0 110.382 167.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -74.8 166.14 29.93 Favored 'Trans proline' 0 CA--C 1.542 0.921 0 C-N-CA 122.771 2.314 . . . . 10.0 111.499 168.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -73.05 176.45 5.77 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.446 -0.784 . . . . 10.0 111.194 163.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -59.18 152.83 19.62 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.911 -1.118 . . . . 10.0 112.128 171.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.7 mtp -132.46 157.19 45.24 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 125.526 1.531 . . . . 10.0 111.946 -172.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 76.4 p -145.93 136.79 24.43 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 125.26 1.424 . . . . 10.0 110.856 169.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 24.9 mm -138.4 133.08 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.581 1.552 . . . . 10.0 109.531 -170.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -63.85 131.12 46.8 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.639 1.175 . . . . 10.0 112.302 173.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -51.54 130.59 28.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.515 1.526 . . . . 10.0 113.305 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.4 -10.25 67.13 Favored Glycine 0 CA--C 1.537 1.426 0 C-N-CA 126.185 1.85 . . . . 10.0 115.175 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.3 mtp180 -72.3 161.33 30.99 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.037 1.418 . . . . 10.0 113.356 177.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -71.49 148.6 46.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.678 1.191 . . . . 10.0 110.637 156.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.8 t -147.06 154.62 41.39 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.941 1.296 . . . . 10.0 111.019 168.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -145.53 166.18 26.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.747 1.219 . . . . 10.0 112.547 165.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 49.5 mtt -133.07 166.9 21.35 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.471 1.908 . . . . 10.0 111.815 -176.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -134.39 117.65 16.56 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.082 1.753 . . . . 10.0 111.694 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -127.83 99.55 5.58 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.551 1.54 . . . . 10.0 111.358 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -66.41 123.31 19.64 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.862 0.865 . . . . 10.0 110.115 172.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 5.9 p -142.45 102.63 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.311 1.845 . . . . 10.0 110.684 -176.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.7 t -75.68 -177.25 3.63 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.003 0.921 . . . . 10.0 111.855 172.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 117.32 160.3 11.73 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 127.356 2.408 . . . . 10.0 113.319 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -149.47 128.38 6.15 Favored Pre-proline 0 CA--C 1.548 0.871 0 C-N-CA 124.797 1.239 . . . . 10.0 110.414 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -66.86 169.61 47.63 Favored 'Cis proline' 0 CA--C 1.54 0.809 0 CA-C-N 121.06 1.414 . . . . 10.0 112.507 -3.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.18 122.59 55.06 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.616 1.166 . . . . 10.0 111.429 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.57 151.39 64.42 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 122.55 2.167 . . . . 10.0 113.284 -173.098 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.99 145.66 46.54 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.337 1.055 . . . . 10.0 109.963 160.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.68 86.37 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.091 1.356 . . . . 10.0 112.103 -165.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.4 m -78.5 116.1 18.66 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.866 1.267 . . . . 10.0 111.506 177.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.1 m95 -90.27 155.77 18.76 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.704 1.001 . . . . 10.0 113.704 177.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.34 160.54 41.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.476 2.311 . . . . 10.0 111.495 -177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.9 tp -147.23 119.76 8.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.392 2.277 . . . . 10.0 110.024 174.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 54.9 15.0 1.01 Allowed 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 126.645 1.978 . . . . 10.0 115.145 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.58 -13.23 35.8 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 126.631 2.063 . . . . 10.0 115.19 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -86.84 159.55 19.04 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 118.971 1.385 . . . . 10.0 110.833 169.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.7 p -73.21 159.15 33.91 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.098 0.959 . . . . 10.0 112.729 174.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 90.5 t -137.12 145.71 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 127.008 2.123 . . . . 10.0 108.775 171.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 80.4 mt-30 -128.1 163.21 25.13 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.295 1.438 . . . . 10.0 111.285 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.5 p -68.35 152.61 45.19 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.657 0.783 . . . . 10.0 112.613 176.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -152.17 168.18 26.16 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.978 1.711 . . . . 10.0 110.641 175.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.45 -35.12 67.53 Favored 'General case' 0 CA--C 1.544 0.741 0 O-C-N 120.906 -1.121 . . . . 10.0 112.76 169.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.0 mt -84.84 -12.99 52.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.608 1.163 . . . . 10.0 113.979 173.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.9 m80 -136.59 71.18 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.633 1.573 . . . . 10.0 111.453 -173.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -71.89 147.45 47.07 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.797 1.239 . . . . 10.0 111.898 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.6 mtt -141.54 107.28 5.11 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 126.846 2.058 . . . . 10.0 109.908 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.0 157.93 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.641 1.176 . . . . 10.0 112.398 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.1 t -133.81 113.93 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.893 1.677 . . . . 10.0 109.928 -177.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 68.7 m -70.38 151.27 45.4 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.954 0.902 . . . . 10.0 112.132 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -57.45 -32.18 66.67 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 125.766 1.627 . . . . 10.0 113.856 -175.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . 0.441 ' HE2' ' HA ' ' A' ' 303' ' ' LYS . 11.3 mmpt? -70.82 -3.39 18.71 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 126.174 1.79 . . . . 10.0 114.425 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.83 49.92 3.91 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 125.006 1.289 . . . . 10.0 112.897 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 65.1 tp -130.72 104.15 7.01 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.455 1.502 . . . . 10.0 110.469 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -83.7 125.9 32.35 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 125.145 1.378 . . . . 10.0 111.229 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.8 m -102.86 142.67 33.58 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.243 1.417 . . . . 10.0 111.739 169.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -130.55 126.07 35.84 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 127.469 2.308 . . . . 10.0 107.884 175.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 44.1 mt -122.1 152.68 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.237 1.415 . . . . 10.0 111.722 -167.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.93 109.98 10.93 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 128.059 2.544 . . . . 10.0 109.064 169.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.33 -38.87 85.59 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.02 -1.05 . . . . 10.0 113.069 177.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.04 88.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 125.723 1.609 . . . . 10.0 110.286 -178.059 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -70.66 141.81 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 O-C-N 121.235 -0.915 . . . . 10.0 112.313 -175.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -126.18 163.21 23.63 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 126.631 1.972 . . . . 10.0 111.958 177.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.1 -31.56 65.4 Favored 'General case' 0 CA--C 1.548 0.875 0 N-CA-C 113.899 1.074 . . . . 10.0 113.899 -177.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.5 m -68.28 -15.91 63.75 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 114.216 1.191 . . . . 10.0 114.216 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -82.83 -5.16 58.84 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.432 1.093 . . . . 10.0 113.308 177.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 150.22 48.84 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.933 -1.104 . . . . 10.0 113.143 178.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.17 -175.19 21.06 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.905 1.241 . . . . 10.0 115.279 174.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.12 98.05 7.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.801 1.64 . . . . 10.0 111.246 175.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -74.5 150.96 39.61 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 123.556 0.742 . . . . 10.0 111.479 167.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.01 161.9 38.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 123.966 0.906 . . . . 10.0 111.997 168.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.1 t -137.31 139.01 40.6 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.737 1.615 . . . . 10.0 110.487 176.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.9 t -117.17 104.7 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.289 1.835 . . . . 10.0 108.862 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -89.64 118.06 28.98 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 126.283 1.833 . . . . 10.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -129.84 132.61 46.53 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.085 1.354 . . . . 10.0 112.598 -176.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -129.44 -179.02 4.92 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.834 1.253 . . . . 10.0 111.513 166.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -61.64 -12.28 15.36 Favored 'General case' 0 N--CA 1.482 1.129 0 N-CA-C 115.726 1.75 . . . . 10.0 115.726 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.18 -20.03 12.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 125.383 1.473 . . . . 10.0 114.424 -178.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 172.92 -169.26 42.42 Favored Glycine 0 CA--C 1.534 1.232 0 N-CA-C 116.101 1.2 . . . . 10.0 116.101 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -134.19 143.8 48.09 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 126.939 2.095 . . . . 10.0 111.909 -171.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.25 165.92 25.0 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.281 1.833 . . . . 10.0 111.076 168.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 19.0 m -141.57 141.59 33.5 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.203 1.001 . . . . 10.0 111.569 -173.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -134.47 150.93 50.87 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.797 1.639 . . . . 10.0 110.556 -178.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -146.4 146.81 30.76 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 124.454 1.102 . . . . 10.0 111.786 -169.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.7 p -152.97 146.68 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 125.251 1.42 . . . . 10.0 112.026 170.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 9.2 tp-100 -100.14 127.47 46.39 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 125.667 1.587 . . . . 10.0 110.245 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -121.18 105.56 10.7 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.542 1.537 . . . . 10.0 111.261 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -93.62 85.79 4.99 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.268 1.427 . . . . 10.0 111.319 175.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.6 t -66.14 115.35 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 121.301 -0.874 . . . . 10.0 110.826 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.3 mt -78.91 100.0 7.04 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.437 1.895 . . . . 10.0 110.356 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.83 147.65 37.51 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 123.947 0.899 . . . . 10.0 112.821 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.56 -18.77 59.66 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 114.736 1.384 . . . . 10.0 114.736 -178.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.254 1.322 0 C-N-CA 126.527 1.931 . . . . 10.0 113.761 -178.844 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.536 0 N-CA-C 111.756 -0.538 . . . . 10.0 111.756 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.22 164.21 16.25 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 124.472 1.109 . . . . 10.0 113.036 176.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.9 ptt? -145.95 -178.89 6.35 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.025 1.73 . . . . 10.0 111.747 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.03 168.98 41.16 Favored Glycine 0 CA--C 1.54 1.63 0 N-CA-C 116.963 1.545 . . . . 10.0 116.963 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.98 161.66 45.35 Favored 'Trans proline' 0 CA--C 1.543 0.935 0 C-N-CA 123.751 2.967 . . . . 10.0 112.943 -174.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -65.39 133.59 35.44 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.351 2.701 . . . . 10.0 111.324 171.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -130.64 134.66 47.14 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 126.698 1.999 . . . . 10.0 110.654 -176.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -48.87 120.39 3.82 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 127.09 2.156 . . . . 10.0 112.58 173.587 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 49.7 mm -113.85 -59.29 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.232 1.013 . . . . 10.0 110.413 171.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.5 tt0 -150.47 136.04 18.12 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.013 0.925 . . . . 10.0 111.531 177.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 21.9 m -117.88 149.75 45.89 Favored Pre-proline 0 N--CA 1.474 0.749 0 C-N-CA 125.367 1.467 . . . . 10.0 109.579 167.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.78 155.96 53.38 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 122.485 2.123 . . . . 10.0 111.92 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -69.98 168.35 15.58 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.74 0.816 . . . . 10.0 111.091 166.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.21 152.19 21.22 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 121.211 -0.931 . . . . 10.0 112.334 173.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 86.1 mtp -127.05 152.44 47.26 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.222 1.409 . . . . 10.0 111.87 -167.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 p -144.15 104.94 4.18 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.265 1.426 . . . . 10.0 111.094 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.9 mm -122.6 130.95 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.401 1.481 . . . . 10.0 110.405 -166.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -65.15 129.97 41.64 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.51 1.124 . . . . 10.0 112.518 175.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -52.57 123.5 11.27 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 125.656 1.582 . . . . 10.0 113.132 -176.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 101.45 -10.25 57.76 Favored Glycine 0 CA--C 1.534 1.269 0 C-N-CA 125.975 1.75 . . . . 10.0 115.551 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -70.77 160.64 32.33 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-N 119.248 1.524 . . . . 10.0 113.086 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -73.43 147.73 43.93 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.663 1.185 . . . . 10.0 110.571 159.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 7.1 t -153.4 168.26 26.69 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.075 0.95 . . . . 10.0 112.607 169.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.1 ptm85 -145.61 166.68 25.05 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.95 1.7 . . . . 10.0 112.82 167.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.3 mtt -121.06 159.82 24.9 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 126.964 2.106 . . . . 10.0 111.241 173.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -140.27 93.21 2.6 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.076 1.35 . . . . 10.0 111.961 -166.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -114.07 106.9 14.94 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.733 1.613 . . . . 10.0 111.651 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -85.88 129.73 34.75 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.027 -1.045 . . . . 10.0 111.513 176.521 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.6 p -132.63 153.68 38.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.072 1.749 . . . . 10.0 110.351 170.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 58.4 m -127.24 126.67 43.13 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.766 1.226 . . . . 10.0 110.889 172.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.1 168.01 40.66 Favored Glycine 0 CA--C 1.534 1.28 0 C-N-CA 126.615 2.055 . . . . 10.0 111.236 175.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.9 tp -146.56 131.39 8.9 Favored Pre-proline 0 CA--C 1.546 0.825 0 C-N-CA 124.474 1.11 . . . . 10.0 110.73 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.13 170.59 45.23 Favored 'Cis proline' 0 CA--C 1.541 0.825 0 CA-C-N 120.414 1.184 . . . . 10.0 112.665 -3.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.13 122.05 45.59 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 124.662 1.185 . . . . 10.0 111.29 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -73.82 164.31 34.98 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.572 2.181 . . . . 10.0 113.845 -170.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -61.58 165.77 4.7 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.114 1.766 . . . . 10.0 111.961 165.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.2 p -139.23 113.6 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.097 1.359 . . . . 10.0 111.455 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -128.92 147.61 50.85 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.945 1.698 . . . . 10.0 110.821 173.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -128.44 153.29 47.27 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.355 1.062 . . . . 10.0 113.545 -174.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -143.3 162.65 35.13 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.324 2.25 . . . . 10.0 111.227 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.5 tp -147.86 123.59 10.54 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 126.905 2.082 . . . . 10.0 110.012 176.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 55.02 10.15 0.37 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.739 2.016 . . . . 10.0 116.049 176.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.01 -5.09 25.58 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.08 1.8 . . . . 10.0 115.607 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -105.58 161.65 14.18 Favored 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 119.176 1.488 . . . . 10.0 111.922 171.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.9 p -70.08 154.94 41.31 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.427 1.091 . . . . 10.0 112.791 176.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.33 101.76 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.791 2.036 . . . . 10.0 108.401 170.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -74.3 157.58 35.54 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.529 0.731 . . . . 10.0 111.319 172.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.2 p -70.61 149.5 47.0 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.691 0.796 . . . . 10.0 112.388 172.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -152.29 179.54 8.45 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.419 1.487 . . . . 10.0 111.063 167.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -57.24 -28.66 63.12 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.425 1.269 . . . . 10.0 114.425 -177.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 48.7 mt -92.41 -11.82 33.83 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.272 1.429 . . . . 10.0 113.391 176.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -134.25 70.91 1.45 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.397 1.879 . . . . 10.0 111.153 -174.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -71.87 143.32 49.44 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.171 1.388 . . . . 10.0 111.052 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -138.9 106.47 5.58 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 126.318 1.847 . . . . 10.0 110.455 -172.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.92 171.79 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.315 1.446 . . . . 10.0 112.229 -177.179 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -135.55 134.23 51.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.807 1.643 . . . . 10.0 109.275 174.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 24.9 p -67.95 172.14 5.89 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.838 1.051 . . . . 10.0 113.838 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -59.37 -20.3 53.68 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.237 1.415 . . . . 10.0 113.436 170.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -117.43 5.64 12.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.278 1.831 . . . . 10.0 114.243 -171.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.78 15.71 36.02 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 124.623 1.106 . . . . 10.0 115.777 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 28.4 tp -80.13 98.0 7.11 Favored 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 118.864 1.332 . . . . 10.0 110.3 171.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -63.5 132.24 50.68 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.926 0.89 . . . . 10.0 110.002 166.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -129.71 126.26 37.84 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 126.33 1.852 . . . . 10.0 111.167 -171.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -126.21 123.35 37.99 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 127.043 2.137 . . . . 10.0 108.027 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 50.9 mt -114.54 153.55 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 125.177 1.391 . . . . 10.0 110.968 -171.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -127.78 109.39 11.59 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.353 2.261 . . . . 10.0 108.897 170.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -68.14 -41.66 81.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.188 -0.945 . . . . 10.0 112.606 174.587 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.83 90.2 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.764 1.625 . . . . 10.0 110.388 -176.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -69.89 151.91 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 O-C-N 121.31 -0.869 . . . . 10.0 112.898 -175.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 86.7 mmt-85 -132.31 159.83 38.0 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 127.019 2.128 . . . . 10.0 111.836 174.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.84 -30.83 64.17 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.386 1.074 . . . . 10.0 113.721 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.9 t -62.99 -23.46 67.46 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.966 1.306 . . . . 10.0 113.646 174.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -78.6 -8.46 58.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.556 1.142 . . . . 10.0 113.64 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 152.58 42.84 Favored 'General case' 0 CA--C 1.547 0.839 0 CA-C-N 119.543 1.065 . . . . 10.0 113.406 -179.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.27 -170.88 22.42 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.928 1.252 . . . . 10.0 114.891 176.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.62 97.67 7.99 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.939 1.696 . . . . 10.0 111.454 176.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -71.55 150.41 44.78 Favored 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 123.948 0.899 . . . . 10.0 111.793 168.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.31 158.08 44.36 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.799 0.84 . . . . 10.0 112.406 168.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.8 t -130.62 141.9 50.44 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 127.162 2.185 . . . . 10.0 109.601 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 28.6 t -124.66 131.74 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.255 1.422 . . . . 10.0 109.489 177.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.43 124.03 40.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.189 1.795 . . . . 10.0 110.705 -177.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 1.9 mppt? -129.04 135.94 49.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.241 1.416 . . . . 10.0 111.602 -176.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -134.77 179.39 6.33 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.269 1.028 . . . . 10.0 111.534 163.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 14.9 ptp180 -62.62 -11.08 14.67 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.551 1.685 . . . . 10.0 115.551 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.17 -18.6 13.96 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.507 1.523 . . . . 10.0 114.167 178.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.04 -171.1 42.85 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 119.854 1.206 . . . . 10.0 115.849 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -135.26 147.09 49.16 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.586 1.955 . . . . 10.0 111.835 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.94 159.08 42.99 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.882 1.673 . . . . 10.0 111.861 170.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 86.9 m -138.75 138.26 37.48 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.76 1.624 . . . . 10.0 110.49 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -131.69 156.06 46.55 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.002 1.721 . . . . 10.0 111.25 -175.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -143.93 147.03 33.4 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.427 1.091 . . . . 10.0 112.392 -170.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.1 p -150.98 158.93 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 126.201 1.8 . . . . 10.0 111.277 168.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.6 tt0 -109.16 135.1 50.83 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.848 1.259 . . . . 10.0 111.538 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.4 tp -119.09 110.16 16.75 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.349 1.86 . . . . 10.0 110.639 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -96.5 83.98 3.61 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 125.825 1.65 . . . . 10.0 111.017 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -65.02 112.28 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 121.405 -0.809 . . . . 10.0 110.649 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.0 mt -74.11 101.37 3.9 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.169 1.788 . . . . 10.0 109.862 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.61 153.61 23.27 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.436 1.094 . . . . 10.0 113.895 -174.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -71.65 -26.39 62.52 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 126.086 1.754 . . . . 10.0 113.444 179.197 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 C--O 1.254 1.301 0 C-N-CA 126.811 2.044 . . . . 10.0 113.933 -179.002 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.505 0 N-CA-C 111.395 -0.682 . . . . 10.0 111.395 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.81 165.81 12.21 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.407 1.083 . . . . 10.0 112.92 175.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 22.9 ptt? -145.09 -179.42 6.61 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.943 1.697 . . . . 10.0 111.765 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.55 169.9 42.15 Favored Glycine 0 CA--C 1.54 1.64 0 N-CA-C 116.881 1.512 . . . . 10.0 116.881 178.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -69.03 159.97 51.8 Favored 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 123.614 2.876 . . . . 10.0 112.511 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -67.91 158.85 55.49 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 122.631 2.22 . . . . 10.0 111.794 171.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 41.6 ttt-85 -142.31 150.69 41.14 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.008 1.323 . . . . 10.0 111.538 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 8.9 m-30 -63.84 133.92 54.27 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.073 0.949 . . . . 10.0 110.161 162.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 32.0 mm -130.83 -59.64 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.095 1.358 . . . . 10.0 109.547 173.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -152.51 141.67 21.38 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.739 1.216 . . . . 10.0 111.21 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -127.5 152.77 77.03 Favored Pre-proline 0 N--CA 1.476 0.853 0 C-N-CA 125.736 1.614 . . . . 10.0 110.522 170.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.74 152.8 59.04 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 122.676 2.251 . . . . 10.0 111.553 171.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -72.76 174.17 8.04 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 123.904 0.882 . . . . 10.0 111.833 164.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -60.45 152.99 24.23 Favored 'General case' 0 CA--C 1.547 0.829 0 O-C-N 121.178 -0.951 . . . . 10.0 112.303 175.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.5 mtp -131.02 158.24 40.86 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 125.121 1.368 . . . . 10.0 112.292 -171.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 46.9 p -143.36 120.43 11.41 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.537 1.535 . . . . 10.0 110.49 172.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.5 mm -129.91 134.46 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.475 1.51 . . . . 10.0 109.796 -169.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.54 130.02 43.22 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.275 1.43 . . . . 10.0 112.39 175.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -51.47 127.21 19.41 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.227 1.411 . . . . 10.0 112.618 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.73 -10.61 60.81 Favored Glycine 0 CA--C 1.537 1.412 0 C-N-CA 126.125 1.821 . . . . 10.0 115.196 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -74.65 160.78 30.37 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 119.28 1.54 . . . . 10.0 113.302 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -74.61 142.65 44.59 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.63 1.172 . . . . 10.0 110.044 155.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.7 p -150.75 170.47 19.15 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 123.575 0.75 . . . . 10.0 112.254 163.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -146.61 162.77 37.72 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.156 1.382 . . . . 10.0 112.669 177.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -137.2 139.73 41.27 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 127.508 2.323 . . . . 10.0 109.151 176.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -134.22 124.05 25.33 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.048 0.939 . . . . 10.0 111.453 -171.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -123.82 110.11 14.48 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 126.517 1.927 . . . . 10.0 110.678 -168.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -72.14 119.63 16.6 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.6 0.76 . . . . 10.0 110.002 173.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.9 p -137.94 110.18 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.762 2.025 . . . . 10.0 110.3 -175.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 5.6 t -75.81 -170.88 1.44 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.378 1.071 . . . . 10.0 112.441 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 103.64 164.25 25.23 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 126.886 2.184 . . . . 10.0 114.039 176.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.8 tp -150.8 133.53 8.46 Favored Pre-proline 0 CA--C 1.548 0.895 0 C-N-CA 125.433 1.493 . . . . 10.0 110.335 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -67.02 168.79 51.76 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 CA-C-N 120.783 1.315 . . . . 10.0 112.528 -3.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.03 124.76 60.78 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.418 1.087 . . . . 10.0 110.846 177.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 155.35 64.46 Favored 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 122.434 2.089 . . . . 10.0 113.375 -170.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -72.8 114.24 10.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.458 1.503 . . . . 10.0 109.327 161.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.53 131.34 56.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.682 1.193 . . . . 10.0 111.289 -175.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.5 m -129.44 156.06 44.7 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 126.073 1.749 . . . . 10.0 111.405 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 63.4 m95 -124.88 156.4 37.97 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.85 1.26 . . . . 10.0 113.194 -176.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -144.4 159.78 42.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 127.119 2.168 . . . . 10.0 111.098 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.8 tp -145.74 119.21 9.05 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 126.887 2.075 . . . . 10.0 110.118 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 54.47 15.69 1.09 Allowed 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.449 1.9 . . . . 10.0 115.019 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.55 -11.87 39.16 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.663 2.078 . . . . 10.0 115.254 -177.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -87.43 158.03 19.08 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.948 1.374 . . . . 10.0 111.125 171.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.1 p -71.54 153.37 42.22 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.395 1.078 . . . . 10.0 112.674 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 53.9 t -132.76 100.85 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.367 1.867 . . . . 10.0 108.715 172.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 59.2 mt-30 -73.23 160.77 31.4 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.554 0.742 . . . . 10.0 111.359 171.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.2 p -68.49 155.67 39.46 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.383 0.673 . . . . 10.0 112.012 168.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -153.07 168.91 24.3 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.484 1.513 . . . . 10.0 110.917 177.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -56.9 -35.37 68.89 Favored 'General case' 0 CA--C 1.545 0.775 0 O-C-N 120.942 -1.098 . . . . 10.0 112.779 169.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.7 mt -84.48 -14.19 49.86 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.48 1.112 . . . . 10.0 113.9 173.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -133.62 70.27 1.46 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.837 1.655 . . . . 10.0 111.264 -174.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -71.29 144.09 50.11 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.834 1.254 . . . . 10.0 111.518 -176.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -141.54 106.06 4.86 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.654 1.982 . . . . 10.0 109.811 -175.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.01 164.99 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.643 1.177 . . . . 10.0 112.37 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 62.3 t -131.58 116.05 30.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 125.992 1.717 . . . . 10.0 109.63 178.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -72.54 143.51 48.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.369 0.667 . . . . 10.0 111.105 170.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.18 -20.33 40.21 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 115.308 1.596 . . . . 10.0 115.308 -174.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -75.45 -5.18 43.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.574 1.55 . . . . 10.0 113.867 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.64 50.75 2.28 Favored Glycine 0 CA--C 1.531 1.064 0 C-N-CA 125.436 1.493 . . . . 10.0 112.855 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 17.9 tp -136.46 106.17 6.2 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.332 1.453 . . . . 10.0 110.511 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -76.51 144.41 39.79 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.582 0.353 . . . . 10.0 110.864 168.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.5 m -130.62 114.76 15.82 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 126.427 1.891 . . . . 10.0 110.603 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -108.59 121.06 44.2 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 127.656 2.383 . . . . 10.0 108.715 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 71.3 mt -121.57 152.17 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.514 1.126 . . . . 10.0 111.304 -168.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.74 110.73 12.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.532 2.333 . . . . 10.0 109.43 171.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -66.11 -39.95 90.33 Favored 'General case' 0 N--CA 1.474 0.749 0 O-C-N 121.285 -0.884 . . . . 10.0 113.038 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -151.22 90.22 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.747 1.619 . . . . 10.0 110.277 -178.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.3 p -69.98 140.96 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 O-C-N 121.287 -0.883 . . . . 10.0 111.995 -177.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.3 mmt180 -124.22 161.81 24.98 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.421 1.888 . . . . 10.0 112.043 177.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.74 -33.89 64.68 Favored 'General case' 0 CA--C 1.546 0.82 0 N-CA-C 113.434 0.902 . . . . 10.0 113.434 -178.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.4 m -65.24 -17.68 64.69 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.355 1.462 . . . . 10.0 114.512 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -82.53 -5.47 58.76 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.685 1.194 . . . . 10.0 113.228 177.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.98 151.98 45.59 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.084 -1.01 . . . . 10.0 113.067 178.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.78 -171.27 22.44 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.746 1.165 . . . . 10.0 114.801 175.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.91 103.87 14.35 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.972 1.709 . . . . 10.0 111.055 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -78.15 152.02 32.98 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.009 0.924 . . . . 10.0 111.839 169.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -139.04 156.34 47.27 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.068 0.947 . . . . 10.0 111.687 168.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.0 t -134.06 136.74 44.2 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.525 1.93 . . . . 10.0 109.472 -175.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 67.8 t -128.25 126.53 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.488 1.515 . . . . 10.0 109.143 -178.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.83 117.4 23.29 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.258 1.823 . . . . 10.0 110.77 -174.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 23.0 mtpp -124.49 133.71 53.26 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.482 1.513 . . . . 10.0 111.536 -174.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 14.4 p30 -131.43 178.81 6.44 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.145 0.978 . . . . 10.0 111.7 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -63.57 -10.04 16.37 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 115.636 1.717 . . . . 10.0 115.636 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.12 -20.33 12.73 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.645 1.578 . . . . 10.0 114.246 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.05 -169.2 42.21 Favored Glycine 0 CA--C 1.535 1.291 0 CA-C-N 119.788 1.176 . . . . 10.0 115.769 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -138.54 147.09 42.69 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.357 1.863 . . . . 10.0 112.013 -173.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.66 153.61 50.86 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.033 1.733 . . . . 10.0 111.242 169.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.7 m -136.67 140.07 42.46 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.566 1.546 . . . . 10.0 110.646 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -133.55 159.28 40.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.966 1.706 . . . . 10.0 111.247 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.6 m -143.43 144.14 31.9 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 124.949 1.3 . . . . 10.0 111.341 -174.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.39 161.4 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.938 1.695 . . . . 10.0 110.563 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.8 tt0 -123.72 138.44 54.52 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 124.484 1.114 . . . . 10.0 111.196 176.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.3 tp -125.24 108.94 12.25 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.035 1.734 . . . . 10.0 110.711 -178.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -93.8 83.15 4.36 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.432 1.493 . . . . 10.0 110.682 174.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.34 114.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 O-C-N 121.452 -0.78 . . . . 10.0 110.418 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.9 mt -75.25 94.09 2.95 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.193 1.797 . . . . 10.0 110.015 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.99 151.54 34.81 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.43 1.092 . . . . 10.0 112.98 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -65.45 -52.21 54.73 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.127 1.371 . . . . 10.0 112.228 177.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.253 1.284 0 C-N-CA 125.985 1.714 . . . . 10.0 113.079 177.14 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 N-CA-C 111.855 -0.498 . . . . 10.0 111.855 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -62.33 107.33 0.89 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.343 1.457 . . . . 10.0 112.733 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.97 162.6 18.94 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 125.169 1.387 . . . . 10.0 112.785 176.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 179.86 170.85 42.07 Favored Glycine 0 CA--C 1.542 1.772 0 O-C-N 121.296 -0.877 . . . . 10.0 115.244 -176.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.14 162.82 41.29 Favored 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 123.816 3.011 . . . . 10.0 113.528 -170.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.71 139.09 56.38 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.02 2.48 . . . . 10.0 111.006 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 53.1 ttt85 -128.78 151.64 49.35 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.457 1.503 . . . . 10.0 112.617 -174.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -76.44 88.72 3.21 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.041 2.137 . . . . 10.0 111.708 177.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.2 mm -82.92 -58.78 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 O-C-N 121.605 -0.684 . . . . 10.0 110.264 171.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 24.8 tt0 -154.29 146.62 23.89 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.735 1.214 . . . . 10.0 111.776 175.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.79 152.29 74.86 Favored Pre-proline 0 N--CA 1.477 0.881 0 C-N-CA 126.452 1.901 . . . . 10.0 110.004 169.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.83 157.45 35.12 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.567 2.178 . . . . 10.0 112.247 -178.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -73.88 168.15 20.02 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.833 0.853 . . . . 10.0 111.326 166.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -60.14 158.14 11.85 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 121.419 -0.8 . . . . 10.0 112.801 176.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -128.47 152.75 47.88 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.714 1.606 . . . . 10.0 111.742 -171.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 39.5 p -141.77 116.85 9.98 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 125.385 1.474 . . . . 10.0 110.416 170.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.9 mm -129.3 129.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.29 1.436 . . . . 10.0 109.995 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -60.66 127.17 30.35 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.173 1.389 . . . . 10.0 112.12 173.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -53.22 134.38 39.2 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.202 1.401 . . . . 10.0 113.161 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.85 -12.02 67.55 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.346 1.927 . . . . 10.0 114.79 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -74.24 161.56 29.81 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 118.972 1.386 . . . . 10.0 113.268 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -75.9 141.16 42.4 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.885 1.274 . . . . 10.0 110.276 156.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.79 172.03 15.29 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.678 0.791 . . . . 10.0 112.065 161.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -152.43 170.21 20.68 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.145 1.378 . . . . 10.0 112.923 174.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.9 mtt -121.8 164.7 17.03 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 126.587 1.955 . . . . 10.0 112.526 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -138.23 103.42 4.92 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 126.353 1.861 . . . . 10.0 111.738 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -115.37 109.61 18.15 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.5 1.52 . . . . 10.0 111.178 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -80.03 74.72 6.79 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 121.302 -0.874 . . . . 10.0 111.496 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -79.84 128.14 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.913 1.285 . . . . 10.0 109.945 163.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 68.6 m -135.28 115.35 13.19 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.787 1.235 . . . . 10.0 111.343 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -158.41 169.85 34.99 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 126.695 2.093 . . . . 10.0 111.55 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 21.8 tp -142.14 120.04 7.47 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.504 1.122 . . . . 10.0 110.449 -177.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -68.05 167.54 63.18 Favored 'Cis proline' 0 CA--C 1.54 0.79 0 CA-C-N 121.018 1.399 . . . . 10.0 112.906 0.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 124.39 62.23 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.791 1.236 . . . . 10.0 111.189 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.49 151.33 59.02 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.41 2.073 . . . . 10.0 113.82 -169.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -69.94 130.45 42.26 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.611 1.564 . . . . 10.0 109.543 159.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.3 m -124.54 134.74 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.891 1.276 . . . . 10.0 112.253 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.6 m -136.47 114.56 11.48 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.673 1.589 . . . . 10.0 111.418 -173.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -87.44 151.98 22.61 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 114.016 1.117 . . . . 10.0 114.016 -178.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -141.61 160.57 39.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.975 2.51 . . . . 10.0 111.017 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -146.97 120.92 9.34 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.541 2.337 . . . . 10.0 109.833 176.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 54.93 14.71 0.97 Allowed 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.494 1.918 . . . . 10.0 115.341 178.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.28 -7.31 34.76 Favored Glycine 0 CA--C 1.539 1.582 0 C-N-CA 126.351 1.929 . . . . 10.0 115.487 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -99.55 159.75 14.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.587 1.555 . . . . 10.0 110.921 171.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.9 p -71.69 158.99 35.17 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.12 0.968 . . . . 10.0 112.788 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 39.0 t -135.71 102.47 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.984 1.714 . . . . 10.0 109.354 173.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.9 mt-30 -70.18 155.21 40.96 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.239 0.615 . . . . 10.0 111.251 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 67.6 p -69.63 160.23 31.96 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 123.562 0.745 . . . . 10.0 112.164 170.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -152.66 169.66 22.16 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.383 1.473 . . . . 10.0 111.024 178.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.9 -35.01 68.47 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 120.867 -1.146 . . . . 10.0 112.749 168.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 77.1 mt -82.65 -14.08 55.33 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.506 1.122 . . . . 10.0 113.889 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -135.25 69.53 1.44 Allowed 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.782 1.633 . . . . 10.0 111.501 -173.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 77.9 mttt -71.34 134.22 46.56 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.037 1.335 . . . . 10.0 110.547 -179.008 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 60.4 mtt -131.75 101.04 5.3 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 126.22 1.808 . . . . 10.0 109.524 -174.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.19 159.15 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 124.839 1.256 . . . . 10.0 112.562 -170.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.53 167.9 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 126.007 1.723 . . . . 10.0 111.992 -177.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 34.2 t -131.14 147.39 52.6 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 125.545 1.538 . . . . 10.0 112.128 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -57.82 -20.37 35.44 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.831 1.652 . . . . 10.0 113.87 168.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -78.0 -1.36 31.74 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.788 1.635 . . . . 10.0 114.355 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 79.87 60.94 2.34 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 124.677 1.132 . . . . 10.0 111.935 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 42.9 tp -150.97 148.53 28.5 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.96 1.704 . . . . 10.0 110.862 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -132.84 129.24 38.21 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.897 2.079 . . . . 10.0 110.097 174.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.1 m -108.81 147.1 32.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.475 1.51 . . . . 10.0 112.146 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.91 108.57 9.48 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 126.623 1.969 . . . . 10.0 108.333 171.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -89.89 151.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 125.268 1.427 . . . . 10.0 110.329 -178.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -130.61 99.69 5.06 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.94 2.096 . . . . 10.0 108.38 167.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -62.4 -38.4 89.49 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 113.225 0.824 . . . . 10.0 113.225 -176.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.8 p -149.65 87.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 125.897 1.679 . . . . 10.0 110.133 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.1 p -70.07 139.53 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 121.347 -0.846 . . . . 10.0 112.029 -176.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.4 mmm180 -128.42 161.68 28.92 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.466 1.907 . . . . 10.0 111.26 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -52.21 -35.95 50.78 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 114.195 1.183 . . . . 10.0 114.195 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.7 -17.72 64.36 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.242 1.417 . . . . 10.0 114.673 176.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -82.52 -5.92 59.02 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.74 1.216 . . . . 10.0 113.473 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 151.01 47.6 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.988 -1.07 . . . . 10.0 113.187 179.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.49 -172.63 22.4 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.872 1.225 . . . . 10.0 115.069 175.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.72 102.54 13.07 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.075 1.75 . . . . 10.0 111.538 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -79.67 149.02 31.37 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 124.291 1.037 . . . . 10.0 111.932 171.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.9 159.26 43.18 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.906 0.882 . . . . 10.0 112.271 170.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 49.8 t -137.68 118.2 13.87 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 125.139 1.375 . . . . 10.0 111.391 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 42.3 t -87.75 124.85 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 125.169 1.388 . . . . 10.0 109.268 172.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -117.65 128.16 54.65 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.456 1.903 . . . . 10.0 111.075 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.0 mtmt -133.83 130.12 37.47 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 126.116 1.767 . . . . 10.0 112.159 -167.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -136.4 -179.56 5.75 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 118.879 0.763 . . . . 10.0 112.305 162.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -59.33 -14.68 12.48 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 115.823 1.786 . . . . 10.0 115.823 -177.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.6 -12.28 15.0 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.452 1.501 . . . . 10.0 114.357 -178.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 162.98 -172.39 38.99 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.443 1.02 . . . . 10.0 115.457 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -134.6 147.76 50.28 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.239 1.816 . . . . 10.0 111.57 -173.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.08 163.26 30.74 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.537 1.935 . . . . 10.0 110.785 169.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 96.4 m -144.29 124.28 13.57 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.514 1.126 . . . . 10.0 110.649 177.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -113.54 155.5 25.27 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.523 1.529 . . . . 10.0 111.17 -176.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.5 m -141.77 148.51 39.05 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.621 1.168 . . . . 10.0 112.41 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.79 171.01 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 127.024 2.13 . . . . 10.0 110.603 168.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -128.78 140.63 51.62 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.924 1.29 . . . . 10.0 111.12 172.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.3 tp -125.41 111.81 15.56 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.4 1.88 . . . . 10.0 110.642 -178.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -97.38 85.85 3.75 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.8 1.64 . . . . 10.0 110.864 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.5 t -67.08 112.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.364 -0.835 . . . . 10.0 110.599 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.51 94.16 3.66 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.037 1.735 . . . . 10.0 110.1 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.43 147.87 39.45 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 124.519 1.127 . . . . 10.0 112.764 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -72.55 -47.85 44.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.601 0.761 . . . . 10.0 112.387 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 C--O 1.254 1.305 0 C-N-CA 126.087 1.755 . . . . 10.0 113.622 -179.798 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.55 0 N-CA-C 111.888 -0.485 . . . . 10.0 111.888 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.49 163.96 14.89 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.403 1.081 . . . . 10.0 113.014 175.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.25 171.75 13.88 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.278 1.831 . . . . 10.0 111.21 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.44 175.86 47.66 Favored Glycine 0 CA--C 1.541 1.69 0 N-CA-C 116.932 1.533 . . . . 10.0 116.932 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.66 162.97 38.84 Favored 'Trans proline' 0 CA--C 1.544 0.991 0 C-N-CA 123.756 2.97 . . . . 10.0 113.31 -172.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -69.73 168.26 22.02 Favored 'Trans proline' 0 CA--C 1.541 0.867 0 C-N-CA 123.249 2.632 . . . . 10.0 112.361 171.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 58.2 ttp85 -134.44 156.42 48.6 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.322 1.449 . . . . 10.0 112.22 -174.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -93.94 64.6 3.4 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 126.816 2.047 . . . . 10.0 111.086 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.48 -66.08 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.095 -1.003 . . . . 10.0 112.679 -170.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -155.24 165.03 37.94 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.0 m -132.92 161.99 60.32 Favored Pre-proline 0 N--CA 1.476 0.829 0 C-N-CA 127.871 2.468 . . . . 10.0 110.492 170.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.67 164.02 32.86 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.832 2.355 . . . . 10.0 111.228 164.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -72.59 169.43 16.55 Favored 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.251 -0.906 . . . . 10.0 112.523 169.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.31 148.79 40.09 Favored 'General case' 0 CA--C 1.546 0.789 0 O-C-N 121.346 -0.846 . . . . 10.0 112.652 173.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 75.8 mtp -130.81 154.07 48.42 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.882 1.273 . . . . 10.0 112.48 -170.117 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 64.6 m -140.48 101.03 4.01 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.302 1.841 . . . . 10.0 110.107 -176.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 37.6 mm -117.8 134.31 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 124.528 1.131 . . . . 10.0 111.292 -166.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -64.11 130.06 42.46 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.816 1.246 . . . . 10.0 112.445 173.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -53.24 129.8 32.64 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.112 1.365 . . . . 10.0 112.925 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.74 -11.5 62.73 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 126.305 1.907 . . . . 10.0 115.041 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -75.72 161.18 29.28 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.001 1.401 . . . . 10.0 113.276 177.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.9 149.22 46.96 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.665 1.186 . . . . 10.0 110.71 157.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 10.7 t -150.39 160.43 43.75 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.755 1.222 . . . . 10.0 111.903 168.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -151.65 167.41 28.23 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.342 1.457 . . . . 10.0 112.883 167.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -132.91 167.03 20.98 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.646 1.978 . . . . 10.0 112.119 -176.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -134.55 108.35 8.03 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.258 1.823 . . . . 10.0 111.775 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -117.67 112.17 20.14 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.448 1.499 . . . . 10.0 111.42 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -71.96 108.5 5.24 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.4 1.08 . . . . 10.0 110.31 174.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 18.0 t -117.59 149.32 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.684 1.594 . . . . 10.0 109.819 177.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.4 t -148.15 -177.58 5.82 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.254 1.422 . . . . 10.0 111.112 175.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 122.77 162.14 11.44 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 127.65 2.548 . . . . 10.0 111.795 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.1 tp -144.61 122.73 6.68 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-O 118.083 -0.96 . . . . 10.0 110.571 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -66.56 167.89 53.29 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.689 1.282 . . . . 10.0 112.627 -1.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.24 126.02 72.72 Favored Pre-proline 0 CA--C 1.549 0.935 0 C-N-CA 124.454 1.102 . . . . 10.0 111.291 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.51 149.9 62.79 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.406 2.071 . . . . 10.0 113.321 -173.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -74.66 151.05 39.33 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.61 1.164 . . . . 10.0 109.918 159.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 59.1 t -131.56 138.46 52.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.963 0.905 . . . . 10.0 112.125 -169.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 63.2 m -132.73 115.27 15.14 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 126.767 2.027 . . . . 10.0 110.61 177.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 53.4 m95 -86.44 158.83 19.5 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 122.001 0.905 . . . . 10.0 112.85 176.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -144.69 159.88 42.11 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 127.063 2.145 . . . . 10.0 111.235 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.6 tp -145.65 118.12 8.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.146 2.178 . . . . 10.0 110.062 175.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 54.87 14.95 0.99 Allowed 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 126.479 1.912 . . . . 10.0 115.092 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.82 -14.02 34.78 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 126.747 2.118 . . . . 10.0 115.165 -177.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -83.41 155.53 23.42 Favored 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 118.981 1.39 . . . . 10.0 110.929 169.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.7 p -71.46 155.14 40.94 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.27 1.028 . . . . 10.0 112.602 173.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 59.5 t -136.63 135.96 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 126.678 1.991 . . . . 10.0 108.976 172.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -119.09 164.01 16.17 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 125.267 1.427 . . . . 10.0 111.344 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 98.1 p -66.89 152.76 45.05 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.655 0.741 . . . . 10.0 112.441 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -151.95 167.96 26.71 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.827 1.651 . . . . 10.0 110.656 176.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.65 -34.92 67.78 Favored 'General case' 0 CA--C 1.545 0.772 0 O-C-N 120.97 -1.081 . . . . 10.0 112.832 169.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.4 mt -85.39 -13.55 49.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.55 1.14 . . . . 10.0 114.001 174.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.3 m80 -136.08 70.35 1.42 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.658 1.583 . . . . 10.0 111.184 -174.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -69.91 145.28 52.06 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.713 1.205 . . . . 10.0 111.636 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.4 mtt -139.41 101.74 4.31 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.785 2.034 . . . . 10.0 109.736 -176.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.37 162.24 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.851 1.26 . . . . 10.0 111.818 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 13.8 p -136.83 134.61 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.631 1.172 . . . . 10.0 111.269 -179.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 40.7 t -65.21 159.89 22.65 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.923 1.289 . . . . 10.0 112.505 177.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -52.19 -33.15 39.53 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.538 1.535 . . . . 10.0 111.965 164.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -81.72 -3.63 54.19 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.405 1.882 . . . . 10.0 113.735 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.25 -3.48 82.23 Favored Glycine 0 CA--C 1.538 1.494 0 C-N-CA 125.75 1.643 . . . . 10.0 115.468 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 48.2 tp -67.97 107.59 2.74 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.846 1.259 . . . . 10.0 111.165 174.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.6 t60 -84.86 124.57 31.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.781 1.632 . . . . 10.0 111.514 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.8 m -97.74 134.1 41.37 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.638 1.575 . . . . 10.0 111.793 171.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -123.07 123.55 41.1 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 127.154 2.182 . . . . 10.0 107.94 171.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 47.4 mt -121.79 153.63 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 125.124 1.37 . . . . 10.0 111.517 -166.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -132.18 108.23 9.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 128.044 2.538 . . . . 10.0 109.224 172.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -66.73 -38.79 87.37 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.846 -1.159 . . . . 10.0 112.914 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.5 p -151.78 89.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.684 1.593 . . . . 10.0 110.441 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.35 140.56 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 121.212 -0.93 . . . . 10.0 111.883 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -129.34 162.3 28.3 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 126.385 1.874 . . . . 10.0 111.267 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -53.11 -35.11 59.28 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.128 1.158 . . . . 10.0 114.128 -175.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.4 m -65.09 -17.83 64.79 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.32 1.448 . . . . 10.0 114.644 176.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -82.9 -7.0 59.7 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.754 1.222 . . . . 10.0 113.518 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.97 147.9 52.64 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.096 -1.003 . . . . 10.0 113.218 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.74 -171.99 24.19 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.507 1.051 . . . . 10.0 115.448 173.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.69 104.15 11.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.846 1.658 . . . . 10.0 110.893 173.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -80.79 151.1 28.93 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.985 0.914 . . . . 10.0 111.751 170.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.93 161.19 38.42 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.093 0.957 . . . . 10.0 112.132 168.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 29.6 t -141.49 104.79 4.64 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.549 1.94 . . . . 10.0 109.766 -172.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.69 131.1 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.576 1.15 . . . . 10.0 109.386 174.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.15 126.15 44.81 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.304 1.842 . . . . 10.0 110.721 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -134.35 135.42 42.69 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.479 1.512 . . . . 10.0 112.435 -169.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -130.04 -178.2 4.63 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.577 1.151 . . . . 10.0 111.712 166.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -59.88 -12.41 7.55 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 115.841 1.793 . . . . 10.0 115.841 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.7 -14.31 12.02 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.448 1.499 . . . . 10.0 114.589 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.32 -170.3 42.88 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-N 119.978 1.263 . . . . 10.0 116.165 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -134.74 144.35 47.67 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.104 2.162 . . . . 10.0 111.674 -172.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.98 163.13 31.44 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.039 1.735 . . . . 10.0 111.043 168.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -142.26 140.44 32.24 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.16 0.984 . . . . 10.0 111.492 -175.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -126.93 156.69 41.09 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 126.097 1.759 . . . . 10.0 110.841 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.8 m -145.3 146.62 31.71 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 124.761 1.224 . . . . 10.0 111.682 -171.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.59 161.65 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 125.894 1.678 . . . . 10.0 110.848 169.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.2 tt0 -116.75 128.52 55.39 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.583 1.153 . . . . 10.0 110.466 170.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.9 tp -118.55 104.15 10.39 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 126.003 1.721 . . . . 10.0 109.831 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -77.99 138.74 38.99 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.23 0.612 . . . . 10.0 110.108 163.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 27.8 t -117.01 105.16 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.051 0.94 . . . . 10.0 109.157 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.8 mt -67.62 97.71 0.63 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.535 1.934 . . . . 10.0 109.869 179.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.52 155.31 22.35 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.382 1.073 . . . . 10.0 112.683 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 23.0 ttpt -122.57 15.23 10.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.216 1.406 . . . . 10.0 113.93 -171.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 . . . . . 0 C--O 1.255 1.382 0 C-N-CA 126.155 1.782 . . . . 10.0 114.496 169.72 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 N-CA-C 111.896 -0.481 . . . . 10.0 111.896 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.36 157.27 26.7 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.277 1.031 . . . . 10.0 112.824 176.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.7 176.98 10.51 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.089 1.755 . . . . 10.0 111.799 -177.039 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.54 171.76 44.46 Favored Glycine 0 CA--C 1.542 1.732 0 N-CA-C 117.135 1.614 . . . . 10.0 117.135 -176.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.95 162.22 43.4 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.771 2.981 . . . . 10.0 113.101 -173.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -66.86 150.84 83.12 Favored 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 122.784 2.322 . . . . 10.0 111.064 168.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 64.2 ttt-85 -138.54 153.74 48.73 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.317 1.447 . . . . 10.0 111.62 -177.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.95 117.2 9.5 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.614 1.166 . . . . 10.0 111.052 169.29 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.32 -57.78 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.102 1.361 . . . . 10.0 110.368 176.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -149.53 137.15 20.17 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.847 1.259 . . . . 10.0 111.547 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -131.96 153.82 81.52 Favored Pre-proline 0 N--CA 1.474 0.736 0 C-N-CA 126.488 1.915 . . . . 10.0 110.028 170.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.75 162.91 36.8 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.627 2.218 . . . . 10.0 111.433 171.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.13 179.92 2.61 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.629 0.772 . . . . 10.0 110.738 161.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -58.11 142.68 46.32 Favored 'General case' 0 CA--C 1.546 0.82 0 O-C-N 120.506 -1.372 . . . . 10.0 111.156 166.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 89.9 mtp -122.53 157.33 32.27 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 125.484 1.513 . . . . 10.0 111.937 -172.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 57.8 p -144.38 129.62 18.73 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.295 1.438 . . . . 10.0 110.691 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.9 mm -134.51 133.97 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.7 1.6 . . . . 10.0 109.288 -170.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -63.94 130.83 45.67 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.616 1.166 . . . . 10.0 112.171 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -52.28 126.69 19.74 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.01 1.324 . . . . 10.0 112.509 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.0 61.46 Favored Glycine 0 CA--C 1.537 1.423 0 C-N-CA 125.842 1.687 . . . . 10.0 115.22 179.033 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -72.72 160.59 31.96 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.379 1.59 . . . . 10.0 113.105 175.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -72.67 149.38 43.9 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 124.488 1.115 . . . . 10.0 110.513 157.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 34.6 t -148.78 157.0 43.13 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.461 1.104 . . . . 10.0 111.272 167.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.808 HH21 ' HG ' ' A' ' 307' ' ' SER . 9.6 ptm180 -144.73 154.47 42.77 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.003 1.321 . . . . 10.0 111.503 164.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.3 mtt -125.61 113.25 17.14 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 125.718 1.607 . . . . 10.0 111.107 -173.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -69.65 127.53 33.27 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.426 1.49 . . . . 10.0 112.766 174.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -137.97 93.82 2.81 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.105 1.362 . . . . 10.0 110.976 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -67.38 121.25 15.34 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.551 0.741 . . . . 10.0 110.124 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.8 p -135.17 115.59 18.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 126.859 2.064 . . . . 10.0 110.189 -173.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 66.2 m -126.98 107.25 9.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.892 1.277 . . . . 10.0 111.59 -173.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -156.15 167.58 33.38 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 127.166 2.317 . . . . 10.0 110.927 169.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -142.14 125.58 9.63 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 124.417 1.087 . . . . 10.0 110.686 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -66.06 168.06 49.72 Favored 'Cis proline' 0 CA--C 1.539 0.763 0 CA-C-N 120.622 1.258 . . . . 10.0 112.453 -2.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 123.45 57.07 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 124.348 1.059 . . . . 10.0 111.264 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.83 149.21 66.14 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.428 2.085 . . . . 10.0 112.999 -172.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -72.1 139.19 48.27 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.263 1.025 . . . . 10.0 109.535 161.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.36 142.05 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.266 1.027 . . . . 10.0 113.136 -172.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.7 m -141.39 115.34 9.2 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 125.841 1.657 . . . . 10.0 111.195 -176.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 71.1 m95 -84.07 151.22 25.08 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 122.2 1.0 . . . . 10.0 113.43 176.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -141.3 161.3 38.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 128.249 2.619 . . . . 10.0 110.776 -179.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.1 tp -147.09 119.78 8.59 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.431 2.292 . . . . 10.0 110.041 176.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 55.02 15.29 1.14 Allowed 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 126.581 1.952 . . . . 10.0 115.045 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.33 -12.53 40.01 Favored Glycine 0 CA--C 1.539 1.564 0 C-N-CA 126.607 2.051 . . . . 10.0 115.104 -177.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -87.67 158.33 18.86 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 119.008 1.404 . . . . 10.0 110.824 170.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.8 p -71.25 158.32 36.59 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.99 0.916 . . . . 10.0 112.345 173.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 40.1 t -134.62 100.82 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.844 1.658 . . . . 10.0 108.779 171.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -71.43 156.22 39.72 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.346 0.658 . . . . 10.0 110.693 170.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.0 p -70.08 151.96 44.9 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 121.559 -0.713 . . . . 10.0 111.908 170.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -152.74 -177.49 6.29 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.051 1.34 . . . . 10.0 111.949 171.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -60.3 -22.75 63.54 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 114.64 1.348 . . . . 10.0 114.64 -177.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 52.9 mt -104.19 -26.19 12.63 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.866 1.666 . . . . 10.0 112.67 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -110.9 74.14 0.86 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.416 1.886 . . . . 10.0 111.052 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 92.2 mttt -77.21 146.31 37.07 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.691 1.196 . . . . 10.0 111.175 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.1 mtt -145.34 102.51 3.73 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 126.06 1.744 . . . . 10.0 110.281 -170.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.91 163.25 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 124.505 1.122 . . . . 10.0 112.468 178.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 54.7 t -121.38 112.58 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.536 1.934 . . . . 10.0 109.266 174.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 74.7 m -69.25 151.51 46.18 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.76 0.824 . . . . 10.0 111.552 173.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -57.96 -19.68 32.2 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 115.346 1.61 . . . . 10.0 115.346 -174.366 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -75.97 -4.0 38.72 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.763 1.625 . . . . 10.0 113.994 178.104 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.09 48.92 4.43 Favored Glycine 0 CA--C 1.531 1.071 0 C-N-CA 125.161 1.363 . . . . 10.0 112.139 -175.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 51.5 tp -136.82 103.56 5.22 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.571 1.549 . . . . 10.0 110.642 -171.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 23.7 t60 -70.45 147.27 49.64 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 122.032 -0.418 . . . . 10.0 110.46 166.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 307' ' ' SER . . . . . 0.808 ' HG ' HH21 ' A' ' 268' ' ' ARG . 5.5 t -135.94 99.53 4.18 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.016 1.326 . . . . 10.0 111.204 176.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -81.86 120.28 24.99 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.485 1.514 . . . . 10.0 108.884 173.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 42.6 mt -115.55 151.6 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 125.125 1.37 . . . . 10.0 111.514 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -129.25 108.04 10.02 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.954 2.502 . . . . 10.0 109.258 170.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -63.94 -42.0 97.47 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.194 -0.942 . . . . 10.0 112.845 175.015 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.47 90.88 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.863 1.665 . . . . 10.0 110.121 -179.226 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.7 140.89 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.296 -0.878 . . . . 10.0 112.212 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -120.86 160.76 22.77 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.454 1.901 . . . . 10.0 112.057 176.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.86 -30.81 66.1 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 113.617 0.969 . . . . 10.0 113.617 -177.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.6 p -67.85 -15.62 63.71 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.921 1.689 . . . . 10.0 114.788 173.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -83.05 -5.08 58.97 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.599 1.16 . . . . 10.0 113.486 176.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.66 151.75 44.07 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.012 -1.055 . . . . 10.0 113.063 177.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.31 -173.07 22.67 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.915 1.245 . . . . 10.0 114.837 176.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -87.6 101.28 13.48 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.9 1.68 . . . . 10.0 111.274 176.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -78.37 151.78 32.65 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.295 1.038 . . . . 10.0 111.972 169.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.8 157.31 43.93 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.246 1.018 . . . . 10.0 112.109 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.6 t -134.97 104.89 6.14 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.645 1.578 . . . . 10.0 110.925 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.1 t -71.42 134.53 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 123.916 0.886 . . . . 10.0 109.131 168.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -133.51 119.46 19.56 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.756 2.023 . . . . 10.0 110.27 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.3 mtpt -134.4 136.06 43.05 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.79 1.236 . . . . 10.0 113.018 -170.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 24.9 p30 -132.51 -178.36 4.89 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.061 1.344 . . . . 10.0 111.547 167.093 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.1 ptm180 -60.97 -14.84 25.45 Favored 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 115.482 1.66 . . . . 10.0 115.482 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.03 -19.65 13.66 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.443 1.497 . . . . 10.0 114.208 -177.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.28 -169.98 42.63 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 116.142 1.217 . . . . 10.0 116.142 177.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -134.54 144.64 48.12 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 127.262 2.225 . . . . 10.0 111.664 -170.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.88 159.91 40.71 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 126.214 1.806 . . . . 10.0 110.794 167.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 32.8 m -140.35 101.14 4.05 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 124.457 1.103 . . . . 10.0 110.733 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -77.66 155.56 31.3 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.777 1.231 . . . . 10.0 111.254 175.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 28.3 m -146.98 146.35 30.05 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.728 1.211 . . . . 10.0 112.057 -174.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.3 p -154.3 145.99 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 125.819 1.648 . . . . 10.0 111.934 170.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -100.45 135.46 41.85 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.611 1.165 . . . . 10.0 110.929 170.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.1 tp -122.39 112.4 18.04 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.98 1.712 . . . . 10.0 111.026 177.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -100.0 85.22 3.01 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.942 1.697 . . . . 10.0 110.834 175.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -64.94 114.49 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.954 0.902 . . . . 10.0 110.684 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.6 mt -75.81 99.78 4.55 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.154 1.781 . . . . 10.0 110.042 179.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.01 148.41 40.26 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.304 1.042 . . . . 10.0 113.525 -175.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -144.43 83.15 1.71 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.759 2.023 . . . . 10.0 110.385 176.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 125.668 1.587 . . . . 10.0 114.397 176.169 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.568 0 N-CA-C 111.853 -0.499 . . . . 10.0 111.853 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.26 162.06 18.13 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.332 1.053 . . . . 10.0 112.94 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.9 174.17 12.13 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 126.096 1.758 . . . . 10.0 111.648 -178.267 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.81 172.96 45.65 Favored Glycine 0 CA--C 1.542 1.757 0 N-CA-C 116.792 1.477 . . . . 10.0 116.792 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.36 161.72 44.75 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.569 2.846 . . . . 10.0 113.161 -172.358 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -67.05 158.78 55.17 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.861 2.374 . . . . 10.0 111.32 168.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.7 tpt85 -135.1 151.44 50.72 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.007 1.323 . . . . 10.0 111.772 -174.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -79.01 65.4 4.17 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 127.251 2.22 . . . . 10.0 111.812 -176.356 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 39.8 mm -63.16 -62.35 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 O-C-N 121.225 -0.922 . . . . 10.0 112.635 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -153.16 149.67 28.27 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.822 0.849 . . . . 10.0 112.59 -178.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.2 m -134.44 151.11 75.56 Favored Pre-proline 0 N--CA 1.477 0.925 0 C-N-CA 126.405 1.882 . . . . 10.0 110.558 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -74.65 159.77 42.06 Favored 'Trans proline' 0 CA--C 1.542 0.916 0 C-N-CA 123.049 2.499 . . . . 10.0 111.596 168.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -77.24 172.61 13.0 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 123.942 0.897 . . . . 10.0 111.542 167.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -49.61 108.86 0.23 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.416 1.486 . . . . 10.0 113.594 178.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.3 mtp -82.41 155.66 24.56 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.349 1.46 . . . . 10.0 112.008 -177.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 71.2 p -140.36 131.81 26.91 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.964 1.306 . . . . 10.0 111.023 170.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.2 mm -137.08 129.46 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.385 1.474 . . . . 10.0 109.94 -170.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -62.26 127.61 32.17 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.785 1.234 . . . . 10.0 112.169 172.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -52.82 135.02 36.59 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.289 1.435 . . . . 10.0 113.171 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.12 -11.27 69.45 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.046 1.784 . . . . 10.0 114.952 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.9 mtp-105 -77.63 162.73 26.82 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 118.989 1.394 . . . . 10.0 113.162 177.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -71.71 151.98 43.17 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.884 1.273 . . . . 10.0 110.763 158.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 36.0 t -148.41 156.83 42.98 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.496 1.118 . . . . 10.0 111.474 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -135.76 139.98 43.97 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 125.516 1.526 . . . . 10.0 110.858 162.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 43.9 mtt -100.77 155.39 17.94 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.801 1.641 . . . . 10.0 109.818 167.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -139.57 118.32 12.37 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.157 1.383 . . . . 10.0 110.984 -170.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -130.52 106.84 8.78 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 125.992 1.717 . . . . 10.0 111.952 -170.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -65.93 127.64 32.84 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.902 0.881 . . . . 10.0 110.52 173.126 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.1 125.34 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.642 1.577 . . . . 10.0 110.769 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 69.4 m -133.21 115.3 14.84 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.674 1.19 . . . . 10.0 111.907 -173.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -161.69 169.76 37.23 Favored Glycine 0 CA--C 1.536 1.393 0 C-N-CA 127.161 2.315 . . . . 10.0 111.381 172.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -143.7 125.3 8.24 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.09 0.956 . . . . 10.0 111.194 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.01 167.64 51.14 Favored 'Cis proline' 0 CA--C 1.539 0.744 0 CA-C-N 120.866 1.345 . . . . 10.0 112.476 -2.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.11 122.32 47.31 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.404 1.081 . . . . 10.0 111.231 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -69.34 148.59 68.16 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.42 2.08 . . . . 10.0 112.922 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -72.06 145.73 48.06 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.143 0.977 . . . . 10.0 109.736 161.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.98 139.72 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.556 1.142 . . . . 10.0 112.575 -172.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 73.2 m -136.81 142.12 42.91 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 126.024 1.729 . . . . 10.0 110.672 177.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -111.86 158.05 19.88 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.474 1.11 . . . . 10.0 113.278 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -145.69 159.57 42.96 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 127.256 2.222 . . . . 10.0 111.329 -174.15 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.4 tp -147.19 119.52 8.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.054 2.142 . . . . 10.0 110.0 175.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 55.26 14.05 0.98 Allowed 'General case' 0 CA--C 1.554 1.106 0 C-N-CA 126.537 1.935 . . . . 10.0 115.376 179.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.17 -12.22 31.4 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.564 2.031 . . . . 10.0 115.182 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -89.9 160.68 16.32 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 118.924 1.362 . . . . 10.0 110.978 169.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.5 p -73.99 158.92 33.48 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.369 1.067 . . . . 10.0 112.752 175.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 87.6 t -136.82 104.98 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 127.097 2.159 . . . . 10.0 108.623 173.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -79.68 161.54 25.77 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.417 0.687 . . . . 10.0 111.131 170.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.9 p -70.27 148.02 49.03 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.564 0.746 . . . . 10.0 112.211 171.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -152.61 -179.93 8.04 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 125.365 1.466 . . . . 10.0 111.328 168.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -57.97 -27.53 63.53 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.698 1.37 . . . . 10.0 114.698 -176.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 57.2 mt -93.11 -13.97 27.84 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.23 1.412 . . . . 10.0 113.084 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -131.97 68.82 1.49 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.545 1.938 . . . . 10.0 111.204 -172.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -72.9 146.61 46.02 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.092 1.357 . . . . 10.0 111.321 -179.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -139.2 110.35 6.89 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 126.547 1.939 . . . . 10.0 110.278 -172.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.26 162.78 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 125.079 1.351 . . . . 10.0 112.212 -177.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.4 t -129.8 104.09 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.518 1.527 . . . . 10.0 109.491 177.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 70.8 m -73.05 166.32 23.33 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 125.063 1.345 . . . . 10.0 112.804 177.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.07 158.52 6.73 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.292 1.437 . . . . 10.0 112.323 175.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt 64.8 9.64 5.45 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 127.392 2.277 . . . . 10.0 114.782 -172.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.2 62.74 1.86 Allowed Glycine 0 CA--C 1.53 1.027 0 C-N-CA 125.178 1.371 . . . . 10.0 113.491 173.235 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 43.2 tp -131.03 99.86 5.04 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.027 1.331 . . . . 10.0 111.09 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -76.68 133.95 39.39 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.923 0.889 . . . . 10.0 110.739 172.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 49.4 m -121.01 141.23 50.92 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.574 1.55 . . . . 10.0 111.434 178.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -133.2 115.78 15.43 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 126.788 2.035 . . . . 10.0 108.641 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 49.5 mt -105.35 154.36 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 124.83 1.252 . . . . 10.0 111.836 -168.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -130.4 107.51 9.3 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.496 2.318 . . . . 10.0 109.019 167.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 -63.77 -42.83 97.72 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.256 -0.902 . . . . 10.0 113.049 178.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 3.5 p -151.66 91.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 125.845 1.658 . . . . 10.0 110.233 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -74.63 142.47 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 O-C-N 121.368 -0.833 . . . . 10.0 112.123 -177.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -129.02 163.26 25.77 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 126.408 1.883 . . . . 10.0 111.394 177.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.5 -31.72 62.28 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -174.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.0 m -67.75 -16.31 64.06 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 114.166 1.173 . . . . 10.0 114.166 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -83.87 -5.98 59.33 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.732 1.213 . . . . 10.0 113.48 178.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.04 151.69 42.31 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 120.985 -1.072 . . . . 10.0 113.1 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 140.11 -174.0 22.68 Favored Glycine 0 CA--C 1.533 1.161 0 C-N-CA 124.317 0.96 . . . . 10.0 114.993 176.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 98.53 9.24 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.888 1.675 . . . . 10.0 111.367 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -76.37 146.92 38.41 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.016 0.926 . . . . 10.0 111.386 168.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.4 160.32 41.25 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.595 0.758 . . . . 10.0 112.425 169.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.0 t -133.39 142.28 48.29 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.091 2.156 . . . . 10.0 109.841 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.29 124.5 71.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.536 1.534 . . . . 10.0 108.72 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.39 124.48 51.3 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.374 1.87 . . . . 10.0 110.451 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -134.16 134.95 42.74 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.01 1.324 . . . . 10.0 112.543 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -130.87 -178.24 4.72 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 124.624 1.17 . . . . 10.0 111.55 166.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 -60.14 -12.61 8.92 Favored 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 115.804 1.779 . . . . 10.0 115.804 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.45 -16.19 13.38 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.381 1.472 . . . . 10.0 114.525 -178.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.78 -168.83 40.92 Favored Glycine 0 CA--C 1.533 1.217 0 CA-C-N 119.884 1.22 . . . . 10.0 116.124 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -134.11 145.78 49.65 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 127.117 2.167 . . . . 10.0 111.878 -170.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.75 161.02 37.12 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.133 1.773 . . . . 10.0 111.205 168.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 60.8 m -137.11 141.92 42.3 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.084 1.354 . . . . 10.0 110.966 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -135.98 137.04 40.86 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.595 1.558 . . . . 10.0 110.056 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.5 m -141.65 143.7 33.76 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.797 0.839 . . . . 10.0 112.049 -167.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.6 p -152.36 142.51 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 125.279 1.431 . . . . 10.0 111.947 171.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -90.34 136.25 33.17 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.996 0.918 . . . . 10.0 110.751 168.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.6 tp -118.82 104.22 10.36 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.879 1.672 . . . . 10.0 110.909 178.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -84.63 88.3 7.33 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.036 1.334 . . . . 10.0 110.846 170.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.78 108.04 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.228 -0.92 . . . . 10.0 109.84 174.055 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.9 mt -73.96 97.03 2.74 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.072 1.749 . . . . 10.0 109.852 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.69 28.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.65 1.18 . . . . 10.0 113.754 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 63.1 tttp -108.64 -39.29 5.42 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.971 2.108 . . . . 10.0 111.976 177.093 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 . . . . . 0 C--O 1.253 1.239 0 C-N-CA 125.137 1.375 . . . . 10.0 113.239 172.256 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.578 0 N-CA-C 111.905 -0.478 . . . . 10.0 111.905 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.94 166.05 14.31 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.637 1.175 . . . . 10.0 113.238 176.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.7 ptt? -148.1 177.42 9.39 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 126.169 1.788 . . . . 10.0 111.662 178.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -175.63 167.79 39.85 Favored Glycine 0 CA--C 1.541 1.702 0 N-CA-C 116.706 1.442 . . . . 10.0 116.706 178.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -67.92 162.77 38.34 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 123.907 3.071 . . . . 10.0 113.228 -173.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -63.99 139.13 66.02 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.963 2.442 . . . . 10.0 110.795 172.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 76.4 ttt-85 -139.41 141.41 37.52 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.39 1.076 . . . . 10.0 113.568 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -59.19 118.88 6.4 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.352 2.261 . . . . 10.0 111.912 171.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.6 -52.75 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.262 1.025 . . . . 10.0 110.001 165.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 40.1 tt0 -150.57 134.86 17.06 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.649 1.18 . . . . 10.0 111.145 176.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 31.7 m -119.35 152.78 53.12 Favored Pre-proline 0 N--CA 1.475 0.791 0 C-N-CA 126.0 1.72 . . . . 10.0 109.266 168.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -75.73 163.77 33.17 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.599 2.2 . . . . 10.0 112.211 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.52 170.77 14.47 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.484 -0.76 . . . . 10.0 110.79 163.091 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.6 p30 -61.18 157.69 15.58 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.167 -0.958 . . . . 10.0 111.867 169.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -127.2 151.92 48.05 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.592 1.557 . . . . 10.0 111.664 -170.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -143.67 84.64 1.8 Allowed 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.304 1.442 . . . . 10.0 111.183 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 40.4 mm -102.41 136.56 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.304 1.441 . . . . 10.0 110.593 -170.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -66.92 129.15 38.96 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.441 1.096 . . . . 10.0 112.414 175.126 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -53.92 128.09 28.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.169 1.388 . . . . 10.0 112.704 178.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 104.7 -13.19 50.38 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 126.564 2.031 . . . . 10.0 114.651 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -77.43 161.86 27.65 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 118.775 1.288 . . . . 10.0 113.577 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -75.32 144.08 42.58 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.683 1.193 . . . . 10.0 110.433 155.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.72 172.36 16.23 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 123.686 0.794 . . . . 10.0 112.394 159.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.89 HH21 ' HG ' ' A' ' 307' ' ' SER . 16.4 ptm180 -147.18 168.3 22.01 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.397 1.479 . . . . 10.0 112.516 173.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 45.8 mtt -118.03 165.88 13.2 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 126.508 1.923 . . . . 10.0 111.7 176.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -142.62 107.95 5.02 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.586 1.555 . . . . 10.0 112.448 -171.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -125.7 101.44 6.88 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 126.489 1.916 . . . . 10.0 111.128 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -76.59 111.2 11.82 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.118 -0.989 . . . . 10.0 109.685 172.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -123.76 102.16 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 125.666 1.586 . . . . 10.0 110.481 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 12.3 t -73.76 173.08 10.35 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.725 0.81 . . . . 10.0 111.357 171.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 124.16 162.89 11.56 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 127.076 2.274 . . . . 10.0 112.431 -176.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -152.52 130.84 6.28 Favored Pre-proline 0 CA--C 1.547 0.835 0 C-N-CA 124.393 1.077 . . . . 10.0 110.828 -177.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -67.89 169.25 54.77 Favored 'Cis proline' 0 CA--C 1.539 0.762 0 CA-C-N 120.891 1.354 . . . . 10.0 112.735 -2.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.04 122.19 46.05 Favored Pre-proline 0 CA--C 1.549 0.917 0 C-N-CA 124.658 1.183 . . . . 10.0 111.038 178.043 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.1 151.0 61.0 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 122.483 2.122 . . . . 10.0 113.295 -170.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 150.45 47.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.158 0.983 . . . . 10.0 109.531 157.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 p -138.48 143.85 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 113.269 0.84 . . . . 10.0 113.269 -174.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 21.6 m -127.12 151.7 48.3 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.901 2.081 . . . . 10.0 110.353 173.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 34.9 m95 -125.51 157.59 36.65 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.282 1.033 . . . . 10.0 112.865 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 74.9 m-85 -147.16 160.13 42.8 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 126.309 1.844 . . . . 10.0 111.553 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.8 tp -148.45 124.77 10.88 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 127.38 2.272 . . . . 10.0 110.121 176.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 53.42 14.18 0.53 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.845 2.058 . . . . 10.0 116.202 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.2 0.49 25.23 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.732 1.634 . . . . 10.0 115.962 -179.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.4 ptp85 -122.21 166.55 14.44 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 125.769 1.628 . . . . 10.0 112.319 173.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 20.1 p -71.58 158.85 35.47 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.835 1.254 . . . . 10.0 113.674 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 97.1 t -136.84 142.52 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 128.069 2.547 . . . . 10.0 108.299 171.037 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.2 mt-30 -128.93 163.67 24.8 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.151 1.38 . . . . 10.0 111.344 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 52.9 p -66.67 148.54 51.77 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.616 0.766 . . . . 10.0 112.383 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -152.44 167.27 29.3 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.727 1.611 . . . . 10.0 110.824 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -56.63 -34.93 67.75 Favored 'General case' 0 CA--C 1.546 0.796 0 O-C-N 121.005 -1.06 . . . . 10.0 112.963 170.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 82.9 mt -84.84 -14.74 47.04 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.527 1.131 . . . . 10.0 113.902 174.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.83 70.52 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.546 1.538 . . . . 10.0 111.371 -172.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.57 147.7 48.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.591 1.156 . . . . 10.0 111.517 -176.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -134.36 107.09 7.42 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 126.927 2.091 . . . . 10.0 109.467 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.31 161.32 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.429 -176.113 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 19.7 t -135.75 120.19 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 125.882 1.673 . . . . 10.0 109.509 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 22.6 t -64.33 160.32 19.12 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.439 1.096 . . . . 10.0 112.341 175.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -51.8 -35.48 44.32 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.781 1.633 . . . . 10.0 112.579 173.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 44.8 mmtm -82.15 -0.7 46.09 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.022 1.729 . . . . 10.0 114.704 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.52 8.65 65.65 Favored Glycine 0 CA--C 1.538 1.479 0 C-N-CA 124.987 1.28 . . . . 10.0 115.345 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 50.3 tp -76.7 102.01 6.03 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.71 1.204 . . . . 10.0 110.699 171.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -78.29 144.21 36.33 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.36 1.064 . . . . 10.0 111.085 168.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 307' ' ' SER . . . . . 0.89 ' HG ' HH21 ' A' ' 268' ' ' ARG . 17.2 m -135.37 155.14 51.07 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.174 1.39 . . . . 10.0 112.833 173.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.05 116.09 15.07 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 128.122 2.569 . . . . 10.0 107.949 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -98.61 154.79 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.405 1.482 . . . . 10.0 111.26 -171.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -130.6 104.91 7.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.127 2.171 . . . . 10.0 108.831 164.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.8 mm-40 -64.0 -37.09 86.15 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.287 -0.883 . . . . 10.0 113.023 178.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.0 p -150.61 91.66 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 125.816 1.646 . . . . 10.0 110.3 177.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.29 139.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 121.3 -0.875 . . . . 10.0 112.194 -176.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -125.9 161.05 28.33 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 126.853 2.061 . . . . 10.0 111.112 176.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.37 -29.64 64.21 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.716 1.206 . . . . 10.0 113.74 -177.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 39.5 p -67.08 -17.07 64.72 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 125.477 1.511 . . . . 10.0 114.597 173.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -82.27 -6.49 59.27 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.7 1.2 . . . . 10.0 113.256 174.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.56 152.45 45.25 Favored 'General case' 0 CA--C 1.546 0.806 0 O-C-N 120.912 -1.117 . . . . 10.0 113.403 -178.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 133.14 -170.21 22.3 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.79 1.186 . . . . 10.0 115.147 174.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.66 105.64 16.37 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.052 1.741 . . . . 10.0 111.197 177.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -81.38 153.75 26.81 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.378 1.071 . . . . 10.0 111.769 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.01 159.09 42.96 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.016 0.927 . . . . 10.0 112.006 167.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 37.6 t -138.81 127.19 22.96 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 127.052 2.141 . . . . 10.0 109.248 -173.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.8 t -122.68 113.09 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.26 1.424 . . . . 10.0 109.49 -175.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -108.44 135.17 50.18 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.64 1.576 . . . . 10.0 111.231 -177.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.28 133.71 37.25 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.735 1.614 . . . . 10.0 111.763 -171.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -135.1 179.99 5.98 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.148 0.979 . . . . 10.0 111.99 166.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -61.32 -9.37 5.1 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 115.83 1.789 . . . . 10.0 115.83 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.84 -12.62 13.29 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 125.823 1.649 . . . . 10.0 114.332 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.77 -170.49 40.59 Favored Glycine 0 CA--C 1.535 1.343 0 CA-C-N 120.02 1.282 . . . . 10.0 115.949 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -135.43 147.56 49.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.858 2.063 . . . . 10.0 111.487 -176.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -141.06 158.36 44.04 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.629 1.572 . . . . 10.0 111.93 172.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 85.4 m -136.71 130.59 32.29 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.096 1.358 . . . . 10.0 111.148 -176.354 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -123.87 156.35 36.4 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.496 1.918 . . . . 10.0 110.815 -178.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.2 m -142.85 145.6 33.3 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 124.463 1.105 . . . . 10.0 111.559 -169.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.0 p -151.59 159.1 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 125.894 1.678 . . . . 10.0 110.85 172.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -121.83 137.17 54.88 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.808 1.243 . . . . 10.0 111.015 176.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.2 tp -124.65 105.3 9.22 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 126.359 1.864 . . . . 10.0 110.277 -178.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -93.97 80.35 4.12 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.676 1.59 . . . . 10.0 110.809 176.342 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -62.3 115.27 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.701 0.8 . . . . 10.0 110.95 -178.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.1 mt -76.03 97.38 4.02 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.702 1.601 . . . . 10.0 109.792 178.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.76 149.3 36.09 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 124.731 1.212 . . . . 10.0 113.962 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.41 ' HZ2' ' HB2' ' A' ' 343' ' ' LYS . 0.5 OUTLIER -95.81 -42.41 8.35 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 127.465 2.306 . . . . 10.0 111.336 174.014 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--O 1.253 1.289 0 C-N-CA 125.685 1.594 . . . . 10.0 113.298 174.503 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.546 0 N-CA-C 111.718 -0.553 . . . . 10.0 111.718 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.48 158.05 24.99 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 124.178 0.991 . . . . 10.0 112.928 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.68 175.09 11.88 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.243 1.817 . . . . 10.0 111.272 -178.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.41 172.89 45.86 Favored Glycine 0 CA--C 1.542 1.737 0 N-CA-C 117.092 1.597 . . . . 10.0 117.092 -176.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -68.77 160.42 49.68 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.679 2.919 . . . . 10.0 113.045 -173.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -70.92 167.56 25.59 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.231 2.62 . . . . 10.0 112.58 173.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -135.42 156.75 48.41 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.223 1.409 . . . . 10.0 112.703 -171.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -96.94 74.37 2.62 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.161 2.185 . . . . 10.0 110.695 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.5 mp -76.05 -71.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.134 -0.979 . . . . 10.0 112.322 -173.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -152.13 143.47 23.34 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.983 0.913 . . . . 10.0 112.281 -174.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.91 152.55 54.1 Favored Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 126.295 1.838 . . . . 10.0 110.57 172.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -74.29 160.84 41.57 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.768 2.312 . . . . 10.0 111.348 172.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -72.16 165.7 23.83 Favored 'General case' 0 CA--C 1.543 0.711 0 O-C-N 121.452 -0.78 . . . . 10.0 111.551 169.217 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -62.19 158.05 17.87 Favored 'General case' 0 CA--C 1.546 0.792 0 O-C-N 121.453 -0.779 . . . . 10.0 112.433 174.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 46.5 mtm -130.15 162.32 29.13 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.318 1.047 . . . . 10.0 112.912 -178.013 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -139.83 96.37 3.06 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.862 2.065 . . . . 10.0 110.482 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.1 mm -112.74 133.29 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 124.594 1.158 . . . . 10.0 111.214 -166.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -60.15 126.93 29.42 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.439 1.496 . . . . 10.0 112.456 172.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -55.18 127.13 27.76 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.273 1.029 . . . . 10.0 112.18 -178.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.92 -10.43 58.67 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 126.004 1.764 . . . . 10.0 114.955 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -73.93 161.19 30.37 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 119.362 1.581 . . . . 10.0 113.333 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -75.98 140.32 41.96 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.328 1.451 . . . . 10.0 110.264 157.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.48 166.3 31.54 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.702 0.801 . . . . 10.0 112.598 165.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm85 -141.69 168.0 20.81 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.88 1.272 . . . . 10.0 113.744 175.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 52.3 mtt -131.76 160.29 35.97 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 127.317 2.247 . . . . 10.0 111.01 175.231 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -140.96 103.52 4.49 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.442 1.497 . . . . 10.0 111.932 -168.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 -113.85 121.59 44.47 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.849 1.66 . . . . 10.0 111.677 -176.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.7 mtpp -77.48 127.35 32.37 Favored 'General case' 0 N--CA 1.478 0.955 0 O-C-N 121.382 -0.824 . . . . 10.0 110.887 173.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.7 p -138.96 145.12 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.596 1.558 . . . . 10.0 111.053 -179.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.9 t -142.99 -176.06 4.76 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.63 1.572 . . . . 10.0 110.886 178.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 118.42 164.49 13.0 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 127.519 2.485 . . . . 10.0 112.005 -172.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.5 tp -147.27 129.08 7.44 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 123.975 0.91 . . . . 10.0 110.785 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.4 169.15 47.01 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 CA-C-N 120.784 1.316 . . . . 10.0 112.373 -3.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.76 53.23 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 124.498 1.119 . . . . 10.0 111.102 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -69.33 150.44 70.82 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.398 2.065 . . . . 10.0 113.049 -172.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -70.4 140.71 52.14 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.129 0.972 . . . . 10.0 109.456 159.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 m -129.01 137.9 55.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.323 1.049 . . . . 10.0 112.521 -170.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 72.2 m -132.92 152.8 51.85 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.165 1.786 . . . . 10.0 110.861 177.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -128.15 152.86 47.52 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.85 1.26 . . . . 10.0 112.765 -175.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -145.48 158.32 43.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 126.08 1.752 . . . . 10.0 111.68 -171.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.8 tp -148.16 123.33 10.17 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.187 2.195 . . . . 10.0 109.875 177.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 54.22 11.0 0.34 Allowed 'General case' 0 CA--C 1.556 1.192 0 N-CA-C 116.571 2.063 . . . . 10.0 116.571 173.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 116.05 -0.64 21.11 Favored Glycine 0 CA--C 1.54 1.608 0 C-N-CA 125.802 1.668 . . . . 10.0 115.875 -178.239 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -119.41 166.45 13.05 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 125.865 1.666 . . . . 10.0 112.108 172.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.1 p -72.49 161.17 31.15 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.756 1.222 . . . . 10.0 113.131 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.92 91.97 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.878 2.071 . . . . 10.0 108.703 173.207 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -69.31 145.34 53.11 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 123.254 0.622 . . . . 10.0 110.661 171.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 44.1 p -73.77 153.93 39.79 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.453 0.701 . . . . 10.0 112.542 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.69 -172.91 4.24 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.527 1.931 . . . . 10.0 111.676 175.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -61.55 -17.76 56.3 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.984 1.475 . . . . 10.0 114.984 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.4 mt -113.26 -18.84 11.98 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 126.285 1.834 . . . . 10.0 113.423 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.9 m80 -121.0 93.38 4.01 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.947 2.099 . . . . 10.0 109.923 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.9 mttt -106.7 121.33 44.14 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.444 1.098 . . . . 10.0 110.79 -169.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -128.71 100.57 5.77 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.258 1.423 . . . . 10.0 110.375 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.18 161.65 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 125.888 1.675 . . . . 10.0 111.934 -174.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.93 167.04 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 125.686 1.594 . . . . 10.0 112.12 -178.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.8 t -133.85 149.55 51.36 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.648 1.579 . . . . 10.0 112.046 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.86 -19.54 42.81 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.904 1.682 . . . . 10.0 114.156 175.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -76.74 -2.23 31.97 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 125.622 1.569 . . . . 10.0 114.142 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.0 46.27 6.0 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.816 1.198 . . . . 10.0 112.703 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 11.6 tp -137.94 150.59 47.18 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.257 1.423 . . . . 10.0 111.265 -174.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -130.81 123.84 29.99 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.767 2.027 . . . . 10.0 109.893 174.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 48.3 m -94.49 156.02 16.66 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.339 1.056 . . . . 10.0 112.506 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.92 116.46 15.62 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.368 1.867 . . . . 10.0 107.205 162.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.36 133.86 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.819 1.248 . . . . 10.0 110.636 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -109.69 108.77 19.28 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.975 2.11 . . . . 10.0 108.916 171.742 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -64.19 -37.74 88.54 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 121.489 -0.757 . . . . 10.0 112.817 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.4 p -151.07 89.45 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.154 1.782 . . . . 10.0 109.918 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -66.32 138.29 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 O-C-N 121.232 -0.918 . . . . 10.0 111.742 -178.081 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.7 mmt180 -121.32 160.35 24.16 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 126.021 1.728 . . . . 10.0 112.208 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.97 -34.37 65.65 Favored 'General case' 0 CA--C 1.546 0.81 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -176.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 19.9 m -65.51 -16.47 63.7 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.498 1.519 . . . . 10.0 114.555 175.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -82.18 -7.48 59.62 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.649 1.179 . . . . 10.0 113.311 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.52 147.33 53.03 Favored 'General case' 0 CA--C 1.546 0.815 0 O-C-N 121.185 -0.947 . . . . 10.0 112.926 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.94 -170.79 23.02 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 124.512 1.053 . . . . 10.0 115.347 175.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.97 107.03 15.28 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.994 1.718 . . . . 10.0 111.326 177.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -83.3 151.13 25.73 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.386 1.075 . . . . 10.0 111.776 170.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.27 160.38 40.59 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 10.0 112.309 169.115 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -133.02 145.84 51.2 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 126.416 1.886 . . . . 10.0 110.027 175.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 66.6 t -127.73 129.15 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 125.624 1.569 . . . . 10.0 108.882 175.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -122.4 120.79 35.0 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.574 1.95 . . . . 10.0 110.469 -175.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -131.56 134.48 46.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.305 1.442 . . . . 10.0 112.11 -171.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -130.63 -178.23 4.69 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.472 1.109 . . . . 10.0 111.645 168.182 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -60.03 -11.3 5.53 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 115.788 1.773 . . . . 10.0 115.788 -179.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.97 -18.48 11.24 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.417 1.487 . . . . 10.0 114.654 -177.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.53 -170.13 43.2 Favored Glycine 0 CA--C 1.534 1.22 0 CA-C-N 120.034 1.288 . . . . 10.0 116.314 179.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.12 143.6 46.66 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.172 2.189 . . . . 10.0 111.764 -172.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.75 160.18 38.99 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.167 1.787 . . . . 10.0 111.173 168.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.4 m -138.89 145.26 39.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 125.229 1.412 . . . . 10.0 110.871 -175.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -136.48 152.92 51.08 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.33 1.452 . . . . 10.0 111.102 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.8 m -145.16 145.88 31.55 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.567 1.147 . . . . 10.0 111.762 -172.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -152.79 171.82 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 126.36 1.864 . . . . 10.0 110.734 171.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -128.53 142.98 50.9 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.755 1.222 . . . . 10.0 111.404 173.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.0 tp -127.36 109.13 11.47 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.04 1.736 . . . . 10.0 110.128 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -78.88 141.89 37.27 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.935 -0.478 . . . . 10.0 110.035 160.091 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 40.0 t -120.5 106.53 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.458 1.103 . . . . 10.0 108.752 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.5 mt -69.37 96.78 0.9 Allowed 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.222 1.809 . . . . 10.0 109.288 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.67 154.33 29.63 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.954 1.302 . . . . 10.0 114.259 -167.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 31.4 ttmt -130.81 -25.62 2.29 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 127.223 2.209 . . . . 10.0 113.28 -176.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 . . . . . 0 C--O 1.253 1.278 0 C-N-CA 125.346 1.458 . . . . 10.0 113.208 169.263 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 N-CA-C 111.7 -0.56 . . . . 10.0 111.7 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.58 167.6 10.66 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 124.443 1.097 . . . . 10.0 112.998 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -141.32 179.86 6.53 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 126.052 1.741 . . . . 10.0 111.864 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 178.87 170.89 41.47 Favored Glycine 0 CA--C 1.541 1.663 0 N-CA-C 116.773 1.469 . . . . 10.0 116.773 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.85 161.19 46.89 Favored 'Trans proline' 0 CA--C 1.543 0.947 0 C-N-CA 123.838 3.025 . . . . 10.0 112.934 -174.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -65.85 145.0 79.27 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 123.017 2.478 . . . . 10.0 111.228 169.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -136.28 147.82 47.68 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.569 1.548 . . . . 10.0 112.384 -175.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -61.22 110.07 1.29 Allowed 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.814 2.046 . . . . 10.0 111.502 171.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 46.9 mm -105.46 -63.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.995 0.918 . . . . 10.0 110.285 172.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -153.36 101.88 2.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.311 1.044 . . . . 10.0 111.456 176.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 25.3 m -72.27 150.07 91.84 Favored Pre-proline 0 N--CA 1.476 0.834 0 C-N-CA 123.019 0.528 . . . . 10.0 110.22 161.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -75.72 161.0 37.25 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 122.859 2.373 . . . . 10.0 112.089 177.179 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -73.2 166.66 22.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 123.912 0.885 . . . . 10.0 111.517 168.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -62.01 157.79 17.93 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 121.34 -0.85 . . . . 10.0 112.644 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.0 mtp -132.6 153.41 51.06 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.349 1.459 . . . . 10.0 112.118 -166.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 16.9 p -147.27 100.95 3.34 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.8 1.64 . . . . 10.0 110.947 178.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.3 mm -117.32 138.95 46.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.044 1.337 . . . . 10.0 110.911 -167.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -67.75 132.18 46.95 Favored 'General case' 0 CA--C 1.543 0.688 0 O-C-N 121.359 -0.838 . . . . 10.0 112.311 176.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -54.63 119.49 5.37 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.564 1.545 . . . . 10.0 112.132 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 108.52 -10.8 35.83 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 126.216 1.865 . . . . 10.0 115.191 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -74.01 162.31 29.17 Favored 'General case' 0 N--CA 1.479 0.985 0 CA-C-N 119.224 1.512 . . . . 10.0 113.577 178.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -73.97 147.18 43.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.565 1.146 . . . . 10.0 110.558 158.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 4.3 t -153.72 173.29 16.03 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.212 1.005 . . . . 10.0 112.541 167.373 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -148.57 166.83 27.07 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 126.039 1.736 . . . . 10.0 112.436 166.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.0 mtt -118.15 157.41 26.97 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.617 1.967 . . . . 10.0 111.333 172.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -140.02 95.01 2.83 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.275 1.43 . . . . 10.0 111.579 -167.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -113.1 100.74 8.83 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.426 1.49 . . . . 10.0 111.609 -175.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -73.4 128.97 36.98 Favored 'General case' 0 N--CA 1.477 0.889 0 O-C-N 121.356 -0.84 . . . . 10.0 111.311 175.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.4 p -146.99 138.52 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.632 1.973 . . . . 10.0 110.501 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 70.4 m -125.68 126.33 44.49 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.641 1.176 . . . . 10.0 111.596 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -172.02 169.02 42.16 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 127.12 2.295 . . . . 10.0 111.338 175.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.6 tp -146.69 131.36 8.81 Favored Pre-proline 0 CA--C 1.548 0.901 0 C-N-CA 124.47 1.108 . . . . 10.0 111.105 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -66.91 169.86 46.94 Favored 'Cis proline' 0 CA--C 1.54 0.797 0 CA-C-N 120.533 1.226 . . . . 10.0 112.546 -3.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.17 120.78 32.36 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 124.605 1.162 . . . . 10.0 111.255 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.41 161.49 45.39 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 122.585 2.19 . . . . 10.0 113.221 -172.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -63.85 163.05 12.51 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.844 1.258 . . . . 10.0 111.692 166.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.4 p -139.31 114.97 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.139 1.375 . . . . 10.0 111.525 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 53.2 m -137.1 158.91 43.38 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.948 1.699 . . . . 10.0 110.876 171.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -133.94 160.86 36.42 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.576 1.151 . . . . 10.0 113.604 -170.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -143.5 161.64 37.92 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.872 2.069 . . . . 10.0 111.529 -177.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.7 tp -146.12 119.26 8.85 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 127.027 2.131 . . . . 10.0 110.188 176.052 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.4 m-20 54.78 16.65 1.48 Allowed 'General case' 0 CA--C 1.554 1.132 0 C-N-CA 126.469 1.908 . . . . 10.0 114.964 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.37 -11.86 47.51 Favored Glycine 0 CA--C 1.538 1.531 0 C-N-CA 126.52 2.01 . . . . 10.0 115.164 -177.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -86.17 156.34 20.37 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 118.932 1.366 . . . . 10.0 110.976 170.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.4 p -70.88 154.14 42.09 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.345 1.058 . . . . 10.0 112.51 173.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -132.89 107.38 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.099 1.76 . . . . 10.0 108.78 173.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -78.68 163.47 25.41 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.027 0.931 . . . . 10.0 111.37 171.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.7 p -72.59 157.13 38.15 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.709 0.803 . . . . 10.0 112.615 173.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -146.95 171.09 15.77 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 126.538 1.935 . . . . 10.0 110.322 170.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -59.97 -31.54 69.99 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.039 -1.038 . . . . 10.0 112.292 167.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 80.2 mt -81.95 -17.2 47.86 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.191 1.396 . . . . 10.0 113.949 173.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.2 m80 -136.28 69.77 1.42 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.985 1.714 . . . . 10.0 110.895 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -68.07 142.72 55.76 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.952 1.301 . . . . 10.0 111.005 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.3 mtt -133.63 102.49 5.51 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 126.494 1.917 . . . . 10.0 110.049 -175.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.84 171.54 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.371 1.468 . . . . 10.0 111.874 -176.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 23.8 m -131.45 134.55 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.021 1.328 . . . . 10.0 110.983 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 23.7 t -77.53 151.0 34.75 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.272 0.629 . . . . 10.0 111.91 173.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -60.74 -20.88 62.26 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.835 1.254 . . . . 10.0 113.224 168.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -75.96 -5.37 45.9 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.718 1.607 . . . . 10.0 113.86 173.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.9 56.54 2.72 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.792 1.186 . . . . 10.0 112.571 -177.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.5 tp -133.58 105.51 6.91 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.619 1.567 . . . . 10.0 110.629 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 9.3 m170 -65.79 129.08 38.52 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.45 0.7 . . . . 10.0 110.101 166.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 66.2 m -125.1 131.56 53.27 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.899 1.679 . . . . 10.0 111.681 -173.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.17 115.87 14.71 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.657 1.983 . . . . 10.0 108.927 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.94 154.36 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 125.187 1.395 . . . . 10.0 110.696 -174.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -127.08 102.8 7.12 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.032 2.133 . . . . 10.0 108.952 164.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.9 mm-40 -65.67 -36.01 82.42 Favored 'General case' 0 N--CA 1.476 0.83 0 O-C-N 121.044 -1.035 . . . . 10.0 112.675 176.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.2 p -151.58 90.23 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.188 1.795 . . . . 10.0 110.012 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.82 131.52 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 O-C-N 121.199 -0.938 . . . . 10.0 111.392 -179.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -110.8 161.07 16.16 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.508 1.523 . . . . 10.0 111.555 177.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.43 -34.45 66.83 Favored 'General case' 0 CA--C 1.546 0.808 0 N-CA-C 113.355 0.872 . . . . 10.0 113.355 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 23.5 m -66.44 -16.59 64.22 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.522 1.529 . . . . 10.0 114.57 176.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -81.32 -7.92 59.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.302 1.041 . . . . 10.0 113.469 179.022 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.12 148.14 48.8 Favored 'General case' 0 CA--C 1.548 0.88 0 CA-C-N 119.428 1.013 . . . . 10.0 113.099 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.24 -172.65 25.26 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.655 1.121 . . . . 10.0 115.079 176.121 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.34 101.92 10.11 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.834 1.654 . . . . 10.0 111.02 174.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -78.83 151.51 31.84 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 124.119 0.968 . . . . 10.0 111.886 171.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.47 161.47 37.97 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.667 0.787 . . . . 10.0 112.179 168.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.1 t -135.28 149.98 49.92 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 126.627 1.971 . . . . 10.0 110.079 177.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -124.05 141.47 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.898 1.279 . . . . 10.0 110.844 174.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.11 120.63 24.93 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.686 1.994 . . . . 10.0 110.095 -178.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -135.11 132.89 38.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 125.176 1.39 . . . . 10.0 111.672 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.2 p30 -134.03 -179.58 5.64 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.744 1.218 . . . . 10.0 111.332 166.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -61.97 -11.78 15.15 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 115.576 1.695 . . . . 10.0 115.576 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.18 -15.28 14.9 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.552 1.541 . . . . 10.0 114.246 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.46 -167.94 37.9 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.839 1.2 . . . . 10.0 116.023 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.85 146.48 47.5 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.84 2.056 . . . . 10.0 112.221 -170.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.79 157.01 46.01 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.317 1.847 . . . . 10.0 111.294 167.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -139.56 135.35 33.3 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.487 1.515 . . . . 10.0 110.069 -179.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -128.43 156.19 43.58 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.47 1.508 . . . . 10.0 111.791 -173.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.9 m -142.39 147.42 36.19 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 124.632 1.173 . . . . 10.0 112.139 -171.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.11 165.9 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 126.484 1.914 . . . . 10.0 110.852 168.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -119.25 131.75 55.83 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.981 1.313 . . . . 10.0 110.827 173.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.5 tp -120.44 108.62 14.33 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 126.206 1.802 . . . . 10.0 110.253 177.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -78.66 146.18 34.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 121.951 -0.468 . . . . 10.0 110.569 160.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.1 t -124.84 104.91 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 124.287 1.035 . . . . 10.0 109.152 174.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.95 98.98 1.7 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.674 1.989 . . . . 10.0 110.253 -175.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -57.64 128.9 39.4 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.878 1.271 . . . . 10.0 112.47 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -73.98 -20.01 60.48 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 125.083 1.353 . . . . 10.0 113.402 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 . . . . . 0 C--O 1.254 1.304 0 C-N-CA 127.407 2.283 . . . . 10.0 113.998 179.062 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.567 0 N-CA-C 111.885 -0.486 . . . . 10.0 111.885 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.03 155.81 30.03 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 124.162 0.985 . . . . 10.0 112.91 177.072 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.43 174.45 13.85 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.31 1.844 . . . . 10.0 111.478 -176.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -173.86 172.63 45.42 Favored Glycine 0 CA--C 1.543 1.833 0 N-CA-C 116.978 1.551 . . . . 10.0 116.978 -175.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -68.13 159.45 53.05 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.628 2.886 . . . . 10.0 113.021 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -69.17 162.38 42.03 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.044 2.496 . . . . 10.0 112.152 175.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.14 162.73 31.3 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.753 1.221 . . . . 10.0 113.561 -171.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -106.55 83.8 1.92 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.654 1.982 . . . . 10.0 110.76 -171.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.4 mm -83.04 -67.94 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.526 0.73 . . . . 10.0 111.7 -173.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 -155.59 148.8 24.68 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.386 1.074 . . . . 10.0 111.955 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 20.8 m -126.02 150.75 70.22 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 125.724 1.61 . . . . 10.0 110.654 172.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -74.63 159.39 42.63 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 123.016 2.478 . . . . 10.0 111.861 174.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -75.6 167.43 21.9 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.745 0.818 . . . . 10.0 112.344 168.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -59.7 152.14 23.36 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.688 0.795 . . . . 10.0 113.027 175.347 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 58.4 mtm -130.16 160.74 32.87 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.207 1.003 . . . . 10.0 112.908 -176.339 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -138.04 108.21 6.42 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 126.2 1.8 . . . . 10.0 110.642 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.7 mm -123.93 132.41 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.267 1.427 . . . . 10.0 110.409 -165.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -63.49 133.69 54.33 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.44 1.096 . . . . 10.0 112.456 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -52.51 132.46 35.2 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.465 1.506 . . . . 10.0 112.981 -179.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 91.4 -9.24 77.83 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.782 1.658 . . . . 10.0 115.394 177.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.44 160.72 32.25 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.206 1.503 . . . . 10.0 113.201 176.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 57.8 t80 -71.96 145.87 48.12 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.836 1.254 . . . . 10.0 110.488 158.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.8 t -150.44 163.48 38.29 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.454 1.102 . . . . 10.0 111.686 170.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.6 ptm85 -144.64 166.82 24.09 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.256 1.422 . . . . 10.0 112.769 169.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.0 mtt -130.87 159.14 38.26 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.956 2.102 . . . . 10.0 110.84 173.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -138.15 95.03 2.95 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.486 1.514 . . . . 10.0 111.34 -167.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -108.89 103.36 12.4 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.794 1.638 . . . . 10.0 111.103 -175.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -68.01 137.37 55.03 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 121.188 -0.945 . . . . 10.0 110.54 174.309 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.09 155.29 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.508 1.523 . . . . 10.0 111.396 -173.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -142.63 170.45 15.68 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.136 1.375 . . . . 10.0 110.992 171.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 137.71 160.47 8.54 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 127.613 2.53 . . . . 10.0 112.573 -176.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.7 tp -150.46 127.01 5.23 Favored Pre-proline 0 CA--C 1.547 0.846 0 C-N-CA 124.396 1.079 . . . . 10.0 110.711 178.495 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -66.78 169.13 49.01 Favored 'Cis proline' 0 CA--C 1.538 0.709 0 CA-C-N 121.346 1.517 . . . . 10.0 112.31 -2.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.58 121.11 36.66 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.708 1.203 . . . . 10.0 111.335 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -70.36 160.23 50.24 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.538 2.158 . . . . 10.0 113.274 -173.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -66.7 169.65 7.55 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 125.481 1.512 . . . . 10.0 111.736 169.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.5 p -133.33 115.71 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 125.708 1.603 . . . . 10.0 111.624 -175.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.9 m -133.84 99.16 4.37 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.515 1.526 . . . . 10.0 110.622 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -84.38 156.06 22.01 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 121.873 0.844 . . . . 10.0 112.798 175.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -143.0 159.58 41.97 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.126 2.17 . . . . 10.0 111.208 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -146.35 118.35 8.23 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.956 2.102 . . . . 10.0 109.892 176.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.2 m-20 55.4 12.26 0.71 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.578 1.951 . . . . 10.0 115.487 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.48 -13.05 23.25 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 126.662 2.077 . . . . 10.0 115.343 -178.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -91.14 161.77 14.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 125.233 1.413 . . . . 10.0 110.923 170.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 289' ' ' THR . . . . . 0.557 ' HG1' HE21 ' A' ' 291' ' ' GLN . 70.5 p -70.92 160.5 32.73 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.61 0.719 . . . . 10.0 112.34 174.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 98.5 t -129.85 113.43 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 126.53 1.932 . . . . 10.0 107.308 166.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . 0.557 HE21 ' HG1' ' A' ' 289' ' ' THR . 68.5 mt-30 -107.59 139.0 42.79 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.014 1.326 . . . . 10.0 109.832 -174.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 51.1 p -63.6 144.5 56.96 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.283 0.846 . . . . 10.0 113.283 -174.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -154.21 -177.77 6.66 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.9 1.68 . . . . 10.0 111.342 172.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -58.95 -18.84 37.4 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.227 1.411 . . . . 10.0 114.721 -177.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.7 mt -107.44 -11.42 15.52 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.74 1.616 . . . . 10.0 113.205 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -130.21 70.85 1.44 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.973 2.109 . . . . 10.0 110.285 -175.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -80.12 144.54 32.99 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.897 1.279 . . . . 10.0 111.706 -173.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -141.65 107.37 5.1 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.418 1.887 . . . . 10.0 110.535 -171.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 164.62 25.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.781 1.232 . . . . 10.0 112.232 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 22.1 t -133.69 116.37 24.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 125.334 1.453 . . . . 10.0 110.012 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 44.6 t -65.37 143.98 57.39 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.097 0.959 . . . . 10.0 111.755 173.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.26 -18.88 41.17 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.926 1.29 . . . . 10.0 113.888 173.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -77.11 -3.7 40.67 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.005 1.722 . . . . 10.0 114.014 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 88.33 45.94 4.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.971 1.272 . . . . 10.0 113.414 178.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.5 tp -135.18 105.6 6.38 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 125.293 1.437 . . . . 10.0 111.005 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -77.34 116.4 17.92 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.501 1.121 . . . . 10.0 110.984 171.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.9 m -93.33 137.14 32.93 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 125.495 1.518 . . . . 10.0 111.672 171.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.37 124.84 31.2 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.13 2.172 . . . . 10.0 107.639 174.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.4 mp -123.37 147.71 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.518 1.127 . . . . 10.0 111.536 -170.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -121.45 107.39 12.41 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 127.707 2.403 . . . . 10.0 109.175 170.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.4 mm-40 -66.68 -37.3 84.47 Favored 'General case' 0 N--CA 1.474 0.775 0 O-C-N 121.076 -1.015 . . . . 10.0 112.924 177.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.15 90.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 125.865 1.666 . . . . 10.0 110.284 -178.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -69.45 147.28 12.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 O-C-N 121.175 -0.953 . . . . 10.0 112.305 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -136.27 156.5 48.58 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.722 1.609 . . . . 10.0 112.721 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.54 -34.91 71.54 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.679 1.192 . . . . 10.0 113.663 -177.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.4 m -64.63 -13.08 52.1 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.453 1.501 . . . . 10.0 114.389 176.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -108.8 8.09 26.53 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.255 1.822 . . . . 10.0 113.009 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.38 158.0 30.41 Favored 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.94 -1.1 . . . . 10.0 112.616 168.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.37 -167.55 21.91 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.549 1.071 . . . . 10.0 115.134 173.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.63 103.25 10.35 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.174 1.79 . . . . 10.0 111.544 178.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -80.72 150.26 29.39 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.711 1.205 . . . . 10.0 111.919 171.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 162.96 35.0 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.113 0.965 . . . . 10.0 112.066 168.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 41.8 t -140.38 127.51 20.96 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.653 1.581 . . . . 10.0 110.768 176.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 89.7 t -102.55 132.78 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 125.666 1.586 . . . . 10.0 109.401 173.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.47 117.55 22.33 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.527 1.931 . . . . 10.0 110.659 -178.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -131.05 139.5 49.93 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.249 1.42 . . . . 10.0 112.056 -172.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -132.92 -177.87 4.7 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.8 1.24 . . . . 10.0 111.355 167.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -61.72 -8.8 5.1 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 115.888 1.81 . . . . 10.0 115.888 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -116.36 -17.44 10.72 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.587 1.555 . . . . 10.0 114.736 -178.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 175.4 -170.36 43.37 Favored Glycine 0 CA--C 1.534 1.232 0 CA-C-N 120.0 1.273 . . . . 10.0 116.257 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -136.58 141.99 43.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.222 2.209 . . . . 10.0 111.68 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.5 158.56 44.14 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.209 1.804 . . . . 10.0 110.953 168.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -143.52 141.32 30.69 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.517 1.127 . . . . 10.0 111.072 -175.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -132.4 154.2 50.04 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.694 1.598 . . . . 10.0 111.349 -176.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.0 m -145.39 145.3 31.1 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 124.672 1.189 . . . . 10.0 112.003 -171.036 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -154.0 172.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 126.572 1.949 . . . . 10.0 110.984 172.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 39.5 tt0 -130.1 143.13 50.62 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 120.665 -1.272 . . . . 10.0 111.557 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.9 tp -129.39 106.58 8.88 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.088 1.755 . . . . 10.0 111.14 -177.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -91.96 85.62 5.61 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.815 1.646 . . . . 10.0 111.307 177.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.9 t -70.15 110.06 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.256 -0.902 . . . . 10.0 110.997 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.8 mt -75.47 98.74 4.0 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 126.454 1.902 . . . . 10.0 110.503 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.73 144.48 52.2 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.255 1.022 . . . . 10.0 112.743 178.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -75.15 -25.05 58.08 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 113.525 0.935 . . . . 10.0 113.525 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.253 1.27 0 C-N-CA 126.934 2.094 . . . . 10.0 112.678 -177.482 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.541 0 N-CA-C 112.08 -0.408 . . . . 10.0 112.08 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.35 162.44 17.58 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.364 1.066 . . . . 10.0 112.931 175.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.83 -179.24 6.46 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 125.816 1.646 . . . . 10.0 112.177 -175.076 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -173.89 171.19 44.32 Favored Glycine 0 CA--C 1.541 1.659 0 N-CA-C 116.731 1.453 . . . . 10.0 116.731 -177.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -69.65 158.95 55.29 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.463 2.775 . . . . 10.0 113.08 -172.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -69.04 164.59 33.25 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.146 2.564 . . . . 10.0 111.52 168.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -141.12 155.32 46.13 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.717 1.207 . . . . 10.0 112.0 -174.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -74.6 102.66 4.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.19 2.196 . . . . 10.0 111.452 178.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . 0.522 HG21 ' H ' ' A' ' 254' ' ' GLN . 0.2 OUTLIER -115.0 -176.69 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 126.026 1.73 . . . . 10.0 110.483 175.76 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.522 ' H ' HG21 ' A' ' 253' ' ' ILE . 0.0 OUTLIER -46.35 102.43 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 128.458 2.703 . . . . 10.0 115.024 -175.033 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.91 151.59 92.99 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 124.385 1.074 . . . . 10.0 111.061 158.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.4 162.65 33.29 Favored 'Trans proline' 0 CA--C 1.541 0.852 0 C-N-CA 123.023 2.482 . . . . 10.0 111.269 170.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -73.3 159.97 32.56 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 121.36 -0.838 . . . . 10.0 111.478 170.395 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -59.45 129.93 44.42 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 121.564 -0.71 . . . . 10.0 111.529 175.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 31.1 mtm -100.09 155.04 17.95 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.928 0.891 . . . . 10.0 112.162 -174.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 23.6 p -134.81 105.76 6.59 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.852 1.661 . . . . 10.0 110.269 175.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.0 mm -125.44 127.06 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.12 1.368 . . . . 10.0 110.206 -164.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -62.91 134.3 56.0 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.157 0.983 . . . . 10.0 112.189 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -53.03 130.16 33.02 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.813 1.245 . . . . 10.0 112.751 -178.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.74 -8.87 76.4 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 125.9 1.714 . . . . 10.0 115.284 177.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -70.15 160.29 32.35 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 119.272 1.536 . . . . 10.0 113.004 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 43.8 t80 -76.95 139.62 40.21 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.818 1.247 . . . . 10.0 110.222 156.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.6 p -149.32 169.71 20.18 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.754 0.822 . . . . 10.0 111.892 162.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 35.5 ptt-85 -145.27 137.78 25.96 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.217 1.007 . . . . 10.0 112.525 172.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.2 mtt -87.47 159.31 18.71 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.888 1.275 . . . . 10.0 110.906 169.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -136.7 132.29 34.69 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.014 1.326 . . . . 10.0 112.025 173.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -134.43 113.92 12.36 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 126.715 2.006 . . . . 10.0 109.645 -176.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.71 146.69 53.53 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 121.067 -1.021 . . . . 10.0 110.206 171.178 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.7 p -149.21 156.51 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.063 1.345 . . . . 10.0 111.492 -174.016 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.1 t -144.53 -176.62 5.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.712 1.605 . . . . 10.0 111.668 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 104.92 162.77 23.98 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.125 2.297 . . . . 10.0 113.54 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -148.74 131.05 7.7 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 125.234 1.414 . . . . 10.0 110.48 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -67.33 170.97 44.65 Favored 'Cis proline' 0 CA--C 1.54 0.778 0 CA-C-N 120.917 1.363 . . . . 10.0 112.615 -3.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.01 120.96 32.83 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.022 1.329 . . . . 10.0 111.437 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.53 152.42 59.86 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 122.481 2.121 . . . . 10.0 113.466 -171.273 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -72.31 141.6 48.84 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.81 1.244 . . . . 10.0 109.899 160.316 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.1 m -128.15 89.23 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.699 1.199 . . . . 10.0 112.233 -166.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.5 m -74.93 115.76 14.9 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.762 1.225 . . . . 10.0 111.251 175.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -96.89 148.77 22.61 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.475 1.11 . . . . 10.0 113.349 177.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 83.1 m-85 -143.21 160.19 40.92 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 126.562 1.945 . . . . 10.0 112.427 -174.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.2 tp -147.13 120.78 9.17 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.721 2.408 . . . . 10.0 109.799 174.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 54.93 15.1 1.05 Allowed 'General case' 0 CA--C 1.556 1.192 0 C-N-CA 126.584 1.954 . . . . 10.0 115.43 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 106.82 -11.01 41.53 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.207 1.86 . . . . 10.0 115.176 -177.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -90.55 159.81 16.28 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.207 1.403 . . . . 10.0 110.677 169.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 25.2 p -74.28 160.49 31.03 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.018 0.927 . . . . 10.0 112.6 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 41.2 t -135.54 104.77 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.979 1.712 . . . . 10.0 109.563 174.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -70.32 148.88 47.95 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.135 0.574 . . . . 10.0 111.209 170.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 34.7 p -73.55 149.5 42.15 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.497 0.719 . . . . 10.0 111.611 166.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -155.04 -177.67 6.7 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.171 1.388 . . . . 10.0 111.977 172.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -59.29 -19.95 50.38 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -177.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.7 mt -105.16 -9.35 17.8 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.501 1.52 . . . . 10.0 113.112 175.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.3 m80 -132.95 65.91 1.58 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 127.22 2.208 . . . . 10.0 110.261 -174.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -76.42 130.74 38.45 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.771 1.229 . . . . 10.0 110.668 -174.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 62.3 mtt -129.32 103.1 6.73 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.241 1.817 . . . . 10.0 109.776 -174.23 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.32 163.46 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.703 1.201 . . . . 10.0 112.763 -172.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.4 m -124.01 166.75 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 126.308 1.843 . . . . 10.0 111.649 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 35.6 t -136.88 149.04 47.43 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.487 1.515 . . . . 10.0 112.365 -178.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -58.72 -19.59 41.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.895 1.678 . . . . 10.0 114.075 174.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.2 mmtt -75.06 -2.17 26.23 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.565 1.546 . . . . 10.0 113.949 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.86 41.7 7.08 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.008 1.29 . . . . 10.0 112.903 -178.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.2 tp -133.51 150.02 51.7 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.276 1.43 . . . . 10.0 111.641 -175.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -132.93 137.78 46.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.02 2.528 . . . . 10.0 108.952 173.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 50.9 m -131.72 153.1 50.38 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.812 0.845 . . . . 10.0 112.471 -175.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.91 102.18 5.95 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.151 1.78 . . . . 10.0 109.059 178.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -86.68 142.32 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 124.841 1.256 . . . . 10.0 109.35 179.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -120.62 104.68 10.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.608 1.963 . . . . 10.0 108.459 167.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -64.85 -39.73 94.03 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.16 85.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.969 1.708 . . . . 10.0 110.111 -178.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.3 p -67.54 142.9 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 O-C-N 121.255 -0.903 . . . . 10.0 112.327 -176.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -124.77 161.07 27.23 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.286 1.834 . . . . 10.0 112.255 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.12 -30.87 64.76 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 113.839 1.051 . . . . 10.0 113.839 -176.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.7 p -67.53 -16.34 64.14 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 125.658 1.583 . . . . 10.0 114.803 173.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -82.18 -7.63 59.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.635 1.174 . . . . 10.0 113.433 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 151.61 45.35 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.136 -0.977 . . . . 10.0 113.021 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.96 -170.97 21.11 Favored Glycine 0 CA--C 1.532 1.141 0 C-N-CA 124.664 1.126 . . . . 10.0 114.935 176.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.41 104.08 14.12 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.067 1.747 . . . . 10.0 111.724 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -78.97 150.39 32.03 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.377 1.071 . . . . 10.0 112.016 170.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.43 160.28 41.82 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 123.778 0.831 . . . . 10.0 112.427 169.097 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.35 142.36 43.8 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.747 1.619 . . . . 10.0 110.414 174.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.2 t -123.14 104.92 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.798 1.639 . . . . 10.0 109.102 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.75 120.54 27.28 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 126.277 1.831 . . . . 10.0 110.835 177.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.64 135.45 51.21 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 125.21 1.404 . . . . 10.0 111.9 -178.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -133.85 -179.16 5.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.05 0.94 . . . . 10.0 111.744 164.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.7 ptp180 -60.53 -12.58 10.27 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 115.797 1.777 . . . . 10.0 115.797 -179.249 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.44 -17.99 13.33 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 125.521 1.528 . . . . 10.0 114.356 -178.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.44 -169.72 42.5 Favored Glycine 0 CA--C 1.535 1.298 0 CA-C-N 119.846 1.203 . . . . 10.0 115.809 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -137.94 145.6 42.22 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.352 1.861 . . . . 10.0 111.958 -173.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.18 162.34 35.5 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.072 1.749 . . . . 10.0 111.385 170.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 64.2 m -135.83 145.94 46.96 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.316 1.046 . . . . 10.0 111.736 -171.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -136.2 149.52 48.6 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.391 1.876 . . . . 10.0 110.63 -177.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -146.42 145.2 30.16 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.597 1.159 . . . . 10.0 111.79 -172.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . 0.406 HG21 ' H ' ' A' ' 337' ' ' GLN . 9.8 p -152.4 172.78 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 126.042 1.737 . . . . 10.0 110.856 168.008 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . 0.406 ' H ' HG21 ' A' ' 336' ' ' VAL . 49.4 tt0 -126.62 147.16 49.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.17 1.388 . . . . 10.0 111.334 172.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 63.6 tp -127.86 113.0 15.34 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 126.09 1.756 . . . . 10.0 111.024 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -92.88 91.57 7.49 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.584 1.554 . . . . 10.0 110.606 171.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.4 t -74.62 106.84 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 O-C-N 121.158 -0.964 . . . . 10.0 110.157 175.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.1 mt -76.64 97.95 4.57 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.846 1.658 . . . . 10.0 110.5 -179.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.33 57.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.077 0.951 . . . . 10.0 112.542 177.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -69.88 -42.6 73.24 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 124.058 0.943 . . . . 10.0 112.964 -178.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.253 1.25 0 C-N-CA 128.296 2.638 . . . . 10.0 114.253 -175.067 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.532 0 N-CA-C 111.652 -0.579 . . . . 10.0 111.652 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.6 159.15 25.35 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.286 1.034 . . . . 10.0 113.044 177.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.29 176.99 10.38 Favored 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 126.314 1.846 . . . . 10.0 111.513 -178.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.62 170.57 43.38 Favored Glycine 0 CA--C 1.542 1.763 0 N-CA-C 116.947 1.539 . . . . 10.0 116.947 -178.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -69.13 158.11 59.03 Favored 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 123.402 2.735 . . . . 10.0 112.85 -173.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.4 143.12 62.37 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.756 2.304 . . . . 10.0 110.766 169.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 38.1 ttp-105 -111.02 152.59 26.67 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.472 1.509 . . . . 10.0 111.429 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -77.64 75.63 4.18 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 126.32 1.848 . . . . 10.0 111.712 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . 0.576 HG21 ' H ' ' A' ' 254' ' ' GLN . 0.7 OUTLIER -75.15 177.45 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.034 0 C-N-CA 124.739 1.216 . . . . 10.0 111.312 175.969 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.576 ' H ' HG21 ' A' ' 253' ' ' ILE . 32.9 tt0 -49.94 113.01 0.75 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.79 2.436 . . . . 10.0 114.439 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 23.6 m -76.41 154.13 83.95 Favored Pre-proline 0 N--CA 1.477 0.905 0 C-N-CA 125.008 1.323 . . . . 10.0 111.19 159.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.45 167.53 25.48 Favored 'Trans proline' 0 CA--C 1.543 0.956 0 C-N-CA 123.265 2.644 . . . . 10.0 111.779 171.259 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.39 167.31 20.77 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.334 -0.854 . . . . 10.0 111.66 166.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -61.88 160.15 12.66 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.345 -0.847 . . . . 10.0 112.767 174.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 91.5 mtp -127.74 154.02 45.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.8 1.64 . . . . 10.0 111.793 -171.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 59.1 p -144.23 120.17 10.65 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 125.061 1.344 . . . . 10.0 110.367 166.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.0 mm -129.02 130.2 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.16 1.384 . . . . 10.0 109.89 -166.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -60.28 126.22 26.66 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.895 1.278 . . . . 10.0 112.238 173.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -52.33 130.71 31.78 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.48 1.512 . . . . 10.0 113.222 -177.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.33 -10.73 67.34 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.077 1.798 . . . . 10.0 115.106 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -71.69 162.06 30.03 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.144 1.472 . . . . 10.0 113.395 176.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -74.03 139.45 44.73 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.494 1.118 . . . . 10.0 110.466 155.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.3 p -148.78 172.66 14.27 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.596 0.758 . . . . 10.0 112.255 159.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.552 HH21 ' HG ' ' A' ' 307' ' ' SER . 8.5 ptm180 -151.77 175.46 12.4 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 126.029 1.732 . . . . 10.0 112.1 175.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.7 mtt -129.14 162.32 28.04 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 126.042 1.737 . . . . 10.0 112.078 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -136.6 108.94 7.31 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.758 1.623 . . . . 10.0 111.525 -177.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -124.71 113.38 17.9 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.482 1.513 . . . . 10.0 111.155 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -67.48 146.38 54.03 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.542 -0.724 . . . . 10.0 111.099 173.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 9.3 p -149.21 139.8 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.444 1.498 . . . . 10.0 111.551 177.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 24.6 m -142.21 115.11 8.69 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.985 1.314 . . . . 10.0 111.19 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.32 166.79 38.9 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 127.086 2.279 . . . . 10.0 111.723 174.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.44 129.81 7.23 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.311 1.045 . . . . 10.0 111.242 -178.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -67.13 169.57 49.18 Favored 'Cis proline' 0 CA--C 1.539 0.739 0 CA-C-N 121.022 1.401 . . . . 10.0 112.686 -2.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.83 120.66 34.67 Favored Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 124.845 1.258 . . . . 10.0 111.478 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.51 159.85 50.14 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.593 2.196 . . . . 10.0 113.45 -173.31 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -66.86 167.49 11.41 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.514 1.526 . . . . 10.0 111.748 167.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.72 107.02 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.708 1.603 . . . . 10.0 110.48 -171.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.0 m -124.62 99.53 6.22 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.418 1.487 . . . . 10.0 111.339 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -81.82 151.83 27.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.051 0.94 . . . . 10.0 113.093 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -140.72 160.24 40.47 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.155 2.182 . . . . 10.0 111.416 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.9 tp -146.56 116.73 7.37 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 127.257 2.223 . . . . 10.0 110.128 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 55.76 12.46 0.85 Allowed 'General case' 0 CA--C 1.556 1.179 0 C-N-CA 126.503 1.921 . . . . 10.0 115.234 -179.556 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.25 -14.76 30.69 Favored Glycine 0 CA--C 1.54 1.611 0 C-N-CA 126.778 2.132 . . . . 10.0 114.959 -176.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -80.9 158.09 25.41 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.996 1.318 . . . . 10.0 110.524 168.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 65.8 p -74.4 162.93 28.37 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.408 0.683 . . . . 10.0 111.855 170.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 16.7 t -136.01 137.43 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.378 1.471 . . . . 10.0 109.44 171.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 25.6 mp0 -107.9 156.53 19.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.321 1.449 . . . . 10.0 111.032 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 63.7 p -71.14 155.68 40.47 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.757 0.823 . . . . 10.0 112.316 173.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -153.48 168.91 24.53 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.476 1.51 . . . . 10.0 110.92 177.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.66 -35.69 70.89 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 120.832 -1.168 . . . . 10.0 112.655 169.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 76.7 mt -81.2 -15.45 55.65 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.527 1.131 . . . . 10.0 113.803 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -135.28 70.41 1.43 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.723 1.609 . . . . 10.0 111.561 -173.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -69.12 136.56 52.41 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.776 1.23 . . . . 10.0 110.478 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 55.6 mtt -134.06 102.46 5.41 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 126.477 1.911 . . . . 10.0 109.357 -173.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.57 162.51 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 125.02 1.328 . . . . 10.0 112.985 -169.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 17.7 t -132.42 113.02 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 126.964 2.106 . . . . 10.0 109.538 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.3 t -68.93 146.41 52.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 124.545 1.138 . . . . 10.0 111.937 173.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -59.0 -19.59 45.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.803 1.241 . . . . 10.0 113.89 172.084 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -77.7 -3.29 40.37 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.381 1.472 . . . . 10.0 113.99 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.94 49.36 4.31 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.942 1.258 . . . . 10.0 113.014 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -144.74 121.39 11.14 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.863 1.665 . . . . 10.0 109.496 -175.034 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -114.14 157.22 22.9 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.424 0.898 . . . . 10.0 113.424 173.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 307' ' ' SER . . . . . 0.552 ' HG ' HH21 ' A' ' 268' ' ' ARG . 74.4 m -143.36 158.58 43.52 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.766 1.226 . . . . 10.0 113.291 -169.517 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.96 104.96 7.43 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.962 2.105 . . . . 10.0 108.549 171.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -79.4 151.01 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.445 1.098 . . . . 10.0 109.736 177.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -131.6 98.84 4.61 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 126.69 1.996 . . . . 10.0 108.195 167.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -62.85 -36.2 82.47 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -178.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.34 83.93 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.142 1.777 . . . . 10.0 109.747 178.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.5 p -66.5 141.45 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.246 -0.909 . . . . 10.0 112.014 -175.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 10.6 mmt180 -127.33 160.91 29.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.028 1.731 . . . . 10.0 112.503 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.9 -33.24 61.86 Favored 'General case' 0 CA--C 1.547 0.865 0 N-CA-C 114.131 1.16 . . . . 10.0 114.131 -177.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 73.6 m -68.62 -15.62 63.59 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.328 1.233 . . . . 10.0 114.328 175.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -81.47 -6.79 59.31 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.386 1.074 . . . . 10.0 113.236 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.06 149.69 49.43 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 120.931 -1.106 . . . . 10.0 113.017 179.014 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.75 -173.87 22.36 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.812 1.196 . . . . 10.0 114.976 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.21 103.16 13.92 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.069 1.748 . . . . 10.0 111.297 176.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 62.7 m-85 -81.04 151.5 28.36 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.0 0.92 . . . . 10.0 112.11 172.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 164.86 29.47 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.223 1.009 . . . . 10.0 112.283 168.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 34.0 t -140.83 117.26 10.77 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.64 1.576 . . . . 10.0 110.643 175.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.8 t -88.3 132.16 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.834 1.253 . . . . 10.0 109.373 170.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -126.58 119.7 27.75 Favored 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 126.459 1.904 . . . . 10.0 110.876 -177.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -131.76 137.11 48.05 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 125.408 1.483 . . . . 10.0 112.32 -170.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.5 p30 -132.53 -177.24 4.39 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.806 1.243 . . . . 10.0 111.572 166.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -59.83 -15.78 23.51 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 115.652 1.723 . . . . 10.0 115.652 -179.28 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -107.97 -20.65 13.11 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.262 1.425 . . . . 10.0 114.192 -176.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.15 -169.7 42.84 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 116.104 1.201 . . . . 10.0 116.104 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -134.67 143.33 47.18 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 127.041 2.136 . . . . 10.0 111.647 -172.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -135.93 164.28 28.33 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.013 1.725 . . . . 10.0 111.153 166.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.5 m -140.75 140.22 34.78 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.479 1.111 . . . . 10.0 110.931 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -124.92 153.09 43.21 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.212 1.805 . . . . 10.0 110.437 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 16.1 m -148.41 146.25 28.38 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 124.197 0.999 . . . . 10.0 112.274 -169.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.2 p -151.36 171.74 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.538 1.935 . . . . 10.0 110.601 171.102 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -130.95 140.03 50.11 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.841 1.256 . . . . 10.0 110.758 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.9 tp -126.2 110.58 13.62 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.321 1.849 . . . . 10.0 110.695 -176.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -97.64 82.56 3.08 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.682 1.593 . . . . 10.0 110.86 175.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.3 114.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.897 0.879 . . . . 10.0 110.779 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 78.3 mt -78.35 93.33 4.66 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 126.279 1.831 . . . . 10.0 110.366 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -63.11 156.59 24.59 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.893 1.277 . . . . 10.0 113.486 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -131.83 -18.12 2.74 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 115.645 1.721 . . . . 10.0 115.645 178.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 124.127 0.971 . . . . 10.0 112.55 166.528 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.58 0 N-CA-C 111.799 -0.521 . . . . 10.0 111.799 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -63.41 153.53 34.96 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.201 1.0 . . . . 10.0 112.714 176.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.74 174.94 12.92 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 126.278 1.831 . . . . 10.0 111.449 -177.101 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.52 171.14 43.39 Favored Glycine 0 CA--C 1.541 1.717 0 N-CA-C 117.063 1.585 . . . . 10.0 117.063 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -73.79 162.84 38.58 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.023 3.149 . . . . 10.0 113.578 -171.088 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -67.56 161.15 44.78 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.116 2.544 . . . . 10.0 112.094 169.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 50.6 ttp180 -144.7 155.55 43.63 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 124.911 1.284 . . . . 10.0 112.649 -173.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -75.15 83.02 2.34 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.915 2.086 . . . . 10.0 111.831 176.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.3 mm -79.12 -66.33 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 O-C-N 121.543 -0.723 . . . . 10.0 110.778 177.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -156.24 145.84 20.92 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 124.833 1.253 . . . . 10.0 111.347 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.5 150.93 74.18 Favored Pre-proline 0 N--CA 1.477 0.882 0 C-N-CA 125.77 1.628 . . . . 10.0 110.331 171.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_endo -73.38 158.08 48.73 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.817 2.345 . . . . 10.0 112.198 176.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -73.81 170.69 14.8 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.928 0.891 . . . . 10.0 111.275 165.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.96 155.18 17.21 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.258 -0.901 . . . . 10.0 112.577 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.4 mtp -132.72 159.45 39.65 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.435 1.494 . . . . 10.0 112.341 -171.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 58.2 p -142.54 128.0 18.96 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 125.657 1.583 . . . . 10.0 110.288 168.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.9 mm -133.73 132.04 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.306 1.442 . . . . 10.0 109.826 -169.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -61.79 128.86 38.23 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.12 1.368 . . . . 10.0 112.347 173.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.32 132.94 29.34 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.717 1.607 . . . . 10.0 113.268 -177.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.62 -9.18 78.41 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 125.767 1.651 . . . . 10.0 115.277 177.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.5 mtp85 -70.22 160.25 32.51 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.185 1.492 . . . . 10.0 113.112 175.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.9 t80 -73.26 138.82 45.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.203 1.001 . . . . 10.0 110.267 154.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.28 172.39 15.95 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.797 0.839 . . . . 10.0 112.103 162.278 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -148.43 171.95 15.23 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.857 1.263 . . . . 10.0 113.005 173.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 55.2 mtt -132.08 154.93 48.94 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 127.72 2.408 . . . . 10.0 110.105 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -134.98 102.09 5.1 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.655 1.582 . . . . 10.0 112.041 -170.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -107.95 106.68 17.04 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 125.651 1.581 . . . . 10.0 110.126 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -65.54 131.9 47.54 Favored 'General case' 0 N--CA 1.474 0.773 0 O-C-N 121.348 -0.845 . . . . 10.0 109.978 172.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.9 p -137.16 155.95 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 125.771 1.628 . . . . 10.0 111.051 -171.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.4 t -142.84 -170.83 3.32 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.464 1.506 . . . . 10.0 111.737 -176.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 93.86 165.44 37.0 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 126.717 2.103 . . . . 10.0 113.301 -176.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.81 130.98 8.55 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 125.818 1.647 . . . . 10.0 109.363 178.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -67.11 169.95 47.65 Favored 'Cis proline' 0 CA--C 1.541 0.847 0 CA-C-N 120.788 1.317 . . . . 10.0 112.635 -3.215 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.0 123.54 54.06 Favored Pre-proline 0 CA--C 1.55 0.952 0 C-N-CA 124.832 1.253 . . . . 10.0 111.209 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.4 150.6 58.53 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 122.324 2.016 . . . . 10.0 114.081 -168.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -68.99 117.28 10.44 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.09 1.756 . . . . 10.0 109.485 160.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -114.71 86.74 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.654 1.582 . . . . 10.0 111.917 -169.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.8 m -72.3 157.48 37.61 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.913 0.885 . . . . 10.0 111.742 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 62.0 m95 -131.24 155.33 47.3 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.914 1.286 . . . . 10.0 112.828 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -146.29 159.52 43.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.435 1.894 . . . . 10.0 111.488 -175.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.4 tp -147.59 121.58 9.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.15 2.18 . . . . 10.0 110.047 176.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 54.18 17.35 1.44 Allowed 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 126.466 1.906 . . . . 10.0 115.241 178.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.46 -7.09 42.57 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 126.181 1.848 . . . . 10.0 115.416 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.8 mtt85 -98.2 161.45 13.7 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.458 1.503 . . . . 10.0 111.219 171.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.7 p -71.56 156.74 39.07 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.535 1.134 . . . . 10.0 113.003 176.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 80.5 t -134.33 141.84 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 127.101 2.16 . . . . 10.0 108.551 170.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -126.18 161.9 26.62 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.228 1.411 . . . . 10.0 111.354 -177.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 55.6 p -68.36 150.14 48.54 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.548 0.739 . . . . 10.0 112.304 174.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -152.68 167.68 28.14 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.826 1.65 . . . . 10.0 110.723 176.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.34 -34.53 66.66 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 121.003 -1.06 . . . . 10.0 112.883 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.3 mt -86.39 -12.94 47.8 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.671 1.188 . . . . 10.0 113.91 174.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.9 m80 -136.39 71.02 1.41 Allowed 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.579 1.551 . . . . 10.0 111.271 -173.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.9 mttt -71.55 144.83 49.42 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.684 1.194 . . . . 10.0 111.574 -176.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 64.6 mtt -137.75 104.93 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.897 2.079 . . . . 10.0 109.602 -176.016 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.3 157.14 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 124.175 0.99 . . . . 10.0 112.616 -177.653 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.58 108.17 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 126.54 1.936 . . . . 10.0 110.752 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 41.7 t -64.8 142.17 58.52 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.75 0.82 . . . . 10.0 111.573 174.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -60.11 -18.44 47.29 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.752 1.221 . . . . 10.0 113.705 172.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -77.51 -3.6 41.38 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.935 1.694 . . . . 10.0 113.849 173.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.0 45.64 4.73 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.155 1.359 . . . . 10.0 113.694 177.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.4 108.28 8.07 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 125.306 1.443 . . . . 10.0 110.478 -177.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.4 t60 -83.31 108.68 16.68 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.141 0.977 . . . . 10.0 111.155 170.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 23.8 m -85.02 136.18 33.7 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.52 1.128 . . . . 10.0 111.585 169.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -128.56 119.33 24.59 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 127.096 2.158 . . . . 10.0 107.918 174.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.6 mt -116.68 152.4 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.762 1.225 . . . . 10.0 111.576 -166.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -129.4 107.97 9.92 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.5 2.32 . . . . 10.0 109.187 169.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.04 -37.99 85.06 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.219 -0.925 . . . . 10.0 112.961 176.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.3 p -151.88 83.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.68 1.592 . . . . 10.0 110.353 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -68.48 143.9 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 O-C-N 121.178 -0.951 . . . . 10.0 112.291 -176.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -126.13 163.33 23.34 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 126.222 1.809 . . . . 10.0 112.276 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.3 -30.8 65.05 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.715 1.006 . . . . 10.0 113.715 -178.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.9 p -67.96 -16.63 64.14 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.673 1.589 . . . . 10.0 114.707 173.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -82.73 -5.97 59.16 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 124.691 1.196 . . . . 10.0 113.354 175.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.33 152.09 45.73 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.035 -1.041 . . . . 10.0 113.082 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.77 -170.56 22.01 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.881 1.229 . . . . 10.0 114.937 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.0 104.56 14.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.025 1.73 . . . . 10.0 111.402 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -80.06 153.11 28.99 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.415 1.086 . . . . 10.0 112.029 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.93 159.9 41.35 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.947 0.899 . . . . 10.0 112.207 167.26 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -132.51 145.15 50.93 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.346 1.858 . . . . 10.0 110.031 176.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 45.3 t -130.14 102.1 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.119 1.368 . . . . 10.0 109.812 -179.657 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.46 125.41 33.01 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 126.649 1.98 . . . . 10.0 111.245 176.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 22.7 mtmt -131.63 131.72 43.43 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.181 1.792 . . . . 10.0 111.996 -175.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.5 p30 -137.15 -179.1 5.51 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 123.461 0.704 . . . . 10.0 112.078 162.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.1 ptp180 -59.6 -14.41 13.36 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 115.763 1.764 . . . . 10.0 115.763 -177.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.3 -15.08 14.56 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.207 1.403 . . . . 10.0 114.402 -178.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.34 -173.5 42.48 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 119.587 1.085 . . . . 10.0 115.709 178.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -134.86 146.99 49.76 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.515 1.926 . . . . 10.0 111.455 -174.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.25 155.94 48.16 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.795 1.638 . . . . 10.0 111.12 170.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.7 m -135.36 131.45 36.37 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.769 1.228 . . . . 10.0 110.753 -173.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -126.17 157.25 38.63 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.364 1.466 . . . . 10.0 111.219 -176.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 20.5 m -146.13 146.34 30.83 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.37 1.068 . . . . 10.0 111.931 -169.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.4 p -152.32 165.81 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 C-N-CA 126.245 1.818 . . . . 10.0 110.629 170.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -126.29 139.17 53.52 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.82 1.248 . . . . 10.0 110.956 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 54.5 tp -126.74 113.12 16.23 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.979 1.712 . . . . 10.0 110.969 -177.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -98.9 85.21 3.23 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.638 1.575 . . . . 10.0 110.964 175.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.0 t -66.96 114.23 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.899 0.88 . . . . 10.0 110.82 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.4 mt -78.33 98.29 5.9 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.387 1.875 . . . . 10.0 110.516 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -64.62 158.43 24.42 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 124.354 1.061 . . . . 10.0 113.577 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -130.97 17.25 5.11 Favored 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 125.85 1.66 . . . . 10.0 114.85 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? . . . . . 0 C--O 1.253 1.272 0 C-N-CA 126.526 1.93 . . . . 10.0 114.874 173.277 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.545 0 N-CA-C 111.722 -0.551 . . . . 10.0 111.722 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.96 162.47 19.18 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.394 1.078 . . . . 10.0 113.064 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.6 174.58 11.3 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 126.407 1.883 . . . . 10.0 111.399 179.829 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.92 176.12 47.86 Favored Glycine 0 CA--C 1.541 1.695 0 N-CA-C 117.03 1.572 . . . . 10.0 117.03 -176.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -67.04 157.19 62.91 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 123.361 2.707 . . . . 10.0 112.633 -173.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.01 159.99 51.71 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.619 2.212 . . . . 10.0 112.218 176.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -112.35 169.05 9.15 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.752 1.621 . . . . 10.0 112.989 -172.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -108.7 97.55 7.18 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.798 2.039 . . . . 10.0 109.417 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . 0.544 HG21 ' H ' ' A' ' 254' ' ' GLN . 1.1 mp -115.37 171.41 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 126.245 1.818 . . . . 10.0 109.868 -174.133 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.544 ' H ' HG21 ' A' ' 253' ' ' ILE . 6.5 tm0? -44.34 122.08 2.85 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.692 2.397 . . . . 10.0 114.655 -173.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.7 m -107.69 158.86 32.29 Favored Pre-proline 0 N--CA 1.476 0.867 0 C-N-CA 127.508 2.323 . . . . 10.0 110.461 172.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -73.6 159.0 46.78 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.456 2.104 . . . . 10.0 111.697 173.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -71.41 172.5 9.34 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 123.71 0.804 . . . . 10.0 111.125 165.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.3 p30 -59.0 151.62 21.67 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 121.109 -0.994 . . . . 10.0 112.067 173.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.8 mtp -134.11 158.18 44.28 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.184 1.394 . . . . 10.0 111.961 -171.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 61.3 p -141.86 131.28 23.74 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 125.483 1.513 . . . . 10.0 110.823 173.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.3 mm -136.57 133.82 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.54 1.536 . . . . 10.0 109.557 -169.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -65.11 131.33 46.25 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.408 1.083 . . . . 10.0 112.428 175.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -51.61 123.44 9.99 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.607 1.563 . . . . 10.0 113.045 -179.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 102.9 -10.39 55.63 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 126.285 1.898 . . . . 10.0 115.106 178.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.7 mtp180 -72.94 160.93 31.34 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 119.127 1.464 . . . . 10.0 113.398 177.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -72.3 148.94 44.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.866 1.266 . . . . 10.0 110.632 157.647 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 45.4 t -149.48 156.05 41.38 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.763 1.225 . . . . 10.0 111.087 169.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -146.35 163.14 36.52 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.605 1.162 . . . . 10.0 112.675 165.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 59.0 mtt -137.51 121.72 18.04 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.784 1.634 . . . . 10.0 111.661 -173.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 26.1 m-20 -80.73 117.9 21.8 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 126.363 1.865 . . . . 10.0 112.353 175.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -128.13 105.46 8.39 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 125.373 1.469 . . . . 10.0 111.448 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -65.78 131.73 47.02 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 121.253 -0.904 . . . . 10.0 111.131 175.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.39 133.2 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.157 1.783 . . . . 10.0 110.73 -177.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -146.86 157.15 43.58 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.599 1.159 . . . . 10.0 111.536 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 149.13 165.52 12.37 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 128.178 2.799 . . . . 10.0 111.332 -173.671 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.0 tp -146.69 125.33 6.31 Favored Pre-proline 0 CA--C 1.546 0.816 0 CA-C-O 118.106 -0.949 . . . . 10.0 111.137 179.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -66.46 167.87 52.77 Favored 'Cis proline' 0 CA--C 1.538 0.708 0 CA-C-N 120.937 1.37 . . . . 10.0 112.669 -1.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.17 121.46 41.9 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.787 1.235 . . . . 10.0 111.341 -178.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -70.52 153.56 65.33 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 122.474 2.116 . . . . 10.0 113.196 -172.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -74.54 141.87 44.79 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.378 1.071 . . . . 10.0 109.55 159.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 47.8 t -130.94 131.7 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.262 1.025 . . . . 10.0 111.475 -170.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.1 m -131.73 156.7 45.46 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.865 1.666 . . . . 10.0 111.966 177.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -123.56 155.45 37.6 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.214 1.405 . . . . 10.0 113.177 -177.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -145.01 160.74 40.89 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 127.142 2.177 . . . . 10.0 111.572 -173.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -145.64 118.08 8.5 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 127.346 2.258 . . . . 10.0 109.905 176.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 54.72 16.24 1.33 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 126.318 1.847 . . . . 10.0 114.793 -179.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.96 -12.65 45.41 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.689 2.09 . . . . 10.0 115.24 -177.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -84.99 158.11 20.59 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 125.088 1.355 . . . . 10.0 110.698 170.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.4 p -72.1 157.11 38.38 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.882 0.873 . . . . 10.0 112.611 174.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 55.0 t -133.86 93.29 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.446 1.898 . . . . 10.0 108.74 173.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 60.8 mt-30 -68.51 155.09 40.61 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.615 0.766 . . . . 10.0 111.223 172.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.2 p -71.12 155.94 40.18 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-O 121.832 0.825 . . . . 10.0 112.327 171.525 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -155.07 170.16 22.44 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 126.68 1.992 . . . . 10.0 110.668 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.95 -34.5 65.72 Favored 'General case' 0 CA--C 1.546 0.805 0 O-C-N 120.568 -1.333 . . . . 10.0 112.828 169.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 66.8 mt -86.08 -13.25 47.87 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.755 1.222 . . . . 10.0 114.289 176.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -138.56 91.84 2.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.509 1.524 . . . . 10.0 111.122 -173.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.4 mttt -95.66 145.06 25.56 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.466 1.106 . . . . 10.0 111.494 -174.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -139.74 104.01 4.8 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 127.031 2.133 . . . . 10.0 109.621 -178.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.58 162.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.119 1.368 . . . . 10.0 111.728 177.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.13 133.68 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 126.147 1.779 . . . . 10.0 109.664 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 60.3 p -66.22 170.59 5.64 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.265 1.026 . . . . 10.0 113.561 176.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -68.99 -4.44 16.81 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.455 1.102 . . . . 10.0 113.886 166.65 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -109.07 -3.64 17.23 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 126.488 1.915 . . . . 10.0 114.134 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 87.55 40.75 6.7 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 124.509 1.052 . . . . 10.0 114.048 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 41.7 tp -124.52 106.81 10.45 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.313 1.445 . . . . 10.0 110.395 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 13.7 t60 -72.75 142.81 48.14 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.633 0.773 . . . . 10.0 111.19 173.122 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 55.1 m -123.55 97.06 5.22 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 126.865 2.066 . . . . 10.0 110.552 175.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -83.03 123.06 29.11 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 125.112 1.365 . . . . 10.0 108.662 169.161 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 37.1 mt -124.94 149.26 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 125.129 1.371 . . . . 10.0 111.705 -169.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -127.1 113.85 16.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 128.362 2.665 . . . . 10.0 109.481 171.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -69.21 -41.52 76.97 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.033 -1.042 . . . . 10.0 112.913 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.57 88.91 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.72 1.608 . . . . 10.0 110.345 -176.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.7 p -70.59 141.49 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.219 -0.925 . . . . 10.0 112.252 -176.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -123.18 162.54 22.34 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.556 1.942 . . . . 10.0 112.045 176.282 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.69 -34.41 65.04 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.463 0.912 . . . . 10.0 113.463 -178.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 24.9 m -64.59 -17.71 64.22 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.386 1.474 . . . . 10.0 114.508 175.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -83.46 -6.16 59.37 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.637 1.175 . . . . 10.0 113.383 178.398 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.84 151.21 46.06 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 121.057 -1.027 . . . . 10.0 112.986 178.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.51 -171.55 22.87 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.746 1.165 . . . . 10.0 114.881 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.78 101.33 11.52 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.858 1.663 . . . . 10.0 111.314 176.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -75.96 148.65 37.99 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.807 0.843 . . . . 10.0 111.661 169.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.83 156.84 46.05 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.852 0.861 . . . . 10.0 112.074 170.282 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.2 t -132.18 140.56 48.78 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 126.865 2.066 . . . . 10.0 109.411 -179.056 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 61.2 t -130.6 125.41 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 125.147 1.379 . . . . 10.0 109.311 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -118.55 125.02 48.92 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.149 1.78 . . . . 10.0 110.542 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -133.03 133.27 42.84 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 125.568 1.547 . . . . 10.0 112.215 -170.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -131.06 -177.74 4.52 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.693 1.197 . . . . 10.0 111.737 168.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.9 ptm180 -59.52 -14.82 14.41 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 115.702 1.742 . . . . 10.0 115.702 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.96 -17.88 13.19 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.524 1.53 . . . . 10.0 114.331 -176.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.75 -169.22 42.32 Favored Glycine 0 CA--C 1.534 1.243 0 N-CA-C 116.175 1.23 . . . . 10.0 116.175 178.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -133.65 144.42 49.19 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 127.331 2.252 . . . . 10.0 111.498 -173.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.94 157.71 46.19 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.009 1.724 . . . . 10.0 111.278 170.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 62.1 m -137.88 145.06 41.7 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.996 1.318 . . . . 10.0 111.408 -173.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -136.63 152.89 50.93 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.191 1.796 . . . . 10.0 110.478 -179.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 22.6 m -145.36 147.35 32.19 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.042 0.937 . . . . 10.0 112.252 -170.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.5 p -151.98 160.87 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 126.308 1.843 . . . . 10.0 111.039 169.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.2 tt0 -116.96 134.96 54.09 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 124.972 1.309 . . . . 10.0 110.912 173.103 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.8 tp -121.02 111.21 17.2 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.022 1.729 . . . . 10.0 110.875 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -97.32 85.88 3.77 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 125.777 1.631 . . . . 10.0 110.968 175.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.1 t -67.04 112.97 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.764 0.826 . . . . 10.0 110.736 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.0 mt -76.03 99.53 4.63 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.214 1.806 . . . . 10.0 110.101 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.94 150.44 33.3 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.109 0.964 . . . . 10.0 112.976 -179.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -77.17 -12.82 59.99 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 114.802 1.408 . . . . 10.0 114.802 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 29.8 mm-40 . . . . . 0 C--O 1.253 1.253 0 C-N-CA 126.888 2.075 . . . . 10.0 113.824 179.304 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.505 0 N-CA-C 111.118 -0.793 . . . . 10.0 111.118 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.16 165.68 10.92 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.372 1.069 . . . . 10.0 112.93 174.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -143.0 172.95 12.0 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 125.99 1.716 . . . . 10.0 111.752 -177.194 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.77 173.76 46.31 Favored Glycine 0 CA--C 1.542 1.779 0 N-CA-C 116.849 1.5 . . . . 10.0 116.849 -175.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -69.84 159.58 52.83 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 123.661 2.907 . . . . 10.0 113.366 -171.714 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.45 164.82 32.77 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.32 2.68 . . . . 10.0 111.787 169.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.6 ttt180 -143.4 158.02 43.98 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.4 1.08 . . . . 10.0 112.366 -173.233 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -82.77 69.7 9.61 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.681 1.992 . . . . 10.0 112.516 -171.258 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . 0.608 HG21 ' H ' ' A' ' 254' ' ' GLN . 2.7 mm -77.88 175.34 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.231 0 C-N-CA 124.338 1.055 . . . . 10.0 110.865 175.624 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.608 ' H ' HG21 ' A' ' 253' ' ' ILE . 47.4 tt0 -48.72 115.42 1.25 Allowed 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 128.302 2.641 . . . . 10.0 115.259 -173.651 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.7 m -78.4 153.7 79.1 Favored Pre-proline 0 N--CA 1.479 0.999 0 C-N-CA 124.927 1.291 . . . . 10.0 111.552 162.439 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -76.31 166.85 26.87 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 123.267 2.645 . . . . 10.0 111.714 169.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.42 164.91 26.03 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.311 -0.868 . . . . 10.0 111.887 169.097 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -63.46 162.22 12.98 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.601 0.76 . . . . 10.0 112.634 172.625 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.6 mtm -134.11 161.43 34.9 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.373 1.069 . . . . 10.0 113.228 -178.234 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -140.15 90.14 2.35 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.887 2.075 . . . . 10.0 110.477 177.411 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . 0.405 HG13 ' HG ' ' A' ' 267' ' ' CYS . 41.7 mm -103.87 138.23 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 124.697 1.199 . . . . 10.0 111.184 -166.797 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -68.83 130.06 41.71 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.108 0.963 . . . . 10.0 112.355 174.613 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -53.23 125.79 18.78 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.448 1.499 . . . . 10.0 112.824 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.95 -8.74 61.38 Favored Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.185 1.85 . . . . 10.0 115.115 -179.234 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.7 mtp85 -74.35 159.79 31.91 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 119.489 1.644 . . . . 10.0 113.102 175.103 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -76.75 141.01 40.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.453 1.101 . . . . 10.0 110.207 156.368 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . 0.405 ' HG ' HG13 ' A' ' 261' ' ' ILE . 31.1 p -150.22 173.61 13.74 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.733 0.813 . . . . 10.0 112.353 162.436 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -145.95 167.89 22.21 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 125.682 1.593 . . . . 10.0 112.356 175.342 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -126.48 159.78 32.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.531 1.933 . . . . 10.0 110.772 172.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -137.43 96.87 3.34 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.448 1.499 . . . . 10.0 111.504 -167.862 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.13 111.39 22.71 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.678 1.591 . . . . 10.0 111.126 -177.037 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 90.7 mttt -66.38 147.35 53.43 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 121.111 -0.993 . . . . 10.0 110.272 169.438 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -150.78 159.95 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.232 1.413 . . . . 10.0 111.458 -175.669 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -143.53 -176.88 5.13 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.648 1.579 . . . . 10.0 111.854 178.102 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.22 161.43 23.53 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.251 2.358 . . . . 10.0 113.481 -178.161 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.9 tp -149.7 130.87 7.25 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 125.124 1.37 . . . . 10.0 110.282 179.823 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -66.0 168.97 45.62 Favored 'Cis proline' 0 CA--C 1.539 0.742 0 CA-C-N 121.194 1.462 . . . . 10.0 112.56 -2.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 121.54 41.15 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 124.783 1.233 . . . . 10.0 111.403 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 151.49 66.55 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.517 2.144 . . . . 10.0 113.102 -173.152 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -71.68 143.57 49.66 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.157 0.983 . . . . 10.0 109.783 160.357 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.64 87.53 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.081 1.353 . . . . 10.0 111.83 -166.073 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 62.5 m -77.08 113.72 15.12 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.549 1.14 . . . . 10.0 111.177 176.318 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -91.17 153.12 20.26 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.19 0.996 . . . . 10.0 113.186 176.481 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -144.11 159.92 41.79 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.658 1.983 . . . . 10.0 111.995 -176.512 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.2 tp -146.02 119.25 8.9 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 127.511 2.325 . . . . 10.0 110.022 176.236 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 54.9 14.14 0.86 Allowed 'General case' 0 CA--C 1.555 1.148 0 C-N-CA 126.419 1.887 . . . . 10.0 115.309 179.221 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.44 -12.19 36.27 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.602 2.049 . . . . 10.0 115.165 -177.345 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -87.95 158.07 18.77 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.974 1.387 . . . . 10.0 110.976 170.097 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.6 p -71.6 156.78 39.01 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.357 1.063 . . . . 10.0 112.656 173.627 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.85 105.94 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 126.373 1.869 . . . . 10.0 108.866 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 63.0 mt-30 -74.31 159.36 32.52 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.458 0.703 . . . . 10.0 111.394 171.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.0 p -69.07 155.92 39.54 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.514 0.726 . . . . 10.0 112.036 169.647 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -153.13 168.55 25.56 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.26 1.424 . . . . 10.0 110.891 175.634 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -57.23 -35.98 70.36 Favored 'General case' 0 CA--C 1.546 0.797 0 O-C-N 120.857 -1.152 . . . . 10.0 112.548 168.692 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.9 mt -80.19 -17.79 51.4 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 124.537 1.135 . . . . 10.0 113.804 173.886 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -134.46 70.51 1.45 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.18 1.792 . . . . 10.0 111.205 -172.186 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -73.16 142.43 47.43 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.4 1.48 . . . . 10.0 111.046 -173.199 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.8 mtt -136.48 98.7 3.89 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.249 1.82 . . . . 10.0 110.074 -174.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.09 159.86 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.363 1.465 . . . . 10.0 111.636 -177.034 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.38 122.57 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.753 1.221 . . . . 10.0 111.504 -177.85 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 67.6 m -69.63 148.6 49.12 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.508 1.123 . . . . 10.0 112.016 177.293 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 19.4 tp10 -55.8 -34.78 65.62 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.656 1.583 . . . . 10.0 113.396 -177.663 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -78.41 0.38 25.95 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 126.082 1.753 . . . . 10.0 114.574 179.369 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.49 50.23 1.88 Allowed Glycine 0 CA--C 1.532 1.133 0 C-N-CA 124.833 1.206 . . . . 10.0 114.841 170.19 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 54.4 tp -133.51 106.5 7.48 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.155 1.382 . . . . 10.0 111.056 176.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -86.45 118.37 25.84 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.954 1.701 . . . . 10.0 111.365 177.484 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -91.71 144.93 25.01 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.903 1.681 . . . . 10.0 112.224 173.658 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -138.21 115.73 11.26 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 126.439 1.896 . . . . 10.0 108.669 173.569 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 154.19 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 C-N-CA 125.36 1.464 . . . . 10.0 111.42 -170.832 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -131.74 108.36 9.41 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 127.007 2.123 . . . . 10.0 109.599 163.565 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 36.5 mm-40 -65.06 -45.32 85.82 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 113.898 1.073 . . . . 10.0 113.898 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.61 70.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 CA-C-O 122.614 1.197 . . . . 10.0 111.344 -172.506 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.96 142.23 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.025 1.33 . . . . 10.0 113.502 -170.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.2 mmt-85 -120.64 162.07 20.29 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 126.5 1.92 . . . . 10.0 112.323 177.04 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.11 -31.32 61.15 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.265 1.026 . . . . 10.0 113.613 177.239 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 43.2 p -67.8 -17.12 64.42 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.539 1.536 . . . . 10.0 114.806 174.287 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -83.31 -7.39 59.59 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.54 1.136 . . . . 10.0 113.409 175.823 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 149.68 49.71 Favored 'General case' 0 CA--C 1.547 0.85 0 O-C-N 120.958 -1.089 . . . . 10.0 112.988 179.38 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.1 -173.44 23.27 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.806 1.193 . . . . 10.0 115.076 176.077 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 106.53 14.8 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.855 1.662 . . . . 10.0 111.094 175.063 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -84.01 150.43 25.62 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 124.347 1.059 . . . . 10.0 111.921 172.902 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.56 162.18 37.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.946 0.898 . . . . 10.0 112.268 170.516 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.3 t -139.01 140.42 38.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.581 1.552 . . . . 10.0 110.487 175.065 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 43.6 t -121.38 104.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.837 1.655 . . . . 10.0 109.07 179.395 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -86.3 122.0 29.67 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.278 1.831 . . . . 10.0 111.078 178.396 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -132.35 132.58 43.04 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.421 1.488 . . . . 10.0 112.224 -177.184 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.2 p30 -130.97 -177.95 4.6 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.488 1.115 . . . . 10.0 111.646 167.085 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.8 ptp180 -59.47 -12.71 6.71 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 115.922 1.823 . . . . 10.0 115.922 -179.37 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -113.52 -16.82 12.34 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 125.382 1.473 . . . . 10.0 114.557 -177.048 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.17 -169.27 42.34 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 120.022 1.283 . . . . 10.0 116.224 178.876 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -135.96 144.06 45.2 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.093 2.157 . . . . 10.0 111.997 -172.311 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.78 161.96 36.3 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.111 1.764 . . . . 10.0 111.151 168.587 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -137.65 144.17 41.74 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.319 1.048 . . . . 10.0 111.599 -172.31 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -134.52 152.38 51.75 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.189 1.796 . . . . 10.0 110.86 -178.214 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 15.4 m -147.85 146.18 29.0 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.525 1.13 . . . . 10.0 111.942 -173.027 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.9 p -153.45 174.21 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 126.49 1.916 . . . . 10.0 110.781 171.838 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -129.63 144.31 51.22 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.689 1.196 . . . . 10.0 111.51 172.773 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.0 tp -128.77 109.12 11.02 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.304 1.842 . . . . 10.0 109.997 179.386 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -79.4 147.0 32.51 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 121.938 -0.477 . . . . 10.0 110.029 158.406 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 30.1 t -128.43 106.83 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.124 0.97 . . . . 10.0 109.344 175.352 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.8 101.99 2.24 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.282 1.833 . . . . 10.0 109.659 -178.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.96 151.99 24.8 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 124.191 0.996 . . . . 10.0 113.22 -175.75 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 29.0 tptp -66.54 -40.91 89.32 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.857 1.263 . . . . 10.0 113.018 -178.042 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 . . . . . 0 C--O 1.253 1.243 0 C-N-CA 125.928 1.691 . . . . 10.0 113.09 176.731 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.501 0 N-CA-C 111.619 -0.592 . . . . 10.0 111.619 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.39 162.82 19.59 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.338 1.055 . . . . 10.0 113.161 176.898 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.94 173.25 12.6 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.4 1.88 . . . . 10.0 111.136 178.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.97 173.93 46.09 Favored Glycine 0 CA--C 1.541 1.695 0 N-CA-C 117.225 1.65 . . . . 10.0 117.225 -175.296 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -71.9 162.93 40.44 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 123.945 3.096 . . . . 10.0 113.483 -171.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -66.88 156.23 67.11 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 C-N-CA 122.933 2.422 . . . . 10.0 112.021 170.888 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.2 ttt85 -146.43 150.48 35.71 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.554 1.142 . . . . 10.0 112.568 -173.374 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -77.59 82.49 4.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.058 2.143 . . . . 10.0 111.65 178.098 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.0 mm -74.89 -56.94 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.613 -0.679 . . . . 10.0 110.502 173.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -154.9 143.49 20.61 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.819 1.248 . . . . 10.0 111.44 176.711 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.39 151.84 79.48 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 126.053 1.741 . . . . 10.0 110.112 171.068 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.01 154.9 47.9 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.929 2.419 . . . . 10.0 112.132 175.736 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -75.63 171.15 14.81 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.353 1.061 . . . . 10.0 112.318 167.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -62.5 153.3 32.08 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 121.269 -0.894 . . . . 10.0 112.607 176.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 73.8 mtp -133.16 157.45 45.31 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.042 1.337 . . . . 10.0 112.408 -169.701 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -141.27 112.79 7.56 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.524 1.53 . . . . 10.0 111.036 178.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 33.2 mm -129.94 128.3 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 125.049 1.339 . . . . 10.0 110.949 -164.68 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -60.37 131.5 50.98 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.083 1.353 . . . . 10.0 112.661 173.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -54.44 136.2 44.52 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.886 1.275 . . . . 10.0 113.001 -177.768 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.76 -6.7 81.95 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.649 1.595 . . . . 10.0 115.312 177.683 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -71.87 158.31 36.28 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 118.944 1.372 . . . . 10.0 112.892 175.783 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -70.65 143.37 51.43 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.316 1.046 . . . . 10.0 109.968 155.1 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.6 t -147.62 165.58 29.96 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.245 1.018 . . . . 10.0 111.634 172.7 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -148.04 159.06 44.3 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.721 1.208 . . . . 10.0 112.868 168.544 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -130.1 151.12 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 126.678 1.991 . . . . 10.0 109.431 170.405 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -143.41 125.6 15.49 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.254 1.021 . . . . 10.0 111.442 -173.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -121.72 156.72 32.5 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.55 2.34 . . . . 10.0 110.196 -175.634 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -114.11 104.06 11.75 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.773 1.229 . . . . 10.0 110.198 175.836 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 43.8 t -109.38 99.15 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.462 1.905 . . . . 10.0 110.021 -170.316 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.5 t -73.44 -175.24 1.89 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.093 0.957 . . . . 10.0 112.527 174.106 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 109.79 155.88 15.91 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 127.312 2.386 . . . . 10.0 113.592 176.379 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 19.2 tp -147.48 125.31 5.92 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.531 . . . . 10.0 109.664 178.513 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.47 169.05 47.71 Favored 'Cis proline' 0 CA--C 1.541 0.834 0 CA-C-N 120.8 1.322 . . . . 10.0 112.567 -2.602 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.36 68.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 C-N-CA 124.205 1.002 . . . . 10.0 111.387 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.81 150.68 68.24 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.476 2.117 . . . . 10.0 113.14 -173.57 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -69.65 142.03 53.51 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.032 1.333 . . . . 10.0 110.431 165.113 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 55.9 t -117.16 126.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.723 1.609 . . . . 10.0 111.269 -167.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.3 m -134.31 106.47 7.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.635 1.574 . . . . 10.0 111.004 175.337 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -82.25 153.59 25.82 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.913 0.885 . . . . 10.0 113.044 176.064 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -142.86 160.44 40.33 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 127.286 2.235 . . . . 10.0 111.378 179.718 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.1 tp -146.4 119.08 8.57 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 127.223 2.209 . . . . 10.0 109.974 175.196 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 54.76 17.15 1.64 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 126.442 1.897 . . . . 10.0 115.014 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.94 -12.87 49.63 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.518 2.009 . . . . 10.0 115.117 -178.236 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.7 mtt85 -84.94 155.72 21.52 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.923 1.362 . . . . 10.0 110.78 169.077 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.5 p -69.84 157.67 36.96 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.02 0.928 . . . . 10.0 112.52 173.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 81.9 t -132.34 143.39 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.667 1.987 . . . . 10.0 108.875 172.442 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -132.85 155.3 49.24 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.629 1.572 . . . . 10.0 110.541 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.0 p -72.43 149.09 44.55 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 123.67 0.788 . . . . 10.0 112.851 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -154.62 -173.11 4.44 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.529 1.932 . . . . 10.0 111.322 175.312 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -60.53 -18.72 53.97 Favored 'General case' 0 CA--C 1.549 0.932 0 N-CA-C 114.84 1.422 . . . . 10.0 114.84 -178.693 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 59.9 mt -113.64 -16.82 12.27 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.556 1.943 . . . . 10.0 113.541 -179.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -122.25 98.34 5.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 126.798 2.039 . . . . 10.0 110.339 -178.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.96 109.77 19.41 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 124.536 1.134 . . . . 10.0 110.857 -168.384 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 5.1 mpp? -116.31 110.22 18.44 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.992 1.717 . . . . 10.0 110.718 -175.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.09 161.46 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.975 1.71 . . . . 10.0 112.096 -172.642 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.1 t -131.22 118.57 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 125.568 1.547 . . . . 10.0 110.238 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 14.5 t -67.55 163.18 21.74 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 124.793 1.237 . . . . 10.0 112.551 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -57.53 -30.52 65.24 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.635 1.574 . . . . 10.0 113.139 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 11.3 mmpt? -86.02 0.11 54.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.922 1.689 . . . . 10.0 114.604 178.356 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.01 6.36 71.98 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 124.896 1.236 . . . . 10.0 114.894 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.54 105.67 1.92 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.579 1.152 . . . . 10.0 109.453 170.329 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.0 t60 -95.8 114.44 26.17 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.612 1.565 . . . . 10.0 111.061 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 41.2 m -101.57 151.02 22.48 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.847 1.259 . . . . 10.0 112.477 -179.782 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -135.81 103.24 5.33 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.439 2.296 . . . . 10.0 108.368 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.32 139.65 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.57 1.148 . . . . 10.0 110.263 -179.524 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -115.14 105.61 13.12 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 127.922 2.489 . . . . 10.0 109.152 171.444 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -64.61 -40.4 95.43 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 120.995 -1.066 . . . . 10.0 113.339 -179.789 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.04 93.22 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.635 1.574 . . . . 10.0 110.402 179.951 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.88 142.47 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.354 -0.842 . . . . 10.0 112.118 -177.548 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -123.08 160.21 26.88 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.145 1.778 . . . . 10.0 112.038 175.393 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.74 -31.87 64.98 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.989 1.107 . . . . 10.0 113.989 -175.2 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.2 t -65.9 -20.85 66.36 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.005 1.322 . . . . 10.0 113.958 175.582 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -78.41 -4.22 47.16 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.908 1.283 . . . . 10.0 113.685 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 155.3 36.61 Favored 'General case' 0 CA--C 1.547 0.84 0 N-CA-C 113.669 0.988 . . . . 10.0 113.669 178.362 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.6 -167.52 17.96 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.933 1.254 . . . . 10.0 114.909 174.312 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.05 105.3 14.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.91 1.684 . . . . 10.0 111.686 179.463 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.6 m-85 -79.58 151.15 30.81 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.311 1.044 . . . . 10.0 111.576 168.633 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.68 159.96 41.54 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.837 0.855 . . . . 10.0 112.226 169.084 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.6 t -137.49 103.95 5.21 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.806 1.642 . . . . 10.0 110.596 -179.501 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 90.0 t -74.95 130.03 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.432 1.093 . . . . 10.0 109.402 170.093 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.93 118.76 24.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.7 2.0 . . . . 10.0 110.259 178.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.9 mtpp -131.76 133.48 44.81 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.969 1.307 . . . . 10.0 112.553 -173.112 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.5 p30 -131.55 -178.91 5.07 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.497 1.119 . . . . 10.0 111.73 167.182 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -60.63 -11.84 8.45 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 115.798 1.777 . . . . 10.0 115.798 -179.101 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.1 -15.11 13.32 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.296 1.438 . . . . 10.0 114.547 -178.378 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.21 -169.57 41.06 Favored Glycine 0 CA--C 1.534 1.256 0 N-CA-C 116.025 1.17 . . . . 10.0 116.025 177.479 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -135.83 145.79 46.83 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.917 2.087 . . . . 10.0 112.002 -169.383 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.91 158.98 43.21 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.393 1.877 . . . . 10.0 110.632 166.017 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.9 m -140.03 100.23 3.87 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.781 1.232 . . . . 10.0 110.414 176.697 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -79.78 154.67 28.32 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.604 1.162 . . . . 10.0 111.187 177.289 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 32.0 m -144.64 145.41 31.74 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 124.456 1.102 . . . . 10.0 111.748 -172.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.92 165.77 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 126.324 1.85 . . . . 10.0 110.559 171.86 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -128.84 140.44 51.7 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.729 1.211 . . . . 10.0 111.549 177.255 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 53.1 tp -128.63 110.45 12.24 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.02 1.728 . . . . 10.0 111.951 -176.905 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -87.78 89.88 8.16 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.155 1.382 . . . . 10.0 110.843 169.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.58 106.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.031 -1.043 . . . . 10.0 109.614 174.131 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.3 mt -72.56 97.91 2.21 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.116 1.766 . . . . 10.0 109.873 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.48 145.73 47.33 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 124.522 1.129 . . . . 10.0 113.399 -175.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -93.47 -14.4 26.75 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 114.907 1.447 . . . . 10.0 114.907 179.012 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 . . . . . 0 C--O 1.253 1.243 0 C-N-CA 125.987 1.715 . . . . 10.0 113.454 177.615 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.522 0 N-CA-C 111.541 -0.624 . . . . 10.0 111.541 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.97 160.9 22.56 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.287 1.035 . . . . 10.0 113.118 176.995 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.6 175.34 11.26 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 126.402 1.881 . . . . 10.0 111.386 -179.89 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.78 173.21 45.87 Favored Glycine 0 CA--C 1.543 1.795 0 N-CA-C 117.332 1.693 . . . . 10.0 117.332 -175.296 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.09 160.96 47.75 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 123.88 3.053 . . . . 10.0 113.258 -172.275 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.55 158.2 58.66 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.961 2.441 . . . . 10.0 112.337 173.667 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -145.18 161.44 39.51 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 125.018 1.327 . . . . 10.0 113.556 -171.533 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -83.45 98.84 9.73 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.022 1.729 . . . . 10.0 111.869 -178.602 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 36.5 mm -90.64 -68.27 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.445 0.698 . . . . 10.0 110.723 177.01 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 37.2 tt0 -155.49 143.78 20.16 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.306 1.042 . . . . 10.0 111.679 177.104 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.1 m -126.07 153.77 74.05 Favored Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 125.85 1.66 . . . . 10.0 110.659 171.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -70.65 155.03 63.83 Favored 'Trans proline' 0 CA--C 1.542 0.876 0 C-N-CA 122.61 2.207 . . . . 10.0 111.834 171.594 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -72.95 174.3 8.02 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.006 0.922 . . . . 10.0 111.311 166.405 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -59.03 152.24 20.39 Favored 'General case' 0 CA--C 1.548 0.886 0 O-C-N 121.051 -1.031 . . . . 10.0 112.371 174.671 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.0 mtp -134.87 159.3 41.85 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 125.59 1.556 . . . . 10.0 111.887 -171.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 67.2 p -142.12 134.25 27.55 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 125.11 1.364 . . . . 10.0 111.242 172.258 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 27.8 mm -139.41 132.83 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 125.62 1.568 . . . . 10.0 109.629 -170.197 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -63.44 132.63 52.02 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.624 1.169 . . . . 10.0 112.4 173.741 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -52.58 128.12 25.07 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.697 1.199 . . . . 10.0 112.786 -179.311 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.21 -9.29 63.13 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 126.017 1.77 . . . . 10.0 115.298 178.412 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -74.47 162.14 29.11 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 119.227 1.514 . . . . 10.0 113.342 176.668 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -72.75 150.97 42.38 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.199 1.4 . . . . 10.0 110.725 159.159 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.9 t -149.97 156.4 41.65 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.663 1.185 . . . . 10.0 111.437 170.425 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm85 -140.87 164.62 29.75 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.558 1.143 . . . . 10.0 112.99 163.372 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.4 mtt -131.73 161.03 33.79 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.801 2.04 . . . . 10.0 111.142 176.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -137.12 94.25 2.93 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.131 1.372 . . . . 10.0 111.612 -167.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 41.7 m-85 -104.04 116.27 31.94 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.313 1.445 . . . . 10.0 110.831 -178.881 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -78.68 131.14 36.52 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.406 -0.809 . . . . 10.0 110.141 172.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 56.9 t -133.25 148.82 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.135 1.774 . . . . 10.0 110.192 -174.107 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.0 t -136.82 -174.32 3.69 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.542 1.537 . . . . 10.0 111.474 173.77 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 110.06 162.0 18.78 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 127.401 2.429 . . . . 10.0 112.549 -173.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -148.04 128.78 6.94 Favored Pre-proline 0 CA--C 1.546 0.826 0 C-N-CA 124.661 1.184 . . . . 10.0 110.591 -179.587 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -66.56 170.01 44.55 Favored 'Cis proline' 0 CA--C 1.54 0.783 0 CA-C-N 120.786 1.316 . . . . 10.0 112.453 -4.225 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.55 123.42 56.8 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.512 1.125 . . . . 10.0 111.375 179.572 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.55 151.09 64.35 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.543 2.162 . . . . 10.0 113.168 -173.371 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -72.96 146.55 45.97 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.248 1.019 . . . . 10.0 109.831 160.158 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.8 m -130.97 135.98 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.662 1.185 . . . . 10.0 112.541 -170.23 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 64.1 m -135.51 119.3 17.25 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.234 1.814 . . . . 10.0 111.037 -178.834 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 62.2 m95 -91.02 156.22 18.11 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.598 0.962 . . . . 10.0 113.598 -179.43 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -143.45 160.25 40.93 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.796 2.438 . . . . 10.0 111.1 -176.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.6 tp -146.18 117.72 8.03 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 127.189 2.196 . . . . 10.0 109.997 176.237 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 55.54 13.33 0.94 Allowed 'General case' 0 CA--C 1.555 1.145 0 C-N-CA 126.467 1.907 . . . . 10.0 115.208 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 109.83 -14.62 31.82 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 126.731 2.11 . . . . 10.0 115.02 -177.313 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -82.09 157.42 24.1 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 118.9 1.35 . . . . 10.0 110.687 168.896 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.8 p -72.91 158.25 35.85 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.936 0.894 . . . . 10.0 112.339 172.358 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.6 t -133.98 90.83 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 126.278 1.831 . . . . 10.0 108.898 172.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -68.77 143.48 54.63 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.254 0.622 . . . . 10.0 110.412 169.815 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.3 p -69.39 149.53 48.28 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.374 0.67 . . . . 10.0 112.163 173.098 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.18 -172.68 4.3 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.186 1.794 . . . . 10.0 111.983 178.103 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.09 -18.34 46.26 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 114.774 1.398 . . . . 10.0 114.774 -178.472 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.8 mt -113.12 -15.07 12.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.915 1.686 . . . . 10.0 113.531 179.479 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -126.43 96.81 4.81 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.82 2.048 . . . . 10.0 109.755 -177.206 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -110.61 126.17 54.19 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.25 1.02 . . . . 10.0 111.207 -168.323 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -128.89 109.06 10.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.427 1.891 . . . . 10.0 110.033 -173.044 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.22 164.83 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 125.615 1.566 . . . . 10.0 111.858 -178.172 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.5 t -125.6 106.82 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 125.513 1.525 . . . . 10.0 109.688 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -74.31 164.93 26.01 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.525 1.13 . . . . 10.0 112.536 176.515 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -57.12 156.61 6.93 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.945 1.298 . . . . 10.0 112.018 173.199 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt 64.68 6.47 3.26 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 127.392 2.277 . . . . 10.0 114.642 -170.431 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 83.77 55.68 2.78 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.307 1.432 . . . . 10.0 114.041 171.854 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.31 101.36 7.92 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.892 1.277 . . . . 10.0 110.11 177.16 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -79.64 112.55 17.01 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.91 1.284 . . . . 10.0 111.197 174.733 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.8 m -83.34 146.78 28.31 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 124.753 1.221 . . . . 10.0 112.197 172.146 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.82 120.1 24.44 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.401 1.88 . . . . 10.0 107.088 161.756 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.7 mt -121.31 139.06 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.494 1.518 . . . . 10.0 110.453 -174.166 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -120.42 110.74 16.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 127.584 2.354 . . . . 10.0 109.522 176.746 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.83 -42.89 85.07 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 121.343 -0.848 . . . . 10.0 113.202 179.465 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.0 89.42 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.806 1.642 . . . . 10.0 110.161 -177.361 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.6 p -70.37 140.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.284 -0.885 . . . . 10.0 112.203 -176.239 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -119.93 160.79 22.03 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.358 1.863 . . . . 10.0 112.157 176.717 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.11 -32.56 66.46 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 113.726 1.01 . . . . 10.0 113.726 -177.45 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.4 t -65.13 -21.75 66.84 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.106 1.362 . . . . 10.0 113.776 175.209 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -79.48 -5.32 54.55 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.779 1.231 . . . . 10.0 113.611 -179.832 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.65 152.17 44.81 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.168 -0.957 . . . . 10.0 113.236 178.624 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.59 -168.98 22.53 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.633 1.111 . . . . 10.0 115.043 174.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.67 103.03 11.88 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.909 1.684 . . . . 10.0 111.551 177.856 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 -78.82 149.7 32.48 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.037 0.935 . . . . 10.0 111.678 169.714 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.94 160.93 40.55 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.901 0.881 . . . . 10.0 112.265 170.413 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.45 120.53 17.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.543 1.537 . . . . 10.0 110.858 177.12 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 59.1 t -92.36 126.39 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.757 1.223 . . . . 10.0 108.996 171.204 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -119.27 126.11 50.7 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 126.428 1.891 . . . . 10.0 110.747 -178.957 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -134.47 133.33 40.31 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 125.259 1.423 . . . . 10.0 112.516 -170.698 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.7 p30 -130.55 -179.1 5.08 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.741 1.216 . . . . 10.0 111.533 166.535 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -60.89 -12.77 12.14 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 115.618 1.71 . . . . 10.0 115.618 -179.465 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -109.44 -17.63 13.73 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.521 1.528 . . . . 10.0 114.392 -178.282 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 168.64 -169.2 41.55 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 115.972 1.149 . . . . 10.0 115.972 177.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -133.77 146.56 50.84 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.986 2.114 . . . . 10.0 111.745 -172.088 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.2 160.1 40.31 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.317 1.847 . . . . 10.0 110.974 169.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.3 m -136.33 130.56 33.06 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.722 1.209 . . . . 10.0 111.379 177.759 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -113.65 153.65 28.56 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.204 1.801 . . . . 10.0 110.659 177.81 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.7 m -143.09 148.19 36.25 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.598 1.159 . . . . 10.0 112.37 -173.13 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.41 169.15 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 C-N-CA 126.994 2.117 . . . . 10.0 110.763 169.468 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 52.4 tt0 -128.04 137.04 52.03 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.196 1.399 . . . . 10.0 111.088 174.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.5 tp -125.65 107.14 10.28 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.958 1.703 . . . . 10.0 111.077 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -88.96 87.47 7.23 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.259 1.424 . . . . 10.0 110.869 172.773 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -67.36 112.35 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.242 -0.911 . . . . 10.0 110.061 175.45 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.6 mt -75.3 94.65 3.05 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 126.104 1.762 . . . . 10.0 109.875 -179.747 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -63.43 151.72 40.28 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.765 1.226 . . . . 10.0 113.53 -175.769 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -68.89 -43.31 75.55 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 125.427 1.491 . . . . 10.0 112.022 171.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 . . . . . 0 C--O 1.254 1.311 0 C-N-CA 126.768 2.027 . . . . 10.0 113.612 -179.481 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.513 0 N-CA-C 111.782 -0.527 . . . . 10.0 111.782 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.3 160.95 20.56 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.281 1.032 . . . . 10.0 112.997 176.341 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.54 176.41 10.08 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 126.12 1.768 . . . . 10.0 111.707 -179.009 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.01 173.14 46.07 Favored Glycine 0 CA--C 1.541 1.706 0 N-CA-C 117.037 1.575 . . . . 10.0 117.037 -176.935 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -69.18 160.72 48.74 Favored 'Trans proline' 0 CA--C 1.544 0.991 0 C-N-CA 123.521 2.814 . . . . 10.0 113.134 -173.316 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -68.07 167.67 21.14 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 123.303 2.668 . . . . 10.0 111.634 169.191 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 2.1 tpt180 -139.42 175.22 9.75 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.664 1.186 . . . . 10.0 112.803 -172.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -103.92 95.48 6.04 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 126.394 1.878 . . . . 10.0 110.326 -175.643 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . 0.59 HG21 ' H ' ' A' ' 254' ' ' GLN . 0.4 OUTLIER -115.61 -179.28 1.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.99 0 C-N-CA 126.298 1.839 . . . . 10.0 109.779 -179.655 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.59 ' H ' HG21 ' A' ' 253' ' ' ILE . 41.8 tt0 -46.15 123.37 4.61 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.507 2.323 . . . . 10.0 115.026 -166.535 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 19.1 m -106.84 153.83 40.56 Favored Pre-proline 0 N--CA 1.474 0.769 0 C-N-CA 126.425 1.89 . . . . 10.0 110.365 167.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.25 158.49 44.94 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.759 2.306 . . . . 10.0 111.705 169.902 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -66.29 172.4 3.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 124.606 1.162 . . . . 10.0 111.841 167.342 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -60.32 153.72 21.93 Favored 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.99 -1.068 . . . . 10.0 111.857 170.311 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 84.8 mtp -133.01 155.9 48.33 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.994 1.318 . . . . 10.0 112.179 -169.647 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 47.6 p -141.81 122.86 14.6 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 125.505 1.522 . . . . 10.0 110.903 175.091 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.5 mm -134.18 132.38 55.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.546 1.538 . . . . 10.0 109.901 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -63.99 129.12 38.78 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.235 1.014 . . . . 10.0 112.101 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -54.31 131.82 42.6 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.201 1.4 . . . . 10.0 112.683 -177.736 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.76 -10.11 66.34 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 126.042 1.782 . . . . 10.0 115.07 179.11 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 78.3 mtp85 -71.47 160.98 31.76 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 119.005 1.402 . . . . 10.0 113.061 175.91 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -71.18 145.8 49.49 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 124.014 0.926 . . . . 10.0 110.368 155.684 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 16.6 t -147.45 163.79 35.4 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.7 1.2 . . . . 10.0 111.405 168.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -143.85 157.52 44.31 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.589 1.556 . . . . 10.0 111.806 167.706 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 53.2 mtt -129.22 150.42 50.61 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 127.117 2.167 . . . . 10.0 109.187 171.454 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -142.12 126.08 17.23 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.317 1.047 . . . . 10.0 111.479 -169.85 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -130.86 123.69 29.59 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 126.745 2.018 . . . . 10.0 111.151 -168.718 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -70.27 130.81 43.02 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.493 -0.754 . . . . 10.0 110.301 171.472 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.77 149.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 126.109 1.763 . . . . 10.0 111.138 -175.592 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 6.1 t -147.24 -174.08 4.42 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 125.144 1.377 . . . . 10.0 112.113 -176.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.18 162.47 23.7 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 127.319 2.39 . . . . 10.0 112.864 -174.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -146.48 128.07 7.48 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.874 1.27 . . . . 10.0 110.567 -179.698 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -66.7 169.4 47.55 Favored 'Cis proline' 0 CA--C 1.539 0.743 0 CA-C-N 120.88 1.35 . . . . 10.0 112.658 -2.149 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.72 122.77 48.04 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.752 1.221 . . . . 10.0 111.575 -178.463 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -71.11 159.95 50.66 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 122.597 2.198 . . . . 10.0 113.359 -174.292 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.7 168.94 10.36 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.799 1.24 . . . . 10.0 111.851 166.426 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 71.5 t -130.24 123.76 56.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.691 1.597 . . . . 10.0 110.397 -178.366 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.2 m -134.82 150.35 50.49 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.68 1.592 . . . . 10.0 110.661 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 47.6 m95 -130.06 157.82 41.34 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 124.884 1.274 . . . . 10.0 112.593 179.151 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -143.91 159.19 43.0 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.674 1.99 . . . . 10.0 111.413 -177.292 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.1 tp -144.99 118.24 8.95 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 127.128 2.171 . . . . 10.0 109.943 175.844 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 54.91 14.79 0.97 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.508 1.923 . . . . 10.0 115.177 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.8 -13.23 35.06 Favored Glycine 0 CA--C 1.539 1.556 0 C-N-CA 126.709 2.1 . . . . 10.0 115.182 -178.061 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.9 mtp180 -85.89 157.11 20.26 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.971 1.385 . . . . 10.0 110.961 170.134 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.6 p -71.41 155.25 40.84 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.358 1.063 . . . . 10.0 112.765 174.432 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 61.1 t -134.0 102.65 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.729 2.012 . . . . 10.0 108.597 172.834 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -74.61 161.4 29.75 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.463 0.705 . . . . 10.0 111.4 172.547 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 58.4 p -67.99 154.41 41.68 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.363 0.665 . . . . 10.0 111.785 168.163 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -153.6 168.68 25.4 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.144 1.377 . . . . 10.0 111.03 177.799 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.8 -35.18 68.43 Favored 'General case' 0 CA--C 1.544 0.749 0 O-C-N 120.933 -1.105 . . . . 10.0 112.696 168.84 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 69.8 mt -82.83 -14.25 54.69 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.553 1.141 . . . . 10.0 113.916 173.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.4 m80 -136.16 69.91 1.42 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.954 1.701 . . . . 10.0 111.216 -173.427 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.53 143.02 51.77 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.786 1.235 . . . . 10.0 111.134 -177.671 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -136.85 103.58 5.22 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.649 1.98 . . . . 10.0 109.718 -174.695 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.45 158.99 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.823 1.249 . . . . 10.0 112.18 -175.389 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -134.5 111.42 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 125.31 1.444 . . . . 10.0 110.035 -178.614 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 58.6 m -66.53 145.83 55.19 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.904 0.882 . . . . 10.0 111.401 173.269 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.47 -17.52 59.71 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.526 1.53 . . . . 10.0 114.622 -176.237 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -75.36 -4.82 41.51 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.058 1.743 . . . . 10.0 114.108 173.621 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.82 47.38 3.68 Favored Glycine 0 CA--C 1.532 1.098 0 C-N-CA 125.134 1.35 . . . . 10.0 113.219 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.94 105.71 6.51 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.085 1.354 . . . . 10.0 110.224 -176.129 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -85.45 124.94 32.61 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.073 1.349 . . . . 10.0 111.447 174.751 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 38.0 m -109.0 142.94 38.95 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.398 1.479 . . . . 10.0 111.915 175.695 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -132.79 115.85 15.83 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.538 2.335 . . . . 10.0 108.887 -178.306 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 153.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.785 1.234 . . . . 10.0 111.44 -171.402 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -128.49 103.65 7.25 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.398 2.279 . . . . 10.0 109.05 164.663 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -65.34 -38.96 91.73 Favored 'General case' 0 N--CA 1.475 0.825 0 O-C-N 120.872 -1.143 . . . . 10.0 113.072 178.738 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.56 87.71 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.838 1.655 . . . . 10.0 110.245 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.58 137.39 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 O-C-N 121.241 -0.912 . . . . 10.0 111.928 -177.555 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -117.34 161.15 19.99 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.091 1.757 . . . . 10.0 112.094 176.57 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.91 -34.12 65.29 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -177.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.0 m -65.37 -16.6 63.77 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 125.515 1.526 . . . . 10.0 114.565 175.468 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -81.95 -5.33 58.21 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.695 1.198 . . . . 10.0 113.348 178.33 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.49 151.44 46.37 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.025 -1.047 . . . . 10.0 112.773 175.908 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.96 -171.89 21.59 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 124.97 1.271 . . . . 10.0 114.846 176.892 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.01 105.74 14.25 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.891 1.676 . . . . 10.0 111.252 176.518 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -80.6 152.7 28.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.206 1.002 . . . . 10.0 111.963 169.479 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.92 44.52 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.905 0.882 . . . . 10.0 111.933 166.231 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 51.3 t -130.66 143.61 50.86 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.666 1.987 . . . . 10.0 109.789 177.018 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 99.0 t -126.38 129.66 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 125.57 1.548 . . . . 10.0 109.673 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -123.58 118.81 28.18 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.404 1.881 . . . . 10.0 110.433 -178.529 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -131.95 138.23 48.24 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 125.373 1.469 . . . . 10.0 111.822 -173.467 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -134.14 -177.48 4.6 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.936 1.295 . . . . 10.0 111.358 168.174 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -60.91 -11.63 8.56 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 115.727 1.751 . . . . 10.0 115.727 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.49 -19.82 12.42 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 125.569 1.548 . . . . 10.0 114.503 -178.107 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.4 -168.92 41.99 Favored Glycine 0 CA--C 1.534 1.252 0 N-CA-C 116.371 1.308 . . . . 10.0 116.371 178.984 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -135.71 142.41 45.05 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.29 2.236 . . . . 10.0 111.683 -172.059 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.05 162.53 33.9 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.052 1.741 . . . . 10.0 111.309 169.011 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -141.4 146.09 36.14 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.023 1.329 . . . . 10.0 110.753 -172.511 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -133.45 154.22 50.97 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.349 1.46 . . . . 10.0 110.774 177.263 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.7 m -144.27 144.71 31.62 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.489 1.116 . . . . 10.0 111.615 -171.491 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.8 p -153.23 164.02 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 126.126 1.77 . . . . 10.0 110.698 172.414 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -125.17 138.71 54.14 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 124.79 1.236 . . . . 10.0 111.13 174.888 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -124.61 120.04 30.77 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.997 1.719 . . . . 10.0 111.068 -177.829 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -105.69 86.24 2.36 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.064 1.746 . . . . 10.0 110.723 176.694 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 23.8 t -67.47 109.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 123.992 0.917 . . . . 10.0 110.607 -179.581 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 66.1 mt -72.98 103.11 3.66 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 126.324 1.85 . . . . 10.0 109.853 178.798 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.48 140.26 56.38 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 113.887 1.069 . . . . 10.0 113.887 -172.069 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -101.05 -32.33 10.66 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 127.304 2.241 . . . . 10.0 111.755 173.563 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 . . . . . 0 C--O 1.254 1.313 0 C-N-CA 126.109 1.764 . . . . 10.0 113.38 174.174 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.547 0 N-CA-C 111.944 -0.462 . . . . 10.0 111.944 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.5 162.92 16.98 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.4 1.08 . . . . 10.0 112.933 175.881 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 24.2 ptt? -147.97 -179.16 6.7 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.897 1.679 . . . . 10.0 111.913 -178.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.79 169.27 41.64 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.83 1.492 . . . . 10.0 116.83 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -72.56 162.85 40.22 Favored 'Trans proline' 0 CA--C 1.544 1.007 0 C-N-CA 123.83 3.02 . . . . 10.0 113.077 -175.106 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.54 160.49 49.1 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 123.146 2.564 . . . . 10.0 112.083 171.013 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.27 168.96 23.69 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.266 1.426 . . . . 10.0 112.539 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -72.98 146.47 45.98 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.517 1.527 . . . . 10.0 111.988 173.269 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.2 mp -136.4 -64.08 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 125.699 1.6 . . . . 10.0 109.054 168.539 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -151.7 138.39 18.8 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.716 1.606 . . . . 10.0 110.521 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.6 m -133.37 151.99 78.5 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.773 1.629 . . . . 10.0 110.404 173.688 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.24 148.03 67.56 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 122.652 2.234 . . . . 10.0 112.348 175.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -74.53 176.5 6.79 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.489 1.115 . . . . 10.0 111.253 166.273 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -54.37 122.86 11.32 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.04 -1.037 . . . . 10.0 112.508 176.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.6 mtp -101.31 159.02 15.62 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.01 1.724 . . . . 10.0 111.872 -177.2 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 p -146.82 115.28 6.71 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.178 1.391 . . . . 10.0 111.259 177.708 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.0 mm -127.01 134.22 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.595 1.558 . . . . 10.0 110.166 -169.221 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -63.98 131.85 48.89 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.683 1.193 . . . . 10.0 112.666 176.202 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -52.74 121.54 7.4 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.758 1.623 . . . . 10.0 112.962 -178.941 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 103.81 -9.31 51.56 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 126.2 1.857 . . . . 10.0 115.106 177.829 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.8 mtp180 -72.05 159.51 34.07 Favored 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 119.173 1.486 . . . . 10.0 113.398 177.449 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -72.55 147.7 45.67 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.54 1.136 . . . . 10.0 110.412 156.513 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 15.0 t -149.49 162.82 39.39 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.329 1.052 . . . . 10.0 111.941 170.199 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.0 ptm85 -143.08 164.26 30.59 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.67 1.588 . . . . 10.0 112.107 165.541 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.0 mtt -126.11 159.97 31.42 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 126.802 2.041 . . . . 10.0 110.654 173.883 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -136.72 89.95 2.5 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.416 1.486 . . . . 10.0 111.025 -169.369 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -100.72 106.06 17.46 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.24 1.416 . . . . 10.0 111.029 -178.329 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -67.05 133.07 49.17 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 121.62 -0.675 . . . . 10.0 110.117 171.17 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.7 p -143.71 146.43 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 125.467 1.507 . . . . 10.0 111.392 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 93.6 p -128.6 -165.7 1.54 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.974 1.71 . . . . 10.0 112.733 -174.687 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 98.99 163.45 29.88 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 126.298 1.904 . . . . 10.0 112.813 -178.264 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -142.68 127.09 9.83 Favored Pre-proline 0 CA--C 1.546 0.797 0 C-N-CA 125.507 1.523 . . . . 10.0 109.555 177.781 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -66.26 169.16 46.24 Favored 'Cis proline' 0 CA--C 1.54 0.825 0 CA-C-N 120.312 1.147 . . . . 10.0 112.584 -4.193 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.96 70.01 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.386 1.075 . . . . 10.0 111.046 178.479 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.63 148.53 59.67 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 122.284 1.989 . . . . 10.0 113.834 -169.155 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -67.43 132.83 48.42 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.384 1.474 . . . . 10.0 109.561 158.43 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.1 m -124.0 138.64 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.514 1.126 . . . . 10.0 112.155 -173.276 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 48.1 m -135.25 154.08 51.7 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.975 1.71 . . . . 10.0 110.755 178.221 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -124.93 153.21 43.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.536 1.135 . . . . 10.0 113.389 -176.469 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.3 m-85 -145.1 160.29 41.64 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.088 2.155 . . . . 10.0 111.15 -172.372 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 58.3 tp -149.87 122.34 8.5 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 126.695 1.998 . . . . 10.0 110.332 178.171 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 54.98 6.97 0.14 Allowed 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 126.995 2.118 . . . . 10.0 116.595 174.864 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 121.21 -6.18 10.92 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.2 1.857 . . . . 10.0 115.725 -177.189 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.0 ptm180 -108.09 165.44 11.47 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 119.254 1.527 . . . . 10.0 112.227 171.637 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.8 p -72.47 158.1 36.37 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.861 1.264 . . . . 10.0 112.437 172.302 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 44.4 t -131.09 101.72 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 126.076 1.751 . . . . 10.0 108.372 171.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 11.5 mp0 -67.04 149.95 49.9 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.573 1.149 . . . . 10.0 111.295 176.818 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.4 p -65.54 138.98 58.42 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.45 0.7 . . . . 10.0 110.922 167.698 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -146.8 167.96 22.58 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.721 1.208 . . . . 10.0 111.819 -176.479 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -56.79 -35.07 68.29 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.162 -0.961 . . . . 10.0 113.105 171.023 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 70.4 mt -85.76 -15.17 42.96 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.996 1.11 . . . . 10.0 113.996 174.834 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.5 m80 -135.72 73.03 1.45 Allowed 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.975 1.71 . . . . 10.0 111.088 -174.35 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -73.02 143.66 47.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 125.144 1.377 . . . . 10.0 111.329 -178.173 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 58.8 mtt -142.44 105.25 4.54 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.864 1.666 . . . . 10.0 110.214 -172.338 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.92 144.77 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.161 0.984 . . . . 10.0 112.46 -178.667 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 48.0 t -95.16 100.52 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 125.154 1.382 . . . . 10.0 108.757 175.484 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 15.2 m -64.3 168.76 5.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.693 1.997 . . . . 10.0 112.741 176.307 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -62.01 165.45 5.54 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.541 1.136 . . . . 10.0 113.793 174.705 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 96.6 mttt 56.76 20.69 5.31 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 126.874 2.07 . . . . 10.0 115.794 173.129 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.42 53.83 2.98 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.816 1.198 . . . . 10.0 114.131 173.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 52.0 tp -137.16 146.56 45.11 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.726 1.61 . . . . 10.0 110.517 179.505 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -126.84 115.72 19.76 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.997 1.319 . . . . 10.0 111.359 -179.784 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.0 m -80.83 129.19 34.4 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.834 1.654 . . . . 10.0 111.819 172.366 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -128.35 119.43 25.04 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.088 2.155 . . . . 10.0 107.645 170.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 54.4 mt -119.68 154.06 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.808 1.243 . . . . 10.0 111.662 -164.464 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -131.57 108.65 9.69 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 127.848 2.459 . . . . 10.0 109.35 173.468 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -66.36 -43.21 86.65 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 120.985 -1.072 . . . . 10.0 113.031 177.432 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.71 89.12 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.791 1.637 . . . . 10.0 110.16 -177.685 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -70.09 139.48 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.353 -0.842 . . . . 10.0 112.26 -176.322 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -121.91 163.53 19.1 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.312 1.845 . . . . 10.0 112.045 175.408 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.06 -30.33 66.1 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.574 0.953 . . . . 10.0 113.574 -178.686 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.7 p -67.82 -16.9 64.32 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.657 1.583 . . . . 10.0 114.681 173.648 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -83.66 -5.63 59.23 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.633 1.173 . . . . 10.0 113.356 175.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.83 154.43 39.16 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.027 -1.046 . . . . 10.0 113.352 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.01 -169.72 21.99 Favored Glycine 0 CA--C 1.532 1.123 0 C-N-CA 124.67 1.128 . . . . 10.0 115.043 174.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.81 100.19 10.79 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.966 1.706 . . . . 10.0 111.392 177.626 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -75.11 151.57 38.6 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.214 1.006 . . . . 10.0 111.679 167.432 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.36 159.01 43.15 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.94 0.896 . . . . 10.0 112.157 168.71 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -130.69 144.47 51.46 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.545 1.938 . . . . 10.0 110.223 177.272 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.3 t -126.57 116.11 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 125.49 1.516 . . . . 10.0 109.347 179.229 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -106.3 126.58 52.41 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.452 1.901 . . . . 10.0 110.806 -178.255 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -132.47 127.58 35.58 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 126.439 1.896 . . . . 10.0 111.774 -168.058 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -134.33 177.73 7.53 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.864 0.757 . . . . 10.0 112.238 164.211 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 -62.47 -11.13 14.25 Favored 'General case' 0 N--CA 1.48 1.072 0 N-CA-C 115.536 1.68 . . . . 10.0 115.536 -178.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.49 -15.37 14.81 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.569 1.548 . . . . 10.0 114.088 178.138 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.18 -170.39 38.61 Favored Glycine 0 CA--C 1.536 1.369 0 CA-C-N 119.659 1.118 . . . . 10.0 115.423 176.365 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -134.06 149.59 51.15 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 126.059 1.744 . . . . 10.0 111.892 -172.775 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.42 162.73 33.71 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.237 1.815 . . . . 10.0 111.501 171.144 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 30.1 m -140.28 135.97 32.81 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.938 1.295 . . . . 10.0 110.758 -175.7 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -129.72 154.02 47.58 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.669 1.588 . . . . 10.0 110.976 -178.059 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -144.84 145.61 31.7 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.236 1.014 . . . . 10.0 112.017 -169.421 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.6 p -152.27 150.46 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 125.661 1.584 . . . . 10.0 111.696 170.46 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.3 tt0 -100.91 139.2 36.94 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.531 1.133 . . . . 10.0 111.004 171.655 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.9 tp -123.25 103.86 8.79 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.89 1.676 . . . . 10.0 110.566 175.898 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -90.73 82.9 5.71 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.63 1.572 . . . . 10.0 110.981 175.861 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.9 t -63.69 112.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.844 0.858 . . . . 10.0 110.621 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.7 mt -75.34 98.54 3.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.288 1.835 . . . . 10.0 110.184 -179.22 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.04 149.5 36.73 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 124.062 0.945 . . . . 10.0 112.72 179.351 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -80.84 -2.48 47.48 Favored 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.218 1.562 . . . . 10.0 115.218 -179.595 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 . . . . . 0 C--O 1.253 1.273 0 C-N-CA 126.826 2.05 . . . . 10.0 114.062 178.757 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo . . . . . 0 CA--C 1.542 0.914 0 N-CA-C 113.258 0.446 . . . . 10.0 113.258 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -66.96 152.08 80.99 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.859 2.373 . . . . 10.0 111.427 168.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 68.9 ttt180 -142.52 162.68 34.84 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 125.764 1.626 . . . . 10.0 111.542 -177.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -71.33 141.29 50.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.321 1.449 . . . . 10.0 112.224 173.259 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.1 mp -135.47 -66.14 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.544 1.538 . . . . 10.0 109.724 171.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 -149.56 140.3 22.67 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.34 1.456 . . . . 10.0 111.105 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 24.7 m -127.26 152.59 76.32 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 126.207 1.803 . . . . 10.0 110.287 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.3 156.91 50.49 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.87 2.38 . . . . 10.0 112.016 176.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.63 167.28 22.12 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.114 0.966 . . . . 10.0 112.67 172.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -60.2 106.9 0.57 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 124.839 1.256 . . . . 10.0 111.698 173.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 26.4 mtm -79.4 154.57 28.88 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 123.653 0.781 . . . . 10.0 112.467 -175.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.7 p -138.43 110.13 7.11 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 125.306 1.442 . . . . 10.0 110.539 170.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.8 mm -126.85 131.12 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.314 1.446 . . . . 10.0 110.391 -163.103 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -59.43 131.92 52.42 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.646 1.178 . . . . 10.0 112.558 173.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -51.97 129.83 28.05 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 125.159 1.384 . . . . 10.0 112.674 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.75 -8.91 76.37 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 125.497 1.522 . . . . 10.0 115.278 177.323 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -70.87 161.61 30.71 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 119.321 1.56 . . . . 10.0 113.051 175.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -73.47 138.48 45.14 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.55 1.14 . . . . 10.0 110.043 155.366 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.1 p -149.42 169.4 20.95 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.468 0.707 . . . . 10.0 112.348 164.219 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -147.45 155.56 42.04 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.855 1.262 . . . . 10.0 112.975 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -122.39 143.36 49.71 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 128.028 2.531 . . . . 10.0 108.925 173.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -139.5 114.56 9.57 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.187 0.995 . . . . 10.0 111.936 -170.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -115.85 113.79 23.84 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.222 2.209 . . . . 10.0 110.42 -173.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.3 mtpp -67.99 133.85 49.74 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.473 -0.767 . . . . 10.0 110.015 170.303 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -140.94 125.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.521 1.528 . . . . 10.0 111.139 -174.035 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 50.6 m -136.03 103.34 5.32 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.798 1.239 . . . . 10.0 111.467 -176.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -154.9 165.08 32.04 Favored Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.983 2.23 . . . . 10.0 110.662 169.141 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.6 tp -141.91 125.85 9.97 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.129 0.971 . . . . 10.0 110.847 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -65.43 167.16 49.53 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.63 1.261 . . . . 10.0 112.511 -2.622 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.09 121.84 44.01 Favored Pre-proline 0 CA--C 1.549 0.915 0 C-N-CA 124.483 1.113 . . . . 10.0 111.202 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.77 150.79 68.64 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.492 2.128 . . . . 10.0 113.076 -172.082 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -73.62 143.77 46.2 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.146 0.979 . . . . 10.0 109.666 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.61 136.23 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.796 0.839 . . . . 10.0 111.858 -174.447 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -126.99 157.71 38.81 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.897 1.679 . . . . 10.0 111.68 173.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 51.0 m95 -125.97 154.88 42.25 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 125.533 1.533 . . . . 10.0 113.666 -173.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -144.49 161.12 39.88 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.26 2.224 . . . . 10.0 111.96 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.1 tp -146.56 124.35 11.91 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.748 2.419 . . . . 10.0 109.69 173.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.01 14.28 0.68 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 126.775 2.03 . . . . 10.0 116.064 175.278 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.36 0.55 24.99 Favored Glycine 0 CA--C 1.539 1.552 0 C-N-CA 125.693 1.616 . . . . 10.0 116.043 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.0 ptp85 -123.93 163.19 21.82 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 125.679 1.592 . . . . 10.0 112.177 173.668 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.4 p -69.65 159.59 33.17 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.596 1.158 . . . . 10.0 113.616 -175.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 92.7 t -134.92 108.1 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 126.93 2.092 . . . . 10.0 108.939 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -77.01 159.66 29.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 123.724 0.81 . . . . 10.0 111.365 170.648 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 81.3 p -76.91 155.48 32.77 Favored 'General case' 0 N--CA 1.473 0.683 0 O-C-N 121.645 -0.659 . . . . 10.0 112.144 168.058 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -155.71 -176.39 5.93 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.578 1.551 . . . . 10.0 111.576 168.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -62.08 -18.18 59.92 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -177.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 68.7 mt -107.37 -26.67 10.88 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.845 1.658 . . . . 10.0 112.266 175.367 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -108.74 68.78 0.69 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.828 2.051 . . . . 10.0 110.711 177.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -74.25 146.09 43.55 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.346 1.058 . . . . 10.0 111.839 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 65.7 mtt -138.89 114.69 9.99 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.533 1.933 . . . . 10.0 110.184 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.55 155.82 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.928 1.291 . . . . 10.0 111.776 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.1 p -141.21 122.02 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.595 1.158 . . . . 10.0 111.238 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 38.7 t -74.87 141.8 44.17 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.485 1.114 . . . . 10.0 111.65 175.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.78 -17.68 37.39 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.769 1.228 . . . . 10.0 113.688 170.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -76.47 -4.2 41.32 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.936 1.694 . . . . 10.0 113.917 174.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.68 39.43 4.15 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.979 1.275 . . . . 10.0 114.867 172.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.2 tp -136.55 114.78 11.61 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 125.109 1.364 . . . . 10.0 111.122 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 5.1 t60 -98.35 132.88 43.46 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.21 1.404 . . . . 10.0 110.994 174.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 37.9 m -121.89 138.07 54.54 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.558 1.543 . . . . 10.0 111.487 -178.018 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -128.06 117.84 22.38 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 127.713 2.405 . . . . 10.0 107.85 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 85.3 mt -118.63 148.45 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.471 1.108 . . . . 10.0 111.064 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -123.07 106.31 10.69 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 127.355 2.262 . . . . 10.0 109.014 171.057 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -63.59 -38.3 90.61 Favored 'General case' 0 N--CA 1.475 0.781 0 O-C-N 121.296 -0.878 . . . . 10.0 113.09 176.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.2 p -150.76 90.1 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.889 1.676 . . . . 10.0 110.248 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -68.48 144.75 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 O-C-N 121.27 -0.894 . . . . 10.0 112.101 -178.545 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -129.21 162.17 28.45 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.03 1.732 . . . . 10.0 112.005 174.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.54 -34.38 64.65 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 113.642 0.979 . . . . 10.0 113.642 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.1 m -64.87 -17.15 64.03 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.387 1.475 . . . . 10.0 114.509 175.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -81.7 -8.28 59.68 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.513 1.125 . . . . 10.0 113.328 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.72 150.64 43.99 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 119.219 0.918 . . . . 10.0 112.933 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.9 -172.2 22.71 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.563 1.078 . . . . 10.0 114.789 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.87 101.95 13.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.963 1.705 . . . . 10.0 111.209 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -76.15 150.85 37.11 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.225 1.01 . . . . 10.0 111.501 167.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.5 161.97 38.49 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.906 0.883 . . . . 10.0 111.545 169.587 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 30.8 p -144.88 161.87 38.25 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.186 0.994 . . . . 10.0 112.044 171.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.98 131.25 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.273 1.429 . . . . 10.0 110.072 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.47 126.8 54.77 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.651 1.98 . . . . 10.0 110.044 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -133.93 129.06 35.75 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.644 1.577 . . . . 10.0 112.012 -169.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.5 p30 -132.21 -179.46 5.44 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.448 1.099 . . . . 10.0 111.832 166.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -60.51 -14.68 21.07 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.657 1.725 . . . . 10.0 115.657 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.84 -16.38 14.48 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.288 1.435 . . . . 10.0 114.276 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.93 -170.17 40.55 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 115.876 1.11 . . . . 10.0 115.876 177.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -134.68 146.72 49.75 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.852 2.061 . . . . 10.0 111.7 -172.224 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.81 153.11 49.68 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.753 1.621 . . . . 10.0 110.982 169.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 25.2 m -137.55 136.78 37.93 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.832 1.253 . . . . 10.0 110.552 -172.164 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -134.89 153.72 51.95 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.964 1.306 . . . . 10.0 111.524 -173.51 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.0 m -142.33 144.5 33.24 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 125.251 1.42 . . . . 10.0 111.456 -173.031 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.9 p -151.8 156.72 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 C-N-CA 125.695 1.598 . . . . 10.0 111.271 170.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -107.89 148.89 29.0 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 124.349 1.06 . . . . 10.0 111.746 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.29 114.96 18.29 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.469 1.907 . . . . 10.0 110.222 174.37 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -103.46 84.74 2.35 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.719 1.608 . . . . 10.0 110.685 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.8 t -67.23 110.96 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.708 0.803 . . . . 10.0 110.871 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 75.7 mt -75.95 101.03 5.05 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.731 2.012 . . . . 10.0 110.567 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.872 0 C-N-CA 124.058 0.943 . . . . 10.0 112.87 175.655 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo . . . . . 0 CA--C 1.543 0.949 0 N-CA-C 113.29 0.458 . . . . 10.0 113.29 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -67.33 148.31 79.59 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.825 2.35 . . . . 10.0 111.435 173.477 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 32.7 ttp-105 -138.09 136.9 37.22 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.855 1.262 . . . . 10.0 113.208 -173.451 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -63.58 117.26 6.54 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 127.274 2.23 . . . . 10.0 110.997 170.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 35.8 mm -108.35 -54.26 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.735 0.814 . . . . 10.0 110.328 171.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -153.18 142.68 21.76 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.412 1.085 . . . . 10.0 111.433 172.252 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.53 148.48 53.06 Favored Pre-proline 0 N--CA 1.476 0.862 0 C-N-CA 125.247 1.419 . . . . 10.0 110.073 169.001 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -77.13 163.69 30.29 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.965 2.443 . . . . 10.0 112.117 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -73.1 166.74 22.54 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.593 0.757 . . . . 10.0 111.43 166.312 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -62.44 160.9 12.64 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.364 -0.835 . . . . 10.0 112.081 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 51.0 mtm -133.49 161.25 35.1 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.181 0.992 . . . . 10.0 112.939 -178.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 55.2 p -137.88 115.64 11.43 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 125.907 1.683 . . . . 10.0 109.854 168.034 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.6 mm -124.51 132.9 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.306 1.442 . . . . 10.0 110.05 -166.46 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -59.56 126.51 27.91 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.402 1.481 . . . . 10.0 112.475 173.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -50.23 126.75 15.5 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.599 1.56 . . . . 10.0 112.679 176.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.99 -11.75 58.91 Favored Glycine 0 CA--C 1.537 1.468 0 C-N-CA 126.182 1.849 . . . . 10.0 115.088 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -75.53 162.39 28.34 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 119.2 1.5 . . . . 10.0 113.418 177.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -76.69 143.3 40.13 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.076 1.351 . . . . 10.0 110.328 157.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 28.6 p -150.82 168.97 22.83 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.608 0.763 . . . . 10.0 112.621 162.525 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.8 ptm85 -144.12 168.93 18.86 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.426 1.49 . . . . 10.0 112.966 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.7 mtt -131.81 158.82 40.27 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.974 2.11 . . . . 10.0 110.867 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -136.15 92.61 2.81 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.144 1.378 . . . . 10.0 112.139 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -108.41 104.02 13.29 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.456 1.502 . . . . 10.0 111.319 -176.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.1 mtpp -81.7 122.98 28.33 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 121.077 -1.014 . . . . 10.0 110.322 173.553 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.43 151.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.803 2.041 . . . . 10.0 110.633 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.9 t -131.1 175.7 8.88 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.18 1.392 . . . . 10.0 111.419 172.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 136.7 167.53 11.17 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 127.418 2.437 . . . . 10.0 112.445 -175.48 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.33 119.79 5.16 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 123.878 0.871 . . . . 10.0 111.707 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.8 169.44 59.05 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 CA-C-N 120.459 1.2 . . . . 10.0 112.473 -1.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.85 127.79 75.31 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.059 0.943 . . . . 10.0 110.838 175.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.69 148.32 65.28 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 122.298 1.999 . . . . 10.0 113.062 -172.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -71.01 142.02 50.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.353 1.061 . . . . 10.0 109.583 160.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 10.8 m -127.02 137.67 57.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 124.618 1.167 . . . . 10.0 112.583 -170.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.1 m -137.57 112.55 9.05 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.109 1.764 . . . . 10.0 110.758 -174.281 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -85.87 152.76 22.73 Favored 'General case' 0 CA--C 1.536 0.417 0 N-CA-C 113.475 0.917 . . . . 10.0 113.475 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.41 158.89 43.21 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.386 2.274 . . . . 10.0 111.129 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.15 117.78 8.62 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 127.153 2.181 . . . . 10.0 110.109 177.045 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 55.14 10.98 0.47 Allowed 'General case' 0 CA--C 1.555 1.172 0 C-N-CA 126.747 2.019 . . . . 10.0 115.573 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.27 -15.63 17.97 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 126.832 2.158 . . . . 10.0 115.047 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -84.09 157.45 21.74 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 118.988 1.394 . . . . 10.0 111.088 169.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.9 p -71.71 157.91 37.09 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.281 1.033 . . . . 10.0 112.137 170.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.8 105.77 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 126.303 1.841 . . . . 10.0 108.676 173.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 23.0 mm100 -76.26 159.83 30.23 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.218 0.607 . . . . 10.0 111.495 173.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 36.7 p -67.06 150.8 48.7 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.692 0.797 . . . . 10.0 111.928 169.489 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -150.76 166.01 31.77 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.179 1.392 . . . . 10.0 111.128 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -54.86 -36.56 65.21 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.147 -0.97 . . . . 10.0 113.1 170.186 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.0 mt -84.22 -13.77 51.79 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.434 1.094 . . . . 10.0 113.863 174.154 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -135.04 70.95 1.43 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.93 1.692 . . . . 10.0 111.322 -173.7 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.08 143.12 49.17 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.049 1.339 . . . . 10.0 111.73 -175.258 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -139.6 101.99 4.35 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.644 1.978 . . . . 10.0 110.055 -174.353 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.14 162.73 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.254 1.422 . . . . 10.0 111.557 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.86 118.15 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.899 1.279 . . . . 10.0 110.994 177.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 63.3 m -68.56 158.44 33.91 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.328 1.051 . . . . 10.0 112.218 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -61.24 -21.26 63.71 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 114.243 1.201 . . . . 10.0 114.243 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.1 mptt -77.06 -5.4 48.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.299 1.84 . . . . 10.0 113.865 173.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.05 3.43 65.59 Favored Glycine 0 CA--C 1.536 1.394 0 C-N-CA 125.6 1.572 . . . . 10.0 115.181 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.8 tp -77.44 101.81 6.58 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 118.686 1.243 . . . . 10.0 111.318 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -78.96 113.55 17.16 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.185 1.394 . . . . 10.0 110.925 170.045 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 75.0 m -84.98 139.44 31.79 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 125.524 1.53 . . . . 10.0 111.986 171.326 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -131.92 121.24 23.68 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 126.704 2.002 . . . . 10.0 107.688 168.229 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 61.0 mt -122.18 152.57 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.855 1.262 . . . . 10.0 111.357 -166.009 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -129.4 109.85 11.42 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 127.519 2.328 . . . . 10.0 109.142 170.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -66.15 -40.22 90.4 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.359 -0.838 . . . . 10.0 113.168 176.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -149.96 88.92 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.838 1.655 . . . . 10.0 110.104 -178.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -68.53 140.29 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 O-C-N 121.378 -0.826 . . . . 10.0 112.045 -176.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -124.78 160.64 28.21 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.463 1.905 . . . . 10.0 111.841 177.258 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.14 -34.32 63.66 Favored 'General case' 0 CA--C 1.547 0.828 0 N-CA-C 113.509 0.929 . . . . 10.0 113.509 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.4 m -65.05 -17.46 64.47 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.499 1.52 . . . . 10.0 114.62 175.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -80.99 -6.53 58.88 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.446 1.098 . . . . 10.0 113.324 177.262 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.88 148.44 51.4 Favored 'General case' 0 CA--C 1.547 0.843 0 O-C-N 121.017 -1.052 . . . . 10.0 112.77 177.469 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 139.75 -174.75 22.19 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.844 1.211 . . . . 10.0 114.815 177.15 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.81 108.68 17.6 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.971 1.708 . . . . 10.0 110.932 175.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.5 m-85 -86.12 151.96 23.25 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.208 1.003 . . . . 10.0 111.869 172.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.97 160.68 39.88 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.933 0.893 . . . . 10.0 112.006 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.0 t -137.57 107.47 6.3 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.753 1.621 . . . . 10.0 110.586 177.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.5 t -76.05 132.9 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.294 1.037 . . . . 10.0 108.937 169.22 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -128.3 121.79 30.08 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 126.372 1.869 . . . . 10.0 110.494 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -134.4 139.45 45.59 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.941 1.297 . . . . 10.0 112.604 -171.758 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.3 p30 -133.74 -178.31 4.95 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.609 1.164 . . . . 10.0 111.259 165.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -61.9 -7.79 4.2 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 115.667 1.729 . . . . 10.0 115.667 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -117.7 -12.7 10.24 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 126.135 1.774 . . . . 10.0 114.578 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.01 -172.66 44.48 Favored Glycine 0 CA--C 1.535 1.308 0 CA-C-N 119.776 1.171 . . . . 10.0 115.924 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -137.8 144.23 41.44 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.992 2.117 . . . . 10.0 111.625 -174.368 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.64 162.96 33.3 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.594 1.957 . . . . 10.0 110.626 168.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -141.99 124.5 15.77 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.389 1.076 . . . . 10.0 110.736 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -105.14 154.39 20.25 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.33 1.452 . . . . 10.0 110.898 178.017 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.7 m -144.03 145.12 31.98 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 124.271 1.028 . . . . 10.0 112.035 -170.579 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.8 p -154.11 171.64 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 C-N-CA 126.595 1.958 . . . . 10.0 110.976 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -131.92 147.88 52.49 Favored 'General case' 0 N--CA 1.471 0.614 0 O-C-N 120.77 -1.206 . . . . 10.0 111.622 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.7 tp -131.14 117.04 18.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 126.283 1.833 . . . . 10.0 110.2 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -106.4 77.68 1.23 Allowed 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.681 1.592 . . . . 10.0 110.481 178.248 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -58.37 114.31 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.414 1.086 . . . . 10.0 111.014 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.5 mt -76.25 99.58 4.8 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.477 1.911 . . . . 10.0 109.831 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.838 0 C-N-CA 123.975 0.91 . . . . 10.0 113.117 -177.656 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo . . . . . 0 CA--C 1.543 0.944 0 N-CA-C 113.027 0.357 . . . . 10.0 113.027 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -68.24 143.19 57.9 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.133 2.555 . . . . 10.0 111.497 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -131.24 149.45 52.57 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.96 1.304 . . . . 10.0 113.757 -174.675 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -77.76 111.13 13.24 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.019 2.527 . . . . 10.0 110.939 176.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.5 mm -109.34 -44.66 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.772 0.829 . . . . 10.0 111.104 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -149.51 142.18 24.53 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.708 1.203 . . . . 10.0 111.494 170.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -122.91 135.69 26.08 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 124.873 1.269 . . . . 10.0 109.278 158.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -75.47 159.88 39.18 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.003 2.468 . . . . 10.0 112.206 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -67.44 164.84 17.86 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.92 1.288 . . . . 10.0 112.111 171.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -62.49 113.77 3.15 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.216 -0.928 . . . . 10.0 111.332 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 29.0 mtm -76.22 148.87 37.37 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.736 -0.603 . . . . 10.0 111.69 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 24.0 p -128.08 102.76 6.87 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 125.705 1.602 . . . . 10.0 110.468 176.122 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.7 mm -121.8 123.61 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.931 1.293 . . . . 10.0 110.63 -163.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -58.86 126.23 26.83 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.134 1.374 . . . . 10.0 111.893 170.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -53.22 136.37 36.58 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.126 1.371 . . . . 10.0 113.468 -176.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 94.93 -10.92 70.09 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 125.97 1.747 . . . . 10.0 114.808 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 73.8 mtp180 -72.5 158.92 34.81 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 118.877 1.339 . . . . 10.0 113.479 177.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -75.31 141.04 43.45 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.373 1.069 . . . . 10.0 110.265 154.212 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 32.0 p -150.76 170.87 18.18 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.583 0.753 . . . . 10.0 112.269 160.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -145.83 144.06 30.02 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.195 1.398 . . . . 10.0 111.74 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.7 mtt -91.75 159.33 15.88 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.084 1.354 . . . . 10.0 110.665 169.028 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -138.15 109.83 7.09 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.231 1.412 . . . . 10.0 112.557 -177.313 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -116.56 98.47 6.56 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.646 1.978 . . . . 10.0 110.383 -176.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 29.5 mtpp -67.87 137.88 55.62 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.148 -0.97 . . . . 10.0 110.196 171.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.28 152.83 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.486 1.514 . . . . 10.0 111.27 -172.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -136.5 174.87 10.14 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.28 1.432 . . . . 10.0 111.164 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 121.07 164.34 12.31 Favored Glycine 0 CA--C 1.538 1.478 0 C-N-CA 127.288 2.375 . . . . 10.0 112.878 -174.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.0 tp -153.04 135.04 8.87 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.752 1.221 . . . . 10.0 110.978 -179.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -68.38 172.11 44.74 Favored 'Cis proline' 0 CA--C 1.54 0.794 0 CA-C-N 120.815 1.327 . . . . 10.0 112.722 -4.42 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.69 122.58 52.33 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.777 1.231 . . . . 10.0 111.777 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -72.17 155.43 56.54 Favored 'Trans proline' 0 CA--C 1.538 0.713 0 C-N-CA 122.618 2.212 . . . . 10.0 113.542 -172.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -79.13 74.41 5.69 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.316 1.846 . . . . 10.0 111.517 177.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 15.3 m -56.69 122.46 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 125.526 1.53 . . . . 10.0 113.194 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 66.3 m -133.69 111.56 10.68 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 126.334 1.853 . . . . 10.0 111.145 -172.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.4 m95 -87.59 149.77 24.11 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 114.43 1.271 . . . . 10.0 114.43 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -141.6 160.43 40.17 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.606 2.363 . . . . 10.0 111.463 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.4 tp -148.19 123.5 10.26 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 127.733 2.413 . . . . 10.0 109.989 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 53.58 16.03 0.87 Allowed 'General case' 0 CA--C 1.556 1.196 0 C-N-CA 126.498 1.919 . . . . 10.0 115.844 175.273 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.25 0.04 33.22 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.679 1.609 . . . . 10.0 115.824 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -117.11 162.4 17.89 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 126.031 1.732 . . . . 10.0 111.376 173.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.1 p -69.28 158.69 34.52 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.499 1.119 . . . . 10.0 113.017 178.419 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 43.6 t -130.82 106.91 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 126.011 1.724 . . . . 10.0 108.607 170.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -72.92 153.25 41.06 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.48 0.712 . . . . 10.0 111.377 172.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 32.2 p -68.25 150.29 48.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.615 0.766 . . . . 10.0 112.026 171.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -151.89 169.65 21.76 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.148 1.379 . . . . 10.0 110.798 175.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -62.52 -31.55 72.34 Favored 'General case' 0 N--CA 1.471 0.625 0 O-C-N 120.464 -1.398 . . . . 10.0 112.549 169.328 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 97.8 mt -73.99 -22.31 59.65 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.012 0.925 . . . . 10.0 113.468 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -136.75 67.91 1.44 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.152 1.781 . . . . 10.0 111.108 -171.498 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 63.8 mttm -69.78 142.73 53.15 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.183 0.993 . . . . 10.0 111.336 -177.253 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -135.51 102.9 5.27 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 126.724 2.01 . . . . 10.0 109.423 -173.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.55 155.71 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 124.165 0.986 . . . . 10.0 112.546 -173.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.66 165.51 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 126.484 1.914 . . . . 10.0 111.188 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 39.0 t -137.72 146.83 44.2 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.797 1.239 . . . . 10.0 112.642 -178.331 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -56.98 -20.47 24.06 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.244 1.818 . . . . 10.0 113.837 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -74.71 -1.51 22.23 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.745 1.618 . . . . 10.0 114.014 176.22 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.2 48.01 5.27 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.072 1.32 . . . . 10.0 112.987 178.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.0 tp -140.28 146.96 39.24 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.475 1.51 . . . . 10.0 111.625 -175.299 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -129.43 132.86 47.08 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.085 2.154 . . . . 10.0 109.678 170.131 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 67.6 m -119.28 149.2 42.17 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.844 1.258 . . . . 10.0 112.319 178.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -136.21 110.19 8.24 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.045 2.138 . . . . 10.0 108.478 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -95.18 153.34 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.641 1.576 . . . . 10.0 111.151 -171.076 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -129.54 107.64 9.63 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.92 2.088 . . . . 10.0 108.761 161.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -63.75 -43.25 96.99 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 121.447 -0.783 . . . . 10.0 113.077 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 2.8 p -150.08 87.08 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 126.156 1.782 . . . . 10.0 109.333 -178.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.8 p -66.99 141.13 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 O-C-N 121.525 -0.734 . . . . 10.0 111.8 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -127.07 160.12 32.13 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 126.429 1.892 . . . . 10.0 111.046 177.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.24 -33.79 59.23 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.009 1.114 . . . . 10.0 114.009 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.41 -17.77 64.09 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.287 1.435 . . . . 10.0 114.547 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -81.4 -8.17 59.69 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.656 1.182 . . . . 10.0 113.413 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -62.97 146.28 53.46 Favored 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.136 -0.977 . . . . 10.0 112.622 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.64 -175.37 23.64 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.024 0.821 . . . . 10.0 114.936 178.39 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.71 105.5 16.99 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 126.196 1.798 . . . . 10.0 111.257 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -84.94 150.76 24.72 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.714 1.206 . . . . 10.0 111.932 173.224 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.64 160.74 40.67 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 123.865 0.866 . . . . 10.0 112.249 170.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 47.3 t -138.21 109.12 6.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.58 1.552 . . . . 10.0 110.753 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 93.9 t -76.98 134.86 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.638 1.175 . . . . 10.0 109.146 169.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -132.37 114.5 14.44 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.245 1.818 . . . . 10.0 110.13 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.6 mtpp -129.8 136.61 49.79 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.409 1.484 . . . . 10.0 111.722 -174.475 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 28.3 p30 -133.26 -179.41 5.49 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.893 1.277 . . . . 10.0 111.371 168.295 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -62.2 -9.93 9.17 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 115.662 1.726 . . . . 10.0 115.662 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.72 -16.12 13.27 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.744 1.618 . . . . 10.0 114.471 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.29 -168.06 40.96 Favored Glycine 0 CA--C 1.536 1.36 0 CA-C-N 119.992 1.269 . . . . 10.0 116.241 176.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -136.24 143.93 44.58 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.995 2.118 . . . . 10.0 112.21 -171.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.25 160.19 40.51 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.774 2.03 . . . . 10.0 110.476 166.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 53.1 m -144.2 116.16 8.33 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.445 1.098 . . . . 10.0 110.61 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -98.0 151.07 20.69 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.16 1.384 . . . . 10.0 110.979 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.5 m -142.32 146.3 34.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 124.613 1.165 . . . . 10.0 111.819 -174.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -153.06 174.58 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 126.721 2.008 . . . . 10.0 110.916 173.306 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -130.47 150.58 51.62 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.176 1.39 . . . . 10.0 111.118 173.047 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.5 tp -125.16 108.36 11.7 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 110.846 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -90.4 81.07 6.03 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.258 1.823 . . . . 10.0 110.473 176.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.9 t -68.44 109.5 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 121.119 -0.988 . . . . 10.0 110.472 177.405 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.7 mt -77.55 97.64 5.11 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.774 1.63 . . . . 10.0 109.548 177.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.867 0 C-N-CA 124.592 1.157 . . . . 10.0 113.957 -172.728 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 CA--C 1.542 0.918 0 N-CA-C 113.116 0.391 . . . . 10.0 113.116 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.76 161.71 44.28 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.934 2.423 . . . . 10.0 111.072 166.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.86 166.47 24.37 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.471 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -85.93 71.95 10.55 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.355 1.862 . . . . 10.0 111.543 -173.497 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 253' ' ' ILE . . . . . 0.499 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.5 OUTLIER -73.55 179.78 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 125.031 1.333 . . . . 10.0 111.137 176.889 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.499 ' H ' HG22 ' A' ' 253' ' ' ILE . 35.3 tt0 -50.06 140.02 13.2 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.152 2.181 . . . . 10.0 114.336 -175.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.4 m -127.12 152.11 75.36 Favored Pre-proline 0 N--CA 1.477 0.915 0 C-N-CA 126.696 1.998 . . . . 10.0 110.982 172.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -77.2 159.22 33.46 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.249 2.632 . . . . 10.0 112.429 174.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -69.47 172.39 7.31 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.19 1.396 . . . . 10.0 112.263 169.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -55.65 111.74 0.98 Allowed 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 124.578 1.151 . . . . 10.0 112.854 173.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.7 mtp -82.58 155.63 24.36 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.769 1.628 . . . . 10.0 112.121 -177.327 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -147.22 109.38 4.49 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.249 1.419 . . . . 10.0 111.062 175.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.2 mm -123.01 133.37 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.248 1.419 . . . . 10.0 110.464 -168.322 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.74 130.98 47.36 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.096 1.359 . . . . 10.0 112.562 174.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -52.78 133.63 37.01 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.254 1.421 . . . . 10.0 112.862 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 93.22 -9.84 74.22 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.784 1.659 . . . . 10.0 115.276 177.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.1 mtp-105 -75.79 161.15 29.27 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 119.179 1.489 . . . . 10.0 113.018 176.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -72.46 147.33 46.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.442 1.097 . . . . 10.0 110.605 157.569 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 9.0 t -149.67 164.8 34.21 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.569 1.148 . . . . 10.0 111.582 165.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.7 ptm180 -149.54 155.41 40.29 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.645 1.578 . . . . 10.0 111.62 163.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 40.6 mtt -102.43 166.85 10.31 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.614 1.566 . . . . 10.0 112.071 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -132.73 110.9 10.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.331 1.852 . . . . 10.0 111.099 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -127.31 101.74 6.61 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 125.322 1.449 . . . . 10.0 111.172 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -60.36 142.76 54.41 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.513 -0.742 . . . . 10.0 110.296 172.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.0 p -148.98 146.3 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 124.597 1.159 . . . . 10.0 111.753 -175.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 51.8 m -139.19 178.59 7.07 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 126.341 1.856 . . . . 10.0 111.454 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 112.64 161.27 15.22 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 126.349 1.928 . . . . 10.0 113.092 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.15 129.93 7.43 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 125.145 1.378 . . . . 10.0 110.638 -179.012 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -66.39 168.86 48.14 Favored 'Cis proline' 0 CA--C 1.54 0.798 0 CA-C-N 120.806 1.324 . . . . 10.0 112.546 -2.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.63 120.62 33.43 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 124.673 1.189 . . . . 10.0 111.658 -177.339 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.0 159.5 52.3 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.597 2.198 . . . . 10.0 113.265 -174.241 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -68.7 169.41 11.28 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.336 1.454 . . . . 10.0 111.923 171.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 87.1 t -131.95 112.99 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.302 1.841 . . . . 10.0 110.165 -176.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 70.8 m -131.54 100.3 5.09 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.238 1.415 . . . . 10.0 110.91 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -84.02 154.64 23.15 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 122.035 0.921 . . . . 10.0 113.29 176.485 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -142.53 160.35 40.45 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.749 2.419 . . . . 10.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -148.83 124.06 10.18 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.104 2.161 . . . . 10.0 109.98 176.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.54 10.99 0.38 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 126.996 2.118 . . . . 10.0 116.378 174.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.51 -0.96 22.02 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.847 1.689 . . . . 10.0 115.852 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -117.36 163.99 15.52 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.795 1.638 . . . . 10.0 111.929 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.0 p -71.63 160.31 32.89 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.626 1.17 . . . . 10.0 112.948 178.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 64.5 t -136.24 111.29 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 126.632 1.973 . . . . 10.0 108.903 173.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -85.02 159.18 20.28 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.831 0.853 . . . . 10.0 111.199 170.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.9 p -69.61 151.06 46.38 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.725 0.81 . . . . 10.0 112.426 171.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -151.36 179.27 8.47 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.492 1.517 . . . . 10.0 110.79 166.071 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -56.71 -30.74 63.79 Favored 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 114.327 1.232 . . . . 10.0 114.327 -177.265 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 55.7 mt -87.63 -13.31 43.06 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.912 1.285 . . . . 10.0 113.514 175.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -135.64 68.12 1.46 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.158 1.783 . . . . 10.0 111.226 -172.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -67.86 145.13 54.92 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.089 1.356 . . . . 10.0 111.167 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.2 mtt -135.21 102.68 5.26 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 126.774 2.029 . . . . 10.0 109.726 -175.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.97 158.54 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.822 1.249 . . . . 10.0 112.212 -175.61 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 38.7 t -133.64 113.97 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 125.778 1.631 . . . . 10.0 109.73 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 46.6 t -64.89 141.15 58.87 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.917 0.887 . . . . 10.0 111.518 172.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -57.76 -19.48 28.18 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.72 1.208 . . . . 10.0 113.946 173.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.5 -3.45 40.59 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.454 1.502 . . . . 10.0 113.697 176.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.66 43.05 4.32 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.293 1.425 . . . . 10.0 113.883 176.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 61.9 tp -137.13 107.03 6.26 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.077 1.351 . . . . 10.0 111.578 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -80.43 138.61 36.63 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 125.379 1.471 . . . . 10.0 111.227 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 60.6 m -122.19 146.51 47.18 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 125.917 1.687 . . . . 10.0 111.807 174.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -134.13 112.54 11.22 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.214 2.206 . . . . 10.0 108.211 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -94.13 154.69 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.399 1.48 . . . . 10.0 111.55 -170.358 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -131.96 99.05 4.62 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.381 2.272 . . . . 10.0 108.96 163.184 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -62.11 -39.23 91.82 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 120.943 -1.098 . . . . 10.0 113.125 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.6 p -150.52 90.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.998 1.719 . . . . 10.0 109.839 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.1 p -68.54 140.23 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 121.39 -0.819 . . . . 10.0 112.148 -175.285 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 27.2 mmt180 -126.13 162.09 26.16 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.463 1.905 . . . . 10.0 111.834 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.98 -33.4 64.78 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.431 0.9 . . . . 10.0 113.431 -177.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 m -64.11 -18.01 64.0 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.386 1.474 . . . . 10.0 114.472 175.231 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -83.33 -5.99 59.32 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.609 1.164 . . . . 10.0 113.32 177.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.06 152.29 44.99 Favored 'General case' 0 CA--C 1.547 0.852 0 O-C-N 121.039 -1.038 . . . . 10.0 113.191 179.156 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 137.08 -173.32 22.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 124.689 1.138 . . . . 10.0 115.161 175.494 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.08 102.05 13.5 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.143 1.777 . . . . 10.0 111.234 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -80.91 153.6 27.48 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.624 1.17 . . . . 10.0 112.169 170.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.21 162.7 36.5 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.238 1.015 . . . . 10.0 111.795 166.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.3 t -139.64 125.52 19.65 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 125.446 1.499 . . . . 10.0 110.827 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 96.2 t -97.63 134.82 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 125.436 1.495 . . . . 10.0 109.7 174.415 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.19 117.33 22.13 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.224 1.809 . . . . 10.0 110.794 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -132.96 140.35 47.76 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.197 1.399 . . . . 10.0 112.196 -172.551 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.4 p30 -135.04 -177.83 4.81 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.234 1.414 . . . . 10.0 111.209 166.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -62.23 -13.26 26.03 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 115.624 1.713 . . . . 10.0 115.624 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -104.15 -22.54 13.39 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.33 1.452 . . . . 10.0 114.183 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.79 -166.24 39.44 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 116.098 1.199 . . . . 10.0 116.098 179.378 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.91 146.13 47.02 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.93 2.092 . . . . 10.0 112.098 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.71 167.0 23.21 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.553 1.941 . . . . 10.0 111.037 166.483 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 10.8 m -145.2 148.68 33.81 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.338 1.055 . . . . 10.0 111.071 -177.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -132.17 151.15 51.95 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.039 1.736 . . . . 10.0 110.647 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.3 m -143.45 145.98 33.05 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 125.034 1.334 . . . . 10.0 111.642 -174.275 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.9 p -154.2 156.42 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 126.016 1.727 . . . . 10.0 110.99 170.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -110.91 141.42 44.34 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.353 1.061 . . . . 10.0 110.485 169.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.4 tp -124.14 106.8 10.62 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.07 1.748 . . . . 10.0 110.321 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -94.54 83.22 4.08 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.435 1.494 . . . . 10.0 110.824 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.0 t -64.05 113.56 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 O-C-N 121.372 -0.83 . . . . 10.0 110.704 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.45 97.49 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.1 1.76 . . . . 10.0 110.073 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.83 0 C-N-CA 124.384 1.074 . . . . 10.0 113.429 -177.405 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_endo . . . . . 0 CA--C 1.544 1.001 0 N-CA-C 113.549 0.557 . . . . 10.0 113.549 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -70.53 148.0 59.1 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.204 2.603 . . . . 10.0 112.054 173.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -136.46 158.59 44.07 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 125.576 1.551 . . . . 10.0 112.758 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -84.41 79.41 9.57 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.293 2.237 . . . . 10.0 112.261 -174.452 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 44.4 mm -73.41 -55.31 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.529 -0.732 . . . . 10.0 111.21 178.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.22 129.52 10.53 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.5 1.12 . . . . 10.0 111.705 176.319 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.1 m -104.09 148.17 35.48 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 124.669 1.188 . . . . 10.0 110.196 158.286 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.32 162.4 36.36 Favored 'Trans proline' 0 CA--C 1.542 0.882 0 C-N-CA 122.99 2.46 . . . . 10.0 111.155 171.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -73.66 168.29 19.65 Favored 'General case' 0 CA--C 1.545 0.783 0 O-C-N 121.389 -0.82 . . . . 10.0 111.655 169.411 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.5 p30 -61.79 160.22 12.28 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.422 -0.799 . . . . 10.0 112.405 172.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.2 mtm -132.56 160.4 36.66 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.079 0.952 . . . . 10.0 113.073 -178.215 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 p -136.07 103.14 5.24 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 126.192 1.797 . . . . 10.0 110.527 175.267 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.5 mm -119.37 131.27 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.247 1.419 . . . . 10.0 110.723 -165.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -60.91 129.07 39.62 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.804 1.242 . . . . 10.0 112.558 173.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -54.21 127.8 28.43 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.825 1.25 . . . . 10.0 112.596 -178.864 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.13 -10.27 61.71 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 126.187 1.851 . . . . 10.0 115.036 178.16 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 27.1 mtp-105 -73.84 163.93 27.3 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.116 1.458 . . . . 10.0 113.099 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -75.37 141.18 43.34 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.895 1.278 . . . . 10.0 110.506 158.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.46 170.32 19.89 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.756 0.822 . . . . 10.0 112.343 162.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -146.84 163.32 36.44 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.37 1.468 . . . . 10.0 112.757 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -134.97 140.3 45.59 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.215 2.206 . . . . 10.0 109.137 175.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -131.97 125.7 32.21 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.795 1.238 . . . . 10.0 111.974 -168.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -129.17 111.81 13.3 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 126.789 2.035 . . . . 10.0 111.624 -167.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -73.65 120.55 19.4 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 121.587 -0.696 . . . . 10.0 109.808 171.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -130.11 108.92 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.792 2.037 . . . . 10.0 110.831 -171.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.8 t -76.79 -174.77 3.17 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.336 1.054 . . . . 10.0 112.301 174.1 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 100.27 160.58 28.25 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 126.92 2.2 . . . . 10.0 113.795 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -151.17 135.26 9.53 Favored Pre-proline 0 CA--C 1.548 0.889 0 C-N-CA 126.044 1.738 . . . . 10.0 109.531 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.18 169.94 37.76 Favored 'Cis proline' 0 CA--C 1.539 0.76 0 CA-C-N 121.15 1.447 . . . . 10.0 112.373 -6.108 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 123.18 51.65 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 124.581 1.153 . . . . 10.0 111.278 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -70.88 161.57 45.61 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 122.501 2.134 . . . . 10.0 113.333 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 40.2 m-20 -65.66 170.56 5.02 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.826 1.25 . . . . 10.0 111.761 165.222 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 5.6 p -138.37 122.96 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.219 1.408 . . . . 10.0 111.471 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.0 m -137.36 106.25 5.94 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.818 1.647 . . . . 10.0 110.563 174.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.8 m95 -85.86 153.54 22.17 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 123.953 0.901 . . . . 10.0 113.223 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.19 159.0 43.1 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.979 2.112 . . . . 10.0 111.295 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -143.93 117.07 8.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 127.072 2.149 . . . . 10.0 110.281 175.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 54.07 18.86 1.85 Allowed 'General case' 0 CA--C 1.554 1.116 0 C-N-CA 126.375 1.87 . . . . 10.0 114.558 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.97 -9.35 46.86 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.422 1.963 . . . . 10.0 115.476 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.18 155.13 19.61 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.044 1.422 . . . . 10.0 110.166 171.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.6 p -69.34 155.24 40.75 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.801 0.84 . . . . 10.0 112.585 173.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 57.4 t -133.12 105.04 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.332 1.853 . . . . 10.0 108.766 173.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 95.4 mm-40 -72.62 159.59 33.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.498 0.719 . . . . 10.0 111.701 173.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.3 p -70.11 154.9 41.36 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.35 0.66 . . . . 10.0 111.67 166.671 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -154.15 168.95 24.78 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.404 1.482 . . . . 10.0 111.025 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -57.83 -34.55 69.8 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.792 -1.193 . . . . 10.0 112.658 168.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.3 mt -82.79 -15.16 52.77 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.556 1.142 . . . . 10.0 113.9 173.26 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -134.61 69.41 1.46 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.011 1.724 . . . . 10.0 111.324 -173.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -70.61 144.4 51.18 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.086 1.354 . . . . 10.0 111.666 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.3 mtt -141.14 103.36 4.43 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 126.835 2.054 . . . . 10.0 109.723 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.75 162.03 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 C-N-CA 124.617 1.167 . . . . 10.0 112.66 -176.683 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 t -133.83 113.91 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.632 1.573 . . . . 10.0 109.698 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 66.8 m -69.04 144.46 54.03 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.47 0.708 . . . . 10.0 111.053 171.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.03 -17.1 56.24 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.487 1.515 . . . . 10.0 114.579 -176.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -74.44 -4.88 39.3 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 126.155 1.782 . . . . 10.0 114.107 173.233 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.17 38.35 5.71 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 125.139 1.352 . . . . 10.0 113.644 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 44.4 tp -125.68 102.54 7.38 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.424 1.489 . . . . 10.0 110.646 -177.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -78.25 145.26 35.56 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.009 0.924 . . . . 10.0 110.926 169.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 32.6 t -134.53 145.52 48.83 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.943 1.297 . . . . 10.0 111.985 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -130.63 120.53 24.1 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.434 2.694 . . . . 10.0 108.115 -178.358 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.4 152.33 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.605 1.162 . . . . 10.0 111.424 -170.131 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -125.96 108.84 11.79 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 127.273 2.229 . . . . 10.0 108.892 168.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -65.98 -38.45 88.56 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.323 -0.861 . . . . 10.0 112.715 175.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.2 p -150.28 86.82 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 126.098 1.759 . . . . 10.0 110.043 -178.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.5 p -66.64 139.6 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 O-C-N 121.3 -0.875 . . . . 10.0 111.827 -177.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -119.69 160.82 21.8 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.964 1.705 . . . . 10.0 112.069 176.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.29 -31.62 65.81 Favored 'General case' 0 CA--C 1.548 0.891 0 N-CA-C 113.709 1.003 . . . . 10.0 113.709 -176.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -65.3 -21.13 66.68 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.125 1.37 . . . . 10.0 113.891 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -77.66 -6.16 52.91 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.68 1.192 . . . . 10.0 113.591 178.354 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.2 147.79 52.82 Favored 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.874 -1.141 . . . . 10.0 112.695 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.76 -172.6 22.49 Favored Glycine 0 CA--C 1.532 1.155 0 C-N-CA 124.767 1.175 . . . . 10.0 114.894 177.171 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.92 109.83 18.43 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.981 1.712 . . . . 10.0 111.06 175.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -85.15 153.72 22.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.473 1.109 . . . . 10.0 112.213 171.681 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.17 159.34 42.42 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.172 0.989 . . . . 10.0 112.069 167.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -139.03 104.26 4.99 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.76 1.624 . . . . 10.0 110.827 -178.023 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.8 t -76.39 129.61 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.316 1.046 . . . . 10.0 109.692 171.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.68 117.91 20.16 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.668 1.987 . . . . 10.0 110.681 178.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -132.11 139.63 48.53 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.299 1.44 . . . . 10.0 112.017 -172.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 26.8 p30 -134.27 -177.98 4.83 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.903 1.281 . . . . 10.0 111.411 167.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -61.29 -11.22 8.91 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.778 1.77 . . . . 10.0 115.778 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.97 -19.78 12.23 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.409 1.484 . . . . 10.0 114.443 -178.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.44 -170.39 43.51 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 116.149 1.22 . . . . 10.0 116.149 178.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -136.8 144.17 43.56 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.968 2.107 . . . . 10.0 111.819 -170.359 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.68 157.1 47.2 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 126.482 1.913 . . . . 10.0 110.534 166.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -140.12 98.03 3.36 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.64 1.176 . . . . 10.0 110.206 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -75.35 156.97 34.96 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.107 0.963 . . . . 10.0 111.467 177.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 33.0 m -144.87 143.47 30.61 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.058 1.343 . . . . 10.0 111.348 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.5 p -153.95 170.74 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 C-N-CA 126.215 1.806 . . . . 10.0 110.867 173.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 -131.15 146.81 52.48 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.756 1.222 . . . . 10.0 111.88 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.5 tp -131.76 119.41 21.25 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.057 1.743 . . . . 10.0 111.018 -178.766 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -104.35 83.02 2.01 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.79 1.636 . . . . 10.0 110.857 176.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.05 110.89 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 O-C-N 121.531 -0.731 . . . . 10.0 110.692 -179.292 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 67.4 mt -73.01 97.95 2.42 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.305 1.842 . . . . 10.0 109.87 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.823 0 C-N-CA 124.644 1.177 . . . . 10.0 113.661 -173.488 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo . . . . . 0 CA--C 1.543 0.963 0 N-CA-C 112.943 0.324 . . . . 10.0 112.943 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -70.23 166.07 29.41 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.144 2.562 . . . . 10.0 112.428 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 21.3 tpp180 -140.77 147.18 38.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.462 1.105 . . . . 10.0 112.436 -174.253 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -76.8 58.06 1.38 Allowed 'General case' 0 CA--C 1.55 0.977 0 C-N-CA 128.564 2.746 . . . . 10.0 112.409 -177.401 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.3 mm -60.64 -58.5 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.964 -1.085 . . . . 10.0 112.63 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -154.35 153.34 31.45 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 119.006 0.821 . . . . 10.0 113.172 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 17.8 m -131.05 155.57 81.37 Favored Pre-proline 0 N--CA 1.479 0.997 0 C-N-CA 127.371 2.269 . . . . 10.0 110.382 167.692 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -74.8 166.14 29.93 Favored 'Trans proline' 0 CA--C 1.542 0.921 0 C-N-CA 122.771 2.314 . . . . 10.0 111.499 168.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -73.05 176.45 5.77 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.446 -0.784 . . . . 10.0 111.194 163.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -59.18 152.83 19.62 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.911 -1.118 . . . . 10.0 112.128 171.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.7 mtp -132.46 157.19 45.24 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 125.526 1.531 . . . . 10.0 111.946 -172.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 76.4 p -145.93 136.79 24.43 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 125.26 1.424 . . . . 10.0 110.856 169.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 24.9 mm -138.4 133.08 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.581 1.552 . . . . 10.0 109.531 -170.366 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -63.85 131.12 46.8 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.639 1.175 . . . . 10.0 112.302 173.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -51.54 130.59 28.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.515 1.526 . . . . 10.0 113.305 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.4 -10.25 67.13 Favored Glycine 0 CA--C 1.537 1.426 0 C-N-CA 126.185 1.85 . . . . 10.0 115.175 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.3 mtp180 -72.3 161.33 30.99 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.037 1.418 . . . . 10.0 113.356 177.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -71.49 148.6 46.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.678 1.191 . . . . 10.0 110.637 156.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.8 t -147.06 154.62 41.39 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.941 1.296 . . . . 10.0 111.019 168.849 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -145.53 166.18 26.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.747 1.219 . . . . 10.0 112.547 165.191 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 49.5 mtt -133.07 166.9 21.35 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.471 1.908 . . . . 10.0 111.815 -176.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -134.39 117.65 16.56 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.082 1.753 . . . . 10.0 111.694 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -127.83 99.55 5.58 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.551 1.54 . . . . 10.0 111.358 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -66.41 123.31 19.64 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.862 0.865 . . . . 10.0 110.115 172.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 5.9 p -142.45 102.63 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.311 1.845 . . . . 10.0 110.684 -176.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.7 t -75.68 -177.25 3.63 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.003 0.921 . . . . 10.0 111.855 172.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 117.32 160.3 11.73 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 127.356 2.408 . . . . 10.0 113.319 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -149.47 128.38 6.15 Favored Pre-proline 0 CA--C 1.548 0.871 0 C-N-CA 124.797 1.239 . . . . 10.0 110.414 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -66.86 169.61 47.63 Favored 'Cis proline' 0 CA--C 1.54 0.809 0 CA-C-N 121.06 1.414 . . . . 10.0 112.507 -3.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.18 122.59 55.06 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.616 1.166 . . . . 10.0 111.429 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.57 151.39 64.42 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 122.55 2.167 . . . . 10.0 113.284 -173.098 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.99 145.66 46.54 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.337 1.055 . . . . 10.0 109.963 160.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.68 86.37 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.091 1.356 . . . . 10.0 112.103 -165.043 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.4 m -78.5 116.1 18.66 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.866 1.267 . . . . 10.0 111.506 177.151 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.1 m95 -90.27 155.77 18.76 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.704 1.001 . . . . 10.0 113.704 177.493 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.34 160.54 41.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.476 2.311 . . . . 10.0 111.495 -177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.9 tp -147.23 119.76 8.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.392 2.277 . . . . 10.0 110.024 174.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 54.9 15.0 1.01 Allowed 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 126.645 1.978 . . . . 10.0 115.145 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.58 -13.23 35.8 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 126.631 2.063 . . . . 10.0 115.19 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -86.84 159.55 19.04 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 118.971 1.385 . . . . 10.0 110.833 169.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.7 p -73.21 159.15 33.91 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.098 0.959 . . . . 10.0 112.729 174.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 90.5 t -137.12 145.71 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 127.008 2.123 . . . . 10.0 108.775 171.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 80.4 mt-30 -128.1 163.21 25.13 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.295 1.438 . . . . 10.0 111.285 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.5 p -68.35 152.61 45.19 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.657 0.783 . . . . 10.0 112.613 176.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -152.17 168.18 26.16 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.978 1.711 . . . . 10.0 110.641 175.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.45 -35.12 67.53 Favored 'General case' 0 CA--C 1.544 0.741 0 O-C-N 120.906 -1.121 . . . . 10.0 112.76 169.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.0 mt -84.84 -12.99 52.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.608 1.163 . . . . 10.0 113.979 173.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.9 m80 -136.59 71.18 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.633 1.573 . . . . 10.0 111.453 -173.434 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -71.89 147.45 47.07 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.797 1.239 . . . . 10.0 111.898 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.6 mtt -141.54 107.28 5.11 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 126.846 2.058 . . . . 10.0 109.908 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.0 157.93 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.641 1.176 . . . . 10.0 112.398 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.1 t -133.81 113.93 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.893 1.677 . . . . 10.0 109.928 -177.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 68.7 m -70.38 151.27 45.4 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.954 0.902 . . . . 10.0 112.132 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -57.45 -32.18 66.67 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 125.766 1.627 . . . . 10.0 113.856 -175.508 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 303' ' ' LYS . . . . . 0.422 ' HA ' ' HE2' ' A' ' 303' ' ' LYS . 11.3 mmpt? -70.82 -3.39 18.71 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 126.174 1.79 . . . . 10.0 114.425 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.83 49.92 3.91 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 125.006 1.289 . . . . 10.0 112.897 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 65.1 tp -130.72 104.15 7.01 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.455 1.502 . . . . 10.0 110.469 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -83.7 125.9 32.35 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 125.145 1.378 . . . . 10.0 111.229 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.8 m -102.86 142.67 33.58 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.243 1.417 . . . . 10.0 111.739 169.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -130.55 126.07 35.84 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 127.469 2.308 . . . . 10.0 107.884 175.232 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 44.1 mt -122.1 152.68 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.237 1.415 . . . . 10.0 111.722 -167.358 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.93 109.98 10.93 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 128.059 2.544 . . . . 10.0 109.064 169.282 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.33 -38.87 85.59 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.02 -1.05 . . . . 10.0 113.069 177.293 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.04 88.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 125.723 1.609 . . . . 10.0 110.286 -178.059 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -70.66 141.81 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 O-C-N 121.235 -0.915 . . . . 10.0 112.313 -175.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -126.18 163.21 23.63 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 126.631 1.972 . . . . 10.0 111.958 177.231 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.1 -31.56 65.4 Favored 'General case' 0 CA--C 1.548 0.875 0 N-CA-C 113.899 1.074 . . . . 10.0 113.899 -177.128 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.5 m -68.28 -15.91 63.75 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 114.216 1.191 . . . . 10.0 114.216 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -82.83 -5.16 58.84 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.432 1.093 . . . . 10.0 113.308 177.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 150.22 48.84 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.933 -1.104 . . . . 10.0 113.143 178.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.17 -175.19 21.06 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.905 1.241 . . . . 10.0 115.279 174.261 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.12 98.05 7.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.801 1.64 . . . . 10.0 111.246 175.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -74.5 150.96 39.61 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 123.556 0.742 . . . . 10.0 111.479 167.412 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.01 161.9 38.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 123.966 0.906 . . . . 10.0 111.997 168.083 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.1 t -137.31 139.01 40.6 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.737 1.615 . . . . 10.0 110.487 176.351 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.9 t -117.17 104.7 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.289 1.835 . . . . 10.0 108.862 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -89.64 118.06 28.98 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 126.283 1.833 . . . . 10.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -129.84 132.61 46.53 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.085 1.354 . . . . 10.0 112.598 -176.021 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -129.44 -179.02 4.92 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.834 1.253 . . . . 10.0 111.513 166.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -61.64 -12.28 15.36 Favored 'General case' 0 N--CA 1.482 1.129 0 N-CA-C 115.726 1.75 . . . . 10.0 115.726 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.18 -20.03 12.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 125.383 1.473 . . . . 10.0 114.424 -178.249 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 172.92 -169.26 42.42 Favored Glycine 0 CA--C 1.534 1.232 0 N-CA-C 116.101 1.2 . . . . 10.0 116.101 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -134.19 143.8 48.09 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 126.939 2.095 . . . . 10.0 111.909 -171.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.25 165.92 25.0 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.281 1.833 . . . . 10.0 111.076 168.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 19.0 m -141.57 141.59 33.5 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.203 1.001 . . . . 10.0 111.569 -173.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -134.47 150.93 50.87 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.797 1.639 . . . . 10.0 110.556 -178.357 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -146.4 146.81 30.76 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 124.454 1.102 . . . . 10.0 111.786 -169.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.7 p -152.97 146.68 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 125.251 1.42 . . . . 10.0 112.026 170.226 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 9.2 tp-100 -100.14 127.47 46.39 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 125.667 1.587 . . . . 10.0 110.245 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -121.18 105.56 10.7 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.542 1.537 . . . . 10.0 111.261 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -93.62 85.79 4.99 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.268 1.427 . . . . 10.0 111.319 175.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.6 t -66.14 115.35 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 121.301 -0.874 . . . . 10.0 110.826 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.3 mt -78.91 100.0 7.04 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.437 1.895 . . . . 10.0 110.356 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.805 0 C-N-CA 123.947 0.899 . . . . 10.0 112.821 179.46 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 CA--C 1.543 0.935 0 N-CA-C 112.943 0.324 . . . . 10.0 112.943 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -65.39 133.59 35.44 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.351 2.701 . . . . 10.0 111.324 171.08 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -130.64 134.66 47.14 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 126.698 1.999 . . . . 10.0 110.654 -176.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -48.87 120.39 3.82 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 127.09 2.156 . . . . 10.0 112.58 173.587 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 49.7 mm -113.85 -59.29 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.232 1.013 . . . . 10.0 110.413 171.287 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.5 tt0 -150.47 136.04 18.12 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.013 0.925 . . . . 10.0 111.531 177.014 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 21.9 m -117.88 149.75 45.89 Favored Pre-proline 0 N--CA 1.474 0.749 0 C-N-CA 125.367 1.467 . . . . 10.0 109.579 167.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.78 155.96 53.38 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 122.485 2.123 . . . . 10.0 111.92 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -69.98 168.35 15.58 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.74 0.816 . . . . 10.0 111.091 166.661 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.21 152.19 21.22 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 121.211 -0.931 . . . . 10.0 112.334 173.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 86.1 mtp -127.05 152.44 47.26 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.222 1.409 . . . . 10.0 111.87 -167.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 p -144.15 104.94 4.18 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.265 1.426 . . . . 10.0 111.094 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.9 mm -122.6 130.95 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.401 1.481 . . . . 10.0 110.405 -166.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -65.15 129.97 41.64 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.51 1.124 . . . . 10.0 112.518 175.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -52.57 123.5 11.27 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 125.656 1.582 . . . . 10.0 113.132 -176.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 101.45 -10.25 57.76 Favored Glycine 0 CA--C 1.534 1.269 0 C-N-CA 125.975 1.75 . . . . 10.0 115.551 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -70.77 160.64 32.33 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-N 119.248 1.524 . . . . 10.0 113.086 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -73.43 147.73 43.93 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.663 1.185 . . . . 10.0 110.571 159.094 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 7.1 t -153.4 168.26 26.69 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.075 0.95 . . . . 10.0 112.607 169.32 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.1 ptm85 -145.61 166.68 25.05 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.95 1.7 . . . . 10.0 112.82 167.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.3 mtt -121.06 159.82 24.9 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 126.964 2.106 . . . . 10.0 111.241 173.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -140.27 93.21 2.6 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.076 1.35 . . . . 10.0 111.961 -166.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -114.07 106.9 14.94 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.733 1.613 . . . . 10.0 111.651 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -85.88 129.73 34.75 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.027 -1.045 . . . . 10.0 111.513 176.521 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.6 p -132.63 153.68 38.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.072 1.749 . . . . 10.0 110.351 170.03 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 58.4 m -127.24 126.67 43.13 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.766 1.226 . . . . 10.0 110.889 172.176 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.1 168.01 40.66 Favored Glycine 0 CA--C 1.534 1.28 0 C-N-CA 126.615 2.055 . . . . 10.0 111.236 175.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.9 tp -146.56 131.39 8.9 Favored Pre-proline 0 CA--C 1.546 0.825 0 C-N-CA 124.474 1.11 . . . . 10.0 110.73 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.13 170.59 45.23 Favored 'Cis proline' 0 CA--C 1.541 0.825 0 CA-C-N 120.414 1.184 . . . . 10.0 112.665 -3.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.13 122.05 45.59 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 124.662 1.185 . . . . 10.0 111.29 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -73.82 164.31 34.98 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.572 2.181 . . . . 10.0 113.845 -170.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -61.58 165.77 4.7 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.114 1.766 . . . . 10.0 111.961 165.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.2 p -139.23 113.6 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.097 1.359 . . . . 10.0 111.455 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -128.92 147.61 50.85 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.945 1.698 . . . . 10.0 110.821 173.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -128.44 153.29 47.27 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.355 1.062 . . . . 10.0 113.545 -174.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -143.3 162.65 35.13 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.324 2.25 . . . . 10.0 111.227 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.5 tp -147.86 123.59 10.54 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 126.905 2.082 . . . . 10.0 110.012 176.381 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 55.02 10.15 0.37 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.739 2.016 . . . . 10.0 116.049 176.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.01 -5.09 25.58 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.08 1.8 . . . . 10.0 115.607 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -105.58 161.65 14.18 Favored 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 119.176 1.488 . . . . 10.0 111.922 171.011 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.9 p -70.08 154.94 41.31 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.427 1.091 . . . . 10.0 112.791 176.175 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.33 101.76 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.791 2.036 . . . . 10.0 108.401 170.468 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -74.3 157.58 35.54 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.529 0.731 . . . . 10.0 111.319 172.504 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.2 p -70.61 149.5 47.0 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.691 0.796 . . . . 10.0 112.388 172.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -152.29 179.54 8.45 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.419 1.487 . . . . 10.0 111.063 167.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -57.24 -28.66 63.12 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.425 1.269 . . . . 10.0 114.425 -177.143 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 48.7 mt -92.41 -11.82 33.83 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.272 1.429 . . . . 10.0 113.391 176.009 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -134.25 70.91 1.45 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.397 1.879 . . . . 10.0 111.153 -174.408 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -71.87 143.32 49.44 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.171 1.388 . . . . 10.0 111.052 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -138.9 106.47 5.58 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 126.318 1.847 . . . . 10.0 110.455 -172.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.92 171.79 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.315 1.446 . . . . 10.0 112.229 -177.179 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -135.55 134.23 51.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.807 1.643 . . . . 10.0 109.275 174.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 24.9 p -67.95 172.14 5.89 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.838 1.051 . . . . 10.0 113.838 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -59.37 -20.3 53.68 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.237 1.415 . . . . 10.0 113.436 170.724 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -117.43 5.64 12.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.278 1.831 . . . . 10.0 114.243 -171.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.78 15.71 36.02 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 124.623 1.106 . . . . 10.0 115.777 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 28.4 tp -80.13 98.0 7.11 Favored 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 118.864 1.332 . . . . 10.0 110.3 171.231 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -63.5 132.24 50.68 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.926 0.89 . . . . 10.0 110.002 166.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -129.71 126.26 37.84 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 126.33 1.852 . . . . 10.0 111.167 -171.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -126.21 123.35 37.99 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 127.043 2.137 . . . . 10.0 108.027 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 50.9 mt -114.54 153.55 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 125.177 1.391 . . . . 10.0 110.968 -171.275 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -127.78 109.39 11.59 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.353 2.261 . . . . 10.0 108.897 170.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -68.14 -41.66 81.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.188 -0.945 . . . . 10.0 112.606 174.587 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.83 90.2 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.764 1.625 . . . . 10.0 110.388 -176.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -69.89 151.91 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 O-C-N 121.31 -0.869 . . . . 10.0 112.898 -175.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 86.7 mmt-85 -132.31 159.83 38.0 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 127.019 2.128 . . . . 10.0 111.836 174.055 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.84 -30.83 64.17 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.386 1.074 . . . . 10.0 113.721 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.9 t -62.99 -23.46 67.46 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.966 1.306 . . . . 10.0 113.646 174.126 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -78.6 -8.46 58.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.556 1.142 . . . . 10.0 113.64 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 152.58 42.84 Favored 'General case' 0 CA--C 1.547 0.839 0 CA-C-N 119.543 1.065 . . . . 10.0 113.406 -179.215 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.27 -170.88 22.42 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.928 1.252 . . . . 10.0 114.891 176.287 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.62 97.67 7.99 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.939 1.696 . . . . 10.0 111.454 176.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -71.55 150.41 44.78 Favored 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 123.948 0.899 . . . . 10.0 111.793 168.271 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.31 158.08 44.36 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.799 0.84 . . . . 10.0 112.406 168.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.8 t -130.62 141.9 50.44 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 127.162 2.185 . . . . 10.0 109.601 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 28.6 t -124.66 131.74 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.255 1.422 . . . . 10.0 109.489 177.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.43 124.03 40.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.189 1.795 . . . . 10.0 110.705 -177.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 1.9 mppt? -129.04 135.94 49.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.241 1.416 . . . . 10.0 111.602 -176.482 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -134.77 179.39 6.33 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.269 1.028 . . . . 10.0 111.534 163.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 14.9 ptp180 -62.62 -11.08 14.67 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.551 1.685 . . . . 10.0 115.551 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.17 -18.6 13.96 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.507 1.523 . . . . 10.0 114.167 178.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.04 -171.1 42.85 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 119.854 1.206 . . . . 10.0 115.849 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -135.26 147.09 49.16 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.586 1.955 . . . . 10.0 111.835 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.94 159.08 42.99 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.882 1.673 . . . . 10.0 111.861 170.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 86.9 m -138.75 138.26 37.48 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.76 1.624 . . . . 10.0 110.49 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -131.69 156.06 46.55 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.002 1.721 . . . . 10.0 111.25 -175.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -143.93 147.03 33.4 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.427 1.091 . . . . 10.0 112.392 -170.121 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.1 p -150.98 158.93 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 126.201 1.8 . . . . 10.0 111.277 168.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.6 tt0 -109.16 135.1 50.83 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.848 1.259 . . . . 10.0 111.538 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.4 tp -119.09 110.16 16.75 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.349 1.86 . . . . 10.0 110.639 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -96.5 83.98 3.61 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 125.825 1.65 . . . . 10.0 111.017 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -65.02 112.28 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 121.405 -0.809 . . . . 10.0 110.649 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.0 mt -74.11 101.37 3.9 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.169 1.788 . . . . 10.0 109.862 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.859 0 C-N-CA 124.436 1.094 . . . . 10.0 113.895 -174.03 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 CA--C 1.542 0.895 0 N-CA-C 112.511 0.158 . . . . 10.0 112.511 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -67.91 158.85 55.49 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 122.631 2.22 . . . . 10.0 111.794 171.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 41.6 ttt-85 -142.31 150.69 41.14 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.008 1.323 . . . . 10.0 111.538 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 8.9 m-30 -63.84 133.92 54.27 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.073 0.949 . . . . 10.0 110.161 162.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 32.0 mm -130.83 -59.64 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.095 1.358 . . . . 10.0 109.547 173.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -152.51 141.67 21.38 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.739 1.216 . . . . 10.0 111.21 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -127.5 152.77 77.03 Favored Pre-proline 0 N--CA 1.476 0.853 0 C-N-CA 125.736 1.614 . . . . 10.0 110.522 170.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.74 152.8 59.04 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 122.676 2.251 . . . . 10.0 111.553 171.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -72.76 174.17 8.04 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 123.904 0.882 . . . . 10.0 111.833 164.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -60.45 152.99 24.23 Favored 'General case' 0 CA--C 1.547 0.829 0 O-C-N 121.178 -0.951 . . . . 10.0 112.303 175.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.5 mtp -131.02 158.24 40.86 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 125.121 1.368 . . . . 10.0 112.292 -171.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 46.9 p -143.36 120.43 11.41 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.537 1.535 . . . . 10.0 110.49 172.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.5 mm -129.91 134.46 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.475 1.51 . . . . 10.0 109.796 -169.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.54 130.02 43.22 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.275 1.43 . . . . 10.0 112.39 175.24 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -51.47 127.21 19.41 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.227 1.411 . . . . 10.0 112.618 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.73 -10.61 60.81 Favored Glycine 0 CA--C 1.537 1.412 0 C-N-CA 126.125 1.821 . . . . 10.0 115.196 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -74.65 160.78 30.37 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 119.28 1.54 . . . . 10.0 113.302 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -74.61 142.65 44.59 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.63 1.172 . . . . 10.0 110.044 155.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.7 p -150.75 170.47 19.15 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 123.575 0.75 . . . . 10.0 112.254 163.245 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -146.61 162.77 37.72 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.156 1.382 . . . . 10.0 112.669 177.393 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -137.2 139.73 41.27 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 127.508 2.323 . . . . 10.0 109.151 176.698 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -134.22 124.05 25.33 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.048 0.939 . . . . 10.0 111.453 -171.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -123.82 110.11 14.48 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 126.517 1.927 . . . . 10.0 110.678 -168.382 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -72.14 119.63 16.6 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.6 0.76 . . . . 10.0 110.002 173.476 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.9 p -137.94 110.18 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.762 2.025 . . . . 10.0 110.3 -175.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 5.6 t -75.81 -170.88 1.44 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.378 1.071 . . . . 10.0 112.441 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 103.64 164.25 25.23 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 126.886 2.184 . . . . 10.0 114.039 176.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.8 tp -150.8 133.53 8.46 Favored Pre-proline 0 CA--C 1.548 0.895 0 C-N-CA 125.433 1.493 . . . . 10.0 110.335 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -67.02 168.79 51.76 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 CA-C-N 120.783 1.315 . . . . 10.0 112.528 -3.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.03 124.76 60.78 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.418 1.087 . . . . 10.0 110.846 177.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 155.35 64.46 Favored 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 122.434 2.089 . . . . 10.0 113.375 -170.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -72.8 114.24 10.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.458 1.503 . . . . 10.0 109.327 161.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.53 131.34 56.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.682 1.193 . . . . 10.0 111.289 -175.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.5 m -129.44 156.06 44.7 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 126.073 1.749 . . . . 10.0 111.405 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 63.4 m95 -124.88 156.4 37.97 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.85 1.26 . . . . 10.0 113.194 -176.503 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -144.4 159.78 42.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 127.119 2.168 . . . . 10.0 111.098 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.8 tp -145.74 119.21 9.05 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 126.887 2.075 . . . . 10.0 110.118 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 54.47 15.69 1.09 Allowed 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.449 1.9 . . . . 10.0 115.019 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.55 -11.87 39.16 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.663 2.078 . . . . 10.0 115.254 -177.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -87.43 158.03 19.08 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.948 1.374 . . . . 10.0 111.125 171.004 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.1 p -71.54 153.37 42.22 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.395 1.078 . . . . 10.0 112.674 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 53.9 t -132.76 100.85 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.367 1.867 . . . . 10.0 108.715 172.177 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 59.2 mt-30 -73.23 160.77 31.4 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.554 0.742 . . . . 10.0 111.359 171.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.2 p -68.49 155.67 39.46 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.383 0.673 . . . . 10.0 112.012 168.549 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -153.07 168.91 24.3 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.484 1.513 . . . . 10.0 110.917 177.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -56.9 -35.37 68.89 Favored 'General case' 0 CA--C 1.545 0.775 0 O-C-N 120.942 -1.098 . . . . 10.0 112.779 169.425 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.7 mt -84.48 -14.19 49.86 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.48 1.112 . . . . 10.0 113.9 173.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -133.62 70.27 1.46 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.837 1.655 . . . . 10.0 111.264 -174.262 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -71.29 144.09 50.11 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.834 1.254 . . . . 10.0 111.518 -176.371 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -141.54 106.06 4.86 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.654 1.982 . . . . 10.0 109.811 -175.018 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.01 164.99 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.643 1.177 . . . . 10.0 112.37 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 62.3 t -131.58 116.05 30.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 125.992 1.717 . . . . 10.0 109.63 178.111 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -72.54 143.51 48.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.369 0.667 . . . . 10.0 111.105 170.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.18 -20.33 40.21 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 115.308 1.596 . . . . 10.0 115.308 -174.405 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -75.45 -5.18 43.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.574 1.55 . . . . 10.0 113.867 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.64 50.75 2.28 Favored Glycine 0 CA--C 1.531 1.064 0 C-N-CA 125.436 1.493 . . . . 10.0 112.855 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 17.9 tp -136.46 106.17 6.2 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.332 1.453 . . . . 10.0 110.511 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -76.51 144.41 39.79 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.582 0.353 . . . . 10.0 110.864 168.11 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.5 m -130.62 114.76 15.82 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 126.427 1.891 . . . . 10.0 110.603 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -108.59 121.06 44.2 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 127.656 2.383 . . . . 10.0 108.715 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 71.3 mt -121.57 152.17 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.514 1.126 . . . . 10.0 111.304 -168.315 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.74 110.73 12.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.532 2.333 . . . . 10.0 109.43 171.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -66.11 -39.95 90.33 Favored 'General case' 0 N--CA 1.474 0.749 0 O-C-N 121.285 -0.884 . . . . 10.0 113.038 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -151.22 90.22 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.747 1.619 . . . . 10.0 110.277 -178.088 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.3 p -69.98 140.96 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 O-C-N 121.287 -0.883 . . . . 10.0 111.995 -177.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.3 mmt180 -124.22 161.81 24.98 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.421 1.888 . . . . 10.0 112.043 177.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.74 -33.89 64.68 Favored 'General case' 0 CA--C 1.546 0.82 0 N-CA-C 113.434 0.902 . . . . 10.0 113.434 -178.435 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.4 m -65.24 -17.68 64.69 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.355 1.462 . . . . 10.0 114.512 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -82.53 -5.47 58.76 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.685 1.194 . . . . 10.0 113.228 177.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.98 151.98 45.59 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.084 -1.01 . . . . 10.0 113.067 178.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.78 -171.27 22.44 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.746 1.165 . . . . 10.0 114.801 175.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.91 103.87 14.35 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.972 1.709 . . . . 10.0 111.055 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -78.15 152.02 32.98 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.009 0.924 . . . . 10.0 111.839 169.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -139.04 156.34 47.27 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.068 0.947 . . . . 10.0 111.687 168.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.0 t -134.06 136.74 44.2 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.525 1.93 . . . . 10.0 109.472 -175.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 67.8 t -128.25 126.53 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.488 1.515 . . . . 10.0 109.143 -178.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.83 117.4 23.29 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.258 1.823 . . . . 10.0 110.77 -174.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 23.0 mtpp -124.49 133.71 53.26 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.482 1.513 . . . . 10.0 111.536 -174.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 14.4 p30 -131.43 178.81 6.44 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.145 0.978 . . . . 10.0 111.7 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -63.57 -10.04 16.37 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 115.636 1.717 . . . . 10.0 115.636 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.12 -20.33 12.73 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.645 1.578 . . . . 10.0 114.246 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.05 -169.2 42.21 Favored Glycine 0 CA--C 1.535 1.291 0 CA-C-N 119.788 1.176 . . . . 10.0 115.769 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -138.54 147.09 42.69 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.357 1.863 . . . . 10.0 112.013 -173.382 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.66 153.61 50.86 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.033 1.733 . . . . 10.0 111.242 169.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.7 m -136.67 140.07 42.46 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.566 1.546 . . . . 10.0 110.646 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -133.55 159.28 40.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.966 1.706 . . . . 10.0 111.247 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.6 m -143.43 144.14 31.9 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 124.949 1.3 . . . . 10.0 111.341 -174.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.39 161.4 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.938 1.695 . . . . 10.0 110.563 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.8 tt0 -123.72 138.44 54.52 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 124.484 1.114 . . . . 10.0 111.196 176.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.3 tp -125.24 108.94 12.25 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.035 1.734 . . . . 10.0 110.711 -178.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -93.8 83.15 4.36 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.432 1.493 . . . . 10.0 110.682 174.45 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.34 114.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 O-C-N 121.452 -0.78 . . . . 10.0 110.418 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.9 mt -75.25 94.09 2.95 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.193 1.797 . . . . 10.0 110.015 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.78 0 C-N-CA 124.43 1.092 . . . . 10.0 112.98 -179.586 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo . . . . . 0 CA--C 1.544 0.976 0 N-CA-C 113.528 0.549 . . . . 10.0 113.528 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.71 139.09 56.38 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.02 2.48 . . . . 10.0 111.006 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 53.1 ttt85 -128.78 151.64 49.35 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.457 1.503 . . . . 10.0 112.617 -174.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -76.44 88.72 3.21 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.041 2.137 . . . . 10.0 111.708 177.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.2 mm -82.92 -58.78 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 O-C-N 121.605 -0.684 . . . . 10.0 110.264 171.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 24.8 tt0 -154.29 146.62 23.89 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.735 1.214 . . . . 10.0 111.776 175.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.79 152.29 74.86 Favored Pre-proline 0 N--CA 1.477 0.881 0 C-N-CA 126.452 1.901 . . . . 10.0 110.004 169.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.83 157.45 35.12 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.567 2.178 . . . . 10.0 112.247 -178.191 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -73.88 168.15 20.02 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.833 0.853 . . . . 10.0 111.326 166.624 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -60.14 158.14 11.85 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 121.419 -0.8 . . . . 10.0 112.801 176.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -128.47 152.75 47.88 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.714 1.606 . . . . 10.0 111.742 -171.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 39.5 p -141.77 116.85 9.98 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 125.385 1.474 . . . . 10.0 110.416 170.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.9 mm -129.3 129.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.29 1.436 . . . . 10.0 109.995 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -60.66 127.17 30.35 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.173 1.389 . . . . 10.0 112.12 173.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -53.22 134.38 39.2 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.202 1.401 . . . . 10.0 113.161 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.85 -12.02 67.55 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.346 1.927 . . . . 10.0 114.79 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -74.24 161.56 29.81 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 118.972 1.386 . . . . 10.0 113.268 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -75.9 141.16 42.4 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.885 1.274 . . . . 10.0 110.276 156.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.79 172.03 15.29 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.678 0.791 . . . . 10.0 112.065 161.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -152.43 170.21 20.68 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.145 1.378 . . . . 10.0 112.923 174.059 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.9 mtt -121.8 164.7 17.03 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 126.587 1.955 . . . . 10.0 112.526 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -138.23 103.42 4.92 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 126.353 1.861 . . . . 10.0 111.738 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -115.37 109.61 18.15 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.5 1.52 . . . . 10.0 111.178 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -80.03 74.72 6.79 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 121.302 -0.874 . . . . 10.0 111.496 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -79.84 128.14 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.913 1.285 . . . . 10.0 109.945 163.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 68.6 m -135.28 115.35 13.19 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.787 1.235 . . . . 10.0 111.343 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -158.41 169.85 34.99 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 126.695 2.093 . . . . 10.0 111.55 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 21.8 tp -142.14 120.04 7.47 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.504 1.122 . . . . 10.0 110.449 -177.433 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -68.05 167.54 63.18 Favored 'Cis proline' 0 CA--C 1.54 0.79 0 CA-C-N 121.018 1.399 . . . . 10.0 112.906 0.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 124.39 62.23 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.791 1.236 . . . . 10.0 111.189 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.49 151.33 59.02 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.41 2.073 . . . . 10.0 113.82 -169.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -69.94 130.45 42.26 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.611 1.564 . . . . 10.0 109.543 159.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.3 m -124.54 134.74 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.891 1.276 . . . . 10.0 112.253 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.6 m -136.47 114.56 11.48 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.673 1.589 . . . . 10.0 111.418 -173.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -87.44 151.98 22.61 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 114.016 1.117 . . . . 10.0 114.016 -178.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -141.61 160.57 39.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.975 2.51 . . . . 10.0 111.017 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -146.97 120.92 9.34 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.541 2.337 . . . . 10.0 109.833 176.432 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 54.93 14.71 0.97 Allowed 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.494 1.918 . . . . 10.0 115.341 178.663 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.28 -7.31 34.76 Favored Glycine 0 CA--C 1.539 1.582 0 C-N-CA 126.351 1.929 . . . . 10.0 115.487 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -99.55 159.75 14.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.587 1.555 . . . . 10.0 110.921 171.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.9 p -71.69 158.99 35.17 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.12 0.968 . . . . 10.0 112.788 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 39.0 t -135.71 102.47 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.984 1.714 . . . . 10.0 109.354 173.105 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.9 mt-30 -70.18 155.21 40.96 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.239 0.615 . . . . 10.0 111.251 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 67.6 p -69.63 160.23 31.96 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 123.562 0.745 . . . . 10.0 112.164 170.193 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -152.66 169.66 22.16 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.383 1.473 . . . . 10.0 111.024 178.325 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.9 -35.01 68.47 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 120.867 -1.146 . . . . 10.0 112.749 168.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 77.1 mt -82.65 -14.08 55.33 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.506 1.122 . . . . 10.0 113.889 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -135.25 69.53 1.44 Allowed 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.782 1.633 . . . . 10.0 111.501 -173.129 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 77.9 mttt -71.34 134.22 46.56 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.037 1.335 . . . . 10.0 110.547 -179.008 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 60.4 mtt -131.75 101.04 5.3 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 126.22 1.808 . . . . 10.0 109.524 -174.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.19 159.15 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 124.839 1.256 . . . . 10.0 112.562 -170.309 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.53 167.9 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 126.007 1.723 . . . . 10.0 111.992 -177.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 34.2 t -131.14 147.39 52.6 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 125.545 1.538 . . . . 10.0 112.128 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -57.82 -20.37 35.44 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.831 1.652 . . . . 10.0 113.87 168.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -78.0 -1.36 31.74 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.788 1.635 . . . . 10.0 114.355 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 79.87 60.94 2.34 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 124.677 1.132 . . . . 10.0 111.935 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 42.9 tp -150.97 148.53 28.5 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.96 1.704 . . . . 10.0 110.862 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -132.84 129.24 38.21 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.897 2.079 . . . . 10.0 110.097 174.141 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.1 m -108.81 147.1 32.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.475 1.51 . . . . 10.0 112.146 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.91 108.57 9.48 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 126.623 1.969 . . . . 10.0 108.333 171.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -89.89 151.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 125.268 1.427 . . . . 10.0 110.329 -178.334 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -130.61 99.69 5.06 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.94 2.096 . . . . 10.0 108.38 167.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -62.4 -38.4 89.49 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 113.225 0.824 . . . . 10.0 113.225 -176.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.8 p -149.65 87.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 125.897 1.679 . . . . 10.0 110.133 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.1 p -70.07 139.53 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 121.347 -0.846 . . . . 10.0 112.029 -176.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.4 mmm180 -128.42 161.68 28.92 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.466 1.907 . . . . 10.0 111.26 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -52.21 -35.95 50.78 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 114.195 1.183 . . . . 10.0 114.195 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.7 -17.72 64.36 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.242 1.417 . . . . 10.0 114.673 176.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -82.52 -5.92 59.02 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.74 1.216 . . . . 10.0 113.473 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 151.01 47.6 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.988 -1.07 . . . . 10.0 113.187 179.129 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.49 -172.63 22.4 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.872 1.225 . . . . 10.0 115.069 175.664 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.72 102.54 13.07 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.075 1.75 . . . . 10.0 111.538 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -79.67 149.02 31.37 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 124.291 1.037 . . . . 10.0 111.932 171.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.9 159.26 43.18 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.906 0.882 . . . . 10.0 112.271 170.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 49.8 t -137.68 118.2 13.87 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 125.139 1.375 . . . . 10.0 111.391 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 42.3 t -87.75 124.85 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 125.169 1.388 . . . . 10.0 109.268 172.128 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -117.65 128.16 54.65 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.456 1.903 . . . . 10.0 111.075 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.0 mtmt -133.83 130.12 37.47 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 126.116 1.767 . . . . 10.0 112.159 -167.04 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -136.4 -179.56 5.75 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 118.879 0.763 . . . . 10.0 112.305 162.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -59.33 -14.68 12.48 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 115.823 1.786 . . . . 10.0 115.823 -177.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.6 -12.28 15.0 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.452 1.501 . . . . 10.0 114.357 -178.43 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 162.98 -172.39 38.99 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.443 1.02 . . . . 10.0 115.457 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -134.6 147.76 50.28 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.239 1.816 . . . . 10.0 111.57 -173.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.08 163.26 30.74 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.537 1.935 . . . . 10.0 110.785 169.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 96.4 m -144.29 124.28 13.57 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.514 1.126 . . . . 10.0 110.649 177.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -113.54 155.5 25.27 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.523 1.529 . . . . 10.0 111.17 -176.772 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.5 m -141.77 148.51 39.05 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.621 1.168 . . . . 10.0 112.41 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.79 171.01 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 127.024 2.13 . . . . 10.0 110.603 168.368 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -128.78 140.63 51.62 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.924 1.29 . . . . 10.0 111.12 172.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.3 tp -125.41 111.81 15.56 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.4 1.88 . . . . 10.0 110.642 -178.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -97.38 85.85 3.75 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.8 1.64 . . . . 10.0 110.864 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.5 t -67.08 112.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.364 -0.835 . . . . 10.0 110.599 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.51 94.16 3.66 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.037 1.735 . . . . 10.0 110.1 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.77 0 C-N-CA 124.519 1.127 . . . . 10.0 112.764 -179.953 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo . . . . . 0 CA--C 1.544 0.991 0 N-CA-C 113.31 0.466 . . . . 10.0 113.31 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -69.73 168.26 22.02 Favored 'Trans proline' 0 CA--C 1.541 0.867 0 C-N-CA 123.249 2.632 . . . . 10.0 112.361 171.599 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 58.2 ttp85 -134.44 156.42 48.6 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.322 1.449 . . . . 10.0 112.22 -174.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -93.94 64.6 3.4 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 126.816 2.047 . . . . 10.0 111.086 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.48 -66.08 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.095 -1.003 . . . . 10.0 112.679 -170.304 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -155.24 165.03 37.94 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.0 m -132.92 161.99 60.32 Favored Pre-proline 0 N--CA 1.476 0.829 0 C-N-CA 127.871 2.468 . . . . 10.0 110.492 170.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.67 164.02 32.86 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.832 2.355 . . . . 10.0 111.228 164.03 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -72.59 169.43 16.55 Favored 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.251 -0.906 . . . . 10.0 112.523 169.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.31 148.79 40.09 Favored 'General case' 0 CA--C 1.546 0.789 0 O-C-N 121.346 -0.846 . . . . 10.0 112.652 173.309 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 75.8 mtp -130.81 154.07 48.42 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.882 1.273 . . . . 10.0 112.48 -170.117 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 64.6 m -140.48 101.03 4.01 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.302 1.841 . . . . 10.0 110.107 -176.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 37.6 mm -117.8 134.31 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 124.528 1.131 . . . . 10.0 111.292 -166.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -64.11 130.06 42.46 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.816 1.246 . . . . 10.0 112.445 173.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -53.24 129.8 32.64 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.112 1.365 . . . . 10.0 112.925 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.74 -11.5 62.73 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 126.305 1.907 . . . . 10.0 115.041 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -75.72 161.18 29.28 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.001 1.401 . . . . 10.0 113.276 177.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.9 149.22 46.96 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.665 1.186 . . . . 10.0 110.71 157.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 10.7 t -150.39 160.43 43.75 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.755 1.222 . . . . 10.0 111.903 168.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -151.65 167.41 28.23 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.342 1.457 . . . . 10.0 112.883 167.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -132.91 167.03 20.98 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.646 1.978 . . . . 10.0 112.119 -176.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -134.55 108.35 8.03 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.258 1.823 . . . . 10.0 111.775 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -117.67 112.17 20.14 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.448 1.499 . . . . 10.0 111.42 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -71.96 108.5 5.24 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.4 1.08 . . . . 10.0 110.31 174.378 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 18.0 t -117.59 149.32 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.684 1.594 . . . . 10.0 109.819 177.473 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.4 t -148.15 -177.58 5.82 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.254 1.422 . . . . 10.0 111.112 175.167 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 122.77 162.14 11.44 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 127.65 2.548 . . . . 10.0 111.795 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.1 tp -144.61 122.73 6.68 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-O 118.083 -0.96 . . . . 10.0 110.571 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -66.56 167.89 53.29 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.689 1.282 . . . . 10.0 112.627 -1.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.24 126.02 72.72 Favored Pre-proline 0 CA--C 1.549 0.935 0 C-N-CA 124.454 1.102 . . . . 10.0 111.291 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.51 149.9 62.79 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.406 2.071 . . . . 10.0 113.321 -173.116 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -74.66 151.05 39.33 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.61 1.164 . . . . 10.0 109.918 159.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 59.1 t -131.56 138.46 52.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.963 0.905 . . . . 10.0 112.125 -169.424 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 63.2 m -132.73 115.27 15.14 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 126.767 2.027 . . . . 10.0 110.61 177.378 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 53.4 m95 -86.44 158.83 19.5 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 122.001 0.905 . . . . 10.0 112.85 176.186 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -144.69 159.88 42.11 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 127.063 2.145 . . . . 10.0 111.235 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.6 tp -145.65 118.12 8.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.146 2.178 . . . . 10.0 110.062 175.599 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 54.87 14.95 0.99 Allowed 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 126.479 1.912 . . . . 10.0 115.092 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.82 -14.02 34.78 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 126.747 2.118 . . . . 10.0 115.165 -177.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -83.41 155.53 23.42 Favored 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 118.981 1.39 . . . . 10.0 110.929 169.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.7 p -71.46 155.14 40.94 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.27 1.028 . . . . 10.0 112.602 173.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 59.5 t -136.63 135.96 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 126.678 1.991 . . . . 10.0 108.976 172.76 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -119.09 164.01 16.17 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 125.267 1.427 . . . . 10.0 111.344 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 98.1 p -66.89 152.76 45.05 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.655 0.741 . . . . 10.0 112.441 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -151.95 167.96 26.71 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.827 1.651 . . . . 10.0 110.656 176.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.65 -34.92 67.78 Favored 'General case' 0 CA--C 1.545 0.772 0 O-C-N 120.97 -1.081 . . . . 10.0 112.832 169.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.4 mt -85.39 -13.55 49.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.55 1.14 . . . . 10.0 114.001 174.077 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.3 m80 -136.08 70.35 1.42 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.658 1.583 . . . . 10.0 111.184 -174.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -69.91 145.28 52.06 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.713 1.205 . . . . 10.0 111.636 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.4 mtt -139.41 101.74 4.31 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.785 2.034 . . . . 10.0 109.736 -176.22 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.37 162.24 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.851 1.26 . . . . 10.0 111.818 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 13.8 p -136.83 134.61 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.631 1.172 . . . . 10.0 111.269 -179.119 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 40.7 t -65.21 159.89 22.65 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.923 1.289 . . . . 10.0 112.505 177.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -52.19 -33.15 39.53 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.538 1.535 . . . . 10.0 111.965 164.056 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -81.72 -3.63 54.19 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.405 1.882 . . . . 10.0 113.735 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.25 -3.48 82.23 Favored Glycine 0 CA--C 1.538 1.494 0 C-N-CA 125.75 1.643 . . . . 10.0 115.468 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 48.2 tp -67.97 107.59 2.74 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.846 1.259 . . . . 10.0 111.165 174.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.6 t60 -84.86 124.57 31.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.781 1.632 . . . . 10.0 111.514 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.8 m -97.74 134.1 41.37 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.638 1.575 . . . . 10.0 111.793 171.275 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -123.07 123.55 41.1 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 127.154 2.182 . . . . 10.0 107.94 171.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 47.4 mt -121.79 153.63 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 125.124 1.37 . . . . 10.0 111.517 -166.034 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -132.18 108.23 9.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 128.044 2.538 . . . . 10.0 109.224 172.173 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -66.73 -38.79 87.37 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.846 -1.159 . . . . 10.0 112.914 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.5 p -151.78 89.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.684 1.593 . . . . 10.0 110.441 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.35 140.56 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 121.212 -0.93 . . . . 10.0 111.883 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -129.34 162.3 28.3 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 126.385 1.874 . . . . 10.0 111.267 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -53.11 -35.11 59.28 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.128 1.158 . . . . 10.0 114.128 -175.146 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.4 m -65.09 -17.83 64.79 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.32 1.448 . . . . 10.0 114.644 176.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -82.9 -7.0 59.7 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.754 1.222 . . . . 10.0 113.518 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.97 147.9 52.64 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.096 -1.003 . . . . 10.0 113.218 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.74 -171.99 24.19 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.507 1.051 . . . . 10.0 115.448 173.563 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.69 104.15 11.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.846 1.658 . . . . 10.0 110.893 173.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -80.79 151.1 28.93 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.985 0.914 . . . . 10.0 111.751 170.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.93 161.19 38.42 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.093 0.957 . . . . 10.0 112.132 168.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 29.6 t -141.49 104.79 4.64 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.549 1.94 . . . . 10.0 109.766 -172.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.69 131.1 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.576 1.15 . . . . 10.0 109.386 174.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.15 126.15 44.81 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.304 1.842 . . . . 10.0 110.721 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -134.35 135.42 42.69 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.479 1.512 . . . . 10.0 112.435 -169.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -130.04 -178.2 4.63 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.577 1.151 . . . . 10.0 111.712 166.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -59.88 -12.41 7.55 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 115.841 1.793 . . . . 10.0 115.841 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.7 -14.31 12.02 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.448 1.499 . . . . 10.0 114.589 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.32 -170.3 42.88 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-N 119.978 1.263 . . . . 10.0 116.165 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -134.74 144.35 47.67 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.104 2.162 . . . . 10.0 111.674 -172.608 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.98 163.13 31.44 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.039 1.735 . . . . 10.0 111.043 168.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -142.26 140.44 32.24 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.16 0.984 . . . . 10.0 111.492 -175.317 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -126.93 156.69 41.09 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 126.097 1.759 . . . . 10.0 110.841 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.8 m -145.3 146.62 31.71 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 124.761 1.224 . . . . 10.0 111.682 -171.221 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.59 161.65 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 125.894 1.678 . . . . 10.0 110.848 169.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.2 tt0 -116.75 128.52 55.39 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.583 1.153 . . . . 10.0 110.466 170.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.9 tp -118.55 104.15 10.39 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 126.003 1.721 . . . . 10.0 109.831 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -77.99 138.74 38.99 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.23 0.612 . . . . 10.0 110.108 163.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 27.8 t -117.01 105.16 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.051 0.94 . . . . 10.0 109.157 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.8 mt -67.62 97.71 0.63 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.535 1.934 . . . . 10.0 109.869 179.155 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.769 0 C-N-CA 124.382 1.073 . . . . 10.0 112.683 -179.385 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 N-CA-C 113.101 0.385 . . . . 10.0 113.101 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -66.86 150.84 83.12 Favored 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 122.784 2.322 . . . . 10.0 111.064 168.419 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 64.2 ttt-85 -138.54 153.74 48.73 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.317 1.447 . . . . 10.0 111.62 -177.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.95 117.2 9.5 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.614 1.166 . . . . 10.0 111.052 169.29 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.32 -57.78 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.102 1.361 . . . . 10.0 110.368 176.118 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -149.53 137.15 20.17 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.847 1.259 . . . . 10.0 111.547 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -131.96 153.82 81.52 Favored Pre-proline 0 N--CA 1.474 0.736 0 C-N-CA 126.488 1.915 . . . . 10.0 110.028 170.345 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.75 162.91 36.8 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.627 2.218 . . . . 10.0 111.433 171.472 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.13 179.92 2.61 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.629 0.772 . . . . 10.0 110.738 161.281 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -58.11 142.68 46.32 Favored 'General case' 0 CA--C 1.546 0.82 0 O-C-N 120.506 -1.372 . . . . 10.0 111.156 166.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 89.9 mtp -122.53 157.33 32.27 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 125.484 1.513 . . . . 10.0 111.937 -172.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 57.8 p -144.38 129.62 18.73 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.295 1.438 . . . . 10.0 110.691 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.9 mm -134.51 133.97 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.7 1.6 . . . . 10.0 109.288 -170.511 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -63.94 130.83 45.67 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.616 1.166 . . . . 10.0 112.171 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -52.28 126.69 19.74 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.01 1.324 . . . . 10.0 112.509 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.0 61.46 Favored Glycine 0 CA--C 1.537 1.423 0 C-N-CA 125.842 1.687 . . . . 10.0 115.22 179.033 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -72.72 160.59 31.96 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.379 1.59 . . . . 10.0 113.105 175.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -72.67 149.38 43.9 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 124.488 1.115 . . . . 10.0 110.513 157.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 34.6 t -148.78 157.0 43.13 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.461 1.104 . . . . 10.0 111.272 167.784 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -144.73 154.47 42.77 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.003 1.321 . . . . 10.0 111.503 164.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.3 mtt -125.61 113.25 17.14 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 125.718 1.607 . . . . 10.0 111.107 -173.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -69.65 127.53 33.27 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.426 1.49 . . . . 10.0 112.766 174.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -137.97 93.82 2.81 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.105 1.362 . . . . 10.0 110.976 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -67.38 121.25 15.34 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.551 0.741 . . . . 10.0 110.124 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.8 p -135.17 115.59 18.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 126.859 2.064 . . . . 10.0 110.189 -173.668 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 66.2 m -126.98 107.25 9.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.892 1.277 . . . . 10.0 111.59 -173.532 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -156.15 167.58 33.38 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 127.166 2.317 . . . . 10.0 110.927 169.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -142.14 125.58 9.63 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 124.417 1.087 . . . . 10.0 110.686 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -66.06 168.06 49.72 Favored 'Cis proline' 0 CA--C 1.539 0.763 0 CA-C-N 120.622 1.258 . . . . 10.0 112.453 -2.634 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 123.45 57.07 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 124.348 1.059 . . . . 10.0 111.264 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.83 149.21 66.14 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.428 2.085 . . . . 10.0 112.999 -172.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -72.1 139.19 48.27 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.263 1.025 . . . . 10.0 109.535 161.26 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.36 142.05 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.266 1.027 . . . . 10.0 113.136 -172.329 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.7 m -141.39 115.34 9.2 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 125.841 1.657 . . . . 10.0 111.195 -176.355 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 71.1 m95 -84.07 151.22 25.08 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 122.2 1.0 . . . . 10.0 113.43 176.396 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -141.3 161.3 38.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 128.249 2.619 . . . . 10.0 110.776 -179.379 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.1 tp -147.09 119.78 8.59 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.431 2.292 . . . . 10.0 110.041 176.508 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 55.02 15.29 1.14 Allowed 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 126.581 1.952 . . . . 10.0 115.045 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.33 -12.53 40.01 Favored Glycine 0 CA--C 1.539 1.564 0 C-N-CA 126.607 2.051 . . . . 10.0 115.104 -177.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -87.67 158.33 18.86 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 119.008 1.404 . . . . 10.0 110.824 170.051 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.8 p -71.25 158.32 36.59 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.99 0.916 . . . . 10.0 112.345 173.317 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 40.1 t -134.62 100.82 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.844 1.658 . . . . 10.0 108.779 171.432 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -71.43 156.22 39.72 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.346 0.658 . . . . 10.0 110.693 170.236 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.0 p -70.08 151.96 44.9 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 121.559 -0.713 . . . . 10.0 111.908 170.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -152.74 -177.49 6.29 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.051 1.34 . . . . 10.0 111.949 171.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -60.3 -22.75 63.54 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 114.64 1.348 . . . . 10.0 114.64 -177.564 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 52.9 mt -104.19 -26.19 12.63 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.866 1.666 . . . . 10.0 112.67 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -110.9 74.14 0.86 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.416 1.886 . . . . 10.0 111.052 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 92.2 mttt -77.21 146.31 37.07 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.691 1.196 . . . . 10.0 111.175 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.1 mtt -145.34 102.51 3.73 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 126.06 1.744 . . . . 10.0 110.281 -170.587 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.91 163.25 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 124.505 1.122 . . . . 10.0 112.468 178.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 54.7 t -121.38 112.58 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.536 1.934 . . . . 10.0 109.266 174.499 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 74.7 m -69.25 151.51 46.18 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.76 0.824 . . . . 10.0 111.552 173.38 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -57.96 -19.68 32.2 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 115.346 1.61 . . . . 10.0 115.346 -174.366 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -75.97 -4.0 38.72 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.763 1.625 . . . . 10.0 113.994 178.104 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.09 48.92 4.43 Favored Glycine 0 CA--C 1.531 1.071 0 C-N-CA 125.161 1.363 . . . . 10.0 112.139 -175.195 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 51.5 tp -136.82 103.56 5.22 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.571 1.549 . . . . 10.0 110.642 -171.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 23.7 t60 -70.45 147.27 49.64 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 122.032 -0.418 . . . . 10.0 110.46 166.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 5.5 t -135.94 99.53 4.18 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.016 1.326 . . . . 10.0 111.204 176.152 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -81.86 120.28 24.99 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.485 1.514 . . . . 10.0 108.884 173.396 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 42.6 mt -115.55 151.6 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 125.125 1.37 . . . . 10.0 111.514 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -129.25 108.04 10.02 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.954 2.502 . . . . 10.0 109.258 170.169 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -63.94 -42.0 97.47 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.194 -0.942 . . . . 10.0 112.845 175.015 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.47 90.88 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.863 1.665 . . . . 10.0 110.121 -179.226 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.7 140.89 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.296 -0.878 . . . . 10.0 112.212 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -120.86 160.76 22.77 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.454 1.901 . . . . 10.0 112.057 176.15 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.86 -30.81 66.1 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 113.617 0.969 . . . . 10.0 113.617 -177.692 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.6 p -67.85 -15.62 63.71 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.921 1.689 . . . . 10.0 114.788 173.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -83.05 -5.08 58.97 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.599 1.16 . . . . 10.0 113.486 176.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.66 151.75 44.07 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.012 -1.055 . . . . 10.0 113.063 177.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.31 -173.07 22.67 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.915 1.245 . . . . 10.0 114.837 176.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -87.6 101.28 13.48 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.9 1.68 . . . . 10.0 111.274 176.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -78.37 151.78 32.65 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.295 1.038 . . . . 10.0 111.972 169.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.8 157.31 43.93 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.246 1.018 . . . . 10.0 112.109 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.6 t -134.97 104.89 6.14 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.645 1.578 . . . . 10.0 110.925 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.1 t -71.42 134.53 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 123.916 0.886 . . . . 10.0 109.131 168.281 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -133.51 119.46 19.56 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.756 2.023 . . . . 10.0 110.27 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.3 mtpt -134.4 136.06 43.05 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.79 1.236 . . . . 10.0 113.018 -170.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 24.9 p30 -132.51 -178.36 4.89 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.061 1.344 . . . . 10.0 111.547 167.093 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.1 ptm180 -60.97 -14.84 25.45 Favored 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 115.482 1.66 . . . . 10.0 115.482 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.03 -19.65 13.66 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.443 1.497 . . . . 10.0 114.208 -177.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.28 -169.98 42.63 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 116.142 1.217 . . . . 10.0 116.142 177.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -134.54 144.64 48.12 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 127.262 2.225 . . . . 10.0 111.664 -170.15 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.88 159.91 40.71 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 126.214 1.806 . . . . 10.0 110.794 167.067 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 32.8 m -140.35 101.14 4.05 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 124.457 1.103 . . . . 10.0 110.733 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -77.66 155.56 31.3 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.777 1.231 . . . . 10.0 111.254 175.277 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 28.3 m -146.98 146.35 30.05 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.728 1.211 . . . . 10.0 112.057 -174.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.3 p -154.3 145.99 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 125.819 1.648 . . . . 10.0 111.934 170.156 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -100.45 135.46 41.85 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.611 1.165 . . . . 10.0 110.929 170.806 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.1 tp -122.39 112.4 18.04 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.98 1.712 . . . . 10.0 111.026 177.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -100.0 85.22 3.01 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.942 1.697 . . . . 10.0 110.834 175.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -64.94 114.49 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.954 0.902 . . . . 10.0 110.684 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.6 mt -75.81 99.78 4.55 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.154 1.781 . . . . 10.0 110.042 179.686 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.861 0 C-N-CA 124.304 1.042 . . . . 10.0 113.525 -175.682 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo . . . . . 0 CA--C 1.543 0.932 0 N-CA-C 113.161 0.408 . . . . 10.0 113.161 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -67.05 158.78 55.17 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.861 2.374 . . . . 10.0 111.32 168.204 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.7 tpt85 -135.1 151.44 50.72 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.007 1.323 . . . . 10.0 111.772 -174.475 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -79.01 65.4 4.17 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 127.251 2.22 . . . . 10.0 111.812 -176.356 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 39.8 mm -63.16 -62.35 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 O-C-N 121.225 -0.922 . . . . 10.0 112.635 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -153.16 149.67 28.27 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.822 0.849 . . . . 10.0 112.59 -178.305 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.2 m -134.44 151.11 75.56 Favored Pre-proline 0 N--CA 1.477 0.925 0 C-N-CA 126.405 1.882 . . . . 10.0 110.558 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -74.65 159.77 42.06 Favored 'Trans proline' 0 CA--C 1.542 0.916 0 C-N-CA 123.049 2.499 . . . . 10.0 111.596 168.031 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -77.24 172.61 13.0 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 123.942 0.897 . . . . 10.0 111.542 167.748 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -49.61 108.86 0.23 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.416 1.486 . . . . 10.0 113.594 178.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.3 mtp -82.41 155.66 24.56 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.349 1.46 . . . . 10.0 112.008 -177.289 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 71.2 p -140.36 131.81 26.91 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.964 1.306 . . . . 10.0 111.023 170.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.2 mm -137.08 129.46 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.385 1.474 . . . . 10.0 109.94 -170.441 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -62.26 127.61 32.17 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.785 1.234 . . . . 10.0 112.169 172.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -52.82 135.02 36.59 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.289 1.435 . . . . 10.0 113.171 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.12 -11.27 69.45 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.046 1.784 . . . . 10.0 114.952 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.9 mtp-105 -77.63 162.73 26.82 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 118.989 1.394 . . . . 10.0 113.162 177.476 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -71.71 151.98 43.17 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.884 1.273 . . . . 10.0 110.763 158.327 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 36.0 t -148.41 156.83 42.98 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.496 1.118 . . . . 10.0 111.474 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -135.76 139.98 43.97 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 125.516 1.526 . . . . 10.0 110.858 162.397 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 43.9 mtt -100.77 155.39 17.94 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.801 1.641 . . . . 10.0 109.818 167.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -139.57 118.32 12.37 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.157 1.383 . . . . 10.0 110.984 -170.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -130.52 106.84 8.78 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 125.992 1.717 . . . . 10.0 111.952 -170.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -65.93 127.64 32.84 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.902 0.881 . . . . 10.0 110.52 173.126 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.1 125.34 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.642 1.577 . . . . 10.0 110.769 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 69.4 m -133.21 115.3 14.84 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.674 1.19 . . . . 10.0 111.907 -173.547 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -161.69 169.76 37.23 Favored Glycine 0 CA--C 1.536 1.393 0 C-N-CA 127.161 2.315 . . . . 10.0 111.381 172.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -143.7 125.3 8.24 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.09 0.956 . . . . 10.0 111.194 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.01 167.64 51.14 Favored 'Cis proline' 0 CA--C 1.539 0.744 0 CA-C-N 120.866 1.345 . . . . 10.0 112.476 -2.215 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.11 122.32 47.31 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.404 1.081 . . . . 10.0 111.231 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -69.34 148.59 68.16 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.42 2.08 . . . . 10.0 112.922 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -72.06 145.73 48.06 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.143 0.977 . . . . 10.0 109.736 161.3 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.98 139.72 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.556 1.142 . . . . 10.0 112.575 -172.054 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 73.2 m -136.81 142.12 42.91 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 126.024 1.729 . . . . 10.0 110.672 177.444 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -111.86 158.05 19.88 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.474 1.11 . . . . 10.0 113.278 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -145.69 159.57 42.96 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 127.256 2.222 . . . . 10.0 111.329 -174.15 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.4 tp -147.19 119.52 8.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.054 2.142 . . . . 10.0 110.0 175.5 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 55.26 14.05 0.98 Allowed 'General case' 0 CA--C 1.554 1.106 0 C-N-CA 126.537 1.935 . . . . 10.0 115.376 179.024 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.17 -12.22 31.4 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.564 2.031 . . . . 10.0 115.182 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -89.9 160.68 16.32 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 118.924 1.362 . . . . 10.0 110.978 169.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.5 p -73.99 158.92 33.48 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.369 1.067 . . . . 10.0 112.752 175.276 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 87.6 t -136.82 104.98 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 127.097 2.159 . . . . 10.0 108.623 173.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -79.68 161.54 25.77 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.417 0.687 . . . . 10.0 111.131 170.24 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.9 p -70.27 148.02 49.03 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.564 0.746 . . . . 10.0 112.211 171.198 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -152.61 -179.93 8.04 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 125.365 1.466 . . . . 10.0 111.328 168.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -57.97 -27.53 63.53 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.698 1.37 . . . . 10.0 114.698 -176.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 57.2 mt -93.11 -13.97 27.84 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.23 1.412 . . . . 10.0 113.084 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -131.97 68.82 1.49 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.545 1.938 . . . . 10.0 111.204 -172.231 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -72.9 146.61 46.02 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.092 1.357 . . . . 10.0 111.321 -179.204 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -139.2 110.35 6.89 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 126.547 1.939 . . . . 10.0 110.278 -172.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.26 162.78 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 125.079 1.351 . . . . 10.0 112.212 -177.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.4 t -129.8 104.09 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.518 1.527 . . . . 10.0 109.491 177.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 70.8 m -73.05 166.32 23.33 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 125.063 1.345 . . . . 10.0 112.804 177.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.07 158.52 6.73 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.292 1.437 . . . . 10.0 112.323 175.02 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt 64.8 9.64 5.45 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 127.392 2.277 . . . . 10.0 114.782 -172.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.2 62.74 1.86 Allowed Glycine 0 CA--C 1.53 1.027 0 C-N-CA 125.178 1.371 . . . . 10.0 113.491 173.235 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 43.2 tp -131.03 99.86 5.04 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.027 1.331 . . . . 10.0 111.09 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -76.68 133.95 39.39 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.923 0.889 . . . . 10.0 110.739 172.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 49.4 m -121.01 141.23 50.92 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.574 1.55 . . . . 10.0 111.434 178.588 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -133.2 115.78 15.43 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 126.788 2.035 . . . . 10.0 108.641 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 49.5 mt -105.35 154.36 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 124.83 1.252 . . . . 10.0 111.836 -168.599 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -130.4 107.51 9.3 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.496 2.318 . . . . 10.0 109.019 167.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 -63.77 -42.83 97.72 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.256 -0.902 . . . . 10.0 113.049 178.2 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 3.5 p -151.66 91.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 125.845 1.658 . . . . 10.0 110.233 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -74.63 142.47 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 O-C-N 121.368 -0.833 . . . . 10.0 112.123 -177.097 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -129.02 163.26 25.77 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 126.408 1.883 . . . . 10.0 111.394 177.134 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.5 -31.72 62.28 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -174.251 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.0 m -67.75 -16.31 64.06 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 114.166 1.173 . . . . 10.0 114.166 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -83.87 -5.98 59.33 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.732 1.213 . . . . 10.0 113.48 178.166 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.04 151.69 42.31 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 120.985 -1.072 . . . . 10.0 113.1 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 140.11 -174.0 22.68 Favored Glycine 0 CA--C 1.533 1.161 0 C-N-CA 124.317 0.96 . . . . 10.0 114.993 176.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 98.53 9.24 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.888 1.675 . . . . 10.0 111.367 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -76.37 146.92 38.41 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.016 0.926 . . . . 10.0 111.386 168.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.4 160.32 41.25 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.595 0.758 . . . . 10.0 112.425 169.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.0 t -133.39 142.28 48.29 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.091 2.156 . . . . 10.0 109.841 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.29 124.5 71.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.536 1.534 . . . . 10.0 108.72 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.39 124.48 51.3 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.374 1.87 . . . . 10.0 110.451 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -134.16 134.95 42.74 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.01 1.324 . . . . 10.0 112.543 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -130.87 -178.24 4.72 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 124.624 1.17 . . . . 10.0 111.55 166.512 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 -60.14 -12.61 8.92 Favored 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 115.804 1.779 . . . . 10.0 115.804 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.45 -16.19 13.38 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.381 1.472 . . . . 10.0 114.525 -178.04 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.78 -168.83 40.92 Favored Glycine 0 CA--C 1.533 1.217 0 CA-C-N 119.884 1.22 . . . . 10.0 116.124 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -134.11 145.78 49.65 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 127.117 2.167 . . . . 10.0 111.878 -170.746 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.75 161.02 37.12 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.133 1.773 . . . . 10.0 111.205 168.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 60.8 m -137.11 141.92 42.3 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.084 1.354 . . . . 10.0 110.966 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -135.98 137.04 40.86 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.595 1.558 . . . . 10.0 110.056 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.5 m -141.65 143.7 33.76 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.797 0.839 . . . . 10.0 112.049 -167.468 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.6 p -152.36 142.51 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 125.279 1.431 . . . . 10.0 111.947 171.37 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -90.34 136.25 33.17 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.996 0.918 . . . . 10.0 110.751 168.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.6 tp -118.82 104.22 10.36 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.879 1.672 . . . . 10.0 110.909 178.365 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -84.63 88.3 7.33 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.036 1.334 . . . . 10.0 110.846 170.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.78 108.04 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.228 -0.92 . . . . 10.0 109.84 174.055 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.9 mt -73.96 97.03 2.74 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.072 1.749 . . . . 10.0 109.852 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.796 0 C-N-CA 124.65 1.18 . . . . 10.0 113.754 -174.825 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 CA--C 1.543 0.953 0 N-CA-C 113.228 0.434 . . . . 10.0 113.228 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -63.99 139.13 66.02 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.963 2.442 . . . . 10.0 110.795 172.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 76.4 ttt-85 -139.41 141.41 37.52 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.39 1.076 . . . . 10.0 113.568 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -59.19 118.88 6.4 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.352 2.261 . . . . 10.0 111.912 171.103 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.6 -52.75 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.262 1.025 . . . . 10.0 110.001 165.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 40.1 tt0 -150.57 134.86 17.06 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.649 1.18 . . . . 10.0 111.145 176.306 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 31.7 m -119.35 152.78 53.12 Favored Pre-proline 0 N--CA 1.475 0.791 0 C-N-CA 126.0 1.72 . . . . 10.0 109.266 168.039 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -75.73 163.77 33.17 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.599 2.2 . . . . 10.0 112.211 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.52 170.77 14.47 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.484 -0.76 . . . . 10.0 110.79 163.091 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.6 p30 -61.18 157.69 15.58 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.167 -0.958 . . . . 10.0 111.867 169.222 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -127.2 151.92 48.05 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.592 1.557 . . . . 10.0 111.664 -170.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -143.67 84.64 1.8 Allowed 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.304 1.442 . . . . 10.0 111.183 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 40.4 mm -102.41 136.56 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.304 1.441 . . . . 10.0 110.593 -170.422 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -66.92 129.15 38.96 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.441 1.096 . . . . 10.0 112.414 175.126 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -53.92 128.09 28.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.169 1.388 . . . . 10.0 112.704 178.702 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 104.7 -13.19 50.38 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 126.564 2.031 . . . . 10.0 114.651 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -77.43 161.86 27.65 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 118.775 1.288 . . . . 10.0 113.577 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -75.32 144.08 42.58 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.683 1.193 . . . . 10.0 110.433 155.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.72 172.36 16.23 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 123.686 0.794 . . . . 10.0 112.394 159.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -147.18 168.3 22.01 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.397 1.479 . . . . 10.0 112.516 173.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 45.8 mtt -118.03 165.88 13.2 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 126.508 1.923 . . . . 10.0 111.7 176.417 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -142.62 107.95 5.02 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.586 1.555 . . . . 10.0 112.448 -171.814 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -125.7 101.44 6.88 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 126.489 1.916 . . . . 10.0 111.128 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -76.59 111.2 11.82 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.118 -0.989 . . . . 10.0 109.685 172.113 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -123.76 102.16 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 125.666 1.586 . . . . 10.0 110.481 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 12.3 t -73.76 173.08 10.35 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.725 0.81 . . . . 10.0 111.357 171.79 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 124.16 162.89 11.56 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 127.076 2.274 . . . . 10.0 112.431 -176.084 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -152.52 130.84 6.28 Favored Pre-proline 0 CA--C 1.547 0.835 0 C-N-CA 124.393 1.077 . . . . 10.0 110.828 -177.006 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -67.89 169.25 54.77 Favored 'Cis proline' 0 CA--C 1.539 0.762 0 CA-C-N 120.891 1.354 . . . . 10.0 112.735 -2.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.04 122.19 46.05 Favored Pre-proline 0 CA--C 1.549 0.917 0 C-N-CA 124.658 1.183 . . . . 10.0 111.038 178.043 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.1 151.0 61.0 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 122.483 2.122 . . . . 10.0 113.295 -170.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 150.45 47.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.158 0.983 . . . . 10.0 109.531 157.402 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 p -138.48 143.85 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 113.269 0.84 . . . . 10.0 113.269 -174.149 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 21.6 m -127.12 151.7 48.3 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.901 2.081 . . . . 10.0 110.353 173.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 34.9 m95 -125.51 157.59 36.65 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.282 1.033 . . . . 10.0 112.865 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 74.9 m-85 -147.16 160.13 42.8 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 126.309 1.844 . . . . 10.0 111.553 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.8 tp -148.45 124.77 10.88 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 127.38 2.272 . . . . 10.0 110.121 176.346 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 53.42 14.18 0.53 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.845 2.058 . . . . 10.0 116.202 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.2 0.49 25.23 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.732 1.634 . . . . 10.0 115.962 -179.338 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.4 ptp85 -122.21 166.55 14.44 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 125.769 1.628 . . . . 10.0 112.319 173.352 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 20.1 p -71.58 158.85 35.47 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.835 1.254 . . . . 10.0 113.674 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 97.1 t -136.84 142.52 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 128.069 2.547 . . . . 10.0 108.299 171.037 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.2 mt-30 -128.93 163.67 24.8 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.151 1.38 . . . . 10.0 111.344 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 52.9 p -66.67 148.54 51.77 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.616 0.766 . . . . 10.0 112.383 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -152.44 167.27 29.3 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.727 1.611 . . . . 10.0 110.824 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -56.63 -34.93 67.75 Favored 'General case' 0 CA--C 1.546 0.796 0 O-C-N 121.005 -1.06 . . . . 10.0 112.963 170.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 82.9 mt -84.84 -14.74 47.04 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.527 1.131 . . . . 10.0 113.902 174.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.83 70.52 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.546 1.538 . . . . 10.0 111.371 -172.57 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.57 147.7 48.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.591 1.156 . . . . 10.0 111.517 -176.509 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -134.36 107.09 7.42 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 126.927 2.091 . . . . 10.0 109.467 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.31 161.32 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.429 -176.113 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 19.7 t -135.75 120.19 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 125.882 1.673 . . . . 10.0 109.509 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 22.6 t -64.33 160.32 19.12 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.439 1.096 . . . . 10.0 112.341 175.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -51.8 -35.48 44.32 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.781 1.633 . . . . 10.0 112.579 173.472 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 44.8 mmtm -82.15 -0.7 46.09 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.022 1.729 . . . . 10.0 114.704 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.52 8.65 65.65 Favored Glycine 0 CA--C 1.538 1.479 0 C-N-CA 124.987 1.28 . . . . 10.0 115.345 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 50.3 tp -76.7 102.01 6.03 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.71 1.204 . . . . 10.0 110.699 171.341 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -78.29 144.21 36.33 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.36 1.064 . . . . 10.0 111.085 168.15 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 17.2 m -135.37 155.14 51.07 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.174 1.39 . . . . 10.0 112.833 173.194 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.05 116.09 15.07 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 128.122 2.569 . . . . 10.0 107.949 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -98.61 154.79 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.405 1.482 . . . . 10.0 111.26 -171.615 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -130.6 104.91 7.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.127 2.171 . . . . 10.0 108.831 164.156 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.8 mm-40 -64.0 -37.09 86.15 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.287 -0.883 . . . . 10.0 113.023 178.018 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.0 p -150.61 91.66 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 125.816 1.646 . . . . 10.0 110.3 177.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.29 139.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 121.3 -0.875 . . . . 10.0 112.194 -176.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -125.9 161.05 28.33 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 126.853 2.061 . . . . 10.0 111.112 176.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.37 -29.64 64.21 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.716 1.206 . . . . 10.0 113.74 -177.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 39.5 p -67.08 -17.07 64.72 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 125.477 1.511 . . . . 10.0 114.597 173.254 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -82.27 -6.49 59.27 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.7 1.2 . . . . 10.0 113.256 174.251 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.56 152.45 45.25 Favored 'General case' 0 CA--C 1.546 0.806 0 O-C-N 120.912 -1.117 . . . . 10.0 113.403 -178.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 133.14 -170.21 22.3 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.79 1.186 . . . . 10.0 115.147 174.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.66 105.64 16.37 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.052 1.741 . . . . 10.0 111.197 177.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -81.38 153.75 26.81 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.378 1.071 . . . . 10.0 111.769 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.01 159.09 42.96 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.016 0.927 . . . . 10.0 112.006 167.436 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 37.6 t -138.81 127.19 22.96 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 127.052 2.141 . . . . 10.0 109.248 -173.416 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.8 t -122.68 113.09 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.26 1.424 . . . . 10.0 109.49 -175.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -108.44 135.17 50.18 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.64 1.576 . . . . 10.0 111.231 -177.098 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.28 133.71 37.25 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.735 1.614 . . . . 10.0 111.763 -171.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -135.1 179.99 5.98 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.148 0.979 . . . . 10.0 111.99 166.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -61.32 -9.37 5.1 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 115.83 1.789 . . . . 10.0 115.83 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.84 -12.62 13.29 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 125.823 1.649 . . . . 10.0 114.332 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.77 -170.49 40.59 Favored Glycine 0 CA--C 1.535 1.343 0 CA-C-N 120.02 1.282 . . . . 10.0 115.949 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -135.43 147.56 49.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.858 2.063 . . . . 10.0 111.487 -176.125 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -141.06 158.36 44.04 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.629 1.572 . . . . 10.0 111.93 172.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 85.4 m -136.71 130.59 32.29 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.096 1.358 . . . . 10.0 111.148 -176.354 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -123.87 156.35 36.4 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.496 1.918 . . . . 10.0 110.815 -178.01 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.2 m -142.85 145.6 33.3 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 124.463 1.105 . . . . 10.0 111.559 -169.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.0 p -151.59 159.1 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 125.894 1.678 . . . . 10.0 110.85 172.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -121.83 137.17 54.88 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.808 1.243 . . . . 10.0 111.015 176.006 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.2 tp -124.65 105.3 9.22 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 126.359 1.864 . . . . 10.0 110.277 -178.698 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -93.97 80.35 4.12 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.676 1.59 . . . . 10.0 110.809 176.342 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -62.3 115.27 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.701 0.8 . . . . 10.0 110.95 -178.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.1 mt -76.03 97.38 4.02 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.702 1.601 . . . . 10.0 109.792 178.417 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.856 0 C-N-CA 124.731 1.212 . . . . 10.0 113.962 -173.185 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo . . . . . 0 CA--C 1.543 0.949 0 N-CA-C 113.045 0.363 . . . . 10.0 113.045 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -70.92 167.56 25.59 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.231 2.62 . . . . 10.0 112.58 173.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -135.42 156.75 48.41 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.223 1.409 . . . . 10.0 112.703 -171.336 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -96.94 74.37 2.62 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.161 2.185 . . . . 10.0 110.695 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.5 mp -76.05 -71.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.134 -0.979 . . . . 10.0 112.322 -173.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -152.13 143.47 23.34 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.983 0.913 . . . . 10.0 112.281 -174.695 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.91 152.55 54.1 Favored Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 126.295 1.838 . . . . 10.0 110.57 172.177 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -74.29 160.84 41.57 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.768 2.312 . . . . 10.0 111.348 172.665 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -72.16 165.7 23.83 Favored 'General case' 0 CA--C 1.543 0.711 0 O-C-N 121.452 -0.78 . . . . 10.0 111.551 169.217 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -62.19 158.05 17.87 Favored 'General case' 0 CA--C 1.546 0.792 0 O-C-N 121.453 -0.779 . . . . 10.0 112.433 174.037 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 46.5 mtm -130.15 162.32 29.13 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.318 1.047 . . . . 10.0 112.912 -178.013 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -139.83 96.37 3.06 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.862 2.065 . . . . 10.0 110.482 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.1 mm -112.74 133.29 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 124.594 1.158 . . . . 10.0 111.214 -166.068 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -60.15 126.93 29.42 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.439 1.496 . . . . 10.0 112.456 172.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -55.18 127.13 27.76 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.273 1.029 . . . . 10.0 112.18 -178.484 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.92 -10.43 58.67 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 126.004 1.764 . . . . 10.0 114.955 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -73.93 161.19 30.37 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 119.362 1.581 . . . . 10.0 113.333 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -75.98 140.32 41.96 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.328 1.451 . . . . 10.0 110.264 157.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.48 166.3 31.54 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.702 0.801 . . . . 10.0 112.598 165.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm85 -141.69 168.0 20.81 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.88 1.272 . . . . 10.0 113.744 175.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 52.3 mtt -131.76 160.29 35.97 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 127.317 2.247 . . . . 10.0 111.01 175.231 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -140.96 103.52 4.49 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.442 1.497 . . . . 10.0 111.932 -168.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 -113.85 121.59 44.47 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.849 1.66 . . . . 10.0 111.677 -176.518 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.7 mtpp -77.48 127.35 32.37 Favored 'General case' 0 N--CA 1.478 0.955 0 O-C-N 121.382 -0.824 . . . . 10.0 110.887 173.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.7 p -138.96 145.12 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.596 1.558 . . . . 10.0 111.053 -179.04 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.9 t -142.99 -176.06 4.76 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.63 1.572 . . . . 10.0 110.886 178.286 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 118.42 164.49 13.0 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 127.519 2.485 . . . . 10.0 112.005 -172.517 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.5 tp -147.27 129.08 7.44 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 123.975 0.91 . . . . 10.0 110.785 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.4 169.15 47.01 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 CA-C-N 120.784 1.316 . . . . 10.0 112.373 -3.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.76 53.23 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 124.498 1.119 . . . . 10.0 111.102 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -69.33 150.44 70.82 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.398 2.065 . . . . 10.0 113.049 -172.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -70.4 140.71 52.14 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.129 0.972 . . . . 10.0 109.456 159.299 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 m -129.01 137.9 55.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.323 1.049 . . . . 10.0 112.521 -170.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 72.2 m -132.92 152.8 51.85 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.165 1.786 . . . . 10.0 110.861 177.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -128.15 152.86 47.52 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.85 1.26 . . . . 10.0 112.765 -175.686 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -145.48 158.32 43.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 126.08 1.752 . . . . 10.0 111.68 -171.084 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.8 tp -148.16 123.33 10.17 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.187 2.195 . . . . 10.0 109.875 177.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 54.22 11.0 0.34 Allowed 'General case' 0 CA--C 1.556 1.192 0 N-CA-C 116.571 2.063 . . . . 10.0 116.571 173.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 116.05 -0.64 21.11 Favored Glycine 0 CA--C 1.54 1.608 0 C-N-CA 125.802 1.668 . . . . 10.0 115.875 -178.239 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -119.41 166.45 13.05 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 125.865 1.666 . . . . 10.0 112.108 172.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.1 p -72.49 161.17 31.15 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.756 1.222 . . . . 10.0 113.131 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.92 91.97 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.878 2.071 . . . . 10.0 108.703 173.207 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -69.31 145.34 53.11 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 123.254 0.622 . . . . 10.0 110.661 171.486 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 44.1 p -73.77 153.93 39.79 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.453 0.701 . . . . 10.0 112.542 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.69 -172.91 4.24 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.527 1.931 . . . . 10.0 111.676 175.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -61.55 -17.76 56.3 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.984 1.475 . . . . 10.0 114.984 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.4 mt -113.26 -18.84 11.98 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 126.285 1.834 . . . . 10.0 113.423 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.9 m80 -121.0 93.38 4.01 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.947 2.099 . . . . 10.0 109.923 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.9 mttt -106.7 121.33 44.14 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.444 1.098 . . . . 10.0 110.79 -169.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -128.71 100.57 5.77 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.258 1.423 . . . . 10.0 110.375 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.18 161.65 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 125.888 1.675 . . . . 10.0 111.934 -174.736 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.93 167.04 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 125.686 1.594 . . . . 10.0 112.12 -178.252 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.8 t -133.85 149.55 51.36 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.648 1.579 . . . . 10.0 112.046 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.86 -19.54 42.81 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.904 1.682 . . . . 10.0 114.156 175.343 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -76.74 -2.23 31.97 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 125.622 1.569 . . . . 10.0 114.142 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.0 46.27 6.0 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.816 1.198 . . . . 10.0 112.703 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 11.6 tp -137.94 150.59 47.18 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.257 1.423 . . . . 10.0 111.265 -174.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -130.81 123.84 29.99 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.767 2.027 . . . . 10.0 109.893 174.404 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 48.3 m -94.49 156.02 16.66 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.339 1.056 . . . . 10.0 112.506 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.92 116.46 15.62 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.368 1.867 . . . . 10.0 107.205 162.344 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.36 133.86 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.819 1.248 . . . . 10.0 110.636 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -109.69 108.77 19.28 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.975 2.11 . . . . 10.0 108.916 171.742 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -64.19 -37.74 88.54 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 121.489 -0.757 . . . . 10.0 112.817 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.4 p -151.07 89.45 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.154 1.782 . . . . 10.0 109.918 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -66.32 138.29 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 O-C-N 121.232 -0.918 . . . . 10.0 111.742 -178.081 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.7 mmt180 -121.32 160.35 24.16 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 126.021 1.728 . . . . 10.0 112.208 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.97 -34.37 65.65 Favored 'General case' 0 CA--C 1.546 0.81 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -176.315 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 19.9 m -65.51 -16.47 63.7 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.498 1.519 . . . . 10.0 114.555 175.5 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -82.18 -7.48 59.62 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.649 1.179 . . . . 10.0 113.311 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.52 147.33 53.03 Favored 'General case' 0 CA--C 1.546 0.815 0 O-C-N 121.185 -0.947 . . . . 10.0 112.926 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.94 -170.79 23.02 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 124.512 1.053 . . . . 10.0 115.347 175.299 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.97 107.03 15.28 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.994 1.718 . . . . 10.0 111.326 177.374 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -83.3 151.13 25.73 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.386 1.075 . . . . 10.0 111.776 170.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.27 160.38 40.59 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 10.0 112.309 169.115 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -133.02 145.84 51.2 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 126.416 1.886 . . . . 10.0 110.027 175.316 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 66.6 t -127.73 129.15 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 125.624 1.569 . . . . 10.0 108.882 175.042 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -122.4 120.79 35.0 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.574 1.95 . . . . 10.0 110.469 -175.531 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -131.56 134.48 46.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.305 1.442 . . . . 10.0 112.11 -171.177 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -130.63 -178.23 4.69 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.472 1.109 . . . . 10.0 111.645 168.182 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -60.03 -11.3 5.53 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 115.788 1.773 . . . . 10.0 115.788 -179.462 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.97 -18.48 11.24 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.417 1.487 . . . . 10.0 114.654 -177.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.53 -170.13 43.2 Favored Glycine 0 CA--C 1.534 1.22 0 CA-C-N 120.034 1.288 . . . . 10.0 116.314 179.429 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.12 143.6 46.66 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.172 2.189 . . . . 10.0 111.764 -172.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.75 160.18 38.99 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.167 1.787 . . . . 10.0 111.173 168.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.4 m -138.89 145.26 39.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 125.229 1.412 . . . . 10.0 110.871 -175.315 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -136.48 152.92 51.08 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.33 1.452 . . . . 10.0 111.102 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.8 m -145.16 145.88 31.55 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.567 1.147 . . . . 10.0 111.762 -172.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -152.79 171.82 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 126.36 1.864 . . . . 10.0 110.734 171.099 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -128.53 142.98 50.9 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.755 1.222 . . . . 10.0 111.404 173.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.0 tp -127.36 109.13 11.47 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.04 1.736 . . . . 10.0 110.128 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -78.88 141.89 37.27 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.935 -0.478 . . . . 10.0 110.035 160.091 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 40.0 t -120.5 106.53 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.458 1.103 . . . . 10.0 108.752 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.5 mt -69.37 96.78 0.9 Allowed 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.222 1.809 . . . . 10.0 109.288 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.792 0 C-N-CA 124.954 1.302 . . . . 10.0 114.259 -167.554 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 CA--C 1.543 0.947 0 N-CA-C 112.934 0.321 . . . . 10.0 112.934 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -65.85 145.0 79.27 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 123.017 2.478 . . . . 10.0 111.228 169.223 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -136.28 147.82 47.68 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.569 1.548 . . . . 10.0 112.384 -175.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -61.22 110.07 1.29 Allowed 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.814 2.046 . . . . 10.0 111.502 171.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 46.9 mm -105.46 -63.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.995 0.918 . . . . 10.0 110.285 172.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -153.36 101.88 2.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.311 1.044 . . . . 10.0 111.456 176.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 25.3 m -72.27 150.07 91.84 Favored Pre-proline 0 N--CA 1.476 0.834 0 C-N-CA 123.019 0.528 . . . . 10.0 110.22 161.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -75.72 161.0 37.25 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 122.859 2.373 . . . . 10.0 112.089 177.179 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -73.2 166.66 22.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 123.912 0.885 . . . . 10.0 111.517 168.391 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -62.01 157.79 17.93 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 121.34 -0.85 . . . . 10.0 112.644 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.0 mtp -132.6 153.41 51.06 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.349 1.459 . . . . 10.0 112.118 -166.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 16.9 p -147.27 100.95 3.34 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.8 1.64 . . . . 10.0 110.947 178.371 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.3 mm -117.32 138.95 46.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.044 1.337 . . . . 10.0 110.911 -167.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -67.75 132.18 46.95 Favored 'General case' 0 CA--C 1.543 0.688 0 O-C-N 121.359 -0.838 . . . . 10.0 112.311 176.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -54.63 119.49 5.37 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.564 1.545 . . . . 10.0 112.132 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 108.52 -10.8 35.83 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 126.216 1.865 . . . . 10.0 115.191 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -74.01 162.31 29.17 Favored 'General case' 0 N--CA 1.479 0.985 0 CA-C-N 119.224 1.512 . . . . 10.0 113.577 178.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -73.97 147.18 43.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.565 1.146 . . . . 10.0 110.558 158.37 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 4.3 t -153.72 173.29 16.03 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.212 1.005 . . . . 10.0 112.541 167.373 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -148.57 166.83 27.07 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 126.039 1.736 . . . . 10.0 112.436 166.665 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.0 mtt -118.15 157.41 26.97 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.617 1.967 . . . . 10.0 111.333 172.613 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -140.02 95.01 2.83 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.275 1.43 . . . . 10.0 111.579 -167.054 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -113.1 100.74 8.83 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.426 1.49 . . . . 10.0 111.609 -175.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -73.4 128.97 36.98 Favored 'General case' 0 N--CA 1.477 0.889 0 O-C-N 121.356 -0.84 . . . . 10.0 111.311 175.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.4 p -146.99 138.52 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.632 1.973 . . . . 10.0 110.501 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 70.4 m -125.68 126.33 44.49 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.641 1.176 . . . . 10.0 111.596 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -172.02 169.02 42.16 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 127.12 2.295 . . . . 10.0 111.338 175.192 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.6 tp -146.69 131.36 8.81 Favored Pre-proline 0 CA--C 1.548 0.901 0 C-N-CA 124.47 1.108 . . . . 10.0 111.105 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -66.91 169.86 46.94 Favored 'Cis proline' 0 CA--C 1.54 0.797 0 CA-C-N 120.533 1.226 . . . . 10.0 112.546 -3.123 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.17 120.78 32.36 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 124.605 1.162 . . . . 10.0 111.255 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.41 161.49 45.39 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 122.585 2.19 . . . . 10.0 113.221 -172.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -63.85 163.05 12.51 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.844 1.258 . . . . 10.0 111.692 166.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.4 p -139.31 114.97 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.139 1.375 . . . . 10.0 111.525 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 53.2 m -137.1 158.91 43.38 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.948 1.699 . . . . 10.0 110.876 171.296 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -133.94 160.86 36.42 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.576 1.151 . . . . 10.0 113.604 -170.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -143.5 161.64 37.92 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.872 2.069 . . . . 10.0 111.529 -177.56 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.7 tp -146.12 119.26 8.85 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 127.027 2.131 . . . . 10.0 110.188 176.052 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.4 m-20 54.78 16.65 1.48 Allowed 'General case' 0 CA--C 1.554 1.132 0 C-N-CA 126.469 1.908 . . . . 10.0 114.964 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.37 -11.86 47.51 Favored Glycine 0 CA--C 1.538 1.531 0 C-N-CA 126.52 2.01 . . . . 10.0 115.164 -177.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -86.17 156.34 20.37 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 118.932 1.366 . . . . 10.0 110.976 170.328 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.4 p -70.88 154.14 42.09 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.345 1.058 . . . . 10.0 112.51 173.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -132.89 107.38 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.099 1.76 . . . . 10.0 108.78 173.157 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -78.68 163.47 25.41 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.027 0.931 . . . . 10.0 111.37 171.516 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.7 p -72.59 157.13 38.15 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.709 0.803 . . . . 10.0 112.615 173.271 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -146.95 171.09 15.77 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 126.538 1.935 . . . . 10.0 110.322 170.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -59.97 -31.54 69.99 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.039 -1.038 . . . . 10.0 112.292 167.663 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 80.2 mt -81.95 -17.2 47.86 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.191 1.396 . . . . 10.0 113.949 173.603 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.2 m80 -136.28 69.77 1.42 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.985 1.714 . . . . 10.0 110.895 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -68.07 142.72 55.76 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.952 1.301 . . . . 10.0 111.005 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.3 mtt -133.63 102.49 5.51 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 126.494 1.917 . . . . 10.0 110.049 -175.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.84 171.54 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.371 1.468 . . . . 10.0 111.874 -176.209 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 23.8 m -131.45 134.55 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.021 1.328 . . . . 10.0 110.983 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 23.7 t -77.53 151.0 34.75 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.272 0.629 . . . . 10.0 111.91 173.362 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -60.74 -20.88 62.26 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.835 1.254 . . . . 10.0 113.224 168.451 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -75.96 -5.37 45.9 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.718 1.607 . . . . 10.0 113.86 173.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.9 56.54 2.72 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.792 1.186 . . . . 10.0 112.571 -177.83 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.5 tp -133.58 105.51 6.91 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.619 1.567 . . . . 10.0 110.629 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 9.3 m170 -65.79 129.08 38.52 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.45 0.7 . . . . 10.0 110.101 166.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 66.2 m -125.1 131.56 53.27 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.899 1.679 . . . . 10.0 111.681 -173.25 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.17 115.87 14.71 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.657 1.983 . . . . 10.0 108.927 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.94 154.36 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 125.187 1.395 . . . . 10.0 110.696 -174.618 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -127.08 102.8 7.12 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.032 2.133 . . . . 10.0 108.952 164.496 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.9 mm-40 -65.67 -36.01 82.42 Favored 'General case' 0 N--CA 1.476 0.83 0 O-C-N 121.044 -1.035 . . . . 10.0 112.675 176.626 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.2 p -151.58 90.23 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.188 1.795 . . . . 10.0 110.012 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.82 131.52 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 O-C-N 121.199 -0.938 . . . . 10.0 111.392 -179.419 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -110.8 161.07 16.16 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.508 1.523 . . . . 10.0 111.555 177.334 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.43 -34.45 66.83 Favored 'General case' 0 CA--C 1.546 0.808 0 N-CA-C 113.355 0.872 . . . . 10.0 113.355 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 23.5 m -66.44 -16.59 64.22 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.522 1.529 . . . . 10.0 114.57 176.011 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -81.32 -7.92 59.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.302 1.041 . . . . 10.0 113.469 179.022 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.12 148.14 48.8 Favored 'General case' 0 CA--C 1.548 0.88 0 CA-C-N 119.428 1.013 . . . . 10.0 113.099 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.24 -172.65 25.26 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.655 1.121 . . . . 10.0 115.079 176.121 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.34 101.92 10.11 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.834 1.654 . . . . 10.0 111.02 174.412 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -78.83 151.51 31.84 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 124.119 0.968 . . . . 10.0 111.886 171.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.47 161.47 37.97 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.667 0.787 . . . . 10.0 112.179 168.57 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.1 t -135.28 149.98 49.92 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 126.627 1.971 . . . . 10.0 110.079 177.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -124.05 141.47 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.898 1.279 . . . . 10.0 110.844 174.438 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.11 120.63 24.93 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.686 1.994 . . . . 10.0 110.095 -178.054 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -135.11 132.89 38.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 125.176 1.39 . . . . 10.0 111.672 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.2 p30 -134.03 -179.58 5.64 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.744 1.218 . . . . 10.0 111.332 166.577 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -61.97 -11.78 15.15 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 115.576 1.695 . . . . 10.0 115.576 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.18 -15.28 14.9 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.552 1.541 . . . . 10.0 114.246 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.46 -167.94 37.9 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.839 1.2 . . . . 10.0 116.023 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.85 146.48 47.5 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.84 2.056 . . . . 10.0 112.221 -170.086 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.79 157.01 46.01 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.317 1.847 . . . . 10.0 111.294 167.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -139.56 135.35 33.3 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.487 1.515 . . . . 10.0 110.069 -179.347 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -128.43 156.19 43.58 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.47 1.508 . . . . 10.0 111.791 -173.004 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.9 m -142.39 147.42 36.19 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 124.632 1.173 . . . . 10.0 112.139 -171.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.11 165.9 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 126.484 1.914 . . . . 10.0 110.852 168.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -119.25 131.75 55.83 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.981 1.313 . . . . 10.0 110.827 173.258 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.5 tp -120.44 108.62 14.33 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 126.206 1.802 . . . . 10.0 110.253 177.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -78.66 146.18 34.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 121.951 -0.468 . . . . 10.0 110.569 160.26 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.1 t -124.84 104.91 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 124.287 1.035 . . . . 10.0 109.152 174.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.95 98.98 1.7 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.674 1.989 . . . . 10.0 110.253 -175.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.745 0 C-N-CA 124.878 1.271 . . . . 10.0 112.47 -178.319 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 N-CA-C 113.021 0.354 . . . . 10.0 113.021 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -69.17 162.38 42.03 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.044 2.496 . . . . 10.0 112.152 175.25 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.14 162.73 31.3 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.753 1.221 . . . . 10.0 113.561 -171.354 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -106.55 83.8 1.92 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.654 1.982 . . . . 10.0 110.76 -171.649 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.4 mm -83.04 -67.94 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.526 0.73 . . . . 10.0 111.7 -173.19 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 -155.59 148.8 24.68 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.386 1.074 . . . . 10.0 111.955 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 20.8 m -126.02 150.75 70.22 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 125.724 1.61 . . . . 10.0 110.654 172.083 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -74.63 159.39 42.63 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 123.016 2.478 . . . . 10.0 111.861 174.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -75.6 167.43 21.9 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.745 0.818 . . . . 10.0 112.344 168.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -59.7 152.14 23.36 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.688 0.795 . . . . 10.0 113.027 175.347 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 58.4 mtm -130.16 160.74 32.87 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.207 1.003 . . . . 10.0 112.908 -176.339 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -138.04 108.21 6.42 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 126.2 1.8 . . . . 10.0 110.642 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.7 mm -123.93 132.41 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.267 1.427 . . . . 10.0 110.409 -165.171 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -63.49 133.69 54.33 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.44 1.096 . . . . 10.0 112.456 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -52.51 132.46 35.2 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.465 1.506 . . . . 10.0 112.981 -179.566 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 91.4 -9.24 77.83 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.782 1.658 . . . . 10.0 115.394 177.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.44 160.72 32.25 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.206 1.503 . . . . 10.0 113.201 176.527 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 57.8 t80 -71.96 145.87 48.12 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.836 1.254 . . . . 10.0 110.488 158.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.8 t -150.44 163.48 38.29 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.454 1.102 . . . . 10.0 111.686 170.243 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.6 ptm85 -144.64 166.82 24.09 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.256 1.422 . . . . 10.0 112.769 169.51 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.0 mtt -130.87 159.14 38.26 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.956 2.102 . . . . 10.0 110.84 173.257 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -138.15 95.03 2.95 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.486 1.514 . . . . 10.0 111.34 -167.531 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -108.89 103.36 12.4 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.794 1.638 . . . . 10.0 111.103 -175.706 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -68.01 137.37 55.03 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 121.188 -0.945 . . . . 10.0 110.54 174.309 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.09 155.29 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.508 1.523 . . . . 10.0 111.396 -173.317 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -142.63 170.45 15.68 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.136 1.375 . . . . 10.0 110.992 171.345 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 137.71 160.47 8.54 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 127.613 2.53 . . . . 10.0 112.573 -176.432 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.7 tp -150.46 127.01 5.23 Favored Pre-proline 0 CA--C 1.547 0.846 0 C-N-CA 124.396 1.079 . . . . 10.0 110.711 178.495 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -66.78 169.13 49.01 Favored 'Cis proline' 0 CA--C 1.538 0.709 0 CA-C-N 121.346 1.517 . . . . 10.0 112.31 -2.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.58 121.11 36.66 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.708 1.203 . . . . 10.0 111.335 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -70.36 160.23 50.24 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.538 2.158 . . . . 10.0 113.274 -173.69 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -66.7 169.65 7.55 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 125.481 1.512 . . . . 10.0 111.736 169.283 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.5 p -133.33 115.71 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 125.708 1.603 . . . . 10.0 111.624 -175.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.9 m -133.84 99.16 4.37 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.515 1.526 . . . . 10.0 110.622 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -84.38 156.06 22.01 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 121.873 0.844 . . . . 10.0 112.798 175.166 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -143.0 159.58 41.97 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.126 2.17 . . . . 10.0 111.208 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -146.35 118.35 8.23 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.956 2.102 . . . . 10.0 109.892 176.245 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.2 m-20 55.4 12.26 0.71 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.578 1.951 . . . . 10.0 115.487 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.48 -13.05 23.25 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 126.662 2.077 . . . . 10.0 115.343 -178.808 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -91.14 161.77 14.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 125.233 1.413 . . . . 10.0 110.923 170.376 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 70.5 p -70.92 160.5 32.73 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.61 0.719 . . . . 10.0 112.34 174.67 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 98.5 t -129.85 113.43 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 126.53 1.932 . . . . 10.0 107.308 166.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -107.59 139.0 42.79 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.014 1.326 . . . . 10.0 109.832 -174.177 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 51.1 p -63.6 144.5 56.96 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.283 0.846 . . . . 10.0 113.283 -174.54 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -154.21 -177.77 6.66 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.9 1.68 . . . . 10.0 111.342 172.588 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -58.95 -18.84 37.4 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.227 1.411 . . . . 10.0 114.721 -177.378 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.7 mt -107.44 -11.42 15.52 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.74 1.616 . . . . 10.0 113.205 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -130.21 70.85 1.44 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.973 2.109 . . . . 10.0 110.285 -175.301 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -80.12 144.54 32.99 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.897 1.279 . . . . 10.0 111.706 -173.272 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -141.65 107.37 5.1 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.418 1.887 . . . . 10.0 110.535 -171.432 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 164.62 25.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.781 1.232 . . . . 10.0 112.232 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 22.1 t -133.69 116.37 24.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 125.334 1.453 . . . . 10.0 110.012 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 44.6 t -65.37 143.98 57.39 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.097 0.959 . . . . 10.0 111.755 173.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.26 -18.88 41.17 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.926 1.29 . . . . 10.0 113.888 173.264 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -77.11 -3.7 40.67 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.005 1.722 . . . . 10.0 114.014 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 88.33 45.94 4.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.971 1.272 . . . . 10.0 113.414 178.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.5 tp -135.18 105.6 6.38 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 125.293 1.437 . . . . 10.0 111.005 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -77.34 116.4 17.92 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.501 1.121 . . . . 10.0 110.984 171.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.9 m -93.33 137.14 32.93 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 125.495 1.518 . . . . 10.0 111.672 171.69 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.37 124.84 31.2 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.13 2.172 . . . . 10.0 107.639 174.012 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.4 mp -123.37 147.71 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.518 1.127 . . . . 10.0 111.536 -170.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -121.45 107.39 12.41 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 127.707 2.403 . . . . 10.0 109.175 170.485 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.4 mm-40 -66.68 -37.3 84.47 Favored 'General case' 0 N--CA 1.474 0.775 0 O-C-N 121.076 -1.015 . . . . 10.0 112.924 177.226 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.15 90.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 125.865 1.666 . . . . 10.0 110.284 -178.268 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -69.45 147.28 12.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 O-C-N 121.175 -0.953 . . . . 10.0 112.305 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -136.27 156.5 48.58 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.722 1.609 . . . . 10.0 112.721 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.54 -34.91 71.54 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.679 1.192 . . . . 10.0 113.663 -177.092 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.4 m -64.63 -13.08 52.1 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.453 1.501 . . . . 10.0 114.389 176.15 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -108.8 8.09 26.53 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.255 1.822 . . . . 10.0 113.009 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.38 158.0 30.41 Favored 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.94 -1.1 . . . . 10.0 112.616 168.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.37 -167.55 21.91 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.549 1.071 . . . . 10.0 115.134 173.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.63 103.25 10.35 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.174 1.79 . . . . 10.0 111.544 178.301 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -80.72 150.26 29.39 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.711 1.205 . . . . 10.0 111.919 171.334 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 162.96 35.0 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.113 0.965 . . . . 10.0 112.066 168.546 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 41.8 t -140.38 127.51 20.96 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.653 1.581 . . . . 10.0 110.768 176.712 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 89.7 t -102.55 132.78 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 125.666 1.586 . . . . 10.0 109.401 173.22 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.47 117.55 22.33 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.527 1.931 . . . . 10.0 110.659 -178.396 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -131.05 139.5 49.93 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.249 1.42 . . . . 10.0 112.056 -172.251 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -132.92 -177.87 4.7 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.8 1.24 . . . . 10.0 111.355 167.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -61.72 -8.8 5.1 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 115.888 1.81 . . . . 10.0 115.888 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -116.36 -17.44 10.72 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.587 1.555 . . . . 10.0 114.736 -178.334 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 175.4 -170.36 43.37 Favored Glycine 0 CA--C 1.534 1.232 0 CA-C-N 120.0 1.273 . . . . 10.0 116.257 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -136.58 141.99 43.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.222 2.209 . . . . 10.0 111.68 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.5 158.56 44.14 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.209 1.804 . . . . 10.0 110.953 168.256 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -143.52 141.32 30.69 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.517 1.127 . . . . 10.0 111.072 -175.68 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -132.4 154.2 50.04 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.694 1.598 . . . . 10.0 111.349 -176.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.0 m -145.39 145.3 31.1 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 124.672 1.189 . . . . 10.0 112.003 -171.036 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -154.0 172.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 126.572 1.949 . . . . 10.0 110.984 172.223 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 39.5 tt0 -130.1 143.13 50.62 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 120.665 -1.272 . . . . 10.0 111.557 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.9 tp -129.39 106.58 8.88 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.088 1.755 . . . . 10.0 111.14 -177.205 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -91.96 85.62 5.61 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.815 1.646 . . . . 10.0 111.307 177.251 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.9 t -70.15 110.06 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.256 -0.902 . . . . 10.0 110.997 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.8 mt -75.47 98.74 4.0 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 126.454 1.902 . . . . 10.0 110.503 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.811 0 C-N-CA 124.255 1.022 . . . . 10.0 112.743 178.38 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo . . . . . 0 CA--C 1.542 0.892 0 N-CA-C 113.08 0.377 . . . . 10.0 113.08 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -69.04 164.59 33.25 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.146 2.564 . . . . 10.0 111.52 168.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -141.12 155.32 46.13 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.717 1.207 . . . . 10.0 112.0 -174.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -74.6 102.66 4.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.19 2.196 . . . . 10.0 111.452 178.666 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 253' ' ' ILE . . . . . 0.489 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.2 OUTLIER -115.0 -176.69 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 126.026 1.73 . . . . 10.0 110.483 175.76 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.489 ' H ' HG22 ' A' ' 253' ' ' ILE . 0.0 OUTLIER -46.35 102.43 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 128.458 2.703 . . . . 10.0 115.024 -175.033 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.91 151.59 92.99 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 124.385 1.074 . . . . 10.0 111.061 158.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.4 162.65 33.29 Favored 'Trans proline' 0 CA--C 1.541 0.852 0 C-N-CA 123.023 2.482 . . . . 10.0 111.269 170.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -73.3 159.97 32.56 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 121.36 -0.838 . . . . 10.0 111.478 170.395 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -59.45 129.93 44.42 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 121.564 -0.71 . . . . 10.0 111.529 175.232 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 31.1 mtm -100.09 155.04 17.95 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.928 0.891 . . . . 10.0 112.162 -174.427 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 23.6 p -134.81 105.76 6.59 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.852 1.661 . . . . 10.0 110.269 175.122 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.0 mm -125.44 127.06 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.12 1.368 . . . . 10.0 110.206 -164.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -62.91 134.3 56.0 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.157 0.983 . . . . 10.0 112.189 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -53.03 130.16 33.02 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.813 1.245 . . . . 10.0 112.751 -178.628 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.74 -8.87 76.4 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 125.9 1.714 . . . . 10.0 115.284 177.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -70.15 160.29 32.35 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 119.272 1.536 . . . . 10.0 113.004 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 43.8 t80 -76.95 139.62 40.21 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.818 1.247 . . . . 10.0 110.222 156.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.6 p -149.32 169.71 20.18 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.754 0.822 . . . . 10.0 111.892 162.112 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 35.5 ptt-85 -145.27 137.78 25.96 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.217 1.007 . . . . 10.0 112.525 172.387 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.2 mtt -87.47 159.31 18.71 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.888 1.275 . . . . 10.0 110.906 169.439 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -136.7 132.29 34.69 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.014 1.326 . . . . 10.0 112.025 173.603 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -134.43 113.92 12.36 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 126.715 2.006 . . . . 10.0 109.645 -176.67 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.71 146.69 53.53 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 121.067 -1.021 . . . . 10.0 110.206 171.178 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.7 p -149.21 156.51 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.063 1.345 . . . . 10.0 111.492 -174.016 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.1 t -144.53 -176.62 5.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.712 1.605 . . . . 10.0 111.668 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 104.92 162.77 23.98 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.125 2.297 . . . . 10.0 113.54 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -148.74 131.05 7.7 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 125.234 1.414 . . . . 10.0 110.48 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -67.33 170.97 44.65 Favored 'Cis proline' 0 CA--C 1.54 0.778 0 CA-C-N 120.917 1.363 . . . . 10.0 112.615 -3.121 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.01 120.96 32.83 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.022 1.329 . . . . 10.0 111.437 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.53 152.42 59.86 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 122.481 2.121 . . . . 10.0 113.466 -171.273 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -72.31 141.6 48.84 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.81 1.244 . . . . 10.0 109.899 160.316 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.1 m -128.15 89.23 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.699 1.199 . . . . 10.0 112.233 -166.422 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.5 m -74.93 115.76 14.9 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.762 1.225 . . . . 10.0 111.251 175.473 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -96.89 148.77 22.61 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.475 1.11 . . . . 10.0 113.349 177.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 83.1 m-85 -143.21 160.19 40.92 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 126.562 1.945 . . . . 10.0 112.427 -174.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.2 tp -147.13 120.78 9.17 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.721 2.408 . . . . 10.0 109.799 174.561 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 54.93 15.1 1.05 Allowed 'General case' 0 CA--C 1.556 1.192 0 C-N-CA 126.584 1.954 . . . . 10.0 115.43 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 106.82 -11.01 41.53 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.207 1.86 . . . . 10.0 115.176 -177.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -90.55 159.81 16.28 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.207 1.403 . . . . 10.0 110.677 169.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 25.2 p -74.28 160.49 31.03 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.018 0.927 . . . . 10.0 112.6 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 41.2 t -135.54 104.77 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.979 1.712 . . . . 10.0 109.563 174.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -70.32 148.88 47.95 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.135 0.574 . . . . 10.0 111.209 170.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 34.7 p -73.55 149.5 42.15 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.497 0.719 . . . . 10.0 111.611 166.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -155.04 -177.67 6.7 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.171 1.388 . . . . 10.0 111.977 172.282 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -59.29 -19.95 50.38 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -177.064 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.7 mt -105.16 -9.35 17.8 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.501 1.52 . . . . 10.0 113.112 175.184 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.3 m80 -132.95 65.91 1.58 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 127.22 2.208 . . . . 10.0 110.261 -174.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -76.42 130.74 38.45 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.771 1.229 . . . . 10.0 110.668 -174.406 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 62.3 mtt -129.32 103.1 6.73 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.241 1.817 . . . . 10.0 109.776 -174.23 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.32 163.46 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.703 1.201 . . . . 10.0 112.763 -172.248 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.4 m -124.01 166.75 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 126.308 1.843 . . . . 10.0 111.649 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 35.6 t -136.88 149.04 47.43 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.487 1.515 . . . . 10.0 112.365 -178.573 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -58.72 -19.59 41.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.895 1.678 . . . . 10.0 114.075 174.291 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.2 mmtt -75.06 -2.17 26.23 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.565 1.546 . . . . 10.0 113.949 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.86 41.7 7.08 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.008 1.29 . . . . 10.0 112.903 -178.478 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.2 tp -133.51 150.02 51.7 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.276 1.43 . . . . 10.0 111.641 -175.405 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -132.93 137.78 46.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.02 2.528 . . . . 10.0 108.952 173.629 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 50.9 m -131.72 153.1 50.38 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.812 0.845 . . . . 10.0 112.471 -175.684 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.91 102.18 5.95 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.151 1.78 . . . . 10.0 109.059 178.568 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -86.68 142.32 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 124.841 1.256 . . . . 10.0 109.35 179.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -120.62 104.68 10.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.608 1.963 . . . . 10.0 108.459 167.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -64.85 -39.73 94.03 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.16 85.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.969 1.708 . . . . 10.0 110.111 -178.405 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.3 p -67.54 142.9 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 O-C-N 121.255 -0.903 . . . . 10.0 112.327 -176.049 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -124.77 161.07 27.23 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.286 1.834 . . . . 10.0 112.255 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.12 -30.87 64.76 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 113.839 1.051 . . . . 10.0 113.839 -176.323 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.7 p -67.53 -16.34 64.14 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 125.658 1.583 . . . . 10.0 114.803 173.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -82.18 -7.63 59.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.635 1.174 . . . . 10.0 113.433 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 151.61 45.35 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.136 -0.977 . . . . 10.0 113.021 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.96 -170.97 21.11 Favored Glycine 0 CA--C 1.532 1.141 0 C-N-CA 124.664 1.126 . . . . 10.0 114.935 176.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.41 104.08 14.12 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.067 1.747 . . . . 10.0 111.724 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -78.97 150.39 32.03 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.377 1.071 . . . . 10.0 112.016 170.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.43 160.28 41.82 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 123.778 0.831 . . . . 10.0 112.427 169.097 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.35 142.36 43.8 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.747 1.619 . . . . 10.0 110.414 174.195 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.2 t -123.14 104.92 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.798 1.639 . . . . 10.0 109.102 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.75 120.54 27.28 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 126.277 1.831 . . . . 10.0 110.835 177.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.64 135.45 51.21 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 125.21 1.404 . . . . 10.0 111.9 -178.599 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -133.85 -179.16 5.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.05 0.94 . . . . 10.0 111.744 164.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.7 ptp180 -60.53 -12.58 10.27 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 115.797 1.777 . . . . 10.0 115.797 -179.249 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.44 -17.99 13.33 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 125.521 1.528 . . . . 10.0 114.356 -178.482 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.44 -169.72 42.5 Favored Glycine 0 CA--C 1.535 1.298 0 CA-C-N 119.846 1.203 . . . . 10.0 115.809 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -137.94 145.6 42.22 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.352 1.861 . . . . 10.0 111.958 -173.642 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.18 162.34 35.5 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.072 1.749 . . . . 10.0 111.385 170.493 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 64.2 m -135.83 145.94 46.96 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.316 1.046 . . . . 10.0 111.736 -171.543 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -136.2 149.52 48.6 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.391 1.876 . . . . 10.0 110.63 -177.539 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -146.42 145.2 30.16 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.597 1.159 . . . . 10.0 111.79 -172.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.8 p -152.4 172.78 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 126.042 1.737 . . . . 10.0 110.856 168.008 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -126.62 147.16 49.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.17 1.388 . . . . 10.0 111.334 172.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 63.6 tp -127.86 113.0 15.34 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 126.09 1.756 . . . . 10.0 111.024 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -92.88 91.57 7.49 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.584 1.554 . . . . 10.0 110.606 171.463 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.4 t -74.62 106.84 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 O-C-N 121.158 -0.964 . . . . 10.0 110.157 175.495 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.1 mt -76.64 97.95 4.57 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.846 1.658 . . . . 10.0 110.5 -179.094 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.786 0 C-N-CA 124.077 0.951 . . . . 10.0 112.542 177.656 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo . . . . . 0 CA--C 1.542 0.905 0 N-CA-C 112.85 0.289 . . . . 10.0 112.85 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.4 143.12 62.37 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.756 2.304 . . . . 10.0 110.766 169.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 38.1 ttp-105 -111.02 152.59 26.67 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.472 1.509 . . . . 10.0 111.429 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -77.64 75.63 4.18 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 126.32 1.848 . . . . 10.0 111.712 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 253' ' ' ILE . . . . . 0.531 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.7 OUTLIER -75.15 177.45 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.034 0 C-N-CA 124.739 1.216 . . . . 10.0 111.312 175.969 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.531 ' H ' HG22 ' A' ' 253' ' ' ILE . 32.9 tt0 -49.94 113.01 0.75 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.79 2.436 . . . . 10.0 114.439 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 23.6 m -76.41 154.13 83.95 Favored Pre-proline 0 N--CA 1.477 0.905 0 C-N-CA 125.008 1.323 . . . . 10.0 111.19 159.2 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.45 167.53 25.48 Favored 'Trans proline' 0 CA--C 1.543 0.956 0 C-N-CA 123.265 2.644 . . . . 10.0 111.779 171.259 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.39 167.31 20.77 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.334 -0.854 . . . . 10.0 111.66 166.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -61.88 160.15 12.66 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.345 -0.847 . . . . 10.0 112.767 174.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 91.5 mtp -127.74 154.02 45.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.8 1.64 . . . . 10.0 111.793 -171.372 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 59.1 p -144.23 120.17 10.65 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 125.061 1.344 . . . . 10.0 110.367 166.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.0 mm -129.02 130.2 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.16 1.384 . . . . 10.0 109.89 -166.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -60.28 126.22 26.66 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.895 1.278 . . . . 10.0 112.238 173.772 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -52.33 130.71 31.78 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.48 1.512 . . . . 10.0 113.222 -177.537 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.33 -10.73 67.34 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.077 1.798 . . . . 10.0 115.106 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -71.69 162.06 30.03 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.144 1.472 . . . . 10.0 113.395 176.49 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -74.03 139.45 44.73 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.494 1.118 . . . . 10.0 110.466 155.58 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.3 p -148.78 172.66 14.27 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.596 0.758 . . . . 10.0 112.255 159.581 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -151.77 175.46 12.4 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 126.029 1.732 . . . . 10.0 112.1 175.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.7 mtt -129.14 162.32 28.04 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 126.042 1.737 . . . . 10.0 112.078 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -136.6 108.94 7.31 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.758 1.623 . . . . 10.0 111.525 -177.581 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -124.71 113.38 17.9 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.482 1.513 . . . . 10.0 111.155 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -67.48 146.38 54.03 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.542 -0.724 . . . . 10.0 111.099 173.445 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 9.3 p -149.21 139.8 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.444 1.498 . . . . 10.0 111.551 177.376 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 24.6 m -142.21 115.11 8.69 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.985 1.314 . . . . 10.0 111.19 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.32 166.79 38.9 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 127.086 2.279 . . . . 10.0 111.723 174.736 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.44 129.81 7.23 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.311 1.045 . . . . 10.0 111.242 -178.661 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -67.13 169.57 49.18 Favored 'Cis proline' 0 CA--C 1.539 0.739 0 CA-C-N 121.022 1.401 . . . . 10.0 112.686 -2.055 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.83 120.66 34.67 Favored Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 124.845 1.258 . . . . 10.0 111.478 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.51 159.85 50.14 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.593 2.196 . . . . 10.0 113.45 -173.31 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -66.86 167.49 11.41 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.514 1.526 . . . . 10.0 111.748 167.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.72 107.02 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.708 1.603 . . . . 10.0 110.48 -171.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.0 m -124.62 99.53 6.22 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.418 1.487 . . . . 10.0 111.339 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -81.82 151.83 27.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.051 0.94 . . . . 10.0 113.093 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -140.72 160.24 40.47 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.155 2.182 . . . . 10.0 111.416 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.9 tp -146.56 116.73 7.37 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 127.257 2.223 . . . . 10.0 110.128 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 55.76 12.46 0.85 Allowed 'General case' 0 CA--C 1.556 1.179 0 C-N-CA 126.503 1.921 . . . . 10.0 115.234 -179.556 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.25 -14.76 30.69 Favored Glycine 0 CA--C 1.54 1.611 0 C-N-CA 126.778 2.132 . . . . 10.0 114.959 -176.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -80.9 158.09 25.41 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.996 1.318 . . . . 10.0 110.524 168.432 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 65.8 p -74.4 162.93 28.37 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.408 0.683 . . . . 10.0 111.855 170.659 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 16.7 t -136.01 137.43 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.378 1.471 . . . . 10.0 109.44 171.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 25.6 mp0 -107.9 156.53 19.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.321 1.449 . . . . 10.0 111.032 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 63.7 p -71.14 155.68 40.47 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.757 0.823 . . . . 10.0 112.316 173.642 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -153.48 168.91 24.53 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.476 1.51 . . . . 10.0 110.92 177.388 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.66 -35.69 70.89 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 120.832 -1.168 . . . . 10.0 112.655 169.031 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 76.7 mt -81.2 -15.45 55.65 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.527 1.131 . . . . 10.0 113.803 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -135.28 70.41 1.43 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.723 1.609 . . . . 10.0 111.561 -173.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -69.12 136.56 52.41 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.776 1.23 . . . . 10.0 110.478 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 55.6 mtt -134.06 102.46 5.41 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 126.477 1.911 . . . . 10.0 109.357 -173.828 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.57 162.51 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 125.02 1.328 . . . . 10.0 112.985 -169.619 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 17.7 t -132.42 113.02 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 126.964 2.106 . . . . 10.0 109.538 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.3 t -68.93 146.41 52.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 124.545 1.138 . . . . 10.0 111.937 173.615 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -59.0 -19.59 45.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.803 1.241 . . . . 10.0 113.89 172.084 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -77.7 -3.29 40.37 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.381 1.472 . . . . 10.0 113.99 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.94 49.36 4.31 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.942 1.258 . . . . 10.0 113.014 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -144.74 121.39 11.14 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.863 1.665 . . . . 10.0 109.496 -175.034 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -114.14 157.22 22.9 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.424 0.898 . . . . 10.0 113.424 173.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.4 m -143.36 158.58 43.52 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.766 1.226 . . . . 10.0 113.291 -169.517 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.96 104.96 7.43 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.962 2.105 . . . . 10.0 108.549 171.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -79.4 151.01 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.445 1.098 . . . . 10.0 109.736 177.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -131.6 98.84 4.61 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 126.69 1.996 . . . . 10.0 108.195 167.843 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -62.85 -36.2 82.47 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -178.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.34 83.93 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.142 1.777 . . . . 10.0 109.747 178.728 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.5 p -66.5 141.45 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.246 -0.909 . . . . 10.0 112.014 -175.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 10.6 mmt180 -127.33 160.91 29.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.028 1.731 . . . . 10.0 112.503 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.9 -33.24 61.86 Favored 'General case' 0 CA--C 1.547 0.865 0 N-CA-C 114.131 1.16 . . . . 10.0 114.131 -177.004 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 73.6 m -68.62 -15.62 63.59 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.328 1.233 . . . . 10.0 114.328 175.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -81.47 -6.79 59.31 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.386 1.074 . . . . 10.0 113.236 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.06 149.69 49.43 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 120.931 -1.106 . . . . 10.0 113.017 179.014 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.75 -173.87 22.36 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.812 1.196 . . . . 10.0 114.976 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.21 103.16 13.92 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.069 1.748 . . . . 10.0 111.297 176.772 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 62.7 m-85 -81.04 151.5 28.36 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.0 0.92 . . . . 10.0 112.11 172.257 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 164.86 29.47 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.223 1.009 . . . . 10.0 112.283 168.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 34.0 t -140.83 117.26 10.77 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.64 1.576 . . . . 10.0 110.643 175.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.8 t -88.3 132.16 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.834 1.253 . . . . 10.0 109.373 170.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -126.58 119.7 27.75 Favored 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 126.459 1.904 . . . . 10.0 110.876 -177.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -131.76 137.11 48.05 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 125.408 1.483 . . . . 10.0 112.32 -170.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.5 p30 -132.53 -177.24 4.39 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.806 1.243 . . . . 10.0 111.572 166.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -59.83 -15.78 23.51 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 115.652 1.723 . . . . 10.0 115.652 -179.28 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -107.97 -20.65 13.11 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.262 1.425 . . . . 10.0 114.192 -176.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.15 -169.7 42.84 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 116.104 1.201 . . . . 10.0 116.104 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -134.67 143.33 47.18 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 127.041 2.136 . . . . 10.0 111.647 -172.37 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -135.93 164.28 28.33 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.013 1.725 . . . . 10.0 111.153 166.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.5 m -140.75 140.22 34.78 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.479 1.111 . . . . 10.0 110.931 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -124.92 153.09 43.21 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.212 1.805 . . . . 10.0 110.437 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 16.1 m -148.41 146.25 28.38 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 124.197 0.999 . . . . 10.0 112.274 -169.553 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.2 p -151.36 171.74 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.538 1.935 . . . . 10.0 110.601 171.102 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -130.95 140.03 50.11 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.841 1.256 . . . . 10.0 110.758 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.9 tp -126.2 110.58 13.62 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.321 1.849 . . . . 10.0 110.695 -176.535 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -97.64 82.56 3.08 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.682 1.593 . . . . 10.0 110.86 175.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.3 114.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.897 0.879 . . . . 10.0 110.779 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 78.3 mt -78.35 93.33 4.66 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 126.279 1.831 . . . . 10.0 110.366 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.874 0 C-N-CA 124.893 1.277 . . . . 10.0 113.486 -179.424 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo . . . . . 0 CA--C 1.544 1.006 0 N-CA-C 113.578 0.569 . . . . 10.0 113.578 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -67.56 161.15 44.78 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.116 2.544 . . . . 10.0 112.094 169.749 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 50.6 ttp180 -144.7 155.55 43.63 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 124.911 1.284 . . . . 10.0 112.649 -173.063 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -75.15 83.02 2.34 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.915 2.086 . . . . 10.0 111.831 176.741 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.3 mm -79.12 -66.33 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 O-C-N 121.543 -0.723 . . . . 10.0 110.778 177.393 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -156.24 145.84 20.92 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 124.833 1.253 . . . . 10.0 111.347 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.5 150.93 74.18 Favored Pre-proline 0 N--CA 1.477 0.882 0 C-N-CA 125.77 1.628 . . . . 10.0 110.331 171.206 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_endo -73.38 158.08 48.73 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.817 2.345 . . . . 10.0 112.198 176.108 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -73.81 170.69 14.8 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.928 0.891 . . . . 10.0 111.275 165.845 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.96 155.18 17.21 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.258 -0.901 . . . . 10.0 112.577 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.4 mtp -132.72 159.45 39.65 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.435 1.494 . . . . 10.0 112.341 -171.14 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 58.2 p -142.54 128.0 18.96 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 125.657 1.583 . . . . 10.0 110.288 168.344 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.9 mm -133.73 132.04 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.306 1.442 . . . . 10.0 109.826 -169.531 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -61.79 128.86 38.23 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.12 1.368 . . . . 10.0 112.347 173.517 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.32 132.94 29.34 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.717 1.607 . . . . 10.0 113.268 -177.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.62 -9.18 78.41 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 125.767 1.651 . . . . 10.0 115.277 177.318 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.5 mtp85 -70.22 160.25 32.51 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.185 1.492 . . . . 10.0 113.112 175.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.9 t80 -73.26 138.82 45.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.203 1.001 . . . . 10.0 110.267 154.438 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.28 172.39 15.95 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.797 0.839 . . . . 10.0 112.103 162.278 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -148.43 171.95 15.23 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.857 1.263 . . . . 10.0 113.005 173.351 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 55.2 mtt -132.08 154.93 48.94 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 127.72 2.408 . . . . 10.0 110.105 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -134.98 102.09 5.1 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.655 1.582 . . . . 10.0 112.041 -170.834 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -107.95 106.68 17.04 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 125.651 1.581 . . . . 10.0 110.126 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -65.54 131.9 47.54 Favored 'General case' 0 N--CA 1.474 0.773 0 O-C-N 121.348 -0.845 . . . . 10.0 109.978 172.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.9 p -137.16 155.95 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 125.771 1.628 . . . . 10.0 111.051 -171.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.4 t -142.84 -170.83 3.32 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.464 1.506 . . . . 10.0 111.737 -176.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 93.86 165.44 37.0 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 126.717 2.103 . . . . 10.0 113.301 -176.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.81 130.98 8.55 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 125.818 1.647 . . . . 10.0 109.363 178.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -67.11 169.95 47.65 Favored 'Cis proline' 0 CA--C 1.541 0.847 0 CA-C-N 120.788 1.317 . . . . 10.0 112.635 -3.215 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.0 123.54 54.06 Favored Pre-proline 0 CA--C 1.55 0.952 0 C-N-CA 124.832 1.253 . . . . 10.0 111.209 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.4 150.6 58.53 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 122.324 2.016 . . . . 10.0 114.081 -168.577 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -68.99 117.28 10.44 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.09 1.756 . . . . 10.0 109.485 160.623 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -114.71 86.74 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.654 1.582 . . . . 10.0 111.917 -169.42 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.8 m -72.3 157.48 37.61 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.913 0.885 . . . . 10.0 111.742 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 62.0 m95 -131.24 155.33 47.3 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.914 1.286 . . . . 10.0 112.828 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -146.29 159.52 43.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.435 1.894 . . . . 10.0 111.488 -175.049 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.4 tp -147.59 121.58 9.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.15 2.18 . . . . 10.0 110.047 176.347 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 54.18 17.35 1.44 Allowed 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 126.466 1.906 . . . . 10.0 115.241 178.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.46 -7.09 42.57 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 126.181 1.848 . . . . 10.0 115.416 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.8 mtt85 -98.2 161.45 13.7 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.458 1.503 . . . . 10.0 111.219 171.124 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.7 p -71.56 156.74 39.07 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.535 1.134 . . . . 10.0 113.003 176.226 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 80.5 t -134.33 141.84 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 127.101 2.16 . . . . 10.0 108.551 170.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -126.18 161.9 26.62 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.228 1.411 . . . . 10.0 111.354 -177.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 55.6 p -68.36 150.14 48.54 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.548 0.739 . . . . 10.0 112.304 174.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -152.68 167.68 28.14 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.826 1.65 . . . . 10.0 110.723 176.72 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.34 -34.53 66.66 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 121.003 -1.06 . . . . 10.0 112.883 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.3 mt -86.39 -12.94 47.8 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.671 1.188 . . . . 10.0 113.91 174.282 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.9 m80 -136.39 71.02 1.41 Allowed 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.579 1.551 . . . . 10.0 111.271 -173.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.9 mttt -71.55 144.83 49.42 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.684 1.194 . . . . 10.0 111.574 -176.006 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 64.6 mtt -137.75 104.93 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.897 2.079 . . . . 10.0 109.602 -176.016 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.3 157.14 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 124.175 0.99 . . . . 10.0 112.616 -177.653 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.58 108.17 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 126.54 1.936 . . . . 10.0 110.752 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 41.7 t -64.8 142.17 58.52 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.75 0.82 . . . . 10.0 111.573 174.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -60.11 -18.44 47.29 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.752 1.221 . . . . 10.0 113.705 172.359 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -77.51 -3.6 41.38 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.935 1.694 . . . . 10.0 113.849 173.753 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.0 45.64 4.73 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.155 1.359 . . . . 10.0 113.694 177.751 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.4 108.28 8.07 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 125.306 1.443 . . . . 10.0 110.478 -177.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.4 t60 -83.31 108.68 16.68 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.141 0.977 . . . . 10.0 111.155 170.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 23.8 m -85.02 136.18 33.7 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.52 1.128 . . . . 10.0 111.585 169.31 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -128.56 119.33 24.59 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 127.096 2.158 . . . . 10.0 107.918 174.311 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.6 mt -116.68 152.4 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.762 1.225 . . . . 10.0 111.576 -166.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -129.4 107.97 9.92 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.5 2.32 . . . . 10.0 109.187 169.317 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.04 -37.99 85.06 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.219 -0.925 . . . . 10.0 112.961 176.758 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.3 p -151.88 83.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.68 1.592 . . . . 10.0 110.353 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -68.48 143.9 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 O-C-N 121.178 -0.951 . . . . 10.0 112.291 -176.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -126.13 163.33 23.34 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 126.222 1.809 . . . . 10.0 112.276 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.3 -30.8 65.05 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.715 1.006 . . . . 10.0 113.715 -178.243 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.9 p -67.96 -16.63 64.14 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.673 1.589 . . . . 10.0 114.707 173.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -82.73 -5.97 59.16 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 124.691 1.196 . . . . 10.0 113.354 175.437 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.33 152.09 45.73 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.035 -1.041 . . . . 10.0 113.082 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.77 -170.56 22.01 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.881 1.229 . . . . 10.0 114.937 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.0 104.56 14.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.025 1.73 . . . . 10.0 111.402 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -80.06 153.11 28.99 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.415 1.086 . . . . 10.0 112.029 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.93 159.9 41.35 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.947 0.899 . . . . 10.0 112.207 167.26 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -132.51 145.15 50.93 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.346 1.858 . . . . 10.0 110.031 176.483 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 45.3 t -130.14 102.1 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.119 1.368 . . . . 10.0 109.812 -179.657 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.46 125.41 33.01 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 126.649 1.98 . . . . 10.0 111.245 176.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 22.7 mtmt -131.63 131.72 43.43 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.181 1.792 . . . . 10.0 111.996 -175.704 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.5 p30 -137.15 -179.1 5.51 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 123.461 0.704 . . . . 10.0 112.078 162.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.1 ptp180 -59.6 -14.41 13.36 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 115.763 1.764 . . . . 10.0 115.763 -177.571 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.3 -15.08 14.56 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.207 1.403 . . . . 10.0 114.402 -178.669 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.34 -173.5 42.48 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 119.587 1.085 . . . . 10.0 115.709 178.442 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -134.86 146.99 49.76 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.515 1.926 . . . . 10.0 111.455 -174.275 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.25 155.94 48.16 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.795 1.638 . . . . 10.0 111.12 170.233 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.7 m -135.36 131.45 36.37 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.769 1.228 . . . . 10.0 110.753 -173.397 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -126.17 157.25 38.63 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.364 1.466 . . . . 10.0 111.219 -176.407 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 20.5 m -146.13 146.34 30.83 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.37 1.068 . . . . 10.0 111.931 -169.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.4 p -152.32 165.81 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 C-N-CA 126.245 1.818 . . . . 10.0 110.629 170.391 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -126.29 139.17 53.52 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.82 1.248 . . . . 10.0 110.956 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 54.5 tp -126.74 113.12 16.23 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.979 1.712 . . . . 10.0 110.969 -177.323 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -98.9 85.21 3.23 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.638 1.575 . . . . 10.0 110.964 175.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.0 t -66.96 114.23 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.899 0.88 . . . . 10.0 110.82 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.4 mt -78.33 98.29 5.9 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.387 1.875 . . . . 10.0 110.516 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.871 0 C-N-CA 124.354 1.061 . . . . 10.0 113.577 -179.78 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo . . . . . 0 CA--C 1.541 0.833 0 N-CA-C 112.633 0.205 . . . . 10.0 112.633 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.01 159.99 51.71 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.619 2.212 . . . . 10.0 112.218 176.503 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -112.35 169.05 9.15 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.752 1.621 . . . . 10.0 112.989 -172.01 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -108.7 97.55 7.18 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.798 2.039 . . . . 10.0 109.417 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 253' ' ' ILE . . . . . 0.512 HG22 ' H ' ' A' ' 254' ' ' GLN . 1.1 mp -115.37 171.41 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 126.245 1.818 . . . . 10.0 109.868 -174.133 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.512 ' H ' HG22 ' A' ' 253' ' ' ILE . 6.5 tm0? -44.34 122.08 2.85 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.692 2.397 . . . . 10.0 114.655 -173.163 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.7 m -107.69 158.86 32.29 Favored Pre-proline 0 N--CA 1.476 0.867 0 C-N-CA 127.508 2.323 . . . . 10.0 110.461 172.768 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -73.6 159.0 46.78 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.456 2.104 . . . . 10.0 111.697 173.356 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -71.41 172.5 9.34 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 123.71 0.804 . . . . 10.0 111.125 165.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.3 p30 -59.0 151.62 21.67 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 121.109 -0.994 . . . . 10.0 112.067 173.132 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.8 mtp -134.11 158.18 44.28 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.184 1.394 . . . . 10.0 111.961 -171.107 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 61.3 p -141.86 131.28 23.74 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 125.483 1.513 . . . . 10.0 110.823 173.502 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.3 mm -136.57 133.82 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.54 1.536 . . . . 10.0 109.557 -169.376 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -65.11 131.33 46.25 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.408 1.083 . . . . 10.0 112.428 175.025 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -51.61 123.44 9.99 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.607 1.563 . . . . 10.0 113.045 -179.22 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 102.9 -10.39 55.63 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 126.285 1.898 . . . . 10.0 115.106 178.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.7 mtp180 -72.94 160.93 31.34 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 119.127 1.464 . . . . 10.0 113.398 177.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -72.3 148.94 44.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.866 1.266 . . . . 10.0 110.632 157.647 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 45.4 t -149.48 156.05 41.38 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.763 1.225 . . . . 10.0 111.087 169.729 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -146.35 163.14 36.52 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.605 1.162 . . . . 10.0 112.675 165.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 59.0 mtt -137.51 121.72 18.04 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.784 1.634 . . . . 10.0 111.661 -173.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 26.1 m-20 -80.73 117.9 21.8 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 126.363 1.865 . . . . 10.0 112.353 175.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -128.13 105.46 8.39 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 125.373 1.469 . . . . 10.0 111.448 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -65.78 131.73 47.02 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 121.253 -0.904 . . . . 10.0 111.131 175.328 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.39 133.2 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.157 1.783 . . . . 10.0 110.73 -177.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -146.86 157.15 43.58 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.599 1.159 . . . . 10.0 111.536 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 149.13 165.52 12.37 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 128.178 2.799 . . . . 10.0 111.332 -173.671 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.0 tp -146.69 125.33 6.31 Favored Pre-proline 0 CA--C 1.546 0.816 0 CA-C-O 118.106 -0.949 . . . . 10.0 111.137 179.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -66.46 167.87 52.77 Favored 'Cis proline' 0 CA--C 1.538 0.708 0 CA-C-N 120.937 1.37 . . . . 10.0 112.669 -1.129 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.17 121.46 41.9 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.787 1.235 . . . . 10.0 111.341 -178.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -70.52 153.56 65.33 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 122.474 2.116 . . . . 10.0 113.196 -172.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -74.54 141.87 44.79 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.378 1.071 . . . . 10.0 109.55 159.021 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 47.8 t -130.94 131.7 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.262 1.025 . . . . 10.0 111.475 -170.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.1 m -131.73 156.7 45.46 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.865 1.666 . . . . 10.0 111.966 177.189 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -123.56 155.45 37.6 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.214 1.405 . . . . 10.0 113.177 -177.634 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -145.01 160.74 40.89 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 127.142 2.177 . . . . 10.0 111.572 -173.402 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -145.64 118.08 8.5 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 127.346 2.258 . . . . 10.0 109.905 176.816 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 54.72 16.24 1.33 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 126.318 1.847 . . . . 10.0 114.793 -179.217 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.96 -12.65 45.41 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.689 2.09 . . . . 10.0 115.24 -177.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -84.99 158.11 20.59 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 125.088 1.355 . . . . 10.0 110.698 170.269 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.4 p -72.1 157.11 38.38 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.882 0.873 . . . . 10.0 112.611 174.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 55.0 t -133.86 93.29 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.446 1.898 . . . . 10.0 108.74 173.187 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 60.8 mt-30 -68.51 155.09 40.61 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.615 0.766 . . . . 10.0 111.223 172.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.2 p -71.12 155.94 40.18 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-O 121.832 0.825 . . . . 10.0 112.327 171.525 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -155.07 170.16 22.44 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 126.68 1.992 . . . . 10.0 110.668 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.95 -34.5 65.72 Favored 'General case' 0 CA--C 1.546 0.805 0 O-C-N 120.568 -1.333 . . . . 10.0 112.828 169.12 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 66.8 mt -86.08 -13.25 47.87 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.755 1.222 . . . . 10.0 114.289 176.385 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -138.56 91.84 2.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.509 1.524 . . . . 10.0 111.122 -173.01 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.4 mttt -95.66 145.06 25.56 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.466 1.106 . . . . 10.0 111.494 -174.26 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -139.74 104.01 4.8 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 127.031 2.133 . . . . 10.0 109.621 -178.037 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.58 162.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.119 1.368 . . . . 10.0 111.728 177.709 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.13 133.68 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 126.147 1.779 . . . . 10.0 109.664 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 60.3 p -66.22 170.59 5.64 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.265 1.026 . . . . 10.0 113.561 176.554 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -68.99 -4.44 16.81 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.455 1.102 . . . . 10.0 113.886 166.65 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -109.07 -3.64 17.23 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 126.488 1.915 . . . . 10.0 114.134 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 87.55 40.75 6.7 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 124.509 1.052 . . . . 10.0 114.048 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 41.7 tp -124.52 106.81 10.45 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.313 1.445 . . . . 10.0 110.395 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 13.7 t60 -72.75 142.81 48.14 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.633 0.773 . . . . 10.0 111.19 173.122 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 55.1 m -123.55 97.06 5.22 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 126.865 2.066 . . . . 10.0 110.552 175.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -83.03 123.06 29.11 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 125.112 1.365 . . . . 10.0 108.662 169.161 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 37.1 mt -124.94 149.26 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 125.129 1.371 . . . . 10.0 111.705 -169.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -127.1 113.85 16.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 128.362 2.665 . . . . 10.0 109.481 171.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -69.21 -41.52 76.97 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.033 -1.042 . . . . 10.0 112.913 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.57 88.91 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.72 1.608 . . . . 10.0 110.345 -176.277 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.7 p -70.59 141.49 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.219 -0.925 . . . . 10.0 112.252 -176.807 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -123.18 162.54 22.34 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.556 1.942 . . . . 10.0 112.045 176.282 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.69 -34.41 65.04 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.463 0.912 . . . . 10.0 113.463 -178.214 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 24.9 m -64.59 -17.71 64.22 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.386 1.474 . . . . 10.0 114.508 175.508 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -83.46 -6.16 59.37 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.637 1.175 . . . . 10.0 113.383 178.398 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.84 151.21 46.06 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 121.057 -1.027 . . . . 10.0 112.986 178.357 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.51 -171.55 22.87 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.746 1.165 . . . . 10.0 114.881 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.78 101.33 11.52 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.858 1.663 . . . . 10.0 111.314 176.334 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -75.96 148.65 37.99 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.807 0.843 . . . . 10.0 111.661 169.038 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.83 156.84 46.05 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.852 0.861 . . . . 10.0 112.074 170.282 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.2 t -132.18 140.56 48.78 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 126.865 2.066 . . . . 10.0 109.411 -179.056 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 61.2 t -130.6 125.41 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 125.147 1.379 . . . . 10.0 109.311 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -118.55 125.02 48.92 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.149 1.78 . . . . 10.0 110.542 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -133.03 133.27 42.84 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 125.568 1.547 . . . . 10.0 112.215 -170.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -131.06 -177.74 4.52 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.693 1.197 . . . . 10.0 111.737 168.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.9 ptm180 -59.52 -14.82 14.41 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 115.702 1.742 . . . . 10.0 115.702 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.96 -17.88 13.19 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.524 1.53 . . . . 10.0 114.331 -176.286 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.75 -169.22 42.32 Favored Glycine 0 CA--C 1.534 1.243 0 N-CA-C 116.175 1.23 . . . . 10.0 116.175 178.226 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -133.65 144.42 49.19 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 127.331 2.252 . . . . 10.0 111.498 -173.821 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.94 157.71 46.19 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.009 1.724 . . . . 10.0 111.278 170.067 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 62.1 m -137.88 145.06 41.7 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.996 1.318 . . . . 10.0 111.408 -173.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -136.63 152.89 50.93 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.191 1.796 . . . . 10.0 110.478 -179.421 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 22.6 m -145.36 147.35 32.19 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.042 0.937 . . . . 10.0 112.252 -170.649 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.5 p -151.98 160.87 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 126.308 1.843 . . . . 10.0 111.039 169.312 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.2 tt0 -116.96 134.96 54.09 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 124.972 1.309 . . . . 10.0 110.912 173.103 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.8 tp -121.02 111.21 17.2 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.022 1.729 . . . . 10.0 110.875 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -97.32 85.88 3.77 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 125.777 1.631 . . . . 10.0 110.968 175.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.1 t -67.04 112.97 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.764 0.826 . . . . 10.0 110.736 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.0 mt -76.03 99.53 4.63 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.214 1.806 . . . . 10.0 110.101 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.836 0 C-N-CA 124.109 0.964 . . . . 10.0 112.976 -179.307 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo . . . . . 0 CA--C 1.544 1.017 0 N-CA-C 113.366 0.487 . . . . 10.0 113.366 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.45 164.82 32.77 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.32 2.68 . . . . 10.0 111.787 169.98 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.6 ttt180 -143.4 158.02 43.98 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.4 1.08 . . . . 10.0 112.366 -173.233 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -82.77 69.7 9.61 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.681 1.992 . . . . 10.0 112.516 -171.258 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 253' ' ' ILE . . . . . 0.566 HG22 ' H ' ' A' ' 254' ' ' GLN . 2.7 mm -77.88 175.34 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.231 0 C-N-CA 124.338 1.055 . . . . 10.0 110.865 175.624 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.566 ' H ' HG22 ' A' ' 253' ' ' ILE . 47.4 tt0 -48.72 115.42 1.25 Allowed 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 128.302 2.641 . . . . 10.0 115.259 -173.651 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.7 m -78.4 153.7 79.1 Favored Pre-proline 0 N--CA 1.479 0.999 0 C-N-CA 124.927 1.291 . . . . 10.0 111.552 162.439 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -76.31 166.85 26.87 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 123.267 2.645 . . . . 10.0 111.714 169.132 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.42 164.91 26.03 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.311 -0.868 . . . . 10.0 111.887 169.097 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -63.46 162.22 12.98 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.601 0.76 . . . . 10.0 112.634 172.625 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.6 mtm -134.11 161.43 34.9 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.373 1.069 . . . . 10.0 113.228 -178.234 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -140.15 90.14 2.35 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.887 2.075 . . . . 10.0 110.477 177.411 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 41.7 mm -103.87 138.23 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 124.697 1.199 . . . . 10.0 111.184 -166.797 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -68.83 130.06 41.71 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.108 0.963 . . . . 10.0 112.355 174.613 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -53.23 125.79 18.78 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.448 1.499 . . . . 10.0 112.824 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.95 -8.74 61.38 Favored Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.185 1.85 . . . . 10.0 115.115 -179.234 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.7 mtp85 -74.35 159.79 31.91 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 119.489 1.644 . . . . 10.0 113.102 175.103 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -76.75 141.01 40.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.453 1.101 . . . . 10.0 110.207 156.368 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 31.1 p -150.22 173.61 13.74 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.733 0.813 . . . . 10.0 112.353 162.436 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -145.95 167.89 22.21 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 125.682 1.593 . . . . 10.0 112.356 175.342 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -126.48 159.78 32.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.531 1.933 . . . . 10.0 110.772 172.427 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -137.43 96.87 3.34 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.448 1.499 . . . . 10.0 111.504 -167.862 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.13 111.39 22.71 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.678 1.591 . . . . 10.0 111.126 -177.037 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 90.7 mttt -66.38 147.35 53.43 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 121.111 -0.993 . . . . 10.0 110.272 169.438 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -150.78 159.95 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.232 1.413 . . . . 10.0 111.458 -175.669 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -143.53 -176.88 5.13 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.648 1.579 . . . . 10.0 111.854 178.102 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.22 161.43 23.53 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.251 2.358 . . . . 10.0 113.481 -178.161 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.9 tp -149.7 130.87 7.25 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 125.124 1.37 . . . . 10.0 110.282 179.823 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -66.0 168.97 45.62 Favored 'Cis proline' 0 CA--C 1.539 0.742 0 CA-C-N 121.194 1.462 . . . . 10.0 112.56 -2.958 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 121.54 41.15 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 124.783 1.233 . . . . 10.0 111.403 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 151.49 66.55 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.517 2.144 . . . . 10.0 113.102 -173.152 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -71.68 143.57 49.66 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.157 0.983 . . . . 10.0 109.783 160.357 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.64 87.53 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.081 1.353 . . . . 10.0 111.83 -166.073 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 62.5 m -77.08 113.72 15.12 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.549 1.14 . . . . 10.0 111.177 176.318 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -91.17 153.12 20.26 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.19 0.996 . . . . 10.0 113.186 176.481 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -144.11 159.92 41.79 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.658 1.983 . . . . 10.0 111.995 -176.512 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.2 tp -146.02 119.25 8.9 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 127.511 2.325 . . . . 10.0 110.022 176.236 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 54.9 14.14 0.86 Allowed 'General case' 0 CA--C 1.555 1.148 0 C-N-CA 126.419 1.887 . . . . 10.0 115.309 179.221 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.44 -12.19 36.27 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.602 2.049 . . . . 10.0 115.165 -177.345 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -87.95 158.07 18.77 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.974 1.387 . . . . 10.0 110.976 170.097 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.6 p -71.6 156.78 39.01 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.357 1.063 . . . . 10.0 112.656 173.627 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.85 105.94 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 126.373 1.869 . . . . 10.0 108.866 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 63.0 mt-30 -74.31 159.36 32.52 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.458 0.703 . . . . 10.0 111.394 171.929 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.0 p -69.07 155.92 39.54 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.514 0.726 . . . . 10.0 112.036 169.647 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -153.13 168.55 25.56 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.26 1.424 . . . . 10.0 110.891 175.634 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -57.23 -35.98 70.36 Favored 'General case' 0 CA--C 1.546 0.797 0 O-C-N 120.857 -1.152 . . . . 10.0 112.548 168.692 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.9 mt -80.19 -17.79 51.4 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 124.537 1.135 . . . . 10.0 113.804 173.886 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -134.46 70.51 1.45 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.18 1.792 . . . . 10.0 111.205 -172.186 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -73.16 142.43 47.43 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.4 1.48 . . . . 10.0 111.046 -173.199 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.8 mtt -136.48 98.7 3.89 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.249 1.82 . . . . 10.0 110.074 -174.427 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.09 159.86 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.363 1.465 . . . . 10.0 111.636 -177.034 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.38 122.57 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.753 1.221 . . . . 10.0 111.504 -177.85 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 67.6 m -69.63 148.6 49.12 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.508 1.123 . . . . 10.0 112.016 177.293 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 19.4 tp10 -55.8 -34.78 65.62 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.656 1.583 . . . . 10.0 113.396 -177.663 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -78.41 0.38 25.95 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 126.082 1.753 . . . . 10.0 114.574 179.369 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.49 50.23 1.88 Allowed Glycine 0 CA--C 1.532 1.133 0 C-N-CA 124.833 1.206 . . . . 10.0 114.841 170.19 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 54.4 tp -133.51 106.5 7.48 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.155 1.382 . . . . 10.0 111.056 176.696 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -86.45 118.37 25.84 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.954 1.701 . . . . 10.0 111.365 177.484 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -91.71 144.93 25.01 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.903 1.681 . . . . 10.0 112.224 173.658 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -138.21 115.73 11.26 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 126.439 1.896 . . . . 10.0 108.669 173.569 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 154.19 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 C-N-CA 125.36 1.464 . . . . 10.0 111.42 -170.832 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -131.74 108.36 9.41 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 127.007 2.123 . . . . 10.0 109.599 163.565 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 36.5 mm-40 -65.06 -45.32 85.82 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 113.898 1.073 . . . . 10.0 113.898 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.61 70.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 CA-C-O 122.614 1.197 . . . . 10.0 111.344 -172.506 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.96 142.23 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.025 1.33 . . . . 10.0 113.502 -170.0 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.2 mmt-85 -120.64 162.07 20.29 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 126.5 1.92 . . . . 10.0 112.323 177.04 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.11 -31.32 61.15 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.265 1.026 . . . . 10.0 113.613 177.239 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 43.2 p -67.8 -17.12 64.42 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.539 1.536 . . . . 10.0 114.806 174.287 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -83.31 -7.39 59.59 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.54 1.136 . . . . 10.0 113.409 175.823 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 149.68 49.71 Favored 'General case' 0 CA--C 1.547 0.85 0 O-C-N 120.958 -1.089 . . . . 10.0 112.988 179.38 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.1 -173.44 23.27 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.806 1.193 . . . . 10.0 115.076 176.077 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 106.53 14.8 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.855 1.662 . . . . 10.0 111.094 175.063 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -84.01 150.43 25.62 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 124.347 1.059 . . . . 10.0 111.921 172.902 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.56 162.18 37.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.946 0.898 . . . . 10.0 112.268 170.516 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.3 t -139.01 140.42 38.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.581 1.552 . . . . 10.0 110.487 175.065 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 43.6 t -121.38 104.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.837 1.655 . . . . 10.0 109.07 179.395 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -86.3 122.0 29.67 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.278 1.831 . . . . 10.0 111.078 178.396 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -132.35 132.58 43.04 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.421 1.488 . . . . 10.0 112.224 -177.184 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.2 p30 -130.97 -177.95 4.6 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.488 1.115 . . . . 10.0 111.646 167.085 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.8 ptp180 -59.47 -12.71 6.71 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 115.922 1.823 . . . . 10.0 115.922 -179.37 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -113.52 -16.82 12.34 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 125.382 1.473 . . . . 10.0 114.557 -177.048 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.17 -169.27 42.34 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 120.022 1.283 . . . . 10.0 116.224 178.876 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -135.96 144.06 45.2 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.093 2.157 . . . . 10.0 111.997 -172.311 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.78 161.96 36.3 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.111 1.764 . . . . 10.0 111.151 168.587 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -137.65 144.17 41.74 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.319 1.048 . . . . 10.0 111.599 -172.31 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -134.52 152.38 51.75 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.189 1.796 . . . . 10.0 110.86 -178.214 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 15.4 m -147.85 146.18 29.0 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.525 1.13 . . . . 10.0 111.942 -173.027 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.9 p -153.45 174.21 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 126.49 1.916 . . . . 10.0 110.781 171.838 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -129.63 144.31 51.22 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.689 1.196 . . . . 10.0 111.51 172.773 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.0 tp -128.77 109.12 11.02 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.304 1.842 . . . . 10.0 109.997 179.386 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -79.4 147.0 32.51 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 121.938 -0.477 . . . . 10.0 110.029 158.406 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 30.1 t -128.43 106.83 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.124 0.97 . . . . 10.0 109.344 175.352 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.8 101.99 2.24 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.282 1.833 . . . . 10.0 109.659 -178.926 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.828 0 C-N-CA 124.191 0.996 . . . . 10.0 113.22 -175.75 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 CA--C 1.542 0.88 0 N-CA-C 113.483 0.532 . . . . 10.0 113.483 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -66.88 156.23 67.11 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 C-N-CA 122.933 2.422 . . . . 10.0 112.021 170.888 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.2 ttt85 -146.43 150.48 35.71 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.554 1.142 . . . . 10.0 112.568 -173.374 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -77.59 82.49 4.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.058 2.143 . . . . 10.0 111.65 178.098 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.0 mm -74.89 -56.94 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.613 -0.679 . . . . 10.0 110.502 173.971 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -154.9 143.49 20.61 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.819 1.248 . . . . 10.0 111.44 176.711 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.39 151.84 79.48 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 126.053 1.741 . . . . 10.0 110.112 171.068 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.01 154.9 47.9 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.929 2.419 . . . . 10.0 112.132 175.736 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -75.63 171.15 14.81 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.353 1.061 . . . . 10.0 112.318 167.948 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -62.5 153.3 32.08 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 121.269 -0.894 . . . . 10.0 112.607 176.757 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 73.8 mtp -133.16 157.45 45.31 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.042 1.337 . . . . 10.0 112.408 -169.701 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -141.27 112.79 7.56 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.524 1.53 . . . . 10.0 111.036 178.755 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 33.2 mm -129.94 128.3 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 125.049 1.339 . . . . 10.0 110.949 -164.68 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -60.37 131.5 50.98 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.083 1.353 . . . . 10.0 112.661 173.864 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -54.44 136.2 44.52 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.886 1.275 . . . . 10.0 113.001 -177.768 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.76 -6.7 81.95 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.649 1.595 . . . . 10.0 115.312 177.683 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -71.87 158.31 36.28 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 118.944 1.372 . . . . 10.0 112.892 175.783 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -70.65 143.37 51.43 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.316 1.046 . . . . 10.0 109.968 155.1 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.6 t -147.62 165.58 29.96 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.245 1.018 . . . . 10.0 111.634 172.7 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -148.04 159.06 44.3 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.721 1.208 . . . . 10.0 112.868 168.544 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -130.1 151.12 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 126.678 1.991 . . . . 10.0 109.431 170.405 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -143.41 125.6 15.49 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.254 1.021 . . . . 10.0 111.442 -173.985 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -121.72 156.72 32.5 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.55 2.34 . . . . 10.0 110.196 -175.634 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -114.11 104.06 11.75 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.773 1.229 . . . . 10.0 110.198 175.836 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 43.8 t -109.38 99.15 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.462 1.905 . . . . 10.0 110.021 -170.316 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.5 t -73.44 -175.24 1.89 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.093 0.957 . . . . 10.0 112.527 174.106 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 109.79 155.88 15.91 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 127.312 2.386 . . . . 10.0 113.592 176.379 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 19.2 tp -147.48 125.31 5.92 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.531 . . . . 10.0 109.664 178.513 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.47 169.05 47.71 Favored 'Cis proline' 0 CA--C 1.541 0.834 0 CA-C-N 120.8 1.322 . . . . 10.0 112.567 -2.602 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.36 68.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 C-N-CA 124.205 1.002 . . . . 10.0 111.387 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.81 150.68 68.24 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.476 2.117 . . . . 10.0 113.14 -173.57 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -69.65 142.03 53.51 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.032 1.333 . . . . 10.0 110.431 165.113 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 55.9 t -117.16 126.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.723 1.609 . . . . 10.0 111.269 -167.977 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.3 m -134.31 106.47 7.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.635 1.574 . . . . 10.0 111.004 175.337 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -82.25 153.59 25.82 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.913 0.885 . . . . 10.0 113.044 176.064 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -142.86 160.44 40.33 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 127.286 2.235 . . . . 10.0 111.378 179.718 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.1 tp -146.4 119.08 8.57 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 127.223 2.209 . . . . 10.0 109.974 175.196 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 54.76 17.15 1.64 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 126.442 1.897 . . . . 10.0 115.014 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.94 -12.87 49.63 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.518 2.009 . . . . 10.0 115.117 -178.236 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.7 mtt85 -84.94 155.72 21.52 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.923 1.362 . . . . 10.0 110.78 169.077 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.5 p -69.84 157.67 36.96 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.02 0.928 . . . . 10.0 112.52 173.275 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 81.9 t -132.34 143.39 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.667 1.987 . . . . 10.0 108.875 172.442 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -132.85 155.3 49.24 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.629 1.572 . . . . 10.0 110.541 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.0 p -72.43 149.09 44.55 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 123.67 0.788 . . . . 10.0 112.851 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -154.62 -173.11 4.44 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.529 1.932 . . . . 10.0 111.322 175.312 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -60.53 -18.72 53.97 Favored 'General case' 0 CA--C 1.549 0.932 0 N-CA-C 114.84 1.422 . . . . 10.0 114.84 -178.693 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 59.9 mt -113.64 -16.82 12.27 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.556 1.943 . . . . 10.0 113.541 -179.587 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -122.25 98.34 5.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 126.798 2.039 . . . . 10.0 110.339 -178.815 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.96 109.77 19.41 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 124.536 1.134 . . . . 10.0 110.857 -168.384 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 5.1 mpp? -116.31 110.22 18.44 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.992 1.717 . . . . 10.0 110.718 -175.968 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.09 161.46 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.975 1.71 . . . . 10.0 112.096 -172.642 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.1 t -131.22 118.57 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 125.568 1.547 . . . . 10.0 110.238 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 14.5 t -67.55 163.18 21.74 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 124.793 1.237 . . . . 10.0 112.551 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -57.53 -30.52 65.24 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.635 1.574 . . . . 10.0 113.139 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 11.3 mmpt? -86.02 0.11 54.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.922 1.689 . . . . 10.0 114.604 178.356 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.01 6.36 71.98 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 124.896 1.236 . . . . 10.0 114.894 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.54 105.67 1.92 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.579 1.152 . . . . 10.0 109.453 170.329 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.0 t60 -95.8 114.44 26.17 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.612 1.565 . . . . 10.0 111.061 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 41.2 m -101.57 151.02 22.48 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.847 1.259 . . . . 10.0 112.477 -179.782 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -135.81 103.24 5.33 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.439 2.296 . . . . 10.0 108.368 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.32 139.65 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.57 1.148 . . . . 10.0 110.263 -179.524 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -115.14 105.61 13.12 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 127.922 2.489 . . . . 10.0 109.152 171.444 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -64.61 -40.4 95.43 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 120.995 -1.066 . . . . 10.0 113.339 -179.789 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.04 93.22 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.635 1.574 . . . . 10.0 110.402 179.951 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.88 142.47 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.354 -0.842 . . . . 10.0 112.118 -177.548 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -123.08 160.21 26.88 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.145 1.778 . . . . 10.0 112.038 175.393 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.74 -31.87 64.98 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.989 1.107 . . . . 10.0 113.989 -175.2 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.2 t -65.9 -20.85 66.36 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.005 1.322 . . . . 10.0 113.958 175.582 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -78.41 -4.22 47.16 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.908 1.283 . . . . 10.0 113.685 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 155.3 36.61 Favored 'General case' 0 CA--C 1.547 0.84 0 N-CA-C 113.669 0.988 . . . . 10.0 113.669 178.362 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.6 -167.52 17.96 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.933 1.254 . . . . 10.0 114.909 174.312 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.05 105.3 14.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.91 1.684 . . . . 10.0 111.686 179.463 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.6 m-85 -79.58 151.15 30.81 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.311 1.044 . . . . 10.0 111.576 168.633 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.68 159.96 41.54 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.837 0.855 . . . . 10.0 112.226 169.084 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.6 t -137.49 103.95 5.21 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.806 1.642 . . . . 10.0 110.596 -179.501 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 90.0 t -74.95 130.03 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.432 1.093 . . . . 10.0 109.402 170.093 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.93 118.76 24.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.7 2.0 . . . . 10.0 110.259 178.825 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.9 mtpp -131.76 133.48 44.81 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.969 1.307 . . . . 10.0 112.553 -173.112 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.5 p30 -131.55 -178.91 5.07 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.497 1.119 . . . . 10.0 111.73 167.182 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -60.63 -11.84 8.45 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 115.798 1.777 . . . . 10.0 115.798 -179.101 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.1 -15.11 13.32 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.296 1.438 . . . . 10.0 114.547 -178.378 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.21 -169.57 41.06 Favored Glycine 0 CA--C 1.534 1.256 0 N-CA-C 116.025 1.17 . . . . 10.0 116.025 177.479 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -135.83 145.79 46.83 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.917 2.087 . . . . 10.0 112.002 -169.383 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.91 158.98 43.21 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.393 1.877 . . . . 10.0 110.632 166.017 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.9 m -140.03 100.23 3.87 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.781 1.232 . . . . 10.0 110.414 176.697 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -79.78 154.67 28.32 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.604 1.162 . . . . 10.0 111.187 177.289 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 32.0 m -144.64 145.41 31.74 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 124.456 1.102 . . . . 10.0 111.748 -172.996 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.92 165.77 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 126.324 1.85 . . . . 10.0 110.559 171.86 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -128.84 140.44 51.7 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.729 1.211 . . . . 10.0 111.549 177.255 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 53.1 tp -128.63 110.45 12.24 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.02 1.728 . . . . 10.0 111.951 -176.905 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -87.78 89.88 8.16 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.155 1.382 . . . . 10.0 110.843 169.757 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.58 106.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.031 -1.043 . . . . 10.0 109.614 174.131 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.3 mt -72.56 97.91 2.21 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.116 1.766 . . . . 10.0 109.873 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.828 0 C-N-CA 124.522 1.129 . . . . 10.0 113.399 -175.918 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo . . . . . 0 CA--C 1.543 0.941 0 N-CA-C 113.258 0.446 . . . . 10.0 113.258 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.55 158.2 58.66 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.961 2.441 . . . . 10.0 112.337 173.667 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -145.18 161.44 39.51 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 125.018 1.327 . . . . 10.0 113.556 -171.533 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -83.45 98.84 9.73 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.022 1.729 . . . . 10.0 111.869 -178.602 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 36.5 mm -90.64 -68.27 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.445 0.698 . . . . 10.0 110.723 177.01 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 37.2 tt0 -155.49 143.78 20.16 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.306 1.042 . . . . 10.0 111.679 177.104 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.1 m -126.07 153.77 74.05 Favored Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 125.85 1.66 . . . . 10.0 110.659 171.992 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -70.65 155.03 63.83 Favored 'Trans proline' 0 CA--C 1.542 0.876 0 C-N-CA 122.61 2.207 . . . . 10.0 111.834 171.594 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -72.95 174.3 8.02 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.006 0.922 . . . . 10.0 111.311 166.405 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -59.03 152.24 20.39 Favored 'General case' 0 CA--C 1.548 0.886 0 O-C-N 121.051 -1.031 . . . . 10.0 112.371 174.671 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.0 mtp -134.87 159.3 41.85 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 125.59 1.556 . . . . 10.0 111.887 -171.406 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 67.2 p -142.12 134.25 27.55 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 125.11 1.364 . . . . 10.0 111.242 172.258 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 27.8 mm -139.41 132.83 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 125.62 1.568 . . . . 10.0 109.629 -170.197 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -63.44 132.63 52.02 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.624 1.169 . . . . 10.0 112.4 173.741 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -52.58 128.12 25.07 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.697 1.199 . . . . 10.0 112.786 -179.311 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.21 -9.29 63.13 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 126.017 1.77 . . . . 10.0 115.298 178.412 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -74.47 162.14 29.11 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 119.227 1.514 . . . . 10.0 113.342 176.668 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -72.75 150.97 42.38 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.199 1.4 . . . . 10.0 110.725 159.159 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.9 t -149.97 156.4 41.65 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.663 1.185 . . . . 10.0 111.437 170.425 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm85 -140.87 164.62 29.75 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.558 1.143 . . . . 10.0 112.99 163.372 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.4 mtt -131.73 161.03 33.79 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.801 2.04 . . . . 10.0 111.142 176.941 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -137.12 94.25 2.93 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.131 1.372 . . . . 10.0 111.612 -167.933 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 41.7 m-85 -104.04 116.27 31.94 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.313 1.445 . . . . 10.0 110.831 -178.881 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -78.68 131.14 36.52 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.406 -0.809 . . . . 10.0 110.141 172.406 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 56.9 t -133.25 148.82 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.135 1.774 . . . . 10.0 110.192 -174.107 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.0 t -136.82 -174.32 3.69 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.542 1.537 . . . . 10.0 111.474 173.77 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 110.06 162.0 18.78 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 127.401 2.429 . . . . 10.0 112.549 -173.031 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -148.04 128.78 6.94 Favored Pre-proline 0 CA--C 1.546 0.826 0 C-N-CA 124.661 1.184 . . . . 10.0 110.591 -179.587 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -66.56 170.01 44.55 Favored 'Cis proline' 0 CA--C 1.54 0.783 0 CA-C-N 120.786 1.316 . . . . 10.0 112.453 -4.225 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.55 123.42 56.8 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.512 1.125 . . . . 10.0 111.375 179.572 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.55 151.09 64.35 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.543 2.162 . . . . 10.0 113.168 -173.371 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -72.96 146.55 45.97 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.248 1.019 . . . . 10.0 109.831 160.158 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.8 m -130.97 135.98 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.662 1.185 . . . . 10.0 112.541 -170.23 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 64.1 m -135.51 119.3 17.25 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.234 1.814 . . . . 10.0 111.037 -178.834 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 283' ' ' TRP . . . . . 0.402 ' CD1' ' HG2' ' A' ' 298' ' ' MET . 62.2 m95 -91.02 156.22 18.11 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.598 0.962 . . . . 10.0 113.598 -179.43 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -143.45 160.25 40.93 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.796 2.438 . . . . 10.0 111.1 -176.987 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.6 tp -146.18 117.72 8.03 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 127.189 2.196 . . . . 10.0 109.997 176.237 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 55.54 13.33 0.94 Allowed 'General case' 0 CA--C 1.555 1.145 0 C-N-CA 126.467 1.907 . . . . 10.0 115.208 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 109.83 -14.62 31.82 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 126.731 2.11 . . . . 10.0 115.02 -177.313 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -82.09 157.42 24.1 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 118.9 1.35 . . . . 10.0 110.687 168.896 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.8 p -72.91 158.25 35.85 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.936 0.894 . . . . 10.0 112.339 172.358 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.6 t -133.98 90.83 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 126.278 1.831 . . . . 10.0 108.898 172.971 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -68.77 143.48 54.63 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.254 0.622 . . . . 10.0 110.412 169.815 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.3 p -69.39 149.53 48.28 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.374 0.67 . . . . 10.0 112.163 173.098 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.18 -172.68 4.3 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.186 1.794 . . . . 10.0 111.983 178.103 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.09 -18.34 46.26 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 114.774 1.398 . . . . 10.0 114.774 -178.472 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.8 mt -113.12 -15.07 12.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.915 1.686 . . . . 10.0 113.531 179.479 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -126.43 96.81 4.81 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.82 2.048 . . . . 10.0 109.755 -177.206 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -110.61 126.17 54.19 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.25 1.02 . . . . 10.0 111.207 -168.323 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 298' ' ' MET . . . . . 0.402 ' HG2' ' CD1' ' A' ' 283' ' ' TRP . 1.8 mpt? -128.89 109.06 10.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.427 1.891 . . . . 10.0 110.033 -173.044 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.22 164.83 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 125.615 1.566 . . . . 10.0 111.858 -178.172 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.5 t -125.6 106.82 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 125.513 1.525 . . . . 10.0 109.688 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -74.31 164.93 26.01 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.525 1.13 . . . . 10.0 112.536 176.515 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -57.12 156.61 6.93 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.945 1.298 . . . . 10.0 112.018 173.199 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt 64.68 6.47 3.26 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 127.392 2.277 . . . . 10.0 114.642 -170.431 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 83.77 55.68 2.78 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.307 1.432 . . . . 10.0 114.041 171.854 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.31 101.36 7.92 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.892 1.277 . . . . 10.0 110.11 177.16 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -79.64 112.55 17.01 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.91 1.284 . . . . 10.0 111.197 174.733 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.8 m -83.34 146.78 28.31 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 124.753 1.221 . . . . 10.0 112.197 172.146 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.82 120.1 24.44 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.401 1.88 . . . . 10.0 107.088 161.756 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.7 mt -121.31 139.06 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.494 1.518 . . . . 10.0 110.453 -174.166 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -120.42 110.74 16.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 127.584 2.354 . . . . 10.0 109.522 176.746 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.83 -42.89 85.07 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 121.343 -0.848 . . . . 10.0 113.202 179.465 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.0 89.42 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.806 1.642 . . . . 10.0 110.161 -177.361 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.6 p -70.37 140.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.284 -0.885 . . . . 10.0 112.203 -176.239 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -119.93 160.79 22.03 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.358 1.863 . . . . 10.0 112.157 176.717 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.11 -32.56 66.46 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 113.726 1.01 . . . . 10.0 113.726 -177.45 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.4 t -65.13 -21.75 66.84 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.106 1.362 . . . . 10.0 113.776 175.209 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -79.48 -5.32 54.55 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.779 1.231 . . . . 10.0 113.611 -179.832 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.65 152.17 44.81 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.168 -0.957 . . . . 10.0 113.236 178.624 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.59 -168.98 22.53 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.633 1.111 . . . . 10.0 115.043 174.977 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.67 103.03 11.88 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.909 1.684 . . . . 10.0 111.551 177.856 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 -78.82 149.7 32.48 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.037 0.935 . . . . 10.0 111.678 169.714 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.94 160.93 40.55 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.901 0.881 . . . . 10.0 112.265 170.413 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.45 120.53 17.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.543 1.537 . . . . 10.0 110.858 177.12 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 59.1 t -92.36 126.39 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.757 1.223 . . . . 10.0 108.996 171.204 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -119.27 126.11 50.7 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 126.428 1.891 . . . . 10.0 110.747 -178.957 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -134.47 133.33 40.31 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 125.259 1.423 . . . . 10.0 112.516 -170.698 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.7 p30 -130.55 -179.1 5.08 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.741 1.216 . . . . 10.0 111.533 166.535 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -60.89 -12.77 12.14 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 115.618 1.71 . . . . 10.0 115.618 -179.465 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -109.44 -17.63 13.73 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.521 1.528 . . . . 10.0 114.392 -178.282 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 168.64 -169.2 41.55 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 115.972 1.149 . . . . 10.0 115.972 177.931 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -133.77 146.56 50.84 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.986 2.114 . . . . 10.0 111.745 -172.088 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.2 160.1 40.31 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.317 1.847 . . . . 10.0 110.974 169.98 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.3 m -136.33 130.56 33.06 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.722 1.209 . . . . 10.0 111.379 177.759 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -113.65 153.65 28.56 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.204 1.801 . . . . 10.0 110.659 177.81 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.7 m -143.09 148.19 36.25 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.598 1.159 . . . . 10.0 112.37 -173.13 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.41 169.15 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 C-N-CA 126.994 2.117 . . . . 10.0 110.763 169.468 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 52.4 tt0 -128.04 137.04 52.03 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.196 1.399 . . . . 10.0 111.088 174.271 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.5 tp -125.65 107.14 10.28 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.958 1.703 . . . . 10.0 111.077 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -88.96 87.47 7.23 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.259 1.424 . . . . 10.0 110.869 172.773 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -67.36 112.35 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.242 -0.911 . . . . 10.0 110.061 175.45 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.6 mt -75.3 94.65 3.05 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 126.104 1.762 . . . . 10.0 109.875 -179.747 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 124.765 1.226 . . . . 10.0 113.53 -175.769 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo . . . . . 0 CA--C 1.544 0.991 0 N-CA-C 113.134 0.398 . . . . 10.0 113.134 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -68.07 167.67 21.14 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 123.303 2.668 . . . . 10.0 111.634 169.191 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 2.1 tpt180 -139.42 175.22 9.75 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.664 1.186 . . . . 10.0 112.803 -172.974 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -103.92 95.48 6.04 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 126.394 1.878 . . . . 10.0 110.326 -175.643 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 253' ' ' ILE . . . . . 0.549 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.4 OUTLIER -115.61 -179.28 1.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.99 0 C-N-CA 126.298 1.839 . . . . 10.0 109.779 -179.655 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.549 ' H ' HG22 ' A' ' 253' ' ' ILE . 41.8 tt0 -46.15 123.37 4.61 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.507 2.323 . . . . 10.0 115.026 -166.535 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 19.1 m -106.84 153.83 40.56 Favored Pre-proline 0 N--CA 1.474 0.769 0 C-N-CA 126.425 1.89 . . . . 10.0 110.365 167.944 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.25 158.49 44.94 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.759 2.306 . . . . 10.0 111.705 169.902 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -66.29 172.4 3.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 124.606 1.162 . . . . 10.0 111.841 167.342 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -60.32 153.72 21.93 Favored 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.99 -1.068 . . . . 10.0 111.857 170.311 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 84.8 mtp -133.01 155.9 48.33 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.994 1.318 . . . . 10.0 112.179 -169.647 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 47.6 p -141.81 122.86 14.6 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 125.505 1.522 . . . . 10.0 110.903 175.091 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.5 mm -134.18 132.38 55.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.546 1.538 . . . . 10.0 109.901 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -63.99 129.12 38.78 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.235 1.014 . . . . 10.0 112.101 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -54.31 131.82 42.6 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.201 1.4 . . . . 10.0 112.683 -177.736 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.76 -10.11 66.34 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 126.042 1.782 . . . . 10.0 115.07 179.11 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 78.3 mtp85 -71.47 160.98 31.76 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 119.005 1.402 . . . . 10.0 113.061 175.91 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -71.18 145.8 49.49 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 124.014 0.926 . . . . 10.0 110.368 155.684 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 16.6 t -147.45 163.79 35.4 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.7 1.2 . . . . 10.0 111.405 168.612 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -143.85 157.52 44.31 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.589 1.556 . . . . 10.0 111.806 167.706 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 53.2 mtt -129.22 150.42 50.61 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 127.117 2.167 . . . . 10.0 109.187 171.454 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -142.12 126.08 17.23 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.317 1.047 . . . . 10.0 111.479 -169.85 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -130.86 123.69 29.59 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 126.745 2.018 . . . . 10.0 111.151 -168.718 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -70.27 130.81 43.02 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.493 -0.754 . . . . 10.0 110.301 171.472 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.77 149.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 126.109 1.763 . . . . 10.0 111.138 -175.592 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 6.1 t -147.24 -174.08 4.42 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 125.144 1.377 . . . . 10.0 112.113 -176.572 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.18 162.47 23.7 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 127.319 2.39 . . . . 10.0 112.864 -174.968 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -146.48 128.07 7.48 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.874 1.27 . . . . 10.0 110.567 -179.698 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -66.7 169.4 47.55 Favored 'Cis proline' 0 CA--C 1.539 0.743 0 CA-C-N 120.88 1.35 . . . . 10.0 112.658 -2.149 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.72 122.77 48.04 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.752 1.221 . . . . 10.0 111.575 -178.463 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -71.11 159.95 50.66 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 122.597 2.198 . . . . 10.0 113.359 -174.292 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.7 168.94 10.36 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.799 1.24 . . . . 10.0 111.851 166.426 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 71.5 t -130.24 123.76 56.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.691 1.597 . . . . 10.0 110.397 -178.366 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.2 m -134.82 150.35 50.49 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.68 1.592 . . . . 10.0 110.661 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 47.6 m95 -130.06 157.82 41.34 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 124.884 1.274 . . . . 10.0 112.593 179.151 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -143.91 159.19 43.0 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.674 1.99 . . . . 10.0 111.413 -177.292 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.1 tp -144.99 118.24 8.95 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 127.128 2.171 . . . . 10.0 109.943 175.844 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 54.91 14.79 0.97 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.508 1.923 . . . . 10.0 115.177 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.8 -13.23 35.06 Favored Glycine 0 CA--C 1.539 1.556 0 C-N-CA 126.709 2.1 . . . . 10.0 115.182 -178.061 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.9 mtp180 -85.89 157.11 20.26 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.971 1.385 . . . . 10.0 110.961 170.134 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.6 p -71.41 155.25 40.84 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.358 1.063 . . . . 10.0 112.765 174.432 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 61.1 t -134.0 102.65 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.729 2.012 . . . . 10.0 108.597 172.834 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -74.61 161.4 29.75 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.463 0.705 . . . . 10.0 111.4 172.547 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 58.4 p -67.99 154.41 41.68 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.363 0.665 . . . . 10.0 111.785 168.163 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -153.6 168.68 25.4 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.144 1.377 . . . . 10.0 111.03 177.799 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.8 -35.18 68.43 Favored 'General case' 0 CA--C 1.544 0.749 0 O-C-N 120.933 -1.105 . . . . 10.0 112.696 168.84 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 69.8 mt -82.83 -14.25 54.69 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.553 1.141 . . . . 10.0 113.916 173.938 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.4 m80 -136.16 69.91 1.42 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.954 1.701 . . . . 10.0 111.216 -173.427 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.53 143.02 51.77 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.786 1.235 . . . . 10.0 111.134 -177.671 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -136.85 103.58 5.22 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.649 1.98 . . . . 10.0 109.718 -174.695 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.45 158.99 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.823 1.249 . . . . 10.0 112.18 -175.389 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -134.5 111.42 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 125.31 1.444 . . . . 10.0 110.035 -178.614 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 58.6 m -66.53 145.83 55.19 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.904 0.882 . . . . 10.0 111.401 173.269 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.47 -17.52 59.71 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.526 1.53 . . . . 10.0 114.622 -176.237 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -75.36 -4.82 41.51 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.058 1.743 . . . . 10.0 114.108 173.621 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.82 47.38 3.68 Favored Glycine 0 CA--C 1.532 1.098 0 C-N-CA 125.134 1.35 . . . . 10.0 113.219 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.94 105.71 6.51 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.085 1.354 . . . . 10.0 110.224 -176.129 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -85.45 124.94 32.61 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.073 1.349 . . . . 10.0 111.447 174.751 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 38.0 m -109.0 142.94 38.95 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.398 1.479 . . . . 10.0 111.915 175.695 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -132.79 115.85 15.83 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.538 2.335 . . . . 10.0 108.887 -178.306 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 153.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.785 1.234 . . . . 10.0 111.44 -171.402 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -128.49 103.65 7.25 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.398 2.279 . . . . 10.0 109.05 164.663 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -65.34 -38.96 91.73 Favored 'General case' 0 N--CA 1.475 0.825 0 O-C-N 120.872 -1.143 . . . . 10.0 113.072 178.738 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.56 87.71 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.838 1.655 . . . . 10.0 110.245 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.58 137.39 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 O-C-N 121.241 -0.912 . . . . 10.0 111.928 -177.555 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -117.34 161.15 19.99 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.091 1.757 . . . . 10.0 112.094 176.57 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.91 -34.12 65.29 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -177.326 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.0 m -65.37 -16.6 63.77 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 125.515 1.526 . . . . 10.0 114.565 175.468 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -81.95 -5.33 58.21 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.695 1.198 . . . . 10.0 113.348 178.33 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.49 151.44 46.37 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.025 -1.047 . . . . 10.0 112.773 175.908 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.96 -171.89 21.59 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 124.97 1.271 . . . . 10.0 114.846 176.892 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.01 105.74 14.25 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.891 1.676 . . . . 10.0 111.252 176.518 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -80.6 152.7 28.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.206 1.002 . . . . 10.0 111.963 169.479 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.92 44.52 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.905 0.882 . . . . 10.0 111.933 166.231 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 51.3 t -130.66 143.61 50.86 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.666 1.987 . . . . 10.0 109.789 177.018 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 99.0 t -126.38 129.66 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 125.57 1.548 . . . . 10.0 109.673 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -123.58 118.81 28.18 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.404 1.881 . . . . 10.0 110.433 -178.529 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -131.95 138.23 48.24 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 125.373 1.469 . . . . 10.0 111.822 -173.467 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -134.14 -177.48 4.6 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.936 1.295 . . . . 10.0 111.358 168.174 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -60.91 -11.63 8.56 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 115.727 1.751 . . . . 10.0 115.727 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.49 -19.82 12.42 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 125.569 1.548 . . . . 10.0 114.503 -178.107 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.4 -168.92 41.99 Favored Glycine 0 CA--C 1.534 1.252 0 N-CA-C 116.371 1.308 . . . . 10.0 116.371 178.984 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -135.71 142.41 45.05 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.29 2.236 . . . . 10.0 111.683 -172.059 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.05 162.53 33.9 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.052 1.741 . . . . 10.0 111.309 169.011 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -141.4 146.09 36.14 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.023 1.329 . . . . 10.0 110.753 -172.511 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -133.45 154.22 50.97 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.349 1.46 . . . . 10.0 110.774 177.263 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.7 m -144.27 144.71 31.62 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.489 1.116 . . . . 10.0 111.615 -171.491 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.8 p -153.23 164.02 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 126.126 1.77 . . . . 10.0 110.698 172.414 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -125.17 138.71 54.14 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 124.79 1.236 . . . . 10.0 111.13 174.888 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -124.61 120.04 30.77 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.997 1.719 . . . . 10.0 111.068 -177.829 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -105.69 86.24 2.36 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.064 1.746 . . . . 10.0 110.723 176.694 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 23.8 t -67.47 109.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 123.992 0.917 . . . . 10.0 110.607 -179.581 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 66.1 mt -72.98 103.11 3.66 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 126.324 1.85 . . . . 10.0 109.853 178.798 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 113.887 1.069 . . . . 10.0 113.887 -172.069 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 CA--C 1.544 1.007 0 N-CA-C 113.077 0.376 . . . . 10.0 113.077 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.54 160.49 49.1 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 123.146 2.564 . . . . 10.0 112.083 171.013 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.27 168.96 23.69 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.266 1.426 . . . . 10.0 112.539 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -72.98 146.47 45.98 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.517 1.527 . . . . 10.0 111.988 173.269 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.2 mp -136.4 -64.08 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 125.699 1.6 . . . . 10.0 109.054 168.539 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -151.7 138.39 18.8 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.716 1.606 . . . . 10.0 110.521 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.6 m -133.37 151.99 78.5 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.773 1.629 . . . . 10.0 110.404 173.688 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.24 148.03 67.56 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 122.652 2.234 . . . . 10.0 112.348 175.932 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -74.53 176.5 6.79 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.489 1.115 . . . . 10.0 111.253 166.273 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -54.37 122.86 11.32 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.04 -1.037 . . . . 10.0 112.508 176.961 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.6 mtp -101.31 159.02 15.62 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.01 1.724 . . . . 10.0 111.872 -177.2 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 p -146.82 115.28 6.71 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.178 1.391 . . . . 10.0 111.259 177.708 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.0 mm -127.01 134.22 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.595 1.558 . . . . 10.0 110.166 -169.221 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -63.98 131.85 48.89 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.683 1.193 . . . . 10.0 112.666 176.202 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -52.74 121.54 7.4 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.758 1.623 . . . . 10.0 112.962 -178.941 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 103.81 -9.31 51.56 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 126.2 1.857 . . . . 10.0 115.106 177.829 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.8 mtp180 -72.05 159.51 34.07 Favored 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 119.173 1.486 . . . . 10.0 113.398 177.449 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -72.55 147.7 45.67 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.54 1.136 . . . . 10.0 110.412 156.513 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 15.0 t -149.49 162.82 39.39 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.329 1.052 . . . . 10.0 111.941 170.199 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.0 ptm85 -143.08 164.26 30.59 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.67 1.588 . . . . 10.0 112.107 165.541 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.0 mtt -126.11 159.97 31.42 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 126.802 2.041 . . . . 10.0 110.654 173.883 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -136.72 89.95 2.5 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.416 1.486 . . . . 10.0 111.025 -169.369 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -100.72 106.06 17.46 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.24 1.416 . . . . 10.0 111.029 -178.329 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -67.05 133.07 49.17 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 121.62 -0.675 . . . . 10.0 110.117 171.17 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.7 p -143.71 146.43 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 125.467 1.507 . . . . 10.0 111.392 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 93.6 p -128.6 -165.7 1.54 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.974 1.71 . . . . 10.0 112.733 -174.687 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 98.99 163.45 29.88 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 126.298 1.904 . . . . 10.0 112.813 -178.264 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -142.68 127.09 9.83 Favored Pre-proline 0 CA--C 1.546 0.797 0 C-N-CA 125.507 1.523 . . . . 10.0 109.555 177.781 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -66.26 169.16 46.24 Favored 'Cis proline' 0 CA--C 1.54 0.825 0 CA-C-N 120.312 1.147 . . . . 10.0 112.584 -4.193 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.96 70.01 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.386 1.075 . . . . 10.0 111.046 178.479 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.63 148.53 59.67 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 122.284 1.989 . . . . 10.0 113.834 -169.155 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -67.43 132.83 48.42 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.384 1.474 . . . . 10.0 109.561 158.43 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.1 m -124.0 138.64 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.514 1.126 . . . . 10.0 112.155 -173.276 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 48.1 m -135.25 154.08 51.7 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.975 1.71 . . . . 10.0 110.755 178.221 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -124.93 153.21 43.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.536 1.135 . . . . 10.0 113.389 -176.469 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.3 m-85 -145.1 160.29 41.64 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.088 2.155 . . . . 10.0 111.15 -172.372 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 58.3 tp -149.87 122.34 8.5 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 126.695 1.998 . . . . 10.0 110.332 178.171 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 54.98 6.97 0.14 Allowed 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 126.995 2.118 . . . . 10.0 116.595 174.864 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 121.21 -6.18 10.92 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.2 1.857 . . . . 10.0 115.725 -177.189 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.0 ptm180 -108.09 165.44 11.47 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 119.254 1.527 . . . . 10.0 112.227 171.637 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.8 p -72.47 158.1 36.37 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.861 1.264 . . . . 10.0 112.437 172.302 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 44.4 t -131.09 101.72 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 126.076 1.751 . . . . 10.0 108.372 171.976 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 11.5 mp0 -67.04 149.95 49.9 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.573 1.149 . . . . 10.0 111.295 176.818 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.4 p -65.54 138.98 58.42 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.45 0.7 . . . . 10.0 110.922 167.698 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -146.8 167.96 22.58 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.721 1.208 . . . . 10.0 111.819 -176.479 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -56.79 -35.07 68.29 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.162 -0.961 . . . . 10.0 113.105 171.023 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 70.4 mt -85.76 -15.17 42.96 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.996 1.11 . . . . 10.0 113.996 174.834 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.5 m80 -135.72 73.03 1.45 Allowed 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.975 1.71 . . . . 10.0 111.088 -174.35 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -73.02 143.66 47.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 125.144 1.377 . . . . 10.0 111.329 -178.173 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 58.8 mtt -142.44 105.25 4.54 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.864 1.666 . . . . 10.0 110.214 -172.338 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.92 144.77 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.161 0.984 . . . . 10.0 112.46 -178.667 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 48.0 t -95.16 100.52 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 125.154 1.382 . . . . 10.0 108.757 175.484 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 15.2 m -64.3 168.76 5.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.693 1.997 . . . . 10.0 112.741 176.307 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -62.01 165.45 5.54 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.541 1.136 . . . . 10.0 113.793 174.705 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 96.6 mttt 56.76 20.69 5.31 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 126.874 2.07 . . . . 10.0 115.794 173.129 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.42 53.83 2.98 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.816 1.198 . . . . 10.0 114.131 173.363 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 52.0 tp -137.16 146.56 45.11 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.726 1.61 . . . . 10.0 110.517 179.505 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -126.84 115.72 19.76 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.997 1.319 . . . . 10.0 111.359 -179.784 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.0 m -80.83 129.19 34.4 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.834 1.654 . . . . 10.0 111.819 172.366 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -128.35 119.43 25.04 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.088 2.155 . . . . 10.0 107.645 170.963 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 54.4 mt -119.68 154.06 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.808 1.243 . . . . 10.0 111.662 -164.464 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -131.57 108.65 9.69 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 127.848 2.459 . . . . 10.0 109.35 173.468 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -66.36 -43.21 86.65 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 120.985 -1.072 . . . . 10.0 113.031 177.432 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.71 89.12 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.791 1.637 . . . . 10.0 110.16 -177.685 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -70.09 139.48 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.353 -0.842 . . . . 10.0 112.26 -176.322 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -121.91 163.53 19.1 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.312 1.845 . . . . 10.0 112.045 175.408 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.06 -30.33 66.1 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.574 0.953 . . . . 10.0 113.574 -178.686 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.7 p -67.82 -16.9 64.32 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.657 1.583 . . . . 10.0 114.681 173.648 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -83.66 -5.63 59.23 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.633 1.173 . . . . 10.0 113.356 175.858 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.83 154.43 39.16 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.027 -1.046 . . . . 10.0 113.352 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.01 -169.72 21.99 Favored Glycine 0 CA--C 1.532 1.123 0 C-N-CA 124.67 1.128 . . . . 10.0 115.043 174.973 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.81 100.19 10.79 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.966 1.706 . . . . 10.0 111.392 177.626 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -75.11 151.57 38.6 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.214 1.006 . . . . 10.0 111.679 167.432 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.36 159.01 43.15 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.94 0.896 . . . . 10.0 112.157 168.71 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -130.69 144.47 51.46 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.545 1.938 . . . . 10.0 110.223 177.272 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.3 t -126.57 116.11 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 125.49 1.516 . . . . 10.0 109.347 179.229 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -106.3 126.58 52.41 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.452 1.901 . . . . 10.0 110.806 -178.255 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -132.47 127.58 35.58 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 126.439 1.896 . . . . 10.0 111.774 -168.058 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -134.33 177.73 7.53 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.864 0.757 . . . . 10.0 112.238 164.211 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 -62.47 -11.13 14.25 Favored 'General case' 0 N--CA 1.48 1.072 0 N-CA-C 115.536 1.68 . . . . 10.0 115.536 -178.932 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.49 -15.37 14.81 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.569 1.548 . . . . 10.0 114.088 178.138 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.18 -170.39 38.61 Favored Glycine 0 CA--C 1.536 1.369 0 CA-C-N 119.659 1.118 . . . . 10.0 115.423 176.365 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -134.06 149.59 51.15 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 126.059 1.744 . . . . 10.0 111.892 -172.775 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.42 162.73 33.71 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.237 1.815 . . . . 10.0 111.501 171.144 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 30.1 m -140.28 135.97 32.81 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.938 1.295 . . . . 10.0 110.758 -175.7 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -129.72 154.02 47.58 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.669 1.588 . . . . 10.0 110.976 -178.059 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -144.84 145.61 31.7 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.236 1.014 . . . . 10.0 112.017 -169.421 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.6 p -152.27 150.46 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 125.661 1.584 . . . . 10.0 111.696 170.46 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.3 tt0 -100.91 139.2 36.94 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.531 1.133 . . . . 10.0 111.004 171.655 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.9 tp -123.25 103.86 8.79 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.89 1.676 . . . . 10.0 110.566 175.898 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -90.73 82.9 5.71 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.63 1.572 . . . . 10.0 110.981 175.861 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.9 t -63.69 112.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.844 0.858 . . . . 10.0 110.621 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.7 mt -75.34 98.54 3.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.288 1.835 . . . . 10.0 110.184 -179.22 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.758 0 C-N-CA 124.062 0.945 . . . . 10.0 112.72 179.351 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.522 0 N-CA-C 111.192 -0.763 . . . . 10.0 111.192 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.32 162.01 15.67 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.232 1.013 . . . . 10.0 112.794 175.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.99 174.09 11.84 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.901 1.681 . . . . 10.0 111.823 -176.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -179.06 173.05 45.27 Favored Glycine 0 CA--C 1.542 1.777 0 N-CA-C 116.858 1.503 . . . . 10.0 116.858 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -70.84 162.18 43.5 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.722 2.948 . . . . 10.0 113.258 -172.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -66.96 152.08 80.99 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.859 2.373 . . . . 10.0 111.427 168.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 68.9 ttt180 -142.52 162.68 34.84 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 125.764 1.626 . . . . 10.0 111.542 -177.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -71.33 141.29 50.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.321 1.449 . . . . 10.0 112.224 173.259 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.1 mp -135.47 -66.14 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.544 1.538 . . . . 10.0 109.724 171.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 -149.56 140.3 22.67 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.34 1.456 . . . . 10.0 111.105 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 24.7 m -127.26 152.59 76.32 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 126.207 1.803 . . . . 10.0 110.287 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.3 156.91 50.49 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.87 2.38 . . . . 10.0 112.016 176.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.63 167.28 22.12 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.114 0.966 . . . . 10.0 112.67 172.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -60.2 106.9 0.57 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 124.839 1.256 . . . . 10.0 111.698 173.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 26.4 mtm -79.4 154.57 28.88 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 123.653 0.781 . . . . 10.0 112.467 -175.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.7 p -138.43 110.13 7.11 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 125.306 1.442 . . . . 10.0 110.539 170.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.8 mm -126.85 131.12 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.314 1.446 . . . . 10.0 110.391 -163.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -59.43 131.92 52.42 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.646 1.178 . . . . 10.0 112.558 173.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -51.97 129.83 28.05 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 125.159 1.384 . . . . 10.0 112.674 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.75 -8.91 76.37 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 125.497 1.522 . . . . 10.0 115.278 177.323 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -70.87 161.61 30.71 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 119.321 1.56 . . . . 10.0 113.051 175.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -73.47 138.48 45.14 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.55 1.14 . . . . 10.0 110.043 155.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.1 p -149.42 169.4 20.95 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.468 0.707 . . . . 10.0 112.348 164.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -147.45 155.56 42.04 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.855 1.262 . . . . 10.0 112.975 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -122.39 143.36 49.71 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 128.028 2.531 . . . . 10.0 108.925 173.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -139.5 114.56 9.57 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.187 0.995 . . . . 10.0 111.936 -170.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -115.85 113.79 23.84 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.222 2.209 . . . . 10.0 110.42 -173.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.3 mtpp -67.99 133.85 49.74 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.473 -0.767 . . . . 10.0 110.015 170.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -140.94 125.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.521 1.528 . . . . 10.0 111.139 -174.035 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 50.6 m -136.03 103.34 5.32 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.798 1.239 . . . . 10.0 111.467 -176.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -154.9 165.08 32.04 Favored Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.983 2.23 . . . . 10.0 110.662 169.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.6 tp -141.91 125.85 9.97 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.129 0.971 . . . . 10.0 110.847 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -65.43 167.16 49.53 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.63 1.261 . . . . 10.0 112.511 -2.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.09 121.84 44.01 Favored Pre-proline 0 CA--C 1.549 0.915 0 C-N-CA 124.483 1.113 . . . . 10.0 111.202 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.77 150.79 68.64 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.492 2.128 . . . . 10.0 113.076 -172.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -73.62 143.77 46.2 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.146 0.979 . . . . 10.0 109.666 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.61 136.23 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.796 0.839 . . . . 10.0 111.858 -174.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -126.99 157.71 38.81 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.897 1.679 . . . . 10.0 111.68 173.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 51.0 m95 -125.97 154.88 42.25 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 125.533 1.533 . . . . 10.0 113.666 -173.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -144.49 161.12 39.88 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.26 2.224 . . . . 10.0 111.96 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.1 tp -146.56 124.35 11.91 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.748 2.419 . . . . 10.0 109.69 173.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.01 14.28 0.68 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 126.775 2.03 . . . . 10.0 116.064 175.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.36 0.55 24.99 Favored Glycine 0 CA--C 1.539 1.552 0 C-N-CA 125.693 1.616 . . . . 10.0 116.043 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.0 ptp85 -123.93 163.19 21.82 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 125.679 1.592 . . . . 10.0 112.177 173.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.4 p -69.65 159.59 33.17 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.596 1.158 . . . . 10.0 113.616 -175.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 92.7 t -134.92 108.1 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 126.93 2.092 . . . . 10.0 108.939 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -77.01 159.66 29.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 123.724 0.81 . . . . 10.0 111.365 170.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 81.3 p -76.91 155.48 32.77 Favored 'General case' 0 N--CA 1.473 0.683 0 O-C-N 121.645 -0.659 . . . . 10.0 112.144 168.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -155.71 -176.39 5.93 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.578 1.551 . . . . 10.0 111.576 168.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -62.08 -18.18 59.92 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -177.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 68.7 mt -107.37 -26.67 10.88 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.845 1.658 . . . . 10.0 112.266 175.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -108.74 68.78 0.69 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.828 2.051 . . . . 10.0 110.711 177.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -74.25 146.09 43.55 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.346 1.058 . . . . 10.0 111.839 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 65.7 mtt -138.89 114.69 9.99 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.533 1.933 . . . . 10.0 110.184 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.55 155.82 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.928 1.291 . . . . 10.0 111.776 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.1 p -141.21 122.02 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.595 1.158 . . . . 10.0 111.238 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 38.7 t -74.87 141.8 44.17 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.485 1.114 . . . . 10.0 111.65 175.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.78 -17.68 37.39 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.769 1.228 . . . . 10.0 113.688 170.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -76.47 -4.2 41.32 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.936 1.694 . . . . 10.0 113.917 174.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.68 39.43 4.15 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.979 1.275 . . . . 10.0 114.867 172.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.2 tp -136.55 114.78 11.61 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 125.109 1.364 . . . . 10.0 111.122 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 5.1 t60 -98.35 132.88 43.46 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.21 1.404 . . . . 10.0 110.994 174.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 37.9 m -121.89 138.07 54.54 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.558 1.543 . . . . 10.0 111.487 -178.018 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -128.06 117.84 22.38 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 127.713 2.405 . . . . 10.0 107.85 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 85.3 mt -118.63 148.45 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.471 1.108 . . . . 10.0 111.064 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -123.07 106.31 10.69 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 127.355 2.262 . . . . 10.0 109.014 171.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -63.59 -38.3 90.61 Favored 'General case' 0 N--CA 1.475 0.781 0 O-C-N 121.296 -0.878 . . . . 10.0 113.09 176.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.2 p -150.76 90.1 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.889 1.676 . . . . 10.0 110.248 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -68.48 144.75 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 O-C-N 121.27 -0.894 . . . . 10.0 112.101 -178.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -129.21 162.17 28.45 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.03 1.732 . . . . 10.0 112.005 174.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.54 -34.38 64.65 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 113.642 0.979 . . . . 10.0 113.642 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.1 m -64.87 -17.15 64.03 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.387 1.475 . . . . 10.0 114.509 175.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -81.7 -8.28 59.68 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.513 1.125 . . . . 10.0 113.328 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.72 150.64 43.99 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 119.219 0.918 . . . . 10.0 112.933 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.9 -172.2 22.71 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.563 1.078 . . . . 10.0 114.789 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.87 101.95 13.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.963 1.705 . . . . 10.0 111.209 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -76.15 150.85 37.11 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.225 1.01 . . . . 10.0 111.501 167.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.5 161.97 38.49 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.906 0.883 . . . . 10.0 111.545 169.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 30.8 p -144.88 161.87 38.25 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.186 0.994 . . . . 10.0 112.044 171.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.98 131.25 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.273 1.429 . . . . 10.0 110.072 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.47 126.8 54.77 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.651 1.98 . . . . 10.0 110.044 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -133.93 129.06 35.75 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.644 1.577 . . . . 10.0 112.012 -169.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.5 p30 -132.21 -179.46 5.44 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.448 1.099 . . . . 10.0 111.832 166.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -60.51 -14.68 21.07 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.657 1.725 . . . . 10.0 115.657 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.84 -16.38 14.48 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.288 1.435 . . . . 10.0 114.276 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.93 -170.17 40.55 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 115.876 1.11 . . . . 10.0 115.876 177.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -134.68 146.72 49.75 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.852 2.061 . . . . 10.0 111.7 -172.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.81 153.11 49.68 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.753 1.621 . . . . 10.0 110.982 169.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 25.2 m -137.55 136.78 37.93 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.832 1.253 . . . . 10.0 110.552 -172.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -134.89 153.72 51.95 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.964 1.306 . . . . 10.0 111.524 -173.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.0 m -142.33 144.5 33.24 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 125.251 1.42 . . . . 10.0 111.456 -173.031 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.9 p -151.8 156.72 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 C-N-CA 125.695 1.598 . . . . 10.0 111.271 170.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -107.89 148.89 29.0 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 124.349 1.06 . . . . 10.0 111.746 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.29 114.96 18.29 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.469 1.907 . . . . 10.0 110.222 174.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -103.46 84.74 2.35 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.719 1.608 . . . . 10.0 110.685 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.8 t -67.23 110.96 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.708 0.803 . . . . 10.0 110.871 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 75.7 mt -75.95 101.03 5.05 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.731 2.012 . . . . 10.0 110.567 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -64.21 161.91 15.57 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.058 0.943 . . . . 10.0 112.87 175.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -127.79 16.04 6.91 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 125.69 1.596 . . . . 10.0 114.889 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? . . . . . 0 C--O 1.253 1.241 0 C-N-CA 126.463 1.905 . . . . 10.0 114.656 172.834 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.577 0 N-CA-C 112.0 -0.44 . . . . 10.0 112.0 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -62.94 143.69 57.47 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.268 1.027 . . . . 10.0 113.013 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -64.62 166.4 8.71 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.666 1.586 . . . . 10.0 113.8 174.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.52 160.6 34.24 Favored Glycine 0 CA--C 1.541 1.69 0 C-N-CA 125.707 1.622 . . . . 10.0 113.166 174.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.1 163.72 36.67 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.865 3.043 . . . . 10.0 113.29 -171.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -67.33 148.31 79.59 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.825 2.35 . . . . 10.0 111.435 173.477 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 32.7 ttp-105 -138.09 136.9 37.22 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.855 1.262 . . . . 10.0 113.208 -173.451 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -63.58 117.26 6.54 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 127.274 2.23 . . . . 10.0 110.997 170.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 35.8 mm -108.35 -54.26 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.735 0.814 . . . . 10.0 110.328 171.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -153.18 142.68 21.76 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.412 1.085 . . . . 10.0 111.433 172.252 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.53 148.48 53.06 Favored Pre-proline 0 N--CA 1.476 0.862 0 C-N-CA 125.247 1.419 . . . . 10.0 110.073 169.001 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -77.13 163.69 30.29 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.965 2.443 . . . . 10.0 112.117 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -73.1 166.74 22.54 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.593 0.757 . . . . 10.0 111.43 166.312 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -62.44 160.9 12.64 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.364 -0.835 . . . . 10.0 112.081 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 51.0 mtm -133.49 161.25 35.1 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.181 0.992 . . . . 10.0 112.939 -178.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 55.2 p -137.88 115.64 11.43 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 125.907 1.683 . . . . 10.0 109.854 168.034 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.6 mm -124.51 132.9 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.306 1.442 . . . . 10.0 110.05 -166.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -59.56 126.51 27.91 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.402 1.481 . . . . 10.0 112.475 173.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -50.23 126.75 15.5 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.599 1.56 . . . . 10.0 112.679 176.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.99 -11.75 58.91 Favored Glycine 0 CA--C 1.537 1.468 0 C-N-CA 126.182 1.849 . . . . 10.0 115.088 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -75.53 162.39 28.34 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 119.2 1.5 . . . . 10.0 113.418 177.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -76.69 143.3 40.13 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.076 1.351 . . . . 10.0 110.328 157.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 28.6 p -150.82 168.97 22.83 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.608 0.763 . . . . 10.0 112.621 162.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.8 ptm85 -144.12 168.93 18.86 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.426 1.49 . . . . 10.0 112.966 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.7 mtt -131.81 158.82 40.27 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.974 2.11 . . . . 10.0 110.867 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -136.15 92.61 2.81 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.144 1.378 . . . . 10.0 112.139 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -108.41 104.02 13.29 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.456 1.502 . . . . 10.0 111.319 -176.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.1 mtpp -81.7 122.98 28.33 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 121.077 -1.014 . . . . 10.0 110.322 173.553 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.43 151.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.803 2.041 . . . . 10.0 110.633 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.9 t -131.1 175.7 8.88 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.18 1.392 . . . . 10.0 111.419 172.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 136.7 167.53 11.17 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 127.418 2.437 . . . . 10.0 112.445 -175.48 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.33 119.79 5.16 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 123.878 0.871 . . . . 10.0 111.707 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.8 169.44 59.05 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 CA-C-N 120.459 1.2 . . . . 10.0 112.473 -1.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.85 127.79 75.31 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.059 0.943 . . . . 10.0 110.838 175.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.69 148.32 65.28 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 122.298 1.999 . . . . 10.0 113.062 -172.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -71.01 142.02 50.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.353 1.061 . . . . 10.0 109.583 160.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 10.8 m -127.02 137.67 57.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 124.618 1.167 . . . . 10.0 112.583 -170.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.1 m -137.57 112.55 9.05 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.109 1.764 . . . . 10.0 110.758 -174.281 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -85.87 152.76 22.73 Favored 'General case' 0 CA--C 1.536 0.417 0 N-CA-C 113.475 0.917 . . . . 10.0 113.475 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.41 158.89 43.21 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.386 2.274 . . . . 10.0 111.129 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.15 117.78 8.62 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 127.153 2.181 . . . . 10.0 110.109 177.045 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 55.14 10.98 0.47 Allowed 'General case' 0 CA--C 1.555 1.172 0 C-N-CA 126.747 2.019 . . . . 10.0 115.573 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.27 -15.63 17.97 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 126.832 2.158 . . . . 10.0 115.047 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -84.09 157.45 21.74 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 118.988 1.394 . . . . 10.0 111.088 169.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.9 p -71.71 157.91 37.09 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.281 1.033 . . . . 10.0 112.137 170.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.8 105.77 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 126.303 1.841 . . . . 10.0 108.676 173.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 23.0 mm100 -76.26 159.83 30.23 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.218 0.607 . . . . 10.0 111.495 173.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 36.7 p -67.06 150.8 48.7 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.692 0.797 . . . . 10.0 111.928 169.489 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -150.76 166.01 31.77 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.179 1.392 . . . . 10.0 111.128 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -54.86 -36.56 65.21 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.147 -0.97 . . . . 10.0 113.1 170.186 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.0 mt -84.22 -13.77 51.79 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.434 1.094 . . . . 10.0 113.863 174.154 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -135.04 70.95 1.43 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.93 1.692 . . . . 10.0 111.322 -173.7 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.08 143.12 49.17 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.049 1.339 . . . . 10.0 111.73 -175.258 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -139.6 101.99 4.35 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.644 1.978 . . . . 10.0 110.055 -174.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.14 162.73 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.254 1.422 . . . . 10.0 111.557 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.86 118.15 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.899 1.279 . . . . 10.0 110.994 177.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 63.3 m -68.56 158.44 33.91 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.328 1.051 . . . . 10.0 112.218 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -61.24 -21.26 63.71 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 114.243 1.201 . . . . 10.0 114.243 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.1 mptt -77.06 -5.4 48.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.299 1.84 . . . . 10.0 113.865 173.196 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.05 3.43 65.59 Favored Glycine 0 CA--C 1.536 1.394 0 C-N-CA 125.6 1.572 . . . . 10.0 115.181 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.8 tp -77.44 101.81 6.58 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 118.686 1.243 . . . . 10.0 111.318 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -78.96 113.55 17.16 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.185 1.394 . . . . 10.0 110.925 170.045 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 75.0 m -84.98 139.44 31.79 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 125.524 1.53 . . . . 10.0 111.986 171.326 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -131.92 121.24 23.68 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 126.704 2.002 . . . . 10.0 107.688 168.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 61.0 mt -122.18 152.57 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.855 1.262 . . . . 10.0 111.357 -166.009 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -129.4 109.85 11.42 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 127.519 2.328 . . . . 10.0 109.142 170.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -66.15 -40.22 90.4 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.359 -0.838 . . . . 10.0 113.168 176.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -149.96 88.92 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.838 1.655 . . . . 10.0 110.104 -178.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -68.53 140.29 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 O-C-N 121.378 -0.826 . . . . 10.0 112.045 -176.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -124.78 160.64 28.21 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.463 1.905 . . . . 10.0 111.841 177.258 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.14 -34.32 63.66 Favored 'General case' 0 CA--C 1.547 0.828 0 N-CA-C 113.509 0.929 . . . . 10.0 113.509 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.4 m -65.05 -17.46 64.47 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.499 1.52 . . . . 10.0 114.62 175.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -80.99 -6.53 58.88 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.446 1.098 . . . . 10.0 113.324 177.262 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.88 148.44 51.4 Favored 'General case' 0 CA--C 1.547 0.843 0 O-C-N 121.017 -1.052 . . . . 10.0 112.77 177.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 139.75 -174.75 22.19 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.844 1.211 . . . . 10.0 114.815 177.15 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.81 108.68 17.6 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.971 1.708 . . . . 10.0 110.932 175.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.5 m-85 -86.12 151.96 23.25 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.208 1.003 . . . . 10.0 111.869 172.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.97 160.68 39.88 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.933 0.893 . . . . 10.0 112.006 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.0 t -137.57 107.47 6.3 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.753 1.621 . . . . 10.0 110.586 177.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.5 t -76.05 132.9 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.294 1.037 . . . . 10.0 108.937 169.22 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -128.3 121.79 30.08 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 126.372 1.869 . . . . 10.0 110.494 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -134.4 139.45 45.59 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.941 1.297 . . . . 10.0 112.604 -171.758 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.3 p30 -133.74 -178.31 4.95 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.609 1.164 . . . . 10.0 111.259 165.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -61.9 -7.79 4.2 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 115.667 1.729 . . . . 10.0 115.667 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -117.7 -12.7 10.24 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 126.135 1.774 . . . . 10.0 114.578 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.01 -172.66 44.48 Favored Glycine 0 CA--C 1.535 1.308 0 CA-C-N 119.776 1.171 . . . . 10.0 115.924 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -137.8 144.23 41.44 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.992 2.117 . . . . 10.0 111.625 -174.368 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.64 162.96 33.3 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.594 1.957 . . . . 10.0 110.626 168.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -141.99 124.5 15.77 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.389 1.076 . . . . 10.0 110.736 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -105.14 154.39 20.25 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.33 1.452 . . . . 10.0 110.898 178.017 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.7 m -144.03 145.12 31.98 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 124.271 1.028 . . . . 10.0 112.035 -170.579 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.8 p -154.11 171.64 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 C-N-CA 126.595 1.958 . . . . 10.0 110.976 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -131.92 147.88 52.49 Favored 'General case' 0 N--CA 1.471 0.614 0 O-C-N 120.77 -1.206 . . . . 10.0 111.622 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.7 tp -131.14 117.04 18.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 126.283 1.833 . . . . 10.0 110.2 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -106.4 77.68 1.23 Allowed 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.681 1.592 . . . . 10.0 110.481 178.248 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -58.37 114.31 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.414 1.086 . . . . 10.0 111.014 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.5 mt -76.25 99.58 4.8 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.477 1.911 . . . . 10.0 109.831 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.49 150.39 31.43 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.975 0.91 . . . . 10.0 113.117 -177.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -77.28 -9.45 58.82 Favored 'General case' 0 N--CA 1.48 1.069 0 N-CA-C 115.104 1.52 . . . . 10.0 115.104 -178.431 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 . . . . . 0 C--O 1.253 1.248 0 C-N-CA 126.829 2.052 . . . . 10.0 114.06 -178.482 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.597 0 N-CA-C 112.154 -0.378 . . . . 10.0 112.154 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.65 166.09 11.34 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 124.449 1.1 . . . . 10.0 112.872 174.639 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.3 ptt? -133.98 177.19 7.93 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 125.614 1.565 . . . . 10.0 112.57 -176.071 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 179.03 172.34 43.22 Favored Glycine 0 CA--C 1.541 1.668 0 N-CA-C 116.708 1.443 . . . . 10.0 116.708 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.16 159.9 47.42 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 123.901 3.068 . . . . 10.0 113.027 -173.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -68.24 143.19 57.9 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.133 2.555 . . . . 10.0 111.497 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -131.24 149.45 52.57 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.96 1.304 . . . . 10.0 113.757 -174.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -77.76 111.13 13.24 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.019 2.527 . . . . 10.0 110.939 176.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.5 mm -109.34 -44.66 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.772 0.829 . . . . 10.0 111.104 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -149.51 142.18 24.53 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.708 1.203 . . . . 10.0 111.494 170.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -122.91 135.69 26.08 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 124.873 1.269 . . . . 10.0 109.278 158.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -75.47 159.88 39.18 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.003 2.468 . . . . 10.0 112.206 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -67.44 164.84 17.86 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.92 1.288 . . . . 10.0 112.111 171.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -62.49 113.77 3.15 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.216 -0.928 . . . . 10.0 111.332 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 29.0 mtm -76.22 148.87 37.37 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.736 -0.603 . . . . 10.0 111.69 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 24.0 p -128.08 102.76 6.87 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 125.705 1.602 . . . . 10.0 110.468 176.122 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.7 mm -121.8 123.61 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.931 1.293 . . . . 10.0 110.63 -163.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -58.86 126.23 26.83 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.134 1.374 . . . . 10.0 111.893 170.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -53.22 136.37 36.58 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.126 1.371 . . . . 10.0 113.468 -176.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 94.93 -10.92 70.09 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 125.97 1.747 . . . . 10.0 114.808 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 73.8 mtp180 -72.5 158.92 34.81 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 118.877 1.339 . . . . 10.0 113.479 177.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -75.31 141.04 43.45 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.373 1.069 . . . . 10.0 110.265 154.212 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 32.0 p -150.76 170.87 18.18 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.583 0.753 . . . . 10.0 112.269 160.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -145.83 144.06 30.02 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.195 1.398 . . . . 10.0 111.74 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.7 mtt -91.75 159.33 15.88 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.084 1.354 . . . . 10.0 110.665 169.028 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -138.15 109.83 7.09 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.231 1.412 . . . . 10.0 112.557 -177.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -116.56 98.47 6.56 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.646 1.978 . . . . 10.0 110.383 -176.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 29.5 mtpp -67.87 137.88 55.62 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.148 -0.97 . . . . 10.0 110.196 171.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.28 152.83 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.486 1.514 . . . . 10.0 111.27 -172.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -136.5 174.87 10.14 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.28 1.432 . . . . 10.0 111.164 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 121.07 164.34 12.31 Favored Glycine 0 CA--C 1.538 1.478 0 C-N-CA 127.288 2.375 . . . . 10.0 112.878 -174.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.0 tp -153.04 135.04 8.87 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.752 1.221 . . . . 10.0 110.978 -179.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -68.38 172.11 44.74 Favored 'Cis proline' 0 CA--C 1.54 0.794 0 CA-C-N 120.815 1.327 . . . . 10.0 112.722 -4.42 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.69 122.58 52.33 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.777 1.231 . . . . 10.0 111.777 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -72.17 155.43 56.54 Favored 'Trans proline' 0 CA--C 1.538 0.713 0 C-N-CA 122.618 2.212 . . . . 10.0 113.542 -172.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -79.13 74.41 5.69 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.316 1.846 . . . . 10.0 111.517 177.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 15.3 m -56.69 122.46 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 125.526 1.53 . . . . 10.0 113.194 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 66.3 m -133.69 111.56 10.68 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 126.334 1.853 . . . . 10.0 111.145 -172.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.4 m95 -87.59 149.77 24.11 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 114.43 1.271 . . . . 10.0 114.43 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -141.6 160.43 40.17 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.606 2.363 . . . . 10.0 111.463 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.4 tp -148.19 123.5 10.26 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 127.733 2.413 . . . . 10.0 109.989 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 53.58 16.03 0.87 Allowed 'General case' 0 CA--C 1.556 1.196 0 C-N-CA 126.498 1.919 . . . . 10.0 115.844 175.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.25 0.04 33.22 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.679 1.609 . . . . 10.0 115.824 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -117.11 162.4 17.89 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 126.031 1.732 . . . . 10.0 111.376 173.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.1 p -69.28 158.69 34.52 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.499 1.119 . . . . 10.0 113.017 178.419 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 43.6 t -130.82 106.91 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 126.011 1.724 . . . . 10.0 108.607 170.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -72.92 153.25 41.06 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.48 0.712 . . . . 10.0 111.377 172.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 32.2 p -68.25 150.29 48.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.615 0.766 . . . . 10.0 112.026 171.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -151.89 169.65 21.76 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.148 1.379 . . . . 10.0 110.798 175.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -62.52 -31.55 72.34 Favored 'General case' 0 N--CA 1.471 0.625 0 O-C-N 120.464 -1.398 . . . . 10.0 112.549 169.328 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 97.8 mt -73.99 -22.31 59.65 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.012 0.925 . . . . 10.0 113.468 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -136.75 67.91 1.44 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.152 1.781 . . . . 10.0 111.108 -171.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 63.8 mttm -69.78 142.73 53.15 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.183 0.993 . . . . 10.0 111.336 -177.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -135.51 102.9 5.27 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 126.724 2.01 . . . . 10.0 109.423 -173.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.55 155.71 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 124.165 0.986 . . . . 10.0 112.546 -173.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.66 165.51 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 126.484 1.914 . . . . 10.0 111.188 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 39.0 t -137.72 146.83 44.2 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.797 1.239 . . . . 10.0 112.642 -178.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -56.98 -20.47 24.06 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.244 1.818 . . . . 10.0 113.837 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -74.71 -1.51 22.23 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.745 1.618 . . . . 10.0 114.014 176.22 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.2 48.01 5.27 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.072 1.32 . . . . 10.0 112.987 178.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.0 tp -140.28 146.96 39.24 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.475 1.51 . . . . 10.0 111.625 -175.299 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -129.43 132.86 47.08 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.085 2.154 . . . . 10.0 109.678 170.131 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 67.6 m -119.28 149.2 42.17 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.844 1.258 . . . . 10.0 112.319 178.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -136.21 110.19 8.24 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.045 2.138 . . . . 10.0 108.478 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -95.18 153.34 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.641 1.576 . . . . 10.0 111.151 -171.076 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -129.54 107.64 9.63 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.92 2.088 . . . . 10.0 108.761 161.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -63.75 -43.25 96.99 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 121.447 -0.783 . . . . 10.0 113.077 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 2.8 p -150.08 87.08 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 126.156 1.782 . . . . 10.0 109.333 -178.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.8 p -66.99 141.13 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 O-C-N 121.525 -0.734 . . . . 10.0 111.8 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -127.07 160.12 32.13 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 126.429 1.892 . . . . 10.0 111.046 177.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.24 -33.79 59.23 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.009 1.114 . . . . 10.0 114.009 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.41 -17.77 64.09 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.287 1.435 . . . . 10.0 114.547 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -81.4 -8.17 59.69 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.656 1.182 . . . . 10.0 113.413 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -62.97 146.28 53.46 Favored 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.136 -0.977 . . . . 10.0 112.622 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.64 -175.37 23.64 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.024 0.821 . . . . 10.0 114.936 178.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.71 105.5 16.99 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 126.196 1.798 . . . . 10.0 111.257 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -84.94 150.76 24.72 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.714 1.206 . . . . 10.0 111.932 173.224 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.64 160.74 40.67 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 123.865 0.866 . . . . 10.0 112.249 170.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 47.3 t -138.21 109.12 6.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.58 1.552 . . . . 10.0 110.753 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 93.9 t -76.98 134.86 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.638 1.175 . . . . 10.0 109.146 169.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -132.37 114.5 14.44 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.245 1.818 . . . . 10.0 110.13 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.6 mtpp -129.8 136.61 49.79 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.409 1.484 . . . . 10.0 111.722 -174.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 28.3 p30 -133.26 -179.41 5.49 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.893 1.277 . . . . 10.0 111.371 168.295 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -62.2 -9.93 9.17 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 115.662 1.726 . . . . 10.0 115.662 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.72 -16.12 13.27 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.744 1.618 . . . . 10.0 114.471 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.29 -168.06 40.96 Favored Glycine 0 CA--C 1.536 1.36 0 CA-C-N 119.992 1.269 . . . . 10.0 116.241 176.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -136.24 143.93 44.58 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.995 2.118 . . . . 10.0 112.21 -171.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.25 160.19 40.51 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.774 2.03 . . . . 10.0 110.476 166.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 53.1 m -144.2 116.16 8.33 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.445 1.098 . . . . 10.0 110.61 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -98.0 151.07 20.69 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.16 1.384 . . . . 10.0 110.979 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.5 m -142.32 146.3 34.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 124.613 1.165 . . . . 10.0 111.819 -174.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -153.06 174.58 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 126.721 2.008 . . . . 10.0 110.916 173.306 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -130.47 150.58 51.62 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.176 1.39 . . . . 10.0 111.118 173.047 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.5 tp -125.16 108.36 11.7 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 110.846 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -90.4 81.07 6.03 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.258 1.823 . . . . 10.0 110.473 176.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.9 t -68.44 109.5 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 121.119 -0.988 . . . . 10.0 110.472 177.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.7 mt -77.55 97.64 5.11 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.774 1.63 . . . . 10.0 109.548 177.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.45 150.51 26.43 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.592 1.157 . . . . 10.0 113.957 -172.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -67.57 -47.29 70.19 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.078 1.751 . . . . 10.0 112.592 179.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 . . . . . 0 C--O 1.253 1.266 0 C-N-CA 126.193 1.797 . . . . 10.0 113.433 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.549 0 N-CA-C 111.793 -0.523 . . . . 10.0 111.793 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.43 160.91 21.0 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.366 1.067 . . . . 10.0 112.983 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.86 178.39 8.72 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 126.026 1.73 . . . . 10.0 112.034 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.83 170.84 43.7 Favored Glycine 0 CA--C 1.541 1.717 0 N-CA-C 116.513 1.365 . . . . 10.0 116.513 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.94 159.58 52.09 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.391 2.727 . . . . 10.0 113.116 -173.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.76 161.71 44.28 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.934 2.423 . . . . 10.0 111.072 166.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.86 166.47 24.37 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.471 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -85.93 71.95 10.55 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.355 1.862 . . . . 10.0 111.543 -173.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 253' ' ' ILE . . . . . 0.499 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.5 OUTLIER -73.55 179.78 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 125.031 1.333 . . . . 10.0 111.137 176.889 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.499 ' H ' HG22 ' A' ' 253' ' ' ILE . 35.3 tt0 -50.06 140.02 13.2 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.152 2.181 . . . . 10.0 114.336 -175.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.4 m -127.12 152.11 75.36 Favored Pre-proline 0 N--CA 1.477 0.915 0 C-N-CA 126.696 1.998 . . . . 10.0 110.982 172.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -77.2 159.22 33.46 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.249 2.632 . . . . 10.0 112.429 174.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -69.47 172.39 7.31 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.19 1.396 . . . . 10.0 112.263 169.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -55.65 111.74 0.98 Allowed 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 124.578 1.151 . . . . 10.0 112.854 173.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.7 mtp -82.58 155.63 24.36 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.769 1.628 . . . . 10.0 112.121 -177.327 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -147.22 109.38 4.49 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.249 1.419 . . . . 10.0 111.062 175.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.2 mm -123.01 133.37 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.248 1.419 . . . . 10.0 110.464 -168.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.74 130.98 47.36 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.096 1.359 . . . . 10.0 112.562 174.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -52.78 133.63 37.01 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.254 1.421 . . . . 10.0 112.862 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 93.22 -9.84 74.22 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.784 1.659 . . . . 10.0 115.276 177.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.1 mtp-105 -75.79 161.15 29.27 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 119.179 1.489 . . . . 10.0 113.018 176.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -72.46 147.33 46.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.442 1.097 . . . . 10.0 110.605 157.569 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 9.0 t -149.67 164.8 34.21 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.569 1.148 . . . . 10.0 111.582 165.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.7 ptm180 -149.54 155.41 40.29 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.645 1.578 . . . . 10.0 111.62 163.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 40.6 mtt -102.43 166.85 10.31 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.614 1.566 . . . . 10.0 112.071 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -132.73 110.9 10.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.331 1.852 . . . . 10.0 111.099 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -127.31 101.74 6.61 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 125.322 1.449 . . . . 10.0 111.172 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -60.36 142.76 54.41 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.513 -0.742 . . . . 10.0 110.296 172.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.0 p -148.98 146.3 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 124.597 1.159 . . . . 10.0 111.753 -175.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 51.8 m -139.19 178.59 7.07 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 126.341 1.856 . . . . 10.0 111.454 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 112.64 161.27 15.22 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 126.349 1.928 . . . . 10.0 113.092 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.15 129.93 7.43 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 125.145 1.378 . . . . 10.0 110.638 -179.012 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -66.39 168.86 48.14 Favored 'Cis proline' 0 CA--C 1.54 0.798 0 CA-C-N 120.806 1.324 . . . . 10.0 112.546 -2.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.63 120.62 33.43 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 124.673 1.189 . . . . 10.0 111.658 -177.339 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.0 159.5 52.3 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.597 2.198 . . . . 10.0 113.265 -174.241 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -68.7 169.41 11.28 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.336 1.454 . . . . 10.0 111.923 171.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 87.1 t -131.95 112.99 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.302 1.841 . . . . 10.0 110.165 -176.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 70.8 m -131.54 100.3 5.09 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.238 1.415 . . . . 10.0 110.91 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -84.02 154.64 23.15 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 122.035 0.921 . . . . 10.0 113.29 176.485 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -142.53 160.35 40.45 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.749 2.419 . . . . 10.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -148.83 124.06 10.18 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.104 2.161 . . . . 10.0 109.98 176.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.54 10.99 0.38 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 126.996 2.118 . . . . 10.0 116.378 174.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.51 -0.96 22.02 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.847 1.689 . . . . 10.0 115.852 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -117.36 163.99 15.52 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.795 1.638 . . . . 10.0 111.929 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.0 p -71.63 160.31 32.89 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.626 1.17 . . . . 10.0 112.948 178.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 64.5 t -136.24 111.29 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 126.632 1.973 . . . . 10.0 108.903 173.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -85.02 159.18 20.28 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.831 0.853 . . . . 10.0 111.199 170.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.9 p -69.61 151.06 46.38 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.725 0.81 . . . . 10.0 112.426 171.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -151.36 179.27 8.47 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.492 1.517 . . . . 10.0 110.79 166.071 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -56.71 -30.74 63.79 Favored 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 114.327 1.232 . . . . 10.0 114.327 -177.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 55.7 mt -87.63 -13.31 43.06 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.912 1.285 . . . . 10.0 113.514 175.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -135.64 68.12 1.46 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.158 1.783 . . . . 10.0 111.226 -172.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -67.86 145.13 54.92 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.089 1.356 . . . . 10.0 111.167 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.2 mtt -135.21 102.68 5.26 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 126.774 2.029 . . . . 10.0 109.726 -175.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.97 158.54 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.822 1.249 . . . . 10.0 112.212 -175.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 38.7 t -133.64 113.97 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 125.778 1.631 . . . . 10.0 109.73 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 46.6 t -64.89 141.15 58.87 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.917 0.887 . . . . 10.0 111.518 172.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -57.76 -19.48 28.18 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.72 1.208 . . . . 10.0 113.946 173.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.5 -3.45 40.59 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.454 1.502 . . . . 10.0 113.697 176.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.66 43.05 4.32 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.293 1.425 . . . . 10.0 113.883 176.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 61.9 tp -137.13 107.03 6.26 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.077 1.351 . . . . 10.0 111.578 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -80.43 138.61 36.63 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 125.379 1.471 . . . . 10.0 111.227 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 60.6 m -122.19 146.51 47.18 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 125.917 1.687 . . . . 10.0 111.807 174.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -134.13 112.54 11.22 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.214 2.206 . . . . 10.0 108.211 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -94.13 154.69 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.399 1.48 . . . . 10.0 111.55 -170.358 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -131.96 99.05 4.62 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.381 2.272 . . . . 10.0 108.96 163.184 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -62.11 -39.23 91.82 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 120.943 -1.098 . . . . 10.0 113.125 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.6 p -150.52 90.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.998 1.719 . . . . 10.0 109.839 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.1 p -68.54 140.23 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 121.39 -0.819 . . . . 10.0 112.148 -175.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 27.2 mmt180 -126.13 162.09 26.16 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.463 1.905 . . . . 10.0 111.834 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.98 -33.4 64.78 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.431 0.9 . . . . 10.0 113.431 -177.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 m -64.11 -18.01 64.0 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.386 1.474 . . . . 10.0 114.472 175.231 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -83.33 -5.99 59.32 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.609 1.164 . . . . 10.0 113.32 177.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.06 152.29 44.99 Favored 'General case' 0 CA--C 1.547 0.852 0 O-C-N 121.039 -1.038 . . . . 10.0 113.191 179.156 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 137.08 -173.32 22.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 124.689 1.138 . . . . 10.0 115.161 175.494 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.08 102.05 13.5 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.143 1.777 . . . . 10.0 111.234 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -80.91 153.6 27.48 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.624 1.17 . . . . 10.0 112.169 170.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.21 162.7 36.5 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.238 1.015 . . . . 10.0 111.795 166.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.3 t -139.64 125.52 19.65 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 125.446 1.499 . . . . 10.0 110.827 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 96.2 t -97.63 134.82 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 125.436 1.495 . . . . 10.0 109.7 174.415 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.19 117.33 22.13 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.224 1.809 . . . . 10.0 110.794 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -132.96 140.35 47.76 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.197 1.399 . . . . 10.0 112.196 -172.551 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.4 p30 -135.04 -177.83 4.81 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.234 1.414 . . . . 10.0 111.209 166.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -62.23 -13.26 26.03 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 115.624 1.713 . . . . 10.0 115.624 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -104.15 -22.54 13.39 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.33 1.452 . . . . 10.0 114.183 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.79 -166.24 39.44 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 116.098 1.199 . . . . 10.0 116.098 179.378 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.91 146.13 47.02 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.93 2.092 . . . . 10.0 112.098 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.71 167.0 23.21 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.553 1.941 . . . . 10.0 111.037 166.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 10.8 m -145.2 148.68 33.81 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.338 1.055 . . . . 10.0 111.071 -177.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -132.17 151.15 51.95 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.039 1.736 . . . . 10.0 110.647 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.3 m -143.45 145.98 33.05 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 125.034 1.334 . . . . 10.0 111.642 -174.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.9 p -154.2 156.42 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 126.016 1.727 . . . . 10.0 110.99 170.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -110.91 141.42 44.34 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.353 1.061 . . . . 10.0 110.485 169.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.4 tp -124.14 106.8 10.62 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.07 1.748 . . . . 10.0 110.321 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -94.54 83.22 4.08 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.435 1.494 . . . . 10.0 110.824 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.0 t -64.05 113.56 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 O-C-N 121.372 -0.83 . . . . 10.0 110.704 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.45 97.49 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.1 1.76 . . . . 10.0 110.073 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.23 151.61 35.72 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 124.384 1.074 . . . . 10.0 113.429 -177.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -142.9 79.2 1.64 Allowed 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 126.462 1.905 . . . . 10.0 110.455 176.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 . . . . . 0 C--O 1.254 1.303 0 C-N-CA 125.623 1.569 . . . . 10.0 114.353 175.672 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.594 0 N-CA-C 111.659 -0.576 . . . . 10.0 111.659 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.61 159.5 21.77 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.302 1.041 . . . . 10.0 112.783 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.64 175.15 11.81 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.168 1.787 . . . . 10.0 111.616 -176.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.79 172.45 45.1 Favored Glycine 0 CA--C 1.543 1.784 0 N-CA-C 117.473 1.749 . . . . 10.0 117.473 -175.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_endo -72.71 159.54 48.37 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 124.128 3.219 . . . . 10.0 113.549 -171.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -70.53 148.0 59.1 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.204 2.603 . . . . 10.0 112.054 173.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -136.46 158.59 44.07 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 125.576 1.551 . . . . 10.0 112.758 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -84.41 79.41 9.57 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.293 2.237 . . . . 10.0 112.261 -174.452 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 44.4 mm -73.41 -55.31 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.529 -0.732 . . . . 10.0 111.21 178.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.22 129.52 10.53 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.5 1.12 . . . . 10.0 111.705 176.319 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.1 m -104.09 148.17 35.48 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 124.669 1.188 . . . . 10.0 110.196 158.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.32 162.4 36.36 Favored 'Trans proline' 0 CA--C 1.542 0.882 0 C-N-CA 122.99 2.46 . . . . 10.0 111.155 171.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -73.66 168.29 19.65 Favored 'General case' 0 CA--C 1.545 0.783 0 O-C-N 121.389 -0.82 . . . . 10.0 111.655 169.411 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.5 p30 -61.79 160.22 12.28 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.422 -0.799 . . . . 10.0 112.405 172.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.2 mtm -132.56 160.4 36.66 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.079 0.952 . . . . 10.0 113.073 -178.215 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 p -136.07 103.14 5.24 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 126.192 1.797 . . . . 10.0 110.527 175.267 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.5 mm -119.37 131.27 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.247 1.419 . . . . 10.0 110.723 -165.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -60.91 129.07 39.62 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.804 1.242 . . . . 10.0 112.558 173.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -54.21 127.8 28.43 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.825 1.25 . . . . 10.0 112.596 -178.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.13 -10.27 61.71 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 126.187 1.851 . . . . 10.0 115.036 178.16 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 27.1 mtp-105 -73.84 163.93 27.3 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.116 1.458 . . . . 10.0 113.099 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -75.37 141.18 43.34 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.895 1.278 . . . . 10.0 110.506 158.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.46 170.32 19.89 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.756 0.822 . . . . 10.0 112.343 162.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -146.84 163.32 36.44 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.37 1.468 . . . . 10.0 112.757 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -134.97 140.3 45.59 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.215 2.206 . . . . 10.0 109.137 175.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -131.97 125.7 32.21 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.795 1.238 . . . . 10.0 111.974 -168.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -129.17 111.81 13.3 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 126.789 2.035 . . . . 10.0 111.624 -167.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -73.65 120.55 19.4 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 121.587 -0.696 . . . . 10.0 109.808 171.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -130.11 108.92 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.792 2.037 . . . . 10.0 110.831 -171.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.8 t -76.79 -174.77 3.17 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.336 1.054 . . . . 10.0 112.301 174.1 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 100.27 160.58 28.25 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 126.92 2.2 . . . . 10.0 113.795 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -151.17 135.26 9.53 Favored Pre-proline 0 CA--C 1.548 0.889 0 C-N-CA 126.044 1.738 . . . . 10.0 109.531 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.18 169.94 37.76 Favored 'Cis proline' 0 CA--C 1.539 0.76 0 CA-C-N 121.15 1.447 . . . . 10.0 112.373 -6.108 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 123.18 51.65 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 124.581 1.153 . . . . 10.0 111.278 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -70.88 161.57 45.61 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 122.501 2.134 . . . . 10.0 113.333 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 40.2 m-20 -65.66 170.56 5.02 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.826 1.25 . . . . 10.0 111.761 165.222 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 5.6 p -138.37 122.96 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.219 1.408 . . . . 10.0 111.471 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.0 m -137.36 106.25 5.94 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.818 1.647 . . . . 10.0 110.563 174.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.8 m95 -85.86 153.54 22.17 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 123.953 0.901 . . . . 10.0 113.223 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.19 159.0 43.1 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.979 2.112 . . . . 10.0 111.295 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -143.93 117.07 8.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 127.072 2.149 . . . . 10.0 110.281 175.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 54.07 18.86 1.85 Allowed 'General case' 0 CA--C 1.554 1.116 0 C-N-CA 126.375 1.87 . . . . 10.0 114.558 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.97 -9.35 46.86 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.422 1.963 . . . . 10.0 115.476 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.18 155.13 19.61 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.044 1.422 . . . . 10.0 110.166 171.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.6 p -69.34 155.24 40.75 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.801 0.84 . . . . 10.0 112.585 173.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 57.4 t -133.12 105.04 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.332 1.853 . . . . 10.0 108.766 173.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 95.4 mm-40 -72.62 159.59 33.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.498 0.719 . . . . 10.0 111.701 173.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.3 p -70.11 154.9 41.36 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.35 0.66 . . . . 10.0 111.67 166.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -154.15 168.95 24.78 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.404 1.482 . . . . 10.0 111.025 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -57.83 -34.55 69.8 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.792 -1.193 . . . . 10.0 112.658 168.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.3 mt -82.79 -15.16 52.77 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.556 1.142 . . . . 10.0 113.9 173.26 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -134.61 69.41 1.46 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.011 1.724 . . . . 10.0 111.324 -173.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -70.61 144.4 51.18 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.086 1.354 . . . . 10.0 111.666 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.3 mtt -141.14 103.36 4.43 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 126.835 2.054 . . . . 10.0 109.723 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.75 162.03 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 C-N-CA 124.617 1.167 . . . . 10.0 112.66 -176.683 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 t -133.83 113.91 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.632 1.573 . . . . 10.0 109.698 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 66.8 m -69.04 144.46 54.03 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.47 0.708 . . . . 10.0 111.053 171.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.03 -17.1 56.24 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.487 1.515 . . . . 10.0 114.579 -176.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -74.44 -4.88 39.3 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 126.155 1.782 . . . . 10.0 114.107 173.233 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.17 38.35 5.71 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 125.139 1.352 . . . . 10.0 113.644 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 44.4 tp -125.68 102.54 7.38 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.424 1.489 . . . . 10.0 110.646 -177.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -78.25 145.26 35.56 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.009 0.924 . . . . 10.0 110.926 169.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 32.6 t -134.53 145.52 48.83 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.943 1.297 . . . . 10.0 111.985 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -130.63 120.53 24.1 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.434 2.694 . . . . 10.0 108.115 -178.358 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.4 152.33 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.605 1.162 . . . . 10.0 111.424 -170.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -125.96 108.84 11.79 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 127.273 2.229 . . . . 10.0 108.892 168.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -65.98 -38.45 88.56 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.323 -0.861 . . . . 10.0 112.715 175.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.2 p -150.28 86.82 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 126.098 1.759 . . . . 10.0 110.043 -178.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.5 p -66.64 139.6 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 O-C-N 121.3 -0.875 . . . . 10.0 111.827 -177.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -119.69 160.82 21.8 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.964 1.705 . . . . 10.0 112.069 176.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.29 -31.62 65.81 Favored 'General case' 0 CA--C 1.548 0.891 0 N-CA-C 113.709 1.003 . . . . 10.0 113.709 -176.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -65.3 -21.13 66.68 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.125 1.37 . . . . 10.0 113.891 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -77.66 -6.16 52.91 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.68 1.192 . . . . 10.0 113.591 178.354 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.2 147.79 52.82 Favored 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.874 -1.141 . . . . 10.0 112.695 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.76 -172.6 22.49 Favored Glycine 0 CA--C 1.532 1.155 0 C-N-CA 124.767 1.175 . . . . 10.0 114.894 177.171 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.92 109.83 18.43 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.981 1.712 . . . . 10.0 111.06 175.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -85.15 153.72 22.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.473 1.109 . . . . 10.0 112.213 171.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.17 159.34 42.42 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.172 0.989 . . . . 10.0 112.069 167.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -139.03 104.26 4.99 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.76 1.624 . . . . 10.0 110.827 -178.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.8 t -76.39 129.61 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.316 1.046 . . . . 10.0 109.692 171.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.68 117.91 20.16 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.668 1.987 . . . . 10.0 110.681 178.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -132.11 139.63 48.53 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.299 1.44 . . . . 10.0 112.017 -172.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 26.8 p30 -134.27 -177.98 4.83 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.903 1.281 . . . . 10.0 111.411 167.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -61.29 -11.22 8.91 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.778 1.77 . . . . 10.0 115.778 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.97 -19.78 12.23 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.409 1.484 . . . . 10.0 114.443 -178.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.44 -170.39 43.51 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 116.149 1.22 . . . . 10.0 116.149 178.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -136.8 144.17 43.56 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.968 2.107 . . . . 10.0 111.819 -170.359 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.68 157.1 47.2 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 126.482 1.913 . . . . 10.0 110.534 166.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -140.12 98.03 3.36 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.64 1.176 . . . . 10.0 110.206 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -75.35 156.97 34.96 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.107 0.963 . . . . 10.0 111.467 177.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 33.0 m -144.87 143.47 30.61 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.058 1.343 . . . . 10.0 111.348 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.5 p -153.95 170.74 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 C-N-CA 126.215 1.806 . . . . 10.0 110.867 173.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 -131.15 146.81 52.48 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.756 1.222 . . . . 10.0 111.88 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.5 tp -131.76 119.41 21.25 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.057 1.743 . . . . 10.0 111.018 -178.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -104.35 83.02 2.01 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.79 1.636 . . . . 10.0 110.857 176.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.05 110.89 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 O-C-N 121.531 -0.731 . . . . 10.0 110.692 -179.292 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 67.4 mt -73.01 97.95 2.42 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.305 1.842 . . . . 10.0 109.87 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.5 147.0 46.78 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.644 1.177 . . . . 10.0 113.661 -173.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -89.25 -26.0 21.42 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 125.932 1.693 . . . . 10.0 113.782 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 . . . . . 0 C--O 1.252 1.236 0 C-N-CA 125.619 1.568 . . . . 10.0 114.619 177.411 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.583 0 N-CA-C 111.928 -0.469 . . . . 10.0 111.928 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.67 158.15 25.34 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.239 1.015 . . . . 10.0 112.961 176.665 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.67 176.78 10.69 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.235 1.814 . . . . 10.0 111.522 -177.215 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.91 172.44 45.38 Favored Glycine 0 CA--C 1.542 1.744 0 N-CA-C 117.5 1.76 . . . . 10.0 117.5 -176.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -69.11 159.52 53.56 Favored 'Trans proline' 0 CA--C 1.543 0.963 0 C-N-CA 123.761 2.974 . . . . 10.0 112.943 -173.59 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -70.23 166.07 29.41 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.144 2.562 . . . . 10.0 112.428 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 21.3 tpp180 -140.77 147.18 38.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.462 1.105 . . . . 10.0 112.436 -174.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -76.8 58.06 1.38 Allowed 'General case' 0 CA--C 1.55 0.977 0 C-N-CA 128.564 2.746 . . . . 10.0 112.409 -177.401 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.3 mm -60.64 -58.5 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.964 -1.085 . . . . 10.0 112.63 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -154.35 153.34 31.45 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 119.006 0.821 . . . . 10.0 113.172 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 17.8 m -131.05 155.57 81.37 Favored Pre-proline 0 N--CA 1.479 0.997 0 C-N-CA 127.371 2.269 . . . . 10.0 110.382 167.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -74.8 166.14 29.93 Favored 'Trans proline' 0 CA--C 1.542 0.921 0 C-N-CA 122.771 2.314 . . . . 10.0 111.499 168.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -73.05 176.45 5.77 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.446 -0.784 . . . . 10.0 111.194 163.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -59.18 152.83 19.62 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.911 -1.118 . . . . 10.0 112.128 171.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.7 mtp -132.46 157.19 45.24 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 125.526 1.531 . . . . 10.0 111.946 -172.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 76.4 p -145.93 136.79 24.43 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 125.26 1.424 . . . . 10.0 110.856 169.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 24.9 mm -138.4 133.08 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.581 1.552 . . . . 10.0 109.531 -170.366 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -63.85 131.12 46.8 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.639 1.175 . . . . 10.0 112.302 173.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -51.54 130.59 28.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.515 1.526 . . . . 10.0 113.305 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.4 -10.25 67.13 Favored Glycine 0 CA--C 1.537 1.426 0 C-N-CA 126.185 1.85 . . . . 10.0 115.175 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.3 mtp180 -72.3 161.33 30.99 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.037 1.418 . . . . 10.0 113.356 177.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -71.49 148.6 46.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.678 1.191 . . . . 10.0 110.637 156.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.8 t -147.06 154.62 41.39 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.941 1.296 . . . . 10.0 111.019 168.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -145.53 166.18 26.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.747 1.219 . . . . 10.0 112.547 165.191 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 49.5 mtt -133.07 166.9 21.35 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.471 1.908 . . . . 10.0 111.815 -176.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -134.39 117.65 16.56 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.082 1.753 . . . . 10.0 111.694 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -127.83 99.55 5.58 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.551 1.54 . . . . 10.0 111.358 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -66.41 123.31 19.64 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.862 0.865 . . . . 10.0 110.115 172.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 5.9 p -142.45 102.63 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.311 1.845 . . . . 10.0 110.684 -176.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.7 t -75.68 -177.25 3.63 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.003 0.921 . . . . 10.0 111.855 172.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 117.32 160.3 11.73 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 127.356 2.408 . . . . 10.0 113.319 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -149.47 128.38 6.15 Favored Pre-proline 0 CA--C 1.548 0.871 0 C-N-CA 124.797 1.239 . . . . 10.0 110.414 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -66.86 169.61 47.63 Favored 'Cis proline' 0 CA--C 1.54 0.809 0 CA-C-N 121.06 1.414 . . . . 10.0 112.507 -3.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.18 122.59 55.06 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.616 1.166 . . . . 10.0 111.429 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.57 151.39 64.42 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 122.55 2.167 . . . . 10.0 113.284 -173.098 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.99 145.66 46.54 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.337 1.055 . . . . 10.0 109.963 160.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.68 86.37 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.091 1.356 . . . . 10.0 112.103 -165.043 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.4 m -78.5 116.1 18.66 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.866 1.267 . . . . 10.0 111.506 177.151 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.1 m95 -90.27 155.77 18.76 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.704 1.001 . . . . 10.0 113.704 177.493 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.34 160.54 41.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.476 2.311 . . . . 10.0 111.495 -177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.9 tp -147.23 119.76 8.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.392 2.277 . . . . 10.0 110.024 174.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 54.9 15.0 1.01 Allowed 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 126.645 1.978 . . . . 10.0 115.145 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.58 -13.23 35.8 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 126.631 2.063 . . . . 10.0 115.19 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -86.84 159.55 19.04 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 118.971 1.385 . . . . 10.0 110.833 169.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.7 p -73.21 159.15 33.91 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.098 0.959 . . . . 10.0 112.729 174.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 90.5 t -137.12 145.71 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 127.008 2.123 . . . . 10.0 108.775 171.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 80.4 mt-30 -128.1 163.21 25.13 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.295 1.438 . . . . 10.0 111.285 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.5 p -68.35 152.61 45.19 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.657 0.783 . . . . 10.0 112.613 176.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -152.17 168.18 26.16 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.978 1.711 . . . . 10.0 110.641 175.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.45 -35.12 67.53 Favored 'General case' 0 CA--C 1.544 0.741 0 O-C-N 120.906 -1.121 . . . . 10.0 112.76 169.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.0 mt -84.84 -12.99 52.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.608 1.163 . . . . 10.0 113.979 173.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.9 m80 -136.59 71.18 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.633 1.573 . . . . 10.0 111.453 -173.434 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -71.89 147.45 47.07 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.797 1.239 . . . . 10.0 111.898 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.6 mtt -141.54 107.28 5.11 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 126.846 2.058 . . . . 10.0 109.908 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.0 157.93 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.641 1.176 . . . . 10.0 112.398 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.1 t -133.81 113.93 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.893 1.677 . . . . 10.0 109.928 -177.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 68.7 m -70.38 151.27 45.4 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.954 0.902 . . . . 10.0 112.132 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -57.45 -32.18 66.67 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 125.766 1.627 . . . . 10.0 113.856 -175.508 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 303' ' ' LYS . . . . . 0.422 ' HA ' ' HE2' ' A' ' 303' ' ' LYS . 11.3 mmpt? -70.82 -3.39 18.71 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 126.174 1.79 . . . . 10.0 114.425 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.83 49.92 3.91 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 125.006 1.289 . . . . 10.0 112.897 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 65.1 tp -130.72 104.15 7.01 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.455 1.502 . . . . 10.0 110.469 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -83.7 125.9 32.35 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 125.145 1.378 . . . . 10.0 111.229 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.8 m -102.86 142.67 33.58 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.243 1.417 . . . . 10.0 111.739 169.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -130.55 126.07 35.84 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 127.469 2.308 . . . . 10.0 107.884 175.232 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 44.1 mt -122.1 152.68 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.237 1.415 . . . . 10.0 111.722 -167.358 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.93 109.98 10.93 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 128.059 2.544 . . . . 10.0 109.064 169.282 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.33 -38.87 85.59 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.02 -1.05 . . . . 10.0 113.069 177.293 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.04 88.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 125.723 1.609 . . . . 10.0 110.286 -178.059 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -70.66 141.81 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 O-C-N 121.235 -0.915 . . . . 10.0 112.313 -175.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -126.18 163.21 23.63 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 126.631 1.972 . . . . 10.0 111.958 177.231 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.1 -31.56 65.4 Favored 'General case' 0 CA--C 1.548 0.875 0 N-CA-C 113.899 1.074 . . . . 10.0 113.899 -177.128 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.5 m -68.28 -15.91 63.75 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 114.216 1.191 . . . . 10.0 114.216 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -82.83 -5.16 58.84 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.432 1.093 . . . . 10.0 113.308 177.031 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 150.22 48.84 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.933 -1.104 . . . . 10.0 113.143 178.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.17 -175.19 21.06 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.905 1.241 . . . . 10.0 115.279 174.261 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.12 98.05 7.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.801 1.64 . . . . 10.0 111.246 175.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -74.5 150.96 39.61 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 123.556 0.742 . . . . 10.0 111.479 167.412 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.01 161.9 38.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 123.966 0.906 . . . . 10.0 111.997 168.083 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.1 t -137.31 139.01 40.6 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.737 1.615 . . . . 10.0 110.487 176.351 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.9 t -117.17 104.7 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.289 1.835 . . . . 10.0 108.862 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -89.64 118.06 28.98 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 126.283 1.833 . . . . 10.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -129.84 132.61 46.53 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.085 1.354 . . . . 10.0 112.598 -176.021 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -129.44 -179.02 4.92 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.834 1.253 . . . . 10.0 111.513 166.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -61.64 -12.28 15.36 Favored 'General case' 0 N--CA 1.482 1.129 0 N-CA-C 115.726 1.75 . . . . 10.0 115.726 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.18 -20.03 12.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 125.383 1.473 . . . . 10.0 114.424 -178.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 172.92 -169.26 42.42 Favored Glycine 0 CA--C 1.534 1.232 0 N-CA-C 116.101 1.2 . . . . 10.0 116.101 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -134.19 143.8 48.09 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 126.939 2.095 . . . . 10.0 111.909 -171.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.25 165.92 25.0 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.281 1.833 . . . . 10.0 111.076 168.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 19.0 m -141.57 141.59 33.5 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.203 1.001 . . . . 10.0 111.569 -173.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -134.47 150.93 50.87 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.797 1.639 . . . . 10.0 110.556 -178.357 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -146.4 146.81 30.76 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 124.454 1.102 . . . . 10.0 111.786 -169.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.7 p -152.97 146.68 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 125.251 1.42 . . . . 10.0 112.026 170.226 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 9.2 tp-100 -100.14 127.47 46.39 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 125.667 1.587 . . . . 10.0 110.245 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -121.18 105.56 10.7 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.542 1.537 . . . . 10.0 111.261 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -93.62 85.79 4.99 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.268 1.427 . . . . 10.0 111.319 175.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.6 t -66.14 115.35 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 121.301 -0.874 . . . . 10.0 110.826 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.3 mt -78.91 100.0 7.04 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.437 1.895 . . . . 10.0 110.356 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.83 147.65 37.51 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 123.947 0.899 . . . . 10.0 112.821 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.56 -18.77 59.66 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 114.736 1.384 . . . . 10.0 114.736 -178.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.254 1.322 0 C-N-CA 126.527 1.931 . . . . 10.0 113.761 -178.844 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.536 0 N-CA-C 111.756 -0.538 . . . . 10.0 111.756 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.22 164.21 16.25 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 124.472 1.109 . . . . 10.0 113.036 176.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.9 ptt? -145.95 -178.89 6.35 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.025 1.73 . . . . 10.0 111.747 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.03 168.98 41.16 Favored Glycine 0 CA--C 1.54 1.63 0 N-CA-C 116.963 1.545 . . . . 10.0 116.963 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.98 161.66 45.35 Favored 'Trans proline' 0 CA--C 1.543 0.935 0 C-N-CA 123.751 2.967 . . . . 10.0 112.943 -174.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -65.39 133.59 35.44 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.351 2.701 . . . . 10.0 111.324 171.08 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -130.64 134.66 47.14 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 126.698 1.999 . . . . 10.0 110.654 -176.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -48.87 120.39 3.82 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 127.09 2.156 . . . . 10.0 112.58 173.587 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 49.7 mm -113.85 -59.29 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.232 1.013 . . . . 10.0 110.413 171.287 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.5 tt0 -150.47 136.04 18.12 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.013 0.925 . . . . 10.0 111.531 177.014 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 21.9 m -117.88 149.75 45.89 Favored Pre-proline 0 N--CA 1.474 0.749 0 C-N-CA 125.367 1.467 . . . . 10.0 109.579 167.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.78 155.96 53.38 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 122.485 2.123 . . . . 10.0 111.92 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -69.98 168.35 15.58 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.74 0.816 . . . . 10.0 111.091 166.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.21 152.19 21.22 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 121.211 -0.931 . . . . 10.0 112.334 173.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 86.1 mtp -127.05 152.44 47.26 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.222 1.409 . . . . 10.0 111.87 -167.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 p -144.15 104.94 4.18 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.265 1.426 . . . . 10.0 111.094 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.9 mm -122.6 130.95 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.401 1.481 . . . . 10.0 110.405 -166.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -65.15 129.97 41.64 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.51 1.124 . . . . 10.0 112.518 175.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -52.57 123.5 11.27 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 125.656 1.582 . . . . 10.0 113.132 -176.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 101.45 -10.25 57.76 Favored Glycine 0 CA--C 1.534 1.269 0 C-N-CA 125.975 1.75 . . . . 10.0 115.551 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -70.77 160.64 32.33 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-N 119.248 1.524 . . . . 10.0 113.086 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -73.43 147.73 43.93 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.663 1.185 . . . . 10.0 110.571 159.094 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 7.1 t -153.4 168.26 26.69 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.075 0.95 . . . . 10.0 112.607 169.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.1 ptm85 -145.61 166.68 25.05 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.95 1.7 . . . . 10.0 112.82 167.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.3 mtt -121.06 159.82 24.9 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 126.964 2.106 . . . . 10.0 111.241 173.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -140.27 93.21 2.6 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.076 1.35 . . . . 10.0 111.961 -166.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -114.07 106.9 14.94 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.733 1.613 . . . . 10.0 111.651 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -85.88 129.73 34.75 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.027 -1.045 . . . . 10.0 111.513 176.521 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.6 p -132.63 153.68 38.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.072 1.749 . . . . 10.0 110.351 170.03 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 58.4 m -127.24 126.67 43.13 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.766 1.226 . . . . 10.0 110.889 172.176 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.1 168.01 40.66 Favored Glycine 0 CA--C 1.534 1.28 0 C-N-CA 126.615 2.055 . . . . 10.0 111.236 175.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.9 tp -146.56 131.39 8.9 Favored Pre-proline 0 CA--C 1.546 0.825 0 C-N-CA 124.474 1.11 . . . . 10.0 110.73 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.13 170.59 45.23 Favored 'Cis proline' 0 CA--C 1.541 0.825 0 CA-C-N 120.414 1.184 . . . . 10.0 112.665 -3.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.13 122.05 45.59 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 124.662 1.185 . . . . 10.0 111.29 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -73.82 164.31 34.98 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.572 2.181 . . . . 10.0 113.845 -170.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -61.58 165.77 4.7 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.114 1.766 . . . . 10.0 111.961 165.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.2 p -139.23 113.6 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.097 1.359 . . . . 10.0 111.455 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -128.92 147.61 50.85 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.945 1.698 . . . . 10.0 110.821 173.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -128.44 153.29 47.27 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.355 1.062 . . . . 10.0 113.545 -174.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -143.3 162.65 35.13 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.324 2.25 . . . . 10.0 111.227 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.5 tp -147.86 123.59 10.54 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 126.905 2.082 . . . . 10.0 110.012 176.381 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 55.02 10.15 0.37 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.739 2.016 . . . . 10.0 116.049 176.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.01 -5.09 25.58 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.08 1.8 . . . . 10.0 115.607 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -105.58 161.65 14.18 Favored 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 119.176 1.488 . . . . 10.0 111.922 171.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.9 p -70.08 154.94 41.31 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.427 1.091 . . . . 10.0 112.791 176.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.33 101.76 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.791 2.036 . . . . 10.0 108.401 170.468 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -74.3 157.58 35.54 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.529 0.731 . . . . 10.0 111.319 172.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.2 p -70.61 149.5 47.0 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.691 0.796 . . . . 10.0 112.388 172.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -152.29 179.54 8.45 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.419 1.487 . . . . 10.0 111.063 167.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -57.24 -28.66 63.12 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.425 1.269 . . . . 10.0 114.425 -177.143 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 48.7 mt -92.41 -11.82 33.83 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.272 1.429 . . . . 10.0 113.391 176.009 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -134.25 70.91 1.45 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.397 1.879 . . . . 10.0 111.153 -174.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -71.87 143.32 49.44 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.171 1.388 . . . . 10.0 111.052 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -138.9 106.47 5.58 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 126.318 1.847 . . . . 10.0 110.455 -172.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.92 171.79 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.315 1.446 . . . . 10.0 112.229 -177.179 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -135.55 134.23 51.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.807 1.643 . . . . 10.0 109.275 174.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 24.9 p -67.95 172.14 5.89 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.838 1.051 . . . . 10.0 113.838 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -59.37 -20.3 53.68 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.237 1.415 . . . . 10.0 113.436 170.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -117.43 5.64 12.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.278 1.831 . . . . 10.0 114.243 -171.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.78 15.71 36.02 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 124.623 1.106 . . . . 10.0 115.777 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 28.4 tp -80.13 98.0 7.11 Favored 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 118.864 1.332 . . . . 10.0 110.3 171.231 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -63.5 132.24 50.68 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.926 0.89 . . . . 10.0 110.002 166.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -129.71 126.26 37.84 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 126.33 1.852 . . . . 10.0 111.167 -171.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -126.21 123.35 37.99 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 127.043 2.137 . . . . 10.0 108.027 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 50.9 mt -114.54 153.55 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 125.177 1.391 . . . . 10.0 110.968 -171.275 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -127.78 109.39 11.59 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.353 2.261 . . . . 10.0 108.897 170.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -68.14 -41.66 81.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.188 -0.945 . . . . 10.0 112.606 174.587 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.83 90.2 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.764 1.625 . . . . 10.0 110.388 -176.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -69.89 151.91 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 O-C-N 121.31 -0.869 . . . . 10.0 112.898 -175.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 86.7 mmt-85 -132.31 159.83 38.0 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 127.019 2.128 . . . . 10.0 111.836 174.055 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.84 -30.83 64.17 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.386 1.074 . . . . 10.0 113.721 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.9 t -62.99 -23.46 67.46 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.966 1.306 . . . . 10.0 113.646 174.126 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -78.6 -8.46 58.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.556 1.142 . . . . 10.0 113.64 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 152.58 42.84 Favored 'General case' 0 CA--C 1.547 0.839 0 CA-C-N 119.543 1.065 . . . . 10.0 113.406 -179.215 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.27 -170.88 22.42 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.928 1.252 . . . . 10.0 114.891 176.287 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.62 97.67 7.99 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.939 1.696 . . . . 10.0 111.454 176.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -71.55 150.41 44.78 Favored 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 123.948 0.899 . . . . 10.0 111.793 168.271 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.31 158.08 44.36 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.799 0.84 . . . . 10.0 112.406 168.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.8 t -130.62 141.9 50.44 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 127.162 2.185 . . . . 10.0 109.601 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 28.6 t -124.66 131.74 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.255 1.422 . . . . 10.0 109.489 177.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.43 124.03 40.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.189 1.795 . . . . 10.0 110.705 -177.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 1.9 mppt? -129.04 135.94 49.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.241 1.416 . . . . 10.0 111.602 -176.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -134.77 179.39 6.33 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.269 1.028 . . . . 10.0 111.534 163.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 14.9 ptp180 -62.62 -11.08 14.67 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.551 1.685 . . . . 10.0 115.551 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.17 -18.6 13.96 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.507 1.523 . . . . 10.0 114.167 178.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.04 -171.1 42.85 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 119.854 1.206 . . . . 10.0 115.849 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -135.26 147.09 49.16 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.586 1.955 . . . . 10.0 111.835 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.94 159.08 42.99 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.882 1.673 . . . . 10.0 111.861 170.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 86.9 m -138.75 138.26 37.48 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.76 1.624 . . . . 10.0 110.49 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -131.69 156.06 46.55 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.002 1.721 . . . . 10.0 111.25 -175.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -143.93 147.03 33.4 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.427 1.091 . . . . 10.0 112.392 -170.121 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.1 p -150.98 158.93 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 126.201 1.8 . . . . 10.0 111.277 168.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.6 tt0 -109.16 135.1 50.83 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.848 1.259 . . . . 10.0 111.538 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.4 tp -119.09 110.16 16.75 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.349 1.86 . . . . 10.0 110.639 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -96.5 83.98 3.61 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 125.825 1.65 . . . . 10.0 111.017 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -65.02 112.28 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 121.405 -0.809 . . . . 10.0 110.649 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.0 mt -74.11 101.37 3.9 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.169 1.788 . . . . 10.0 109.862 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.61 153.61 23.27 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.436 1.094 . . . . 10.0 113.895 -174.03 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -71.65 -26.39 62.52 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 126.086 1.754 . . . . 10.0 113.444 179.197 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 C--O 1.254 1.301 0 C-N-CA 126.811 2.044 . . . . 10.0 113.933 -179.002 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.505 0 N-CA-C 111.395 -0.682 . . . . 10.0 111.395 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.81 165.81 12.21 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.407 1.083 . . . . 10.0 112.92 175.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 22.9 ptt? -145.09 -179.42 6.61 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.943 1.697 . . . . 10.0 111.765 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.55 169.9 42.15 Favored Glycine 0 CA--C 1.54 1.64 0 N-CA-C 116.881 1.512 . . . . 10.0 116.881 178.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -69.03 159.97 51.8 Favored 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 123.614 2.876 . . . . 10.0 112.511 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -67.91 158.85 55.49 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 122.631 2.22 . . . . 10.0 111.794 171.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 41.6 ttt-85 -142.31 150.69 41.14 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.008 1.323 . . . . 10.0 111.538 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 8.9 m-30 -63.84 133.92 54.27 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.073 0.949 . . . . 10.0 110.161 162.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 32.0 mm -130.83 -59.64 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.095 1.358 . . . . 10.0 109.547 173.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -152.51 141.67 21.38 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.739 1.216 . . . . 10.0 111.21 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -127.5 152.77 77.03 Favored Pre-proline 0 N--CA 1.476 0.853 0 C-N-CA 125.736 1.614 . . . . 10.0 110.522 170.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.74 152.8 59.04 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 122.676 2.251 . . . . 10.0 111.553 171.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -72.76 174.17 8.04 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 123.904 0.882 . . . . 10.0 111.833 164.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -60.45 152.99 24.23 Favored 'General case' 0 CA--C 1.547 0.829 0 O-C-N 121.178 -0.951 . . . . 10.0 112.303 175.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.5 mtp -131.02 158.24 40.86 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 125.121 1.368 . . . . 10.0 112.292 -171.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 46.9 p -143.36 120.43 11.41 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.537 1.535 . . . . 10.0 110.49 172.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.5 mm -129.91 134.46 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.475 1.51 . . . . 10.0 109.796 -169.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.54 130.02 43.22 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.275 1.43 . . . . 10.0 112.39 175.24 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -51.47 127.21 19.41 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.227 1.411 . . . . 10.0 112.618 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.73 -10.61 60.81 Favored Glycine 0 CA--C 1.537 1.412 0 C-N-CA 126.125 1.821 . . . . 10.0 115.196 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -74.65 160.78 30.37 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 119.28 1.54 . . . . 10.0 113.302 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -74.61 142.65 44.59 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.63 1.172 . . . . 10.0 110.044 155.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.7 p -150.75 170.47 19.15 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 123.575 0.75 . . . . 10.0 112.254 163.245 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -146.61 162.77 37.72 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.156 1.382 . . . . 10.0 112.669 177.393 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -137.2 139.73 41.27 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 127.508 2.323 . . . . 10.0 109.151 176.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -134.22 124.05 25.33 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.048 0.939 . . . . 10.0 111.453 -171.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -123.82 110.11 14.48 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 126.517 1.927 . . . . 10.0 110.678 -168.382 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -72.14 119.63 16.6 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.6 0.76 . . . . 10.0 110.002 173.476 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.9 p -137.94 110.18 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.762 2.025 . . . . 10.0 110.3 -175.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 5.6 t -75.81 -170.88 1.44 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.378 1.071 . . . . 10.0 112.441 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 103.64 164.25 25.23 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 126.886 2.184 . . . . 10.0 114.039 176.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.8 tp -150.8 133.53 8.46 Favored Pre-proline 0 CA--C 1.548 0.895 0 C-N-CA 125.433 1.493 . . . . 10.0 110.335 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -67.02 168.79 51.76 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 CA-C-N 120.783 1.315 . . . . 10.0 112.528 -3.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.03 124.76 60.78 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.418 1.087 . . . . 10.0 110.846 177.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 155.35 64.46 Favored 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 122.434 2.089 . . . . 10.0 113.375 -170.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -72.8 114.24 10.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.458 1.503 . . . . 10.0 109.327 161.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.53 131.34 56.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.682 1.193 . . . . 10.0 111.289 -175.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.5 m -129.44 156.06 44.7 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 126.073 1.749 . . . . 10.0 111.405 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 63.4 m95 -124.88 156.4 37.97 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.85 1.26 . . . . 10.0 113.194 -176.503 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -144.4 159.78 42.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 127.119 2.168 . . . . 10.0 111.098 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.8 tp -145.74 119.21 9.05 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 126.887 2.075 . . . . 10.0 110.118 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 54.47 15.69 1.09 Allowed 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.449 1.9 . . . . 10.0 115.019 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.55 -11.87 39.16 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.663 2.078 . . . . 10.0 115.254 -177.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -87.43 158.03 19.08 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.948 1.374 . . . . 10.0 111.125 171.004 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.1 p -71.54 153.37 42.22 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.395 1.078 . . . . 10.0 112.674 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 53.9 t -132.76 100.85 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.367 1.867 . . . . 10.0 108.715 172.177 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 59.2 mt-30 -73.23 160.77 31.4 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.554 0.742 . . . . 10.0 111.359 171.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.2 p -68.49 155.67 39.46 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.383 0.673 . . . . 10.0 112.012 168.549 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -153.07 168.91 24.3 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.484 1.513 . . . . 10.0 110.917 177.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -56.9 -35.37 68.89 Favored 'General case' 0 CA--C 1.545 0.775 0 O-C-N 120.942 -1.098 . . . . 10.0 112.779 169.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.7 mt -84.48 -14.19 49.86 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.48 1.112 . . . . 10.0 113.9 173.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -133.62 70.27 1.46 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.837 1.655 . . . . 10.0 111.264 -174.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -71.29 144.09 50.11 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.834 1.254 . . . . 10.0 111.518 -176.371 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -141.54 106.06 4.86 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.654 1.982 . . . . 10.0 109.811 -175.018 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.01 164.99 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.643 1.177 . . . . 10.0 112.37 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 62.3 t -131.58 116.05 30.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 125.992 1.717 . . . . 10.0 109.63 178.111 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -72.54 143.51 48.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.369 0.667 . . . . 10.0 111.105 170.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.18 -20.33 40.21 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 115.308 1.596 . . . . 10.0 115.308 -174.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -75.45 -5.18 43.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.574 1.55 . . . . 10.0 113.867 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.64 50.75 2.28 Favored Glycine 0 CA--C 1.531 1.064 0 C-N-CA 125.436 1.493 . . . . 10.0 112.855 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 17.9 tp -136.46 106.17 6.2 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.332 1.453 . . . . 10.0 110.511 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -76.51 144.41 39.79 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.582 0.353 . . . . 10.0 110.864 168.11 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.5 m -130.62 114.76 15.82 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 126.427 1.891 . . . . 10.0 110.603 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -108.59 121.06 44.2 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 127.656 2.383 . . . . 10.0 108.715 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 71.3 mt -121.57 152.17 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.514 1.126 . . . . 10.0 111.304 -168.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.74 110.73 12.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.532 2.333 . . . . 10.0 109.43 171.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -66.11 -39.95 90.33 Favored 'General case' 0 N--CA 1.474 0.749 0 O-C-N 121.285 -0.884 . . . . 10.0 113.038 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -151.22 90.22 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.747 1.619 . . . . 10.0 110.277 -178.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.3 p -69.98 140.96 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 O-C-N 121.287 -0.883 . . . . 10.0 111.995 -177.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.3 mmt180 -124.22 161.81 24.98 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.421 1.888 . . . . 10.0 112.043 177.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.74 -33.89 64.68 Favored 'General case' 0 CA--C 1.546 0.82 0 N-CA-C 113.434 0.902 . . . . 10.0 113.434 -178.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.4 m -65.24 -17.68 64.69 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.355 1.462 . . . . 10.0 114.512 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -82.53 -5.47 58.76 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.685 1.194 . . . . 10.0 113.228 177.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.98 151.98 45.59 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.084 -1.01 . . . . 10.0 113.067 178.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.78 -171.27 22.44 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.746 1.165 . . . . 10.0 114.801 175.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.91 103.87 14.35 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.972 1.709 . . . . 10.0 111.055 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -78.15 152.02 32.98 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.009 0.924 . . . . 10.0 111.839 169.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -139.04 156.34 47.27 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.068 0.947 . . . . 10.0 111.687 168.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.0 t -134.06 136.74 44.2 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.525 1.93 . . . . 10.0 109.472 -175.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 67.8 t -128.25 126.53 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.488 1.515 . . . . 10.0 109.143 -178.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.83 117.4 23.29 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.258 1.823 . . . . 10.0 110.77 -174.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 23.0 mtpp -124.49 133.71 53.26 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.482 1.513 . . . . 10.0 111.536 -174.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 14.4 p30 -131.43 178.81 6.44 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.145 0.978 . . . . 10.0 111.7 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -63.57 -10.04 16.37 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 115.636 1.717 . . . . 10.0 115.636 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.12 -20.33 12.73 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.645 1.578 . . . . 10.0 114.246 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.05 -169.2 42.21 Favored Glycine 0 CA--C 1.535 1.291 0 CA-C-N 119.788 1.176 . . . . 10.0 115.769 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -138.54 147.09 42.69 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.357 1.863 . . . . 10.0 112.013 -173.382 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.66 153.61 50.86 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.033 1.733 . . . . 10.0 111.242 169.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.7 m -136.67 140.07 42.46 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.566 1.546 . . . . 10.0 110.646 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -133.55 159.28 40.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.966 1.706 . . . . 10.0 111.247 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.6 m -143.43 144.14 31.9 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 124.949 1.3 . . . . 10.0 111.341 -174.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.39 161.4 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.938 1.695 . . . . 10.0 110.563 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.8 tt0 -123.72 138.44 54.52 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 124.484 1.114 . . . . 10.0 111.196 176.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.3 tp -125.24 108.94 12.25 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.035 1.734 . . . . 10.0 110.711 -178.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -93.8 83.15 4.36 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.432 1.493 . . . . 10.0 110.682 174.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.34 114.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 O-C-N 121.452 -0.78 . . . . 10.0 110.418 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.9 mt -75.25 94.09 2.95 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.193 1.797 . . . . 10.0 110.015 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.99 151.54 34.81 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.43 1.092 . . . . 10.0 112.98 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -65.45 -52.21 54.73 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.127 1.371 . . . . 10.0 112.228 177.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.253 1.284 0 C-N-CA 125.985 1.714 . . . . 10.0 113.079 177.14 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 N-CA-C 111.855 -0.498 . . . . 10.0 111.855 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -62.33 107.33 0.89 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.343 1.457 . . . . 10.0 112.733 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.97 162.6 18.94 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 125.169 1.387 . . . . 10.0 112.785 176.082 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 179.86 170.85 42.07 Favored Glycine 0 CA--C 1.542 1.772 0 O-C-N 121.296 -0.877 . . . . 10.0 115.244 -176.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.14 162.82 41.29 Favored 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 123.816 3.011 . . . . 10.0 113.528 -170.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.71 139.09 56.38 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.02 2.48 . . . . 10.0 111.006 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 53.1 ttt85 -128.78 151.64 49.35 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.457 1.503 . . . . 10.0 112.617 -174.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -76.44 88.72 3.21 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.041 2.137 . . . . 10.0 111.708 177.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.2 mm -82.92 -58.78 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 O-C-N 121.605 -0.684 . . . . 10.0 110.264 171.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 24.8 tt0 -154.29 146.62 23.89 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.735 1.214 . . . . 10.0 111.776 175.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.79 152.29 74.86 Favored Pre-proline 0 N--CA 1.477 0.881 0 C-N-CA 126.452 1.901 . . . . 10.0 110.004 169.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.83 157.45 35.12 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.567 2.178 . . . . 10.0 112.247 -178.191 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -73.88 168.15 20.02 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.833 0.853 . . . . 10.0 111.326 166.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -60.14 158.14 11.85 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 121.419 -0.8 . . . . 10.0 112.801 176.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -128.47 152.75 47.88 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.714 1.606 . . . . 10.0 111.742 -171.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 39.5 p -141.77 116.85 9.98 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 125.385 1.474 . . . . 10.0 110.416 170.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.9 mm -129.3 129.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.29 1.436 . . . . 10.0 109.995 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -60.66 127.17 30.35 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.173 1.389 . . . . 10.0 112.12 173.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -53.22 134.38 39.2 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.202 1.401 . . . . 10.0 113.161 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.85 -12.02 67.55 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.346 1.927 . . . . 10.0 114.79 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -74.24 161.56 29.81 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 118.972 1.386 . . . . 10.0 113.268 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -75.9 141.16 42.4 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.885 1.274 . . . . 10.0 110.276 156.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.79 172.03 15.29 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.678 0.791 . . . . 10.0 112.065 161.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -152.43 170.21 20.68 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.145 1.378 . . . . 10.0 112.923 174.059 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.9 mtt -121.8 164.7 17.03 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 126.587 1.955 . . . . 10.0 112.526 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -138.23 103.42 4.92 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 126.353 1.861 . . . . 10.0 111.738 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -115.37 109.61 18.15 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.5 1.52 . . . . 10.0 111.178 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -80.03 74.72 6.79 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 121.302 -0.874 . . . . 10.0 111.496 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -79.84 128.14 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.913 1.285 . . . . 10.0 109.945 163.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 68.6 m -135.28 115.35 13.19 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.787 1.235 . . . . 10.0 111.343 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -158.41 169.85 34.99 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 126.695 2.093 . . . . 10.0 111.55 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 21.8 tp -142.14 120.04 7.47 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.504 1.122 . . . . 10.0 110.449 -177.433 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -68.05 167.54 63.18 Favored 'Cis proline' 0 CA--C 1.54 0.79 0 CA-C-N 121.018 1.399 . . . . 10.0 112.906 0.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 124.39 62.23 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.791 1.236 . . . . 10.0 111.189 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.49 151.33 59.02 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.41 2.073 . . . . 10.0 113.82 -169.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -69.94 130.45 42.26 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.611 1.564 . . . . 10.0 109.543 159.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.3 m -124.54 134.74 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.891 1.276 . . . . 10.0 112.253 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.6 m -136.47 114.56 11.48 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.673 1.589 . . . . 10.0 111.418 -173.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -87.44 151.98 22.61 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 114.016 1.117 . . . . 10.0 114.016 -178.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -141.61 160.57 39.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.975 2.51 . . . . 10.0 111.017 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -146.97 120.92 9.34 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.541 2.337 . . . . 10.0 109.833 176.432 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 54.93 14.71 0.97 Allowed 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.494 1.918 . . . . 10.0 115.341 178.663 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.28 -7.31 34.76 Favored Glycine 0 CA--C 1.539 1.582 0 C-N-CA 126.351 1.929 . . . . 10.0 115.487 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -99.55 159.75 14.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.587 1.555 . . . . 10.0 110.921 171.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.9 p -71.69 158.99 35.17 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.12 0.968 . . . . 10.0 112.788 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 39.0 t -135.71 102.47 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.984 1.714 . . . . 10.0 109.354 173.105 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.9 mt-30 -70.18 155.21 40.96 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.239 0.615 . . . . 10.0 111.251 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 67.6 p -69.63 160.23 31.96 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 123.562 0.745 . . . . 10.0 112.164 170.193 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -152.66 169.66 22.16 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.383 1.473 . . . . 10.0 111.024 178.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.9 -35.01 68.47 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 120.867 -1.146 . . . . 10.0 112.749 168.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 77.1 mt -82.65 -14.08 55.33 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.506 1.122 . . . . 10.0 113.889 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -135.25 69.53 1.44 Allowed 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.782 1.633 . . . . 10.0 111.501 -173.129 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 77.9 mttt -71.34 134.22 46.56 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.037 1.335 . . . . 10.0 110.547 -179.008 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 60.4 mtt -131.75 101.04 5.3 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 126.22 1.808 . . . . 10.0 109.524 -174.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.19 159.15 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 124.839 1.256 . . . . 10.0 112.562 -170.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.53 167.9 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 126.007 1.723 . . . . 10.0 111.992 -177.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 34.2 t -131.14 147.39 52.6 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 125.545 1.538 . . . . 10.0 112.128 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -57.82 -20.37 35.44 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.831 1.652 . . . . 10.0 113.87 168.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -78.0 -1.36 31.74 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.788 1.635 . . . . 10.0 114.355 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 79.87 60.94 2.34 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 124.677 1.132 . . . . 10.0 111.935 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 42.9 tp -150.97 148.53 28.5 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.96 1.704 . . . . 10.0 110.862 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -132.84 129.24 38.21 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.897 2.079 . . . . 10.0 110.097 174.141 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.1 m -108.81 147.1 32.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.475 1.51 . . . . 10.0 112.146 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.91 108.57 9.48 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 126.623 1.969 . . . . 10.0 108.333 171.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -89.89 151.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 125.268 1.427 . . . . 10.0 110.329 -178.334 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -130.61 99.69 5.06 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.94 2.096 . . . . 10.0 108.38 167.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -62.4 -38.4 89.49 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 113.225 0.824 . . . . 10.0 113.225 -176.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.8 p -149.65 87.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 125.897 1.679 . . . . 10.0 110.133 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.1 p -70.07 139.53 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 121.347 -0.846 . . . . 10.0 112.029 -176.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.4 mmm180 -128.42 161.68 28.92 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.466 1.907 . . . . 10.0 111.26 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -52.21 -35.95 50.78 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 114.195 1.183 . . . . 10.0 114.195 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.7 -17.72 64.36 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.242 1.417 . . . . 10.0 114.673 176.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -82.52 -5.92 59.02 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.74 1.216 . . . . 10.0 113.473 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 151.01 47.6 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.988 -1.07 . . . . 10.0 113.187 179.129 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.49 -172.63 22.4 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.872 1.225 . . . . 10.0 115.069 175.664 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.72 102.54 13.07 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.075 1.75 . . . . 10.0 111.538 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -79.67 149.02 31.37 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 124.291 1.037 . . . . 10.0 111.932 171.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.9 159.26 43.18 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.906 0.882 . . . . 10.0 112.271 170.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 49.8 t -137.68 118.2 13.87 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 125.139 1.375 . . . . 10.0 111.391 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 42.3 t -87.75 124.85 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 125.169 1.388 . . . . 10.0 109.268 172.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -117.65 128.16 54.65 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.456 1.903 . . . . 10.0 111.075 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.0 mtmt -133.83 130.12 37.47 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 126.116 1.767 . . . . 10.0 112.159 -167.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -136.4 -179.56 5.75 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 118.879 0.763 . . . . 10.0 112.305 162.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -59.33 -14.68 12.48 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 115.823 1.786 . . . . 10.0 115.823 -177.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.6 -12.28 15.0 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.452 1.501 . . . . 10.0 114.357 -178.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 162.98 -172.39 38.99 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.443 1.02 . . . . 10.0 115.457 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -134.6 147.76 50.28 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.239 1.816 . . . . 10.0 111.57 -173.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.08 163.26 30.74 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.537 1.935 . . . . 10.0 110.785 169.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 96.4 m -144.29 124.28 13.57 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.514 1.126 . . . . 10.0 110.649 177.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -113.54 155.5 25.27 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.523 1.529 . . . . 10.0 111.17 -176.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.5 m -141.77 148.51 39.05 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.621 1.168 . . . . 10.0 112.41 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.79 171.01 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 127.024 2.13 . . . . 10.0 110.603 168.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -128.78 140.63 51.62 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.924 1.29 . . . . 10.0 111.12 172.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.3 tp -125.41 111.81 15.56 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.4 1.88 . . . . 10.0 110.642 -178.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -97.38 85.85 3.75 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.8 1.64 . . . . 10.0 110.864 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.5 t -67.08 112.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.364 -0.835 . . . . 10.0 110.599 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.51 94.16 3.66 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.037 1.735 . . . . 10.0 110.1 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.43 147.87 39.45 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 124.519 1.127 . . . . 10.0 112.764 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -72.55 -47.85 44.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.601 0.761 . . . . 10.0 112.387 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 C--O 1.254 1.305 0 C-N-CA 126.087 1.755 . . . . 10.0 113.622 -179.798 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.55 0 N-CA-C 111.888 -0.485 . . . . 10.0 111.888 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.49 163.96 14.89 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.403 1.081 . . . . 10.0 113.014 175.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.25 171.75 13.88 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.278 1.831 . . . . 10.0 111.21 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.44 175.86 47.66 Favored Glycine 0 CA--C 1.541 1.69 0 N-CA-C 116.932 1.533 . . . . 10.0 116.932 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.66 162.97 38.84 Favored 'Trans proline' 0 CA--C 1.544 0.991 0 C-N-CA 123.756 2.97 . . . . 10.0 113.31 -172.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -69.73 168.26 22.02 Favored 'Trans proline' 0 CA--C 1.541 0.867 0 C-N-CA 123.249 2.632 . . . . 10.0 112.361 171.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 58.2 ttp85 -134.44 156.42 48.6 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.322 1.449 . . . . 10.0 112.22 -174.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -93.94 64.6 3.4 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 126.816 2.047 . . . . 10.0 111.086 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.48 -66.08 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.095 -1.003 . . . . 10.0 112.679 -170.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -155.24 165.03 37.94 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.0 m -132.92 161.99 60.32 Favored Pre-proline 0 N--CA 1.476 0.829 0 C-N-CA 127.871 2.468 . . . . 10.0 110.492 170.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.67 164.02 32.86 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.832 2.355 . . . . 10.0 111.228 164.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -72.59 169.43 16.55 Favored 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.251 -0.906 . . . . 10.0 112.523 169.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.31 148.79 40.09 Favored 'General case' 0 CA--C 1.546 0.789 0 O-C-N 121.346 -0.846 . . . . 10.0 112.652 173.309 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 75.8 mtp -130.81 154.07 48.42 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.882 1.273 . . . . 10.0 112.48 -170.117 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 64.6 m -140.48 101.03 4.01 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.302 1.841 . . . . 10.0 110.107 -176.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 37.6 mm -117.8 134.31 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 124.528 1.131 . . . . 10.0 111.292 -166.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -64.11 130.06 42.46 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.816 1.246 . . . . 10.0 112.445 173.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -53.24 129.8 32.64 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.112 1.365 . . . . 10.0 112.925 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.74 -11.5 62.73 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 126.305 1.907 . . . . 10.0 115.041 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -75.72 161.18 29.28 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.001 1.401 . . . . 10.0 113.276 177.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.9 149.22 46.96 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.665 1.186 . . . . 10.0 110.71 157.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 10.7 t -150.39 160.43 43.75 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.755 1.222 . . . . 10.0 111.903 168.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -151.65 167.41 28.23 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.342 1.457 . . . . 10.0 112.883 167.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -132.91 167.03 20.98 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.646 1.978 . . . . 10.0 112.119 -176.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -134.55 108.35 8.03 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.258 1.823 . . . . 10.0 111.775 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -117.67 112.17 20.14 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.448 1.499 . . . . 10.0 111.42 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -71.96 108.5 5.24 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.4 1.08 . . . . 10.0 110.31 174.378 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 18.0 t -117.59 149.32 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.684 1.594 . . . . 10.0 109.819 177.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.4 t -148.15 -177.58 5.82 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.254 1.422 . . . . 10.0 111.112 175.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 122.77 162.14 11.44 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 127.65 2.548 . . . . 10.0 111.795 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.1 tp -144.61 122.73 6.68 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-O 118.083 -0.96 . . . . 10.0 110.571 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -66.56 167.89 53.29 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.689 1.282 . . . . 10.0 112.627 -1.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.24 126.02 72.72 Favored Pre-proline 0 CA--C 1.549 0.935 0 C-N-CA 124.454 1.102 . . . . 10.0 111.291 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.51 149.9 62.79 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.406 2.071 . . . . 10.0 113.321 -173.116 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -74.66 151.05 39.33 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.61 1.164 . . . . 10.0 109.918 159.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 59.1 t -131.56 138.46 52.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.963 0.905 . . . . 10.0 112.125 -169.424 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 63.2 m -132.73 115.27 15.14 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 126.767 2.027 . . . . 10.0 110.61 177.378 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 53.4 m95 -86.44 158.83 19.5 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 122.001 0.905 . . . . 10.0 112.85 176.186 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -144.69 159.88 42.11 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 127.063 2.145 . . . . 10.0 111.235 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.6 tp -145.65 118.12 8.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.146 2.178 . . . . 10.0 110.062 175.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 54.87 14.95 0.99 Allowed 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 126.479 1.912 . . . . 10.0 115.092 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.82 -14.02 34.78 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 126.747 2.118 . . . . 10.0 115.165 -177.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -83.41 155.53 23.42 Favored 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 118.981 1.39 . . . . 10.0 110.929 169.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.7 p -71.46 155.14 40.94 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.27 1.028 . . . . 10.0 112.602 173.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 59.5 t -136.63 135.96 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 126.678 1.991 . . . . 10.0 108.976 172.76 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -119.09 164.01 16.17 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 125.267 1.427 . . . . 10.0 111.344 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 98.1 p -66.89 152.76 45.05 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.655 0.741 . . . . 10.0 112.441 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -151.95 167.96 26.71 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.827 1.651 . . . . 10.0 110.656 176.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.65 -34.92 67.78 Favored 'General case' 0 CA--C 1.545 0.772 0 O-C-N 120.97 -1.081 . . . . 10.0 112.832 169.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.4 mt -85.39 -13.55 49.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.55 1.14 . . . . 10.0 114.001 174.077 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.3 m80 -136.08 70.35 1.42 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.658 1.583 . . . . 10.0 111.184 -174.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -69.91 145.28 52.06 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.713 1.205 . . . . 10.0 111.636 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.4 mtt -139.41 101.74 4.31 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.785 2.034 . . . . 10.0 109.736 -176.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.37 162.24 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.851 1.26 . . . . 10.0 111.818 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 13.8 p -136.83 134.61 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.631 1.172 . . . . 10.0 111.269 -179.119 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 40.7 t -65.21 159.89 22.65 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.923 1.289 . . . . 10.0 112.505 177.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -52.19 -33.15 39.53 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.538 1.535 . . . . 10.0 111.965 164.056 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -81.72 -3.63 54.19 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.405 1.882 . . . . 10.0 113.735 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.25 -3.48 82.23 Favored Glycine 0 CA--C 1.538 1.494 0 C-N-CA 125.75 1.643 . . . . 10.0 115.468 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 48.2 tp -67.97 107.59 2.74 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.846 1.259 . . . . 10.0 111.165 174.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.6 t60 -84.86 124.57 31.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.781 1.632 . . . . 10.0 111.514 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.8 m -97.74 134.1 41.37 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.638 1.575 . . . . 10.0 111.793 171.275 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -123.07 123.55 41.1 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 127.154 2.182 . . . . 10.0 107.94 171.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 47.4 mt -121.79 153.63 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 125.124 1.37 . . . . 10.0 111.517 -166.034 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -132.18 108.23 9.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 128.044 2.538 . . . . 10.0 109.224 172.173 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -66.73 -38.79 87.37 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.846 -1.159 . . . . 10.0 112.914 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.5 p -151.78 89.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.684 1.593 . . . . 10.0 110.441 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.35 140.56 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 121.212 -0.93 . . . . 10.0 111.883 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -129.34 162.3 28.3 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 126.385 1.874 . . . . 10.0 111.267 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -53.11 -35.11 59.28 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.128 1.158 . . . . 10.0 114.128 -175.146 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.4 m -65.09 -17.83 64.79 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.32 1.448 . . . . 10.0 114.644 176.436 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -82.9 -7.0 59.7 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.754 1.222 . . . . 10.0 113.518 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.97 147.9 52.64 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.096 -1.003 . . . . 10.0 113.218 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.74 -171.99 24.19 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.507 1.051 . . . . 10.0 115.448 173.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.69 104.15 11.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.846 1.658 . . . . 10.0 110.893 173.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -80.79 151.1 28.93 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.985 0.914 . . . . 10.0 111.751 170.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.93 161.19 38.42 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.093 0.957 . . . . 10.0 112.132 168.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 29.6 t -141.49 104.79 4.64 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.549 1.94 . . . . 10.0 109.766 -172.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.69 131.1 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.576 1.15 . . . . 10.0 109.386 174.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.15 126.15 44.81 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.304 1.842 . . . . 10.0 110.721 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -134.35 135.42 42.69 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.479 1.512 . . . . 10.0 112.435 -169.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -130.04 -178.2 4.63 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.577 1.151 . . . . 10.0 111.712 166.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -59.88 -12.41 7.55 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 115.841 1.793 . . . . 10.0 115.841 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.7 -14.31 12.02 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.448 1.499 . . . . 10.0 114.589 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.32 -170.3 42.88 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-N 119.978 1.263 . . . . 10.0 116.165 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -134.74 144.35 47.67 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.104 2.162 . . . . 10.0 111.674 -172.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.98 163.13 31.44 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.039 1.735 . . . . 10.0 111.043 168.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -142.26 140.44 32.24 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.16 0.984 . . . . 10.0 111.492 -175.317 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -126.93 156.69 41.09 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 126.097 1.759 . . . . 10.0 110.841 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.8 m -145.3 146.62 31.71 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 124.761 1.224 . . . . 10.0 111.682 -171.221 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.59 161.65 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 125.894 1.678 . . . . 10.0 110.848 169.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.2 tt0 -116.75 128.52 55.39 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.583 1.153 . . . . 10.0 110.466 170.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.9 tp -118.55 104.15 10.39 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 126.003 1.721 . . . . 10.0 109.831 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -77.99 138.74 38.99 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.23 0.612 . . . . 10.0 110.108 163.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 27.8 t -117.01 105.16 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.051 0.94 . . . . 10.0 109.157 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.8 mt -67.62 97.71 0.63 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.535 1.934 . . . . 10.0 109.869 179.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.52 155.31 22.35 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.382 1.073 . . . . 10.0 112.683 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 23.0 ttpt -122.57 15.23 10.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.216 1.406 . . . . 10.0 113.93 -171.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 . . . . . 0 C--O 1.255 1.382 0 C-N-CA 126.155 1.782 . . . . 10.0 114.496 169.72 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 N-CA-C 111.896 -0.481 . . . . 10.0 111.896 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.36 157.27 26.7 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.277 1.031 . . . . 10.0 112.824 176.496 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.7 176.98 10.51 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.089 1.755 . . . . 10.0 111.799 -177.039 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.54 171.76 44.46 Favored Glycine 0 CA--C 1.542 1.732 0 N-CA-C 117.135 1.614 . . . . 10.0 117.135 -176.606 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.95 162.22 43.4 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.771 2.981 . . . . 10.0 113.101 -173.109 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -66.86 150.84 83.12 Favored 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 122.784 2.322 . . . . 10.0 111.064 168.419 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 64.2 ttt-85 -138.54 153.74 48.73 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.317 1.447 . . . . 10.0 111.62 -177.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.95 117.2 9.5 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.614 1.166 . . . . 10.0 111.052 169.29 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.32 -57.78 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.102 1.361 . . . . 10.0 110.368 176.118 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -149.53 137.15 20.17 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.847 1.259 . . . . 10.0 111.547 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -131.96 153.82 81.52 Favored Pre-proline 0 N--CA 1.474 0.736 0 C-N-CA 126.488 1.915 . . . . 10.0 110.028 170.345 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.75 162.91 36.8 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.627 2.218 . . . . 10.0 111.433 171.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.13 179.92 2.61 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.629 0.772 . . . . 10.0 110.738 161.281 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -58.11 142.68 46.32 Favored 'General case' 0 CA--C 1.546 0.82 0 O-C-N 120.506 -1.372 . . . . 10.0 111.156 166.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 89.9 mtp -122.53 157.33 32.27 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 125.484 1.513 . . . . 10.0 111.937 -172.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 57.8 p -144.38 129.62 18.73 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.295 1.438 . . . . 10.0 110.691 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.9 mm -134.51 133.97 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.7 1.6 . . . . 10.0 109.288 -170.511 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -63.94 130.83 45.67 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.616 1.166 . . . . 10.0 112.171 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -52.28 126.69 19.74 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.01 1.324 . . . . 10.0 112.509 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.0 61.46 Favored Glycine 0 CA--C 1.537 1.423 0 C-N-CA 125.842 1.687 . . . . 10.0 115.22 179.033 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -72.72 160.59 31.96 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.379 1.59 . . . . 10.0 113.105 175.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -72.67 149.38 43.9 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 124.488 1.115 . . . . 10.0 110.513 157.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 34.6 t -148.78 157.0 43.13 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.461 1.104 . . . . 10.0 111.272 167.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -144.73 154.47 42.77 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.003 1.321 . . . . 10.0 111.503 164.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.3 mtt -125.61 113.25 17.14 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 125.718 1.607 . . . . 10.0 111.107 -173.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -69.65 127.53 33.27 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.426 1.49 . . . . 10.0 112.766 174.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -137.97 93.82 2.81 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.105 1.362 . . . . 10.0 110.976 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -67.38 121.25 15.34 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.551 0.741 . . . . 10.0 110.124 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.8 p -135.17 115.59 18.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 126.859 2.064 . . . . 10.0 110.189 -173.668 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 66.2 m -126.98 107.25 9.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.892 1.277 . . . . 10.0 111.59 -173.532 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -156.15 167.58 33.38 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 127.166 2.317 . . . . 10.0 110.927 169.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -142.14 125.58 9.63 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 124.417 1.087 . . . . 10.0 110.686 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -66.06 168.06 49.72 Favored 'Cis proline' 0 CA--C 1.539 0.763 0 CA-C-N 120.622 1.258 . . . . 10.0 112.453 -2.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 123.45 57.07 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 124.348 1.059 . . . . 10.0 111.264 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.83 149.21 66.14 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.428 2.085 . . . . 10.0 112.999 -172.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -72.1 139.19 48.27 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.263 1.025 . . . . 10.0 109.535 161.26 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.36 142.05 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.266 1.027 . . . . 10.0 113.136 -172.329 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.7 m -141.39 115.34 9.2 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 125.841 1.657 . . . . 10.0 111.195 -176.355 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 71.1 m95 -84.07 151.22 25.08 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 122.2 1.0 . . . . 10.0 113.43 176.396 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -141.3 161.3 38.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 128.249 2.619 . . . . 10.0 110.776 -179.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.1 tp -147.09 119.78 8.59 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.431 2.292 . . . . 10.0 110.041 176.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 55.02 15.29 1.14 Allowed 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 126.581 1.952 . . . . 10.0 115.045 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.33 -12.53 40.01 Favored Glycine 0 CA--C 1.539 1.564 0 C-N-CA 126.607 2.051 . . . . 10.0 115.104 -177.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -87.67 158.33 18.86 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 119.008 1.404 . . . . 10.0 110.824 170.051 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.8 p -71.25 158.32 36.59 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.99 0.916 . . . . 10.0 112.345 173.317 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 40.1 t -134.62 100.82 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.844 1.658 . . . . 10.0 108.779 171.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -71.43 156.22 39.72 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.346 0.658 . . . . 10.0 110.693 170.236 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.0 p -70.08 151.96 44.9 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 121.559 -0.713 . . . . 10.0 111.908 170.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -152.74 -177.49 6.29 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.051 1.34 . . . . 10.0 111.949 171.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -60.3 -22.75 63.54 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 114.64 1.348 . . . . 10.0 114.64 -177.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 52.9 mt -104.19 -26.19 12.63 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.866 1.666 . . . . 10.0 112.67 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -110.9 74.14 0.86 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.416 1.886 . . . . 10.0 111.052 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 92.2 mttt -77.21 146.31 37.07 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.691 1.196 . . . . 10.0 111.175 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.1 mtt -145.34 102.51 3.73 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 126.06 1.744 . . . . 10.0 110.281 -170.587 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.91 163.25 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 124.505 1.122 . . . . 10.0 112.468 178.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 54.7 t -121.38 112.58 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.536 1.934 . . . . 10.0 109.266 174.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 74.7 m -69.25 151.51 46.18 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.76 0.824 . . . . 10.0 111.552 173.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -57.96 -19.68 32.2 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 115.346 1.61 . . . . 10.0 115.346 -174.366 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -75.97 -4.0 38.72 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.763 1.625 . . . . 10.0 113.994 178.104 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.09 48.92 4.43 Favored Glycine 0 CA--C 1.531 1.071 0 C-N-CA 125.161 1.363 . . . . 10.0 112.139 -175.195 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 51.5 tp -136.82 103.56 5.22 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.571 1.549 . . . . 10.0 110.642 -171.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 23.7 t60 -70.45 147.27 49.64 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 122.032 -0.418 . . . . 10.0 110.46 166.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 5.5 t -135.94 99.53 4.18 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.016 1.326 . . . . 10.0 111.204 176.152 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -81.86 120.28 24.99 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.485 1.514 . . . . 10.0 108.884 173.396 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 42.6 mt -115.55 151.6 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 125.125 1.37 . . . . 10.0 111.514 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -129.25 108.04 10.02 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.954 2.502 . . . . 10.0 109.258 170.169 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -63.94 -42.0 97.47 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.194 -0.942 . . . . 10.0 112.845 175.015 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.47 90.88 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.863 1.665 . . . . 10.0 110.121 -179.226 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.7 140.89 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.296 -0.878 . . . . 10.0 112.212 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -120.86 160.76 22.77 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.454 1.901 . . . . 10.0 112.057 176.15 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.86 -30.81 66.1 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 113.617 0.969 . . . . 10.0 113.617 -177.692 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.6 p -67.85 -15.62 63.71 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.921 1.689 . . . . 10.0 114.788 173.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -83.05 -5.08 58.97 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.599 1.16 . . . . 10.0 113.486 176.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.66 151.75 44.07 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.012 -1.055 . . . . 10.0 113.063 177.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.31 -173.07 22.67 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.915 1.245 . . . . 10.0 114.837 176.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -87.6 101.28 13.48 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.9 1.68 . . . . 10.0 111.274 176.642 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -78.37 151.78 32.65 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.295 1.038 . . . . 10.0 111.972 169.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.8 157.31 43.93 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.246 1.018 . . . . 10.0 112.109 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.6 t -134.97 104.89 6.14 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.645 1.578 . . . . 10.0 110.925 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.1 t -71.42 134.53 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 123.916 0.886 . . . . 10.0 109.131 168.281 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -133.51 119.46 19.56 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.756 2.023 . . . . 10.0 110.27 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.3 mtpt -134.4 136.06 43.05 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.79 1.236 . . . . 10.0 113.018 -170.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 24.9 p30 -132.51 -178.36 4.89 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.061 1.344 . . . . 10.0 111.547 167.093 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.1 ptm180 -60.97 -14.84 25.45 Favored 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 115.482 1.66 . . . . 10.0 115.482 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.03 -19.65 13.66 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.443 1.497 . . . . 10.0 114.208 -177.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.28 -169.98 42.63 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 116.142 1.217 . . . . 10.0 116.142 177.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -134.54 144.64 48.12 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 127.262 2.225 . . . . 10.0 111.664 -170.15 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.88 159.91 40.71 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 126.214 1.806 . . . . 10.0 110.794 167.067 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 32.8 m -140.35 101.14 4.05 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 124.457 1.103 . . . . 10.0 110.733 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -77.66 155.56 31.3 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.777 1.231 . . . . 10.0 111.254 175.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 28.3 m -146.98 146.35 30.05 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.728 1.211 . . . . 10.0 112.057 -174.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.3 p -154.3 145.99 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 125.819 1.648 . . . . 10.0 111.934 170.156 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -100.45 135.46 41.85 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.611 1.165 . . . . 10.0 110.929 170.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.1 tp -122.39 112.4 18.04 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.98 1.712 . . . . 10.0 111.026 177.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -100.0 85.22 3.01 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.942 1.697 . . . . 10.0 110.834 175.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -64.94 114.49 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.954 0.902 . . . . 10.0 110.684 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.6 mt -75.81 99.78 4.55 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.154 1.781 . . . . 10.0 110.042 179.686 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.01 148.41 40.26 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.304 1.042 . . . . 10.0 113.525 -175.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -144.43 83.15 1.71 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.759 2.023 . . . . 10.0 110.385 176.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 125.668 1.587 . . . . 10.0 114.397 176.169 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.568 0 N-CA-C 111.853 -0.499 . . . . 10.0 111.853 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.26 162.06 18.13 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.332 1.053 . . . . 10.0 112.94 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.9 174.17 12.13 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 126.096 1.758 . . . . 10.0 111.648 -178.267 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.81 172.96 45.65 Favored Glycine 0 CA--C 1.542 1.757 0 N-CA-C 116.792 1.477 . . . . 10.0 116.792 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.36 161.72 44.75 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.569 2.846 . . . . 10.0 113.161 -172.358 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -67.05 158.78 55.17 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.861 2.374 . . . . 10.0 111.32 168.204 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.7 tpt85 -135.1 151.44 50.72 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.007 1.323 . . . . 10.0 111.772 -174.475 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -79.01 65.4 4.17 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 127.251 2.22 . . . . 10.0 111.812 -176.356 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 39.8 mm -63.16 -62.35 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 O-C-N 121.225 -0.922 . . . . 10.0 112.635 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -153.16 149.67 28.27 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.822 0.849 . . . . 10.0 112.59 -178.305 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.2 m -134.44 151.11 75.56 Favored Pre-proline 0 N--CA 1.477 0.925 0 C-N-CA 126.405 1.882 . . . . 10.0 110.558 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -74.65 159.77 42.06 Favored 'Trans proline' 0 CA--C 1.542 0.916 0 C-N-CA 123.049 2.499 . . . . 10.0 111.596 168.031 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -77.24 172.61 13.0 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 123.942 0.897 . . . . 10.0 111.542 167.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -49.61 108.86 0.23 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.416 1.486 . . . . 10.0 113.594 178.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.3 mtp -82.41 155.66 24.56 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.349 1.46 . . . . 10.0 112.008 -177.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 71.2 p -140.36 131.81 26.91 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.964 1.306 . . . . 10.0 111.023 170.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.2 mm -137.08 129.46 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.385 1.474 . . . . 10.0 109.94 -170.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -62.26 127.61 32.17 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.785 1.234 . . . . 10.0 112.169 172.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -52.82 135.02 36.59 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.289 1.435 . . . . 10.0 113.171 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.12 -11.27 69.45 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.046 1.784 . . . . 10.0 114.952 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.9 mtp-105 -77.63 162.73 26.82 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 118.989 1.394 . . . . 10.0 113.162 177.476 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -71.71 151.98 43.17 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.884 1.273 . . . . 10.0 110.763 158.327 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 36.0 t -148.41 156.83 42.98 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.496 1.118 . . . . 10.0 111.474 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -135.76 139.98 43.97 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 125.516 1.526 . . . . 10.0 110.858 162.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 43.9 mtt -100.77 155.39 17.94 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.801 1.641 . . . . 10.0 109.818 167.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -139.57 118.32 12.37 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.157 1.383 . . . . 10.0 110.984 -170.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -130.52 106.84 8.78 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 125.992 1.717 . . . . 10.0 111.952 -170.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -65.93 127.64 32.84 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.902 0.881 . . . . 10.0 110.52 173.126 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.1 125.34 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.642 1.577 . . . . 10.0 110.769 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 69.4 m -133.21 115.3 14.84 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.674 1.19 . . . . 10.0 111.907 -173.547 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -161.69 169.76 37.23 Favored Glycine 0 CA--C 1.536 1.393 0 C-N-CA 127.161 2.315 . . . . 10.0 111.381 172.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -143.7 125.3 8.24 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.09 0.956 . . . . 10.0 111.194 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.01 167.64 51.14 Favored 'Cis proline' 0 CA--C 1.539 0.744 0 CA-C-N 120.866 1.345 . . . . 10.0 112.476 -2.215 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.11 122.32 47.31 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.404 1.081 . . . . 10.0 111.231 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -69.34 148.59 68.16 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.42 2.08 . . . . 10.0 112.922 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -72.06 145.73 48.06 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.143 0.977 . . . . 10.0 109.736 161.3 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.98 139.72 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.556 1.142 . . . . 10.0 112.575 -172.054 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 73.2 m -136.81 142.12 42.91 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 126.024 1.729 . . . . 10.0 110.672 177.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -111.86 158.05 19.88 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.474 1.11 . . . . 10.0 113.278 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -145.69 159.57 42.96 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 127.256 2.222 . . . . 10.0 111.329 -174.15 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.4 tp -147.19 119.52 8.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.054 2.142 . . . . 10.0 110.0 175.5 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 55.26 14.05 0.98 Allowed 'General case' 0 CA--C 1.554 1.106 0 C-N-CA 126.537 1.935 . . . . 10.0 115.376 179.024 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.17 -12.22 31.4 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.564 2.031 . . . . 10.0 115.182 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -89.9 160.68 16.32 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 118.924 1.362 . . . . 10.0 110.978 169.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.5 p -73.99 158.92 33.48 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.369 1.067 . . . . 10.0 112.752 175.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 87.6 t -136.82 104.98 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 127.097 2.159 . . . . 10.0 108.623 173.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -79.68 161.54 25.77 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.417 0.687 . . . . 10.0 111.131 170.24 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.9 p -70.27 148.02 49.03 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.564 0.746 . . . . 10.0 112.211 171.198 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -152.61 -179.93 8.04 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 125.365 1.466 . . . . 10.0 111.328 168.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -57.97 -27.53 63.53 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.698 1.37 . . . . 10.0 114.698 -176.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 57.2 mt -93.11 -13.97 27.84 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.23 1.412 . . . . 10.0 113.084 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -131.97 68.82 1.49 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.545 1.938 . . . . 10.0 111.204 -172.231 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -72.9 146.61 46.02 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.092 1.357 . . . . 10.0 111.321 -179.204 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -139.2 110.35 6.89 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 126.547 1.939 . . . . 10.0 110.278 -172.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.26 162.78 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 125.079 1.351 . . . . 10.0 112.212 -177.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.4 t -129.8 104.09 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.518 1.527 . . . . 10.0 109.491 177.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 70.8 m -73.05 166.32 23.33 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 125.063 1.345 . . . . 10.0 112.804 177.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.07 158.52 6.73 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.292 1.437 . . . . 10.0 112.323 175.02 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt 64.8 9.64 5.45 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 127.392 2.277 . . . . 10.0 114.782 -172.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.2 62.74 1.86 Allowed Glycine 0 CA--C 1.53 1.027 0 C-N-CA 125.178 1.371 . . . . 10.0 113.491 173.235 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 43.2 tp -131.03 99.86 5.04 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.027 1.331 . . . . 10.0 111.09 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -76.68 133.95 39.39 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.923 0.889 . . . . 10.0 110.739 172.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 49.4 m -121.01 141.23 50.92 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.574 1.55 . . . . 10.0 111.434 178.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -133.2 115.78 15.43 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 126.788 2.035 . . . . 10.0 108.641 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 49.5 mt -105.35 154.36 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 124.83 1.252 . . . . 10.0 111.836 -168.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -130.4 107.51 9.3 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.496 2.318 . . . . 10.0 109.019 167.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 -63.77 -42.83 97.72 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.256 -0.902 . . . . 10.0 113.049 178.2 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 3.5 p -151.66 91.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 125.845 1.658 . . . . 10.0 110.233 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -74.63 142.47 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 O-C-N 121.368 -0.833 . . . . 10.0 112.123 -177.097 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -129.02 163.26 25.77 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 126.408 1.883 . . . . 10.0 111.394 177.134 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.5 -31.72 62.28 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -174.251 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.0 m -67.75 -16.31 64.06 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 114.166 1.173 . . . . 10.0 114.166 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -83.87 -5.98 59.33 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.732 1.213 . . . . 10.0 113.48 178.166 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.04 151.69 42.31 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 120.985 -1.072 . . . . 10.0 113.1 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 140.11 -174.0 22.68 Favored Glycine 0 CA--C 1.533 1.161 0 C-N-CA 124.317 0.96 . . . . 10.0 114.993 176.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 98.53 9.24 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.888 1.675 . . . . 10.0 111.367 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -76.37 146.92 38.41 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.016 0.926 . . . . 10.0 111.386 168.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.4 160.32 41.25 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.595 0.758 . . . . 10.0 112.425 169.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.0 t -133.39 142.28 48.29 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.091 2.156 . . . . 10.0 109.841 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.29 124.5 71.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.536 1.534 . . . . 10.0 108.72 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.39 124.48 51.3 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.374 1.87 . . . . 10.0 110.451 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -134.16 134.95 42.74 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.01 1.324 . . . . 10.0 112.543 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -130.87 -178.24 4.72 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 124.624 1.17 . . . . 10.0 111.55 166.512 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 -60.14 -12.61 8.92 Favored 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 115.804 1.779 . . . . 10.0 115.804 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.45 -16.19 13.38 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.381 1.472 . . . . 10.0 114.525 -178.04 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.78 -168.83 40.92 Favored Glycine 0 CA--C 1.533 1.217 0 CA-C-N 119.884 1.22 . . . . 10.0 116.124 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -134.11 145.78 49.65 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 127.117 2.167 . . . . 10.0 111.878 -170.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.75 161.02 37.12 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.133 1.773 . . . . 10.0 111.205 168.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 60.8 m -137.11 141.92 42.3 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.084 1.354 . . . . 10.0 110.966 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -135.98 137.04 40.86 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.595 1.558 . . . . 10.0 110.056 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.5 m -141.65 143.7 33.76 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.797 0.839 . . . . 10.0 112.049 -167.468 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.6 p -152.36 142.51 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 125.279 1.431 . . . . 10.0 111.947 171.37 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -90.34 136.25 33.17 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.996 0.918 . . . . 10.0 110.751 168.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.6 tp -118.82 104.22 10.36 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.879 1.672 . . . . 10.0 110.909 178.365 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -84.63 88.3 7.33 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.036 1.334 . . . . 10.0 110.846 170.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.78 108.04 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.228 -0.92 . . . . 10.0 109.84 174.055 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.9 mt -73.96 97.03 2.74 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.072 1.749 . . . . 10.0 109.852 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.69 28.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.65 1.18 . . . . 10.0 113.754 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 63.1 tttp -108.64 -39.29 5.42 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.971 2.108 . . . . 10.0 111.976 177.093 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 . . . . . 0 C--O 1.253 1.239 0 C-N-CA 125.137 1.375 . . . . 10.0 113.239 172.256 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.578 0 N-CA-C 111.905 -0.478 . . . . 10.0 111.905 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.94 166.05 14.31 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.637 1.175 . . . . 10.0 113.238 176.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.7 ptt? -148.1 177.42 9.39 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 126.169 1.788 . . . . 10.0 111.662 178.014 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -175.63 167.79 39.85 Favored Glycine 0 CA--C 1.541 1.702 0 N-CA-C 116.706 1.442 . . . . 10.0 116.706 178.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -67.92 162.77 38.34 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 123.907 3.071 . . . . 10.0 113.228 -173.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -63.99 139.13 66.02 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.963 2.442 . . . . 10.0 110.795 172.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 76.4 ttt-85 -139.41 141.41 37.52 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.39 1.076 . . . . 10.0 113.568 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -59.19 118.88 6.4 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.352 2.261 . . . . 10.0 111.912 171.103 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.6 -52.75 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.262 1.025 . . . . 10.0 110.001 165.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 40.1 tt0 -150.57 134.86 17.06 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.649 1.18 . . . . 10.0 111.145 176.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 31.7 m -119.35 152.78 53.12 Favored Pre-proline 0 N--CA 1.475 0.791 0 C-N-CA 126.0 1.72 . . . . 10.0 109.266 168.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -75.73 163.77 33.17 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.599 2.2 . . . . 10.0 112.211 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.52 170.77 14.47 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.484 -0.76 . . . . 10.0 110.79 163.091 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.6 p30 -61.18 157.69 15.58 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.167 -0.958 . . . . 10.0 111.867 169.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -127.2 151.92 48.05 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.592 1.557 . . . . 10.0 111.664 -170.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -143.67 84.64 1.8 Allowed 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.304 1.442 . . . . 10.0 111.183 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 40.4 mm -102.41 136.56 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.304 1.441 . . . . 10.0 110.593 -170.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -66.92 129.15 38.96 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.441 1.096 . . . . 10.0 112.414 175.126 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -53.92 128.09 28.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.169 1.388 . . . . 10.0 112.704 178.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 104.7 -13.19 50.38 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 126.564 2.031 . . . . 10.0 114.651 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -77.43 161.86 27.65 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 118.775 1.288 . . . . 10.0 113.577 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -75.32 144.08 42.58 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.683 1.193 . . . . 10.0 110.433 155.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.72 172.36 16.23 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 123.686 0.794 . . . . 10.0 112.394 159.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -147.18 168.3 22.01 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.397 1.479 . . . . 10.0 112.516 173.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 45.8 mtt -118.03 165.88 13.2 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 126.508 1.923 . . . . 10.0 111.7 176.417 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -142.62 107.95 5.02 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.586 1.555 . . . . 10.0 112.448 -171.814 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -125.7 101.44 6.88 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 126.489 1.916 . . . . 10.0 111.128 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -76.59 111.2 11.82 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.118 -0.989 . . . . 10.0 109.685 172.113 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -123.76 102.16 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 125.666 1.586 . . . . 10.0 110.481 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 12.3 t -73.76 173.08 10.35 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.725 0.81 . . . . 10.0 111.357 171.79 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 124.16 162.89 11.56 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 127.076 2.274 . . . . 10.0 112.431 -176.084 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -152.52 130.84 6.28 Favored Pre-proline 0 CA--C 1.547 0.835 0 C-N-CA 124.393 1.077 . . . . 10.0 110.828 -177.006 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -67.89 169.25 54.77 Favored 'Cis proline' 0 CA--C 1.539 0.762 0 CA-C-N 120.891 1.354 . . . . 10.0 112.735 -2.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.04 122.19 46.05 Favored Pre-proline 0 CA--C 1.549 0.917 0 C-N-CA 124.658 1.183 . . . . 10.0 111.038 178.043 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.1 151.0 61.0 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 122.483 2.122 . . . . 10.0 113.295 -170.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 150.45 47.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.158 0.983 . . . . 10.0 109.531 157.402 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 p -138.48 143.85 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 113.269 0.84 . . . . 10.0 113.269 -174.149 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 21.6 m -127.12 151.7 48.3 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.901 2.081 . . . . 10.0 110.353 173.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 34.9 m95 -125.51 157.59 36.65 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.282 1.033 . . . . 10.0 112.865 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 74.9 m-85 -147.16 160.13 42.8 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 126.309 1.844 . . . . 10.0 111.553 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.8 tp -148.45 124.77 10.88 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 127.38 2.272 . . . . 10.0 110.121 176.346 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 53.42 14.18 0.53 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.845 2.058 . . . . 10.0 116.202 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.2 0.49 25.23 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.732 1.634 . . . . 10.0 115.962 -179.338 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.4 ptp85 -122.21 166.55 14.44 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 125.769 1.628 . . . . 10.0 112.319 173.352 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 20.1 p -71.58 158.85 35.47 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.835 1.254 . . . . 10.0 113.674 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 97.1 t -136.84 142.52 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 128.069 2.547 . . . . 10.0 108.299 171.037 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.2 mt-30 -128.93 163.67 24.8 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.151 1.38 . . . . 10.0 111.344 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 52.9 p -66.67 148.54 51.77 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.616 0.766 . . . . 10.0 112.383 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -152.44 167.27 29.3 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.727 1.611 . . . . 10.0 110.824 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -56.63 -34.93 67.75 Favored 'General case' 0 CA--C 1.546 0.796 0 O-C-N 121.005 -1.06 . . . . 10.0 112.963 170.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 82.9 mt -84.84 -14.74 47.04 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.527 1.131 . . . . 10.0 113.902 174.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.83 70.52 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.546 1.538 . . . . 10.0 111.371 -172.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.57 147.7 48.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.591 1.156 . . . . 10.0 111.517 -176.509 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -134.36 107.09 7.42 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 126.927 2.091 . . . . 10.0 109.467 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.31 161.32 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.429 -176.113 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 19.7 t -135.75 120.19 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 125.882 1.673 . . . . 10.0 109.509 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 22.6 t -64.33 160.32 19.12 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.439 1.096 . . . . 10.0 112.341 175.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -51.8 -35.48 44.32 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.781 1.633 . . . . 10.0 112.579 173.472 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 44.8 mmtm -82.15 -0.7 46.09 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.022 1.729 . . . . 10.0 114.704 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.52 8.65 65.65 Favored Glycine 0 CA--C 1.538 1.479 0 C-N-CA 124.987 1.28 . . . . 10.0 115.345 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 50.3 tp -76.7 102.01 6.03 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.71 1.204 . . . . 10.0 110.699 171.341 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -78.29 144.21 36.33 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.36 1.064 . . . . 10.0 111.085 168.15 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 17.2 m -135.37 155.14 51.07 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.174 1.39 . . . . 10.0 112.833 173.194 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.05 116.09 15.07 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 128.122 2.569 . . . . 10.0 107.949 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -98.61 154.79 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.405 1.482 . . . . 10.0 111.26 -171.615 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -130.6 104.91 7.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.127 2.171 . . . . 10.0 108.831 164.156 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.8 mm-40 -64.0 -37.09 86.15 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.287 -0.883 . . . . 10.0 113.023 178.018 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.0 p -150.61 91.66 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 125.816 1.646 . . . . 10.0 110.3 177.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.29 139.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 121.3 -0.875 . . . . 10.0 112.194 -176.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -125.9 161.05 28.33 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 126.853 2.061 . . . . 10.0 111.112 176.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.37 -29.64 64.21 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.716 1.206 . . . . 10.0 113.74 -177.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 39.5 p -67.08 -17.07 64.72 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 125.477 1.511 . . . . 10.0 114.597 173.254 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -82.27 -6.49 59.27 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.7 1.2 . . . . 10.0 113.256 174.251 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.56 152.45 45.25 Favored 'General case' 0 CA--C 1.546 0.806 0 O-C-N 120.912 -1.117 . . . . 10.0 113.403 -178.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 133.14 -170.21 22.3 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.79 1.186 . . . . 10.0 115.147 174.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.66 105.64 16.37 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.052 1.741 . . . . 10.0 111.197 177.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -81.38 153.75 26.81 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.378 1.071 . . . . 10.0 111.769 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.01 159.09 42.96 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.016 0.927 . . . . 10.0 112.006 167.436 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 37.6 t -138.81 127.19 22.96 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 127.052 2.141 . . . . 10.0 109.248 -173.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.8 t -122.68 113.09 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.26 1.424 . . . . 10.0 109.49 -175.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -108.44 135.17 50.18 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.64 1.576 . . . . 10.0 111.231 -177.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.28 133.71 37.25 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.735 1.614 . . . . 10.0 111.763 -171.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -135.1 179.99 5.98 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.148 0.979 . . . . 10.0 111.99 166.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -61.32 -9.37 5.1 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 115.83 1.789 . . . . 10.0 115.83 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.84 -12.62 13.29 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 125.823 1.649 . . . . 10.0 114.332 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.77 -170.49 40.59 Favored Glycine 0 CA--C 1.535 1.343 0 CA-C-N 120.02 1.282 . . . . 10.0 115.949 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -135.43 147.56 49.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.858 2.063 . . . . 10.0 111.487 -176.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -141.06 158.36 44.04 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.629 1.572 . . . . 10.0 111.93 172.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 85.4 m -136.71 130.59 32.29 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.096 1.358 . . . . 10.0 111.148 -176.354 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -123.87 156.35 36.4 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.496 1.918 . . . . 10.0 110.815 -178.01 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.2 m -142.85 145.6 33.3 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 124.463 1.105 . . . . 10.0 111.559 -169.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.0 p -151.59 159.1 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 125.894 1.678 . . . . 10.0 110.85 172.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -121.83 137.17 54.88 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.808 1.243 . . . . 10.0 111.015 176.006 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.2 tp -124.65 105.3 9.22 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 126.359 1.864 . . . . 10.0 110.277 -178.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -93.97 80.35 4.12 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.676 1.59 . . . . 10.0 110.809 176.342 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -62.3 115.27 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.701 0.8 . . . . 10.0 110.95 -178.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.1 mt -76.03 97.38 4.02 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.702 1.601 . . . . 10.0 109.792 178.417 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.76 149.3 36.09 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 124.731 1.212 . . . . 10.0 113.962 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -95.81 -42.41 8.35 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 127.465 2.306 . . . . 10.0 111.336 174.014 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--O 1.253 1.289 0 C-N-CA 125.685 1.594 . . . . 10.0 113.298 174.503 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.546 0 N-CA-C 111.718 -0.553 . . . . 10.0 111.718 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.48 158.05 24.99 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 124.178 0.991 . . . . 10.0 112.928 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.68 175.09 11.88 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.243 1.817 . . . . 10.0 111.272 -178.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.41 172.89 45.86 Favored Glycine 0 CA--C 1.542 1.737 0 N-CA-C 117.092 1.597 . . . . 10.0 117.092 -176.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -68.77 160.42 49.68 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.679 2.919 . . . . 10.0 113.045 -173.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -70.92 167.56 25.59 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.231 2.62 . . . . 10.0 112.58 173.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -135.42 156.75 48.41 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.223 1.409 . . . . 10.0 112.703 -171.336 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -96.94 74.37 2.62 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.161 2.185 . . . . 10.0 110.695 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.5 mp -76.05 -71.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.134 -0.979 . . . . 10.0 112.322 -173.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -152.13 143.47 23.34 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.983 0.913 . . . . 10.0 112.281 -174.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.91 152.55 54.1 Favored Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 126.295 1.838 . . . . 10.0 110.57 172.177 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -74.29 160.84 41.57 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.768 2.312 . . . . 10.0 111.348 172.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -72.16 165.7 23.83 Favored 'General case' 0 CA--C 1.543 0.711 0 O-C-N 121.452 -0.78 . . . . 10.0 111.551 169.217 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -62.19 158.05 17.87 Favored 'General case' 0 CA--C 1.546 0.792 0 O-C-N 121.453 -0.779 . . . . 10.0 112.433 174.037 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 46.5 mtm -130.15 162.32 29.13 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.318 1.047 . . . . 10.0 112.912 -178.013 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -139.83 96.37 3.06 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.862 2.065 . . . . 10.0 110.482 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.1 mm -112.74 133.29 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 124.594 1.158 . . . . 10.0 111.214 -166.068 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -60.15 126.93 29.42 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.439 1.496 . . . . 10.0 112.456 172.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -55.18 127.13 27.76 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.273 1.029 . . . . 10.0 112.18 -178.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.92 -10.43 58.67 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 126.004 1.764 . . . . 10.0 114.955 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -73.93 161.19 30.37 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 119.362 1.581 . . . . 10.0 113.333 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -75.98 140.32 41.96 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.328 1.451 . . . . 10.0 110.264 157.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.48 166.3 31.54 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.702 0.801 . . . . 10.0 112.598 165.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm85 -141.69 168.0 20.81 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.88 1.272 . . . . 10.0 113.744 175.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 52.3 mtt -131.76 160.29 35.97 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 127.317 2.247 . . . . 10.0 111.01 175.231 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -140.96 103.52 4.49 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.442 1.497 . . . . 10.0 111.932 -168.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 -113.85 121.59 44.47 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.849 1.66 . . . . 10.0 111.677 -176.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.7 mtpp -77.48 127.35 32.37 Favored 'General case' 0 N--CA 1.478 0.955 0 O-C-N 121.382 -0.824 . . . . 10.0 110.887 173.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.7 p -138.96 145.12 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.596 1.558 . . . . 10.0 111.053 -179.04 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.9 t -142.99 -176.06 4.76 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.63 1.572 . . . . 10.0 110.886 178.286 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 118.42 164.49 13.0 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 127.519 2.485 . . . . 10.0 112.005 -172.517 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.5 tp -147.27 129.08 7.44 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 123.975 0.91 . . . . 10.0 110.785 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.4 169.15 47.01 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 CA-C-N 120.784 1.316 . . . . 10.0 112.373 -3.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.76 53.23 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 124.498 1.119 . . . . 10.0 111.102 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -69.33 150.44 70.82 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.398 2.065 . . . . 10.0 113.049 -172.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -70.4 140.71 52.14 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.129 0.972 . . . . 10.0 109.456 159.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 m -129.01 137.9 55.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.323 1.049 . . . . 10.0 112.521 -170.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 72.2 m -132.92 152.8 51.85 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.165 1.786 . . . . 10.0 110.861 177.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -128.15 152.86 47.52 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.85 1.26 . . . . 10.0 112.765 -175.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -145.48 158.32 43.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 126.08 1.752 . . . . 10.0 111.68 -171.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.8 tp -148.16 123.33 10.17 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.187 2.195 . . . . 10.0 109.875 177.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 54.22 11.0 0.34 Allowed 'General case' 0 CA--C 1.556 1.192 0 N-CA-C 116.571 2.063 . . . . 10.0 116.571 173.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 116.05 -0.64 21.11 Favored Glycine 0 CA--C 1.54 1.608 0 C-N-CA 125.802 1.668 . . . . 10.0 115.875 -178.239 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -119.41 166.45 13.05 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 125.865 1.666 . . . . 10.0 112.108 172.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.1 p -72.49 161.17 31.15 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.756 1.222 . . . . 10.0 113.131 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.92 91.97 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.878 2.071 . . . . 10.0 108.703 173.207 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -69.31 145.34 53.11 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 123.254 0.622 . . . . 10.0 110.661 171.486 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 44.1 p -73.77 153.93 39.79 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.453 0.701 . . . . 10.0 112.542 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.69 -172.91 4.24 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.527 1.931 . . . . 10.0 111.676 175.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -61.55 -17.76 56.3 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.984 1.475 . . . . 10.0 114.984 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.4 mt -113.26 -18.84 11.98 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 126.285 1.834 . . . . 10.0 113.423 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.9 m80 -121.0 93.38 4.01 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.947 2.099 . . . . 10.0 109.923 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.9 mttt -106.7 121.33 44.14 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.444 1.098 . . . . 10.0 110.79 -169.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -128.71 100.57 5.77 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.258 1.423 . . . . 10.0 110.375 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.18 161.65 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 125.888 1.675 . . . . 10.0 111.934 -174.736 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.93 167.04 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 125.686 1.594 . . . . 10.0 112.12 -178.252 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.8 t -133.85 149.55 51.36 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.648 1.579 . . . . 10.0 112.046 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.86 -19.54 42.81 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.904 1.682 . . . . 10.0 114.156 175.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -76.74 -2.23 31.97 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 125.622 1.569 . . . . 10.0 114.142 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.0 46.27 6.0 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.816 1.198 . . . . 10.0 112.703 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 11.6 tp -137.94 150.59 47.18 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.257 1.423 . . . . 10.0 111.265 -174.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -130.81 123.84 29.99 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.767 2.027 . . . . 10.0 109.893 174.404 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 48.3 m -94.49 156.02 16.66 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.339 1.056 . . . . 10.0 112.506 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.92 116.46 15.62 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.368 1.867 . . . . 10.0 107.205 162.344 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.36 133.86 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.819 1.248 . . . . 10.0 110.636 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -109.69 108.77 19.28 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.975 2.11 . . . . 10.0 108.916 171.742 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -64.19 -37.74 88.54 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 121.489 -0.757 . . . . 10.0 112.817 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.4 p -151.07 89.45 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.154 1.782 . . . . 10.0 109.918 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -66.32 138.29 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 O-C-N 121.232 -0.918 . . . . 10.0 111.742 -178.081 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.7 mmt180 -121.32 160.35 24.16 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 126.021 1.728 . . . . 10.0 112.208 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.97 -34.37 65.65 Favored 'General case' 0 CA--C 1.546 0.81 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -176.315 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 19.9 m -65.51 -16.47 63.7 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.498 1.519 . . . . 10.0 114.555 175.5 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -82.18 -7.48 59.62 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.649 1.179 . . . . 10.0 113.311 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.52 147.33 53.03 Favored 'General case' 0 CA--C 1.546 0.815 0 O-C-N 121.185 -0.947 . . . . 10.0 112.926 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.94 -170.79 23.02 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 124.512 1.053 . . . . 10.0 115.347 175.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.97 107.03 15.28 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.994 1.718 . . . . 10.0 111.326 177.374 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -83.3 151.13 25.73 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.386 1.075 . . . . 10.0 111.776 170.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.27 160.38 40.59 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 10.0 112.309 169.115 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -133.02 145.84 51.2 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 126.416 1.886 . . . . 10.0 110.027 175.316 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 66.6 t -127.73 129.15 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 125.624 1.569 . . . . 10.0 108.882 175.042 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -122.4 120.79 35.0 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.574 1.95 . . . . 10.0 110.469 -175.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -131.56 134.48 46.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.305 1.442 . . . . 10.0 112.11 -171.177 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -130.63 -178.23 4.69 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.472 1.109 . . . . 10.0 111.645 168.182 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -60.03 -11.3 5.53 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 115.788 1.773 . . . . 10.0 115.788 -179.462 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.97 -18.48 11.24 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.417 1.487 . . . . 10.0 114.654 -177.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.53 -170.13 43.2 Favored Glycine 0 CA--C 1.534 1.22 0 CA-C-N 120.034 1.288 . . . . 10.0 116.314 179.429 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.12 143.6 46.66 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.172 2.189 . . . . 10.0 111.764 -172.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.75 160.18 38.99 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.167 1.787 . . . . 10.0 111.173 168.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.4 m -138.89 145.26 39.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 125.229 1.412 . . . . 10.0 110.871 -175.315 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -136.48 152.92 51.08 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.33 1.452 . . . . 10.0 111.102 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.8 m -145.16 145.88 31.55 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.567 1.147 . . . . 10.0 111.762 -172.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -152.79 171.82 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 126.36 1.864 . . . . 10.0 110.734 171.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -128.53 142.98 50.9 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.755 1.222 . . . . 10.0 111.404 173.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.0 tp -127.36 109.13 11.47 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.04 1.736 . . . . 10.0 110.128 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -78.88 141.89 37.27 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.935 -0.478 . . . . 10.0 110.035 160.091 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 40.0 t -120.5 106.53 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.458 1.103 . . . . 10.0 108.752 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.5 mt -69.37 96.78 0.9 Allowed 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.222 1.809 . . . . 10.0 109.288 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.67 154.33 29.63 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.954 1.302 . . . . 10.0 114.259 -167.554 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 31.4 ttmt -130.81 -25.62 2.29 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 127.223 2.209 . . . . 10.0 113.28 -176.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 . . . . . 0 C--O 1.253 1.278 0 C-N-CA 125.346 1.458 . . . . 10.0 113.208 169.263 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 N-CA-C 111.7 -0.56 . . . . 10.0 111.7 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.58 167.6 10.66 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 124.443 1.097 . . . . 10.0 112.998 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -141.32 179.86 6.53 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 126.052 1.741 . . . . 10.0 111.864 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 178.87 170.89 41.47 Favored Glycine 0 CA--C 1.541 1.663 0 N-CA-C 116.773 1.469 . . . . 10.0 116.773 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.85 161.19 46.89 Favored 'Trans proline' 0 CA--C 1.543 0.947 0 C-N-CA 123.838 3.025 . . . . 10.0 112.934 -174.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -65.85 145.0 79.27 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 123.017 2.478 . . . . 10.0 111.228 169.223 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -136.28 147.82 47.68 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.569 1.548 . . . . 10.0 112.384 -175.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -61.22 110.07 1.29 Allowed 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.814 2.046 . . . . 10.0 111.502 171.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 46.9 mm -105.46 -63.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.995 0.918 . . . . 10.0 110.285 172.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -153.36 101.88 2.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.311 1.044 . . . . 10.0 111.456 176.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 25.3 m -72.27 150.07 91.84 Favored Pre-proline 0 N--CA 1.476 0.834 0 C-N-CA 123.019 0.528 . . . . 10.0 110.22 161.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -75.72 161.0 37.25 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 122.859 2.373 . . . . 10.0 112.089 177.179 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -73.2 166.66 22.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 123.912 0.885 . . . . 10.0 111.517 168.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -62.01 157.79 17.93 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 121.34 -0.85 . . . . 10.0 112.644 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.0 mtp -132.6 153.41 51.06 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.349 1.459 . . . . 10.0 112.118 -166.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 16.9 p -147.27 100.95 3.34 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.8 1.64 . . . . 10.0 110.947 178.371 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.3 mm -117.32 138.95 46.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.044 1.337 . . . . 10.0 110.911 -167.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -67.75 132.18 46.95 Favored 'General case' 0 CA--C 1.543 0.688 0 O-C-N 121.359 -0.838 . . . . 10.0 112.311 176.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -54.63 119.49 5.37 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.564 1.545 . . . . 10.0 112.132 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 108.52 -10.8 35.83 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 126.216 1.865 . . . . 10.0 115.191 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -74.01 162.31 29.17 Favored 'General case' 0 N--CA 1.479 0.985 0 CA-C-N 119.224 1.512 . . . . 10.0 113.577 178.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -73.97 147.18 43.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.565 1.146 . . . . 10.0 110.558 158.37 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 4.3 t -153.72 173.29 16.03 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.212 1.005 . . . . 10.0 112.541 167.373 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -148.57 166.83 27.07 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 126.039 1.736 . . . . 10.0 112.436 166.665 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.0 mtt -118.15 157.41 26.97 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.617 1.967 . . . . 10.0 111.333 172.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -140.02 95.01 2.83 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.275 1.43 . . . . 10.0 111.579 -167.054 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -113.1 100.74 8.83 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.426 1.49 . . . . 10.0 111.609 -175.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -73.4 128.97 36.98 Favored 'General case' 0 N--CA 1.477 0.889 0 O-C-N 121.356 -0.84 . . . . 10.0 111.311 175.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.4 p -146.99 138.52 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.632 1.973 . . . . 10.0 110.501 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 70.4 m -125.68 126.33 44.49 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.641 1.176 . . . . 10.0 111.596 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -172.02 169.02 42.16 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 127.12 2.295 . . . . 10.0 111.338 175.192 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.6 tp -146.69 131.36 8.81 Favored Pre-proline 0 CA--C 1.548 0.901 0 C-N-CA 124.47 1.108 . . . . 10.0 111.105 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -66.91 169.86 46.94 Favored 'Cis proline' 0 CA--C 1.54 0.797 0 CA-C-N 120.533 1.226 . . . . 10.0 112.546 -3.123 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.17 120.78 32.36 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 124.605 1.162 . . . . 10.0 111.255 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.41 161.49 45.39 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 122.585 2.19 . . . . 10.0 113.221 -172.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -63.85 163.05 12.51 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.844 1.258 . . . . 10.0 111.692 166.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.4 p -139.31 114.97 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.139 1.375 . . . . 10.0 111.525 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 53.2 m -137.1 158.91 43.38 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.948 1.699 . . . . 10.0 110.876 171.296 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -133.94 160.86 36.42 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.576 1.151 . . . . 10.0 113.604 -170.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -143.5 161.64 37.92 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.872 2.069 . . . . 10.0 111.529 -177.56 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.7 tp -146.12 119.26 8.85 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 127.027 2.131 . . . . 10.0 110.188 176.052 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.4 m-20 54.78 16.65 1.48 Allowed 'General case' 0 CA--C 1.554 1.132 0 C-N-CA 126.469 1.908 . . . . 10.0 114.964 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.37 -11.86 47.51 Favored Glycine 0 CA--C 1.538 1.531 0 C-N-CA 126.52 2.01 . . . . 10.0 115.164 -177.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -86.17 156.34 20.37 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 118.932 1.366 . . . . 10.0 110.976 170.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.4 p -70.88 154.14 42.09 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.345 1.058 . . . . 10.0 112.51 173.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -132.89 107.38 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.099 1.76 . . . . 10.0 108.78 173.157 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -78.68 163.47 25.41 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.027 0.931 . . . . 10.0 111.37 171.516 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.7 p -72.59 157.13 38.15 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.709 0.803 . . . . 10.0 112.615 173.271 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -146.95 171.09 15.77 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 126.538 1.935 . . . . 10.0 110.322 170.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -59.97 -31.54 69.99 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.039 -1.038 . . . . 10.0 112.292 167.663 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 80.2 mt -81.95 -17.2 47.86 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.191 1.396 . . . . 10.0 113.949 173.603 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.2 m80 -136.28 69.77 1.42 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.985 1.714 . . . . 10.0 110.895 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -68.07 142.72 55.76 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.952 1.301 . . . . 10.0 111.005 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.3 mtt -133.63 102.49 5.51 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 126.494 1.917 . . . . 10.0 110.049 -175.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.84 171.54 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.371 1.468 . . . . 10.0 111.874 -176.209 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 23.8 m -131.45 134.55 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.021 1.328 . . . . 10.0 110.983 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 23.7 t -77.53 151.0 34.75 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.272 0.629 . . . . 10.0 111.91 173.362 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -60.74 -20.88 62.26 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.835 1.254 . . . . 10.0 113.224 168.451 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -75.96 -5.37 45.9 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.718 1.607 . . . . 10.0 113.86 173.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.9 56.54 2.72 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.792 1.186 . . . . 10.0 112.571 -177.83 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.5 tp -133.58 105.51 6.91 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.619 1.567 . . . . 10.0 110.629 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 9.3 m170 -65.79 129.08 38.52 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.45 0.7 . . . . 10.0 110.101 166.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 66.2 m -125.1 131.56 53.27 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.899 1.679 . . . . 10.0 111.681 -173.25 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.17 115.87 14.71 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.657 1.983 . . . . 10.0 108.927 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.94 154.36 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 125.187 1.395 . . . . 10.0 110.696 -174.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -127.08 102.8 7.12 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.032 2.133 . . . . 10.0 108.952 164.496 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.9 mm-40 -65.67 -36.01 82.42 Favored 'General case' 0 N--CA 1.476 0.83 0 O-C-N 121.044 -1.035 . . . . 10.0 112.675 176.626 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.2 p -151.58 90.23 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.188 1.795 . . . . 10.0 110.012 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.82 131.52 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 O-C-N 121.199 -0.938 . . . . 10.0 111.392 -179.419 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -110.8 161.07 16.16 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.508 1.523 . . . . 10.0 111.555 177.334 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.43 -34.45 66.83 Favored 'General case' 0 CA--C 1.546 0.808 0 N-CA-C 113.355 0.872 . . . . 10.0 113.355 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 23.5 m -66.44 -16.59 64.22 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.522 1.529 . . . . 10.0 114.57 176.011 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -81.32 -7.92 59.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.302 1.041 . . . . 10.0 113.469 179.022 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.12 148.14 48.8 Favored 'General case' 0 CA--C 1.548 0.88 0 CA-C-N 119.428 1.013 . . . . 10.0 113.099 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.24 -172.65 25.26 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.655 1.121 . . . . 10.0 115.079 176.121 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.34 101.92 10.11 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.834 1.654 . . . . 10.0 111.02 174.412 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -78.83 151.51 31.84 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 124.119 0.968 . . . . 10.0 111.886 171.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.47 161.47 37.97 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.667 0.787 . . . . 10.0 112.179 168.57 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.1 t -135.28 149.98 49.92 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 126.627 1.971 . . . . 10.0 110.079 177.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -124.05 141.47 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.898 1.279 . . . . 10.0 110.844 174.438 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.11 120.63 24.93 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.686 1.994 . . . . 10.0 110.095 -178.054 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -135.11 132.89 38.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 125.176 1.39 . . . . 10.0 111.672 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.2 p30 -134.03 -179.58 5.64 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.744 1.218 . . . . 10.0 111.332 166.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -61.97 -11.78 15.15 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 115.576 1.695 . . . . 10.0 115.576 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.18 -15.28 14.9 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.552 1.541 . . . . 10.0 114.246 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.46 -167.94 37.9 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.839 1.2 . . . . 10.0 116.023 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.85 146.48 47.5 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.84 2.056 . . . . 10.0 112.221 -170.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.79 157.01 46.01 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.317 1.847 . . . . 10.0 111.294 167.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -139.56 135.35 33.3 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.487 1.515 . . . . 10.0 110.069 -179.347 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -128.43 156.19 43.58 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.47 1.508 . . . . 10.0 111.791 -173.004 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.9 m -142.39 147.42 36.19 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 124.632 1.173 . . . . 10.0 112.139 -171.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.11 165.9 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 126.484 1.914 . . . . 10.0 110.852 168.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -119.25 131.75 55.83 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.981 1.313 . . . . 10.0 110.827 173.258 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.5 tp -120.44 108.62 14.33 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 126.206 1.802 . . . . 10.0 110.253 177.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -78.66 146.18 34.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 121.951 -0.468 . . . . 10.0 110.569 160.26 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.1 t -124.84 104.91 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 124.287 1.035 . . . . 10.0 109.152 174.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.95 98.98 1.7 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.674 1.989 . . . . 10.0 110.253 -175.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -57.64 128.9 39.4 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.878 1.271 . . . . 10.0 112.47 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -73.98 -20.01 60.48 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 125.083 1.353 . . . . 10.0 113.402 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 . . . . . 0 C--O 1.254 1.304 0 C-N-CA 127.407 2.283 . . . . 10.0 113.998 179.062 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.567 0 N-CA-C 111.885 -0.486 . . . . 10.0 111.885 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.03 155.81 30.03 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 124.162 0.985 . . . . 10.0 112.91 177.072 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.43 174.45 13.85 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.31 1.844 . . . . 10.0 111.478 -176.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -173.86 172.63 45.42 Favored Glycine 0 CA--C 1.543 1.833 0 N-CA-C 116.978 1.551 . . . . 10.0 116.978 -175.526 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -68.13 159.45 53.05 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.628 2.886 . . . . 10.0 113.021 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -69.17 162.38 42.03 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.044 2.496 . . . . 10.0 112.152 175.25 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.14 162.73 31.3 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.753 1.221 . . . . 10.0 113.561 -171.354 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -106.55 83.8 1.92 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.654 1.982 . . . . 10.0 110.76 -171.649 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.4 mm -83.04 -67.94 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.526 0.73 . . . . 10.0 111.7 -173.19 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 -155.59 148.8 24.68 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.386 1.074 . . . . 10.0 111.955 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 20.8 m -126.02 150.75 70.22 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 125.724 1.61 . . . . 10.0 110.654 172.083 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -74.63 159.39 42.63 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 123.016 2.478 . . . . 10.0 111.861 174.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -75.6 167.43 21.9 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.745 0.818 . . . . 10.0 112.344 168.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -59.7 152.14 23.36 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.688 0.795 . . . . 10.0 113.027 175.347 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 58.4 mtm -130.16 160.74 32.87 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.207 1.003 . . . . 10.0 112.908 -176.339 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -138.04 108.21 6.42 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 126.2 1.8 . . . . 10.0 110.642 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.7 mm -123.93 132.41 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.267 1.427 . . . . 10.0 110.409 -165.171 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -63.49 133.69 54.33 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.44 1.096 . . . . 10.0 112.456 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -52.51 132.46 35.2 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.465 1.506 . . . . 10.0 112.981 -179.566 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 91.4 -9.24 77.83 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.782 1.658 . . . . 10.0 115.394 177.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.44 160.72 32.25 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.206 1.503 . . . . 10.0 113.201 176.527 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 57.8 t80 -71.96 145.87 48.12 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.836 1.254 . . . . 10.0 110.488 158.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.8 t -150.44 163.48 38.29 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.454 1.102 . . . . 10.0 111.686 170.243 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.6 ptm85 -144.64 166.82 24.09 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.256 1.422 . . . . 10.0 112.769 169.51 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.0 mtt -130.87 159.14 38.26 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.956 2.102 . . . . 10.0 110.84 173.257 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -138.15 95.03 2.95 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.486 1.514 . . . . 10.0 111.34 -167.531 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -108.89 103.36 12.4 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.794 1.638 . . . . 10.0 111.103 -175.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -68.01 137.37 55.03 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 121.188 -0.945 . . . . 10.0 110.54 174.309 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.09 155.29 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.508 1.523 . . . . 10.0 111.396 -173.317 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -142.63 170.45 15.68 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.136 1.375 . . . . 10.0 110.992 171.345 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 137.71 160.47 8.54 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 127.613 2.53 . . . . 10.0 112.573 -176.432 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.7 tp -150.46 127.01 5.23 Favored Pre-proline 0 CA--C 1.547 0.846 0 C-N-CA 124.396 1.079 . . . . 10.0 110.711 178.495 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -66.78 169.13 49.01 Favored 'Cis proline' 0 CA--C 1.538 0.709 0 CA-C-N 121.346 1.517 . . . . 10.0 112.31 -2.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.58 121.11 36.66 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.708 1.203 . . . . 10.0 111.335 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -70.36 160.23 50.24 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.538 2.158 . . . . 10.0 113.274 -173.69 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -66.7 169.65 7.55 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 125.481 1.512 . . . . 10.0 111.736 169.283 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.5 p -133.33 115.71 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 125.708 1.603 . . . . 10.0 111.624 -175.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.9 m -133.84 99.16 4.37 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.515 1.526 . . . . 10.0 110.622 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -84.38 156.06 22.01 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 121.873 0.844 . . . . 10.0 112.798 175.166 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -143.0 159.58 41.97 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.126 2.17 . . . . 10.0 111.208 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -146.35 118.35 8.23 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.956 2.102 . . . . 10.0 109.892 176.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.2 m-20 55.4 12.26 0.71 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.578 1.951 . . . . 10.0 115.487 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.48 -13.05 23.25 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 126.662 2.077 . . . . 10.0 115.343 -178.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -91.14 161.77 14.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 125.233 1.413 . . . . 10.0 110.923 170.376 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 70.5 p -70.92 160.5 32.73 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.61 0.719 . . . . 10.0 112.34 174.67 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 98.5 t -129.85 113.43 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 126.53 1.932 . . . . 10.0 107.308 166.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -107.59 139.0 42.79 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.014 1.326 . . . . 10.0 109.832 -174.177 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 51.1 p -63.6 144.5 56.96 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.283 0.846 . . . . 10.0 113.283 -174.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -154.21 -177.77 6.66 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.9 1.68 . . . . 10.0 111.342 172.588 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -58.95 -18.84 37.4 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.227 1.411 . . . . 10.0 114.721 -177.378 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.7 mt -107.44 -11.42 15.52 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.74 1.616 . . . . 10.0 113.205 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -130.21 70.85 1.44 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.973 2.109 . . . . 10.0 110.285 -175.301 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -80.12 144.54 32.99 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.897 1.279 . . . . 10.0 111.706 -173.272 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -141.65 107.37 5.1 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.418 1.887 . . . . 10.0 110.535 -171.432 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 164.62 25.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.781 1.232 . . . . 10.0 112.232 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 22.1 t -133.69 116.37 24.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 125.334 1.453 . . . . 10.0 110.012 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 44.6 t -65.37 143.98 57.39 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.097 0.959 . . . . 10.0 111.755 173.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.26 -18.88 41.17 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.926 1.29 . . . . 10.0 113.888 173.264 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -77.11 -3.7 40.67 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.005 1.722 . . . . 10.0 114.014 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 88.33 45.94 4.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.971 1.272 . . . . 10.0 113.414 178.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.5 tp -135.18 105.6 6.38 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 125.293 1.437 . . . . 10.0 111.005 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -77.34 116.4 17.92 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.501 1.121 . . . . 10.0 110.984 171.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.9 m -93.33 137.14 32.93 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 125.495 1.518 . . . . 10.0 111.672 171.69 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.37 124.84 31.2 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.13 2.172 . . . . 10.0 107.639 174.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.4 mp -123.37 147.71 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.518 1.127 . . . . 10.0 111.536 -170.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -121.45 107.39 12.41 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 127.707 2.403 . . . . 10.0 109.175 170.485 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.4 mm-40 -66.68 -37.3 84.47 Favored 'General case' 0 N--CA 1.474 0.775 0 O-C-N 121.076 -1.015 . . . . 10.0 112.924 177.226 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.15 90.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 125.865 1.666 . . . . 10.0 110.284 -178.268 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -69.45 147.28 12.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 O-C-N 121.175 -0.953 . . . . 10.0 112.305 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -136.27 156.5 48.58 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.722 1.609 . . . . 10.0 112.721 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.54 -34.91 71.54 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.679 1.192 . . . . 10.0 113.663 -177.092 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.4 m -64.63 -13.08 52.1 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.453 1.501 . . . . 10.0 114.389 176.15 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -108.8 8.09 26.53 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.255 1.822 . . . . 10.0 113.009 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.38 158.0 30.41 Favored 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.94 -1.1 . . . . 10.0 112.616 168.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.37 -167.55 21.91 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.549 1.071 . . . . 10.0 115.134 173.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.63 103.25 10.35 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.174 1.79 . . . . 10.0 111.544 178.301 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -80.72 150.26 29.39 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.711 1.205 . . . . 10.0 111.919 171.334 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 162.96 35.0 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.113 0.965 . . . . 10.0 112.066 168.546 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 41.8 t -140.38 127.51 20.96 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.653 1.581 . . . . 10.0 110.768 176.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 89.7 t -102.55 132.78 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 125.666 1.586 . . . . 10.0 109.401 173.22 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.47 117.55 22.33 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.527 1.931 . . . . 10.0 110.659 -178.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -131.05 139.5 49.93 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.249 1.42 . . . . 10.0 112.056 -172.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -132.92 -177.87 4.7 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.8 1.24 . . . . 10.0 111.355 167.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -61.72 -8.8 5.1 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 115.888 1.81 . . . . 10.0 115.888 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -116.36 -17.44 10.72 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.587 1.555 . . . . 10.0 114.736 -178.334 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 175.4 -170.36 43.37 Favored Glycine 0 CA--C 1.534 1.232 0 CA-C-N 120.0 1.273 . . . . 10.0 116.257 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -136.58 141.99 43.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.222 2.209 . . . . 10.0 111.68 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.5 158.56 44.14 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.209 1.804 . . . . 10.0 110.953 168.256 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -143.52 141.32 30.69 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.517 1.127 . . . . 10.0 111.072 -175.68 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -132.4 154.2 50.04 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.694 1.598 . . . . 10.0 111.349 -176.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.0 m -145.39 145.3 31.1 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 124.672 1.189 . . . . 10.0 112.003 -171.036 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -154.0 172.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 126.572 1.949 . . . . 10.0 110.984 172.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 39.5 tt0 -130.1 143.13 50.62 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 120.665 -1.272 . . . . 10.0 111.557 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.9 tp -129.39 106.58 8.88 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.088 1.755 . . . . 10.0 111.14 -177.205 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -91.96 85.62 5.61 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.815 1.646 . . . . 10.0 111.307 177.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.9 t -70.15 110.06 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.256 -0.902 . . . . 10.0 110.997 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.8 mt -75.47 98.74 4.0 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 126.454 1.902 . . . . 10.0 110.503 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.73 144.48 52.2 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.255 1.022 . . . . 10.0 112.743 178.38 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -75.15 -25.05 58.08 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 113.525 0.935 . . . . 10.0 113.525 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.253 1.27 0 C-N-CA 126.934 2.094 . . . . 10.0 112.678 -177.482 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.541 0 N-CA-C 112.08 -0.408 . . . . 10.0 112.08 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.35 162.44 17.58 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.364 1.066 . . . . 10.0 112.931 175.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.83 -179.24 6.46 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 125.816 1.646 . . . . 10.0 112.177 -175.076 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -173.89 171.19 44.32 Favored Glycine 0 CA--C 1.541 1.659 0 N-CA-C 116.731 1.453 . . . . 10.0 116.731 -177.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -69.65 158.95 55.29 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.463 2.775 . . . . 10.0 113.08 -172.514 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -69.04 164.59 33.25 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.146 2.564 . . . . 10.0 111.52 168.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -141.12 155.32 46.13 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.717 1.207 . . . . 10.0 112.0 -174.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -74.6 102.66 4.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.19 2.196 . . . . 10.0 111.452 178.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 253' ' ' ILE . . . . . 0.489 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.2 OUTLIER -115.0 -176.69 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 126.026 1.73 . . . . 10.0 110.483 175.76 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.489 ' H ' HG22 ' A' ' 253' ' ' ILE . 0.0 OUTLIER -46.35 102.43 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 128.458 2.703 . . . . 10.0 115.024 -175.033 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.91 151.59 92.99 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 124.385 1.074 . . . . 10.0 111.061 158.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.4 162.65 33.29 Favored 'Trans proline' 0 CA--C 1.541 0.852 0 C-N-CA 123.023 2.482 . . . . 10.0 111.269 170.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -73.3 159.97 32.56 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 121.36 -0.838 . . . . 10.0 111.478 170.395 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -59.45 129.93 44.42 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 121.564 -0.71 . . . . 10.0 111.529 175.232 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 31.1 mtm -100.09 155.04 17.95 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.928 0.891 . . . . 10.0 112.162 -174.427 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 23.6 p -134.81 105.76 6.59 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.852 1.661 . . . . 10.0 110.269 175.122 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.0 mm -125.44 127.06 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.12 1.368 . . . . 10.0 110.206 -164.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -62.91 134.3 56.0 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.157 0.983 . . . . 10.0 112.189 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -53.03 130.16 33.02 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.813 1.245 . . . . 10.0 112.751 -178.628 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.74 -8.87 76.4 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 125.9 1.714 . . . . 10.0 115.284 177.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -70.15 160.29 32.35 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 119.272 1.536 . . . . 10.0 113.004 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 43.8 t80 -76.95 139.62 40.21 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.818 1.247 . . . . 10.0 110.222 156.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.6 p -149.32 169.71 20.18 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.754 0.822 . . . . 10.0 111.892 162.112 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 35.5 ptt-85 -145.27 137.78 25.96 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.217 1.007 . . . . 10.0 112.525 172.387 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.2 mtt -87.47 159.31 18.71 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.888 1.275 . . . . 10.0 110.906 169.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -136.7 132.29 34.69 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.014 1.326 . . . . 10.0 112.025 173.603 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -134.43 113.92 12.36 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 126.715 2.006 . . . . 10.0 109.645 -176.67 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.71 146.69 53.53 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 121.067 -1.021 . . . . 10.0 110.206 171.178 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.7 p -149.21 156.51 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.063 1.345 . . . . 10.0 111.492 -174.016 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.1 t -144.53 -176.62 5.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.712 1.605 . . . . 10.0 111.668 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 104.92 162.77 23.98 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.125 2.297 . . . . 10.0 113.54 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -148.74 131.05 7.7 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 125.234 1.414 . . . . 10.0 110.48 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -67.33 170.97 44.65 Favored 'Cis proline' 0 CA--C 1.54 0.778 0 CA-C-N 120.917 1.363 . . . . 10.0 112.615 -3.121 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.01 120.96 32.83 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.022 1.329 . . . . 10.0 111.437 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.53 152.42 59.86 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 122.481 2.121 . . . . 10.0 113.466 -171.273 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -72.31 141.6 48.84 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.81 1.244 . . . . 10.0 109.899 160.316 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.1 m -128.15 89.23 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.699 1.199 . . . . 10.0 112.233 -166.422 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.5 m -74.93 115.76 14.9 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.762 1.225 . . . . 10.0 111.251 175.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -96.89 148.77 22.61 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.475 1.11 . . . . 10.0 113.349 177.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 83.1 m-85 -143.21 160.19 40.92 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 126.562 1.945 . . . . 10.0 112.427 -174.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.2 tp -147.13 120.78 9.17 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.721 2.408 . . . . 10.0 109.799 174.561 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 54.93 15.1 1.05 Allowed 'General case' 0 CA--C 1.556 1.192 0 C-N-CA 126.584 1.954 . . . . 10.0 115.43 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 106.82 -11.01 41.53 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.207 1.86 . . . . 10.0 115.176 -177.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -90.55 159.81 16.28 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.207 1.403 . . . . 10.0 110.677 169.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 25.2 p -74.28 160.49 31.03 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.018 0.927 . . . . 10.0 112.6 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 41.2 t -135.54 104.77 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.979 1.712 . . . . 10.0 109.563 174.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -70.32 148.88 47.95 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.135 0.574 . . . . 10.0 111.209 170.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 34.7 p -73.55 149.5 42.15 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.497 0.719 . . . . 10.0 111.611 166.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -155.04 -177.67 6.7 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.171 1.388 . . . . 10.0 111.977 172.282 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -59.29 -19.95 50.38 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -177.064 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.7 mt -105.16 -9.35 17.8 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.501 1.52 . . . . 10.0 113.112 175.184 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.3 m80 -132.95 65.91 1.58 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 127.22 2.208 . . . . 10.0 110.261 -174.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -76.42 130.74 38.45 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.771 1.229 . . . . 10.0 110.668 -174.406 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 62.3 mtt -129.32 103.1 6.73 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.241 1.817 . . . . 10.0 109.776 -174.23 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.32 163.46 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.703 1.201 . . . . 10.0 112.763 -172.248 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.4 m -124.01 166.75 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 126.308 1.843 . . . . 10.0 111.649 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 35.6 t -136.88 149.04 47.43 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.487 1.515 . . . . 10.0 112.365 -178.573 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -58.72 -19.59 41.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.895 1.678 . . . . 10.0 114.075 174.291 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.2 mmtt -75.06 -2.17 26.23 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.565 1.546 . . . . 10.0 113.949 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.86 41.7 7.08 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.008 1.29 . . . . 10.0 112.903 -178.478 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.2 tp -133.51 150.02 51.7 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.276 1.43 . . . . 10.0 111.641 -175.405 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -132.93 137.78 46.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.02 2.528 . . . . 10.0 108.952 173.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 50.9 m -131.72 153.1 50.38 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.812 0.845 . . . . 10.0 112.471 -175.684 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.91 102.18 5.95 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.151 1.78 . . . . 10.0 109.059 178.568 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -86.68 142.32 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 124.841 1.256 . . . . 10.0 109.35 179.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -120.62 104.68 10.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.608 1.963 . . . . 10.0 108.459 167.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -64.85 -39.73 94.03 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.16 85.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.969 1.708 . . . . 10.0 110.111 -178.405 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.3 p -67.54 142.9 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 O-C-N 121.255 -0.903 . . . . 10.0 112.327 -176.049 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -124.77 161.07 27.23 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.286 1.834 . . . . 10.0 112.255 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.12 -30.87 64.76 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 113.839 1.051 . . . . 10.0 113.839 -176.323 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.7 p -67.53 -16.34 64.14 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 125.658 1.583 . . . . 10.0 114.803 173.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -82.18 -7.63 59.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.635 1.174 . . . . 10.0 113.433 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 151.61 45.35 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.136 -0.977 . . . . 10.0 113.021 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.96 -170.97 21.11 Favored Glycine 0 CA--C 1.532 1.141 0 C-N-CA 124.664 1.126 . . . . 10.0 114.935 176.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.41 104.08 14.12 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.067 1.747 . . . . 10.0 111.724 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -78.97 150.39 32.03 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.377 1.071 . . . . 10.0 112.016 170.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.43 160.28 41.82 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 123.778 0.831 . . . . 10.0 112.427 169.097 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.35 142.36 43.8 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.747 1.619 . . . . 10.0 110.414 174.195 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.2 t -123.14 104.92 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.798 1.639 . . . . 10.0 109.102 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.75 120.54 27.28 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 126.277 1.831 . . . . 10.0 110.835 177.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.64 135.45 51.21 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 125.21 1.404 . . . . 10.0 111.9 -178.599 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -133.85 -179.16 5.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.05 0.94 . . . . 10.0 111.744 164.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.7 ptp180 -60.53 -12.58 10.27 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 115.797 1.777 . . . . 10.0 115.797 -179.249 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.44 -17.99 13.33 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 125.521 1.528 . . . . 10.0 114.356 -178.482 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.44 -169.72 42.5 Favored Glycine 0 CA--C 1.535 1.298 0 CA-C-N 119.846 1.203 . . . . 10.0 115.809 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -137.94 145.6 42.22 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.352 1.861 . . . . 10.0 111.958 -173.642 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.18 162.34 35.5 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.072 1.749 . . . . 10.0 111.385 170.493 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 64.2 m -135.83 145.94 46.96 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.316 1.046 . . . . 10.0 111.736 -171.543 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -136.2 149.52 48.6 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.391 1.876 . . . . 10.0 110.63 -177.539 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -146.42 145.2 30.16 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.597 1.159 . . . . 10.0 111.79 -172.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.8 p -152.4 172.78 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 126.042 1.737 . . . . 10.0 110.856 168.008 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -126.62 147.16 49.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.17 1.388 . . . . 10.0 111.334 172.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 63.6 tp -127.86 113.0 15.34 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 126.09 1.756 . . . . 10.0 111.024 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -92.88 91.57 7.49 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.584 1.554 . . . . 10.0 110.606 171.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.4 t -74.62 106.84 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 O-C-N 121.158 -0.964 . . . . 10.0 110.157 175.495 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.1 mt -76.64 97.95 4.57 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.846 1.658 . . . . 10.0 110.5 -179.094 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.33 57.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.077 0.951 . . . . 10.0 112.542 177.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -69.88 -42.6 73.24 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 124.058 0.943 . . . . 10.0 112.964 -178.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.253 1.25 0 C-N-CA 128.296 2.638 . . . . 10.0 114.253 -175.067 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.532 0 N-CA-C 111.652 -0.579 . . . . 10.0 111.652 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.6 159.15 25.35 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.286 1.034 . . . . 10.0 113.044 177.081 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.29 176.99 10.38 Favored 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 126.314 1.846 . . . . 10.0 111.513 -178.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.62 170.57 43.38 Favored Glycine 0 CA--C 1.542 1.763 0 N-CA-C 116.947 1.539 . . . . 10.0 116.947 -178.284 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -69.13 158.11 59.03 Favored 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 123.402 2.735 . . . . 10.0 112.85 -173.109 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.4 143.12 62.37 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.756 2.304 . . . . 10.0 110.766 169.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 38.1 ttp-105 -111.02 152.59 26.67 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.472 1.509 . . . . 10.0 111.429 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -77.64 75.63 4.18 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 126.32 1.848 . . . . 10.0 111.712 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 253' ' ' ILE . . . . . 0.531 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.7 OUTLIER -75.15 177.45 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.034 0 C-N-CA 124.739 1.216 . . . . 10.0 111.312 175.969 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.531 ' H ' HG22 ' A' ' 253' ' ' ILE . 32.9 tt0 -49.94 113.01 0.75 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.79 2.436 . . . . 10.0 114.439 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 23.6 m -76.41 154.13 83.95 Favored Pre-proline 0 N--CA 1.477 0.905 0 C-N-CA 125.008 1.323 . . . . 10.0 111.19 159.2 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.45 167.53 25.48 Favored 'Trans proline' 0 CA--C 1.543 0.956 0 C-N-CA 123.265 2.644 . . . . 10.0 111.779 171.259 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.39 167.31 20.77 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.334 -0.854 . . . . 10.0 111.66 166.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -61.88 160.15 12.66 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.345 -0.847 . . . . 10.0 112.767 174.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 91.5 mtp -127.74 154.02 45.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.8 1.64 . . . . 10.0 111.793 -171.372 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 59.1 p -144.23 120.17 10.65 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 125.061 1.344 . . . . 10.0 110.367 166.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.0 mm -129.02 130.2 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.16 1.384 . . . . 10.0 109.89 -166.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -60.28 126.22 26.66 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.895 1.278 . . . . 10.0 112.238 173.772 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -52.33 130.71 31.78 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.48 1.512 . . . . 10.0 113.222 -177.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.33 -10.73 67.34 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.077 1.798 . . . . 10.0 115.106 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -71.69 162.06 30.03 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.144 1.472 . . . . 10.0 113.395 176.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -74.03 139.45 44.73 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.494 1.118 . . . . 10.0 110.466 155.58 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.3 p -148.78 172.66 14.27 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.596 0.758 . . . . 10.0 112.255 159.581 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -151.77 175.46 12.4 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 126.029 1.732 . . . . 10.0 112.1 175.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.7 mtt -129.14 162.32 28.04 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 126.042 1.737 . . . . 10.0 112.078 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -136.6 108.94 7.31 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.758 1.623 . . . . 10.0 111.525 -177.581 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -124.71 113.38 17.9 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.482 1.513 . . . . 10.0 111.155 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -67.48 146.38 54.03 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.542 -0.724 . . . . 10.0 111.099 173.445 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 9.3 p -149.21 139.8 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.444 1.498 . . . . 10.0 111.551 177.376 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 24.6 m -142.21 115.11 8.69 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.985 1.314 . . . . 10.0 111.19 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.32 166.79 38.9 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 127.086 2.279 . . . . 10.0 111.723 174.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.44 129.81 7.23 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.311 1.045 . . . . 10.0 111.242 -178.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -67.13 169.57 49.18 Favored 'Cis proline' 0 CA--C 1.539 0.739 0 CA-C-N 121.022 1.401 . . . . 10.0 112.686 -2.055 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.83 120.66 34.67 Favored Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 124.845 1.258 . . . . 10.0 111.478 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.51 159.85 50.14 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.593 2.196 . . . . 10.0 113.45 -173.31 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -66.86 167.49 11.41 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.514 1.526 . . . . 10.0 111.748 167.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.72 107.02 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.708 1.603 . . . . 10.0 110.48 -171.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.0 m -124.62 99.53 6.22 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.418 1.487 . . . . 10.0 111.339 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -81.82 151.83 27.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.051 0.94 . . . . 10.0 113.093 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -140.72 160.24 40.47 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.155 2.182 . . . . 10.0 111.416 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.9 tp -146.56 116.73 7.37 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 127.257 2.223 . . . . 10.0 110.128 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 55.76 12.46 0.85 Allowed 'General case' 0 CA--C 1.556 1.179 0 C-N-CA 126.503 1.921 . . . . 10.0 115.234 -179.556 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.25 -14.76 30.69 Favored Glycine 0 CA--C 1.54 1.611 0 C-N-CA 126.778 2.132 . . . . 10.0 114.959 -176.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -80.9 158.09 25.41 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.996 1.318 . . . . 10.0 110.524 168.432 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 65.8 p -74.4 162.93 28.37 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.408 0.683 . . . . 10.0 111.855 170.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 16.7 t -136.01 137.43 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.378 1.471 . . . . 10.0 109.44 171.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 25.6 mp0 -107.9 156.53 19.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.321 1.449 . . . . 10.0 111.032 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 63.7 p -71.14 155.68 40.47 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.757 0.823 . . . . 10.0 112.316 173.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -153.48 168.91 24.53 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.476 1.51 . . . . 10.0 110.92 177.388 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.66 -35.69 70.89 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 120.832 -1.168 . . . . 10.0 112.655 169.031 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 76.7 mt -81.2 -15.45 55.65 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.527 1.131 . . . . 10.0 113.803 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -135.28 70.41 1.43 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.723 1.609 . . . . 10.0 111.561 -173.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -69.12 136.56 52.41 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.776 1.23 . . . . 10.0 110.478 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 55.6 mtt -134.06 102.46 5.41 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 126.477 1.911 . . . . 10.0 109.357 -173.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.57 162.51 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 125.02 1.328 . . . . 10.0 112.985 -169.619 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 17.7 t -132.42 113.02 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 126.964 2.106 . . . . 10.0 109.538 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.3 t -68.93 146.41 52.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 124.545 1.138 . . . . 10.0 111.937 173.615 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -59.0 -19.59 45.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.803 1.241 . . . . 10.0 113.89 172.084 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -77.7 -3.29 40.37 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.381 1.472 . . . . 10.0 113.99 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.94 49.36 4.31 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.942 1.258 . . . . 10.0 113.014 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -144.74 121.39 11.14 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.863 1.665 . . . . 10.0 109.496 -175.034 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -114.14 157.22 22.9 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.424 0.898 . . . . 10.0 113.424 173.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.4 m -143.36 158.58 43.52 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.766 1.226 . . . . 10.0 113.291 -169.517 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.96 104.96 7.43 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.962 2.105 . . . . 10.0 108.549 171.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -79.4 151.01 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.445 1.098 . . . . 10.0 109.736 177.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -131.6 98.84 4.61 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 126.69 1.996 . . . . 10.0 108.195 167.843 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -62.85 -36.2 82.47 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -178.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.34 83.93 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.142 1.777 . . . . 10.0 109.747 178.728 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.5 p -66.5 141.45 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.246 -0.909 . . . . 10.0 112.014 -175.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 10.6 mmt180 -127.33 160.91 29.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.028 1.731 . . . . 10.0 112.503 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.9 -33.24 61.86 Favored 'General case' 0 CA--C 1.547 0.865 0 N-CA-C 114.131 1.16 . . . . 10.0 114.131 -177.004 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 73.6 m -68.62 -15.62 63.59 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.328 1.233 . . . . 10.0 114.328 175.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -81.47 -6.79 59.31 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.386 1.074 . . . . 10.0 113.236 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.06 149.69 49.43 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 120.931 -1.106 . . . . 10.0 113.017 179.014 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.75 -173.87 22.36 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.812 1.196 . . . . 10.0 114.976 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.21 103.16 13.92 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.069 1.748 . . . . 10.0 111.297 176.772 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 62.7 m-85 -81.04 151.5 28.36 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.0 0.92 . . . . 10.0 112.11 172.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 164.86 29.47 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.223 1.009 . . . . 10.0 112.283 168.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 34.0 t -140.83 117.26 10.77 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.64 1.576 . . . . 10.0 110.643 175.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.8 t -88.3 132.16 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.834 1.253 . . . . 10.0 109.373 170.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -126.58 119.7 27.75 Favored 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 126.459 1.904 . . . . 10.0 110.876 -177.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -131.76 137.11 48.05 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 125.408 1.483 . . . . 10.0 112.32 -170.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.5 p30 -132.53 -177.24 4.39 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.806 1.243 . . . . 10.0 111.572 166.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -59.83 -15.78 23.51 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 115.652 1.723 . . . . 10.0 115.652 -179.28 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -107.97 -20.65 13.11 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.262 1.425 . . . . 10.0 114.192 -176.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.15 -169.7 42.84 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 116.104 1.201 . . . . 10.0 116.104 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -134.67 143.33 47.18 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 127.041 2.136 . . . . 10.0 111.647 -172.37 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -135.93 164.28 28.33 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.013 1.725 . . . . 10.0 111.153 166.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.5 m -140.75 140.22 34.78 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.479 1.111 . . . . 10.0 110.931 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -124.92 153.09 43.21 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.212 1.805 . . . . 10.0 110.437 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 16.1 m -148.41 146.25 28.38 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 124.197 0.999 . . . . 10.0 112.274 -169.553 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.2 p -151.36 171.74 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.538 1.935 . . . . 10.0 110.601 171.102 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -130.95 140.03 50.11 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.841 1.256 . . . . 10.0 110.758 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.9 tp -126.2 110.58 13.62 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.321 1.849 . . . . 10.0 110.695 -176.535 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -97.64 82.56 3.08 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.682 1.593 . . . . 10.0 110.86 175.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.3 114.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.897 0.879 . . . . 10.0 110.779 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 78.3 mt -78.35 93.33 4.66 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 126.279 1.831 . . . . 10.0 110.366 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -63.11 156.59 24.59 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.893 1.277 . . . . 10.0 113.486 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -131.83 -18.12 2.74 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 115.645 1.721 . . . . 10.0 115.645 178.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 124.127 0.971 . . . . 10.0 112.55 166.528 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.58 0 N-CA-C 111.799 -0.521 . . . . 10.0 111.799 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -63.41 153.53 34.96 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.201 1.0 . . . . 10.0 112.714 176.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.74 174.94 12.92 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 126.278 1.831 . . . . 10.0 111.449 -177.101 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.52 171.14 43.39 Favored Glycine 0 CA--C 1.541 1.717 0 N-CA-C 117.063 1.585 . . . . 10.0 117.063 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -73.79 162.84 38.58 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.023 3.149 . . . . 10.0 113.578 -171.088 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -67.56 161.15 44.78 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.116 2.544 . . . . 10.0 112.094 169.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 50.6 ttp180 -144.7 155.55 43.63 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 124.911 1.284 . . . . 10.0 112.649 -173.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -75.15 83.02 2.34 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.915 2.086 . . . . 10.0 111.831 176.741 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.3 mm -79.12 -66.33 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 O-C-N 121.543 -0.723 . . . . 10.0 110.778 177.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -156.24 145.84 20.92 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 124.833 1.253 . . . . 10.0 111.347 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.5 150.93 74.18 Favored Pre-proline 0 N--CA 1.477 0.882 0 C-N-CA 125.77 1.628 . . . . 10.0 110.331 171.206 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_endo -73.38 158.08 48.73 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.817 2.345 . . . . 10.0 112.198 176.108 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -73.81 170.69 14.8 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.928 0.891 . . . . 10.0 111.275 165.845 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.96 155.18 17.21 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.258 -0.901 . . . . 10.0 112.577 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.4 mtp -132.72 159.45 39.65 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.435 1.494 . . . . 10.0 112.341 -171.14 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 58.2 p -142.54 128.0 18.96 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 125.657 1.583 . . . . 10.0 110.288 168.344 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.9 mm -133.73 132.04 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.306 1.442 . . . . 10.0 109.826 -169.531 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -61.79 128.86 38.23 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.12 1.368 . . . . 10.0 112.347 173.517 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.32 132.94 29.34 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.717 1.607 . . . . 10.0 113.268 -177.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.62 -9.18 78.41 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 125.767 1.651 . . . . 10.0 115.277 177.318 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.5 mtp85 -70.22 160.25 32.51 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.185 1.492 . . . . 10.0 113.112 175.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.9 t80 -73.26 138.82 45.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.203 1.001 . . . . 10.0 110.267 154.438 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.28 172.39 15.95 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.797 0.839 . . . . 10.0 112.103 162.278 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -148.43 171.95 15.23 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.857 1.263 . . . . 10.0 113.005 173.351 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 55.2 mtt -132.08 154.93 48.94 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 127.72 2.408 . . . . 10.0 110.105 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -134.98 102.09 5.1 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.655 1.582 . . . . 10.0 112.041 -170.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -107.95 106.68 17.04 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 125.651 1.581 . . . . 10.0 110.126 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -65.54 131.9 47.54 Favored 'General case' 0 N--CA 1.474 0.773 0 O-C-N 121.348 -0.845 . . . . 10.0 109.978 172.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.9 p -137.16 155.95 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 125.771 1.628 . . . . 10.0 111.051 -171.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.4 t -142.84 -170.83 3.32 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.464 1.506 . . . . 10.0 111.737 -176.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 93.86 165.44 37.0 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 126.717 2.103 . . . . 10.0 113.301 -176.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.81 130.98 8.55 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 125.818 1.647 . . . . 10.0 109.363 178.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -67.11 169.95 47.65 Favored 'Cis proline' 0 CA--C 1.541 0.847 0 CA-C-N 120.788 1.317 . . . . 10.0 112.635 -3.215 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.0 123.54 54.06 Favored Pre-proline 0 CA--C 1.55 0.952 0 C-N-CA 124.832 1.253 . . . . 10.0 111.209 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.4 150.6 58.53 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 122.324 2.016 . . . . 10.0 114.081 -168.577 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -68.99 117.28 10.44 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.09 1.756 . . . . 10.0 109.485 160.623 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -114.71 86.74 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.654 1.582 . . . . 10.0 111.917 -169.42 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.8 m -72.3 157.48 37.61 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.913 0.885 . . . . 10.0 111.742 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 62.0 m95 -131.24 155.33 47.3 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.914 1.286 . . . . 10.0 112.828 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -146.29 159.52 43.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.435 1.894 . . . . 10.0 111.488 -175.049 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.4 tp -147.59 121.58 9.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.15 2.18 . . . . 10.0 110.047 176.347 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 54.18 17.35 1.44 Allowed 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 126.466 1.906 . . . . 10.0 115.241 178.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.46 -7.09 42.57 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 126.181 1.848 . . . . 10.0 115.416 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.8 mtt85 -98.2 161.45 13.7 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.458 1.503 . . . . 10.0 111.219 171.124 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.7 p -71.56 156.74 39.07 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.535 1.134 . . . . 10.0 113.003 176.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 80.5 t -134.33 141.84 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 127.101 2.16 . . . . 10.0 108.551 170.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -126.18 161.9 26.62 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.228 1.411 . . . . 10.0 111.354 -177.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 55.6 p -68.36 150.14 48.54 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.548 0.739 . . . . 10.0 112.304 174.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -152.68 167.68 28.14 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.826 1.65 . . . . 10.0 110.723 176.72 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.34 -34.53 66.66 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 121.003 -1.06 . . . . 10.0 112.883 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.3 mt -86.39 -12.94 47.8 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.671 1.188 . . . . 10.0 113.91 174.282 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.9 m80 -136.39 71.02 1.41 Allowed 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.579 1.551 . . . . 10.0 111.271 -173.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.9 mttt -71.55 144.83 49.42 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.684 1.194 . . . . 10.0 111.574 -176.006 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 64.6 mtt -137.75 104.93 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.897 2.079 . . . . 10.0 109.602 -176.016 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.3 157.14 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 124.175 0.99 . . . . 10.0 112.616 -177.653 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.58 108.17 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 126.54 1.936 . . . . 10.0 110.752 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 41.7 t -64.8 142.17 58.52 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.75 0.82 . . . . 10.0 111.573 174.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -60.11 -18.44 47.29 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.752 1.221 . . . . 10.0 113.705 172.359 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -77.51 -3.6 41.38 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.935 1.694 . . . . 10.0 113.849 173.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.0 45.64 4.73 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.155 1.359 . . . . 10.0 113.694 177.751 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.4 108.28 8.07 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 125.306 1.443 . . . . 10.0 110.478 -177.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.4 t60 -83.31 108.68 16.68 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.141 0.977 . . . . 10.0 111.155 170.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 23.8 m -85.02 136.18 33.7 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.52 1.128 . . . . 10.0 111.585 169.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -128.56 119.33 24.59 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 127.096 2.158 . . . . 10.0 107.918 174.311 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.6 mt -116.68 152.4 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.762 1.225 . . . . 10.0 111.576 -166.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -129.4 107.97 9.92 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.5 2.32 . . . . 10.0 109.187 169.317 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.04 -37.99 85.06 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.219 -0.925 . . . . 10.0 112.961 176.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.3 p -151.88 83.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.68 1.592 . . . . 10.0 110.353 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -68.48 143.9 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 O-C-N 121.178 -0.951 . . . . 10.0 112.291 -176.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -126.13 163.33 23.34 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 126.222 1.809 . . . . 10.0 112.276 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.3 -30.8 65.05 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.715 1.006 . . . . 10.0 113.715 -178.243 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.9 p -67.96 -16.63 64.14 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.673 1.589 . . . . 10.0 114.707 173.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -82.73 -5.97 59.16 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 124.691 1.196 . . . . 10.0 113.354 175.437 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.33 152.09 45.73 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.035 -1.041 . . . . 10.0 113.082 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.77 -170.56 22.01 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.881 1.229 . . . . 10.0 114.937 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.0 104.56 14.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.025 1.73 . . . . 10.0 111.402 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -80.06 153.11 28.99 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.415 1.086 . . . . 10.0 112.029 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.93 159.9 41.35 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.947 0.899 . . . . 10.0 112.207 167.26 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -132.51 145.15 50.93 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.346 1.858 . . . . 10.0 110.031 176.483 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 45.3 t -130.14 102.1 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.119 1.368 . . . . 10.0 109.812 -179.657 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.46 125.41 33.01 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 126.649 1.98 . . . . 10.0 111.245 176.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 22.7 mtmt -131.63 131.72 43.43 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.181 1.792 . . . . 10.0 111.996 -175.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.5 p30 -137.15 -179.1 5.51 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 123.461 0.704 . . . . 10.0 112.078 162.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.1 ptp180 -59.6 -14.41 13.36 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 115.763 1.764 . . . . 10.0 115.763 -177.571 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.3 -15.08 14.56 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.207 1.403 . . . . 10.0 114.402 -178.669 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.34 -173.5 42.48 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 119.587 1.085 . . . . 10.0 115.709 178.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -134.86 146.99 49.76 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.515 1.926 . . . . 10.0 111.455 -174.275 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.25 155.94 48.16 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.795 1.638 . . . . 10.0 111.12 170.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.7 m -135.36 131.45 36.37 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.769 1.228 . . . . 10.0 110.753 -173.397 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -126.17 157.25 38.63 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.364 1.466 . . . . 10.0 111.219 -176.407 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 20.5 m -146.13 146.34 30.83 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.37 1.068 . . . . 10.0 111.931 -169.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.4 p -152.32 165.81 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 C-N-CA 126.245 1.818 . . . . 10.0 110.629 170.391 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -126.29 139.17 53.52 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.82 1.248 . . . . 10.0 110.956 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 54.5 tp -126.74 113.12 16.23 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.979 1.712 . . . . 10.0 110.969 -177.323 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -98.9 85.21 3.23 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.638 1.575 . . . . 10.0 110.964 175.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.0 t -66.96 114.23 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.899 0.88 . . . . 10.0 110.82 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.4 mt -78.33 98.29 5.9 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.387 1.875 . . . . 10.0 110.516 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -64.62 158.43 24.42 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 124.354 1.061 . . . . 10.0 113.577 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -130.97 17.25 5.11 Favored 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 125.85 1.66 . . . . 10.0 114.85 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? . . . . . 0 C--O 1.253 1.272 0 C-N-CA 126.526 1.93 . . . . 10.0 114.874 173.277 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.545 0 N-CA-C 111.722 -0.551 . . . . 10.0 111.722 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.96 162.47 19.18 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.394 1.078 . . . . 10.0 113.064 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.6 174.58 11.3 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 126.407 1.883 . . . . 10.0 111.399 179.829 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.92 176.12 47.86 Favored Glycine 0 CA--C 1.541 1.695 0 N-CA-C 117.03 1.572 . . . . 10.0 117.03 -176.421 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -67.04 157.19 62.91 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 123.361 2.707 . . . . 10.0 112.633 -173.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.01 159.99 51.71 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.619 2.212 . . . . 10.0 112.218 176.503 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -112.35 169.05 9.15 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.752 1.621 . . . . 10.0 112.989 -172.01 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -108.7 97.55 7.18 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.798 2.039 . . . . 10.0 109.417 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 253' ' ' ILE . . . . . 0.512 HG22 ' H ' ' A' ' 254' ' ' GLN . 1.1 mp -115.37 171.41 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 126.245 1.818 . . . . 10.0 109.868 -174.133 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.512 ' H ' HG22 ' A' ' 253' ' ' ILE . 6.5 tm0? -44.34 122.08 2.85 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.692 2.397 . . . . 10.0 114.655 -173.163 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.7 m -107.69 158.86 32.29 Favored Pre-proline 0 N--CA 1.476 0.867 0 C-N-CA 127.508 2.323 . . . . 10.0 110.461 172.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -73.6 159.0 46.78 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.456 2.104 . . . . 10.0 111.697 173.356 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -71.41 172.5 9.34 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 123.71 0.804 . . . . 10.0 111.125 165.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.3 p30 -59.0 151.62 21.67 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 121.109 -0.994 . . . . 10.0 112.067 173.132 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.8 mtp -134.11 158.18 44.28 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.184 1.394 . . . . 10.0 111.961 -171.107 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 61.3 p -141.86 131.28 23.74 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 125.483 1.513 . . . . 10.0 110.823 173.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.3 mm -136.57 133.82 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.54 1.536 . . . . 10.0 109.557 -169.376 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -65.11 131.33 46.25 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.408 1.083 . . . . 10.0 112.428 175.025 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -51.61 123.44 9.99 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.607 1.563 . . . . 10.0 113.045 -179.22 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 102.9 -10.39 55.63 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 126.285 1.898 . . . . 10.0 115.106 178.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.7 mtp180 -72.94 160.93 31.34 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 119.127 1.464 . . . . 10.0 113.398 177.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -72.3 148.94 44.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.866 1.266 . . . . 10.0 110.632 157.647 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 45.4 t -149.48 156.05 41.38 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.763 1.225 . . . . 10.0 111.087 169.729 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -146.35 163.14 36.52 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.605 1.162 . . . . 10.0 112.675 165.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 59.0 mtt -137.51 121.72 18.04 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.784 1.634 . . . . 10.0 111.661 -173.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 26.1 m-20 -80.73 117.9 21.8 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 126.363 1.865 . . . . 10.0 112.353 175.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -128.13 105.46 8.39 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 125.373 1.469 . . . . 10.0 111.448 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -65.78 131.73 47.02 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 121.253 -0.904 . . . . 10.0 111.131 175.328 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.39 133.2 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.157 1.783 . . . . 10.0 110.73 -177.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -146.86 157.15 43.58 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.599 1.159 . . . . 10.0 111.536 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 149.13 165.52 12.37 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 128.178 2.799 . . . . 10.0 111.332 -173.671 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.0 tp -146.69 125.33 6.31 Favored Pre-proline 0 CA--C 1.546 0.816 0 CA-C-O 118.106 -0.949 . . . . 10.0 111.137 179.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -66.46 167.87 52.77 Favored 'Cis proline' 0 CA--C 1.538 0.708 0 CA-C-N 120.937 1.37 . . . . 10.0 112.669 -1.129 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.17 121.46 41.9 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.787 1.235 . . . . 10.0 111.341 -178.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -70.52 153.56 65.33 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 122.474 2.116 . . . . 10.0 113.196 -172.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -74.54 141.87 44.79 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.378 1.071 . . . . 10.0 109.55 159.021 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 47.8 t -130.94 131.7 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.262 1.025 . . . . 10.0 111.475 -170.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.1 m -131.73 156.7 45.46 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.865 1.666 . . . . 10.0 111.966 177.189 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -123.56 155.45 37.6 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.214 1.405 . . . . 10.0 113.177 -177.634 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -145.01 160.74 40.89 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 127.142 2.177 . . . . 10.0 111.572 -173.402 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -145.64 118.08 8.5 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 127.346 2.258 . . . . 10.0 109.905 176.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 54.72 16.24 1.33 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 126.318 1.847 . . . . 10.0 114.793 -179.217 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.96 -12.65 45.41 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.689 2.09 . . . . 10.0 115.24 -177.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -84.99 158.11 20.59 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 125.088 1.355 . . . . 10.0 110.698 170.269 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.4 p -72.1 157.11 38.38 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.882 0.873 . . . . 10.0 112.611 174.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 55.0 t -133.86 93.29 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.446 1.898 . . . . 10.0 108.74 173.187 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 60.8 mt-30 -68.51 155.09 40.61 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.615 0.766 . . . . 10.0 111.223 172.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.2 p -71.12 155.94 40.18 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-O 121.832 0.825 . . . . 10.0 112.327 171.525 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -155.07 170.16 22.44 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 126.68 1.992 . . . . 10.0 110.668 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.95 -34.5 65.72 Favored 'General case' 0 CA--C 1.546 0.805 0 O-C-N 120.568 -1.333 . . . . 10.0 112.828 169.12 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 66.8 mt -86.08 -13.25 47.87 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.755 1.222 . . . . 10.0 114.289 176.385 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -138.56 91.84 2.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.509 1.524 . . . . 10.0 111.122 -173.01 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.4 mttt -95.66 145.06 25.56 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.466 1.106 . . . . 10.0 111.494 -174.26 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -139.74 104.01 4.8 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 127.031 2.133 . . . . 10.0 109.621 -178.037 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.58 162.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.119 1.368 . . . . 10.0 111.728 177.709 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.13 133.68 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 126.147 1.779 . . . . 10.0 109.664 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 60.3 p -66.22 170.59 5.64 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.265 1.026 . . . . 10.0 113.561 176.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -68.99 -4.44 16.81 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.455 1.102 . . . . 10.0 113.886 166.65 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -109.07 -3.64 17.23 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 126.488 1.915 . . . . 10.0 114.134 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 87.55 40.75 6.7 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 124.509 1.052 . . . . 10.0 114.048 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 41.7 tp -124.52 106.81 10.45 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.313 1.445 . . . . 10.0 110.395 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 13.7 t60 -72.75 142.81 48.14 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.633 0.773 . . . . 10.0 111.19 173.122 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 55.1 m -123.55 97.06 5.22 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 126.865 2.066 . . . . 10.0 110.552 175.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -83.03 123.06 29.11 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 125.112 1.365 . . . . 10.0 108.662 169.161 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 37.1 mt -124.94 149.26 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 125.129 1.371 . . . . 10.0 111.705 -169.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -127.1 113.85 16.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 128.362 2.665 . . . . 10.0 109.481 171.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -69.21 -41.52 76.97 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.033 -1.042 . . . . 10.0 112.913 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.57 88.91 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.72 1.608 . . . . 10.0 110.345 -176.277 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.7 p -70.59 141.49 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.219 -0.925 . . . . 10.0 112.252 -176.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -123.18 162.54 22.34 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.556 1.942 . . . . 10.0 112.045 176.282 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.69 -34.41 65.04 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.463 0.912 . . . . 10.0 113.463 -178.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 24.9 m -64.59 -17.71 64.22 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.386 1.474 . . . . 10.0 114.508 175.508 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -83.46 -6.16 59.37 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.637 1.175 . . . . 10.0 113.383 178.398 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.84 151.21 46.06 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 121.057 -1.027 . . . . 10.0 112.986 178.357 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.51 -171.55 22.87 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.746 1.165 . . . . 10.0 114.881 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.78 101.33 11.52 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.858 1.663 . . . . 10.0 111.314 176.334 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -75.96 148.65 37.99 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.807 0.843 . . . . 10.0 111.661 169.038 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.83 156.84 46.05 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.852 0.861 . . . . 10.0 112.074 170.282 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.2 t -132.18 140.56 48.78 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 126.865 2.066 . . . . 10.0 109.411 -179.056 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 61.2 t -130.6 125.41 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 125.147 1.379 . . . . 10.0 109.311 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -118.55 125.02 48.92 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.149 1.78 . . . . 10.0 110.542 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -133.03 133.27 42.84 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 125.568 1.547 . . . . 10.0 112.215 -170.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -131.06 -177.74 4.52 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.693 1.197 . . . . 10.0 111.737 168.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.9 ptm180 -59.52 -14.82 14.41 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 115.702 1.742 . . . . 10.0 115.702 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.96 -17.88 13.19 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.524 1.53 . . . . 10.0 114.331 -176.286 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.75 -169.22 42.32 Favored Glycine 0 CA--C 1.534 1.243 0 N-CA-C 116.175 1.23 . . . . 10.0 116.175 178.226 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -133.65 144.42 49.19 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 127.331 2.252 . . . . 10.0 111.498 -173.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.94 157.71 46.19 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.009 1.724 . . . . 10.0 111.278 170.067 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 62.1 m -137.88 145.06 41.7 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.996 1.318 . . . . 10.0 111.408 -173.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -136.63 152.89 50.93 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.191 1.796 . . . . 10.0 110.478 -179.421 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 22.6 m -145.36 147.35 32.19 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.042 0.937 . . . . 10.0 112.252 -170.649 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.5 p -151.98 160.87 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 126.308 1.843 . . . . 10.0 111.039 169.312 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.2 tt0 -116.96 134.96 54.09 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 124.972 1.309 . . . . 10.0 110.912 173.103 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.8 tp -121.02 111.21 17.2 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.022 1.729 . . . . 10.0 110.875 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -97.32 85.88 3.77 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 125.777 1.631 . . . . 10.0 110.968 175.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.1 t -67.04 112.97 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.764 0.826 . . . . 10.0 110.736 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.0 mt -76.03 99.53 4.63 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.214 1.806 . . . . 10.0 110.101 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.94 150.44 33.3 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.109 0.964 . . . . 10.0 112.976 -179.307 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -77.17 -12.82 59.99 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 114.802 1.408 . . . . 10.0 114.802 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 29.8 mm-40 . . . . . 0 C--O 1.253 1.253 0 C-N-CA 126.888 2.075 . . . . 10.0 113.824 179.304 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.505 0 N-CA-C 111.118 -0.793 . . . . 10.0 111.118 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.16 165.68 10.92 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.372 1.069 . . . . 10.0 112.93 174.96 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -143.0 172.95 12.0 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 125.99 1.716 . . . . 10.0 111.752 -177.194 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.77 173.76 46.31 Favored Glycine 0 CA--C 1.542 1.779 0 N-CA-C 116.849 1.5 . . . . 10.0 116.849 -175.994 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -69.84 159.58 52.83 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 123.661 2.907 . . . . 10.0 113.366 -171.714 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.45 164.82 32.77 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.32 2.68 . . . . 10.0 111.787 169.98 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.6 ttt180 -143.4 158.02 43.98 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.4 1.08 . . . . 10.0 112.366 -173.233 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -82.77 69.7 9.61 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.681 1.992 . . . . 10.0 112.516 -171.258 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 253' ' ' ILE . . . . . 0.566 HG22 ' H ' ' A' ' 254' ' ' GLN . 2.7 mm -77.88 175.34 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.231 0 C-N-CA 124.338 1.055 . . . . 10.0 110.865 175.624 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.566 ' H ' HG22 ' A' ' 253' ' ' ILE . 47.4 tt0 -48.72 115.42 1.25 Allowed 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 128.302 2.641 . . . . 10.0 115.259 -173.651 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.7 m -78.4 153.7 79.1 Favored Pre-proline 0 N--CA 1.479 0.999 0 C-N-CA 124.927 1.291 . . . . 10.0 111.552 162.439 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -76.31 166.85 26.87 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 123.267 2.645 . . . . 10.0 111.714 169.132 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.42 164.91 26.03 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.311 -0.868 . . . . 10.0 111.887 169.097 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -63.46 162.22 12.98 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.601 0.76 . . . . 10.0 112.634 172.625 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.6 mtm -134.11 161.43 34.9 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.373 1.069 . . . . 10.0 113.228 -178.234 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -140.15 90.14 2.35 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.887 2.075 . . . . 10.0 110.477 177.411 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 41.7 mm -103.87 138.23 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 124.697 1.199 . . . . 10.0 111.184 -166.797 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -68.83 130.06 41.71 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.108 0.963 . . . . 10.0 112.355 174.613 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -53.23 125.79 18.78 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.448 1.499 . . . . 10.0 112.824 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.95 -8.74 61.38 Favored Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.185 1.85 . . . . 10.0 115.115 -179.234 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.7 mtp85 -74.35 159.79 31.91 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 119.489 1.644 . . . . 10.0 113.102 175.103 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -76.75 141.01 40.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.453 1.101 . . . . 10.0 110.207 156.368 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 31.1 p -150.22 173.61 13.74 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.733 0.813 . . . . 10.0 112.353 162.436 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -145.95 167.89 22.21 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 125.682 1.593 . . . . 10.0 112.356 175.342 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -126.48 159.78 32.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.531 1.933 . . . . 10.0 110.772 172.427 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -137.43 96.87 3.34 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.448 1.499 . . . . 10.0 111.504 -167.862 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.13 111.39 22.71 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.678 1.591 . . . . 10.0 111.126 -177.037 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 90.7 mttt -66.38 147.35 53.43 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 121.111 -0.993 . . . . 10.0 110.272 169.438 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -150.78 159.95 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.232 1.413 . . . . 10.0 111.458 -175.669 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -143.53 -176.88 5.13 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.648 1.579 . . . . 10.0 111.854 178.102 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.22 161.43 23.53 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.251 2.358 . . . . 10.0 113.481 -178.161 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.9 tp -149.7 130.87 7.25 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 125.124 1.37 . . . . 10.0 110.282 179.823 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -66.0 168.97 45.62 Favored 'Cis proline' 0 CA--C 1.539 0.742 0 CA-C-N 121.194 1.462 . . . . 10.0 112.56 -2.958 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 121.54 41.15 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 124.783 1.233 . . . . 10.0 111.403 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 151.49 66.55 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.517 2.144 . . . . 10.0 113.102 -173.152 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -71.68 143.57 49.66 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.157 0.983 . . . . 10.0 109.783 160.357 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.64 87.53 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.081 1.353 . . . . 10.0 111.83 -166.073 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 62.5 m -77.08 113.72 15.12 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.549 1.14 . . . . 10.0 111.177 176.318 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -91.17 153.12 20.26 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.19 0.996 . . . . 10.0 113.186 176.481 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -144.11 159.92 41.79 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.658 1.983 . . . . 10.0 111.995 -176.512 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.2 tp -146.02 119.25 8.9 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 127.511 2.325 . . . . 10.0 110.022 176.236 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 54.9 14.14 0.86 Allowed 'General case' 0 CA--C 1.555 1.148 0 C-N-CA 126.419 1.887 . . . . 10.0 115.309 179.221 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.44 -12.19 36.27 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.602 2.049 . . . . 10.0 115.165 -177.345 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -87.95 158.07 18.77 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.974 1.387 . . . . 10.0 110.976 170.097 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.6 p -71.6 156.78 39.01 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.357 1.063 . . . . 10.0 112.656 173.627 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.85 105.94 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 126.373 1.869 . . . . 10.0 108.866 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 63.0 mt-30 -74.31 159.36 32.52 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.458 0.703 . . . . 10.0 111.394 171.929 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.0 p -69.07 155.92 39.54 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.514 0.726 . . . . 10.0 112.036 169.647 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -153.13 168.55 25.56 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.26 1.424 . . . . 10.0 110.891 175.634 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -57.23 -35.98 70.36 Favored 'General case' 0 CA--C 1.546 0.797 0 O-C-N 120.857 -1.152 . . . . 10.0 112.548 168.692 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.9 mt -80.19 -17.79 51.4 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 124.537 1.135 . . . . 10.0 113.804 173.886 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -134.46 70.51 1.45 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.18 1.792 . . . . 10.0 111.205 -172.186 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -73.16 142.43 47.43 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.4 1.48 . . . . 10.0 111.046 -173.199 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.8 mtt -136.48 98.7 3.89 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.249 1.82 . . . . 10.0 110.074 -174.427 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.09 159.86 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.363 1.465 . . . . 10.0 111.636 -177.034 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.38 122.57 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.753 1.221 . . . . 10.0 111.504 -177.85 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 67.6 m -69.63 148.6 49.12 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.508 1.123 . . . . 10.0 112.016 177.293 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 19.4 tp10 -55.8 -34.78 65.62 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.656 1.583 . . . . 10.0 113.396 -177.663 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -78.41 0.38 25.95 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 126.082 1.753 . . . . 10.0 114.574 179.369 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.49 50.23 1.88 Allowed Glycine 0 CA--C 1.532 1.133 0 C-N-CA 124.833 1.206 . . . . 10.0 114.841 170.19 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 54.4 tp -133.51 106.5 7.48 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.155 1.382 . . . . 10.0 111.056 176.696 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -86.45 118.37 25.84 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.954 1.701 . . . . 10.0 111.365 177.484 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -91.71 144.93 25.01 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.903 1.681 . . . . 10.0 112.224 173.658 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -138.21 115.73 11.26 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 126.439 1.896 . . . . 10.0 108.669 173.569 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 154.19 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 C-N-CA 125.36 1.464 . . . . 10.0 111.42 -170.832 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -131.74 108.36 9.41 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 127.007 2.123 . . . . 10.0 109.599 163.565 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 36.5 mm-40 -65.06 -45.32 85.82 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 113.898 1.073 . . . . 10.0 113.898 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.61 70.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 CA-C-O 122.614 1.197 . . . . 10.0 111.344 -172.506 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.96 142.23 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.025 1.33 . . . . 10.0 113.502 -170.0 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.2 mmt-85 -120.64 162.07 20.29 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 126.5 1.92 . . . . 10.0 112.323 177.04 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.11 -31.32 61.15 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.265 1.026 . . . . 10.0 113.613 177.239 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 43.2 p -67.8 -17.12 64.42 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.539 1.536 . . . . 10.0 114.806 174.287 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -83.31 -7.39 59.59 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.54 1.136 . . . . 10.0 113.409 175.823 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 149.68 49.71 Favored 'General case' 0 CA--C 1.547 0.85 0 O-C-N 120.958 -1.089 . . . . 10.0 112.988 179.38 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.1 -173.44 23.27 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.806 1.193 . . . . 10.0 115.076 176.077 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 106.53 14.8 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.855 1.662 . . . . 10.0 111.094 175.063 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -84.01 150.43 25.62 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 124.347 1.059 . . . . 10.0 111.921 172.902 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.56 162.18 37.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.946 0.898 . . . . 10.0 112.268 170.516 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.3 t -139.01 140.42 38.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.581 1.552 . . . . 10.0 110.487 175.065 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 43.6 t -121.38 104.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.837 1.655 . . . . 10.0 109.07 179.395 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -86.3 122.0 29.67 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.278 1.831 . . . . 10.0 111.078 178.396 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -132.35 132.58 43.04 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.421 1.488 . . . . 10.0 112.224 -177.184 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.2 p30 -130.97 -177.95 4.6 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.488 1.115 . . . . 10.0 111.646 167.085 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.8 ptp180 -59.47 -12.71 6.71 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 115.922 1.823 . . . . 10.0 115.922 -179.37 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -113.52 -16.82 12.34 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 125.382 1.473 . . . . 10.0 114.557 -177.048 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.17 -169.27 42.34 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 120.022 1.283 . . . . 10.0 116.224 178.876 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -135.96 144.06 45.2 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.093 2.157 . . . . 10.0 111.997 -172.311 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.78 161.96 36.3 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.111 1.764 . . . . 10.0 111.151 168.587 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -137.65 144.17 41.74 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.319 1.048 . . . . 10.0 111.599 -172.31 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -134.52 152.38 51.75 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.189 1.796 . . . . 10.0 110.86 -178.214 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 15.4 m -147.85 146.18 29.0 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.525 1.13 . . . . 10.0 111.942 -173.027 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.9 p -153.45 174.21 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 126.49 1.916 . . . . 10.0 110.781 171.838 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -129.63 144.31 51.22 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.689 1.196 . . . . 10.0 111.51 172.773 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.0 tp -128.77 109.12 11.02 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.304 1.842 . . . . 10.0 109.997 179.386 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -79.4 147.0 32.51 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 121.938 -0.477 . . . . 10.0 110.029 158.406 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 30.1 t -128.43 106.83 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.124 0.97 . . . . 10.0 109.344 175.352 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.8 101.99 2.24 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.282 1.833 . . . . 10.0 109.659 -178.926 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.96 151.99 24.8 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 124.191 0.996 . . . . 10.0 113.22 -175.75 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 29.0 tptp -66.54 -40.91 89.32 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.857 1.263 . . . . 10.0 113.018 -178.042 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 . . . . . 0 C--O 1.253 1.243 0 C-N-CA 125.928 1.691 . . . . 10.0 113.09 176.731 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.501 0 N-CA-C 111.619 -0.592 . . . . 10.0 111.619 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.39 162.82 19.59 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.338 1.055 . . . . 10.0 113.161 176.898 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.94 173.25 12.6 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.4 1.88 . . . . 10.0 111.136 178.882 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.97 173.93 46.09 Favored Glycine 0 CA--C 1.541 1.695 0 N-CA-C 117.225 1.65 . . . . 10.0 117.225 -175.296 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -71.9 162.93 40.44 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 123.945 3.096 . . . . 10.0 113.483 -171.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -66.88 156.23 67.11 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 C-N-CA 122.933 2.422 . . . . 10.0 112.021 170.888 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.2 ttt85 -146.43 150.48 35.71 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.554 1.142 . . . . 10.0 112.568 -173.374 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -77.59 82.49 4.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.058 2.143 . . . . 10.0 111.65 178.098 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.0 mm -74.89 -56.94 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.613 -0.679 . . . . 10.0 110.502 173.971 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -154.9 143.49 20.61 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.819 1.248 . . . . 10.0 111.44 176.711 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.39 151.84 79.48 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 126.053 1.741 . . . . 10.0 110.112 171.068 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.01 154.9 47.9 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.929 2.419 . . . . 10.0 112.132 175.736 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -75.63 171.15 14.81 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.353 1.061 . . . . 10.0 112.318 167.948 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -62.5 153.3 32.08 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 121.269 -0.894 . . . . 10.0 112.607 176.757 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 73.8 mtp -133.16 157.45 45.31 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.042 1.337 . . . . 10.0 112.408 -169.701 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -141.27 112.79 7.56 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.524 1.53 . . . . 10.0 111.036 178.755 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 33.2 mm -129.94 128.3 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 125.049 1.339 . . . . 10.0 110.949 -164.68 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -60.37 131.5 50.98 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.083 1.353 . . . . 10.0 112.661 173.864 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -54.44 136.2 44.52 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.886 1.275 . . . . 10.0 113.001 -177.768 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.76 -6.7 81.95 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.649 1.595 . . . . 10.0 115.312 177.683 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -71.87 158.31 36.28 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 118.944 1.372 . . . . 10.0 112.892 175.783 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -70.65 143.37 51.43 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.316 1.046 . . . . 10.0 109.968 155.1 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.6 t -147.62 165.58 29.96 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.245 1.018 . . . . 10.0 111.634 172.7 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -148.04 159.06 44.3 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.721 1.208 . . . . 10.0 112.868 168.544 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -130.1 151.12 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 126.678 1.991 . . . . 10.0 109.431 170.405 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -143.41 125.6 15.49 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.254 1.021 . . . . 10.0 111.442 -173.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -121.72 156.72 32.5 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.55 2.34 . . . . 10.0 110.196 -175.634 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -114.11 104.06 11.75 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.773 1.229 . . . . 10.0 110.198 175.836 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 43.8 t -109.38 99.15 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.462 1.905 . . . . 10.0 110.021 -170.316 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.5 t -73.44 -175.24 1.89 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.093 0.957 . . . . 10.0 112.527 174.106 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 109.79 155.88 15.91 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 127.312 2.386 . . . . 10.0 113.592 176.379 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 19.2 tp -147.48 125.31 5.92 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.531 . . . . 10.0 109.664 178.513 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.47 169.05 47.71 Favored 'Cis proline' 0 CA--C 1.541 0.834 0 CA-C-N 120.8 1.322 . . . . 10.0 112.567 -2.602 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.36 68.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 C-N-CA 124.205 1.002 . . . . 10.0 111.387 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.81 150.68 68.24 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.476 2.117 . . . . 10.0 113.14 -173.57 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -69.65 142.03 53.51 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.032 1.333 . . . . 10.0 110.431 165.113 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 55.9 t -117.16 126.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.723 1.609 . . . . 10.0 111.269 -167.977 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.3 m -134.31 106.47 7.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.635 1.574 . . . . 10.0 111.004 175.337 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -82.25 153.59 25.82 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.913 0.885 . . . . 10.0 113.044 176.064 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -142.86 160.44 40.33 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 127.286 2.235 . . . . 10.0 111.378 179.718 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.1 tp -146.4 119.08 8.57 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 127.223 2.209 . . . . 10.0 109.974 175.196 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 54.76 17.15 1.64 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 126.442 1.897 . . . . 10.0 115.014 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.94 -12.87 49.63 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.518 2.009 . . . . 10.0 115.117 -178.236 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.7 mtt85 -84.94 155.72 21.52 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.923 1.362 . . . . 10.0 110.78 169.077 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.5 p -69.84 157.67 36.96 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.02 0.928 . . . . 10.0 112.52 173.275 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 81.9 t -132.34 143.39 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.667 1.987 . . . . 10.0 108.875 172.442 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -132.85 155.3 49.24 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.629 1.572 . . . . 10.0 110.541 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.0 p -72.43 149.09 44.55 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 123.67 0.788 . . . . 10.0 112.851 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -154.62 -173.11 4.44 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.529 1.932 . . . . 10.0 111.322 175.312 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -60.53 -18.72 53.97 Favored 'General case' 0 CA--C 1.549 0.932 0 N-CA-C 114.84 1.422 . . . . 10.0 114.84 -178.693 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 59.9 mt -113.64 -16.82 12.27 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.556 1.943 . . . . 10.0 113.541 -179.587 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -122.25 98.34 5.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 126.798 2.039 . . . . 10.0 110.339 -178.815 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.96 109.77 19.41 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 124.536 1.134 . . . . 10.0 110.857 -168.384 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 5.1 mpp? -116.31 110.22 18.44 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.992 1.717 . . . . 10.0 110.718 -175.968 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.09 161.46 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.975 1.71 . . . . 10.0 112.096 -172.642 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.1 t -131.22 118.57 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 125.568 1.547 . . . . 10.0 110.238 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 14.5 t -67.55 163.18 21.74 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 124.793 1.237 . . . . 10.0 112.551 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -57.53 -30.52 65.24 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.635 1.574 . . . . 10.0 113.139 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 11.3 mmpt? -86.02 0.11 54.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.922 1.689 . . . . 10.0 114.604 178.356 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.01 6.36 71.98 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 124.896 1.236 . . . . 10.0 114.894 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.54 105.67 1.92 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.579 1.152 . . . . 10.0 109.453 170.329 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.0 t60 -95.8 114.44 26.17 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.612 1.565 . . . . 10.0 111.061 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 41.2 m -101.57 151.02 22.48 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.847 1.259 . . . . 10.0 112.477 -179.782 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -135.81 103.24 5.33 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.439 2.296 . . . . 10.0 108.368 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.32 139.65 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.57 1.148 . . . . 10.0 110.263 -179.524 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -115.14 105.61 13.12 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 127.922 2.489 . . . . 10.0 109.152 171.444 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -64.61 -40.4 95.43 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 120.995 -1.066 . . . . 10.0 113.339 -179.789 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.04 93.22 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.635 1.574 . . . . 10.0 110.402 179.951 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.88 142.47 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.354 -0.842 . . . . 10.0 112.118 -177.548 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -123.08 160.21 26.88 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.145 1.778 . . . . 10.0 112.038 175.393 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.74 -31.87 64.98 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.989 1.107 . . . . 10.0 113.989 -175.2 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.2 t -65.9 -20.85 66.36 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.005 1.322 . . . . 10.0 113.958 175.582 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -78.41 -4.22 47.16 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.908 1.283 . . . . 10.0 113.685 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 155.3 36.61 Favored 'General case' 0 CA--C 1.547 0.84 0 N-CA-C 113.669 0.988 . . . . 10.0 113.669 178.362 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.6 -167.52 17.96 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.933 1.254 . . . . 10.0 114.909 174.312 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.05 105.3 14.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.91 1.684 . . . . 10.0 111.686 179.463 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.6 m-85 -79.58 151.15 30.81 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.311 1.044 . . . . 10.0 111.576 168.633 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.68 159.96 41.54 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.837 0.855 . . . . 10.0 112.226 169.084 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.6 t -137.49 103.95 5.21 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.806 1.642 . . . . 10.0 110.596 -179.501 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 90.0 t -74.95 130.03 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.432 1.093 . . . . 10.0 109.402 170.093 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.93 118.76 24.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.7 2.0 . . . . 10.0 110.259 178.825 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.9 mtpp -131.76 133.48 44.81 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.969 1.307 . . . . 10.0 112.553 -173.112 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.5 p30 -131.55 -178.91 5.07 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.497 1.119 . . . . 10.0 111.73 167.182 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -60.63 -11.84 8.45 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 115.798 1.777 . . . . 10.0 115.798 -179.101 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.1 -15.11 13.32 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.296 1.438 . . . . 10.0 114.547 -178.378 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.21 -169.57 41.06 Favored Glycine 0 CA--C 1.534 1.256 0 N-CA-C 116.025 1.17 . . . . 10.0 116.025 177.479 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -135.83 145.79 46.83 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.917 2.087 . . . . 10.0 112.002 -169.383 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.91 158.98 43.21 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.393 1.877 . . . . 10.0 110.632 166.017 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.9 m -140.03 100.23 3.87 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.781 1.232 . . . . 10.0 110.414 176.697 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -79.78 154.67 28.32 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.604 1.162 . . . . 10.0 111.187 177.289 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 32.0 m -144.64 145.41 31.74 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 124.456 1.102 . . . . 10.0 111.748 -172.996 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.92 165.77 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 126.324 1.85 . . . . 10.0 110.559 171.86 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -128.84 140.44 51.7 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.729 1.211 . . . . 10.0 111.549 177.255 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 53.1 tp -128.63 110.45 12.24 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.02 1.728 . . . . 10.0 111.951 -176.905 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -87.78 89.88 8.16 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.155 1.382 . . . . 10.0 110.843 169.757 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.58 106.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.031 -1.043 . . . . 10.0 109.614 174.131 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.3 mt -72.56 97.91 2.21 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.116 1.766 . . . . 10.0 109.873 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.48 145.73 47.33 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 124.522 1.129 . . . . 10.0 113.399 -175.918 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -93.47 -14.4 26.75 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 114.907 1.447 . . . . 10.0 114.907 179.012 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 . . . . . 0 C--O 1.253 1.243 0 C-N-CA 125.987 1.715 . . . . 10.0 113.454 177.615 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.522 0 N-CA-C 111.541 -0.624 . . . . 10.0 111.541 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.97 160.9 22.56 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.287 1.035 . . . . 10.0 113.118 176.995 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.6 175.34 11.26 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 126.402 1.881 . . . . 10.0 111.386 -179.89 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.78 173.21 45.87 Favored Glycine 0 CA--C 1.543 1.795 0 N-CA-C 117.332 1.693 . . . . 10.0 117.332 -175.296 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.09 160.96 47.75 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 123.88 3.053 . . . . 10.0 113.258 -172.275 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.55 158.2 58.66 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.961 2.441 . . . . 10.0 112.337 173.667 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -145.18 161.44 39.51 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 125.018 1.327 . . . . 10.0 113.556 -171.533 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -83.45 98.84 9.73 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.022 1.729 . . . . 10.0 111.869 -178.602 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 36.5 mm -90.64 -68.27 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.445 0.698 . . . . 10.0 110.723 177.01 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 37.2 tt0 -155.49 143.78 20.16 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.306 1.042 . . . . 10.0 111.679 177.104 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.1 m -126.07 153.77 74.05 Favored Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 125.85 1.66 . . . . 10.0 110.659 171.992 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -70.65 155.03 63.83 Favored 'Trans proline' 0 CA--C 1.542 0.876 0 C-N-CA 122.61 2.207 . . . . 10.0 111.834 171.594 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -72.95 174.3 8.02 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.006 0.922 . . . . 10.0 111.311 166.405 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -59.03 152.24 20.39 Favored 'General case' 0 CA--C 1.548 0.886 0 O-C-N 121.051 -1.031 . . . . 10.0 112.371 174.671 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.0 mtp -134.87 159.3 41.85 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 125.59 1.556 . . . . 10.0 111.887 -171.406 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 67.2 p -142.12 134.25 27.55 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 125.11 1.364 . . . . 10.0 111.242 172.258 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 27.8 mm -139.41 132.83 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 125.62 1.568 . . . . 10.0 109.629 -170.197 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -63.44 132.63 52.02 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.624 1.169 . . . . 10.0 112.4 173.741 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -52.58 128.12 25.07 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.697 1.199 . . . . 10.0 112.786 -179.311 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.21 -9.29 63.13 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 126.017 1.77 . . . . 10.0 115.298 178.412 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -74.47 162.14 29.11 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 119.227 1.514 . . . . 10.0 113.342 176.668 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -72.75 150.97 42.38 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.199 1.4 . . . . 10.0 110.725 159.159 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.9 t -149.97 156.4 41.65 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.663 1.185 . . . . 10.0 111.437 170.425 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm85 -140.87 164.62 29.75 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.558 1.143 . . . . 10.0 112.99 163.372 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.4 mtt -131.73 161.03 33.79 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.801 2.04 . . . . 10.0 111.142 176.941 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -137.12 94.25 2.93 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.131 1.372 . . . . 10.0 111.612 -167.933 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 41.7 m-85 -104.04 116.27 31.94 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.313 1.445 . . . . 10.0 110.831 -178.881 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -78.68 131.14 36.52 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.406 -0.809 . . . . 10.0 110.141 172.406 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 56.9 t -133.25 148.82 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.135 1.774 . . . . 10.0 110.192 -174.107 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.0 t -136.82 -174.32 3.69 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.542 1.537 . . . . 10.0 111.474 173.77 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 110.06 162.0 18.78 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 127.401 2.429 . . . . 10.0 112.549 -173.031 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -148.04 128.78 6.94 Favored Pre-proline 0 CA--C 1.546 0.826 0 C-N-CA 124.661 1.184 . . . . 10.0 110.591 -179.587 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -66.56 170.01 44.55 Favored 'Cis proline' 0 CA--C 1.54 0.783 0 CA-C-N 120.786 1.316 . . . . 10.0 112.453 -4.225 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.55 123.42 56.8 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.512 1.125 . . . . 10.0 111.375 179.572 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.55 151.09 64.35 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.543 2.162 . . . . 10.0 113.168 -173.371 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -72.96 146.55 45.97 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.248 1.019 . . . . 10.0 109.831 160.158 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.8 m -130.97 135.98 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.662 1.185 . . . . 10.0 112.541 -170.23 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 64.1 m -135.51 119.3 17.25 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.234 1.814 . . . . 10.0 111.037 -178.834 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 283' ' ' TRP . . . . . 0.402 ' CD1' ' HG2' ' A' ' 298' ' ' MET . 62.2 m95 -91.02 156.22 18.11 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.598 0.962 . . . . 10.0 113.598 -179.43 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -143.45 160.25 40.93 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.796 2.438 . . . . 10.0 111.1 -176.987 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.6 tp -146.18 117.72 8.03 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 127.189 2.196 . . . . 10.0 109.997 176.237 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 55.54 13.33 0.94 Allowed 'General case' 0 CA--C 1.555 1.145 0 C-N-CA 126.467 1.907 . . . . 10.0 115.208 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 109.83 -14.62 31.82 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 126.731 2.11 . . . . 10.0 115.02 -177.313 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -82.09 157.42 24.1 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 118.9 1.35 . . . . 10.0 110.687 168.896 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.8 p -72.91 158.25 35.85 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.936 0.894 . . . . 10.0 112.339 172.358 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.6 t -133.98 90.83 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 126.278 1.831 . . . . 10.0 108.898 172.971 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -68.77 143.48 54.63 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.254 0.622 . . . . 10.0 110.412 169.815 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.3 p -69.39 149.53 48.28 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.374 0.67 . . . . 10.0 112.163 173.098 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.18 -172.68 4.3 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.186 1.794 . . . . 10.0 111.983 178.103 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.09 -18.34 46.26 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 114.774 1.398 . . . . 10.0 114.774 -178.472 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.8 mt -113.12 -15.07 12.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.915 1.686 . . . . 10.0 113.531 179.479 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -126.43 96.81 4.81 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.82 2.048 . . . . 10.0 109.755 -177.206 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -110.61 126.17 54.19 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.25 1.02 . . . . 10.0 111.207 -168.323 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 298' ' ' MET . . . . . 0.402 ' HG2' ' CD1' ' A' ' 283' ' ' TRP . 1.8 mpt? -128.89 109.06 10.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.427 1.891 . . . . 10.0 110.033 -173.044 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.22 164.83 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 125.615 1.566 . . . . 10.0 111.858 -178.172 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.5 t -125.6 106.82 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 125.513 1.525 . . . . 10.0 109.688 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -74.31 164.93 26.01 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.525 1.13 . . . . 10.0 112.536 176.515 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -57.12 156.61 6.93 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.945 1.298 . . . . 10.0 112.018 173.199 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt 64.68 6.47 3.26 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 127.392 2.277 . . . . 10.0 114.642 -170.431 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 83.77 55.68 2.78 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.307 1.432 . . . . 10.0 114.041 171.854 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.31 101.36 7.92 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.892 1.277 . . . . 10.0 110.11 177.16 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -79.64 112.55 17.01 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.91 1.284 . . . . 10.0 111.197 174.733 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.8 m -83.34 146.78 28.31 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 124.753 1.221 . . . . 10.0 112.197 172.146 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.82 120.1 24.44 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.401 1.88 . . . . 10.0 107.088 161.756 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.7 mt -121.31 139.06 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.494 1.518 . . . . 10.0 110.453 -174.166 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -120.42 110.74 16.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 127.584 2.354 . . . . 10.0 109.522 176.746 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.83 -42.89 85.07 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 121.343 -0.848 . . . . 10.0 113.202 179.465 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.0 89.42 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.806 1.642 . . . . 10.0 110.161 -177.361 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.6 p -70.37 140.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.284 -0.885 . . . . 10.0 112.203 -176.239 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -119.93 160.79 22.03 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.358 1.863 . . . . 10.0 112.157 176.717 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.11 -32.56 66.46 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 113.726 1.01 . . . . 10.0 113.726 -177.45 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.4 t -65.13 -21.75 66.84 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.106 1.362 . . . . 10.0 113.776 175.209 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -79.48 -5.32 54.55 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.779 1.231 . . . . 10.0 113.611 -179.832 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.65 152.17 44.81 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.168 -0.957 . . . . 10.0 113.236 178.624 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.59 -168.98 22.53 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.633 1.111 . . . . 10.0 115.043 174.977 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.67 103.03 11.88 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.909 1.684 . . . . 10.0 111.551 177.856 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 -78.82 149.7 32.48 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.037 0.935 . . . . 10.0 111.678 169.714 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.94 160.93 40.55 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.901 0.881 . . . . 10.0 112.265 170.413 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.45 120.53 17.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.543 1.537 . . . . 10.0 110.858 177.12 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 59.1 t -92.36 126.39 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.757 1.223 . . . . 10.0 108.996 171.204 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -119.27 126.11 50.7 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 126.428 1.891 . . . . 10.0 110.747 -178.957 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -134.47 133.33 40.31 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 125.259 1.423 . . . . 10.0 112.516 -170.698 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.7 p30 -130.55 -179.1 5.08 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.741 1.216 . . . . 10.0 111.533 166.535 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -60.89 -12.77 12.14 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 115.618 1.71 . . . . 10.0 115.618 -179.465 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -109.44 -17.63 13.73 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.521 1.528 . . . . 10.0 114.392 -178.282 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 168.64 -169.2 41.55 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 115.972 1.149 . . . . 10.0 115.972 177.931 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -133.77 146.56 50.84 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.986 2.114 . . . . 10.0 111.745 -172.088 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.2 160.1 40.31 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.317 1.847 . . . . 10.0 110.974 169.98 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.3 m -136.33 130.56 33.06 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.722 1.209 . . . . 10.0 111.379 177.759 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -113.65 153.65 28.56 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.204 1.801 . . . . 10.0 110.659 177.81 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.7 m -143.09 148.19 36.25 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.598 1.159 . . . . 10.0 112.37 -173.13 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.41 169.15 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 C-N-CA 126.994 2.117 . . . . 10.0 110.763 169.468 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 52.4 tt0 -128.04 137.04 52.03 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.196 1.399 . . . . 10.0 111.088 174.271 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.5 tp -125.65 107.14 10.28 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.958 1.703 . . . . 10.0 111.077 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -88.96 87.47 7.23 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.259 1.424 . . . . 10.0 110.869 172.773 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -67.36 112.35 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.242 -0.911 . . . . 10.0 110.061 175.45 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.6 mt -75.3 94.65 3.05 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 126.104 1.762 . . . . 10.0 109.875 -179.747 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -63.43 151.72 40.28 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.765 1.226 . . . . 10.0 113.53 -175.769 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -68.89 -43.31 75.55 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 125.427 1.491 . . . . 10.0 112.022 171.516 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 . . . . . 0 C--O 1.254 1.311 0 C-N-CA 126.768 2.027 . . . . 10.0 113.612 -179.481 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.513 0 N-CA-C 111.782 -0.527 . . . . 10.0 111.782 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.3 160.95 20.56 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.281 1.032 . . . . 10.0 112.997 176.341 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.54 176.41 10.08 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 126.12 1.768 . . . . 10.0 111.707 -179.009 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.01 173.14 46.07 Favored Glycine 0 CA--C 1.541 1.706 0 N-CA-C 117.037 1.575 . . . . 10.0 117.037 -176.935 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -69.18 160.72 48.74 Favored 'Trans proline' 0 CA--C 1.544 0.991 0 C-N-CA 123.521 2.814 . . . . 10.0 113.134 -173.316 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -68.07 167.67 21.14 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 123.303 2.668 . . . . 10.0 111.634 169.191 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 2.1 tpt180 -139.42 175.22 9.75 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.664 1.186 . . . . 10.0 112.803 -172.974 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -103.92 95.48 6.04 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 126.394 1.878 . . . . 10.0 110.326 -175.643 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 253' ' ' ILE . . . . . 0.549 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.4 OUTLIER -115.61 -179.28 1.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.99 0 C-N-CA 126.298 1.839 . . . . 10.0 109.779 -179.655 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.549 ' H ' HG22 ' A' ' 253' ' ' ILE . 41.8 tt0 -46.15 123.37 4.61 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.507 2.323 . . . . 10.0 115.026 -166.535 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 19.1 m -106.84 153.83 40.56 Favored Pre-proline 0 N--CA 1.474 0.769 0 C-N-CA 126.425 1.89 . . . . 10.0 110.365 167.944 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.25 158.49 44.94 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.759 2.306 . . . . 10.0 111.705 169.902 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -66.29 172.4 3.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 124.606 1.162 . . . . 10.0 111.841 167.342 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -60.32 153.72 21.93 Favored 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.99 -1.068 . . . . 10.0 111.857 170.311 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 84.8 mtp -133.01 155.9 48.33 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.994 1.318 . . . . 10.0 112.179 -169.647 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 47.6 p -141.81 122.86 14.6 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 125.505 1.522 . . . . 10.0 110.903 175.091 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.5 mm -134.18 132.38 55.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.546 1.538 . . . . 10.0 109.901 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -63.99 129.12 38.78 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.235 1.014 . . . . 10.0 112.101 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -54.31 131.82 42.6 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.201 1.4 . . . . 10.0 112.683 -177.736 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.76 -10.11 66.34 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 126.042 1.782 . . . . 10.0 115.07 179.11 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 78.3 mtp85 -71.47 160.98 31.76 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 119.005 1.402 . . . . 10.0 113.061 175.91 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -71.18 145.8 49.49 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 124.014 0.926 . . . . 10.0 110.368 155.684 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 16.6 t -147.45 163.79 35.4 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.7 1.2 . . . . 10.0 111.405 168.612 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -143.85 157.52 44.31 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.589 1.556 . . . . 10.0 111.806 167.706 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 53.2 mtt -129.22 150.42 50.61 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 127.117 2.167 . . . . 10.0 109.187 171.454 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -142.12 126.08 17.23 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.317 1.047 . . . . 10.0 111.479 -169.85 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -130.86 123.69 29.59 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 126.745 2.018 . . . . 10.0 111.151 -168.718 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -70.27 130.81 43.02 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.493 -0.754 . . . . 10.0 110.301 171.472 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.77 149.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 126.109 1.763 . . . . 10.0 111.138 -175.592 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 6.1 t -147.24 -174.08 4.42 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 125.144 1.377 . . . . 10.0 112.113 -176.572 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.18 162.47 23.7 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 127.319 2.39 . . . . 10.0 112.864 -174.968 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -146.48 128.07 7.48 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.874 1.27 . . . . 10.0 110.567 -179.698 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -66.7 169.4 47.55 Favored 'Cis proline' 0 CA--C 1.539 0.743 0 CA-C-N 120.88 1.35 . . . . 10.0 112.658 -2.149 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.72 122.77 48.04 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.752 1.221 . . . . 10.0 111.575 -178.463 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -71.11 159.95 50.66 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 122.597 2.198 . . . . 10.0 113.359 -174.292 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.7 168.94 10.36 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.799 1.24 . . . . 10.0 111.851 166.426 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 71.5 t -130.24 123.76 56.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.691 1.597 . . . . 10.0 110.397 -178.366 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.2 m -134.82 150.35 50.49 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.68 1.592 . . . . 10.0 110.661 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 47.6 m95 -130.06 157.82 41.34 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 124.884 1.274 . . . . 10.0 112.593 179.151 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -143.91 159.19 43.0 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.674 1.99 . . . . 10.0 111.413 -177.292 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.1 tp -144.99 118.24 8.95 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 127.128 2.171 . . . . 10.0 109.943 175.844 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 54.91 14.79 0.97 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.508 1.923 . . . . 10.0 115.177 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.8 -13.23 35.06 Favored Glycine 0 CA--C 1.539 1.556 0 C-N-CA 126.709 2.1 . . . . 10.0 115.182 -178.061 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.9 mtp180 -85.89 157.11 20.26 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.971 1.385 . . . . 10.0 110.961 170.134 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.6 p -71.41 155.25 40.84 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.358 1.063 . . . . 10.0 112.765 174.432 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 61.1 t -134.0 102.65 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.729 2.012 . . . . 10.0 108.597 172.834 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -74.61 161.4 29.75 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.463 0.705 . . . . 10.0 111.4 172.547 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 58.4 p -67.99 154.41 41.68 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.363 0.665 . . . . 10.0 111.785 168.163 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -153.6 168.68 25.4 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.144 1.377 . . . . 10.0 111.03 177.799 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.8 -35.18 68.43 Favored 'General case' 0 CA--C 1.544 0.749 0 O-C-N 120.933 -1.105 . . . . 10.0 112.696 168.84 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 69.8 mt -82.83 -14.25 54.69 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.553 1.141 . . . . 10.0 113.916 173.938 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.4 m80 -136.16 69.91 1.42 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.954 1.701 . . . . 10.0 111.216 -173.427 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.53 143.02 51.77 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.786 1.235 . . . . 10.0 111.134 -177.671 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -136.85 103.58 5.22 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.649 1.98 . . . . 10.0 109.718 -174.695 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.45 158.99 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.823 1.249 . . . . 10.0 112.18 -175.389 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -134.5 111.42 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 125.31 1.444 . . . . 10.0 110.035 -178.614 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 58.6 m -66.53 145.83 55.19 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.904 0.882 . . . . 10.0 111.401 173.269 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.47 -17.52 59.71 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.526 1.53 . . . . 10.0 114.622 -176.237 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -75.36 -4.82 41.51 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.058 1.743 . . . . 10.0 114.108 173.621 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.82 47.38 3.68 Favored Glycine 0 CA--C 1.532 1.098 0 C-N-CA 125.134 1.35 . . . . 10.0 113.219 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.94 105.71 6.51 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.085 1.354 . . . . 10.0 110.224 -176.129 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -85.45 124.94 32.61 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.073 1.349 . . . . 10.0 111.447 174.751 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 38.0 m -109.0 142.94 38.95 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.398 1.479 . . . . 10.0 111.915 175.695 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -132.79 115.85 15.83 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.538 2.335 . . . . 10.0 108.887 -178.306 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 153.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.785 1.234 . . . . 10.0 111.44 -171.402 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -128.49 103.65 7.25 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.398 2.279 . . . . 10.0 109.05 164.663 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -65.34 -38.96 91.73 Favored 'General case' 0 N--CA 1.475 0.825 0 O-C-N 120.872 -1.143 . . . . 10.0 113.072 178.738 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.56 87.71 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.838 1.655 . . . . 10.0 110.245 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.58 137.39 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 O-C-N 121.241 -0.912 . . . . 10.0 111.928 -177.555 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -117.34 161.15 19.99 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.091 1.757 . . . . 10.0 112.094 176.57 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.91 -34.12 65.29 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -177.326 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.0 m -65.37 -16.6 63.77 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 125.515 1.526 . . . . 10.0 114.565 175.468 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -81.95 -5.33 58.21 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.695 1.198 . . . . 10.0 113.348 178.33 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.49 151.44 46.37 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.025 -1.047 . . . . 10.0 112.773 175.908 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.96 -171.89 21.59 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 124.97 1.271 . . . . 10.0 114.846 176.892 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.01 105.74 14.25 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.891 1.676 . . . . 10.0 111.252 176.518 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -80.6 152.7 28.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.206 1.002 . . . . 10.0 111.963 169.479 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.92 44.52 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.905 0.882 . . . . 10.0 111.933 166.231 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 51.3 t -130.66 143.61 50.86 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.666 1.987 . . . . 10.0 109.789 177.018 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 99.0 t -126.38 129.66 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 125.57 1.548 . . . . 10.0 109.673 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -123.58 118.81 28.18 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.404 1.881 . . . . 10.0 110.433 -178.529 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -131.95 138.23 48.24 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 125.373 1.469 . . . . 10.0 111.822 -173.467 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -134.14 -177.48 4.6 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.936 1.295 . . . . 10.0 111.358 168.174 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -60.91 -11.63 8.56 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 115.727 1.751 . . . . 10.0 115.727 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.49 -19.82 12.42 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 125.569 1.548 . . . . 10.0 114.503 -178.107 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.4 -168.92 41.99 Favored Glycine 0 CA--C 1.534 1.252 0 N-CA-C 116.371 1.308 . . . . 10.0 116.371 178.984 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -135.71 142.41 45.05 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.29 2.236 . . . . 10.0 111.683 -172.059 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.05 162.53 33.9 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.052 1.741 . . . . 10.0 111.309 169.011 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -141.4 146.09 36.14 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.023 1.329 . . . . 10.0 110.753 -172.511 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -133.45 154.22 50.97 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.349 1.46 . . . . 10.0 110.774 177.263 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.7 m -144.27 144.71 31.62 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.489 1.116 . . . . 10.0 111.615 -171.491 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.8 p -153.23 164.02 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 126.126 1.77 . . . . 10.0 110.698 172.414 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -125.17 138.71 54.14 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 124.79 1.236 . . . . 10.0 111.13 174.888 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -124.61 120.04 30.77 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.997 1.719 . . . . 10.0 111.068 -177.829 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -105.69 86.24 2.36 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.064 1.746 . . . . 10.0 110.723 176.694 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 23.8 t -67.47 109.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 123.992 0.917 . . . . 10.0 110.607 -179.581 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 66.1 mt -72.98 103.11 3.66 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 126.324 1.85 . . . . 10.0 109.853 178.798 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.48 140.26 56.38 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 113.887 1.069 . . . . 10.0 113.887 -172.069 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -101.05 -32.33 10.66 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 127.304 2.241 . . . . 10.0 111.755 173.563 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 . . . . . 0 C--O 1.254 1.313 0 C-N-CA 126.109 1.764 . . . . 10.0 113.38 174.174 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.547 0 N-CA-C 111.944 -0.462 . . . . 10.0 111.944 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.5 162.92 16.98 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.4 1.08 . . . . 10.0 112.933 175.881 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 24.2 ptt? -147.97 -179.16 6.7 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.897 1.679 . . . . 10.0 111.913 -178.951 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.79 169.27 41.64 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.83 1.492 . . . . 10.0 116.83 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -72.56 162.85 40.22 Favored 'Trans proline' 0 CA--C 1.544 1.007 0 C-N-CA 123.83 3.02 . . . . 10.0 113.077 -175.106 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.54 160.49 49.1 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 123.146 2.564 . . . . 10.0 112.083 171.013 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.27 168.96 23.69 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.266 1.426 . . . . 10.0 112.539 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -72.98 146.47 45.98 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.517 1.527 . . . . 10.0 111.988 173.269 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.2 mp -136.4 -64.08 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 125.699 1.6 . . . . 10.0 109.054 168.539 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -151.7 138.39 18.8 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.716 1.606 . . . . 10.0 110.521 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.6 m -133.37 151.99 78.5 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.773 1.629 . . . . 10.0 110.404 173.688 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.24 148.03 67.56 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 122.652 2.234 . . . . 10.0 112.348 175.932 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -74.53 176.5 6.79 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.489 1.115 . . . . 10.0 111.253 166.273 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -54.37 122.86 11.32 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.04 -1.037 . . . . 10.0 112.508 176.961 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.6 mtp -101.31 159.02 15.62 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.01 1.724 . . . . 10.0 111.872 -177.2 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 p -146.82 115.28 6.71 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.178 1.391 . . . . 10.0 111.259 177.708 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.0 mm -127.01 134.22 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.595 1.558 . . . . 10.0 110.166 -169.221 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -63.98 131.85 48.89 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.683 1.193 . . . . 10.0 112.666 176.202 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -52.74 121.54 7.4 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.758 1.623 . . . . 10.0 112.962 -178.941 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 103.81 -9.31 51.56 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 126.2 1.857 . . . . 10.0 115.106 177.829 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.8 mtp180 -72.05 159.51 34.07 Favored 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 119.173 1.486 . . . . 10.0 113.398 177.449 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -72.55 147.7 45.67 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.54 1.136 . . . . 10.0 110.412 156.513 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 15.0 t -149.49 162.82 39.39 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.329 1.052 . . . . 10.0 111.941 170.199 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.0 ptm85 -143.08 164.26 30.59 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.67 1.588 . . . . 10.0 112.107 165.541 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.0 mtt -126.11 159.97 31.42 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 126.802 2.041 . . . . 10.0 110.654 173.883 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -136.72 89.95 2.5 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.416 1.486 . . . . 10.0 111.025 -169.369 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -100.72 106.06 17.46 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.24 1.416 . . . . 10.0 111.029 -178.329 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -67.05 133.07 49.17 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 121.62 -0.675 . . . . 10.0 110.117 171.17 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.7 p -143.71 146.43 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 125.467 1.507 . . . . 10.0 111.392 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 93.6 p -128.6 -165.7 1.54 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.974 1.71 . . . . 10.0 112.733 -174.687 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 98.99 163.45 29.88 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 126.298 1.904 . . . . 10.0 112.813 -178.264 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -142.68 127.09 9.83 Favored Pre-proline 0 CA--C 1.546 0.797 0 C-N-CA 125.507 1.523 . . . . 10.0 109.555 177.781 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -66.26 169.16 46.24 Favored 'Cis proline' 0 CA--C 1.54 0.825 0 CA-C-N 120.312 1.147 . . . . 10.0 112.584 -4.193 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.96 70.01 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.386 1.075 . . . . 10.0 111.046 178.479 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.63 148.53 59.67 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 122.284 1.989 . . . . 10.0 113.834 -169.155 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -67.43 132.83 48.42 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.384 1.474 . . . . 10.0 109.561 158.43 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.1 m -124.0 138.64 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.514 1.126 . . . . 10.0 112.155 -173.276 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 48.1 m -135.25 154.08 51.7 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.975 1.71 . . . . 10.0 110.755 178.221 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -124.93 153.21 43.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.536 1.135 . . . . 10.0 113.389 -176.469 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.3 m-85 -145.1 160.29 41.64 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.088 2.155 . . . . 10.0 111.15 -172.372 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 58.3 tp -149.87 122.34 8.5 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 126.695 1.998 . . . . 10.0 110.332 178.171 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 54.98 6.97 0.14 Allowed 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 126.995 2.118 . . . . 10.0 116.595 174.864 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 121.21 -6.18 10.92 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.2 1.857 . . . . 10.0 115.725 -177.189 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.0 ptm180 -108.09 165.44 11.47 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 119.254 1.527 . . . . 10.0 112.227 171.637 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.8 p -72.47 158.1 36.37 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.861 1.264 . . . . 10.0 112.437 172.302 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 44.4 t -131.09 101.72 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 126.076 1.751 . . . . 10.0 108.372 171.976 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 11.5 mp0 -67.04 149.95 49.9 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.573 1.149 . . . . 10.0 111.295 176.818 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.4 p -65.54 138.98 58.42 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.45 0.7 . . . . 10.0 110.922 167.698 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -146.8 167.96 22.58 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.721 1.208 . . . . 10.0 111.819 -176.479 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -56.79 -35.07 68.29 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.162 -0.961 . . . . 10.0 113.105 171.023 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 70.4 mt -85.76 -15.17 42.96 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.996 1.11 . . . . 10.0 113.996 174.834 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.5 m80 -135.72 73.03 1.45 Allowed 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.975 1.71 . . . . 10.0 111.088 -174.35 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -73.02 143.66 47.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 125.144 1.377 . . . . 10.0 111.329 -178.173 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 58.8 mtt -142.44 105.25 4.54 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.864 1.666 . . . . 10.0 110.214 -172.338 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.92 144.77 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.161 0.984 . . . . 10.0 112.46 -178.667 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 48.0 t -95.16 100.52 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 125.154 1.382 . . . . 10.0 108.757 175.484 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 15.2 m -64.3 168.76 5.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.693 1.997 . . . . 10.0 112.741 176.307 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -62.01 165.45 5.54 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.541 1.136 . . . . 10.0 113.793 174.705 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 96.6 mttt 56.76 20.69 5.31 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 126.874 2.07 . . . . 10.0 115.794 173.129 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.42 53.83 2.98 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.816 1.198 . . . . 10.0 114.131 173.363 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 52.0 tp -137.16 146.56 45.11 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.726 1.61 . . . . 10.0 110.517 179.505 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -126.84 115.72 19.76 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.997 1.319 . . . . 10.0 111.359 -179.784 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.0 m -80.83 129.19 34.4 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.834 1.654 . . . . 10.0 111.819 172.366 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -128.35 119.43 25.04 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.088 2.155 . . . . 10.0 107.645 170.963 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 54.4 mt -119.68 154.06 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.808 1.243 . . . . 10.0 111.662 -164.464 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -131.57 108.65 9.69 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 127.848 2.459 . . . . 10.0 109.35 173.468 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -66.36 -43.21 86.65 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 120.985 -1.072 . . . . 10.0 113.031 177.432 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.71 89.12 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.791 1.637 . . . . 10.0 110.16 -177.685 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -70.09 139.48 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.353 -0.842 . . . . 10.0 112.26 -176.322 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -121.91 163.53 19.1 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.312 1.845 . . . . 10.0 112.045 175.408 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.06 -30.33 66.1 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.574 0.953 . . . . 10.0 113.574 -178.686 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.7 p -67.82 -16.9 64.32 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.657 1.583 . . . . 10.0 114.681 173.648 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -83.66 -5.63 59.23 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.633 1.173 . . . . 10.0 113.356 175.858 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.83 154.43 39.16 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.027 -1.046 . . . . 10.0 113.352 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.01 -169.72 21.99 Favored Glycine 0 CA--C 1.532 1.123 0 C-N-CA 124.67 1.128 . . . . 10.0 115.043 174.973 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.81 100.19 10.79 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.966 1.706 . . . . 10.0 111.392 177.626 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -75.11 151.57 38.6 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.214 1.006 . . . . 10.0 111.679 167.432 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.36 159.01 43.15 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.94 0.896 . . . . 10.0 112.157 168.71 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -130.69 144.47 51.46 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.545 1.938 . . . . 10.0 110.223 177.272 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.3 t -126.57 116.11 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 125.49 1.516 . . . . 10.0 109.347 179.229 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -106.3 126.58 52.41 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.452 1.901 . . . . 10.0 110.806 -178.255 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -132.47 127.58 35.58 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 126.439 1.896 . . . . 10.0 111.774 -168.058 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -134.33 177.73 7.53 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.864 0.757 . . . . 10.0 112.238 164.211 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 -62.47 -11.13 14.25 Favored 'General case' 0 N--CA 1.48 1.072 0 N-CA-C 115.536 1.68 . . . . 10.0 115.536 -178.932 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.49 -15.37 14.81 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.569 1.548 . . . . 10.0 114.088 178.138 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.18 -170.39 38.61 Favored Glycine 0 CA--C 1.536 1.369 0 CA-C-N 119.659 1.118 . . . . 10.0 115.423 176.365 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -134.06 149.59 51.15 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 126.059 1.744 . . . . 10.0 111.892 -172.775 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.42 162.73 33.71 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.237 1.815 . . . . 10.0 111.501 171.144 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 30.1 m -140.28 135.97 32.81 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.938 1.295 . . . . 10.0 110.758 -175.7 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -129.72 154.02 47.58 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.669 1.588 . . . . 10.0 110.976 -178.059 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -144.84 145.61 31.7 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.236 1.014 . . . . 10.0 112.017 -169.421 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.6 p -152.27 150.46 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 125.661 1.584 . . . . 10.0 111.696 170.46 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.3 tt0 -100.91 139.2 36.94 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.531 1.133 . . . . 10.0 111.004 171.655 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.9 tp -123.25 103.86 8.79 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.89 1.676 . . . . 10.0 110.566 175.898 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -90.73 82.9 5.71 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.63 1.572 . . . . 10.0 110.981 175.861 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.9 t -63.69 112.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.844 0.858 . . . . 10.0 110.621 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.7 mt -75.34 98.54 3.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.288 1.835 . . . . 10.0 110.184 -179.22 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.04 149.5 36.73 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 124.062 0.945 . . . . 10.0 112.72 179.351 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -80.84 -2.48 47.48 Favored 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.218 1.562 . . . . 10.0 115.218 -179.595 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 . . . . . 0 C--O 1.253 1.273 0 C-N-CA 126.826 2.05 . . . . 10.0 114.062 178.757 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo . . . . . 0 CA--C 1.542 0.914 0 N-CA-C 113.258 0.446 . . . . 10.0 113.258 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -66.96 152.08 80.99 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.859 2.373 . . . . 10.0 111.427 168.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 68.9 ttt180 -142.52 162.68 34.84 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 125.764 1.626 . . . . 10.0 111.542 -177.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -71.33 141.29 50.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.321 1.449 . . . . 10.0 112.224 173.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.1 mp -135.47 -66.14 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.544 1.538 . . . . 10.0 109.724 171.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 -149.56 140.3 22.67 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.34 1.456 . . . . 10.0 111.105 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 24.7 m -127.26 152.59 76.32 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 126.207 1.803 . . . . 10.0 110.287 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.3 156.91 50.49 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.87 2.38 . . . . 10.0 112.016 176.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.63 167.28 22.12 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.114 0.966 . . . . 10.0 112.67 172.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -60.2 106.9 0.57 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 124.839 1.256 . . . . 10.0 111.698 173.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 26.4 mtm -79.4 154.57 28.88 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 123.653 0.781 . . . . 10.0 112.467 -175.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.7 p -138.43 110.13 7.11 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 125.306 1.442 . . . . 10.0 110.539 170.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.8 mm -126.85 131.12 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.314 1.446 . . . . 10.0 110.391 -163.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -59.43 131.92 52.42 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.646 1.178 . . . . 10.0 112.558 173.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -51.97 129.83 28.05 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 125.159 1.384 . . . . 10.0 112.674 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.75 -8.91 76.37 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 125.497 1.522 . . . . 10.0 115.278 177.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -70.87 161.61 30.71 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 119.321 1.56 . . . . 10.0 113.051 175.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -73.47 138.48 45.14 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.55 1.14 . . . . 10.0 110.043 155.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.1 p -149.42 169.4 20.95 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.468 0.707 . . . . 10.0 112.348 164.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -147.45 155.56 42.04 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.855 1.262 . . . . 10.0 112.975 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -122.39 143.36 49.71 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 128.028 2.531 . . . . 10.0 108.925 173.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -139.5 114.56 9.57 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.187 0.995 . . . . 10.0 111.936 -170.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -115.85 113.79 23.84 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.222 2.209 . . . . 10.0 110.42 -173.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.3 mtpp -67.99 133.85 49.74 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.473 -0.767 . . . . 10.0 110.015 170.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -140.94 125.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.521 1.528 . . . . 10.0 111.139 -174.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 50.6 m -136.03 103.34 5.32 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.798 1.239 . . . . 10.0 111.467 -176.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -154.9 165.08 32.04 Favored Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.983 2.23 . . . . 10.0 110.662 169.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.6 tp -141.91 125.85 9.97 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.129 0.971 . . . . 10.0 110.847 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -65.43 167.16 49.53 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.63 1.261 . . . . 10.0 112.511 -2.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.09 121.84 44.01 Favored Pre-proline 0 CA--C 1.549 0.915 0 C-N-CA 124.483 1.113 . . . . 10.0 111.202 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.77 150.79 68.64 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.492 2.128 . . . . 10.0 113.076 -172.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -73.62 143.77 46.2 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.146 0.979 . . . . 10.0 109.666 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.61 136.23 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.796 0.839 . . . . 10.0 111.858 -174.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -126.99 157.71 38.81 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.897 1.679 . . . . 10.0 111.68 173.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 51.0 m95 -125.97 154.88 42.25 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 125.533 1.533 . . . . 10.0 113.666 -173.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -144.49 161.12 39.88 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.26 2.224 . . . . 10.0 111.96 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.1 tp -146.56 124.35 11.91 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.748 2.419 . . . . 10.0 109.69 173.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.01 14.28 0.68 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 126.775 2.03 . . . . 10.0 116.064 175.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.36 0.55 24.99 Favored Glycine 0 CA--C 1.539 1.552 0 C-N-CA 125.693 1.616 . . . . 10.0 116.043 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.0 ptp85 -123.93 163.19 21.82 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 125.679 1.592 . . . . 10.0 112.177 173.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.4 p -69.65 159.59 33.17 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.596 1.158 . . . . 10.0 113.616 -175.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 92.7 t -134.92 108.1 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 126.93 2.092 . . . . 10.0 108.939 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -77.01 159.66 29.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 123.724 0.81 . . . . 10.0 111.365 170.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 81.3 p -76.91 155.48 32.77 Favored 'General case' 0 N--CA 1.473 0.683 0 O-C-N 121.645 -0.659 . . . . 10.0 112.144 168.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -155.71 -176.39 5.93 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.578 1.551 . . . . 10.0 111.576 168.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -62.08 -18.18 59.92 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -177.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 68.7 mt -107.37 -26.67 10.88 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.845 1.658 . . . . 10.0 112.266 175.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -108.74 68.78 0.69 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.828 2.051 . . . . 10.0 110.711 177.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -74.25 146.09 43.55 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.346 1.058 . . . . 10.0 111.839 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 65.7 mtt -138.89 114.69 9.99 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.533 1.933 . . . . 10.0 110.184 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.55 155.82 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.928 1.291 . . . . 10.0 111.776 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.1 p -141.21 122.02 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.595 1.158 . . . . 10.0 111.238 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 38.7 t -74.87 141.8 44.17 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.485 1.114 . . . . 10.0 111.65 175.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.78 -17.68 37.39 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.769 1.228 . . . . 10.0 113.688 170.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -76.47 -4.2 41.32 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.936 1.694 . . . . 10.0 113.917 174.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.68 39.43 4.15 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.979 1.275 . . . . 10.0 114.867 172.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.2 tp -136.55 114.78 11.61 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 125.109 1.364 . . . . 10.0 111.122 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 5.1 t60 -98.35 132.88 43.46 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.21 1.404 . . . . 10.0 110.994 174.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 37.9 m -121.89 138.07 54.54 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.558 1.543 . . . . 10.0 111.487 -178.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -128.06 117.84 22.38 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 127.713 2.405 . . . . 10.0 107.85 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 85.3 mt -118.63 148.45 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.471 1.108 . . . . 10.0 111.064 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -123.07 106.31 10.69 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 127.355 2.262 . . . . 10.0 109.014 171.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -63.59 -38.3 90.61 Favored 'General case' 0 N--CA 1.475 0.781 0 O-C-N 121.296 -0.878 . . . . 10.0 113.09 176.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.2 p -150.76 90.1 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.889 1.676 . . . . 10.0 110.248 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -68.48 144.75 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 O-C-N 121.27 -0.894 . . . . 10.0 112.101 -178.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -129.21 162.17 28.45 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.03 1.732 . . . . 10.0 112.005 174.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.54 -34.38 64.65 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 113.642 0.979 . . . . 10.0 113.642 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.1 m -64.87 -17.15 64.03 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.387 1.475 . . . . 10.0 114.509 175.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -81.7 -8.28 59.68 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.513 1.125 . . . . 10.0 113.328 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.72 150.64 43.99 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 119.219 0.918 . . . . 10.0 112.933 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.9 -172.2 22.71 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.563 1.078 . . . . 10.0 114.789 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.87 101.95 13.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.963 1.705 . . . . 10.0 111.209 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -76.15 150.85 37.11 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.225 1.01 . . . . 10.0 111.501 167.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.5 161.97 38.49 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.906 0.883 . . . . 10.0 111.545 169.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 30.8 p -144.88 161.87 38.25 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.186 0.994 . . . . 10.0 112.044 171.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.98 131.25 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.273 1.429 . . . . 10.0 110.072 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.47 126.8 54.77 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.651 1.98 . . . . 10.0 110.044 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -133.93 129.06 35.75 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.644 1.577 . . . . 10.0 112.012 -169.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.5 p30 -132.21 -179.46 5.44 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.448 1.099 . . . . 10.0 111.832 166.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -60.51 -14.68 21.07 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.657 1.725 . . . . 10.0 115.657 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.84 -16.38 14.48 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.288 1.435 . . . . 10.0 114.276 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.93 -170.17 40.55 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 115.876 1.11 . . . . 10.0 115.876 177.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -134.68 146.72 49.75 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.852 2.061 . . . . 10.0 111.7 -172.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.81 153.11 49.68 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.753 1.621 . . . . 10.0 110.982 169.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 25.2 m -137.55 136.78 37.93 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.832 1.253 . . . . 10.0 110.552 -172.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -134.89 153.72 51.95 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.964 1.306 . . . . 10.0 111.524 -173.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.0 m -142.33 144.5 33.24 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 125.251 1.42 . . . . 10.0 111.456 -173.031 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.9 p -151.8 156.72 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 C-N-CA 125.695 1.598 . . . . 10.0 111.271 170.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -107.89 148.89 29.0 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 124.349 1.06 . . . . 10.0 111.746 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.29 114.96 18.29 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.469 1.907 . . . . 10.0 110.222 174.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -103.46 84.74 2.35 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.719 1.608 . . . . 10.0 110.685 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.8 t -67.23 110.96 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.708 0.803 . . . . 10.0 110.871 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 75.7 mt -75.95 101.03 5.05 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.731 2.012 . . . . 10.0 110.567 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.872 0 C-N-CA 124.058 0.943 . . . . 10.0 112.87 175.655 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo . . . . . 0 CA--C 1.543 0.949 0 N-CA-C 113.29 0.458 . . . . 10.0 113.29 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -67.33 148.31 79.59 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.825 2.35 . . . . 10.0 111.435 173.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 32.7 ttp-105 -138.09 136.9 37.22 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.855 1.262 . . . . 10.0 113.208 -173.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -63.58 117.26 6.54 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 127.274 2.23 . . . . 10.0 110.997 170.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 35.8 mm -108.35 -54.26 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.735 0.814 . . . . 10.0 110.328 171.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -153.18 142.68 21.76 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.412 1.085 . . . . 10.0 111.433 172.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.53 148.48 53.06 Favored Pre-proline 0 N--CA 1.476 0.862 0 C-N-CA 125.247 1.419 . . . . 10.0 110.073 169.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -77.13 163.69 30.29 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.965 2.443 . . . . 10.0 112.117 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -73.1 166.74 22.54 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.593 0.757 . . . . 10.0 111.43 166.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -62.44 160.9 12.64 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.364 -0.835 . . . . 10.0 112.081 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 51.0 mtm -133.49 161.25 35.1 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.181 0.992 . . . . 10.0 112.939 -178.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 55.2 p -137.88 115.64 11.43 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 125.907 1.683 . . . . 10.0 109.854 168.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.6 mm -124.51 132.9 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.306 1.442 . . . . 10.0 110.05 -166.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -59.56 126.51 27.91 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.402 1.481 . . . . 10.0 112.475 173.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -50.23 126.75 15.5 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.599 1.56 . . . . 10.0 112.679 176.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.99 -11.75 58.91 Favored Glycine 0 CA--C 1.537 1.468 0 C-N-CA 126.182 1.849 . . . . 10.0 115.088 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -75.53 162.39 28.34 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 119.2 1.5 . . . . 10.0 113.418 177.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -76.69 143.3 40.13 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.076 1.351 . . . . 10.0 110.328 157.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 28.6 p -150.82 168.97 22.83 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.608 0.763 . . . . 10.0 112.621 162.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.8 ptm85 -144.12 168.93 18.86 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.426 1.49 . . . . 10.0 112.966 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.7 mtt -131.81 158.82 40.27 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.974 2.11 . . . . 10.0 110.867 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -136.15 92.61 2.81 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.144 1.378 . . . . 10.0 112.139 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -108.41 104.02 13.29 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.456 1.502 . . . . 10.0 111.319 -176.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.1 mtpp -81.7 122.98 28.33 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 121.077 -1.014 . . . . 10.0 110.322 173.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.43 151.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.803 2.041 . . . . 10.0 110.633 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.9 t -131.1 175.7 8.88 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.18 1.392 . . . . 10.0 111.419 172.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 136.7 167.53 11.17 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 127.418 2.437 . . . . 10.0 112.445 -175.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.33 119.79 5.16 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 123.878 0.871 . . . . 10.0 111.707 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.8 169.44 59.05 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 CA-C-N 120.459 1.2 . . . . 10.0 112.473 -1.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.85 127.79 75.31 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.059 0.943 . . . . 10.0 110.838 175.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.69 148.32 65.28 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 122.298 1.999 . . . . 10.0 113.062 -172.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -71.01 142.02 50.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.353 1.061 . . . . 10.0 109.583 160.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 10.8 m -127.02 137.67 57.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 124.618 1.167 . . . . 10.0 112.583 -170.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.1 m -137.57 112.55 9.05 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.109 1.764 . . . . 10.0 110.758 -174.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -85.87 152.76 22.73 Favored 'General case' 0 CA--C 1.536 0.417 0 N-CA-C 113.475 0.917 . . . . 10.0 113.475 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.41 158.89 43.21 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.386 2.274 . . . . 10.0 111.129 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.15 117.78 8.62 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 127.153 2.181 . . . . 10.0 110.109 177.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 55.14 10.98 0.47 Allowed 'General case' 0 CA--C 1.555 1.172 0 C-N-CA 126.747 2.019 . . . . 10.0 115.573 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.27 -15.63 17.97 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 126.832 2.158 . . . . 10.0 115.047 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -84.09 157.45 21.74 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 118.988 1.394 . . . . 10.0 111.088 169.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.9 p -71.71 157.91 37.09 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.281 1.033 . . . . 10.0 112.137 170.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.8 105.77 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 126.303 1.841 . . . . 10.0 108.676 173.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 23.0 mm100 -76.26 159.83 30.23 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.218 0.607 . . . . 10.0 111.495 173.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 36.7 p -67.06 150.8 48.7 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.692 0.797 . . . . 10.0 111.928 169.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -150.76 166.01 31.77 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.179 1.392 . . . . 10.0 111.128 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -54.86 -36.56 65.21 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.147 -0.97 . . . . 10.0 113.1 170.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.0 mt -84.22 -13.77 51.79 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.434 1.094 . . . . 10.0 113.863 174.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -135.04 70.95 1.43 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.93 1.692 . . . . 10.0 111.322 -173.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.08 143.12 49.17 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.049 1.339 . . . . 10.0 111.73 -175.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -139.6 101.99 4.35 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.644 1.978 . . . . 10.0 110.055 -174.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.14 162.73 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.254 1.422 . . . . 10.0 111.557 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.86 118.15 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.899 1.279 . . . . 10.0 110.994 177.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 63.3 m -68.56 158.44 33.91 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.328 1.051 . . . . 10.0 112.218 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -61.24 -21.26 63.71 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 114.243 1.201 . . . . 10.0 114.243 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.1 mptt -77.06 -5.4 48.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.299 1.84 . . . . 10.0 113.865 173.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.05 3.43 65.59 Favored Glycine 0 CA--C 1.536 1.394 0 C-N-CA 125.6 1.572 . . . . 10.0 115.181 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.8 tp -77.44 101.81 6.58 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 118.686 1.243 . . . . 10.0 111.318 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -78.96 113.55 17.16 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.185 1.394 . . . . 10.0 110.925 170.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 75.0 m -84.98 139.44 31.79 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 125.524 1.53 . . . . 10.0 111.986 171.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -131.92 121.24 23.68 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 126.704 2.002 . . . . 10.0 107.688 168.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 61.0 mt -122.18 152.57 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.855 1.262 . . . . 10.0 111.357 -166.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -129.4 109.85 11.42 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 127.519 2.328 . . . . 10.0 109.142 170.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -66.15 -40.22 90.4 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.359 -0.838 . . . . 10.0 113.168 176.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -149.96 88.92 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.838 1.655 . . . . 10.0 110.104 -178.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -68.53 140.29 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 O-C-N 121.378 -0.826 . . . . 10.0 112.045 -176.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -124.78 160.64 28.21 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.463 1.905 . . . . 10.0 111.841 177.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.14 -34.32 63.66 Favored 'General case' 0 CA--C 1.547 0.828 0 N-CA-C 113.509 0.929 . . . . 10.0 113.509 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.4 m -65.05 -17.46 64.47 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.499 1.52 . . . . 10.0 114.62 175.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -80.99 -6.53 58.88 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.446 1.098 . . . . 10.0 113.324 177.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.88 148.44 51.4 Favored 'General case' 0 CA--C 1.547 0.843 0 O-C-N 121.017 -1.052 . . . . 10.0 112.77 177.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 139.75 -174.75 22.19 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.844 1.211 . . . . 10.0 114.815 177.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.81 108.68 17.6 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.971 1.708 . . . . 10.0 110.932 175.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.5 m-85 -86.12 151.96 23.25 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.208 1.003 . . . . 10.0 111.869 172.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.97 160.68 39.88 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.933 0.893 . . . . 10.0 112.006 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.0 t -137.57 107.47 6.3 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.753 1.621 . . . . 10.0 110.586 177.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.5 t -76.05 132.9 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.294 1.037 . . . . 10.0 108.937 169.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -128.3 121.79 30.08 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 126.372 1.869 . . . . 10.0 110.494 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -134.4 139.45 45.59 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.941 1.297 . . . . 10.0 112.604 -171.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.3 p30 -133.74 -178.31 4.95 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.609 1.164 . . . . 10.0 111.259 165.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -61.9 -7.79 4.2 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 115.667 1.729 . . . . 10.0 115.667 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -117.7 -12.7 10.24 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 126.135 1.774 . . . . 10.0 114.578 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.01 -172.66 44.48 Favored Glycine 0 CA--C 1.535 1.308 0 CA-C-N 119.776 1.171 . . . . 10.0 115.924 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -137.8 144.23 41.44 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.992 2.117 . . . . 10.0 111.625 -174.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.64 162.96 33.3 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.594 1.957 . . . . 10.0 110.626 168.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -141.99 124.5 15.77 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.389 1.076 . . . . 10.0 110.736 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -105.14 154.39 20.25 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.33 1.452 . . . . 10.0 110.898 178.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.7 m -144.03 145.12 31.98 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 124.271 1.028 . . . . 10.0 112.035 -170.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.8 p -154.11 171.64 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 C-N-CA 126.595 1.958 . . . . 10.0 110.976 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -131.92 147.88 52.49 Favored 'General case' 0 N--CA 1.471 0.614 0 O-C-N 120.77 -1.206 . . . . 10.0 111.622 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.7 tp -131.14 117.04 18.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 126.283 1.833 . . . . 10.0 110.2 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -106.4 77.68 1.23 Allowed 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.681 1.592 . . . . 10.0 110.481 178.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -58.37 114.31 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.414 1.086 . . . . 10.0 111.014 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.5 mt -76.25 99.58 4.8 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.477 1.911 . . . . 10.0 109.831 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.838 0 C-N-CA 123.975 0.91 . . . . 10.0 113.117 -177.656 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo . . . . . 0 CA--C 1.543 0.944 0 N-CA-C 113.027 0.357 . . . . 10.0 113.027 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -68.24 143.19 57.9 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.133 2.555 . . . . 10.0 111.497 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -131.24 149.45 52.57 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.96 1.304 . . . . 10.0 113.757 -174.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -77.76 111.13 13.24 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.019 2.527 . . . . 10.0 110.939 176.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.5 mm -109.34 -44.66 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.772 0.829 . . . . 10.0 111.104 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -149.51 142.18 24.53 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.708 1.203 . . . . 10.0 111.494 170.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -122.91 135.69 26.08 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 124.873 1.269 . . . . 10.0 109.278 158.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -75.47 159.88 39.18 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.003 2.468 . . . . 10.0 112.206 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -67.44 164.84 17.86 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.92 1.288 . . . . 10.0 112.111 171.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -62.49 113.77 3.15 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.216 -0.928 . . . . 10.0 111.332 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 29.0 mtm -76.22 148.87 37.37 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.736 -0.603 . . . . 10.0 111.69 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 24.0 p -128.08 102.76 6.87 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 125.705 1.602 . . . . 10.0 110.468 176.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.7 mm -121.8 123.61 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.931 1.293 . . . . 10.0 110.63 -163.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -58.86 126.23 26.83 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.134 1.374 . . . . 10.0 111.893 170.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -53.22 136.37 36.58 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.126 1.371 . . . . 10.0 113.468 -176.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 94.93 -10.92 70.09 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 125.97 1.747 . . . . 10.0 114.808 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 73.8 mtp180 -72.5 158.92 34.81 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 118.877 1.339 . . . . 10.0 113.479 177.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -75.31 141.04 43.45 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.373 1.069 . . . . 10.0 110.265 154.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 32.0 p -150.76 170.87 18.18 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.583 0.753 . . . . 10.0 112.269 160.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -145.83 144.06 30.02 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.195 1.398 . . . . 10.0 111.74 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.7 mtt -91.75 159.33 15.88 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.084 1.354 . . . . 10.0 110.665 169.028 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -138.15 109.83 7.09 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.231 1.412 . . . . 10.0 112.557 -177.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -116.56 98.47 6.56 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.646 1.978 . . . . 10.0 110.383 -176.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 29.5 mtpp -67.87 137.88 55.62 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.148 -0.97 . . . . 10.0 110.196 171.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.28 152.83 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.486 1.514 . . . . 10.0 111.27 -172.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -136.5 174.87 10.14 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.28 1.432 . . . . 10.0 111.164 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 121.07 164.34 12.31 Favored Glycine 0 CA--C 1.538 1.478 0 C-N-CA 127.288 2.375 . . . . 10.0 112.878 -174.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.0 tp -153.04 135.04 8.87 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.752 1.221 . . . . 10.0 110.978 -179.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -68.38 172.11 44.74 Favored 'Cis proline' 0 CA--C 1.54 0.794 0 CA-C-N 120.815 1.327 . . . . 10.0 112.722 -4.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.69 122.58 52.33 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.777 1.231 . . . . 10.0 111.777 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -72.17 155.43 56.54 Favored 'Trans proline' 0 CA--C 1.538 0.713 0 C-N-CA 122.618 2.212 . . . . 10.0 113.542 -172.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -79.13 74.41 5.69 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.316 1.846 . . . . 10.0 111.517 177.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 15.3 m -56.69 122.46 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 125.526 1.53 . . . . 10.0 113.194 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 66.3 m -133.69 111.56 10.68 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 126.334 1.853 . . . . 10.0 111.145 -172.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.4 m95 -87.59 149.77 24.11 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 114.43 1.271 . . . . 10.0 114.43 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -141.6 160.43 40.17 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.606 2.363 . . . . 10.0 111.463 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.4 tp -148.19 123.5 10.26 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 127.733 2.413 . . . . 10.0 109.989 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 53.58 16.03 0.87 Allowed 'General case' 0 CA--C 1.556 1.196 0 C-N-CA 126.498 1.919 . . . . 10.0 115.844 175.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.25 0.04 33.22 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.679 1.609 . . . . 10.0 115.824 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -117.11 162.4 17.89 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 126.031 1.732 . . . . 10.0 111.376 173.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.1 p -69.28 158.69 34.52 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.499 1.119 . . . . 10.0 113.017 178.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 43.6 t -130.82 106.91 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 126.011 1.724 . . . . 10.0 108.607 170.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -72.92 153.25 41.06 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.48 0.712 . . . . 10.0 111.377 172.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 32.2 p -68.25 150.29 48.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.615 0.766 . . . . 10.0 112.026 171.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -151.89 169.65 21.76 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.148 1.379 . . . . 10.0 110.798 175.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -62.52 -31.55 72.34 Favored 'General case' 0 N--CA 1.471 0.625 0 O-C-N 120.464 -1.398 . . . . 10.0 112.549 169.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 97.8 mt -73.99 -22.31 59.65 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.012 0.925 . . . . 10.0 113.468 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -136.75 67.91 1.44 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.152 1.781 . . . . 10.0 111.108 -171.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 63.8 mttm -69.78 142.73 53.15 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.183 0.993 . . . . 10.0 111.336 -177.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -135.51 102.9 5.27 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 126.724 2.01 . . . . 10.0 109.423 -173.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.55 155.71 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 124.165 0.986 . . . . 10.0 112.546 -173.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.66 165.51 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 126.484 1.914 . . . . 10.0 111.188 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 39.0 t -137.72 146.83 44.2 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.797 1.239 . . . . 10.0 112.642 -178.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -56.98 -20.47 24.06 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.244 1.818 . . . . 10.0 113.837 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -74.71 -1.51 22.23 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.745 1.618 . . . . 10.0 114.014 176.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.2 48.01 5.27 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.072 1.32 . . . . 10.0 112.987 178.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.0 tp -140.28 146.96 39.24 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.475 1.51 . . . . 10.0 111.625 -175.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -129.43 132.86 47.08 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.085 2.154 . . . . 10.0 109.678 170.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 67.6 m -119.28 149.2 42.17 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.844 1.258 . . . . 10.0 112.319 178.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -136.21 110.19 8.24 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.045 2.138 . . . . 10.0 108.478 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -95.18 153.34 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.641 1.576 . . . . 10.0 111.151 -171.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -129.54 107.64 9.63 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.92 2.088 . . . . 10.0 108.761 161.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -63.75 -43.25 96.99 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 121.447 -0.783 . . . . 10.0 113.077 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 2.8 p -150.08 87.08 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 126.156 1.782 . . . . 10.0 109.333 -178.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.8 p -66.99 141.13 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 O-C-N 121.525 -0.734 . . . . 10.0 111.8 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -127.07 160.12 32.13 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 126.429 1.892 . . . . 10.0 111.046 177.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.24 -33.79 59.23 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.009 1.114 . . . . 10.0 114.009 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.41 -17.77 64.09 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.287 1.435 . . . . 10.0 114.547 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -81.4 -8.17 59.69 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.656 1.182 . . . . 10.0 113.413 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -62.97 146.28 53.46 Favored 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.136 -0.977 . . . . 10.0 112.622 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.64 -175.37 23.64 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.024 0.821 . . . . 10.0 114.936 178.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.71 105.5 16.99 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 126.196 1.798 . . . . 10.0 111.257 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -84.94 150.76 24.72 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.714 1.206 . . . . 10.0 111.932 173.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.64 160.74 40.67 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 123.865 0.866 . . . . 10.0 112.249 170.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 47.3 t -138.21 109.12 6.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.58 1.552 . . . . 10.0 110.753 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 93.9 t -76.98 134.86 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.638 1.175 . . . . 10.0 109.146 169.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -132.37 114.5 14.44 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.245 1.818 . . . . 10.0 110.13 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.6 mtpp -129.8 136.61 49.79 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.409 1.484 . . . . 10.0 111.722 -174.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 28.3 p30 -133.26 -179.41 5.49 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.893 1.277 . . . . 10.0 111.371 168.295 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -62.2 -9.93 9.17 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 115.662 1.726 . . . . 10.0 115.662 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.72 -16.12 13.27 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.744 1.618 . . . . 10.0 114.471 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.29 -168.06 40.96 Favored Glycine 0 CA--C 1.536 1.36 0 CA-C-N 119.992 1.269 . . . . 10.0 116.241 176.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -136.24 143.93 44.58 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.995 2.118 . . . . 10.0 112.21 -171.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.25 160.19 40.51 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.774 2.03 . . . . 10.0 110.476 166.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 53.1 m -144.2 116.16 8.33 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.445 1.098 . . . . 10.0 110.61 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -98.0 151.07 20.69 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.16 1.384 . . . . 10.0 110.979 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.5 m -142.32 146.3 34.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 124.613 1.165 . . . . 10.0 111.819 -174.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -153.06 174.58 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 126.721 2.008 . . . . 10.0 110.916 173.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -130.47 150.58 51.62 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.176 1.39 . . . . 10.0 111.118 173.047 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.5 tp -125.16 108.36 11.7 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 110.846 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -90.4 81.07 6.03 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.258 1.823 . . . . 10.0 110.473 176.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.9 t -68.44 109.5 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 121.119 -0.988 . . . . 10.0 110.472 177.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.7 mt -77.55 97.64 5.11 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.774 1.63 . . . . 10.0 109.548 177.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.867 0 C-N-CA 124.592 1.157 . . . . 10.0 113.957 -172.728 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 CA--C 1.542 0.918 0 N-CA-C 113.116 0.391 . . . . 10.0 113.116 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.76 161.71 44.28 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.934 2.423 . . . . 10.0 111.072 166.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.86 166.47 24.37 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.471 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -85.93 71.95 10.55 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.355 1.862 . . . . 10.0 111.543 -173.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . 0.499 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.5 OUTLIER -73.55 179.78 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 125.031 1.333 . . . . 10.0 111.137 176.889 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.499 ' H ' HG22 ' A' ' 253' ' ' ILE . 35.3 tt0 -50.06 140.02 13.2 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.152 2.181 . . . . 10.0 114.336 -175.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.4 m -127.12 152.11 75.36 Favored Pre-proline 0 N--CA 1.477 0.915 0 C-N-CA 126.696 1.998 . . . . 10.0 110.982 172.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -77.2 159.22 33.46 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.249 2.632 . . . . 10.0 112.429 174.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -69.47 172.39 7.31 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.19 1.396 . . . . 10.0 112.263 169.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -55.65 111.74 0.98 Allowed 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 124.578 1.151 . . . . 10.0 112.854 173.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.7 mtp -82.58 155.63 24.36 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.769 1.628 . . . . 10.0 112.121 -177.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -147.22 109.38 4.49 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.249 1.419 . . . . 10.0 111.062 175.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.2 mm -123.01 133.37 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.248 1.419 . . . . 10.0 110.464 -168.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.74 130.98 47.36 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.096 1.359 . . . . 10.0 112.562 174.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -52.78 133.63 37.01 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.254 1.421 . . . . 10.0 112.862 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 93.22 -9.84 74.22 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.784 1.659 . . . . 10.0 115.276 177.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.1 mtp-105 -75.79 161.15 29.27 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 119.179 1.489 . . . . 10.0 113.018 176.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -72.46 147.33 46.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.442 1.097 . . . . 10.0 110.605 157.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 9.0 t -149.67 164.8 34.21 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.569 1.148 . . . . 10.0 111.582 165.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.7 ptm180 -149.54 155.41 40.29 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.645 1.578 . . . . 10.0 111.62 163.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 40.6 mtt -102.43 166.85 10.31 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.614 1.566 . . . . 10.0 112.071 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -132.73 110.9 10.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.331 1.852 . . . . 10.0 111.099 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -127.31 101.74 6.61 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 125.322 1.449 . . . . 10.0 111.172 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -60.36 142.76 54.41 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.513 -0.742 . . . . 10.0 110.296 172.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.0 p -148.98 146.3 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 124.597 1.159 . . . . 10.0 111.753 -175.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 51.8 m -139.19 178.59 7.07 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 126.341 1.856 . . . . 10.0 111.454 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 112.64 161.27 15.22 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 126.349 1.928 . . . . 10.0 113.092 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.15 129.93 7.43 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 125.145 1.378 . . . . 10.0 110.638 -179.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -66.39 168.86 48.14 Favored 'Cis proline' 0 CA--C 1.54 0.798 0 CA-C-N 120.806 1.324 . . . . 10.0 112.546 -2.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.63 120.62 33.43 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 124.673 1.189 . . . . 10.0 111.658 -177.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.0 159.5 52.3 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.597 2.198 . . . . 10.0 113.265 -174.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -68.7 169.41 11.28 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.336 1.454 . . . . 10.0 111.923 171.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 87.1 t -131.95 112.99 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.302 1.841 . . . . 10.0 110.165 -176.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 70.8 m -131.54 100.3 5.09 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.238 1.415 . . . . 10.0 110.91 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -84.02 154.64 23.15 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 122.035 0.921 . . . . 10.0 113.29 176.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -142.53 160.35 40.45 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.749 2.419 . . . . 10.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -148.83 124.06 10.18 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.104 2.161 . . . . 10.0 109.98 176.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.54 10.99 0.38 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 126.996 2.118 . . . . 10.0 116.378 174.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.51 -0.96 22.02 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.847 1.689 . . . . 10.0 115.852 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -117.36 163.99 15.52 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.795 1.638 . . . . 10.0 111.929 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.0 p -71.63 160.31 32.89 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.626 1.17 . . . . 10.0 112.948 178.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 64.5 t -136.24 111.29 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 126.632 1.973 . . . . 10.0 108.903 173.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -85.02 159.18 20.28 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.831 0.853 . . . . 10.0 111.199 170.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.9 p -69.61 151.06 46.38 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.725 0.81 . . . . 10.0 112.426 171.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -151.36 179.27 8.47 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.492 1.517 . . . . 10.0 110.79 166.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -56.71 -30.74 63.79 Favored 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 114.327 1.232 . . . . 10.0 114.327 -177.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 55.7 mt -87.63 -13.31 43.06 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.912 1.285 . . . . 10.0 113.514 175.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -135.64 68.12 1.46 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.158 1.783 . . . . 10.0 111.226 -172.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -67.86 145.13 54.92 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.089 1.356 . . . . 10.0 111.167 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.2 mtt -135.21 102.68 5.26 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 126.774 2.029 . . . . 10.0 109.726 -175.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.97 158.54 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.822 1.249 . . . . 10.0 112.212 -175.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 38.7 t -133.64 113.97 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 125.778 1.631 . . . . 10.0 109.73 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 46.6 t -64.89 141.15 58.87 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.917 0.887 . . . . 10.0 111.518 172.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -57.76 -19.48 28.18 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.72 1.208 . . . . 10.0 113.946 173.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.5 -3.45 40.59 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.454 1.502 . . . . 10.0 113.697 176.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.66 43.05 4.32 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.293 1.425 . . . . 10.0 113.883 176.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 61.9 tp -137.13 107.03 6.26 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.077 1.351 . . . . 10.0 111.578 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -80.43 138.61 36.63 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 125.379 1.471 . . . . 10.0 111.227 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 60.6 m -122.19 146.51 47.18 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 125.917 1.687 . . . . 10.0 111.807 174.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -134.13 112.54 11.22 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.214 2.206 . . . . 10.0 108.211 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -94.13 154.69 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.399 1.48 . . . . 10.0 111.55 -170.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -131.96 99.05 4.62 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.381 2.272 . . . . 10.0 108.96 163.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -62.11 -39.23 91.82 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 120.943 -1.098 . . . . 10.0 113.125 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.6 p -150.52 90.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.998 1.719 . . . . 10.0 109.839 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.1 p -68.54 140.23 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 121.39 -0.819 . . . . 10.0 112.148 -175.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 27.2 mmt180 -126.13 162.09 26.16 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.463 1.905 . . . . 10.0 111.834 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.98 -33.4 64.78 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.431 0.9 . . . . 10.0 113.431 -177.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 m -64.11 -18.01 64.0 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.386 1.474 . . . . 10.0 114.472 175.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -83.33 -5.99 59.32 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.609 1.164 . . . . 10.0 113.32 177.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.06 152.29 44.99 Favored 'General case' 0 CA--C 1.547 0.852 0 O-C-N 121.039 -1.038 . . . . 10.0 113.191 179.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 137.08 -173.32 22.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 124.689 1.138 . . . . 10.0 115.161 175.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.08 102.05 13.5 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.143 1.777 . . . . 10.0 111.234 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -80.91 153.6 27.48 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.624 1.17 . . . . 10.0 112.169 170.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.21 162.7 36.5 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.238 1.015 . . . . 10.0 111.795 166.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.3 t -139.64 125.52 19.65 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 125.446 1.499 . . . . 10.0 110.827 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 96.2 t -97.63 134.82 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 125.436 1.495 . . . . 10.0 109.7 174.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.19 117.33 22.13 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.224 1.809 . . . . 10.0 110.794 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -132.96 140.35 47.76 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.197 1.399 . . . . 10.0 112.196 -172.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.4 p30 -135.04 -177.83 4.81 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.234 1.414 . . . . 10.0 111.209 166.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -62.23 -13.26 26.03 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 115.624 1.713 . . . . 10.0 115.624 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -104.15 -22.54 13.39 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.33 1.452 . . . . 10.0 114.183 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.79 -166.24 39.44 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 116.098 1.199 . . . . 10.0 116.098 179.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.91 146.13 47.02 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.93 2.092 . . . . 10.0 112.098 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.71 167.0 23.21 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.553 1.941 . . . . 10.0 111.037 166.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 10.8 m -145.2 148.68 33.81 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.338 1.055 . . . . 10.0 111.071 -177.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -132.17 151.15 51.95 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.039 1.736 . . . . 10.0 110.647 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.3 m -143.45 145.98 33.05 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 125.034 1.334 . . . . 10.0 111.642 -174.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.9 p -154.2 156.42 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 126.016 1.727 . . . . 10.0 110.99 170.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -110.91 141.42 44.34 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.353 1.061 . . . . 10.0 110.485 169.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.4 tp -124.14 106.8 10.62 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.07 1.748 . . . . 10.0 110.321 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -94.54 83.22 4.08 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.435 1.494 . . . . 10.0 110.824 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.0 t -64.05 113.56 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 O-C-N 121.372 -0.83 . . . . 10.0 110.704 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.45 97.49 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.1 1.76 . . . . 10.0 110.073 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.83 0 C-N-CA 124.384 1.074 . . . . 10.0 113.429 -177.405 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_endo . . . . . 0 CA--C 1.544 1.001 0 N-CA-C 113.549 0.557 . . . . 10.0 113.549 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -70.53 148.0 59.1 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.204 2.603 . . . . 10.0 112.054 173.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -136.46 158.59 44.07 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 125.576 1.551 . . . . 10.0 112.758 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -84.41 79.41 9.57 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.293 2.237 . . . . 10.0 112.261 -174.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 44.4 mm -73.41 -55.31 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.529 -0.732 . . . . 10.0 111.21 178.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.22 129.52 10.53 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.5 1.12 . . . . 10.0 111.705 176.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.1 m -104.09 148.17 35.48 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 124.669 1.188 . . . . 10.0 110.196 158.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.32 162.4 36.36 Favored 'Trans proline' 0 CA--C 1.542 0.882 0 C-N-CA 122.99 2.46 . . . . 10.0 111.155 171.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -73.66 168.29 19.65 Favored 'General case' 0 CA--C 1.545 0.783 0 O-C-N 121.389 -0.82 . . . . 10.0 111.655 169.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.5 p30 -61.79 160.22 12.28 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.422 -0.799 . . . . 10.0 112.405 172.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.2 mtm -132.56 160.4 36.66 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.079 0.952 . . . . 10.0 113.073 -178.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 p -136.07 103.14 5.24 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 126.192 1.797 . . . . 10.0 110.527 175.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.5 mm -119.37 131.27 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.247 1.419 . . . . 10.0 110.723 -165.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -60.91 129.07 39.62 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.804 1.242 . . . . 10.0 112.558 173.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -54.21 127.8 28.43 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.825 1.25 . . . . 10.0 112.596 -178.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.13 -10.27 61.71 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 126.187 1.851 . . . . 10.0 115.036 178.16 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 27.1 mtp-105 -73.84 163.93 27.3 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.116 1.458 . . . . 10.0 113.099 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -75.37 141.18 43.34 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.895 1.278 . . . . 10.0 110.506 158.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.46 170.32 19.89 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.756 0.822 . . . . 10.0 112.343 162.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -146.84 163.32 36.44 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.37 1.468 . . . . 10.0 112.757 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -134.97 140.3 45.59 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.215 2.206 . . . . 10.0 109.137 175.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -131.97 125.7 32.21 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.795 1.238 . . . . 10.0 111.974 -168.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -129.17 111.81 13.3 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 126.789 2.035 . . . . 10.0 111.624 -167.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -73.65 120.55 19.4 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 121.587 -0.696 . . . . 10.0 109.808 171.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -130.11 108.92 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.792 2.037 . . . . 10.0 110.831 -171.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.8 t -76.79 -174.77 3.17 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.336 1.054 . . . . 10.0 112.301 174.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 100.27 160.58 28.25 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 126.92 2.2 . . . . 10.0 113.795 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -151.17 135.26 9.53 Favored Pre-proline 0 CA--C 1.548 0.889 0 C-N-CA 126.044 1.738 . . . . 10.0 109.531 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.18 169.94 37.76 Favored 'Cis proline' 0 CA--C 1.539 0.76 0 CA-C-N 121.15 1.447 . . . . 10.0 112.373 -6.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 123.18 51.65 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 124.581 1.153 . . . . 10.0 111.278 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -70.88 161.57 45.61 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 122.501 2.134 . . . . 10.0 113.333 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 40.2 m-20 -65.66 170.56 5.02 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.826 1.25 . . . . 10.0 111.761 165.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 5.6 p -138.37 122.96 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.219 1.408 . . . . 10.0 111.471 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.0 m -137.36 106.25 5.94 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.818 1.647 . . . . 10.0 110.563 174.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.8 m95 -85.86 153.54 22.17 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 123.953 0.901 . . . . 10.0 113.223 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.19 159.0 43.1 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.979 2.112 . . . . 10.0 111.295 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -143.93 117.07 8.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 127.072 2.149 . . . . 10.0 110.281 175.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 54.07 18.86 1.85 Allowed 'General case' 0 CA--C 1.554 1.116 0 C-N-CA 126.375 1.87 . . . . 10.0 114.558 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.97 -9.35 46.86 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.422 1.963 . . . . 10.0 115.476 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.18 155.13 19.61 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.044 1.422 . . . . 10.0 110.166 171.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.6 p -69.34 155.24 40.75 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.801 0.84 . . . . 10.0 112.585 173.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 57.4 t -133.12 105.04 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.332 1.853 . . . . 10.0 108.766 173.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 95.4 mm-40 -72.62 159.59 33.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.498 0.719 . . . . 10.0 111.701 173.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.3 p -70.11 154.9 41.36 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.35 0.66 . . . . 10.0 111.67 166.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -154.15 168.95 24.78 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.404 1.482 . . . . 10.0 111.025 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -57.83 -34.55 69.8 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.792 -1.193 . . . . 10.0 112.658 168.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.3 mt -82.79 -15.16 52.77 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.556 1.142 . . . . 10.0 113.9 173.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -134.61 69.41 1.46 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.011 1.724 . . . . 10.0 111.324 -173.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -70.61 144.4 51.18 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.086 1.354 . . . . 10.0 111.666 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.3 mtt -141.14 103.36 4.43 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 126.835 2.054 . . . . 10.0 109.723 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.75 162.03 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 C-N-CA 124.617 1.167 . . . . 10.0 112.66 -176.683 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 t -133.83 113.91 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.632 1.573 . . . . 10.0 109.698 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 66.8 m -69.04 144.46 54.03 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.47 0.708 . . . . 10.0 111.053 171.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.03 -17.1 56.24 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.487 1.515 . . . . 10.0 114.579 -176.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -74.44 -4.88 39.3 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 126.155 1.782 . . . . 10.0 114.107 173.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.17 38.35 5.71 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 125.139 1.352 . . . . 10.0 113.644 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 44.4 tp -125.68 102.54 7.38 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.424 1.489 . . . . 10.0 110.646 -177.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -78.25 145.26 35.56 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.009 0.924 . . . . 10.0 110.926 169.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 32.6 t -134.53 145.52 48.83 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.943 1.297 . . . . 10.0 111.985 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -130.63 120.53 24.1 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.434 2.694 . . . . 10.0 108.115 -178.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.4 152.33 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.605 1.162 . . . . 10.0 111.424 -170.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -125.96 108.84 11.79 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 127.273 2.229 . . . . 10.0 108.892 168.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -65.98 -38.45 88.56 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.323 -0.861 . . . . 10.0 112.715 175.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.2 p -150.28 86.82 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 126.098 1.759 . . . . 10.0 110.043 -178.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.5 p -66.64 139.6 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 O-C-N 121.3 -0.875 . . . . 10.0 111.827 -177.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -119.69 160.82 21.8 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.964 1.705 . . . . 10.0 112.069 176.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.29 -31.62 65.81 Favored 'General case' 0 CA--C 1.548 0.891 0 N-CA-C 113.709 1.003 . . . . 10.0 113.709 -176.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -65.3 -21.13 66.68 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.125 1.37 . . . . 10.0 113.891 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -77.66 -6.16 52.91 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.68 1.192 . . . . 10.0 113.591 178.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.2 147.79 52.82 Favored 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.874 -1.141 . . . . 10.0 112.695 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.76 -172.6 22.49 Favored Glycine 0 CA--C 1.532 1.155 0 C-N-CA 124.767 1.175 . . . . 10.0 114.894 177.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.92 109.83 18.43 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.981 1.712 . . . . 10.0 111.06 175.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -85.15 153.72 22.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.473 1.109 . . . . 10.0 112.213 171.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.17 159.34 42.42 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.172 0.989 . . . . 10.0 112.069 167.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -139.03 104.26 4.99 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.76 1.624 . . . . 10.0 110.827 -178.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.8 t -76.39 129.61 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.316 1.046 . . . . 10.0 109.692 171.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.68 117.91 20.16 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.668 1.987 . . . . 10.0 110.681 178.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -132.11 139.63 48.53 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.299 1.44 . . . . 10.0 112.017 -172.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 26.8 p30 -134.27 -177.98 4.83 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.903 1.281 . . . . 10.0 111.411 167.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -61.29 -11.22 8.91 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.778 1.77 . . . . 10.0 115.778 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.97 -19.78 12.23 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.409 1.484 . . . . 10.0 114.443 -178.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.44 -170.39 43.51 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 116.149 1.22 . . . . 10.0 116.149 178.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -136.8 144.17 43.56 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.968 2.107 . . . . 10.0 111.819 -170.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.68 157.1 47.2 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 126.482 1.913 . . . . 10.0 110.534 166.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -140.12 98.03 3.36 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.64 1.176 . . . . 10.0 110.206 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -75.35 156.97 34.96 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.107 0.963 . . . . 10.0 111.467 177.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 33.0 m -144.87 143.47 30.61 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.058 1.343 . . . . 10.0 111.348 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.5 p -153.95 170.74 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 C-N-CA 126.215 1.806 . . . . 10.0 110.867 173.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 -131.15 146.81 52.48 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.756 1.222 . . . . 10.0 111.88 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.5 tp -131.76 119.41 21.25 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.057 1.743 . . . . 10.0 111.018 -178.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -104.35 83.02 2.01 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.79 1.636 . . . . 10.0 110.857 176.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.05 110.89 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 O-C-N 121.531 -0.731 . . . . 10.0 110.692 -179.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 67.4 mt -73.01 97.95 2.42 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.305 1.842 . . . . 10.0 109.87 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.823 0 C-N-CA 124.644 1.177 . . . . 10.0 113.661 -173.488 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo . . . . . 0 CA--C 1.543 0.963 0 N-CA-C 112.943 0.324 . . . . 10.0 112.943 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -70.23 166.07 29.41 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.144 2.562 . . . . 10.0 112.428 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 21.3 tpp180 -140.77 147.18 38.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.462 1.105 . . . . 10.0 112.436 -174.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -76.8 58.06 1.38 Allowed 'General case' 0 CA--C 1.55 0.977 0 C-N-CA 128.564 2.746 . . . . 10.0 112.409 -177.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.3 mm -60.64 -58.5 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.964 -1.085 . . . . 10.0 112.63 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -154.35 153.34 31.45 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 119.006 0.821 . . . . 10.0 113.172 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 17.8 m -131.05 155.57 81.37 Favored Pre-proline 0 N--CA 1.479 0.997 0 C-N-CA 127.371 2.269 . . . . 10.0 110.382 167.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -74.8 166.14 29.93 Favored 'Trans proline' 0 CA--C 1.542 0.921 0 C-N-CA 122.771 2.314 . . . . 10.0 111.499 168.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -73.05 176.45 5.77 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.446 -0.784 . . . . 10.0 111.194 163.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -59.18 152.83 19.62 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.911 -1.118 . . . . 10.0 112.128 171.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.7 mtp -132.46 157.19 45.24 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 125.526 1.531 . . . . 10.0 111.946 -172.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 76.4 p -145.93 136.79 24.43 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 125.26 1.424 . . . . 10.0 110.856 169.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 24.9 mm -138.4 133.08 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.581 1.552 . . . . 10.0 109.531 -170.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -63.85 131.12 46.8 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.639 1.175 . . . . 10.0 112.302 173.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -51.54 130.59 28.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.515 1.526 . . . . 10.0 113.305 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.4 -10.25 67.13 Favored Glycine 0 CA--C 1.537 1.426 0 C-N-CA 126.185 1.85 . . . . 10.0 115.175 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.3 mtp180 -72.3 161.33 30.99 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.037 1.418 . . . . 10.0 113.356 177.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -71.49 148.6 46.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.678 1.191 . . . . 10.0 110.637 156.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.8 t -147.06 154.62 41.39 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.941 1.296 . . . . 10.0 111.019 168.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -145.53 166.18 26.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.747 1.219 . . . . 10.0 112.547 165.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 49.5 mtt -133.07 166.9 21.35 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.471 1.908 . . . . 10.0 111.815 -176.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -134.39 117.65 16.56 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.082 1.753 . . . . 10.0 111.694 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -127.83 99.55 5.58 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.551 1.54 . . . . 10.0 111.358 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -66.41 123.31 19.64 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.862 0.865 . . . . 10.0 110.115 172.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 5.9 p -142.45 102.63 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.311 1.845 . . . . 10.0 110.684 -176.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.7 t -75.68 -177.25 3.63 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.003 0.921 . . . . 10.0 111.855 172.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 117.32 160.3 11.73 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 127.356 2.408 . . . . 10.0 113.319 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -149.47 128.38 6.15 Favored Pre-proline 0 CA--C 1.548 0.871 0 C-N-CA 124.797 1.239 . . . . 10.0 110.414 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -66.86 169.61 47.63 Favored 'Cis proline' 0 CA--C 1.54 0.809 0 CA-C-N 121.06 1.414 . . . . 10.0 112.507 -3.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.18 122.59 55.06 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.616 1.166 . . . . 10.0 111.429 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.57 151.39 64.42 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 122.55 2.167 . . . . 10.0 113.284 -173.098 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.99 145.66 46.54 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.337 1.055 . . . . 10.0 109.963 160.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.68 86.37 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.091 1.356 . . . . 10.0 112.103 -165.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.4 m -78.5 116.1 18.66 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.866 1.267 . . . . 10.0 111.506 177.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.1 m95 -90.27 155.77 18.76 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.704 1.001 . . . . 10.0 113.704 177.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.34 160.54 41.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.476 2.311 . . . . 10.0 111.495 -177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.9 tp -147.23 119.76 8.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.392 2.277 . . . . 10.0 110.024 174.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 54.9 15.0 1.01 Allowed 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 126.645 1.978 . . . . 10.0 115.145 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.58 -13.23 35.8 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 126.631 2.063 . . . . 10.0 115.19 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -86.84 159.55 19.04 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 118.971 1.385 . . . . 10.0 110.833 169.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.7 p -73.21 159.15 33.91 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.098 0.959 . . . . 10.0 112.729 174.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 90.5 t -137.12 145.71 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 127.008 2.123 . . . . 10.0 108.775 171.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 80.4 mt-30 -128.1 163.21 25.13 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.295 1.438 . . . . 10.0 111.285 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.5 p -68.35 152.61 45.19 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.657 0.783 . . . . 10.0 112.613 176.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -152.17 168.18 26.16 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.978 1.711 . . . . 10.0 110.641 175.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.45 -35.12 67.53 Favored 'General case' 0 CA--C 1.544 0.741 0 O-C-N 120.906 -1.121 . . . . 10.0 112.76 169.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.0 mt -84.84 -12.99 52.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.608 1.163 . . . . 10.0 113.979 173.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.9 m80 -136.59 71.18 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.633 1.573 . . . . 10.0 111.453 -173.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -71.89 147.45 47.07 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.797 1.239 . . . . 10.0 111.898 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.6 mtt -141.54 107.28 5.11 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 126.846 2.058 . . . . 10.0 109.908 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.0 157.93 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.641 1.176 . . . . 10.0 112.398 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.1 t -133.81 113.93 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.893 1.677 . . . . 10.0 109.928 -177.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 68.7 m -70.38 151.27 45.4 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.954 0.902 . . . . 10.0 112.132 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -57.45 -32.18 66.67 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 125.766 1.627 . . . . 10.0 113.856 -175.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . 0.422 ' HA ' ' HE2' ' A' ' 303' ' ' LYS . 11.3 mmpt? -70.82 -3.39 18.71 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 126.174 1.79 . . . . 10.0 114.425 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.83 49.92 3.91 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 125.006 1.289 . . . . 10.0 112.897 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 65.1 tp -130.72 104.15 7.01 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.455 1.502 . . . . 10.0 110.469 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -83.7 125.9 32.35 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 125.145 1.378 . . . . 10.0 111.229 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.8 m -102.86 142.67 33.58 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.243 1.417 . . . . 10.0 111.739 169.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -130.55 126.07 35.84 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 127.469 2.308 . . . . 10.0 107.884 175.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 44.1 mt -122.1 152.68 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.237 1.415 . . . . 10.0 111.722 -167.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.93 109.98 10.93 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 128.059 2.544 . . . . 10.0 109.064 169.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.33 -38.87 85.59 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.02 -1.05 . . . . 10.0 113.069 177.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.04 88.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 125.723 1.609 . . . . 10.0 110.286 -178.059 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -70.66 141.81 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 O-C-N 121.235 -0.915 . . . . 10.0 112.313 -175.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -126.18 163.21 23.63 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 126.631 1.972 . . . . 10.0 111.958 177.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.1 -31.56 65.4 Favored 'General case' 0 CA--C 1.548 0.875 0 N-CA-C 113.899 1.074 . . . . 10.0 113.899 -177.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.5 m -68.28 -15.91 63.75 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 114.216 1.191 . . . . 10.0 114.216 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -82.83 -5.16 58.84 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.432 1.093 . . . . 10.0 113.308 177.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 150.22 48.84 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.933 -1.104 . . . . 10.0 113.143 178.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.17 -175.19 21.06 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.905 1.241 . . . . 10.0 115.279 174.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.12 98.05 7.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.801 1.64 . . . . 10.0 111.246 175.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -74.5 150.96 39.61 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 123.556 0.742 . . . . 10.0 111.479 167.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.01 161.9 38.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 123.966 0.906 . . . . 10.0 111.997 168.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.1 t -137.31 139.01 40.6 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.737 1.615 . . . . 10.0 110.487 176.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.9 t -117.17 104.7 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.289 1.835 . . . . 10.0 108.862 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -89.64 118.06 28.98 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 126.283 1.833 . . . . 10.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -129.84 132.61 46.53 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.085 1.354 . . . . 10.0 112.598 -176.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -129.44 -179.02 4.92 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.834 1.253 . . . . 10.0 111.513 166.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -61.64 -12.28 15.36 Favored 'General case' 0 N--CA 1.482 1.129 0 N-CA-C 115.726 1.75 . . . . 10.0 115.726 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.18 -20.03 12.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 125.383 1.473 . . . . 10.0 114.424 -178.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 172.92 -169.26 42.42 Favored Glycine 0 CA--C 1.534 1.232 0 N-CA-C 116.101 1.2 . . . . 10.0 116.101 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -134.19 143.8 48.09 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 126.939 2.095 . . . . 10.0 111.909 -171.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.25 165.92 25.0 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.281 1.833 . . . . 10.0 111.076 168.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 19.0 m -141.57 141.59 33.5 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.203 1.001 . . . . 10.0 111.569 -173.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -134.47 150.93 50.87 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.797 1.639 . . . . 10.0 110.556 -178.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -146.4 146.81 30.76 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 124.454 1.102 . . . . 10.0 111.786 -169.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.7 p -152.97 146.68 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 125.251 1.42 . . . . 10.0 112.026 170.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 9.2 tp-100 -100.14 127.47 46.39 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 125.667 1.587 . . . . 10.0 110.245 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -121.18 105.56 10.7 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.542 1.537 . . . . 10.0 111.261 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -93.62 85.79 4.99 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.268 1.427 . . . . 10.0 111.319 175.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.6 t -66.14 115.35 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 121.301 -0.874 . . . . 10.0 110.826 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.3 mt -78.91 100.0 7.04 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.437 1.895 . . . . 10.0 110.356 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.805 0 C-N-CA 123.947 0.899 . . . . 10.0 112.821 179.46 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 CA--C 1.543 0.935 0 N-CA-C 112.943 0.324 . . . . 10.0 112.943 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -65.39 133.59 35.44 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.351 2.701 . . . . 10.0 111.324 171.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -130.64 134.66 47.14 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 126.698 1.999 . . . . 10.0 110.654 -176.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -48.87 120.39 3.82 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 127.09 2.156 . . . . 10.0 112.58 173.587 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 49.7 mm -113.85 -59.29 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.232 1.013 . . . . 10.0 110.413 171.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.5 tt0 -150.47 136.04 18.12 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.013 0.925 . . . . 10.0 111.531 177.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 21.9 m -117.88 149.75 45.89 Favored Pre-proline 0 N--CA 1.474 0.749 0 C-N-CA 125.367 1.467 . . . . 10.0 109.579 167.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.78 155.96 53.38 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 122.485 2.123 . . . . 10.0 111.92 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -69.98 168.35 15.58 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.74 0.816 . . . . 10.0 111.091 166.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.21 152.19 21.22 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 121.211 -0.931 . . . . 10.0 112.334 173.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 86.1 mtp -127.05 152.44 47.26 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.222 1.409 . . . . 10.0 111.87 -167.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 p -144.15 104.94 4.18 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.265 1.426 . . . . 10.0 111.094 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.9 mm -122.6 130.95 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.401 1.481 . . . . 10.0 110.405 -166.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -65.15 129.97 41.64 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.51 1.124 . . . . 10.0 112.518 175.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -52.57 123.5 11.27 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 125.656 1.582 . . . . 10.0 113.132 -176.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 101.45 -10.25 57.76 Favored Glycine 0 CA--C 1.534 1.269 0 C-N-CA 125.975 1.75 . . . . 10.0 115.551 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -70.77 160.64 32.33 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-N 119.248 1.524 . . . . 10.0 113.086 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -73.43 147.73 43.93 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.663 1.185 . . . . 10.0 110.571 159.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 7.1 t -153.4 168.26 26.69 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.075 0.95 . . . . 10.0 112.607 169.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.1 ptm85 -145.61 166.68 25.05 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.95 1.7 . . . . 10.0 112.82 167.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.3 mtt -121.06 159.82 24.9 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 126.964 2.106 . . . . 10.0 111.241 173.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -140.27 93.21 2.6 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.076 1.35 . . . . 10.0 111.961 -166.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -114.07 106.9 14.94 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.733 1.613 . . . . 10.0 111.651 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -85.88 129.73 34.75 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.027 -1.045 . . . . 10.0 111.513 176.521 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.6 p -132.63 153.68 38.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.072 1.749 . . . . 10.0 110.351 170.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 58.4 m -127.24 126.67 43.13 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.766 1.226 . . . . 10.0 110.889 172.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.1 168.01 40.66 Favored Glycine 0 CA--C 1.534 1.28 0 C-N-CA 126.615 2.055 . . . . 10.0 111.236 175.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.9 tp -146.56 131.39 8.9 Favored Pre-proline 0 CA--C 1.546 0.825 0 C-N-CA 124.474 1.11 . . . . 10.0 110.73 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.13 170.59 45.23 Favored 'Cis proline' 0 CA--C 1.541 0.825 0 CA-C-N 120.414 1.184 . . . . 10.0 112.665 -3.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.13 122.05 45.59 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 124.662 1.185 . . . . 10.0 111.29 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -73.82 164.31 34.98 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.572 2.181 . . . . 10.0 113.845 -170.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -61.58 165.77 4.7 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.114 1.766 . . . . 10.0 111.961 165.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.2 p -139.23 113.6 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.097 1.359 . . . . 10.0 111.455 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -128.92 147.61 50.85 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.945 1.698 . . . . 10.0 110.821 173.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -128.44 153.29 47.27 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.355 1.062 . . . . 10.0 113.545 -174.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -143.3 162.65 35.13 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.324 2.25 . . . . 10.0 111.227 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.5 tp -147.86 123.59 10.54 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 126.905 2.082 . . . . 10.0 110.012 176.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 55.02 10.15 0.37 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.739 2.016 . . . . 10.0 116.049 176.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.01 -5.09 25.58 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.08 1.8 . . . . 10.0 115.607 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -105.58 161.65 14.18 Favored 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 119.176 1.488 . . . . 10.0 111.922 171.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.9 p -70.08 154.94 41.31 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.427 1.091 . . . . 10.0 112.791 176.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.33 101.76 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.791 2.036 . . . . 10.0 108.401 170.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -74.3 157.58 35.54 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.529 0.731 . . . . 10.0 111.319 172.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.2 p -70.61 149.5 47.0 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.691 0.796 . . . . 10.0 112.388 172.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -152.29 179.54 8.45 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.419 1.487 . . . . 10.0 111.063 167.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -57.24 -28.66 63.12 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.425 1.269 . . . . 10.0 114.425 -177.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 48.7 mt -92.41 -11.82 33.83 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.272 1.429 . . . . 10.0 113.391 176.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -134.25 70.91 1.45 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.397 1.879 . . . . 10.0 111.153 -174.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -71.87 143.32 49.44 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.171 1.388 . . . . 10.0 111.052 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -138.9 106.47 5.58 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 126.318 1.847 . . . . 10.0 110.455 -172.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.92 171.79 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.315 1.446 . . . . 10.0 112.229 -177.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -135.55 134.23 51.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.807 1.643 . . . . 10.0 109.275 174.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 24.9 p -67.95 172.14 5.89 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.838 1.051 . . . . 10.0 113.838 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -59.37 -20.3 53.68 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.237 1.415 . . . . 10.0 113.436 170.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -117.43 5.64 12.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.278 1.831 . . . . 10.0 114.243 -171.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.78 15.71 36.02 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 124.623 1.106 . . . . 10.0 115.777 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 28.4 tp -80.13 98.0 7.11 Favored 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 118.864 1.332 . . . . 10.0 110.3 171.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -63.5 132.24 50.68 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.926 0.89 . . . . 10.0 110.002 166.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -129.71 126.26 37.84 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 126.33 1.852 . . . . 10.0 111.167 -171.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -126.21 123.35 37.99 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 127.043 2.137 . . . . 10.0 108.027 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 50.9 mt -114.54 153.55 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 125.177 1.391 . . . . 10.0 110.968 -171.275 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -127.78 109.39 11.59 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.353 2.261 . . . . 10.0 108.897 170.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -68.14 -41.66 81.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.188 -0.945 . . . . 10.0 112.606 174.587 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.83 90.2 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.764 1.625 . . . . 10.0 110.388 -176.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -69.89 151.91 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 O-C-N 121.31 -0.869 . . . . 10.0 112.898 -175.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 86.7 mmt-85 -132.31 159.83 38.0 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 127.019 2.128 . . . . 10.0 111.836 174.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.84 -30.83 64.17 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.386 1.074 . . . . 10.0 113.721 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.9 t -62.99 -23.46 67.46 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.966 1.306 . . . . 10.0 113.646 174.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -78.6 -8.46 58.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.556 1.142 . . . . 10.0 113.64 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 152.58 42.84 Favored 'General case' 0 CA--C 1.547 0.839 0 CA-C-N 119.543 1.065 . . . . 10.0 113.406 -179.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.27 -170.88 22.42 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.928 1.252 . . . . 10.0 114.891 176.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.62 97.67 7.99 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.939 1.696 . . . . 10.0 111.454 176.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -71.55 150.41 44.78 Favored 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 123.948 0.899 . . . . 10.0 111.793 168.271 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.31 158.08 44.36 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.799 0.84 . . . . 10.0 112.406 168.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.8 t -130.62 141.9 50.44 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 127.162 2.185 . . . . 10.0 109.601 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 28.6 t -124.66 131.74 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.255 1.422 . . . . 10.0 109.489 177.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.43 124.03 40.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.189 1.795 . . . . 10.0 110.705 -177.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 1.9 mppt? -129.04 135.94 49.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.241 1.416 . . . . 10.0 111.602 -176.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -134.77 179.39 6.33 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.269 1.028 . . . . 10.0 111.534 163.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 14.9 ptp180 -62.62 -11.08 14.67 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.551 1.685 . . . . 10.0 115.551 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.17 -18.6 13.96 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.507 1.523 . . . . 10.0 114.167 178.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.04 -171.1 42.85 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 119.854 1.206 . . . . 10.0 115.849 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -135.26 147.09 49.16 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.586 1.955 . . . . 10.0 111.835 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.94 159.08 42.99 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.882 1.673 . . . . 10.0 111.861 170.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 86.9 m -138.75 138.26 37.48 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.76 1.624 . . . . 10.0 110.49 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -131.69 156.06 46.55 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.002 1.721 . . . . 10.0 111.25 -175.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -143.93 147.03 33.4 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.427 1.091 . . . . 10.0 112.392 -170.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.1 p -150.98 158.93 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 126.201 1.8 . . . . 10.0 111.277 168.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.6 tt0 -109.16 135.1 50.83 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.848 1.259 . . . . 10.0 111.538 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.4 tp -119.09 110.16 16.75 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.349 1.86 . . . . 10.0 110.639 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -96.5 83.98 3.61 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 125.825 1.65 . . . . 10.0 111.017 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -65.02 112.28 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 121.405 -0.809 . . . . 10.0 110.649 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.0 mt -74.11 101.37 3.9 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.169 1.788 . . . . 10.0 109.862 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.859 0 C-N-CA 124.436 1.094 . . . . 10.0 113.895 -174.03 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 CA--C 1.542 0.895 0 N-CA-C 112.511 0.158 . . . . 10.0 112.511 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -67.91 158.85 55.49 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 122.631 2.22 . . . . 10.0 111.794 171.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 41.6 ttt-85 -142.31 150.69 41.14 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.008 1.323 . . . . 10.0 111.538 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 8.9 m-30 -63.84 133.92 54.27 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.073 0.949 . . . . 10.0 110.161 162.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 32.0 mm -130.83 -59.64 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.095 1.358 . . . . 10.0 109.547 173.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -152.51 141.67 21.38 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.739 1.216 . . . . 10.0 111.21 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -127.5 152.77 77.03 Favored Pre-proline 0 N--CA 1.476 0.853 0 C-N-CA 125.736 1.614 . . . . 10.0 110.522 170.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.74 152.8 59.04 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 122.676 2.251 . . . . 10.0 111.553 171.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -72.76 174.17 8.04 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 123.904 0.882 . . . . 10.0 111.833 164.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -60.45 152.99 24.23 Favored 'General case' 0 CA--C 1.547 0.829 0 O-C-N 121.178 -0.951 . . . . 10.0 112.303 175.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.5 mtp -131.02 158.24 40.86 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 125.121 1.368 . . . . 10.0 112.292 -171.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 46.9 p -143.36 120.43 11.41 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.537 1.535 . . . . 10.0 110.49 172.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.5 mm -129.91 134.46 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.475 1.51 . . . . 10.0 109.796 -169.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.54 130.02 43.22 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.275 1.43 . . . . 10.0 112.39 175.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -51.47 127.21 19.41 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.227 1.411 . . . . 10.0 112.618 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.73 -10.61 60.81 Favored Glycine 0 CA--C 1.537 1.412 0 C-N-CA 126.125 1.821 . . . . 10.0 115.196 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -74.65 160.78 30.37 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 119.28 1.54 . . . . 10.0 113.302 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -74.61 142.65 44.59 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.63 1.172 . . . . 10.0 110.044 155.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.7 p -150.75 170.47 19.15 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 123.575 0.75 . . . . 10.0 112.254 163.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -146.61 162.77 37.72 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.156 1.382 . . . . 10.0 112.669 177.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -137.2 139.73 41.27 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 127.508 2.323 . . . . 10.0 109.151 176.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -134.22 124.05 25.33 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.048 0.939 . . . . 10.0 111.453 -171.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -123.82 110.11 14.48 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 126.517 1.927 . . . . 10.0 110.678 -168.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -72.14 119.63 16.6 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.6 0.76 . . . . 10.0 110.002 173.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.9 p -137.94 110.18 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.762 2.025 . . . . 10.0 110.3 -175.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 5.6 t -75.81 -170.88 1.44 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.378 1.071 . . . . 10.0 112.441 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 103.64 164.25 25.23 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 126.886 2.184 . . . . 10.0 114.039 176.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.8 tp -150.8 133.53 8.46 Favored Pre-proline 0 CA--C 1.548 0.895 0 C-N-CA 125.433 1.493 . . . . 10.0 110.335 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -67.02 168.79 51.76 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 CA-C-N 120.783 1.315 . . . . 10.0 112.528 -3.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.03 124.76 60.78 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.418 1.087 . . . . 10.0 110.846 177.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 155.35 64.46 Favored 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 122.434 2.089 . . . . 10.0 113.375 -170.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -72.8 114.24 10.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.458 1.503 . . . . 10.0 109.327 161.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.53 131.34 56.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.682 1.193 . . . . 10.0 111.289 -175.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.5 m -129.44 156.06 44.7 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 126.073 1.749 . . . . 10.0 111.405 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 63.4 m95 -124.88 156.4 37.97 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.85 1.26 . . . . 10.0 113.194 -176.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -144.4 159.78 42.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 127.119 2.168 . . . . 10.0 111.098 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.8 tp -145.74 119.21 9.05 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 126.887 2.075 . . . . 10.0 110.118 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 54.47 15.69 1.09 Allowed 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.449 1.9 . . . . 10.0 115.019 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.55 -11.87 39.16 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.663 2.078 . . . . 10.0 115.254 -177.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -87.43 158.03 19.08 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.948 1.374 . . . . 10.0 111.125 171.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.1 p -71.54 153.37 42.22 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.395 1.078 . . . . 10.0 112.674 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 53.9 t -132.76 100.85 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.367 1.867 . . . . 10.0 108.715 172.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 59.2 mt-30 -73.23 160.77 31.4 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.554 0.742 . . . . 10.0 111.359 171.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.2 p -68.49 155.67 39.46 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.383 0.673 . . . . 10.0 112.012 168.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -153.07 168.91 24.3 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.484 1.513 . . . . 10.0 110.917 177.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -56.9 -35.37 68.89 Favored 'General case' 0 CA--C 1.545 0.775 0 O-C-N 120.942 -1.098 . . . . 10.0 112.779 169.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.7 mt -84.48 -14.19 49.86 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.48 1.112 . . . . 10.0 113.9 173.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -133.62 70.27 1.46 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.837 1.655 . . . . 10.0 111.264 -174.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -71.29 144.09 50.11 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.834 1.254 . . . . 10.0 111.518 -176.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -141.54 106.06 4.86 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.654 1.982 . . . . 10.0 109.811 -175.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.01 164.99 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.643 1.177 . . . . 10.0 112.37 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 62.3 t -131.58 116.05 30.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 125.992 1.717 . . . . 10.0 109.63 178.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -72.54 143.51 48.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.369 0.667 . . . . 10.0 111.105 170.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.18 -20.33 40.21 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 115.308 1.596 . . . . 10.0 115.308 -174.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -75.45 -5.18 43.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.574 1.55 . . . . 10.0 113.867 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.64 50.75 2.28 Favored Glycine 0 CA--C 1.531 1.064 0 C-N-CA 125.436 1.493 . . . . 10.0 112.855 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 17.9 tp -136.46 106.17 6.2 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.332 1.453 . . . . 10.0 110.511 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -76.51 144.41 39.79 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.582 0.353 . . . . 10.0 110.864 168.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.5 m -130.62 114.76 15.82 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 126.427 1.891 . . . . 10.0 110.603 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -108.59 121.06 44.2 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 127.656 2.383 . . . . 10.0 108.715 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 71.3 mt -121.57 152.17 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.514 1.126 . . . . 10.0 111.304 -168.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.74 110.73 12.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.532 2.333 . . . . 10.0 109.43 171.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -66.11 -39.95 90.33 Favored 'General case' 0 N--CA 1.474 0.749 0 O-C-N 121.285 -0.884 . . . . 10.0 113.038 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -151.22 90.22 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.747 1.619 . . . . 10.0 110.277 -178.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.3 p -69.98 140.96 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 O-C-N 121.287 -0.883 . . . . 10.0 111.995 -177.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.3 mmt180 -124.22 161.81 24.98 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.421 1.888 . . . . 10.0 112.043 177.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.74 -33.89 64.68 Favored 'General case' 0 CA--C 1.546 0.82 0 N-CA-C 113.434 0.902 . . . . 10.0 113.434 -178.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.4 m -65.24 -17.68 64.69 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.355 1.462 . . . . 10.0 114.512 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -82.53 -5.47 58.76 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.685 1.194 . . . . 10.0 113.228 177.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.98 151.98 45.59 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.084 -1.01 . . . . 10.0 113.067 178.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.78 -171.27 22.44 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.746 1.165 . . . . 10.0 114.801 175.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.91 103.87 14.35 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.972 1.709 . . . . 10.0 111.055 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -78.15 152.02 32.98 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.009 0.924 . . . . 10.0 111.839 169.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -139.04 156.34 47.27 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.068 0.947 . . . . 10.0 111.687 168.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.0 t -134.06 136.74 44.2 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.525 1.93 . . . . 10.0 109.472 -175.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 67.8 t -128.25 126.53 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.488 1.515 . . . . 10.0 109.143 -178.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.83 117.4 23.29 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.258 1.823 . . . . 10.0 110.77 -174.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 23.0 mtpp -124.49 133.71 53.26 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.482 1.513 . . . . 10.0 111.536 -174.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 14.4 p30 -131.43 178.81 6.44 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.145 0.978 . . . . 10.0 111.7 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -63.57 -10.04 16.37 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 115.636 1.717 . . . . 10.0 115.636 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.12 -20.33 12.73 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.645 1.578 . . . . 10.0 114.246 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.05 -169.2 42.21 Favored Glycine 0 CA--C 1.535 1.291 0 CA-C-N 119.788 1.176 . . . . 10.0 115.769 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -138.54 147.09 42.69 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.357 1.863 . . . . 10.0 112.013 -173.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.66 153.61 50.86 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.033 1.733 . . . . 10.0 111.242 169.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.7 m -136.67 140.07 42.46 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.566 1.546 . . . . 10.0 110.646 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -133.55 159.28 40.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.966 1.706 . . . . 10.0 111.247 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.6 m -143.43 144.14 31.9 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 124.949 1.3 . . . . 10.0 111.341 -174.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.39 161.4 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.938 1.695 . . . . 10.0 110.563 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.8 tt0 -123.72 138.44 54.52 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 124.484 1.114 . . . . 10.0 111.196 176.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.3 tp -125.24 108.94 12.25 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.035 1.734 . . . . 10.0 110.711 -178.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -93.8 83.15 4.36 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.432 1.493 . . . . 10.0 110.682 174.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.34 114.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 O-C-N 121.452 -0.78 . . . . 10.0 110.418 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.9 mt -75.25 94.09 2.95 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.193 1.797 . . . . 10.0 110.015 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.78 0 C-N-CA 124.43 1.092 . . . . 10.0 112.98 -179.586 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo . . . . . 0 CA--C 1.544 0.976 0 N-CA-C 113.528 0.549 . . . . 10.0 113.528 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.71 139.09 56.38 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.02 2.48 . . . . 10.0 111.006 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 53.1 ttt85 -128.78 151.64 49.35 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.457 1.503 . . . . 10.0 112.617 -174.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -76.44 88.72 3.21 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.041 2.137 . . . . 10.0 111.708 177.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.2 mm -82.92 -58.78 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 O-C-N 121.605 -0.684 . . . . 10.0 110.264 171.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 24.8 tt0 -154.29 146.62 23.89 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.735 1.214 . . . . 10.0 111.776 175.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.79 152.29 74.86 Favored Pre-proline 0 N--CA 1.477 0.881 0 C-N-CA 126.452 1.901 . . . . 10.0 110.004 169.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.83 157.45 35.12 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.567 2.178 . . . . 10.0 112.247 -178.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -73.88 168.15 20.02 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.833 0.853 . . . . 10.0 111.326 166.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -60.14 158.14 11.85 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 121.419 -0.8 . . . . 10.0 112.801 176.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -128.47 152.75 47.88 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.714 1.606 . . . . 10.0 111.742 -171.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 39.5 p -141.77 116.85 9.98 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 125.385 1.474 . . . . 10.0 110.416 170.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.9 mm -129.3 129.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.29 1.436 . . . . 10.0 109.995 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -60.66 127.17 30.35 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.173 1.389 . . . . 10.0 112.12 173.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -53.22 134.38 39.2 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.202 1.401 . . . . 10.0 113.161 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.85 -12.02 67.55 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.346 1.927 . . . . 10.0 114.79 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -74.24 161.56 29.81 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 118.972 1.386 . . . . 10.0 113.268 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -75.9 141.16 42.4 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.885 1.274 . . . . 10.0 110.276 156.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.79 172.03 15.29 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.678 0.791 . . . . 10.0 112.065 161.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -152.43 170.21 20.68 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.145 1.378 . . . . 10.0 112.923 174.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.9 mtt -121.8 164.7 17.03 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 126.587 1.955 . . . . 10.0 112.526 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -138.23 103.42 4.92 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 126.353 1.861 . . . . 10.0 111.738 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -115.37 109.61 18.15 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.5 1.52 . . . . 10.0 111.178 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -80.03 74.72 6.79 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 121.302 -0.874 . . . . 10.0 111.496 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -79.84 128.14 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.913 1.285 . . . . 10.0 109.945 163.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 68.6 m -135.28 115.35 13.19 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.787 1.235 . . . . 10.0 111.343 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -158.41 169.85 34.99 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 126.695 2.093 . . . . 10.0 111.55 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 21.8 tp -142.14 120.04 7.47 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.504 1.122 . . . . 10.0 110.449 -177.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -68.05 167.54 63.18 Favored 'Cis proline' 0 CA--C 1.54 0.79 0 CA-C-N 121.018 1.399 . . . . 10.0 112.906 0.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 124.39 62.23 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.791 1.236 . . . . 10.0 111.189 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.49 151.33 59.02 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.41 2.073 . . . . 10.0 113.82 -169.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -69.94 130.45 42.26 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.611 1.564 . . . . 10.0 109.543 159.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.3 m -124.54 134.74 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.891 1.276 . . . . 10.0 112.253 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.6 m -136.47 114.56 11.48 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.673 1.589 . . . . 10.0 111.418 -173.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -87.44 151.98 22.61 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 114.016 1.117 . . . . 10.0 114.016 -178.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -141.61 160.57 39.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.975 2.51 . . . . 10.0 111.017 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -146.97 120.92 9.34 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.541 2.337 . . . . 10.0 109.833 176.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 54.93 14.71 0.97 Allowed 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.494 1.918 . . . . 10.0 115.341 178.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.28 -7.31 34.76 Favored Glycine 0 CA--C 1.539 1.582 0 C-N-CA 126.351 1.929 . . . . 10.0 115.487 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -99.55 159.75 14.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.587 1.555 . . . . 10.0 110.921 171.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.9 p -71.69 158.99 35.17 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.12 0.968 . . . . 10.0 112.788 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 39.0 t -135.71 102.47 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.984 1.714 . . . . 10.0 109.354 173.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.9 mt-30 -70.18 155.21 40.96 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.239 0.615 . . . . 10.0 111.251 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 67.6 p -69.63 160.23 31.96 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 123.562 0.745 . . . . 10.0 112.164 170.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -152.66 169.66 22.16 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.383 1.473 . . . . 10.0 111.024 178.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.9 -35.01 68.47 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 120.867 -1.146 . . . . 10.0 112.749 168.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 77.1 mt -82.65 -14.08 55.33 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.506 1.122 . . . . 10.0 113.889 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -135.25 69.53 1.44 Allowed 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.782 1.633 . . . . 10.0 111.501 -173.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 77.9 mttt -71.34 134.22 46.56 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.037 1.335 . . . . 10.0 110.547 -179.008 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 60.4 mtt -131.75 101.04 5.3 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 126.22 1.808 . . . . 10.0 109.524 -174.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.19 159.15 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 124.839 1.256 . . . . 10.0 112.562 -170.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.53 167.9 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 126.007 1.723 . . . . 10.0 111.992 -177.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 34.2 t -131.14 147.39 52.6 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 125.545 1.538 . . . . 10.0 112.128 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -57.82 -20.37 35.44 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.831 1.652 . . . . 10.0 113.87 168.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -78.0 -1.36 31.74 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.788 1.635 . . . . 10.0 114.355 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 79.87 60.94 2.34 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 124.677 1.132 . . . . 10.0 111.935 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 42.9 tp -150.97 148.53 28.5 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.96 1.704 . . . . 10.0 110.862 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -132.84 129.24 38.21 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.897 2.079 . . . . 10.0 110.097 174.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.1 m -108.81 147.1 32.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.475 1.51 . . . . 10.0 112.146 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.91 108.57 9.48 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 126.623 1.969 . . . . 10.0 108.333 171.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -89.89 151.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 125.268 1.427 . . . . 10.0 110.329 -178.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -130.61 99.69 5.06 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.94 2.096 . . . . 10.0 108.38 167.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -62.4 -38.4 89.49 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 113.225 0.824 . . . . 10.0 113.225 -176.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.8 p -149.65 87.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 125.897 1.679 . . . . 10.0 110.133 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.1 p -70.07 139.53 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 121.347 -0.846 . . . . 10.0 112.029 -176.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.4 mmm180 -128.42 161.68 28.92 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.466 1.907 . . . . 10.0 111.26 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -52.21 -35.95 50.78 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 114.195 1.183 . . . . 10.0 114.195 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.7 -17.72 64.36 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.242 1.417 . . . . 10.0 114.673 176.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -82.52 -5.92 59.02 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.74 1.216 . . . . 10.0 113.473 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 151.01 47.6 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.988 -1.07 . . . . 10.0 113.187 179.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.49 -172.63 22.4 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.872 1.225 . . . . 10.0 115.069 175.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.72 102.54 13.07 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.075 1.75 . . . . 10.0 111.538 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -79.67 149.02 31.37 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 124.291 1.037 . . . . 10.0 111.932 171.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.9 159.26 43.18 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.906 0.882 . . . . 10.0 112.271 170.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 49.8 t -137.68 118.2 13.87 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 125.139 1.375 . . . . 10.0 111.391 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 42.3 t -87.75 124.85 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 125.169 1.388 . . . . 10.0 109.268 172.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -117.65 128.16 54.65 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.456 1.903 . . . . 10.0 111.075 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.0 mtmt -133.83 130.12 37.47 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 126.116 1.767 . . . . 10.0 112.159 -167.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -136.4 -179.56 5.75 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 118.879 0.763 . . . . 10.0 112.305 162.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -59.33 -14.68 12.48 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 115.823 1.786 . . . . 10.0 115.823 -177.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.6 -12.28 15.0 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.452 1.501 . . . . 10.0 114.357 -178.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 162.98 -172.39 38.99 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.443 1.02 . . . . 10.0 115.457 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -134.6 147.76 50.28 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.239 1.816 . . . . 10.0 111.57 -173.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.08 163.26 30.74 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.537 1.935 . . . . 10.0 110.785 169.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 96.4 m -144.29 124.28 13.57 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.514 1.126 . . . . 10.0 110.649 177.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -113.54 155.5 25.27 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.523 1.529 . . . . 10.0 111.17 -176.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.5 m -141.77 148.51 39.05 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.621 1.168 . . . . 10.0 112.41 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.79 171.01 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 127.024 2.13 . . . . 10.0 110.603 168.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -128.78 140.63 51.62 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.924 1.29 . . . . 10.0 111.12 172.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.3 tp -125.41 111.81 15.56 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.4 1.88 . . . . 10.0 110.642 -178.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -97.38 85.85 3.75 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.8 1.64 . . . . 10.0 110.864 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.5 t -67.08 112.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.364 -0.835 . . . . 10.0 110.599 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.51 94.16 3.66 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.037 1.735 . . . . 10.0 110.1 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.77 0 C-N-CA 124.519 1.127 . . . . 10.0 112.764 -179.953 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo . . . . . 0 CA--C 1.544 0.991 0 N-CA-C 113.31 0.466 . . . . 10.0 113.31 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -69.73 168.26 22.02 Favored 'Trans proline' 0 CA--C 1.541 0.867 0 C-N-CA 123.249 2.632 . . . . 10.0 112.361 171.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 58.2 ttp85 -134.44 156.42 48.6 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.322 1.449 . . . . 10.0 112.22 -174.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -93.94 64.6 3.4 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 126.816 2.047 . . . . 10.0 111.086 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.48 -66.08 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.095 -1.003 . . . . 10.0 112.679 -170.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -155.24 165.03 37.94 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.0 m -132.92 161.99 60.32 Favored Pre-proline 0 N--CA 1.476 0.829 0 C-N-CA 127.871 2.468 . . . . 10.0 110.492 170.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.67 164.02 32.86 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.832 2.355 . . . . 10.0 111.228 164.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -72.59 169.43 16.55 Favored 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.251 -0.906 . . . . 10.0 112.523 169.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.31 148.79 40.09 Favored 'General case' 0 CA--C 1.546 0.789 0 O-C-N 121.346 -0.846 . . . . 10.0 112.652 173.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 75.8 mtp -130.81 154.07 48.42 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.882 1.273 . . . . 10.0 112.48 -170.117 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 64.6 m -140.48 101.03 4.01 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.302 1.841 . . . . 10.0 110.107 -176.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 37.6 mm -117.8 134.31 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 124.528 1.131 . . . . 10.0 111.292 -166.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -64.11 130.06 42.46 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.816 1.246 . . . . 10.0 112.445 173.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -53.24 129.8 32.64 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.112 1.365 . . . . 10.0 112.925 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.74 -11.5 62.73 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 126.305 1.907 . . . . 10.0 115.041 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -75.72 161.18 29.28 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.001 1.401 . . . . 10.0 113.276 177.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.9 149.22 46.96 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.665 1.186 . . . . 10.0 110.71 157.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 10.7 t -150.39 160.43 43.75 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.755 1.222 . . . . 10.0 111.903 168.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -151.65 167.41 28.23 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.342 1.457 . . . . 10.0 112.883 167.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -132.91 167.03 20.98 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.646 1.978 . . . . 10.0 112.119 -176.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -134.55 108.35 8.03 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.258 1.823 . . . . 10.0 111.775 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -117.67 112.17 20.14 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.448 1.499 . . . . 10.0 111.42 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -71.96 108.5 5.24 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.4 1.08 . . . . 10.0 110.31 174.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 18.0 t -117.59 149.32 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.684 1.594 . . . . 10.0 109.819 177.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.4 t -148.15 -177.58 5.82 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.254 1.422 . . . . 10.0 111.112 175.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 122.77 162.14 11.44 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 127.65 2.548 . . . . 10.0 111.795 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.1 tp -144.61 122.73 6.68 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-O 118.083 -0.96 . . . . 10.0 110.571 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -66.56 167.89 53.29 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.689 1.282 . . . . 10.0 112.627 -1.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.24 126.02 72.72 Favored Pre-proline 0 CA--C 1.549 0.935 0 C-N-CA 124.454 1.102 . . . . 10.0 111.291 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.51 149.9 62.79 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.406 2.071 . . . . 10.0 113.321 -173.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -74.66 151.05 39.33 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.61 1.164 . . . . 10.0 109.918 159.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 59.1 t -131.56 138.46 52.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.963 0.905 . . . . 10.0 112.125 -169.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 63.2 m -132.73 115.27 15.14 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 126.767 2.027 . . . . 10.0 110.61 177.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 53.4 m95 -86.44 158.83 19.5 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 122.001 0.905 . . . . 10.0 112.85 176.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -144.69 159.88 42.11 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 127.063 2.145 . . . . 10.0 111.235 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.6 tp -145.65 118.12 8.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.146 2.178 . . . . 10.0 110.062 175.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 54.87 14.95 0.99 Allowed 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 126.479 1.912 . . . . 10.0 115.092 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.82 -14.02 34.78 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 126.747 2.118 . . . . 10.0 115.165 -177.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -83.41 155.53 23.42 Favored 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 118.981 1.39 . . . . 10.0 110.929 169.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.7 p -71.46 155.14 40.94 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.27 1.028 . . . . 10.0 112.602 173.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 59.5 t -136.63 135.96 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 126.678 1.991 . . . . 10.0 108.976 172.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -119.09 164.01 16.17 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 125.267 1.427 . . . . 10.0 111.344 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 98.1 p -66.89 152.76 45.05 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.655 0.741 . . . . 10.0 112.441 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -151.95 167.96 26.71 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.827 1.651 . . . . 10.0 110.656 176.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.65 -34.92 67.78 Favored 'General case' 0 CA--C 1.545 0.772 0 O-C-N 120.97 -1.081 . . . . 10.0 112.832 169.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.4 mt -85.39 -13.55 49.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.55 1.14 . . . . 10.0 114.001 174.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.3 m80 -136.08 70.35 1.42 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.658 1.583 . . . . 10.0 111.184 -174.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -69.91 145.28 52.06 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.713 1.205 . . . . 10.0 111.636 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.4 mtt -139.41 101.74 4.31 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.785 2.034 . . . . 10.0 109.736 -176.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.37 162.24 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.851 1.26 . . . . 10.0 111.818 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 13.8 p -136.83 134.61 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.631 1.172 . . . . 10.0 111.269 -179.119 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 40.7 t -65.21 159.89 22.65 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.923 1.289 . . . . 10.0 112.505 177.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -52.19 -33.15 39.53 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.538 1.535 . . . . 10.0 111.965 164.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -81.72 -3.63 54.19 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.405 1.882 . . . . 10.0 113.735 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.25 -3.48 82.23 Favored Glycine 0 CA--C 1.538 1.494 0 C-N-CA 125.75 1.643 . . . . 10.0 115.468 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 48.2 tp -67.97 107.59 2.74 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.846 1.259 . . . . 10.0 111.165 174.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.6 t60 -84.86 124.57 31.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.781 1.632 . . . . 10.0 111.514 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.8 m -97.74 134.1 41.37 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.638 1.575 . . . . 10.0 111.793 171.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -123.07 123.55 41.1 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 127.154 2.182 . . . . 10.0 107.94 171.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 47.4 mt -121.79 153.63 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 125.124 1.37 . . . . 10.0 111.517 -166.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -132.18 108.23 9.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 128.044 2.538 . . . . 10.0 109.224 172.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -66.73 -38.79 87.37 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.846 -1.159 . . . . 10.0 112.914 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.5 p -151.78 89.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.684 1.593 . . . . 10.0 110.441 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.35 140.56 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 121.212 -0.93 . . . . 10.0 111.883 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -129.34 162.3 28.3 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 126.385 1.874 . . . . 10.0 111.267 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -53.11 -35.11 59.28 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.128 1.158 . . . . 10.0 114.128 -175.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.4 m -65.09 -17.83 64.79 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.32 1.448 . . . . 10.0 114.644 176.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -82.9 -7.0 59.7 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.754 1.222 . . . . 10.0 113.518 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.97 147.9 52.64 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.096 -1.003 . . . . 10.0 113.218 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.74 -171.99 24.19 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.507 1.051 . . . . 10.0 115.448 173.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.69 104.15 11.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.846 1.658 . . . . 10.0 110.893 173.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -80.79 151.1 28.93 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.985 0.914 . . . . 10.0 111.751 170.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.93 161.19 38.42 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.093 0.957 . . . . 10.0 112.132 168.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 29.6 t -141.49 104.79 4.64 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.549 1.94 . . . . 10.0 109.766 -172.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.69 131.1 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.576 1.15 . . . . 10.0 109.386 174.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.15 126.15 44.81 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.304 1.842 . . . . 10.0 110.721 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -134.35 135.42 42.69 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.479 1.512 . . . . 10.0 112.435 -169.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -130.04 -178.2 4.63 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.577 1.151 . . . . 10.0 111.712 166.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -59.88 -12.41 7.55 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 115.841 1.793 . . . . 10.0 115.841 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.7 -14.31 12.02 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.448 1.499 . . . . 10.0 114.589 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.32 -170.3 42.88 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-N 119.978 1.263 . . . . 10.0 116.165 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -134.74 144.35 47.67 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.104 2.162 . . . . 10.0 111.674 -172.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.98 163.13 31.44 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.039 1.735 . . . . 10.0 111.043 168.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -142.26 140.44 32.24 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.16 0.984 . . . . 10.0 111.492 -175.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -126.93 156.69 41.09 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 126.097 1.759 . . . . 10.0 110.841 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.8 m -145.3 146.62 31.71 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 124.761 1.224 . . . . 10.0 111.682 -171.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.59 161.65 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 125.894 1.678 . . . . 10.0 110.848 169.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.2 tt0 -116.75 128.52 55.39 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.583 1.153 . . . . 10.0 110.466 170.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.9 tp -118.55 104.15 10.39 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 126.003 1.721 . . . . 10.0 109.831 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -77.99 138.74 38.99 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.23 0.612 . . . . 10.0 110.108 163.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 27.8 t -117.01 105.16 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.051 0.94 . . . . 10.0 109.157 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.8 mt -67.62 97.71 0.63 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.535 1.934 . . . . 10.0 109.869 179.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.769 0 C-N-CA 124.382 1.073 . . . . 10.0 112.683 -179.385 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 N-CA-C 113.101 0.385 . . . . 10.0 113.101 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -66.86 150.84 83.12 Favored 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 122.784 2.322 . . . . 10.0 111.064 168.419 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 64.2 ttt-85 -138.54 153.74 48.73 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.317 1.447 . . . . 10.0 111.62 -177.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.95 117.2 9.5 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.614 1.166 . . . . 10.0 111.052 169.29 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.32 -57.78 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.102 1.361 . . . . 10.0 110.368 176.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -149.53 137.15 20.17 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.847 1.259 . . . . 10.0 111.547 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -131.96 153.82 81.52 Favored Pre-proline 0 N--CA 1.474 0.736 0 C-N-CA 126.488 1.915 . . . . 10.0 110.028 170.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.75 162.91 36.8 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.627 2.218 . . . . 10.0 111.433 171.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.13 179.92 2.61 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.629 0.772 . . . . 10.0 110.738 161.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -58.11 142.68 46.32 Favored 'General case' 0 CA--C 1.546 0.82 0 O-C-N 120.506 -1.372 . . . . 10.0 111.156 166.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 89.9 mtp -122.53 157.33 32.27 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 125.484 1.513 . . . . 10.0 111.937 -172.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 57.8 p -144.38 129.62 18.73 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.295 1.438 . . . . 10.0 110.691 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.9 mm -134.51 133.97 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.7 1.6 . . . . 10.0 109.288 -170.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -63.94 130.83 45.67 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.616 1.166 . . . . 10.0 112.171 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -52.28 126.69 19.74 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.01 1.324 . . . . 10.0 112.509 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.0 61.46 Favored Glycine 0 CA--C 1.537 1.423 0 C-N-CA 125.842 1.687 . . . . 10.0 115.22 179.033 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -72.72 160.59 31.96 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.379 1.59 . . . . 10.0 113.105 175.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -72.67 149.38 43.9 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 124.488 1.115 . . . . 10.0 110.513 157.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 34.6 t -148.78 157.0 43.13 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.461 1.104 . . . . 10.0 111.272 167.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -144.73 154.47 42.77 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.003 1.321 . . . . 10.0 111.503 164.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.3 mtt -125.61 113.25 17.14 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 125.718 1.607 . . . . 10.0 111.107 -173.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -69.65 127.53 33.27 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.426 1.49 . . . . 10.0 112.766 174.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -137.97 93.82 2.81 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.105 1.362 . . . . 10.0 110.976 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -67.38 121.25 15.34 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.551 0.741 . . . . 10.0 110.124 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.8 p -135.17 115.59 18.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 126.859 2.064 . . . . 10.0 110.189 -173.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 66.2 m -126.98 107.25 9.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.892 1.277 . . . . 10.0 111.59 -173.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -156.15 167.58 33.38 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 127.166 2.317 . . . . 10.0 110.927 169.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -142.14 125.58 9.63 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 124.417 1.087 . . . . 10.0 110.686 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -66.06 168.06 49.72 Favored 'Cis proline' 0 CA--C 1.539 0.763 0 CA-C-N 120.622 1.258 . . . . 10.0 112.453 -2.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 123.45 57.07 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 124.348 1.059 . . . . 10.0 111.264 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.83 149.21 66.14 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.428 2.085 . . . . 10.0 112.999 -172.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -72.1 139.19 48.27 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.263 1.025 . . . . 10.0 109.535 161.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.36 142.05 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.266 1.027 . . . . 10.0 113.136 -172.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.7 m -141.39 115.34 9.2 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 125.841 1.657 . . . . 10.0 111.195 -176.355 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 71.1 m95 -84.07 151.22 25.08 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 122.2 1.0 . . . . 10.0 113.43 176.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -141.3 161.3 38.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 128.249 2.619 . . . . 10.0 110.776 -179.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.1 tp -147.09 119.78 8.59 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.431 2.292 . . . . 10.0 110.041 176.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 55.02 15.29 1.14 Allowed 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 126.581 1.952 . . . . 10.0 115.045 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.33 -12.53 40.01 Favored Glycine 0 CA--C 1.539 1.564 0 C-N-CA 126.607 2.051 . . . . 10.0 115.104 -177.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -87.67 158.33 18.86 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 119.008 1.404 . . . . 10.0 110.824 170.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.8 p -71.25 158.32 36.59 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.99 0.916 . . . . 10.0 112.345 173.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 40.1 t -134.62 100.82 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.844 1.658 . . . . 10.0 108.779 171.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -71.43 156.22 39.72 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.346 0.658 . . . . 10.0 110.693 170.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.0 p -70.08 151.96 44.9 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 121.559 -0.713 . . . . 10.0 111.908 170.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -152.74 -177.49 6.29 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.051 1.34 . . . . 10.0 111.949 171.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -60.3 -22.75 63.54 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 114.64 1.348 . . . . 10.0 114.64 -177.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 52.9 mt -104.19 -26.19 12.63 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.866 1.666 . . . . 10.0 112.67 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -110.9 74.14 0.86 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.416 1.886 . . . . 10.0 111.052 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 92.2 mttt -77.21 146.31 37.07 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.691 1.196 . . . . 10.0 111.175 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.1 mtt -145.34 102.51 3.73 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 126.06 1.744 . . . . 10.0 110.281 -170.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.91 163.25 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 124.505 1.122 . . . . 10.0 112.468 178.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 54.7 t -121.38 112.58 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.536 1.934 . . . . 10.0 109.266 174.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 74.7 m -69.25 151.51 46.18 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.76 0.824 . . . . 10.0 111.552 173.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -57.96 -19.68 32.2 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 115.346 1.61 . . . . 10.0 115.346 -174.366 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -75.97 -4.0 38.72 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.763 1.625 . . . . 10.0 113.994 178.104 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.09 48.92 4.43 Favored Glycine 0 CA--C 1.531 1.071 0 C-N-CA 125.161 1.363 . . . . 10.0 112.139 -175.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 51.5 tp -136.82 103.56 5.22 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.571 1.549 . . . . 10.0 110.642 -171.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 23.7 t60 -70.45 147.27 49.64 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 122.032 -0.418 . . . . 10.0 110.46 166.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 5.5 t -135.94 99.53 4.18 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.016 1.326 . . . . 10.0 111.204 176.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -81.86 120.28 24.99 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.485 1.514 . . . . 10.0 108.884 173.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 42.6 mt -115.55 151.6 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 125.125 1.37 . . . . 10.0 111.514 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -129.25 108.04 10.02 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.954 2.502 . . . . 10.0 109.258 170.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -63.94 -42.0 97.47 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.194 -0.942 . . . . 10.0 112.845 175.015 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.47 90.88 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.863 1.665 . . . . 10.0 110.121 -179.226 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.7 140.89 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.296 -0.878 . . . . 10.0 112.212 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -120.86 160.76 22.77 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.454 1.901 . . . . 10.0 112.057 176.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.86 -30.81 66.1 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 113.617 0.969 . . . . 10.0 113.617 -177.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.6 p -67.85 -15.62 63.71 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.921 1.689 . . . . 10.0 114.788 173.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -83.05 -5.08 58.97 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.599 1.16 . . . . 10.0 113.486 176.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.66 151.75 44.07 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.012 -1.055 . . . . 10.0 113.063 177.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.31 -173.07 22.67 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.915 1.245 . . . . 10.0 114.837 176.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -87.6 101.28 13.48 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.9 1.68 . . . . 10.0 111.274 176.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -78.37 151.78 32.65 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.295 1.038 . . . . 10.0 111.972 169.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.8 157.31 43.93 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.246 1.018 . . . . 10.0 112.109 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.6 t -134.97 104.89 6.14 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.645 1.578 . . . . 10.0 110.925 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.1 t -71.42 134.53 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 123.916 0.886 . . . . 10.0 109.131 168.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -133.51 119.46 19.56 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.756 2.023 . . . . 10.0 110.27 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.3 mtpt -134.4 136.06 43.05 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.79 1.236 . . . . 10.0 113.018 -170.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 24.9 p30 -132.51 -178.36 4.89 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.061 1.344 . . . . 10.0 111.547 167.093 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.1 ptm180 -60.97 -14.84 25.45 Favored 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 115.482 1.66 . . . . 10.0 115.482 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.03 -19.65 13.66 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.443 1.497 . . . . 10.0 114.208 -177.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.28 -169.98 42.63 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 116.142 1.217 . . . . 10.0 116.142 177.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -134.54 144.64 48.12 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 127.262 2.225 . . . . 10.0 111.664 -170.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.88 159.91 40.71 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 126.214 1.806 . . . . 10.0 110.794 167.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 32.8 m -140.35 101.14 4.05 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 124.457 1.103 . . . . 10.0 110.733 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -77.66 155.56 31.3 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.777 1.231 . . . . 10.0 111.254 175.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 28.3 m -146.98 146.35 30.05 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.728 1.211 . . . . 10.0 112.057 -174.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.3 p -154.3 145.99 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 125.819 1.648 . . . . 10.0 111.934 170.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -100.45 135.46 41.85 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.611 1.165 . . . . 10.0 110.929 170.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.1 tp -122.39 112.4 18.04 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.98 1.712 . . . . 10.0 111.026 177.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -100.0 85.22 3.01 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.942 1.697 . . . . 10.0 110.834 175.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -64.94 114.49 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.954 0.902 . . . . 10.0 110.684 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.6 mt -75.81 99.78 4.55 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.154 1.781 . . . . 10.0 110.042 179.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.861 0 C-N-CA 124.304 1.042 . . . . 10.0 113.525 -175.682 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo . . . . . 0 CA--C 1.543 0.932 0 N-CA-C 113.161 0.408 . . . . 10.0 113.161 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -67.05 158.78 55.17 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.861 2.374 . . . . 10.0 111.32 168.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.7 tpt85 -135.1 151.44 50.72 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.007 1.323 . . . . 10.0 111.772 -174.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -79.01 65.4 4.17 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 127.251 2.22 . . . . 10.0 111.812 -176.356 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 39.8 mm -63.16 -62.35 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 O-C-N 121.225 -0.922 . . . . 10.0 112.635 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -153.16 149.67 28.27 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.822 0.849 . . . . 10.0 112.59 -178.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.2 m -134.44 151.11 75.56 Favored Pre-proline 0 N--CA 1.477 0.925 0 C-N-CA 126.405 1.882 . . . . 10.0 110.558 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -74.65 159.77 42.06 Favored 'Trans proline' 0 CA--C 1.542 0.916 0 C-N-CA 123.049 2.499 . . . . 10.0 111.596 168.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -77.24 172.61 13.0 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 123.942 0.897 . . . . 10.0 111.542 167.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -49.61 108.86 0.23 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.416 1.486 . . . . 10.0 113.594 178.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.3 mtp -82.41 155.66 24.56 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.349 1.46 . . . . 10.0 112.008 -177.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 71.2 p -140.36 131.81 26.91 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.964 1.306 . . . . 10.0 111.023 170.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.2 mm -137.08 129.46 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.385 1.474 . . . . 10.0 109.94 -170.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -62.26 127.61 32.17 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.785 1.234 . . . . 10.0 112.169 172.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -52.82 135.02 36.59 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.289 1.435 . . . . 10.0 113.171 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.12 -11.27 69.45 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.046 1.784 . . . . 10.0 114.952 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.9 mtp-105 -77.63 162.73 26.82 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 118.989 1.394 . . . . 10.0 113.162 177.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -71.71 151.98 43.17 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.884 1.273 . . . . 10.0 110.763 158.327 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 36.0 t -148.41 156.83 42.98 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.496 1.118 . . . . 10.0 111.474 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -135.76 139.98 43.97 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 125.516 1.526 . . . . 10.0 110.858 162.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 43.9 mtt -100.77 155.39 17.94 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.801 1.641 . . . . 10.0 109.818 167.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -139.57 118.32 12.37 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.157 1.383 . . . . 10.0 110.984 -170.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -130.52 106.84 8.78 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 125.992 1.717 . . . . 10.0 111.952 -170.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -65.93 127.64 32.84 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.902 0.881 . . . . 10.0 110.52 173.126 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.1 125.34 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.642 1.577 . . . . 10.0 110.769 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 69.4 m -133.21 115.3 14.84 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.674 1.19 . . . . 10.0 111.907 -173.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -161.69 169.76 37.23 Favored Glycine 0 CA--C 1.536 1.393 0 C-N-CA 127.161 2.315 . . . . 10.0 111.381 172.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -143.7 125.3 8.24 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.09 0.956 . . . . 10.0 111.194 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.01 167.64 51.14 Favored 'Cis proline' 0 CA--C 1.539 0.744 0 CA-C-N 120.866 1.345 . . . . 10.0 112.476 -2.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.11 122.32 47.31 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.404 1.081 . . . . 10.0 111.231 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -69.34 148.59 68.16 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.42 2.08 . . . . 10.0 112.922 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -72.06 145.73 48.06 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.143 0.977 . . . . 10.0 109.736 161.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.98 139.72 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.556 1.142 . . . . 10.0 112.575 -172.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 73.2 m -136.81 142.12 42.91 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 126.024 1.729 . . . . 10.0 110.672 177.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -111.86 158.05 19.88 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.474 1.11 . . . . 10.0 113.278 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -145.69 159.57 42.96 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 127.256 2.222 . . . . 10.0 111.329 -174.15 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.4 tp -147.19 119.52 8.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.054 2.142 . . . . 10.0 110.0 175.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 55.26 14.05 0.98 Allowed 'General case' 0 CA--C 1.554 1.106 0 C-N-CA 126.537 1.935 . . . . 10.0 115.376 179.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.17 -12.22 31.4 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.564 2.031 . . . . 10.0 115.182 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -89.9 160.68 16.32 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 118.924 1.362 . . . . 10.0 110.978 169.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.5 p -73.99 158.92 33.48 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.369 1.067 . . . . 10.0 112.752 175.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 87.6 t -136.82 104.98 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 127.097 2.159 . . . . 10.0 108.623 173.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -79.68 161.54 25.77 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.417 0.687 . . . . 10.0 111.131 170.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.9 p -70.27 148.02 49.03 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.564 0.746 . . . . 10.0 112.211 171.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -152.61 -179.93 8.04 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 125.365 1.466 . . . . 10.0 111.328 168.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -57.97 -27.53 63.53 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.698 1.37 . . . . 10.0 114.698 -176.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 57.2 mt -93.11 -13.97 27.84 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.23 1.412 . . . . 10.0 113.084 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -131.97 68.82 1.49 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.545 1.938 . . . . 10.0 111.204 -172.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -72.9 146.61 46.02 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.092 1.357 . . . . 10.0 111.321 -179.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -139.2 110.35 6.89 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 126.547 1.939 . . . . 10.0 110.278 -172.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.26 162.78 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 125.079 1.351 . . . . 10.0 112.212 -177.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.4 t -129.8 104.09 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.518 1.527 . . . . 10.0 109.491 177.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 70.8 m -73.05 166.32 23.33 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 125.063 1.345 . . . . 10.0 112.804 177.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.07 158.52 6.73 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.292 1.437 . . . . 10.0 112.323 175.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt 64.8 9.64 5.45 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 127.392 2.277 . . . . 10.0 114.782 -172.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.2 62.74 1.86 Allowed Glycine 0 CA--C 1.53 1.027 0 C-N-CA 125.178 1.371 . . . . 10.0 113.491 173.235 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 43.2 tp -131.03 99.86 5.04 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.027 1.331 . . . . 10.0 111.09 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -76.68 133.95 39.39 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.923 0.889 . . . . 10.0 110.739 172.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 49.4 m -121.01 141.23 50.92 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.574 1.55 . . . . 10.0 111.434 178.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -133.2 115.78 15.43 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 126.788 2.035 . . . . 10.0 108.641 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 49.5 mt -105.35 154.36 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 124.83 1.252 . . . . 10.0 111.836 -168.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -130.4 107.51 9.3 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.496 2.318 . . . . 10.0 109.019 167.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 -63.77 -42.83 97.72 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.256 -0.902 . . . . 10.0 113.049 178.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 3.5 p -151.66 91.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 125.845 1.658 . . . . 10.0 110.233 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -74.63 142.47 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 O-C-N 121.368 -0.833 . . . . 10.0 112.123 -177.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -129.02 163.26 25.77 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 126.408 1.883 . . . . 10.0 111.394 177.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.5 -31.72 62.28 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -174.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.0 m -67.75 -16.31 64.06 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 114.166 1.173 . . . . 10.0 114.166 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -83.87 -5.98 59.33 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.732 1.213 . . . . 10.0 113.48 178.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.04 151.69 42.31 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 120.985 -1.072 . . . . 10.0 113.1 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 140.11 -174.0 22.68 Favored Glycine 0 CA--C 1.533 1.161 0 C-N-CA 124.317 0.96 . . . . 10.0 114.993 176.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 98.53 9.24 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.888 1.675 . . . . 10.0 111.367 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -76.37 146.92 38.41 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.016 0.926 . . . . 10.0 111.386 168.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.4 160.32 41.25 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.595 0.758 . . . . 10.0 112.425 169.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.0 t -133.39 142.28 48.29 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.091 2.156 . . . . 10.0 109.841 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.29 124.5 71.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.536 1.534 . . . . 10.0 108.72 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.39 124.48 51.3 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.374 1.87 . . . . 10.0 110.451 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -134.16 134.95 42.74 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.01 1.324 . . . . 10.0 112.543 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -130.87 -178.24 4.72 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 124.624 1.17 . . . . 10.0 111.55 166.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 -60.14 -12.61 8.92 Favored 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 115.804 1.779 . . . . 10.0 115.804 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.45 -16.19 13.38 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.381 1.472 . . . . 10.0 114.525 -178.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.78 -168.83 40.92 Favored Glycine 0 CA--C 1.533 1.217 0 CA-C-N 119.884 1.22 . . . . 10.0 116.124 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -134.11 145.78 49.65 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 127.117 2.167 . . . . 10.0 111.878 -170.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.75 161.02 37.12 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.133 1.773 . . . . 10.0 111.205 168.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 60.8 m -137.11 141.92 42.3 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.084 1.354 . . . . 10.0 110.966 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -135.98 137.04 40.86 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.595 1.558 . . . . 10.0 110.056 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.5 m -141.65 143.7 33.76 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.797 0.839 . . . . 10.0 112.049 -167.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.6 p -152.36 142.51 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 125.279 1.431 . . . . 10.0 111.947 171.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -90.34 136.25 33.17 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.996 0.918 . . . . 10.0 110.751 168.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.6 tp -118.82 104.22 10.36 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.879 1.672 . . . . 10.0 110.909 178.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -84.63 88.3 7.33 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.036 1.334 . . . . 10.0 110.846 170.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.78 108.04 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.228 -0.92 . . . . 10.0 109.84 174.055 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.9 mt -73.96 97.03 2.74 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.072 1.749 . . . . 10.0 109.852 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.796 0 C-N-CA 124.65 1.18 . . . . 10.0 113.754 -174.825 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 CA--C 1.543 0.953 0 N-CA-C 113.228 0.434 . . . . 10.0 113.228 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -63.99 139.13 66.02 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.963 2.442 . . . . 10.0 110.795 172.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 76.4 ttt-85 -139.41 141.41 37.52 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.39 1.076 . . . . 10.0 113.568 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -59.19 118.88 6.4 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.352 2.261 . . . . 10.0 111.912 171.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.6 -52.75 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.262 1.025 . . . . 10.0 110.001 165.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 40.1 tt0 -150.57 134.86 17.06 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.649 1.18 . . . . 10.0 111.145 176.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 31.7 m -119.35 152.78 53.12 Favored Pre-proline 0 N--CA 1.475 0.791 0 C-N-CA 126.0 1.72 . . . . 10.0 109.266 168.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -75.73 163.77 33.17 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.599 2.2 . . . . 10.0 112.211 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.52 170.77 14.47 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.484 -0.76 . . . . 10.0 110.79 163.091 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.6 p30 -61.18 157.69 15.58 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.167 -0.958 . . . . 10.0 111.867 169.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -127.2 151.92 48.05 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.592 1.557 . . . . 10.0 111.664 -170.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -143.67 84.64 1.8 Allowed 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.304 1.442 . . . . 10.0 111.183 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 40.4 mm -102.41 136.56 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.304 1.441 . . . . 10.0 110.593 -170.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -66.92 129.15 38.96 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.441 1.096 . . . . 10.0 112.414 175.126 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -53.92 128.09 28.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.169 1.388 . . . . 10.0 112.704 178.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 104.7 -13.19 50.38 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 126.564 2.031 . . . . 10.0 114.651 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -77.43 161.86 27.65 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 118.775 1.288 . . . . 10.0 113.577 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -75.32 144.08 42.58 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.683 1.193 . . . . 10.0 110.433 155.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.72 172.36 16.23 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 123.686 0.794 . . . . 10.0 112.394 159.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -147.18 168.3 22.01 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.397 1.479 . . . . 10.0 112.516 173.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 45.8 mtt -118.03 165.88 13.2 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 126.508 1.923 . . . . 10.0 111.7 176.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -142.62 107.95 5.02 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.586 1.555 . . . . 10.0 112.448 -171.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -125.7 101.44 6.88 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 126.489 1.916 . . . . 10.0 111.128 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -76.59 111.2 11.82 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.118 -0.989 . . . . 10.0 109.685 172.113 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -123.76 102.16 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 125.666 1.586 . . . . 10.0 110.481 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 12.3 t -73.76 173.08 10.35 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.725 0.81 . . . . 10.0 111.357 171.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 124.16 162.89 11.56 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 127.076 2.274 . . . . 10.0 112.431 -176.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -152.52 130.84 6.28 Favored Pre-proline 0 CA--C 1.547 0.835 0 C-N-CA 124.393 1.077 . . . . 10.0 110.828 -177.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -67.89 169.25 54.77 Favored 'Cis proline' 0 CA--C 1.539 0.762 0 CA-C-N 120.891 1.354 . . . . 10.0 112.735 -2.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.04 122.19 46.05 Favored Pre-proline 0 CA--C 1.549 0.917 0 C-N-CA 124.658 1.183 . . . . 10.0 111.038 178.043 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.1 151.0 61.0 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 122.483 2.122 . . . . 10.0 113.295 -170.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 150.45 47.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.158 0.983 . . . . 10.0 109.531 157.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 p -138.48 143.85 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 113.269 0.84 . . . . 10.0 113.269 -174.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 21.6 m -127.12 151.7 48.3 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.901 2.081 . . . . 10.0 110.353 173.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 34.9 m95 -125.51 157.59 36.65 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.282 1.033 . . . . 10.0 112.865 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 74.9 m-85 -147.16 160.13 42.8 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 126.309 1.844 . . . . 10.0 111.553 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.8 tp -148.45 124.77 10.88 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 127.38 2.272 . . . . 10.0 110.121 176.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 53.42 14.18 0.53 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.845 2.058 . . . . 10.0 116.202 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.2 0.49 25.23 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.732 1.634 . . . . 10.0 115.962 -179.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.4 ptp85 -122.21 166.55 14.44 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 125.769 1.628 . . . . 10.0 112.319 173.352 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 20.1 p -71.58 158.85 35.47 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.835 1.254 . . . . 10.0 113.674 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 97.1 t -136.84 142.52 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 128.069 2.547 . . . . 10.0 108.299 171.037 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.2 mt-30 -128.93 163.67 24.8 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.151 1.38 . . . . 10.0 111.344 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 52.9 p -66.67 148.54 51.77 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.616 0.766 . . . . 10.0 112.383 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -152.44 167.27 29.3 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.727 1.611 . . . . 10.0 110.824 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -56.63 -34.93 67.75 Favored 'General case' 0 CA--C 1.546 0.796 0 O-C-N 121.005 -1.06 . . . . 10.0 112.963 170.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 82.9 mt -84.84 -14.74 47.04 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.527 1.131 . . . . 10.0 113.902 174.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.83 70.52 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.546 1.538 . . . . 10.0 111.371 -172.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.57 147.7 48.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.591 1.156 . . . . 10.0 111.517 -176.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -134.36 107.09 7.42 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 126.927 2.091 . . . . 10.0 109.467 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.31 161.32 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.429 -176.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 19.7 t -135.75 120.19 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 125.882 1.673 . . . . 10.0 109.509 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 22.6 t -64.33 160.32 19.12 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.439 1.096 . . . . 10.0 112.341 175.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -51.8 -35.48 44.32 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.781 1.633 . . . . 10.0 112.579 173.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 44.8 mmtm -82.15 -0.7 46.09 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.022 1.729 . . . . 10.0 114.704 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.52 8.65 65.65 Favored Glycine 0 CA--C 1.538 1.479 0 C-N-CA 124.987 1.28 . . . . 10.0 115.345 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 50.3 tp -76.7 102.01 6.03 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.71 1.204 . . . . 10.0 110.699 171.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -78.29 144.21 36.33 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.36 1.064 . . . . 10.0 111.085 168.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 17.2 m -135.37 155.14 51.07 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.174 1.39 . . . . 10.0 112.833 173.194 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.05 116.09 15.07 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 128.122 2.569 . . . . 10.0 107.949 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -98.61 154.79 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.405 1.482 . . . . 10.0 111.26 -171.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -130.6 104.91 7.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.127 2.171 . . . . 10.0 108.831 164.156 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.8 mm-40 -64.0 -37.09 86.15 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.287 -0.883 . . . . 10.0 113.023 178.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.0 p -150.61 91.66 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 125.816 1.646 . . . . 10.0 110.3 177.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.29 139.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 121.3 -0.875 . . . . 10.0 112.194 -176.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -125.9 161.05 28.33 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 126.853 2.061 . . . . 10.0 111.112 176.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.37 -29.64 64.21 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.716 1.206 . . . . 10.0 113.74 -177.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 39.5 p -67.08 -17.07 64.72 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 125.477 1.511 . . . . 10.0 114.597 173.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -82.27 -6.49 59.27 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.7 1.2 . . . . 10.0 113.256 174.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.56 152.45 45.25 Favored 'General case' 0 CA--C 1.546 0.806 0 O-C-N 120.912 -1.117 . . . . 10.0 113.403 -178.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 133.14 -170.21 22.3 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.79 1.186 . . . . 10.0 115.147 174.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.66 105.64 16.37 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.052 1.741 . . . . 10.0 111.197 177.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -81.38 153.75 26.81 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.378 1.071 . . . . 10.0 111.769 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.01 159.09 42.96 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.016 0.927 . . . . 10.0 112.006 167.436 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 37.6 t -138.81 127.19 22.96 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 127.052 2.141 . . . . 10.0 109.248 -173.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.8 t -122.68 113.09 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.26 1.424 . . . . 10.0 109.49 -175.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -108.44 135.17 50.18 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.64 1.576 . . . . 10.0 111.231 -177.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.28 133.71 37.25 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.735 1.614 . . . . 10.0 111.763 -171.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -135.1 179.99 5.98 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.148 0.979 . . . . 10.0 111.99 166.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -61.32 -9.37 5.1 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 115.83 1.789 . . . . 10.0 115.83 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.84 -12.62 13.29 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 125.823 1.649 . . . . 10.0 114.332 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.77 -170.49 40.59 Favored Glycine 0 CA--C 1.535 1.343 0 CA-C-N 120.02 1.282 . . . . 10.0 115.949 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -135.43 147.56 49.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.858 2.063 . . . . 10.0 111.487 -176.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -141.06 158.36 44.04 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.629 1.572 . . . . 10.0 111.93 172.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 85.4 m -136.71 130.59 32.29 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.096 1.358 . . . . 10.0 111.148 -176.354 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -123.87 156.35 36.4 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.496 1.918 . . . . 10.0 110.815 -178.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.2 m -142.85 145.6 33.3 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 124.463 1.105 . . . . 10.0 111.559 -169.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.0 p -151.59 159.1 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 125.894 1.678 . . . . 10.0 110.85 172.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -121.83 137.17 54.88 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.808 1.243 . . . . 10.0 111.015 176.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.2 tp -124.65 105.3 9.22 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 126.359 1.864 . . . . 10.0 110.277 -178.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -93.97 80.35 4.12 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.676 1.59 . . . . 10.0 110.809 176.342 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -62.3 115.27 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.701 0.8 . . . . 10.0 110.95 -178.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.1 mt -76.03 97.38 4.02 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.702 1.601 . . . . 10.0 109.792 178.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.856 0 C-N-CA 124.731 1.212 . . . . 10.0 113.962 -173.185 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo . . . . . 0 CA--C 1.543 0.949 0 N-CA-C 113.045 0.363 . . . . 10.0 113.045 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -70.92 167.56 25.59 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.231 2.62 . . . . 10.0 112.58 173.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -135.42 156.75 48.41 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.223 1.409 . . . . 10.0 112.703 -171.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -96.94 74.37 2.62 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.161 2.185 . . . . 10.0 110.695 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.5 mp -76.05 -71.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.134 -0.979 . . . . 10.0 112.322 -173.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -152.13 143.47 23.34 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.983 0.913 . . . . 10.0 112.281 -174.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.91 152.55 54.1 Favored Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 126.295 1.838 . . . . 10.0 110.57 172.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -74.29 160.84 41.57 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.768 2.312 . . . . 10.0 111.348 172.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -72.16 165.7 23.83 Favored 'General case' 0 CA--C 1.543 0.711 0 O-C-N 121.452 -0.78 . . . . 10.0 111.551 169.217 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -62.19 158.05 17.87 Favored 'General case' 0 CA--C 1.546 0.792 0 O-C-N 121.453 -0.779 . . . . 10.0 112.433 174.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 46.5 mtm -130.15 162.32 29.13 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.318 1.047 . . . . 10.0 112.912 -178.013 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -139.83 96.37 3.06 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.862 2.065 . . . . 10.0 110.482 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.1 mm -112.74 133.29 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 124.594 1.158 . . . . 10.0 111.214 -166.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -60.15 126.93 29.42 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.439 1.496 . . . . 10.0 112.456 172.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -55.18 127.13 27.76 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.273 1.029 . . . . 10.0 112.18 -178.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.92 -10.43 58.67 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 126.004 1.764 . . . . 10.0 114.955 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -73.93 161.19 30.37 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 119.362 1.581 . . . . 10.0 113.333 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -75.98 140.32 41.96 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.328 1.451 . . . . 10.0 110.264 157.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.48 166.3 31.54 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.702 0.801 . . . . 10.0 112.598 165.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm85 -141.69 168.0 20.81 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.88 1.272 . . . . 10.0 113.744 175.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 52.3 mtt -131.76 160.29 35.97 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 127.317 2.247 . . . . 10.0 111.01 175.231 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -140.96 103.52 4.49 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.442 1.497 . . . . 10.0 111.932 -168.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 -113.85 121.59 44.47 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.849 1.66 . . . . 10.0 111.677 -176.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.7 mtpp -77.48 127.35 32.37 Favored 'General case' 0 N--CA 1.478 0.955 0 O-C-N 121.382 -0.824 . . . . 10.0 110.887 173.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.7 p -138.96 145.12 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.596 1.558 . . . . 10.0 111.053 -179.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.9 t -142.99 -176.06 4.76 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.63 1.572 . . . . 10.0 110.886 178.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 118.42 164.49 13.0 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 127.519 2.485 . . . . 10.0 112.005 -172.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.5 tp -147.27 129.08 7.44 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 123.975 0.91 . . . . 10.0 110.785 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.4 169.15 47.01 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 CA-C-N 120.784 1.316 . . . . 10.0 112.373 -3.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.76 53.23 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 124.498 1.119 . . . . 10.0 111.102 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -69.33 150.44 70.82 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.398 2.065 . . . . 10.0 113.049 -172.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -70.4 140.71 52.14 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.129 0.972 . . . . 10.0 109.456 159.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 m -129.01 137.9 55.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.323 1.049 . . . . 10.0 112.521 -170.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 72.2 m -132.92 152.8 51.85 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.165 1.786 . . . . 10.0 110.861 177.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -128.15 152.86 47.52 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.85 1.26 . . . . 10.0 112.765 -175.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -145.48 158.32 43.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 126.08 1.752 . . . . 10.0 111.68 -171.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.8 tp -148.16 123.33 10.17 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.187 2.195 . . . . 10.0 109.875 177.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 54.22 11.0 0.34 Allowed 'General case' 0 CA--C 1.556 1.192 0 N-CA-C 116.571 2.063 . . . . 10.0 116.571 173.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 116.05 -0.64 21.11 Favored Glycine 0 CA--C 1.54 1.608 0 C-N-CA 125.802 1.668 . . . . 10.0 115.875 -178.239 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -119.41 166.45 13.05 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 125.865 1.666 . . . . 10.0 112.108 172.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.1 p -72.49 161.17 31.15 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.756 1.222 . . . . 10.0 113.131 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.92 91.97 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.878 2.071 . . . . 10.0 108.703 173.207 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -69.31 145.34 53.11 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 123.254 0.622 . . . . 10.0 110.661 171.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 44.1 p -73.77 153.93 39.79 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.453 0.701 . . . . 10.0 112.542 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.69 -172.91 4.24 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.527 1.931 . . . . 10.0 111.676 175.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -61.55 -17.76 56.3 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.984 1.475 . . . . 10.0 114.984 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.4 mt -113.26 -18.84 11.98 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 126.285 1.834 . . . . 10.0 113.423 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.9 m80 -121.0 93.38 4.01 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.947 2.099 . . . . 10.0 109.923 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.9 mttt -106.7 121.33 44.14 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.444 1.098 . . . . 10.0 110.79 -169.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -128.71 100.57 5.77 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.258 1.423 . . . . 10.0 110.375 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.18 161.65 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 125.888 1.675 . . . . 10.0 111.934 -174.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.93 167.04 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 125.686 1.594 . . . . 10.0 112.12 -178.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.8 t -133.85 149.55 51.36 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.648 1.579 . . . . 10.0 112.046 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.86 -19.54 42.81 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.904 1.682 . . . . 10.0 114.156 175.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -76.74 -2.23 31.97 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 125.622 1.569 . . . . 10.0 114.142 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.0 46.27 6.0 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.816 1.198 . . . . 10.0 112.703 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 11.6 tp -137.94 150.59 47.18 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.257 1.423 . . . . 10.0 111.265 -174.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -130.81 123.84 29.99 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.767 2.027 . . . . 10.0 109.893 174.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 48.3 m -94.49 156.02 16.66 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.339 1.056 . . . . 10.0 112.506 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.92 116.46 15.62 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.368 1.867 . . . . 10.0 107.205 162.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.36 133.86 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.819 1.248 . . . . 10.0 110.636 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -109.69 108.77 19.28 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.975 2.11 . . . . 10.0 108.916 171.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -64.19 -37.74 88.54 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 121.489 -0.757 . . . . 10.0 112.817 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.4 p -151.07 89.45 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.154 1.782 . . . . 10.0 109.918 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -66.32 138.29 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 O-C-N 121.232 -0.918 . . . . 10.0 111.742 -178.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.7 mmt180 -121.32 160.35 24.16 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 126.021 1.728 . . . . 10.0 112.208 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.97 -34.37 65.65 Favored 'General case' 0 CA--C 1.546 0.81 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -176.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 19.9 m -65.51 -16.47 63.7 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.498 1.519 . . . . 10.0 114.555 175.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -82.18 -7.48 59.62 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.649 1.179 . . . . 10.0 113.311 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.52 147.33 53.03 Favored 'General case' 0 CA--C 1.546 0.815 0 O-C-N 121.185 -0.947 . . . . 10.0 112.926 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.94 -170.79 23.02 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 124.512 1.053 . . . . 10.0 115.347 175.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.97 107.03 15.28 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.994 1.718 . . . . 10.0 111.326 177.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -83.3 151.13 25.73 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.386 1.075 . . . . 10.0 111.776 170.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.27 160.38 40.59 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 10.0 112.309 169.115 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -133.02 145.84 51.2 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 126.416 1.886 . . . . 10.0 110.027 175.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 66.6 t -127.73 129.15 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 125.624 1.569 . . . . 10.0 108.882 175.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -122.4 120.79 35.0 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.574 1.95 . . . . 10.0 110.469 -175.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -131.56 134.48 46.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.305 1.442 . . . . 10.0 112.11 -171.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -130.63 -178.23 4.69 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.472 1.109 . . . . 10.0 111.645 168.182 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -60.03 -11.3 5.53 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 115.788 1.773 . . . . 10.0 115.788 -179.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.97 -18.48 11.24 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.417 1.487 . . . . 10.0 114.654 -177.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.53 -170.13 43.2 Favored Glycine 0 CA--C 1.534 1.22 0 CA-C-N 120.034 1.288 . . . . 10.0 116.314 179.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.12 143.6 46.66 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.172 2.189 . . . . 10.0 111.764 -172.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.75 160.18 38.99 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.167 1.787 . . . . 10.0 111.173 168.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.4 m -138.89 145.26 39.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 125.229 1.412 . . . . 10.0 110.871 -175.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -136.48 152.92 51.08 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.33 1.452 . . . . 10.0 111.102 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.8 m -145.16 145.88 31.55 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.567 1.147 . . . . 10.0 111.762 -172.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -152.79 171.82 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 126.36 1.864 . . . . 10.0 110.734 171.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -128.53 142.98 50.9 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.755 1.222 . . . . 10.0 111.404 173.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.0 tp -127.36 109.13 11.47 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.04 1.736 . . . . 10.0 110.128 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -78.88 141.89 37.27 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.935 -0.478 . . . . 10.0 110.035 160.091 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 40.0 t -120.5 106.53 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.458 1.103 . . . . 10.0 108.752 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.5 mt -69.37 96.78 0.9 Allowed 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.222 1.809 . . . . 10.0 109.288 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.792 0 C-N-CA 124.954 1.302 . . . . 10.0 114.259 -167.554 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 CA--C 1.543 0.947 0 N-CA-C 112.934 0.321 . . . . 10.0 112.934 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -65.85 145.0 79.27 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 123.017 2.478 . . . . 10.0 111.228 169.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -136.28 147.82 47.68 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.569 1.548 . . . . 10.0 112.384 -175.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -61.22 110.07 1.29 Allowed 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.814 2.046 . . . . 10.0 111.502 171.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 46.9 mm -105.46 -63.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.995 0.918 . . . . 10.0 110.285 172.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -153.36 101.88 2.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.311 1.044 . . . . 10.0 111.456 176.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 25.3 m -72.27 150.07 91.84 Favored Pre-proline 0 N--CA 1.476 0.834 0 C-N-CA 123.019 0.528 . . . . 10.0 110.22 161.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -75.72 161.0 37.25 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 122.859 2.373 . . . . 10.0 112.089 177.179 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -73.2 166.66 22.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 123.912 0.885 . . . . 10.0 111.517 168.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -62.01 157.79 17.93 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 121.34 -0.85 . . . . 10.0 112.644 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.0 mtp -132.6 153.41 51.06 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.349 1.459 . . . . 10.0 112.118 -166.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 16.9 p -147.27 100.95 3.34 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.8 1.64 . . . . 10.0 110.947 178.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.3 mm -117.32 138.95 46.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.044 1.337 . . . . 10.0 110.911 -167.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -67.75 132.18 46.95 Favored 'General case' 0 CA--C 1.543 0.688 0 O-C-N 121.359 -0.838 . . . . 10.0 112.311 176.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -54.63 119.49 5.37 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.564 1.545 . . . . 10.0 112.132 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 108.52 -10.8 35.83 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 126.216 1.865 . . . . 10.0 115.191 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -74.01 162.31 29.17 Favored 'General case' 0 N--CA 1.479 0.985 0 CA-C-N 119.224 1.512 . . . . 10.0 113.577 178.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -73.97 147.18 43.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.565 1.146 . . . . 10.0 110.558 158.37 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 4.3 t -153.72 173.29 16.03 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.212 1.005 . . . . 10.0 112.541 167.373 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -148.57 166.83 27.07 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 126.039 1.736 . . . . 10.0 112.436 166.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.0 mtt -118.15 157.41 26.97 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.617 1.967 . . . . 10.0 111.333 172.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -140.02 95.01 2.83 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.275 1.43 . . . . 10.0 111.579 -167.054 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -113.1 100.74 8.83 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.426 1.49 . . . . 10.0 111.609 -175.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -73.4 128.97 36.98 Favored 'General case' 0 N--CA 1.477 0.889 0 O-C-N 121.356 -0.84 . . . . 10.0 111.311 175.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.4 p -146.99 138.52 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.632 1.973 . . . . 10.0 110.501 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 70.4 m -125.68 126.33 44.49 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.641 1.176 . . . . 10.0 111.596 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -172.02 169.02 42.16 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 127.12 2.295 . . . . 10.0 111.338 175.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.6 tp -146.69 131.36 8.81 Favored Pre-proline 0 CA--C 1.548 0.901 0 C-N-CA 124.47 1.108 . . . . 10.0 111.105 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -66.91 169.86 46.94 Favored 'Cis proline' 0 CA--C 1.54 0.797 0 CA-C-N 120.533 1.226 . . . . 10.0 112.546 -3.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.17 120.78 32.36 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 124.605 1.162 . . . . 10.0 111.255 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.41 161.49 45.39 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 122.585 2.19 . . . . 10.0 113.221 -172.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -63.85 163.05 12.51 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.844 1.258 . . . . 10.0 111.692 166.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.4 p -139.31 114.97 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.139 1.375 . . . . 10.0 111.525 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 53.2 m -137.1 158.91 43.38 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.948 1.699 . . . . 10.0 110.876 171.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -133.94 160.86 36.42 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.576 1.151 . . . . 10.0 113.604 -170.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -143.5 161.64 37.92 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.872 2.069 . . . . 10.0 111.529 -177.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.7 tp -146.12 119.26 8.85 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 127.027 2.131 . . . . 10.0 110.188 176.052 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.4 m-20 54.78 16.65 1.48 Allowed 'General case' 0 CA--C 1.554 1.132 0 C-N-CA 126.469 1.908 . . . . 10.0 114.964 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.37 -11.86 47.51 Favored Glycine 0 CA--C 1.538 1.531 0 C-N-CA 126.52 2.01 . . . . 10.0 115.164 -177.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -86.17 156.34 20.37 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 118.932 1.366 . . . . 10.0 110.976 170.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.4 p -70.88 154.14 42.09 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.345 1.058 . . . . 10.0 112.51 173.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -132.89 107.38 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.099 1.76 . . . . 10.0 108.78 173.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -78.68 163.47 25.41 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.027 0.931 . . . . 10.0 111.37 171.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.7 p -72.59 157.13 38.15 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.709 0.803 . . . . 10.0 112.615 173.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -146.95 171.09 15.77 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 126.538 1.935 . . . . 10.0 110.322 170.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -59.97 -31.54 69.99 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.039 -1.038 . . . . 10.0 112.292 167.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 80.2 mt -81.95 -17.2 47.86 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.191 1.396 . . . . 10.0 113.949 173.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.2 m80 -136.28 69.77 1.42 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.985 1.714 . . . . 10.0 110.895 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -68.07 142.72 55.76 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.952 1.301 . . . . 10.0 111.005 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.3 mtt -133.63 102.49 5.51 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 126.494 1.917 . . . . 10.0 110.049 -175.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.84 171.54 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.371 1.468 . . . . 10.0 111.874 -176.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 23.8 m -131.45 134.55 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.021 1.328 . . . . 10.0 110.983 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 23.7 t -77.53 151.0 34.75 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.272 0.629 . . . . 10.0 111.91 173.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -60.74 -20.88 62.26 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.835 1.254 . . . . 10.0 113.224 168.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -75.96 -5.37 45.9 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.718 1.607 . . . . 10.0 113.86 173.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.9 56.54 2.72 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.792 1.186 . . . . 10.0 112.571 -177.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.5 tp -133.58 105.51 6.91 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.619 1.567 . . . . 10.0 110.629 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 9.3 m170 -65.79 129.08 38.52 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.45 0.7 . . . . 10.0 110.101 166.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 66.2 m -125.1 131.56 53.27 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.899 1.679 . . . . 10.0 111.681 -173.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.17 115.87 14.71 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.657 1.983 . . . . 10.0 108.927 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.94 154.36 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 125.187 1.395 . . . . 10.0 110.696 -174.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -127.08 102.8 7.12 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.032 2.133 . . . . 10.0 108.952 164.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.9 mm-40 -65.67 -36.01 82.42 Favored 'General case' 0 N--CA 1.476 0.83 0 O-C-N 121.044 -1.035 . . . . 10.0 112.675 176.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.2 p -151.58 90.23 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.188 1.795 . . . . 10.0 110.012 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.82 131.52 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 O-C-N 121.199 -0.938 . . . . 10.0 111.392 -179.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -110.8 161.07 16.16 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.508 1.523 . . . . 10.0 111.555 177.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.43 -34.45 66.83 Favored 'General case' 0 CA--C 1.546 0.808 0 N-CA-C 113.355 0.872 . . . . 10.0 113.355 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 23.5 m -66.44 -16.59 64.22 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.522 1.529 . . . . 10.0 114.57 176.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -81.32 -7.92 59.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.302 1.041 . . . . 10.0 113.469 179.022 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.12 148.14 48.8 Favored 'General case' 0 CA--C 1.548 0.88 0 CA-C-N 119.428 1.013 . . . . 10.0 113.099 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.24 -172.65 25.26 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.655 1.121 . . . . 10.0 115.079 176.121 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.34 101.92 10.11 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.834 1.654 . . . . 10.0 111.02 174.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -78.83 151.51 31.84 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 124.119 0.968 . . . . 10.0 111.886 171.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.47 161.47 37.97 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.667 0.787 . . . . 10.0 112.179 168.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.1 t -135.28 149.98 49.92 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 126.627 1.971 . . . . 10.0 110.079 177.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -124.05 141.47 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.898 1.279 . . . . 10.0 110.844 174.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.11 120.63 24.93 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.686 1.994 . . . . 10.0 110.095 -178.054 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -135.11 132.89 38.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 125.176 1.39 . . . . 10.0 111.672 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.2 p30 -134.03 -179.58 5.64 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.744 1.218 . . . . 10.0 111.332 166.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -61.97 -11.78 15.15 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 115.576 1.695 . . . . 10.0 115.576 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.18 -15.28 14.9 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.552 1.541 . . . . 10.0 114.246 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.46 -167.94 37.9 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.839 1.2 . . . . 10.0 116.023 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.85 146.48 47.5 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.84 2.056 . . . . 10.0 112.221 -170.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.79 157.01 46.01 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.317 1.847 . . . . 10.0 111.294 167.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -139.56 135.35 33.3 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.487 1.515 . . . . 10.0 110.069 -179.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -128.43 156.19 43.58 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.47 1.508 . . . . 10.0 111.791 -173.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.9 m -142.39 147.42 36.19 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 124.632 1.173 . . . . 10.0 112.139 -171.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.11 165.9 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 126.484 1.914 . . . . 10.0 110.852 168.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -119.25 131.75 55.83 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.981 1.313 . . . . 10.0 110.827 173.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.5 tp -120.44 108.62 14.33 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 126.206 1.802 . . . . 10.0 110.253 177.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -78.66 146.18 34.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 121.951 -0.468 . . . . 10.0 110.569 160.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.1 t -124.84 104.91 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 124.287 1.035 . . . . 10.0 109.152 174.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.95 98.98 1.7 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.674 1.989 . . . . 10.0 110.253 -175.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.745 0 C-N-CA 124.878 1.271 . . . . 10.0 112.47 -178.319 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 N-CA-C 113.021 0.354 . . . . 10.0 113.021 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -69.17 162.38 42.03 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.044 2.496 . . . . 10.0 112.152 175.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.14 162.73 31.3 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.753 1.221 . . . . 10.0 113.561 -171.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -106.55 83.8 1.92 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.654 1.982 . . . . 10.0 110.76 -171.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.4 mm -83.04 -67.94 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.526 0.73 . . . . 10.0 111.7 -173.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 -155.59 148.8 24.68 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.386 1.074 . . . . 10.0 111.955 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 20.8 m -126.02 150.75 70.22 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 125.724 1.61 . . . . 10.0 110.654 172.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -74.63 159.39 42.63 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 123.016 2.478 . . . . 10.0 111.861 174.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -75.6 167.43 21.9 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.745 0.818 . . . . 10.0 112.344 168.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -59.7 152.14 23.36 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.688 0.795 . . . . 10.0 113.027 175.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 58.4 mtm -130.16 160.74 32.87 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.207 1.003 . . . . 10.0 112.908 -176.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -138.04 108.21 6.42 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 126.2 1.8 . . . . 10.0 110.642 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.7 mm -123.93 132.41 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.267 1.427 . . . . 10.0 110.409 -165.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -63.49 133.69 54.33 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.44 1.096 . . . . 10.0 112.456 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -52.51 132.46 35.2 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.465 1.506 . . . . 10.0 112.981 -179.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 91.4 -9.24 77.83 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.782 1.658 . . . . 10.0 115.394 177.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.44 160.72 32.25 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.206 1.503 . . . . 10.0 113.201 176.527 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 57.8 t80 -71.96 145.87 48.12 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.836 1.254 . . . . 10.0 110.488 158.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.8 t -150.44 163.48 38.29 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.454 1.102 . . . . 10.0 111.686 170.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.6 ptm85 -144.64 166.82 24.09 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.256 1.422 . . . . 10.0 112.769 169.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.0 mtt -130.87 159.14 38.26 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.956 2.102 . . . . 10.0 110.84 173.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -138.15 95.03 2.95 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.486 1.514 . . . . 10.0 111.34 -167.531 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -108.89 103.36 12.4 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.794 1.638 . . . . 10.0 111.103 -175.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -68.01 137.37 55.03 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 121.188 -0.945 . . . . 10.0 110.54 174.309 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.09 155.29 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.508 1.523 . . . . 10.0 111.396 -173.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -142.63 170.45 15.68 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.136 1.375 . . . . 10.0 110.992 171.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 137.71 160.47 8.54 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 127.613 2.53 . . . . 10.0 112.573 -176.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.7 tp -150.46 127.01 5.23 Favored Pre-proline 0 CA--C 1.547 0.846 0 C-N-CA 124.396 1.079 . . . . 10.0 110.711 178.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -66.78 169.13 49.01 Favored 'Cis proline' 0 CA--C 1.538 0.709 0 CA-C-N 121.346 1.517 . . . . 10.0 112.31 -2.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.58 121.11 36.66 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.708 1.203 . . . . 10.0 111.335 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -70.36 160.23 50.24 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.538 2.158 . . . . 10.0 113.274 -173.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -66.7 169.65 7.55 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 125.481 1.512 . . . . 10.0 111.736 169.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.5 p -133.33 115.71 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 125.708 1.603 . . . . 10.0 111.624 -175.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.9 m -133.84 99.16 4.37 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.515 1.526 . . . . 10.0 110.622 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -84.38 156.06 22.01 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 121.873 0.844 . . . . 10.0 112.798 175.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -143.0 159.58 41.97 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.126 2.17 . . . . 10.0 111.208 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -146.35 118.35 8.23 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.956 2.102 . . . . 10.0 109.892 176.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.2 m-20 55.4 12.26 0.71 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.578 1.951 . . . . 10.0 115.487 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.48 -13.05 23.25 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 126.662 2.077 . . . . 10.0 115.343 -178.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -91.14 161.77 14.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 125.233 1.413 . . . . 10.0 110.923 170.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 70.5 p -70.92 160.5 32.73 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.61 0.719 . . . . 10.0 112.34 174.67 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 98.5 t -129.85 113.43 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 126.53 1.932 . . . . 10.0 107.308 166.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -107.59 139.0 42.79 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.014 1.326 . . . . 10.0 109.832 -174.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 51.1 p -63.6 144.5 56.96 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.283 0.846 . . . . 10.0 113.283 -174.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -154.21 -177.77 6.66 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.9 1.68 . . . . 10.0 111.342 172.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -58.95 -18.84 37.4 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.227 1.411 . . . . 10.0 114.721 -177.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.7 mt -107.44 -11.42 15.52 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.74 1.616 . . . . 10.0 113.205 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -130.21 70.85 1.44 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.973 2.109 . . . . 10.0 110.285 -175.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -80.12 144.54 32.99 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.897 1.279 . . . . 10.0 111.706 -173.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -141.65 107.37 5.1 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.418 1.887 . . . . 10.0 110.535 -171.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 164.62 25.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.781 1.232 . . . . 10.0 112.232 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 22.1 t -133.69 116.37 24.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 125.334 1.453 . . . . 10.0 110.012 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 44.6 t -65.37 143.98 57.39 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.097 0.959 . . . . 10.0 111.755 173.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.26 -18.88 41.17 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.926 1.29 . . . . 10.0 113.888 173.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -77.11 -3.7 40.67 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.005 1.722 . . . . 10.0 114.014 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 88.33 45.94 4.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.971 1.272 . . . . 10.0 113.414 178.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.5 tp -135.18 105.6 6.38 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 125.293 1.437 . . . . 10.0 111.005 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -77.34 116.4 17.92 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.501 1.121 . . . . 10.0 110.984 171.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.9 m -93.33 137.14 32.93 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 125.495 1.518 . . . . 10.0 111.672 171.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.37 124.84 31.2 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.13 2.172 . . . . 10.0 107.639 174.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.4 mp -123.37 147.71 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.518 1.127 . . . . 10.0 111.536 -170.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -121.45 107.39 12.41 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 127.707 2.403 . . . . 10.0 109.175 170.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.4 mm-40 -66.68 -37.3 84.47 Favored 'General case' 0 N--CA 1.474 0.775 0 O-C-N 121.076 -1.015 . . . . 10.0 112.924 177.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.15 90.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 125.865 1.666 . . . . 10.0 110.284 -178.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -69.45 147.28 12.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 O-C-N 121.175 -0.953 . . . . 10.0 112.305 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -136.27 156.5 48.58 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.722 1.609 . . . . 10.0 112.721 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.54 -34.91 71.54 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.679 1.192 . . . . 10.0 113.663 -177.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.4 m -64.63 -13.08 52.1 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.453 1.501 . . . . 10.0 114.389 176.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -108.8 8.09 26.53 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.255 1.822 . . . . 10.0 113.009 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.38 158.0 30.41 Favored 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.94 -1.1 . . . . 10.0 112.616 168.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.37 -167.55 21.91 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.549 1.071 . . . . 10.0 115.134 173.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.63 103.25 10.35 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.174 1.79 . . . . 10.0 111.544 178.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -80.72 150.26 29.39 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.711 1.205 . . . . 10.0 111.919 171.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 162.96 35.0 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.113 0.965 . . . . 10.0 112.066 168.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 41.8 t -140.38 127.51 20.96 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.653 1.581 . . . . 10.0 110.768 176.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 89.7 t -102.55 132.78 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 125.666 1.586 . . . . 10.0 109.401 173.22 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.47 117.55 22.33 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.527 1.931 . . . . 10.0 110.659 -178.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -131.05 139.5 49.93 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.249 1.42 . . . . 10.0 112.056 -172.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -132.92 -177.87 4.7 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.8 1.24 . . . . 10.0 111.355 167.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -61.72 -8.8 5.1 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 115.888 1.81 . . . . 10.0 115.888 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -116.36 -17.44 10.72 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.587 1.555 . . . . 10.0 114.736 -178.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 175.4 -170.36 43.37 Favored Glycine 0 CA--C 1.534 1.232 0 CA-C-N 120.0 1.273 . . . . 10.0 116.257 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -136.58 141.99 43.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.222 2.209 . . . . 10.0 111.68 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.5 158.56 44.14 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.209 1.804 . . . . 10.0 110.953 168.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -143.52 141.32 30.69 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.517 1.127 . . . . 10.0 111.072 -175.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -132.4 154.2 50.04 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.694 1.598 . . . . 10.0 111.349 -176.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.0 m -145.39 145.3 31.1 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 124.672 1.189 . . . . 10.0 112.003 -171.036 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -154.0 172.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 126.572 1.949 . . . . 10.0 110.984 172.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 39.5 tt0 -130.1 143.13 50.62 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 120.665 -1.272 . . . . 10.0 111.557 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.9 tp -129.39 106.58 8.88 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.088 1.755 . . . . 10.0 111.14 -177.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -91.96 85.62 5.61 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.815 1.646 . . . . 10.0 111.307 177.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.9 t -70.15 110.06 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.256 -0.902 . . . . 10.0 110.997 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.8 mt -75.47 98.74 4.0 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 126.454 1.902 . . . . 10.0 110.503 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.811 0 C-N-CA 124.255 1.022 . . . . 10.0 112.743 178.38 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo . . . . . 0 CA--C 1.542 0.892 0 N-CA-C 113.08 0.377 . . . . 10.0 113.08 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -69.04 164.59 33.25 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.146 2.564 . . . . 10.0 111.52 168.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -141.12 155.32 46.13 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.717 1.207 . . . . 10.0 112.0 -174.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -74.6 102.66 4.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.19 2.196 . . . . 10.0 111.452 178.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . 0.489 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.2 OUTLIER -115.0 -176.69 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 126.026 1.73 . . . . 10.0 110.483 175.76 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.489 ' H ' HG22 ' A' ' 253' ' ' ILE . 0.0 OUTLIER -46.35 102.43 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 128.458 2.703 . . . . 10.0 115.024 -175.033 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.91 151.59 92.99 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 124.385 1.074 . . . . 10.0 111.061 158.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.4 162.65 33.29 Favored 'Trans proline' 0 CA--C 1.541 0.852 0 C-N-CA 123.023 2.482 . . . . 10.0 111.269 170.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -73.3 159.97 32.56 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 121.36 -0.838 . . . . 10.0 111.478 170.395 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -59.45 129.93 44.42 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 121.564 -0.71 . . . . 10.0 111.529 175.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 31.1 mtm -100.09 155.04 17.95 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.928 0.891 . . . . 10.0 112.162 -174.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 23.6 p -134.81 105.76 6.59 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.852 1.661 . . . . 10.0 110.269 175.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.0 mm -125.44 127.06 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.12 1.368 . . . . 10.0 110.206 -164.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -62.91 134.3 56.0 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.157 0.983 . . . . 10.0 112.189 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -53.03 130.16 33.02 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.813 1.245 . . . . 10.0 112.751 -178.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.74 -8.87 76.4 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 125.9 1.714 . . . . 10.0 115.284 177.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -70.15 160.29 32.35 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 119.272 1.536 . . . . 10.0 113.004 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 43.8 t80 -76.95 139.62 40.21 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.818 1.247 . . . . 10.0 110.222 156.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.6 p -149.32 169.71 20.18 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.754 0.822 . . . . 10.0 111.892 162.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 35.5 ptt-85 -145.27 137.78 25.96 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.217 1.007 . . . . 10.0 112.525 172.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.2 mtt -87.47 159.31 18.71 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.888 1.275 . . . . 10.0 110.906 169.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -136.7 132.29 34.69 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.014 1.326 . . . . 10.0 112.025 173.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -134.43 113.92 12.36 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 126.715 2.006 . . . . 10.0 109.645 -176.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.71 146.69 53.53 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 121.067 -1.021 . . . . 10.0 110.206 171.178 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.7 p -149.21 156.51 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.063 1.345 . . . . 10.0 111.492 -174.016 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.1 t -144.53 -176.62 5.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.712 1.605 . . . . 10.0 111.668 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 104.92 162.77 23.98 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.125 2.297 . . . . 10.0 113.54 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -148.74 131.05 7.7 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 125.234 1.414 . . . . 10.0 110.48 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -67.33 170.97 44.65 Favored 'Cis proline' 0 CA--C 1.54 0.778 0 CA-C-N 120.917 1.363 . . . . 10.0 112.615 -3.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.01 120.96 32.83 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.022 1.329 . . . . 10.0 111.437 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.53 152.42 59.86 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 122.481 2.121 . . . . 10.0 113.466 -171.273 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -72.31 141.6 48.84 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.81 1.244 . . . . 10.0 109.899 160.316 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.1 m -128.15 89.23 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.699 1.199 . . . . 10.0 112.233 -166.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.5 m -74.93 115.76 14.9 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.762 1.225 . . . . 10.0 111.251 175.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -96.89 148.77 22.61 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.475 1.11 . . . . 10.0 113.349 177.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 83.1 m-85 -143.21 160.19 40.92 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 126.562 1.945 . . . . 10.0 112.427 -174.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.2 tp -147.13 120.78 9.17 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.721 2.408 . . . . 10.0 109.799 174.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 54.93 15.1 1.05 Allowed 'General case' 0 CA--C 1.556 1.192 0 C-N-CA 126.584 1.954 . . . . 10.0 115.43 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 106.82 -11.01 41.53 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.207 1.86 . . . . 10.0 115.176 -177.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -90.55 159.81 16.28 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.207 1.403 . . . . 10.0 110.677 169.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 25.2 p -74.28 160.49 31.03 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.018 0.927 . . . . 10.0 112.6 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 41.2 t -135.54 104.77 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.979 1.712 . . . . 10.0 109.563 174.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -70.32 148.88 47.95 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.135 0.574 . . . . 10.0 111.209 170.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 34.7 p -73.55 149.5 42.15 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.497 0.719 . . . . 10.0 111.611 166.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -155.04 -177.67 6.7 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.171 1.388 . . . . 10.0 111.977 172.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -59.29 -19.95 50.38 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -177.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.7 mt -105.16 -9.35 17.8 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.501 1.52 . . . . 10.0 113.112 175.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.3 m80 -132.95 65.91 1.58 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 127.22 2.208 . . . . 10.0 110.261 -174.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -76.42 130.74 38.45 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.771 1.229 . . . . 10.0 110.668 -174.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 62.3 mtt -129.32 103.1 6.73 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.241 1.817 . . . . 10.0 109.776 -174.23 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.32 163.46 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.703 1.201 . . . . 10.0 112.763 -172.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.4 m -124.01 166.75 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 126.308 1.843 . . . . 10.0 111.649 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 35.6 t -136.88 149.04 47.43 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.487 1.515 . . . . 10.0 112.365 -178.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -58.72 -19.59 41.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.895 1.678 . . . . 10.0 114.075 174.291 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.2 mmtt -75.06 -2.17 26.23 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.565 1.546 . . . . 10.0 113.949 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.86 41.7 7.08 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.008 1.29 . . . . 10.0 112.903 -178.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.2 tp -133.51 150.02 51.7 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.276 1.43 . . . . 10.0 111.641 -175.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -132.93 137.78 46.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.02 2.528 . . . . 10.0 108.952 173.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 50.9 m -131.72 153.1 50.38 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.812 0.845 . . . . 10.0 112.471 -175.684 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.91 102.18 5.95 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.151 1.78 . . . . 10.0 109.059 178.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -86.68 142.32 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 124.841 1.256 . . . . 10.0 109.35 179.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -120.62 104.68 10.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.608 1.963 . . . . 10.0 108.459 167.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -64.85 -39.73 94.03 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.16 85.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.969 1.708 . . . . 10.0 110.111 -178.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.3 p -67.54 142.9 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 O-C-N 121.255 -0.903 . . . . 10.0 112.327 -176.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -124.77 161.07 27.23 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.286 1.834 . . . . 10.0 112.255 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.12 -30.87 64.76 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 113.839 1.051 . . . . 10.0 113.839 -176.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.7 p -67.53 -16.34 64.14 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 125.658 1.583 . . . . 10.0 114.803 173.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -82.18 -7.63 59.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.635 1.174 . . . . 10.0 113.433 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 151.61 45.35 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.136 -0.977 . . . . 10.0 113.021 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.96 -170.97 21.11 Favored Glycine 0 CA--C 1.532 1.141 0 C-N-CA 124.664 1.126 . . . . 10.0 114.935 176.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.41 104.08 14.12 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.067 1.747 . . . . 10.0 111.724 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -78.97 150.39 32.03 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.377 1.071 . . . . 10.0 112.016 170.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.43 160.28 41.82 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 123.778 0.831 . . . . 10.0 112.427 169.097 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.35 142.36 43.8 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.747 1.619 . . . . 10.0 110.414 174.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.2 t -123.14 104.92 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.798 1.639 . . . . 10.0 109.102 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.75 120.54 27.28 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 126.277 1.831 . . . . 10.0 110.835 177.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.64 135.45 51.21 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 125.21 1.404 . . . . 10.0 111.9 -178.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -133.85 -179.16 5.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.05 0.94 . . . . 10.0 111.744 164.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.7 ptp180 -60.53 -12.58 10.27 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 115.797 1.777 . . . . 10.0 115.797 -179.249 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.44 -17.99 13.33 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 125.521 1.528 . . . . 10.0 114.356 -178.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.44 -169.72 42.5 Favored Glycine 0 CA--C 1.535 1.298 0 CA-C-N 119.846 1.203 . . . . 10.0 115.809 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -137.94 145.6 42.22 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.352 1.861 . . . . 10.0 111.958 -173.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.18 162.34 35.5 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.072 1.749 . . . . 10.0 111.385 170.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 64.2 m -135.83 145.94 46.96 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.316 1.046 . . . . 10.0 111.736 -171.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -136.2 149.52 48.6 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.391 1.876 . . . . 10.0 110.63 -177.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -146.42 145.2 30.16 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.597 1.159 . . . . 10.0 111.79 -172.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.8 p -152.4 172.78 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 126.042 1.737 . . . . 10.0 110.856 168.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -126.62 147.16 49.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.17 1.388 . . . . 10.0 111.334 172.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 63.6 tp -127.86 113.0 15.34 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 126.09 1.756 . . . . 10.0 111.024 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -92.88 91.57 7.49 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.584 1.554 . . . . 10.0 110.606 171.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.4 t -74.62 106.84 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 O-C-N 121.158 -0.964 . . . . 10.0 110.157 175.495 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.1 mt -76.64 97.95 4.57 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.846 1.658 . . . . 10.0 110.5 -179.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.786 0 C-N-CA 124.077 0.951 . . . . 10.0 112.542 177.656 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo . . . . . 0 CA--C 1.542 0.905 0 N-CA-C 112.85 0.289 . . . . 10.0 112.85 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.4 143.12 62.37 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.756 2.304 . . . . 10.0 110.766 169.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 38.1 ttp-105 -111.02 152.59 26.67 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.472 1.509 . . . . 10.0 111.429 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -77.64 75.63 4.18 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 126.32 1.848 . . . . 10.0 111.712 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . 0.531 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.7 OUTLIER -75.15 177.45 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.034 0 C-N-CA 124.739 1.216 . . . . 10.0 111.312 175.969 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.531 ' H ' HG22 ' A' ' 253' ' ' ILE . 32.9 tt0 -49.94 113.01 0.75 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.79 2.436 . . . . 10.0 114.439 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 23.6 m -76.41 154.13 83.95 Favored Pre-proline 0 N--CA 1.477 0.905 0 C-N-CA 125.008 1.323 . . . . 10.0 111.19 159.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.45 167.53 25.48 Favored 'Trans proline' 0 CA--C 1.543 0.956 0 C-N-CA 123.265 2.644 . . . . 10.0 111.779 171.259 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.39 167.31 20.77 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.334 -0.854 . . . . 10.0 111.66 166.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -61.88 160.15 12.66 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.345 -0.847 . . . . 10.0 112.767 174.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 91.5 mtp -127.74 154.02 45.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.8 1.64 . . . . 10.0 111.793 -171.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 59.1 p -144.23 120.17 10.65 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 125.061 1.344 . . . . 10.0 110.367 166.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.0 mm -129.02 130.2 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.16 1.384 . . . . 10.0 109.89 -166.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -60.28 126.22 26.66 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.895 1.278 . . . . 10.0 112.238 173.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -52.33 130.71 31.78 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.48 1.512 . . . . 10.0 113.222 -177.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.33 -10.73 67.34 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.077 1.798 . . . . 10.0 115.106 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -71.69 162.06 30.03 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.144 1.472 . . . . 10.0 113.395 176.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -74.03 139.45 44.73 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.494 1.118 . . . . 10.0 110.466 155.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.3 p -148.78 172.66 14.27 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.596 0.758 . . . . 10.0 112.255 159.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -151.77 175.46 12.4 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 126.029 1.732 . . . . 10.0 112.1 175.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.7 mtt -129.14 162.32 28.04 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 126.042 1.737 . . . . 10.0 112.078 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -136.6 108.94 7.31 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.758 1.623 . . . . 10.0 111.525 -177.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -124.71 113.38 17.9 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.482 1.513 . . . . 10.0 111.155 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -67.48 146.38 54.03 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.542 -0.724 . . . . 10.0 111.099 173.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 9.3 p -149.21 139.8 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.444 1.498 . . . . 10.0 111.551 177.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 24.6 m -142.21 115.11 8.69 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.985 1.314 . . . . 10.0 111.19 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.32 166.79 38.9 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 127.086 2.279 . . . . 10.0 111.723 174.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.44 129.81 7.23 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.311 1.045 . . . . 10.0 111.242 -178.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -67.13 169.57 49.18 Favored 'Cis proline' 0 CA--C 1.539 0.739 0 CA-C-N 121.022 1.401 . . . . 10.0 112.686 -2.055 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.83 120.66 34.67 Favored Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 124.845 1.258 . . . . 10.0 111.478 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.51 159.85 50.14 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.593 2.196 . . . . 10.0 113.45 -173.31 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -66.86 167.49 11.41 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.514 1.526 . . . . 10.0 111.748 167.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.72 107.02 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.708 1.603 . . . . 10.0 110.48 -171.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.0 m -124.62 99.53 6.22 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.418 1.487 . . . . 10.0 111.339 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -81.82 151.83 27.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.051 0.94 . . . . 10.0 113.093 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -140.72 160.24 40.47 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.155 2.182 . . . . 10.0 111.416 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.9 tp -146.56 116.73 7.37 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 127.257 2.223 . . . . 10.0 110.128 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 55.76 12.46 0.85 Allowed 'General case' 0 CA--C 1.556 1.179 0 C-N-CA 126.503 1.921 . . . . 10.0 115.234 -179.556 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.25 -14.76 30.69 Favored Glycine 0 CA--C 1.54 1.611 0 C-N-CA 126.778 2.132 . . . . 10.0 114.959 -176.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -80.9 158.09 25.41 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.996 1.318 . . . . 10.0 110.524 168.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 65.8 p -74.4 162.93 28.37 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.408 0.683 . . . . 10.0 111.855 170.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 16.7 t -136.01 137.43 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.378 1.471 . . . . 10.0 109.44 171.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 25.6 mp0 -107.9 156.53 19.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.321 1.449 . . . . 10.0 111.032 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 63.7 p -71.14 155.68 40.47 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.757 0.823 . . . . 10.0 112.316 173.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -153.48 168.91 24.53 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.476 1.51 . . . . 10.0 110.92 177.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.66 -35.69 70.89 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 120.832 -1.168 . . . . 10.0 112.655 169.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 76.7 mt -81.2 -15.45 55.65 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.527 1.131 . . . . 10.0 113.803 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -135.28 70.41 1.43 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.723 1.609 . . . . 10.0 111.561 -173.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -69.12 136.56 52.41 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.776 1.23 . . . . 10.0 110.478 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 55.6 mtt -134.06 102.46 5.41 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 126.477 1.911 . . . . 10.0 109.357 -173.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.57 162.51 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 125.02 1.328 . . . . 10.0 112.985 -169.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 17.7 t -132.42 113.02 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 126.964 2.106 . . . . 10.0 109.538 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.3 t -68.93 146.41 52.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 124.545 1.138 . . . . 10.0 111.937 173.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -59.0 -19.59 45.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.803 1.241 . . . . 10.0 113.89 172.084 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -77.7 -3.29 40.37 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.381 1.472 . . . . 10.0 113.99 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.94 49.36 4.31 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.942 1.258 . . . . 10.0 113.014 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -144.74 121.39 11.14 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.863 1.665 . . . . 10.0 109.496 -175.034 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -114.14 157.22 22.9 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.424 0.898 . . . . 10.0 113.424 173.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.4 m -143.36 158.58 43.52 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.766 1.226 . . . . 10.0 113.291 -169.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.96 104.96 7.43 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.962 2.105 . . . . 10.0 108.549 171.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -79.4 151.01 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.445 1.098 . . . . 10.0 109.736 177.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -131.6 98.84 4.61 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 126.69 1.996 . . . . 10.0 108.195 167.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -62.85 -36.2 82.47 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -178.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.34 83.93 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.142 1.777 . . . . 10.0 109.747 178.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.5 p -66.5 141.45 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.246 -0.909 . . . . 10.0 112.014 -175.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 10.6 mmt180 -127.33 160.91 29.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.028 1.731 . . . . 10.0 112.503 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.9 -33.24 61.86 Favored 'General case' 0 CA--C 1.547 0.865 0 N-CA-C 114.131 1.16 . . . . 10.0 114.131 -177.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 73.6 m -68.62 -15.62 63.59 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.328 1.233 . . . . 10.0 114.328 175.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -81.47 -6.79 59.31 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.386 1.074 . . . . 10.0 113.236 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.06 149.69 49.43 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 120.931 -1.106 . . . . 10.0 113.017 179.014 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.75 -173.87 22.36 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.812 1.196 . . . . 10.0 114.976 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.21 103.16 13.92 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.069 1.748 . . . . 10.0 111.297 176.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 62.7 m-85 -81.04 151.5 28.36 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.0 0.92 . . . . 10.0 112.11 172.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 164.86 29.47 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.223 1.009 . . . . 10.0 112.283 168.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 34.0 t -140.83 117.26 10.77 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.64 1.576 . . . . 10.0 110.643 175.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.8 t -88.3 132.16 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.834 1.253 . . . . 10.0 109.373 170.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -126.58 119.7 27.75 Favored 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 126.459 1.904 . . . . 10.0 110.876 -177.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -131.76 137.11 48.05 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 125.408 1.483 . . . . 10.0 112.32 -170.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.5 p30 -132.53 -177.24 4.39 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.806 1.243 . . . . 10.0 111.572 166.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -59.83 -15.78 23.51 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 115.652 1.723 . . . . 10.0 115.652 -179.28 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -107.97 -20.65 13.11 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.262 1.425 . . . . 10.0 114.192 -176.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.15 -169.7 42.84 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 116.104 1.201 . . . . 10.0 116.104 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -134.67 143.33 47.18 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 127.041 2.136 . . . . 10.0 111.647 -172.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -135.93 164.28 28.33 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.013 1.725 . . . . 10.0 111.153 166.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.5 m -140.75 140.22 34.78 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.479 1.111 . . . . 10.0 110.931 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -124.92 153.09 43.21 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.212 1.805 . . . . 10.0 110.437 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 16.1 m -148.41 146.25 28.38 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 124.197 0.999 . . . . 10.0 112.274 -169.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.2 p -151.36 171.74 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.538 1.935 . . . . 10.0 110.601 171.102 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -130.95 140.03 50.11 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.841 1.256 . . . . 10.0 110.758 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.9 tp -126.2 110.58 13.62 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.321 1.849 . . . . 10.0 110.695 -176.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -97.64 82.56 3.08 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.682 1.593 . . . . 10.0 110.86 175.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.3 114.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.897 0.879 . . . . 10.0 110.779 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 78.3 mt -78.35 93.33 4.66 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 126.279 1.831 . . . . 10.0 110.366 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.874 0 C-N-CA 124.893 1.277 . . . . 10.0 113.486 -179.424 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo . . . . . 0 CA--C 1.544 1.006 0 N-CA-C 113.578 0.569 . . . . 10.0 113.578 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -67.56 161.15 44.78 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.116 2.544 . . . . 10.0 112.094 169.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 50.6 ttp180 -144.7 155.55 43.63 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 124.911 1.284 . . . . 10.0 112.649 -173.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -75.15 83.02 2.34 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.915 2.086 . . . . 10.0 111.831 176.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.3 mm -79.12 -66.33 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 O-C-N 121.543 -0.723 . . . . 10.0 110.778 177.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -156.24 145.84 20.92 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 124.833 1.253 . . . . 10.0 111.347 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.5 150.93 74.18 Favored Pre-proline 0 N--CA 1.477 0.882 0 C-N-CA 125.77 1.628 . . . . 10.0 110.331 171.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_endo -73.38 158.08 48.73 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.817 2.345 . . . . 10.0 112.198 176.108 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -73.81 170.69 14.8 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.928 0.891 . . . . 10.0 111.275 165.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.96 155.18 17.21 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.258 -0.901 . . . . 10.0 112.577 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.4 mtp -132.72 159.45 39.65 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.435 1.494 . . . . 10.0 112.341 -171.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 58.2 p -142.54 128.0 18.96 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 125.657 1.583 . . . . 10.0 110.288 168.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.9 mm -133.73 132.04 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.306 1.442 . . . . 10.0 109.826 -169.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -61.79 128.86 38.23 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.12 1.368 . . . . 10.0 112.347 173.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.32 132.94 29.34 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.717 1.607 . . . . 10.0 113.268 -177.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.62 -9.18 78.41 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 125.767 1.651 . . . . 10.0 115.277 177.318 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.5 mtp85 -70.22 160.25 32.51 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.185 1.492 . . . . 10.0 113.112 175.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.9 t80 -73.26 138.82 45.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.203 1.001 . . . . 10.0 110.267 154.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.28 172.39 15.95 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.797 0.839 . . . . 10.0 112.103 162.278 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -148.43 171.95 15.23 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.857 1.263 . . . . 10.0 113.005 173.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 55.2 mtt -132.08 154.93 48.94 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 127.72 2.408 . . . . 10.0 110.105 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -134.98 102.09 5.1 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.655 1.582 . . . . 10.0 112.041 -170.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -107.95 106.68 17.04 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 125.651 1.581 . . . . 10.0 110.126 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -65.54 131.9 47.54 Favored 'General case' 0 N--CA 1.474 0.773 0 O-C-N 121.348 -0.845 . . . . 10.0 109.978 172.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.9 p -137.16 155.95 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 125.771 1.628 . . . . 10.0 111.051 -171.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.4 t -142.84 -170.83 3.32 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.464 1.506 . . . . 10.0 111.737 -176.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 93.86 165.44 37.0 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 126.717 2.103 . . . . 10.0 113.301 -176.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.81 130.98 8.55 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 125.818 1.647 . . . . 10.0 109.363 178.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -67.11 169.95 47.65 Favored 'Cis proline' 0 CA--C 1.541 0.847 0 CA-C-N 120.788 1.317 . . . . 10.0 112.635 -3.215 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.0 123.54 54.06 Favored Pre-proline 0 CA--C 1.55 0.952 0 C-N-CA 124.832 1.253 . . . . 10.0 111.209 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.4 150.6 58.53 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 122.324 2.016 . . . . 10.0 114.081 -168.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -68.99 117.28 10.44 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.09 1.756 . . . . 10.0 109.485 160.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -114.71 86.74 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.654 1.582 . . . . 10.0 111.917 -169.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.8 m -72.3 157.48 37.61 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.913 0.885 . . . . 10.0 111.742 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 62.0 m95 -131.24 155.33 47.3 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.914 1.286 . . . . 10.0 112.828 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -146.29 159.52 43.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.435 1.894 . . . . 10.0 111.488 -175.049 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.4 tp -147.59 121.58 9.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.15 2.18 . . . . 10.0 110.047 176.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 54.18 17.35 1.44 Allowed 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 126.466 1.906 . . . . 10.0 115.241 178.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.46 -7.09 42.57 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 126.181 1.848 . . . . 10.0 115.416 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.8 mtt85 -98.2 161.45 13.7 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.458 1.503 . . . . 10.0 111.219 171.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.7 p -71.56 156.74 39.07 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.535 1.134 . . . . 10.0 113.003 176.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 80.5 t -134.33 141.84 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 127.101 2.16 . . . . 10.0 108.551 170.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -126.18 161.9 26.62 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.228 1.411 . . . . 10.0 111.354 -177.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 55.6 p -68.36 150.14 48.54 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.548 0.739 . . . . 10.0 112.304 174.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -152.68 167.68 28.14 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.826 1.65 . . . . 10.0 110.723 176.72 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.34 -34.53 66.66 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 121.003 -1.06 . . . . 10.0 112.883 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.3 mt -86.39 -12.94 47.8 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.671 1.188 . . . . 10.0 113.91 174.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.9 m80 -136.39 71.02 1.41 Allowed 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.579 1.551 . . . . 10.0 111.271 -173.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.9 mttt -71.55 144.83 49.42 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.684 1.194 . . . . 10.0 111.574 -176.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 64.6 mtt -137.75 104.93 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.897 2.079 . . . . 10.0 109.602 -176.016 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.3 157.14 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 124.175 0.99 . . . . 10.0 112.616 -177.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.58 108.17 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 126.54 1.936 . . . . 10.0 110.752 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 41.7 t -64.8 142.17 58.52 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.75 0.82 . . . . 10.0 111.573 174.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -60.11 -18.44 47.29 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.752 1.221 . . . . 10.0 113.705 172.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -77.51 -3.6 41.38 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.935 1.694 . . . . 10.0 113.849 173.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.0 45.64 4.73 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.155 1.359 . . . . 10.0 113.694 177.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.4 108.28 8.07 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 125.306 1.443 . . . . 10.0 110.478 -177.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.4 t60 -83.31 108.68 16.68 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.141 0.977 . . . . 10.0 111.155 170.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 23.8 m -85.02 136.18 33.7 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.52 1.128 . . . . 10.0 111.585 169.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -128.56 119.33 24.59 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 127.096 2.158 . . . . 10.0 107.918 174.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.6 mt -116.68 152.4 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.762 1.225 . . . . 10.0 111.576 -166.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -129.4 107.97 9.92 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.5 2.32 . . . . 10.0 109.187 169.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.04 -37.99 85.06 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.219 -0.925 . . . . 10.0 112.961 176.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.3 p -151.88 83.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.68 1.592 . . . . 10.0 110.353 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -68.48 143.9 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 O-C-N 121.178 -0.951 . . . . 10.0 112.291 -176.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -126.13 163.33 23.34 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 126.222 1.809 . . . . 10.0 112.276 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.3 -30.8 65.05 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.715 1.006 . . . . 10.0 113.715 -178.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.9 p -67.96 -16.63 64.14 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.673 1.589 . . . . 10.0 114.707 173.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -82.73 -5.97 59.16 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 124.691 1.196 . . . . 10.0 113.354 175.437 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.33 152.09 45.73 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.035 -1.041 . . . . 10.0 113.082 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.77 -170.56 22.01 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.881 1.229 . . . . 10.0 114.937 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.0 104.56 14.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.025 1.73 . . . . 10.0 111.402 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -80.06 153.11 28.99 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.415 1.086 . . . . 10.0 112.029 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.93 159.9 41.35 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.947 0.899 . . . . 10.0 112.207 167.26 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -132.51 145.15 50.93 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.346 1.858 . . . . 10.0 110.031 176.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 45.3 t -130.14 102.1 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.119 1.368 . . . . 10.0 109.812 -179.657 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.46 125.41 33.01 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 126.649 1.98 . . . . 10.0 111.245 176.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 22.7 mtmt -131.63 131.72 43.43 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.181 1.792 . . . . 10.0 111.996 -175.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.5 p30 -137.15 -179.1 5.51 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 123.461 0.704 . . . . 10.0 112.078 162.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.1 ptp180 -59.6 -14.41 13.36 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 115.763 1.764 . . . . 10.0 115.763 -177.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.3 -15.08 14.56 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.207 1.403 . . . . 10.0 114.402 -178.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.34 -173.5 42.48 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 119.587 1.085 . . . . 10.0 115.709 178.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -134.86 146.99 49.76 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.515 1.926 . . . . 10.0 111.455 -174.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.25 155.94 48.16 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.795 1.638 . . . . 10.0 111.12 170.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.7 m -135.36 131.45 36.37 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.769 1.228 . . . . 10.0 110.753 -173.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -126.17 157.25 38.63 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.364 1.466 . . . . 10.0 111.219 -176.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 20.5 m -146.13 146.34 30.83 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.37 1.068 . . . . 10.0 111.931 -169.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.4 p -152.32 165.81 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 C-N-CA 126.245 1.818 . . . . 10.0 110.629 170.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -126.29 139.17 53.52 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.82 1.248 . . . . 10.0 110.956 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 54.5 tp -126.74 113.12 16.23 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.979 1.712 . . . . 10.0 110.969 -177.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -98.9 85.21 3.23 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.638 1.575 . . . . 10.0 110.964 175.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.0 t -66.96 114.23 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.899 0.88 . . . . 10.0 110.82 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.4 mt -78.33 98.29 5.9 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.387 1.875 . . . . 10.0 110.516 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.871 0 C-N-CA 124.354 1.061 . . . . 10.0 113.577 -179.78 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo . . . . . 0 CA--C 1.541 0.833 0 N-CA-C 112.633 0.205 . . . . 10.0 112.633 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.01 159.99 51.71 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.619 2.212 . . . . 10.0 112.218 176.503 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -112.35 169.05 9.15 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.752 1.621 . . . . 10.0 112.989 -172.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -108.7 97.55 7.18 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.798 2.039 . . . . 10.0 109.417 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . 0.512 HG22 ' H ' ' A' ' 254' ' ' GLN . 1.1 mp -115.37 171.41 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 126.245 1.818 . . . . 10.0 109.868 -174.133 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.512 ' H ' HG22 ' A' ' 253' ' ' ILE . 6.5 tm0? -44.34 122.08 2.85 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.692 2.397 . . . . 10.0 114.655 -173.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.7 m -107.69 158.86 32.29 Favored Pre-proline 0 N--CA 1.476 0.867 0 C-N-CA 127.508 2.323 . . . . 10.0 110.461 172.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -73.6 159.0 46.78 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.456 2.104 . . . . 10.0 111.697 173.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -71.41 172.5 9.34 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 123.71 0.804 . . . . 10.0 111.125 165.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.3 p30 -59.0 151.62 21.67 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 121.109 -0.994 . . . . 10.0 112.067 173.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.8 mtp -134.11 158.18 44.28 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.184 1.394 . . . . 10.0 111.961 -171.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 61.3 p -141.86 131.28 23.74 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 125.483 1.513 . . . . 10.0 110.823 173.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.3 mm -136.57 133.82 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.54 1.536 . . . . 10.0 109.557 -169.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -65.11 131.33 46.25 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.408 1.083 . . . . 10.0 112.428 175.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -51.61 123.44 9.99 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.607 1.563 . . . . 10.0 113.045 -179.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 102.9 -10.39 55.63 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 126.285 1.898 . . . . 10.0 115.106 178.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.7 mtp180 -72.94 160.93 31.34 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 119.127 1.464 . . . . 10.0 113.398 177.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -72.3 148.94 44.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.866 1.266 . . . . 10.0 110.632 157.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 45.4 t -149.48 156.05 41.38 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.763 1.225 . . . . 10.0 111.087 169.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -146.35 163.14 36.52 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.605 1.162 . . . . 10.0 112.675 165.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 59.0 mtt -137.51 121.72 18.04 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.784 1.634 . . . . 10.0 111.661 -173.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 26.1 m-20 -80.73 117.9 21.8 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 126.363 1.865 . . . . 10.0 112.353 175.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -128.13 105.46 8.39 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 125.373 1.469 . . . . 10.0 111.448 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -65.78 131.73 47.02 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 121.253 -0.904 . . . . 10.0 111.131 175.328 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.39 133.2 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.157 1.783 . . . . 10.0 110.73 -177.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -146.86 157.15 43.58 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.599 1.159 . . . . 10.0 111.536 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 149.13 165.52 12.37 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 128.178 2.799 . . . . 10.0 111.332 -173.671 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.0 tp -146.69 125.33 6.31 Favored Pre-proline 0 CA--C 1.546 0.816 0 CA-C-O 118.106 -0.949 . . . . 10.0 111.137 179.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -66.46 167.87 52.77 Favored 'Cis proline' 0 CA--C 1.538 0.708 0 CA-C-N 120.937 1.37 . . . . 10.0 112.669 -1.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.17 121.46 41.9 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.787 1.235 . . . . 10.0 111.341 -178.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -70.52 153.56 65.33 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 122.474 2.116 . . . . 10.0 113.196 -172.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -74.54 141.87 44.79 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.378 1.071 . . . . 10.0 109.55 159.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 47.8 t -130.94 131.7 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.262 1.025 . . . . 10.0 111.475 -170.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.1 m -131.73 156.7 45.46 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.865 1.666 . . . . 10.0 111.966 177.189 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -123.56 155.45 37.6 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.214 1.405 . . . . 10.0 113.177 -177.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -145.01 160.74 40.89 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 127.142 2.177 . . . . 10.0 111.572 -173.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -145.64 118.08 8.5 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 127.346 2.258 . . . . 10.0 109.905 176.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 54.72 16.24 1.33 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 126.318 1.847 . . . . 10.0 114.793 -179.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.96 -12.65 45.41 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.689 2.09 . . . . 10.0 115.24 -177.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -84.99 158.11 20.59 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 125.088 1.355 . . . . 10.0 110.698 170.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.4 p -72.1 157.11 38.38 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.882 0.873 . . . . 10.0 112.611 174.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 55.0 t -133.86 93.29 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.446 1.898 . . . . 10.0 108.74 173.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 60.8 mt-30 -68.51 155.09 40.61 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.615 0.766 . . . . 10.0 111.223 172.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.2 p -71.12 155.94 40.18 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-O 121.832 0.825 . . . . 10.0 112.327 171.525 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -155.07 170.16 22.44 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 126.68 1.992 . . . . 10.0 110.668 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.95 -34.5 65.72 Favored 'General case' 0 CA--C 1.546 0.805 0 O-C-N 120.568 -1.333 . . . . 10.0 112.828 169.12 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 66.8 mt -86.08 -13.25 47.87 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.755 1.222 . . . . 10.0 114.289 176.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -138.56 91.84 2.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.509 1.524 . . . . 10.0 111.122 -173.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.4 mttt -95.66 145.06 25.56 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.466 1.106 . . . . 10.0 111.494 -174.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -139.74 104.01 4.8 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 127.031 2.133 . . . . 10.0 109.621 -178.037 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.58 162.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.119 1.368 . . . . 10.0 111.728 177.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.13 133.68 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 126.147 1.779 . . . . 10.0 109.664 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 60.3 p -66.22 170.59 5.64 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.265 1.026 . . . . 10.0 113.561 176.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -68.99 -4.44 16.81 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.455 1.102 . . . . 10.0 113.886 166.65 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -109.07 -3.64 17.23 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 126.488 1.915 . . . . 10.0 114.134 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 87.55 40.75 6.7 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 124.509 1.052 . . . . 10.0 114.048 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 41.7 tp -124.52 106.81 10.45 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.313 1.445 . . . . 10.0 110.395 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 13.7 t60 -72.75 142.81 48.14 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.633 0.773 . . . . 10.0 111.19 173.122 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 55.1 m -123.55 97.06 5.22 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 126.865 2.066 . . . . 10.0 110.552 175.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -83.03 123.06 29.11 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 125.112 1.365 . . . . 10.0 108.662 169.161 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 37.1 mt -124.94 149.26 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 125.129 1.371 . . . . 10.0 111.705 -169.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -127.1 113.85 16.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 128.362 2.665 . . . . 10.0 109.481 171.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -69.21 -41.52 76.97 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.033 -1.042 . . . . 10.0 112.913 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.57 88.91 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.72 1.608 . . . . 10.0 110.345 -176.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.7 p -70.59 141.49 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.219 -0.925 . . . . 10.0 112.252 -176.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -123.18 162.54 22.34 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.556 1.942 . . . . 10.0 112.045 176.282 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.69 -34.41 65.04 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.463 0.912 . . . . 10.0 113.463 -178.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 24.9 m -64.59 -17.71 64.22 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.386 1.474 . . . . 10.0 114.508 175.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -83.46 -6.16 59.37 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.637 1.175 . . . . 10.0 113.383 178.398 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.84 151.21 46.06 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 121.057 -1.027 . . . . 10.0 112.986 178.357 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.51 -171.55 22.87 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.746 1.165 . . . . 10.0 114.881 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.78 101.33 11.52 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.858 1.663 . . . . 10.0 111.314 176.334 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -75.96 148.65 37.99 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.807 0.843 . . . . 10.0 111.661 169.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.83 156.84 46.05 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.852 0.861 . . . . 10.0 112.074 170.282 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.2 t -132.18 140.56 48.78 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 126.865 2.066 . . . . 10.0 109.411 -179.056 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 61.2 t -130.6 125.41 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 125.147 1.379 . . . . 10.0 109.311 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -118.55 125.02 48.92 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.149 1.78 . . . . 10.0 110.542 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -133.03 133.27 42.84 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 125.568 1.547 . . . . 10.0 112.215 -170.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -131.06 -177.74 4.52 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.693 1.197 . . . . 10.0 111.737 168.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.9 ptm180 -59.52 -14.82 14.41 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 115.702 1.742 . . . . 10.0 115.702 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.96 -17.88 13.19 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.524 1.53 . . . . 10.0 114.331 -176.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.75 -169.22 42.32 Favored Glycine 0 CA--C 1.534 1.243 0 N-CA-C 116.175 1.23 . . . . 10.0 116.175 178.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -133.65 144.42 49.19 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 127.331 2.252 . . . . 10.0 111.498 -173.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.94 157.71 46.19 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.009 1.724 . . . . 10.0 111.278 170.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 62.1 m -137.88 145.06 41.7 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.996 1.318 . . . . 10.0 111.408 -173.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -136.63 152.89 50.93 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.191 1.796 . . . . 10.0 110.478 -179.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 22.6 m -145.36 147.35 32.19 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.042 0.937 . . . . 10.0 112.252 -170.649 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.5 p -151.98 160.87 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 126.308 1.843 . . . . 10.0 111.039 169.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.2 tt0 -116.96 134.96 54.09 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 124.972 1.309 . . . . 10.0 110.912 173.103 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.8 tp -121.02 111.21 17.2 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.022 1.729 . . . . 10.0 110.875 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -97.32 85.88 3.77 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 125.777 1.631 . . . . 10.0 110.968 175.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.1 t -67.04 112.97 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.764 0.826 . . . . 10.0 110.736 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.0 mt -76.03 99.53 4.63 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.214 1.806 . . . . 10.0 110.101 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.836 0 C-N-CA 124.109 0.964 . . . . 10.0 112.976 -179.307 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo . . . . . 0 CA--C 1.544 1.017 0 N-CA-C 113.366 0.487 . . . . 10.0 113.366 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.45 164.82 32.77 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.32 2.68 . . . . 10.0 111.787 169.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.6 ttt180 -143.4 158.02 43.98 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.4 1.08 . . . . 10.0 112.366 -173.233 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -82.77 69.7 9.61 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.681 1.992 . . . . 10.0 112.516 -171.258 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . 0.566 HG22 ' H ' ' A' ' 254' ' ' GLN . 2.7 mm -77.88 175.34 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.231 0 C-N-CA 124.338 1.055 . . . . 10.0 110.865 175.624 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.566 ' H ' HG22 ' A' ' 253' ' ' ILE . 47.4 tt0 -48.72 115.42 1.25 Allowed 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 128.302 2.641 . . . . 10.0 115.259 -173.651 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.7 m -78.4 153.7 79.1 Favored Pre-proline 0 N--CA 1.479 0.999 0 C-N-CA 124.927 1.291 . . . . 10.0 111.552 162.439 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -76.31 166.85 26.87 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 123.267 2.645 . . . . 10.0 111.714 169.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.42 164.91 26.03 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.311 -0.868 . . . . 10.0 111.887 169.097 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -63.46 162.22 12.98 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.601 0.76 . . . . 10.0 112.634 172.625 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.6 mtm -134.11 161.43 34.9 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.373 1.069 . . . . 10.0 113.228 -178.234 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -140.15 90.14 2.35 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.887 2.075 . . . . 10.0 110.477 177.411 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 41.7 mm -103.87 138.23 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 124.697 1.199 . . . . 10.0 111.184 -166.797 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -68.83 130.06 41.71 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.108 0.963 . . . . 10.0 112.355 174.613 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -53.23 125.79 18.78 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.448 1.499 . . . . 10.0 112.824 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.95 -8.74 61.38 Favored Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.185 1.85 . . . . 10.0 115.115 -179.234 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.7 mtp85 -74.35 159.79 31.91 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 119.489 1.644 . . . . 10.0 113.102 175.103 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -76.75 141.01 40.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.453 1.101 . . . . 10.0 110.207 156.368 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 31.1 p -150.22 173.61 13.74 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.733 0.813 . . . . 10.0 112.353 162.436 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -145.95 167.89 22.21 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 125.682 1.593 . . . . 10.0 112.356 175.342 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -126.48 159.78 32.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.531 1.933 . . . . 10.0 110.772 172.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -137.43 96.87 3.34 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.448 1.499 . . . . 10.0 111.504 -167.862 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.13 111.39 22.71 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.678 1.591 . . . . 10.0 111.126 -177.037 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 90.7 mttt -66.38 147.35 53.43 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 121.111 -0.993 . . . . 10.0 110.272 169.438 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -150.78 159.95 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.232 1.413 . . . . 10.0 111.458 -175.669 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -143.53 -176.88 5.13 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.648 1.579 . . . . 10.0 111.854 178.102 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.22 161.43 23.53 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.251 2.358 . . . . 10.0 113.481 -178.161 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.9 tp -149.7 130.87 7.25 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 125.124 1.37 . . . . 10.0 110.282 179.823 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -66.0 168.97 45.62 Favored 'Cis proline' 0 CA--C 1.539 0.742 0 CA-C-N 121.194 1.462 . . . . 10.0 112.56 -2.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 121.54 41.15 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 124.783 1.233 . . . . 10.0 111.403 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 151.49 66.55 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.517 2.144 . . . . 10.0 113.102 -173.152 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -71.68 143.57 49.66 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.157 0.983 . . . . 10.0 109.783 160.357 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.64 87.53 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.081 1.353 . . . . 10.0 111.83 -166.073 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 62.5 m -77.08 113.72 15.12 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.549 1.14 . . . . 10.0 111.177 176.318 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -91.17 153.12 20.26 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.19 0.996 . . . . 10.0 113.186 176.481 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -144.11 159.92 41.79 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.658 1.983 . . . . 10.0 111.995 -176.512 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.2 tp -146.02 119.25 8.9 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 127.511 2.325 . . . . 10.0 110.022 176.236 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 54.9 14.14 0.86 Allowed 'General case' 0 CA--C 1.555 1.148 0 C-N-CA 126.419 1.887 . . . . 10.0 115.309 179.221 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.44 -12.19 36.27 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.602 2.049 . . . . 10.0 115.165 -177.345 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -87.95 158.07 18.77 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.974 1.387 . . . . 10.0 110.976 170.097 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.6 p -71.6 156.78 39.01 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.357 1.063 . . . . 10.0 112.656 173.627 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.85 105.94 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 126.373 1.869 . . . . 10.0 108.866 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 63.0 mt-30 -74.31 159.36 32.52 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.458 0.703 . . . . 10.0 111.394 171.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.0 p -69.07 155.92 39.54 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.514 0.726 . . . . 10.0 112.036 169.647 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -153.13 168.55 25.56 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.26 1.424 . . . . 10.0 110.891 175.634 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -57.23 -35.98 70.36 Favored 'General case' 0 CA--C 1.546 0.797 0 O-C-N 120.857 -1.152 . . . . 10.0 112.548 168.692 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.9 mt -80.19 -17.79 51.4 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 124.537 1.135 . . . . 10.0 113.804 173.886 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -134.46 70.51 1.45 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.18 1.792 . . . . 10.0 111.205 -172.186 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -73.16 142.43 47.43 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.4 1.48 . . . . 10.0 111.046 -173.199 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.8 mtt -136.48 98.7 3.89 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.249 1.82 . . . . 10.0 110.074 -174.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.09 159.86 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.363 1.465 . . . . 10.0 111.636 -177.034 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.38 122.57 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.753 1.221 . . . . 10.0 111.504 -177.85 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 67.6 m -69.63 148.6 49.12 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.508 1.123 . . . . 10.0 112.016 177.293 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 19.4 tp10 -55.8 -34.78 65.62 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.656 1.583 . . . . 10.0 113.396 -177.663 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -78.41 0.38 25.95 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 126.082 1.753 . . . . 10.0 114.574 179.369 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.49 50.23 1.88 Allowed Glycine 0 CA--C 1.532 1.133 0 C-N-CA 124.833 1.206 . . . . 10.0 114.841 170.19 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 54.4 tp -133.51 106.5 7.48 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.155 1.382 . . . . 10.0 111.056 176.696 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -86.45 118.37 25.84 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.954 1.701 . . . . 10.0 111.365 177.484 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -91.71 144.93 25.01 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.903 1.681 . . . . 10.0 112.224 173.658 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -138.21 115.73 11.26 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 126.439 1.896 . . . . 10.0 108.669 173.569 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 154.19 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 C-N-CA 125.36 1.464 . . . . 10.0 111.42 -170.832 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -131.74 108.36 9.41 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 127.007 2.123 . . . . 10.0 109.599 163.565 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 36.5 mm-40 -65.06 -45.32 85.82 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 113.898 1.073 . . . . 10.0 113.898 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.61 70.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 CA-C-O 122.614 1.197 . . . . 10.0 111.344 -172.506 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.96 142.23 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.025 1.33 . . . . 10.0 113.502 -170.0 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.2 mmt-85 -120.64 162.07 20.29 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 126.5 1.92 . . . . 10.0 112.323 177.04 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.11 -31.32 61.15 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.265 1.026 . . . . 10.0 113.613 177.239 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 43.2 p -67.8 -17.12 64.42 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.539 1.536 . . . . 10.0 114.806 174.287 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -83.31 -7.39 59.59 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.54 1.136 . . . . 10.0 113.409 175.823 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 149.68 49.71 Favored 'General case' 0 CA--C 1.547 0.85 0 O-C-N 120.958 -1.089 . . . . 10.0 112.988 179.38 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.1 -173.44 23.27 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.806 1.193 . . . . 10.0 115.076 176.077 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 106.53 14.8 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.855 1.662 . . . . 10.0 111.094 175.063 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -84.01 150.43 25.62 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 124.347 1.059 . . . . 10.0 111.921 172.902 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.56 162.18 37.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.946 0.898 . . . . 10.0 112.268 170.516 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.3 t -139.01 140.42 38.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.581 1.552 . . . . 10.0 110.487 175.065 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 43.6 t -121.38 104.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.837 1.655 . . . . 10.0 109.07 179.395 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -86.3 122.0 29.67 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.278 1.831 . . . . 10.0 111.078 178.396 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -132.35 132.58 43.04 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.421 1.488 . . . . 10.0 112.224 -177.184 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.2 p30 -130.97 -177.95 4.6 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.488 1.115 . . . . 10.0 111.646 167.085 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.8 ptp180 -59.47 -12.71 6.71 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 115.922 1.823 . . . . 10.0 115.922 -179.37 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -113.52 -16.82 12.34 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 125.382 1.473 . . . . 10.0 114.557 -177.048 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.17 -169.27 42.34 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 120.022 1.283 . . . . 10.0 116.224 178.876 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -135.96 144.06 45.2 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.093 2.157 . . . . 10.0 111.997 -172.311 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.78 161.96 36.3 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.111 1.764 . . . . 10.0 111.151 168.587 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -137.65 144.17 41.74 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.319 1.048 . . . . 10.0 111.599 -172.31 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -134.52 152.38 51.75 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.189 1.796 . . . . 10.0 110.86 -178.214 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 15.4 m -147.85 146.18 29.0 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.525 1.13 . . . . 10.0 111.942 -173.027 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.9 p -153.45 174.21 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 126.49 1.916 . . . . 10.0 110.781 171.838 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -129.63 144.31 51.22 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.689 1.196 . . . . 10.0 111.51 172.773 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.0 tp -128.77 109.12 11.02 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.304 1.842 . . . . 10.0 109.997 179.386 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -79.4 147.0 32.51 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 121.938 -0.477 . . . . 10.0 110.029 158.406 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 30.1 t -128.43 106.83 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.124 0.97 . . . . 10.0 109.344 175.352 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.8 101.99 2.24 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.282 1.833 . . . . 10.0 109.659 -178.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.828 0 C-N-CA 124.191 0.996 . . . . 10.0 113.22 -175.75 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 CA--C 1.542 0.88 0 N-CA-C 113.483 0.532 . . . . 10.0 113.483 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -66.88 156.23 67.11 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 C-N-CA 122.933 2.422 . . . . 10.0 112.021 170.888 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.2 ttt85 -146.43 150.48 35.71 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.554 1.142 . . . . 10.0 112.568 -173.374 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -77.59 82.49 4.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.058 2.143 . . . . 10.0 111.65 178.098 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.0 mm -74.89 -56.94 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.613 -0.679 . . . . 10.0 110.502 173.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -154.9 143.49 20.61 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.819 1.248 . . . . 10.0 111.44 176.711 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.39 151.84 79.48 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 126.053 1.741 . . . . 10.0 110.112 171.068 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.01 154.9 47.9 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.929 2.419 . . . . 10.0 112.132 175.736 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -75.63 171.15 14.81 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.353 1.061 . . . . 10.0 112.318 167.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -62.5 153.3 32.08 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 121.269 -0.894 . . . . 10.0 112.607 176.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 73.8 mtp -133.16 157.45 45.31 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.042 1.337 . . . . 10.0 112.408 -169.701 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -141.27 112.79 7.56 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.524 1.53 . . . . 10.0 111.036 178.755 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 33.2 mm -129.94 128.3 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 125.049 1.339 . . . . 10.0 110.949 -164.68 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -60.37 131.5 50.98 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.083 1.353 . . . . 10.0 112.661 173.864 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -54.44 136.2 44.52 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.886 1.275 . . . . 10.0 113.001 -177.768 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.76 -6.7 81.95 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.649 1.595 . . . . 10.0 115.312 177.683 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -71.87 158.31 36.28 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 118.944 1.372 . . . . 10.0 112.892 175.783 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -70.65 143.37 51.43 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.316 1.046 . . . . 10.0 109.968 155.1 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.6 t -147.62 165.58 29.96 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.245 1.018 . . . . 10.0 111.634 172.7 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -148.04 159.06 44.3 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.721 1.208 . . . . 10.0 112.868 168.544 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -130.1 151.12 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 126.678 1.991 . . . . 10.0 109.431 170.405 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -143.41 125.6 15.49 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.254 1.021 . . . . 10.0 111.442 -173.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -121.72 156.72 32.5 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.55 2.34 . . . . 10.0 110.196 -175.634 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -114.11 104.06 11.75 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.773 1.229 . . . . 10.0 110.198 175.836 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 43.8 t -109.38 99.15 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.462 1.905 . . . . 10.0 110.021 -170.316 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.5 t -73.44 -175.24 1.89 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.093 0.957 . . . . 10.0 112.527 174.106 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 109.79 155.88 15.91 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 127.312 2.386 . . . . 10.0 113.592 176.379 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 19.2 tp -147.48 125.31 5.92 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.531 . . . . 10.0 109.664 178.513 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.47 169.05 47.71 Favored 'Cis proline' 0 CA--C 1.541 0.834 0 CA-C-N 120.8 1.322 . . . . 10.0 112.567 -2.602 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.36 68.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 C-N-CA 124.205 1.002 . . . . 10.0 111.387 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.81 150.68 68.24 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.476 2.117 . . . . 10.0 113.14 -173.57 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -69.65 142.03 53.51 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.032 1.333 . . . . 10.0 110.431 165.113 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 55.9 t -117.16 126.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.723 1.609 . . . . 10.0 111.269 -167.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.3 m -134.31 106.47 7.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.635 1.574 . . . . 10.0 111.004 175.337 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -82.25 153.59 25.82 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.913 0.885 . . . . 10.0 113.044 176.064 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -142.86 160.44 40.33 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 127.286 2.235 . . . . 10.0 111.378 179.718 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.1 tp -146.4 119.08 8.57 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 127.223 2.209 . . . . 10.0 109.974 175.196 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 54.76 17.15 1.64 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 126.442 1.897 . . . . 10.0 115.014 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.94 -12.87 49.63 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.518 2.009 . . . . 10.0 115.117 -178.236 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.7 mtt85 -84.94 155.72 21.52 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.923 1.362 . . . . 10.0 110.78 169.077 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.5 p -69.84 157.67 36.96 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.02 0.928 . . . . 10.0 112.52 173.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 81.9 t -132.34 143.39 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.667 1.987 . . . . 10.0 108.875 172.442 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -132.85 155.3 49.24 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.629 1.572 . . . . 10.0 110.541 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.0 p -72.43 149.09 44.55 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 123.67 0.788 . . . . 10.0 112.851 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -154.62 -173.11 4.44 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.529 1.932 . . . . 10.0 111.322 175.312 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -60.53 -18.72 53.97 Favored 'General case' 0 CA--C 1.549 0.932 0 N-CA-C 114.84 1.422 . . . . 10.0 114.84 -178.693 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 59.9 mt -113.64 -16.82 12.27 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.556 1.943 . . . . 10.0 113.541 -179.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -122.25 98.34 5.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 126.798 2.039 . . . . 10.0 110.339 -178.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.96 109.77 19.41 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 124.536 1.134 . . . . 10.0 110.857 -168.384 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 5.1 mpp? -116.31 110.22 18.44 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.992 1.717 . . . . 10.0 110.718 -175.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.09 161.46 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.975 1.71 . . . . 10.0 112.096 -172.642 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.1 t -131.22 118.57 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 125.568 1.547 . . . . 10.0 110.238 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 14.5 t -67.55 163.18 21.74 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 124.793 1.237 . . . . 10.0 112.551 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -57.53 -30.52 65.24 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.635 1.574 . . . . 10.0 113.139 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 11.3 mmpt? -86.02 0.11 54.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.922 1.689 . . . . 10.0 114.604 178.356 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.01 6.36 71.98 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 124.896 1.236 . . . . 10.0 114.894 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.54 105.67 1.92 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.579 1.152 . . . . 10.0 109.453 170.329 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.0 t60 -95.8 114.44 26.17 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.612 1.565 . . . . 10.0 111.061 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 41.2 m -101.57 151.02 22.48 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.847 1.259 . . . . 10.0 112.477 -179.782 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -135.81 103.24 5.33 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.439 2.296 . . . . 10.0 108.368 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.32 139.65 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.57 1.148 . . . . 10.0 110.263 -179.524 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -115.14 105.61 13.12 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 127.922 2.489 . . . . 10.0 109.152 171.444 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -64.61 -40.4 95.43 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 120.995 -1.066 . . . . 10.0 113.339 -179.789 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.04 93.22 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.635 1.574 . . . . 10.0 110.402 179.951 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.88 142.47 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.354 -0.842 . . . . 10.0 112.118 -177.548 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -123.08 160.21 26.88 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.145 1.778 . . . . 10.0 112.038 175.393 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.74 -31.87 64.98 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.989 1.107 . . . . 10.0 113.989 -175.2 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.2 t -65.9 -20.85 66.36 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.005 1.322 . . . . 10.0 113.958 175.582 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -78.41 -4.22 47.16 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.908 1.283 . . . . 10.0 113.685 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 155.3 36.61 Favored 'General case' 0 CA--C 1.547 0.84 0 N-CA-C 113.669 0.988 . . . . 10.0 113.669 178.362 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.6 -167.52 17.96 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.933 1.254 . . . . 10.0 114.909 174.312 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.05 105.3 14.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.91 1.684 . . . . 10.0 111.686 179.463 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.6 m-85 -79.58 151.15 30.81 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.311 1.044 . . . . 10.0 111.576 168.633 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.68 159.96 41.54 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.837 0.855 . . . . 10.0 112.226 169.084 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.6 t -137.49 103.95 5.21 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.806 1.642 . . . . 10.0 110.596 -179.501 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 90.0 t -74.95 130.03 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.432 1.093 . . . . 10.0 109.402 170.093 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.93 118.76 24.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.7 2.0 . . . . 10.0 110.259 178.825 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.9 mtpp -131.76 133.48 44.81 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.969 1.307 . . . . 10.0 112.553 -173.112 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.5 p30 -131.55 -178.91 5.07 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.497 1.119 . . . . 10.0 111.73 167.182 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -60.63 -11.84 8.45 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 115.798 1.777 . . . . 10.0 115.798 -179.101 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.1 -15.11 13.32 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.296 1.438 . . . . 10.0 114.547 -178.378 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.21 -169.57 41.06 Favored Glycine 0 CA--C 1.534 1.256 0 N-CA-C 116.025 1.17 . . . . 10.0 116.025 177.479 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -135.83 145.79 46.83 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.917 2.087 . . . . 10.0 112.002 -169.383 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.91 158.98 43.21 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.393 1.877 . . . . 10.0 110.632 166.017 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.9 m -140.03 100.23 3.87 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.781 1.232 . . . . 10.0 110.414 176.697 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -79.78 154.67 28.32 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.604 1.162 . . . . 10.0 111.187 177.289 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 32.0 m -144.64 145.41 31.74 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 124.456 1.102 . . . . 10.0 111.748 -172.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.92 165.77 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 126.324 1.85 . . . . 10.0 110.559 171.86 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -128.84 140.44 51.7 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.729 1.211 . . . . 10.0 111.549 177.255 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 53.1 tp -128.63 110.45 12.24 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.02 1.728 . . . . 10.0 111.951 -176.905 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -87.78 89.88 8.16 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.155 1.382 . . . . 10.0 110.843 169.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.58 106.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.031 -1.043 . . . . 10.0 109.614 174.131 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.3 mt -72.56 97.91 2.21 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.116 1.766 . . . . 10.0 109.873 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.828 0 C-N-CA 124.522 1.129 . . . . 10.0 113.399 -175.918 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo . . . . . 0 CA--C 1.543 0.941 0 N-CA-C 113.258 0.446 . . . . 10.0 113.258 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.55 158.2 58.66 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.961 2.441 . . . . 10.0 112.337 173.667 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -145.18 161.44 39.51 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 125.018 1.327 . . . . 10.0 113.556 -171.533 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -83.45 98.84 9.73 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.022 1.729 . . . . 10.0 111.869 -178.602 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 36.5 mm -90.64 -68.27 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.445 0.698 . . . . 10.0 110.723 177.01 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 37.2 tt0 -155.49 143.78 20.16 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.306 1.042 . . . . 10.0 111.679 177.104 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.1 m -126.07 153.77 74.05 Favored Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 125.85 1.66 . . . . 10.0 110.659 171.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -70.65 155.03 63.83 Favored 'Trans proline' 0 CA--C 1.542 0.876 0 C-N-CA 122.61 2.207 . . . . 10.0 111.834 171.594 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -72.95 174.3 8.02 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.006 0.922 . . . . 10.0 111.311 166.405 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -59.03 152.24 20.39 Favored 'General case' 0 CA--C 1.548 0.886 0 O-C-N 121.051 -1.031 . . . . 10.0 112.371 174.671 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.0 mtp -134.87 159.3 41.85 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 125.59 1.556 . . . . 10.0 111.887 -171.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 67.2 p -142.12 134.25 27.55 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 125.11 1.364 . . . . 10.0 111.242 172.258 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 27.8 mm -139.41 132.83 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 125.62 1.568 . . . . 10.0 109.629 -170.197 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -63.44 132.63 52.02 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.624 1.169 . . . . 10.0 112.4 173.741 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -52.58 128.12 25.07 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.697 1.199 . . . . 10.0 112.786 -179.311 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.21 -9.29 63.13 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 126.017 1.77 . . . . 10.0 115.298 178.412 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -74.47 162.14 29.11 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 119.227 1.514 . . . . 10.0 113.342 176.668 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -72.75 150.97 42.38 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.199 1.4 . . . . 10.0 110.725 159.159 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.9 t -149.97 156.4 41.65 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.663 1.185 . . . . 10.0 111.437 170.425 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm85 -140.87 164.62 29.75 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.558 1.143 . . . . 10.0 112.99 163.372 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.4 mtt -131.73 161.03 33.79 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.801 2.04 . . . . 10.0 111.142 176.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -137.12 94.25 2.93 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.131 1.372 . . . . 10.0 111.612 -167.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 41.7 m-85 -104.04 116.27 31.94 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.313 1.445 . . . . 10.0 110.831 -178.881 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -78.68 131.14 36.52 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.406 -0.809 . . . . 10.0 110.141 172.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 56.9 t -133.25 148.82 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.135 1.774 . . . . 10.0 110.192 -174.107 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.0 t -136.82 -174.32 3.69 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.542 1.537 . . . . 10.0 111.474 173.77 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 110.06 162.0 18.78 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 127.401 2.429 . . . . 10.0 112.549 -173.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -148.04 128.78 6.94 Favored Pre-proline 0 CA--C 1.546 0.826 0 C-N-CA 124.661 1.184 . . . . 10.0 110.591 -179.587 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -66.56 170.01 44.55 Favored 'Cis proline' 0 CA--C 1.54 0.783 0 CA-C-N 120.786 1.316 . . . . 10.0 112.453 -4.225 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.55 123.42 56.8 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.512 1.125 . . . . 10.0 111.375 179.572 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.55 151.09 64.35 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.543 2.162 . . . . 10.0 113.168 -173.371 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -72.96 146.55 45.97 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.248 1.019 . . . . 10.0 109.831 160.158 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.8 m -130.97 135.98 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.662 1.185 . . . . 10.0 112.541 -170.23 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 64.1 m -135.51 119.3 17.25 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.234 1.814 . . . . 10.0 111.037 -178.834 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . 0.402 ' CD1' ' HG2' ' A' ' 298' ' ' MET . 62.2 m95 -91.02 156.22 18.11 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.598 0.962 . . . . 10.0 113.598 -179.43 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -143.45 160.25 40.93 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.796 2.438 . . . . 10.0 111.1 -176.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.6 tp -146.18 117.72 8.03 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 127.189 2.196 . . . . 10.0 109.997 176.237 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 55.54 13.33 0.94 Allowed 'General case' 0 CA--C 1.555 1.145 0 C-N-CA 126.467 1.907 . . . . 10.0 115.208 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 109.83 -14.62 31.82 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 126.731 2.11 . . . . 10.0 115.02 -177.313 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -82.09 157.42 24.1 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 118.9 1.35 . . . . 10.0 110.687 168.896 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.8 p -72.91 158.25 35.85 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.936 0.894 . . . . 10.0 112.339 172.358 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.6 t -133.98 90.83 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 126.278 1.831 . . . . 10.0 108.898 172.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -68.77 143.48 54.63 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.254 0.622 . . . . 10.0 110.412 169.815 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.3 p -69.39 149.53 48.28 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.374 0.67 . . . . 10.0 112.163 173.098 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.18 -172.68 4.3 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.186 1.794 . . . . 10.0 111.983 178.103 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.09 -18.34 46.26 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 114.774 1.398 . . . . 10.0 114.774 -178.472 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.8 mt -113.12 -15.07 12.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.915 1.686 . . . . 10.0 113.531 179.479 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -126.43 96.81 4.81 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.82 2.048 . . . . 10.0 109.755 -177.206 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -110.61 126.17 54.19 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.25 1.02 . . . . 10.0 111.207 -168.323 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . 0.402 ' HG2' ' CD1' ' A' ' 283' ' ' TRP . 1.8 mpt? -128.89 109.06 10.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.427 1.891 . . . . 10.0 110.033 -173.044 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.22 164.83 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 125.615 1.566 . . . . 10.0 111.858 -178.172 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.5 t -125.6 106.82 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 125.513 1.525 . . . . 10.0 109.688 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -74.31 164.93 26.01 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.525 1.13 . . . . 10.0 112.536 176.515 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -57.12 156.61 6.93 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.945 1.298 . . . . 10.0 112.018 173.199 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt 64.68 6.47 3.26 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 127.392 2.277 . . . . 10.0 114.642 -170.431 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 83.77 55.68 2.78 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.307 1.432 . . . . 10.0 114.041 171.854 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.31 101.36 7.92 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.892 1.277 . . . . 10.0 110.11 177.16 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -79.64 112.55 17.01 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.91 1.284 . . . . 10.0 111.197 174.733 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.8 m -83.34 146.78 28.31 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 124.753 1.221 . . . . 10.0 112.197 172.146 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.82 120.1 24.44 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.401 1.88 . . . . 10.0 107.088 161.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.7 mt -121.31 139.06 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.494 1.518 . . . . 10.0 110.453 -174.166 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -120.42 110.74 16.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 127.584 2.354 . . . . 10.0 109.522 176.746 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.83 -42.89 85.07 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 121.343 -0.848 . . . . 10.0 113.202 179.465 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.0 89.42 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.806 1.642 . . . . 10.0 110.161 -177.361 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.6 p -70.37 140.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.284 -0.885 . . . . 10.0 112.203 -176.239 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -119.93 160.79 22.03 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.358 1.863 . . . . 10.0 112.157 176.717 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.11 -32.56 66.46 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 113.726 1.01 . . . . 10.0 113.726 -177.45 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.4 t -65.13 -21.75 66.84 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.106 1.362 . . . . 10.0 113.776 175.209 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -79.48 -5.32 54.55 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.779 1.231 . . . . 10.0 113.611 -179.832 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.65 152.17 44.81 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.168 -0.957 . . . . 10.0 113.236 178.624 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.59 -168.98 22.53 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.633 1.111 . . . . 10.0 115.043 174.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.67 103.03 11.88 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.909 1.684 . . . . 10.0 111.551 177.856 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 -78.82 149.7 32.48 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.037 0.935 . . . . 10.0 111.678 169.714 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.94 160.93 40.55 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.901 0.881 . . . . 10.0 112.265 170.413 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.45 120.53 17.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.543 1.537 . . . . 10.0 110.858 177.12 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 59.1 t -92.36 126.39 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.757 1.223 . . . . 10.0 108.996 171.204 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -119.27 126.11 50.7 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 126.428 1.891 . . . . 10.0 110.747 -178.957 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -134.47 133.33 40.31 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 125.259 1.423 . . . . 10.0 112.516 -170.698 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.7 p30 -130.55 -179.1 5.08 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.741 1.216 . . . . 10.0 111.533 166.535 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -60.89 -12.77 12.14 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 115.618 1.71 . . . . 10.0 115.618 -179.465 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -109.44 -17.63 13.73 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.521 1.528 . . . . 10.0 114.392 -178.282 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 168.64 -169.2 41.55 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 115.972 1.149 . . . . 10.0 115.972 177.931 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -133.77 146.56 50.84 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.986 2.114 . . . . 10.0 111.745 -172.088 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.2 160.1 40.31 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.317 1.847 . . . . 10.0 110.974 169.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.3 m -136.33 130.56 33.06 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.722 1.209 . . . . 10.0 111.379 177.759 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -113.65 153.65 28.56 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.204 1.801 . . . . 10.0 110.659 177.81 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.7 m -143.09 148.19 36.25 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.598 1.159 . . . . 10.0 112.37 -173.13 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.41 169.15 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 C-N-CA 126.994 2.117 . . . . 10.0 110.763 169.468 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 52.4 tt0 -128.04 137.04 52.03 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.196 1.399 . . . . 10.0 111.088 174.271 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.5 tp -125.65 107.14 10.28 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.958 1.703 . . . . 10.0 111.077 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -88.96 87.47 7.23 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.259 1.424 . . . . 10.0 110.869 172.773 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -67.36 112.35 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.242 -0.911 . . . . 10.0 110.061 175.45 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.6 mt -75.3 94.65 3.05 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 126.104 1.762 . . . . 10.0 109.875 -179.747 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 124.765 1.226 . . . . 10.0 113.53 -175.769 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo . . . . . 0 CA--C 1.544 0.991 0 N-CA-C 113.134 0.398 . . . . 10.0 113.134 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -68.07 167.67 21.14 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 123.303 2.668 . . . . 10.0 111.634 169.191 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 2.1 tpt180 -139.42 175.22 9.75 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.664 1.186 . . . . 10.0 112.803 -172.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -103.92 95.48 6.04 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 126.394 1.878 . . . . 10.0 110.326 -175.643 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . 0.549 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.4 OUTLIER -115.61 -179.28 1.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.99 0 C-N-CA 126.298 1.839 . . . . 10.0 109.779 -179.655 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.549 ' H ' HG22 ' A' ' 253' ' ' ILE . 41.8 tt0 -46.15 123.37 4.61 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.507 2.323 . . . . 10.0 115.026 -166.535 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 19.1 m -106.84 153.83 40.56 Favored Pre-proline 0 N--CA 1.474 0.769 0 C-N-CA 126.425 1.89 . . . . 10.0 110.365 167.944 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.25 158.49 44.94 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.759 2.306 . . . . 10.0 111.705 169.902 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -66.29 172.4 3.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 124.606 1.162 . . . . 10.0 111.841 167.342 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -60.32 153.72 21.93 Favored 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.99 -1.068 . . . . 10.0 111.857 170.311 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 84.8 mtp -133.01 155.9 48.33 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.994 1.318 . . . . 10.0 112.179 -169.647 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 47.6 p -141.81 122.86 14.6 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 125.505 1.522 . . . . 10.0 110.903 175.091 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.5 mm -134.18 132.38 55.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.546 1.538 . . . . 10.0 109.901 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -63.99 129.12 38.78 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.235 1.014 . . . . 10.0 112.101 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -54.31 131.82 42.6 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.201 1.4 . . . . 10.0 112.683 -177.736 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.76 -10.11 66.34 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 126.042 1.782 . . . . 10.0 115.07 179.11 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 78.3 mtp85 -71.47 160.98 31.76 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 119.005 1.402 . . . . 10.0 113.061 175.91 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -71.18 145.8 49.49 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 124.014 0.926 . . . . 10.0 110.368 155.684 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 16.6 t -147.45 163.79 35.4 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.7 1.2 . . . . 10.0 111.405 168.612 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -143.85 157.52 44.31 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.589 1.556 . . . . 10.0 111.806 167.706 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 53.2 mtt -129.22 150.42 50.61 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 127.117 2.167 . . . . 10.0 109.187 171.454 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -142.12 126.08 17.23 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.317 1.047 . . . . 10.0 111.479 -169.85 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -130.86 123.69 29.59 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 126.745 2.018 . . . . 10.0 111.151 -168.718 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -70.27 130.81 43.02 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.493 -0.754 . . . . 10.0 110.301 171.472 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.77 149.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 126.109 1.763 . . . . 10.0 111.138 -175.592 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 6.1 t -147.24 -174.08 4.42 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 125.144 1.377 . . . . 10.0 112.113 -176.572 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.18 162.47 23.7 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 127.319 2.39 . . . . 10.0 112.864 -174.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -146.48 128.07 7.48 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.874 1.27 . . . . 10.0 110.567 -179.698 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -66.7 169.4 47.55 Favored 'Cis proline' 0 CA--C 1.539 0.743 0 CA-C-N 120.88 1.35 . . . . 10.0 112.658 -2.149 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.72 122.77 48.04 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.752 1.221 . . . . 10.0 111.575 -178.463 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -71.11 159.95 50.66 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 122.597 2.198 . . . . 10.0 113.359 -174.292 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.7 168.94 10.36 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.799 1.24 . . . . 10.0 111.851 166.426 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 71.5 t -130.24 123.76 56.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.691 1.597 . . . . 10.0 110.397 -178.366 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.2 m -134.82 150.35 50.49 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.68 1.592 . . . . 10.0 110.661 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 47.6 m95 -130.06 157.82 41.34 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 124.884 1.274 . . . . 10.0 112.593 179.151 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -143.91 159.19 43.0 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.674 1.99 . . . . 10.0 111.413 -177.292 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.1 tp -144.99 118.24 8.95 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 127.128 2.171 . . . . 10.0 109.943 175.844 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 54.91 14.79 0.97 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.508 1.923 . . . . 10.0 115.177 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.8 -13.23 35.06 Favored Glycine 0 CA--C 1.539 1.556 0 C-N-CA 126.709 2.1 . . . . 10.0 115.182 -178.061 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.9 mtp180 -85.89 157.11 20.26 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.971 1.385 . . . . 10.0 110.961 170.134 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.6 p -71.41 155.25 40.84 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.358 1.063 . . . . 10.0 112.765 174.432 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 61.1 t -134.0 102.65 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.729 2.012 . . . . 10.0 108.597 172.834 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -74.61 161.4 29.75 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.463 0.705 . . . . 10.0 111.4 172.547 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 58.4 p -67.99 154.41 41.68 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.363 0.665 . . . . 10.0 111.785 168.163 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -153.6 168.68 25.4 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.144 1.377 . . . . 10.0 111.03 177.799 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.8 -35.18 68.43 Favored 'General case' 0 CA--C 1.544 0.749 0 O-C-N 120.933 -1.105 . . . . 10.0 112.696 168.84 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 69.8 mt -82.83 -14.25 54.69 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.553 1.141 . . . . 10.0 113.916 173.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.4 m80 -136.16 69.91 1.42 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.954 1.701 . . . . 10.0 111.216 -173.427 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.53 143.02 51.77 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.786 1.235 . . . . 10.0 111.134 -177.671 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -136.85 103.58 5.22 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.649 1.98 . . . . 10.0 109.718 -174.695 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.45 158.99 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.823 1.249 . . . . 10.0 112.18 -175.389 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -134.5 111.42 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 125.31 1.444 . . . . 10.0 110.035 -178.614 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 58.6 m -66.53 145.83 55.19 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.904 0.882 . . . . 10.0 111.401 173.269 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.47 -17.52 59.71 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.526 1.53 . . . . 10.0 114.622 -176.237 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -75.36 -4.82 41.51 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.058 1.743 . . . . 10.0 114.108 173.621 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.82 47.38 3.68 Favored Glycine 0 CA--C 1.532 1.098 0 C-N-CA 125.134 1.35 . . . . 10.0 113.219 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.94 105.71 6.51 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.085 1.354 . . . . 10.0 110.224 -176.129 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -85.45 124.94 32.61 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.073 1.349 . . . . 10.0 111.447 174.751 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 38.0 m -109.0 142.94 38.95 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.398 1.479 . . . . 10.0 111.915 175.695 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -132.79 115.85 15.83 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.538 2.335 . . . . 10.0 108.887 -178.306 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 153.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.785 1.234 . . . . 10.0 111.44 -171.402 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -128.49 103.65 7.25 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.398 2.279 . . . . 10.0 109.05 164.663 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -65.34 -38.96 91.73 Favored 'General case' 0 N--CA 1.475 0.825 0 O-C-N 120.872 -1.143 . . . . 10.0 113.072 178.738 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.56 87.71 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.838 1.655 . . . . 10.0 110.245 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.58 137.39 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 O-C-N 121.241 -0.912 . . . . 10.0 111.928 -177.555 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -117.34 161.15 19.99 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.091 1.757 . . . . 10.0 112.094 176.57 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.91 -34.12 65.29 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -177.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.0 m -65.37 -16.6 63.77 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 125.515 1.526 . . . . 10.0 114.565 175.468 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -81.95 -5.33 58.21 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.695 1.198 . . . . 10.0 113.348 178.33 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.49 151.44 46.37 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.025 -1.047 . . . . 10.0 112.773 175.908 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.96 -171.89 21.59 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 124.97 1.271 . . . . 10.0 114.846 176.892 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.01 105.74 14.25 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.891 1.676 . . . . 10.0 111.252 176.518 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -80.6 152.7 28.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.206 1.002 . . . . 10.0 111.963 169.479 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.92 44.52 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.905 0.882 . . . . 10.0 111.933 166.231 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 51.3 t -130.66 143.61 50.86 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.666 1.987 . . . . 10.0 109.789 177.018 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 99.0 t -126.38 129.66 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 125.57 1.548 . . . . 10.0 109.673 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -123.58 118.81 28.18 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.404 1.881 . . . . 10.0 110.433 -178.529 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -131.95 138.23 48.24 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 125.373 1.469 . . . . 10.0 111.822 -173.467 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -134.14 -177.48 4.6 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.936 1.295 . . . . 10.0 111.358 168.174 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -60.91 -11.63 8.56 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 115.727 1.751 . . . . 10.0 115.727 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.49 -19.82 12.42 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 125.569 1.548 . . . . 10.0 114.503 -178.107 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.4 -168.92 41.99 Favored Glycine 0 CA--C 1.534 1.252 0 N-CA-C 116.371 1.308 . . . . 10.0 116.371 178.984 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -135.71 142.41 45.05 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.29 2.236 . . . . 10.0 111.683 -172.059 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.05 162.53 33.9 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.052 1.741 . . . . 10.0 111.309 169.011 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -141.4 146.09 36.14 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.023 1.329 . . . . 10.0 110.753 -172.511 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -133.45 154.22 50.97 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.349 1.46 . . . . 10.0 110.774 177.263 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.7 m -144.27 144.71 31.62 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.489 1.116 . . . . 10.0 111.615 -171.491 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.8 p -153.23 164.02 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 126.126 1.77 . . . . 10.0 110.698 172.414 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -125.17 138.71 54.14 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 124.79 1.236 . . . . 10.0 111.13 174.888 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -124.61 120.04 30.77 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.997 1.719 . . . . 10.0 111.068 -177.829 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -105.69 86.24 2.36 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.064 1.746 . . . . 10.0 110.723 176.694 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 23.8 t -67.47 109.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 123.992 0.917 . . . . 10.0 110.607 -179.581 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 66.1 mt -72.98 103.11 3.66 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 126.324 1.85 . . . . 10.0 109.853 178.798 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 113.887 1.069 . . . . 10.0 113.887 -172.069 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 CA--C 1.544 1.007 0 N-CA-C 113.077 0.376 . . . . 10.0 113.077 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.54 160.49 49.1 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 123.146 2.564 . . . . 10.0 112.083 171.013 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.27 168.96 23.69 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.266 1.426 . . . . 10.0 112.539 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -72.98 146.47 45.98 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.517 1.527 . . . . 10.0 111.988 173.269 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.2 mp -136.4 -64.08 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 125.699 1.6 . . . . 10.0 109.054 168.539 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -151.7 138.39 18.8 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.716 1.606 . . . . 10.0 110.521 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.6 m -133.37 151.99 78.5 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.773 1.629 . . . . 10.0 110.404 173.688 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.24 148.03 67.56 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 122.652 2.234 . . . . 10.0 112.348 175.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -74.53 176.5 6.79 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.489 1.115 . . . . 10.0 111.253 166.273 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -54.37 122.86 11.32 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.04 -1.037 . . . . 10.0 112.508 176.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.6 mtp -101.31 159.02 15.62 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.01 1.724 . . . . 10.0 111.872 -177.2 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 p -146.82 115.28 6.71 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.178 1.391 . . . . 10.0 111.259 177.708 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.0 mm -127.01 134.22 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.595 1.558 . . . . 10.0 110.166 -169.221 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -63.98 131.85 48.89 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.683 1.193 . . . . 10.0 112.666 176.202 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -52.74 121.54 7.4 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.758 1.623 . . . . 10.0 112.962 -178.941 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 103.81 -9.31 51.56 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 126.2 1.857 . . . . 10.0 115.106 177.829 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.8 mtp180 -72.05 159.51 34.07 Favored 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 119.173 1.486 . . . . 10.0 113.398 177.449 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -72.55 147.7 45.67 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.54 1.136 . . . . 10.0 110.412 156.513 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 15.0 t -149.49 162.82 39.39 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.329 1.052 . . . . 10.0 111.941 170.199 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.0 ptm85 -143.08 164.26 30.59 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.67 1.588 . . . . 10.0 112.107 165.541 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.0 mtt -126.11 159.97 31.42 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 126.802 2.041 . . . . 10.0 110.654 173.883 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -136.72 89.95 2.5 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.416 1.486 . . . . 10.0 111.025 -169.369 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -100.72 106.06 17.46 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.24 1.416 . . . . 10.0 111.029 -178.329 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -67.05 133.07 49.17 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 121.62 -0.675 . . . . 10.0 110.117 171.17 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.7 p -143.71 146.43 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 125.467 1.507 . . . . 10.0 111.392 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 93.6 p -128.6 -165.7 1.54 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.974 1.71 . . . . 10.0 112.733 -174.687 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 98.99 163.45 29.88 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 126.298 1.904 . . . . 10.0 112.813 -178.264 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -142.68 127.09 9.83 Favored Pre-proline 0 CA--C 1.546 0.797 0 C-N-CA 125.507 1.523 . . . . 10.0 109.555 177.781 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -66.26 169.16 46.24 Favored 'Cis proline' 0 CA--C 1.54 0.825 0 CA-C-N 120.312 1.147 . . . . 10.0 112.584 -4.193 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.96 70.01 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.386 1.075 . . . . 10.0 111.046 178.479 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.63 148.53 59.67 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 122.284 1.989 . . . . 10.0 113.834 -169.155 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -67.43 132.83 48.42 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.384 1.474 . . . . 10.0 109.561 158.43 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.1 m -124.0 138.64 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.514 1.126 . . . . 10.0 112.155 -173.276 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 48.1 m -135.25 154.08 51.7 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.975 1.71 . . . . 10.0 110.755 178.221 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -124.93 153.21 43.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.536 1.135 . . . . 10.0 113.389 -176.469 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.3 m-85 -145.1 160.29 41.64 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.088 2.155 . . . . 10.0 111.15 -172.372 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 58.3 tp -149.87 122.34 8.5 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 126.695 1.998 . . . . 10.0 110.332 178.171 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 54.98 6.97 0.14 Allowed 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 126.995 2.118 . . . . 10.0 116.595 174.864 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 121.21 -6.18 10.92 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.2 1.857 . . . . 10.0 115.725 -177.189 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.0 ptm180 -108.09 165.44 11.47 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 119.254 1.527 . . . . 10.0 112.227 171.637 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.8 p -72.47 158.1 36.37 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.861 1.264 . . . . 10.0 112.437 172.302 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 44.4 t -131.09 101.72 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 126.076 1.751 . . . . 10.0 108.372 171.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 11.5 mp0 -67.04 149.95 49.9 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.573 1.149 . . . . 10.0 111.295 176.818 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.4 p -65.54 138.98 58.42 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.45 0.7 . . . . 10.0 110.922 167.698 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -146.8 167.96 22.58 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.721 1.208 . . . . 10.0 111.819 -176.479 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -56.79 -35.07 68.29 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.162 -0.961 . . . . 10.0 113.105 171.023 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 70.4 mt -85.76 -15.17 42.96 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.996 1.11 . . . . 10.0 113.996 174.834 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.5 m80 -135.72 73.03 1.45 Allowed 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.975 1.71 . . . . 10.0 111.088 -174.35 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -73.02 143.66 47.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 125.144 1.377 . . . . 10.0 111.329 -178.173 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 58.8 mtt -142.44 105.25 4.54 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.864 1.666 . . . . 10.0 110.214 -172.338 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.92 144.77 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.161 0.984 . . . . 10.0 112.46 -178.667 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 48.0 t -95.16 100.52 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 125.154 1.382 . . . . 10.0 108.757 175.484 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 15.2 m -64.3 168.76 5.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.693 1.997 . . . . 10.0 112.741 176.307 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -62.01 165.45 5.54 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.541 1.136 . . . . 10.0 113.793 174.705 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 96.6 mttt 56.76 20.69 5.31 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 126.874 2.07 . . . . 10.0 115.794 173.129 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.42 53.83 2.98 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.816 1.198 . . . . 10.0 114.131 173.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 52.0 tp -137.16 146.56 45.11 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.726 1.61 . . . . 10.0 110.517 179.505 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -126.84 115.72 19.76 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.997 1.319 . . . . 10.0 111.359 -179.784 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.0 m -80.83 129.19 34.4 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.834 1.654 . . . . 10.0 111.819 172.366 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -128.35 119.43 25.04 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.088 2.155 . . . . 10.0 107.645 170.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 54.4 mt -119.68 154.06 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.808 1.243 . . . . 10.0 111.662 -164.464 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -131.57 108.65 9.69 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 127.848 2.459 . . . . 10.0 109.35 173.468 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -66.36 -43.21 86.65 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 120.985 -1.072 . . . . 10.0 113.031 177.432 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.71 89.12 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.791 1.637 . . . . 10.0 110.16 -177.685 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -70.09 139.48 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.353 -0.842 . . . . 10.0 112.26 -176.322 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -121.91 163.53 19.1 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.312 1.845 . . . . 10.0 112.045 175.408 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.06 -30.33 66.1 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.574 0.953 . . . . 10.0 113.574 -178.686 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.7 p -67.82 -16.9 64.32 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.657 1.583 . . . . 10.0 114.681 173.648 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -83.66 -5.63 59.23 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.633 1.173 . . . . 10.0 113.356 175.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.83 154.43 39.16 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.027 -1.046 . . . . 10.0 113.352 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.01 -169.72 21.99 Favored Glycine 0 CA--C 1.532 1.123 0 C-N-CA 124.67 1.128 . . . . 10.0 115.043 174.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.81 100.19 10.79 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.966 1.706 . . . . 10.0 111.392 177.626 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -75.11 151.57 38.6 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.214 1.006 . . . . 10.0 111.679 167.432 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.36 159.01 43.15 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.94 0.896 . . . . 10.0 112.157 168.71 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -130.69 144.47 51.46 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.545 1.938 . . . . 10.0 110.223 177.272 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.3 t -126.57 116.11 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 125.49 1.516 . . . . 10.0 109.347 179.229 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -106.3 126.58 52.41 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.452 1.901 . . . . 10.0 110.806 -178.255 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -132.47 127.58 35.58 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 126.439 1.896 . . . . 10.0 111.774 -168.058 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -134.33 177.73 7.53 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.864 0.757 . . . . 10.0 112.238 164.211 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 -62.47 -11.13 14.25 Favored 'General case' 0 N--CA 1.48 1.072 0 N-CA-C 115.536 1.68 . . . . 10.0 115.536 -178.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.49 -15.37 14.81 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.569 1.548 . . . . 10.0 114.088 178.138 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.18 -170.39 38.61 Favored Glycine 0 CA--C 1.536 1.369 0 CA-C-N 119.659 1.118 . . . . 10.0 115.423 176.365 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -134.06 149.59 51.15 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 126.059 1.744 . . . . 10.0 111.892 -172.775 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.42 162.73 33.71 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.237 1.815 . . . . 10.0 111.501 171.144 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 30.1 m -140.28 135.97 32.81 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.938 1.295 . . . . 10.0 110.758 -175.7 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -129.72 154.02 47.58 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.669 1.588 . . . . 10.0 110.976 -178.059 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -144.84 145.61 31.7 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.236 1.014 . . . . 10.0 112.017 -169.421 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.6 p -152.27 150.46 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 125.661 1.584 . . . . 10.0 111.696 170.46 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.3 tt0 -100.91 139.2 36.94 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.531 1.133 . . . . 10.0 111.004 171.655 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.9 tp -123.25 103.86 8.79 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.89 1.676 . . . . 10.0 110.566 175.898 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -90.73 82.9 5.71 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.63 1.572 . . . . 10.0 110.981 175.861 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.9 t -63.69 112.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.844 0.858 . . . . 10.0 110.621 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.7 mt -75.34 98.54 3.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.288 1.835 . . . . 10.0 110.184 -179.22 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.758 0 C-N-CA 124.062 0.945 . . . . 10.0 112.72 179.351 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.522 0 N-CA-C 111.192 -0.763 . . . . 10.0 111.192 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.32 162.01 15.67 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.232 1.013 . . . . 10.0 112.794 175.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.99 174.09 11.84 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.901 1.681 . . . . 10.0 111.823 -176.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -179.06 173.05 45.27 Favored Glycine 0 CA--C 1.542 1.777 0 N-CA-C 116.858 1.503 . . . . 10.0 116.858 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -70.84 162.18 43.5 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.722 2.948 . . . . 10.0 113.258 -172.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -66.96 152.08 80.99 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.859 2.373 . . . . 10.0 111.427 168.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 68.9 ttt180 -142.52 162.68 34.84 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 125.764 1.626 . . . . 10.0 111.542 -177.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -71.33 141.29 50.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.321 1.449 . . . . 10.0 112.224 173.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.1 mp -135.47 -66.14 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.544 1.538 . . . . 10.0 109.724 171.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 -149.56 140.3 22.67 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.34 1.456 . . . . 10.0 111.105 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 24.7 m -127.26 152.59 76.32 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 126.207 1.803 . . . . 10.0 110.287 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.3 156.91 50.49 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 122.87 2.38 . . . . 10.0 112.016 176.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.63 167.28 22.12 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.114 0.966 . . . . 10.0 112.67 172.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -60.2 106.9 0.57 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 124.839 1.256 . . . . 10.0 111.698 173.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 26.4 mtm -79.4 154.57 28.88 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 123.653 0.781 . . . . 10.0 112.467 -175.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.7 p -138.43 110.13 7.11 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 125.306 1.442 . . . . 10.0 110.539 170.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.8 mm -126.85 131.12 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.314 1.446 . . . . 10.0 110.391 -163.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -59.43 131.92 52.42 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.646 1.178 . . . . 10.0 112.558 173.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -51.97 129.83 28.05 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 125.159 1.384 . . . . 10.0 112.674 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.75 -8.91 76.37 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 125.497 1.522 . . . . 10.0 115.278 177.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -70.87 161.61 30.71 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 119.321 1.56 . . . . 10.0 113.051 175.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -73.47 138.48 45.14 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.55 1.14 . . . . 10.0 110.043 155.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.1 p -149.42 169.4 20.95 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.468 0.707 . . . . 10.0 112.348 164.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -147.45 155.56 42.04 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.855 1.262 . . . . 10.0 112.975 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -122.39 143.36 49.71 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 128.028 2.531 . . . . 10.0 108.925 173.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -139.5 114.56 9.57 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.187 0.995 . . . . 10.0 111.936 -170.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -115.85 113.79 23.84 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.222 2.209 . . . . 10.0 110.42 -173.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.3 mtpp -67.99 133.85 49.74 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.473 -0.767 . . . . 10.0 110.015 170.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -140.94 125.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.521 1.528 . . . . 10.0 111.139 -174.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 50.6 m -136.03 103.34 5.32 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.798 1.239 . . . . 10.0 111.467 -176.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -154.9 165.08 32.04 Favored Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.983 2.23 . . . . 10.0 110.662 169.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.6 tp -141.91 125.85 9.97 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.129 0.971 . . . . 10.0 110.847 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -65.43 167.16 49.53 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.63 1.261 . . . . 10.0 112.511 -2.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.09 121.84 44.01 Favored Pre-proline 0 CA--C 1.549 0.915 0 C-N-CA 124.483 1.113 . . . . 10.0 111.202 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.77 150.79 68.64 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.492 2.128 . . . . 10.0 113.076 -172.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -73.62 143.77 46.2 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.146 0.979 . . . . 10.0 109.666 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.61 136.23 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.796 0.839 . . . . 10.0 111.858 -174.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -126.99 157.71 38.81 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.897 1.679 . . . . 10.0 111.68 173.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 51.0 m95 -125.97 154.88 42.25 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 125.533 1.533 . . . . 10.0 113.666 -173.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -144.49 161.12 39.88 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.26 2.224 . . . . 10.0 111.96 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.1 tp -146.56 124.35 11.91 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.748 2.419 . . . . 10.0 109.69 173.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.01 14.28 0.68 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 126.775 2.03 . . . . 10.0 116.064 175.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.36 0.55 24.99 Favored Glycine 0 CA--C 1.539 1.552 0 C-N-CA 125.693 1.616 . . . . 10.0 116.043 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.0 ptp85 -123.93 163.19 21.82 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 125.679 1.592 . . . . 10.0 112.177 173.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.4 p -69.65 159.59 33.17 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.596 1.158 . . . . 10.0 113.616 -175.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 92.7 t -134.92 108.1 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 126.93 2.092 . . . . 10.0 108.939 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -77.01 159.66 29.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 123.724 0.81 . . . . 10.0 111.365 170.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 81.3 p -76.91 155.48 32.77 Favored 'General case' 0 N--CA 1.473 0.683 0 O-C-N 121.645 -0.659 . . . . 10.0 112.144 168.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -155.71 -176.39 5.93 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.578 1.551 . . . . 10.0 111.576 168.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -62.08 -18.18 59.92 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 114.952 1.464 . . . . 10.0 114.952 -177.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 68.7 mt -107.37 -26.67 10.88 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.845 1.658 . . . . 10.0 112.266 175.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -108.74 68.78 0.69 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.828 2.051 . . . . 10.0 110.711 177.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -74.25 146.09 43.55 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.346 1.058 . . . . 10.0 111.839 -175.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 65.7 mtt -138.89 114.69 9.99 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.533 1.933 . . . . 10.0 110.184 -177.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.55 155.82 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.928 1.291 . . . . 10.0 111.776 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.1 p -141.21 122.02 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.595 1.158 . . . . 10.0 111.238 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 38.7 t -74.87 141.8 44.17 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.485 1.114 . . . . 10.0 111.65 175.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.78 -17.68 37.39 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.769 1.228 . . . . 10.0 113.688 170.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -76.47 -4.2 41.32 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.936 1.694 . . . . 10.0 113.917 174.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.68 39.43 4.15 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.979 1.275 . . . . 10.0 114.867 172.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.2 tp -136.55 114.78 11.61 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 125.109 1.364 . . . . 10.0 111.122 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 5.1 t60 -98.35 132.88 43.46 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.21 1.404 . . . . 10.0 110.994 174.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 37.9 m -121.89 138.07 54.54 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.558 1.543 . . . . 10.0 111.487 -178.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -128.06 117.84 22.38 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 127.713 2.405 . . . . 10.0 107.85 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 85.3 mt -118.63 148.45 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.471 1.108 . . . . 10.0 111.064 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -123.07 106.31 10.69 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 127.355 2.262 . . . . 10.0 109.014 171.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -63.59 -38.3 90.61 Favored 'General case' 0 N--CA 1.475 0.781 0 O-C-N 121.296 -0.878 . . . . 10.0 113.09 176.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.2 p -150.76 90.1 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.889 1.676 . . . . 10.0 110.248 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -68.48 144.75 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 O-C-N 121.27 -0.894 . . . . 10.0 112.101 -178.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -129.21 162.17 28.45 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.03 1.732 . . . . 10.0 112.005 174.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.54 -34.38 64.65 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 113.642 0.979 . . . . 10.0 113.642 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.1 m -64.87 -17.15 64.03 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.387 1.475 . . . . 10.0 114.509 175.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -81.7 -8.28 59.68 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.513 1.125 . . . . 10.0 113.328 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.72 150.64 43.99 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 119.219 0.918 . . . . 10.0 112.933 178.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.9 -172.2 22.71 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.563 1.078 . . . . 10.0 114.789 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.87 101.95 13.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.963 1.705 . . . . 10.0 111.209 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -76.15 150.85 37.11 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.225 1.01 . . . . 10.0 111.501 167.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.5 161.97 38.49 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.906 0.883 . . . . 10.0 111.545 169.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 30.8 p -144.88 161.87 38.25 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.186 0.994 . . . . 10.0 112.044 171.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.98 131.25 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.273 1.429 . . . . 10.0 110.072 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.47 126.8 54.77 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.651 1.98 . . . . 10.0 110.044 -178.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -133.93 129.06 35.75 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.644 1.577 . . . . 10.0 112.012 -169.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.5 p30 -132.21 -179.46 5.44 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.448 1.099 . . . . 10.0 111.832 166.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -60.51 -14.68 21.07 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.657 1.725 . . . . 10.0 115.657 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.84 -16.38 14.48 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.288 1.435 . . . . 10.0 114.276 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.93 -170.17 40.55 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 115.876 1.11 . . . . 10.0 115.876 177.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -134.68 146.72 49.75 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.852 2.061 . . . . 10.0 111.7 -172.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.81 153.11 49.68 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.753 1.621 . . . . 10.0 110.982 169.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 25.2 m -137.55 136.78 37.93 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.832 1.253 . . . . 10.0 110.552 -172.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -134.89 153.72 51.95 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.964 1.306 . . . . 10.0 111.524 -173.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.0 m -142.33 144.5 33.24 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 125.251 1.42 . . . . 10.0 111.456 -173.031 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.9 p -151.8 156.72 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 C-N-CA 125.695 1.598 . . . . 10.0 111.271 170.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -107.89 148.89 29.0 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 124.349 1.06 . . . . 10.0 111.746 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.29 114.96 18.29 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.469 1.907 . . . . 10.0 110.222 174.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -103.46 84.74 2.35 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.719 1.608 . . . . 10.0 110.685 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.8 t -67.23 110.96 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.708 0.803 . . . . 10.0 110.871 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 75.7 mt -75.95 101.03 5.05 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.731 2.012 . . . . 10.0 110.567 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -64.21 161.91 15.57 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.058 0.943 . . . . 10.0 112.87 175.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -127.79 16.04 6.91 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 125.69 1.596 . . . . 10.0 114.889 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? . . . . . 0 C--O 1.253 1.241 0 C-N-CA 126.463 1.905 . . . . 10.0 114.656 172.834 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.577 0 N-CA-C 112.0 -0.44 . . . . 10.0 112.0 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -62.94 143.69 57.47 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.268 1.027 . . . . 10.0 113.013 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -64.62 166.4 8.71 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.666 1.586 . . . . 10.0 113.8 174.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.52 160.6 34.24 Favored Glycine 0 CA--C 1.541 1.69 0 C-N-CA 125.707 1.622 . . . . 10.0 113.166 174.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.1 163.72 36.67 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.865 3.043 . . . . 10.0 113.29 -171.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -67.33 148.31 79.59 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.825 2.35 . . . . 10.0 111.435 173.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 32.7 ttp-105 -138.09 136.9 37.22 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.855 1.262 . . . . 10.0 113.208 -173.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -63.58 117.26 6.54 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 127.274 2.23 . . . . 10.0 110.997 170.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 35.8 mm -108.35 -54.26 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.735 0.814 . . . . 10.0 110.328 171.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -153.18 142.68 21.76 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.412 1.085 . . . . 10.0 111.433 172.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.53 148.48 53.06 Favored Pre-proline 0 N--CA 1.476 0.862 0 C-N-CA 125.247 1.419 . . . . 10.0 110.073 169.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -77.13 163.69 30.29 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.965 2.443 . . . . 10.0 112.117 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -73.1 166.74 22.54 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.593 0.757 . . . . 10.0 111.43 166.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -62.44 160.9 12.64 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.364 -0.835 . . . . 10.0 112.081 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 51.0 mtm -133.49 161.25 35.1 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.181 0.992 . . . . 10.0 112.939 -178.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 55.2 p -137.88 115.64 11.43 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 125.907 1.683 . . . . 10.0 109.854 168.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.6 mm -124.51 132.9 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.306 1.442 . . . . 10.0 110.05 -166.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -59.56 126.51 27.91 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.402 1.481 . . . . 10.0 112.475 173.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 70.0 tt0 -50.23 126.75 15.5 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.599 1.56 . . . . 10.0 112.679 176.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.99 -11.75 58.91 Favored Glycine 0 CA--C 1.537 1.468 0 C-N-CA 126.182 1.849 . . . . 10.0 115.088 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -75.53 162.39 28.34 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 119.2 1.5 . . . . 10.0 113.418 177.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -76.69 143.3 40.13 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.076 1.351 . . . . 10.0 110.328 157.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 28.6 p -150.82 168.97 22.83 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.608 0.763 . . . . 10.0 112.621 162.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.8 ptm85 -144.12 168.93 18.86 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.426 1.49 . . . . 10.0 112.966 176.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.7 mtt -131.81 158.82 40.27 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.974 2.11 . . . . 10.0 110.867 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -136.15 92.61 2.81 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.144 1.378 . . . . 10.0 112.139 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -108.41 104.02 13.29 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.456 1.502 . . . . 10.0 111.319 -176.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.1 mtpp -81.7 122.98 28.33 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 121.077 -1.014 . . . . 10.0 110.322 173.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.43 151.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.803 2.041 . . . . 10.0 110.633 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.9 t -131.1 175.7 8.88 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.18 1.392 . . . . 10.0 111.419 172.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 136.7 167.53 11.17 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 127.418 2.437 . . . . 10.0 112.445 -175.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.33 119.79 5.16 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 123.878 0.871 . . . . 10.0 111.707 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.8 169.44 59.05 Favored 'Cis proline' 0 CA--C 1.541 0.826 0 CA-C-N 120.459 1.2 . . . . 10.0 112.473 -1.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.85 127.79 75.31 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.059 0.943 . . . . 10.0 110.838 175.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.69 148.32 65.28 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 122.298 1.999 . . . . 10.0 113.062 -172.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -71.01 142.02 50.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.353 1.061 . . . . 10.0 109.583 160.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 10.8 m -127.02 137.67 57.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 124.618 1.167 . . . . 10.0 112.583 -170.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.1 m -137.57 112.55 9.05 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.109 1.764 . . . . 10.0 110.758 -174.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -85.87 152.76 22.73 Favored 'General case' 0 CA--C 1.536 0.417 0 N-CA-C 113.475 0.917 . . . . 10.0 113.475 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.41 158.89 43.21 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.386 2.274 . . . . 10.0 111.129 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.8 tp -145.15 117.78 8.62 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 127.153 2.181 . . . . 10.0 110.109 177.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 55.14 10.98 0.47 Allowed 'General case' 0 CA--C 1.555 1.172 0 C-N-CA 126.747 2.019 . . . . 10.0 115.573 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.27 -15.63 17.97 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 126.832 2.158 . . . . 10.0 115.047 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -84.09 157.45 21.74 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 118.988 1.394 . . . . 10.0 111.088 169.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.9 p -71.71 157.91 37.09 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.281 1.033 . . . . 10.0 112.137 170.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.8 105.77 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 126.303 1.841 . . . . 10.0 108.676 173.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 23.0 mm100 -76.26 159.83 30.23 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.218 0.607 . . . . 10.0 111.495 173.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 36.7 p -67.06 150.8 48.7 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.692 0.797 . . . . 10.0 111.928 169.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -150.76 166.01 31.77 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.179 1.392 . . . . 10.0 111.128 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -54.86 -36.56 65.21 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.147 -0.97 . . . . 10.0 113.1 170.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.0 mt -84.22 -13.77 51.79 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.434 1.094 . . . . 10.0 113.863 174.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -135.04 70.95 1.43 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.93 1.692 . . . . 10.0 111.322 -173.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.08 143.12 49.17 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.049 1.339 . . . . 10.0 111.73 -175.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -139.6 101.99 4.35 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.644 1.978 . . . . 10.0 110.055 -174.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.14 162.73 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.254 1.422 . . . . 10.0 111.557 -178.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.86 118.15 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.899 1.279 . . . . 10.0 110.994 177.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 63.3 m -68.56 158.44 33.91 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.328 1.051 . . . . 10.0 112.218 178.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -61.24 -21.26 63.71 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 114.243 1.201 . . . . 10.0 114.243 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.1 mptt -77.06 -5.4 48.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.299 1.84 . . . . 10.0 113.865 173.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.05 3.43 65.59 Favored Glycine 0 CA--C 1.536 1.394 0 C-N-CA 125.6 1.572 . . . . 10.0 115.181 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 57.8 tp -77.44 101.81 6.58 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 118.686 1.243 . . . . 10.0 111.318 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -78.96 113.55 17.16 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.185 1.394 . . . . 10.0 110.925 170.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 75.0 m -84.98 139.44 31.79 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 125.524 1.53 . . . . 10.0 111.986 171.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -131.92 121.24 23.68 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 126.704 2.002 . . . . 10.0 107.688 168.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 61.0 mt -122.18 152.57 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.855 1.262 . . . . 10.0 111.357 -166.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -129.4 109.85 11.42 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 127.519 2.328 . . . . 10.0 109.142 170.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -66.15 -40.22 90.4 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.359 -0.838 . . . . 10.0 113.168 176.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -149.96 88.92 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.838 1.655 . . . . 10.0 110.104 -178.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -68.53 140.29 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 O-C-N 121.378 -0.826 . . . . 10.0 112.045 -176.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -124.78 160.64 28.21 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.463 1.905 . . . . 10.0 111.841 177.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.14 -34.32 63.66 Favored 'General case' 0 CA--C 1.547 0.828 0 N-CA-C 113.509 0.929 . . . . 10.0 113.509 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.4 m -65.05 -17.46 64.47 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.499 1.52 . . . . 10.0 114.62 175.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -80.99 -6.53 58.88 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.446 1.098 . . . . 10.0 113.324 177.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.88 148.44 51.4 Favored 'General case' 0 CA--C 1.547 0.843 0 O-C-N 121.017 -1.052 . . . . 10.0 112.77 177.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 139.75 -174.75 22.19 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.844 1.211 . . . . 10.0 114.815 177.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.81 108.68 17.6 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.971 1.708 . . . . 10.0 110.932 175.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.5 m-85 -86.12 151.96 23.25 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.208 1.003 . . . . 10.0 111.869 172.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.97 160.68 39.88 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.933 0.893 . . . . 10.0 112.006 169.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.0 t -137.57 107.47 6.3 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.753 1.621 . . . . 10.0 110.586 177.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.5 t -76.05 132.9 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.294 1.037 . . . . 10.0 108.937 169.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -128.3 121.79 30.08 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 126.372 1.869 . . . . 10.0 110.494 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -134.4 139.45 45.59 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.941 1.297 . . . . 10.0 112.604 -171.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.3 p30 -133.74 -178.31 4.95 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.609 1.164 . . . . 10.0 111.259 165.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -61.9 -7.79 4.2 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 115.667 1.729 . . . . 10.0 115.667 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -117.7 -12.7 10.24 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 126.135 1.774 . . . . 10.0 114.578 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.01 -172.66 44.48 Favored Glycine 0 CA--C 1.535 1.308 0 CA-C-N 119.776 1.171 . . . . 10.0 115.924 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -137.8 144.23 41.44 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.992 2.117 . . . . 10.0 111.625 -174.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.64 162.96 33.3 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.594 1.957 . . . . 10.0 110.626 168.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -141.99 124.5 15.77 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.389 1.076 . . . . 10.0 110.736 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -105.14 154.39 20.25 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.33 1.452 . . . . 10.0 110.898 178.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.7 m -144.03 145.12 31.98 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 124.271 1.028 . . . . 10.0 112.035 -170.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.8 p -154.11 171.64 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 C-N-CA 126.595 1.958 . . . . 10.0 110.976 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -131.92 147.88 52.49 Favored 'General case' 0 N--CA 1.471 0.614 0 O-C-N 120.77 -1.206 . . . . 10.0 111.622 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.7 tp -131.14 117.04 18.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 126.283 1.833 . . . . 10.0 110.2 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -106.4 77.68 1.23 Allowed 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.681 1.592 . . . . 10.0 110.481 178.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -58.37 114.31 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.414 1.086 . . . . 10.0 111.014 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.5 mt -76.25 99.58 4.8 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.477 1.911 . . . . 10.0 109.831 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.49 150.39 31.43 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.975 0.91 . . . . 10.0 113.117 -177.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -77.28 -9.45 58.82 Favored 'General case' 0 N--CA 1.48 1.069 0 N-CA-C 115.104 1.52 . . . . 10.0 115.104 -178.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 . . . . . 0 C--O 1.253 1.248 0 C-N-CA 126.829 2.052 . . . . 10.0 114.06 -178.482 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.597 0 N-CA-C 112.154 -0.378 . . . . 10.0 112.154 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.65 166.09 11.34 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 124.449 1.1 . . . . 10.0 112.872 174.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.3 ptt? -133.98 177.19 7.93 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 125.614 1.565 . . . . 10.0 112.57 -176.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 179.03 172.34 43.22 Favored Glycine 0 CA--C 1.541 1.668 0 N-CA-C 116.708 1.443 . . . . 10.0 116.708 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.16 159.9 47.42 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 123.901 3.068 . . . . 10.0 113.027 -173.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -68.24 143.19 57.9 Favored 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 123.133 2.555 . . . . 10.0 111.497 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -131.24 149.45 52.57 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.96 1.304 . . . . 10.0 113.757 -174.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -77.76 111.13 13.24 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.019 2.527 . . . . 10.0 110.939 176.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.5 mm -109.34 -44.66 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.772 0.829 . . . . 10.0 111.104 175.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -149.51 142.18 24.53 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.708 1.203 . . . . 10.0 111.494 170.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -122.91 135.69 26.08 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 124.873 1.269 . . . . 10.0 109.278 158.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -75.47 159.88 39.18 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.003 2.468 . . . . 10.0 112.206 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -67.44 164.84 17.86 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.92 1.288 . . . . 10.0 112.111 171.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -62.49 113.77 3.15 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.216 -0.928 . . . . 10.0 111.332 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 29.0 mtm -76.22 148.87 37.37 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.736 -0.603 . . . . 10.0 111.69 -178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 24.0 p -128.08 102.76 6.87 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 125.705 1.602 . . . . 10.0 110.468 176.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.7 mm -121.8 123.61 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.931 1.293 . . . . 10.0 110.63 -163.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -58.86 126.23 26.83 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.134 1.374 . . . . 10.0 111.893 170.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -53.22 136.37 36.58 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.126 1.371 . . . . 10.0 113.468 -176.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 94.93 -10.92 70.09 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 125.97 1.747 . . . . 10.0 114.808 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 73.8 mtp180 -72.5 158.92 34.81 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 118.877 1.339 . . . . 10.0 113.479 177.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -75.31 141.04 43.45 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.373 1.069 . . . . 10.0 110.265 154.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 32.0 p -150.76 170.87 18.18 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.583 0.753 . . . . 10.0 112.269 160.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -145.83 144.06 30.02 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.195 1.398 . . . . 10.0 111.74 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.7 mtt -91.75 159.33 15.88 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.084 1.354 . . . . 10.0 110.665 169.028 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -138.15 109.83 7.09 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.231 1.412 . . . . 10.0 112.557 -177.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -116.56 98.47 6.56 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.646 1.978 . . . . 10.0 110.383 -176.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 29.5 mtpp -67.87 137.88 55.62 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.148 -0.97 . . . . 10.0 110.196 171.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.28 152.83 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.486 1.514 . . . . 10.0 111.27 -172.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -136.5 174.87 10.14 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.28 1.432 . . . . 10.0 111.164 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 121.07 164.34 12.31 Favored Glycine 0 CA--C 1.538 1.478 0 C-N-CA 127.288 2.375 . . . . 10.0 112.878 -174.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.0 tp -153.04 135.04 8.87 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.752 1.221 . . . . 10.0 110.978 -179.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -68.38 172.11 44.74 Favored 'Cis proline' 0 CA--C 1.54 0.794 0 CA-C-N 120.815 1.327 . . . . 10.0 112.722 -4.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.69 122.58 52.33 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.777 1.231 . . . . 10.0 111.777 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -72.17 155.43 56.54 Favored 'Trans proline' 0 CA--C 1.538 0.713 0 C-N-CA 122.618 2.212 . . . . 10.0 113.542 -172.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -79.13 74.41 5.69 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.316 1.846 . . . . 10.0 111.517 177.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 15.3 m -56.69 122.46 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 125.526 1.53 . . . . 10.0 113.194 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 66.3 m -133.69 111.56 10.68 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 126.334 1.853 . . . . 10.0 111.145 -172.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.4 m95 -87.59 149.77 24.11 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 114.43 1.271 . . . . 10.0 114.43 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -141.6 160.43 40.17 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.606 2.363 . . . . 10.0 111.463 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.4 tp -148.19 123.5 10.26 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 127.733 2.413 . . . . 10.0 109.989 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 53.58 16.03 0.87 Allowed 'General case' 0 CA--C 1.556 1.196 0 C-N-CA 126.498 1.919 . . . . 10.0 115.844 175.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.25 0.04 33.22 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.679 1.609 . . . . 10.0 115.824 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -117.11 162.4 17.89 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 126.031 1.732 . . . . 10.0 111.376 173.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.1 p -69.28 158.69 34.52 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 124.499 1.119 . . . . 10.0 113.017 178.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 43.6 t -130.82 106.91 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 126.011 1.724 . . . . 10.0 108.607 170.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -72.92 153.25 41.06 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.48 0.712 . . . . 10.0 111.377 172.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 32.2 p -68.25 150.29 48.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.615 0.766 . . . . 10.0 112.026 171.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -151.89 169.65 21.76 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.148 1.379 . . . . 10.0 110.798 175.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -62.52 -31.55 72.34 Favored 'General case' 0 N--CA 1.471 0.625 0 O-C-N 120.464 -1.398 . . . . 10.0 112.549 169.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 97.8 mt -73.99 -22.31 59.65 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.012 0.925 . . . . 10.0 113.468 171.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -136.75 67.91 1.44 Allowed 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.152 1.781 . . . . 10.0 111.108 -171.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 63.8 mttm -69.78 142.73 53.15 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.183 0.993 . . . . 10.0 111.336 -177.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -135.51 102.9 5.27 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 126.724 2.01 . . . . 10.0 109.423 -173.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.55 155.71 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 124.165 0.986 . . . . 10.0 112.546 -173.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.66 165.51 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 126.484 1.914 . . . . 10.0 111.188 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 39.0 t -137.72 146.83 44.2 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.797 1.239 . . . . 10.0 112.642 -178.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -56.98 -20.47 24.06 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.244 1.818 . . . . 10.0 113.837 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -74.71 -1.51 22.23 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.745 1.618 . . . . 10.0 114.014 176.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.2 48.01 5.27 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.072 1.32 . . . . 10.0 112.987 178.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.0 tp -140.28 146.96 39.24 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.475 1.51 . . . . 10.0 111.625 -175.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -129.43 132.86 47.08 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.085 2.154 . . . . 10.0 109.678 170.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 67.6 m -119.28 149.2 42.17 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.844 1.258 . . . . 10.0 112.319 178.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -136.21 110.19 8.24 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.045 2.138 . . . . 10.0 108.478 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -95.18 153.34 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.641 1.576 . . . . 10.0 111.151 -171.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -129.54 107.64 9.63 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.92 2.088 . . . . 10.0 108.761 161.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -63.75 -43.25 96.99 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 121.447 -0.783 . . . . 10.0 113.077 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 2.8 p -150.08 87.08 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 126.156 1.782 . . . . 10.0 109.333 -178.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.8 p -66.99 141.13 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 O-C-N 121.525 -0.734 . . . . 10.0 111.8 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -127.07 160.12 32.13 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 126.429 1.892 . . . . 10.0 111.046 177.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.24 -33.79 59.23 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.009 1.114 . . . . 10.0 114.009 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.41 -17.77 64.09 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.287 1.435 . . . . 10.0 114.547 175.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -81.4 -8.17 59.69 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.656 1.182 . . . . 10.0 113.413 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -62.97 146.28 53.46 Favored 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.136 -0.977 . . . . 10.0 112.622 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.64 -175.37 23.64 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.024 0.821 . . . . 10.0 114.936 178.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.71 105.5 16.99 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 126.196 1.798 . . . . 10.0 111.257 177.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.2 m-85 -84.94 150.76 24.72 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.714 1.206 . . . . 10.0 111.932 173.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.64 160.74 40.67 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 123.865 0.866 . . . . 10.0 112.249 170.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 47.3 t -138.21 109.12 6.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.58 1.552 . . . . 10.0 110.753 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 93.9 t -76.98 134.86 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.638 1.175 . . . . 10.0 109.146 169.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -132.37 114.5 14.44 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.245 1.818 . . . . 10.0 110.13 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.6 mtpp -129.8 136.61 49.79 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.409 1.484 . . . . 10.0 111.722 -174.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 28.3 p30 -133.26 -179.41 5.49 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.893 1.277 . . . . 10.0 111.371 168.295 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -62.2 -9.93 9.17 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 115.662 1.726 . . . . 10.0 115.662 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.72 -16.12 13.27 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.744 1.618 . . . . 10.0 114.471 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.29 -168.06 40.96 Favored Glycine 0 CA--C 1.536 1.36 0 CA-C-N 119.992 1.269 . . . . 10.0 116.241 176.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -136.24 143.93 44.58 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.995 2.118 . . . . 10.0 112.21 -171.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.25 160.19 40.51 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.774 2.03 . . . . 10.0 110.476 166.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 53.1 m -144.2 116.16 8.33 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.445 1.098 . . . . 10.0 110.61 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -98.0 151.07 20.69 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.16 1.384 . . . . 10.0 110.979 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.5 m -142.32 146.3 34.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 124.613 1.165 . . . . 10.0 111.819 -174.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -153.06 174.58 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 126.721 2.008 . . . . 10.0 110.916 173.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -130.47 150.58 51.62 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.176 1.39 . . . . 10.0 111.118 173.047 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.5 tp -125.16 108.36 11.7 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.332 1.453 . . . . 10.0 110.846 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -90.4 81.07 6.03 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.258 1.823 . . . . 10.0 110.473 176.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.9 t -68.44 109.5 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 121.119 -0.988 . . . . 10.0 110.472 177.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.7 mt -77.55 97.64 5.11 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.774 1.63 . . . . 10.0 109.548 177.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.45 150.51 26.43 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.592 1.157 . . . . 10.0 113.957 -172.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -67.57 -47.29 70.19 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.078 1.751 . . . . 10.0 112.592 179.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 . . . . . 0 C--O 1.253 1.266 0 C-N-CA 126.193 1.797 . . . . 10.0 113.433 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.549 0 N-CA-C 111.793 -0.523 . . . . 10.0 111.793 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.43 160.91 21.0 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.366 1.067 . . . . 10.0 112.983 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.86 178.39 8.72 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 126.026 1.73 . . . . 10.0 112.034 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.83 170.84 43.7 Favored Glycine 0 CA--C 1.541 1.717 0 N-CA-C 116.513 1.365 . . . . 10.0 116.513 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.94 159.58 52.09 Favored 'Trans proline' 0 CA--C 1.542 0.918 0 C-N-CA 123.391 2.727 . . . . 10.0 113.116 -173.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.76 161.71 44.28 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.934 2.423 . . . . 10.0 111.072 166.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.86 166.47 24.37 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.471 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -85.93 71.95 10.55 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.355 1.862 . . . . 10.0 111.543 -173.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . 0.499 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.5 OUTLIER -73.55 179.78 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 125.031 1.333 . . . . 10.0 111.137 176.889 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.499 ' H ' HG22 ' A' ' 253' ' ' ILE . 35.3 tt0 -50.06 140.02 13.2 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.152 2.181 . . . . 10.0 114.336 -175.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.4 m -127.12 152.11 75.36 Favored Pre-proline 0 N--CA 1.477 0.915 0 C-N-CA 126.696 1.998 . . . . 10.0 110.982 172.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -77.2 159.22 33.46 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.249 2.632 . . . . 10.0 112.429 174.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -69.47 172.39 7.31 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.19 1.396 . . . . 10.0 112.263 169.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -55.65 111.74 0.98 Allowed 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 124.578 1.151 . . . . 10.0 112.854 173.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.7 mtp -82.58 155.63 24.36 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.769 1.628 . . . . 10.0 112.121 -177.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -147.22 109.38 4.49 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.249 1.419 . . . . 10.0 111.062 175.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.2 mm -123.01 133.37 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.248 1.419 . . . . 10.0 110.464 -168.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.74 130.98 47.36 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.096 1.359 . . . . 10.0 112.562 174.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -52.78 133.63 37.01 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.254 1.421 . . . . 10.0 112.862 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 93.22 -9.84 74.22 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.784 1.659 . . . . 10.0 115.276 177.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.1 mtp-105 -75.79 161.15 29.27 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 119.179 1.489 . . . . 10.0 113.018 176.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -72.46 147.33 46.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.442 1.097 . . . . 10.0 110.605 157.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 9.0 t -149.67 164.8 34.21 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.569 1.148 . . . . 10.0 111.582 165.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.7 ptm180 -149.54 155.41 40.29 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.645 1.578 . . . . 10.0 111.62 163.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 40.6 mtt -102.43 166.85 10.31 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.614 1.566 . . . . 10.0 112.071 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -132.73 110.9 10.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.331 1.852 . . . . 10.0 111.099 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -127.31 101.74 6.61 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 125.322 1.449 . . . . 10.0 111.172 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -60.36 142.76 54.41 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.513 -0.742 . . . . 10.0 110.296 172.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.0 p -148.98 146.3 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 124.597 1.159 . . . . 10.0 111.753 -175.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 51.8 m -139.19 178.59 7.07 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 126.341 1.856 . . . . 10.0 111.454 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 112.64 161.27 15.22 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 126.349 1.928 . . . . 10.0 113.092 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.15 129.93 7.43 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 125.145 1.378 . . . . 10.0 110.638 -179.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -66.39 168.86 48.14 Favored 'Cis proline' 0 CA--C 1.54 0.798 0 CA-C-N 120.806 1.324 . . . . 10.0 112.546 -2.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.63 120.62 33.43 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 124.673 1.189 . . . . 10.0 111.658 -177.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.0 159.5 52.3 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.597 2.198 . . . . 10.0 113.265 -174.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -68.7 169.41 11.28 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.336 1.454 . . . . 10.0 111.923 171.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 87.1 t -131.95 112.99 21.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.302 1.841 . . . . 10.0 110.165 -176.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 70.8 m -131.54 100.3 5.09 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.238 1.415 . . . . 10.0 110.91 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -84.02 154.64 23.15 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 122.035 0.921 . . . . 10.0 113.29 176.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -142.53 160.35 40.45 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.749 2.419 . . . . 10.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -148.83 124.06 10.18 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.104 2.161 . . . . 10.0 109.98 176.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 54.54 10.99 0.38 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 126.996 2.118 . . . . 10.0 116.378 174.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 115.51 -0.96 22.02 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.847 1.689 . . . . 10.0 115.852 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -117.36 163.99 15.52 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.795 1.638 . . . . 10.0 111.929 172.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.0 p -71.63 160.31 32.89 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.626 1.17 . . . . 10.0 112.948 178.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 64.5 t -136.24 111.29 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 126.632 1.973 . . . . 10.0 108.903 173.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -85.02 159.18 20.28 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.831 0.853 . . . . 10.0 111.199 170.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.9 p -69.61 151.06 46.38 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.725 0.81 . . . . 10.0 112.426 171.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -151.36 179.27 8.47 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.492 1.517 . . . . 10.0 110.79 166.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -56.71 -30.74 63.79 Favored 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 114.327 1.232 . . . . 10.0 114.327 -177.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 55.7 mt -87.63 -13.31 43.06 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.912 1.285 . . . . 10.0 113.514 175.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -135.64 68.12 1.46 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.158 1.783 . . . . 10.0 111.226 -172.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.4 mttt -67.86 145.13 54.92 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.089 1.356 . . . . 10.0 111.167 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.2 mtt -135.21 102.68 5.26 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 126.774 2.029 . . . . 10.0 109.726 -175.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.97 158.54 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.822 1.249 . . . . 10.0 112.212 -175.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 38.7 t -133.64 113.97 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 125.778 1.631 . . . . 10.0 109.73 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 46.6 t -64.89 141.15 58.87 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.917 0.887 . . . . 10.0 111.518 172.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -57.76 -19.48 28.18 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.72 1.208 . . . . 10.0 113.946 173.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.5 -3.45 40.59 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.454 1.502 . . . . 10.0 113.697 176.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.66 43.05 4.32 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 125.293 1.425 . . . . 10.0 113.883 176.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 61.9 tp -137.13 107.03 6.26 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.077 1.351 . . . . 10.0 111.578 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -80.43 138.61 36.63 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 125.379 1.471 . . . . 10.0 111.227 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 60.6 m -122.19 146.51 47.18 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 125.917 1.687 . . . . 10.0 111.807 174.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -134.13 112.54 11.22 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.214 2.206 . . . . 10.0 108.211 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -94.13 154.69 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.399 1.48 . . . . 10.0 111.55 -170.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -131.96 99.05 4.62 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.381 2.272 . . . . 10.0 108.96 163.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -62.11 -39.23 91.82 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 120.943 -1.098 . . . . 10.0 113.125 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.6 p -150.52 90.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.998 1.719 . . . . 10.0 109.839 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.1 p -68.54 140.23 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 121.39 -0.819 . . . . 10.0 112.148 -175.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 27.2 mmt180 -126.13 162.09 26.16 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.463 1.905 . . . . 10.0 111.834 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.98 -33.4 64.78 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.431 0.9 . . . . 10.0 113.431 -177.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 m -64.11 -18.01 64.0 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.386 1.474 . . . . 10.0 114.472 175.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -83.33 -5.99 59.32 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.609 1.164 . . . . 10.0 113.32 177.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.06 152.29 44.99 Favored 'General case' 0 CA--C 1.547 0.852 0 O-C-N 121.039 -1.038 . . . . 10.0 113.191 179.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 137.08 -173.32 22.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 124.689 1.138 . . . . 10.0 115.161 175.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -86.08 102.05 13.5 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.143 1.777 . . . . 10.0 111.234 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -80.91 153.6 27.48 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.624 1.17 . . . . 10.0 112.169 170.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.21 162.7 36.5 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.238 1.015 . . . . 10.0 111.795 166.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.3 t -139.64 125.52 19.65 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 125.446 1.499 . . . . 10.0 110.827 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 96.2 t -97.63 134.82 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 125.436 1.495 . . . . 10.0 109.7 174.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.19 117.33 22.13 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.224 1.809 . . . . 10.0 110.794 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -132.96 140.35 47.76 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.197 1.399 . . . . 10.0 112.196 -172.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.4 p30 -135.04 -177.83 4.81 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.234 1.414 . . . . 10.0 111.209 166.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -62.23 -13.26 26.03 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 115.624 1.713 . . . . 10.0 115.624 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -104.15 -22.54 13.39 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.33 1.452 . . . . 10.0 114.183 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.79 -166.24 39.44 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 116.098 1.199 . . . . 10.0 116.098 179.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.91 146.13 47.02 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.93 2.092 . . . . 10.0 112.098 -169.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.71 167.0 23.21 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.553 1.941 . . . . 10.0 111.037 166.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 10.8 m -145.2 148.68 33.81 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.338 1.055 . . . . 10.0 111.071 -177.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -132.17 151.15 51.95 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.039 1.736 . . . . 10.0 110.647 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.3 m -143.45 145.98 33.05 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 125.034 1.334 . . . . 10.0 111.642 -174.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.9 p -154.2 156.42 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 126.016 1.727 . . . . 10.0 110.99 170.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -110.91 141.42 44.34 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.353 1.061 . . . . 10.0 110.485 169.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.4 tp -124.14 106.8 10.62 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.07 1.748 . . . . 10.0 110.321 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -94.54 83.22 4.08 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.435 1.494 . . . . 10.0 110.824 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.0 t -64.05 113.56 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 O-C-N 121.372 -0.83 . . . . 10.0 110.704 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.45 97.49 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.1 1.76 . . . . 10.0 110.073 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.23 151.61 35.72 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 124.384 1.074 . . . . 10.0 113.429 -177.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -142.9 79.2 1.64 Allowed 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 126.462 1.905 . . . . 10.0 110.455 176.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 . . . . . 0 C--O 1.254 1.303 0 C-N-CA 125.623 1.569 . . . . 10.0 114.353 175.672 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.594 0 N-CA-C 111.659 -0.576 . . . . 10.0 111.659 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.61 159.5 21.77 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.302 1.041 . . . . 10.0 112.783 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.64 175.15 11.81 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.168 1.787 . . . . 10.0 111.616 -176.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.79 172.45 45.1 Favored Glycine 0 CA--C 1.543 1.784 0 N-CA-C 117.473 1.749 . . . . 10.0 117.473 -175.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_endo -72.71 159.54 48.37 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 124.128 3.219 . . . . 10.0 113.549 -171.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -70.53 148.0 59.1 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.204 2.603 . . . . 10.0 112.054 173.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -136.46 158.59 44.07 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 125.576 1.551 . . . . 10.0 112.758 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -84.41 79.41 9.57 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.293 2.237 . . . . 10.0 112.261 -174.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 44.4 mm -73.41 -55.31 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.529 -0.732 . . . . 10.0 111.21 178.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.22 129.52 10.53 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.5 1.12 . . . . 10.0 111.705 176.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.1 m -104.09 148.17 35.48 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 124.669 1.188 . . . . 10.0 110.196 158.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.32 162.4 36.36 Favored 'Trans proline' 0 CA--C 1.542 0.882 0 C-N-CA 122.99 2.46 . . . . 10.0 111.155 171.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -73.66 168.29 19.65 Favored 'General case' 0 CA--C 1.545 0.783 0 O-C-N 121.389 -0.82 . . . . 10.0 111.655 169.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.5 p30 -61.79 160.22 12.28 Favored 'General case' 0 CA--C 1.547 0.864 0 O-C-N 121.422 -0.799 . . . . 10.0 112.405 172.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.2 mtm -132.56 160.4 36.66 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.079 0.952 . . . . 10.0 113.073 -178.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 p -136.07 103.14 5.24 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 126.192 1.797 . . . . 10.0 110.527 175.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.5 mm -119.37 131.27 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.247 1.419 . . . . 10.0 110.723 -165.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -60.91 129.07 39.62 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.804 1.242 . . . . 10.0 112.558 173.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -54.21 127.8 28.43 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.825 1.25 . . . . 10.0 112.596 -178.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.13 -10.27 61.71 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 126.187 1.851 . . . . 10.0 115.036 178.16 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 27.1 mtp-105 -73.84 163.93 27.3 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.116 1.458 . . . . 10.0 113.099 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -75.37 141.18 43.34 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.895 1.278 . . . . 10.0 110.506 158.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.46 170.32 19.89 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.756 0.822 . . . . 10.0 112.343 162.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -146.84 163.32 36.44 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.37 1.468 . . . . 10.0 112.757 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -134.97 140.3 45.59 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.215 2.206 . . . . 10.0 109.137 175.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -131.97 125.7 32.21 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.795 1.238 . . . . 10.0 111.974 -168.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -129.17 111.81 13.3 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 126.789 2.035 . . . . 10.0 111.624 -167.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -73.65 120.55 19.4 Favored 'General case' 0 N--CA 1.474 0.738 0 O-C-N 121.587 -0.696 . . . . 10.0 109.808 171.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -130.11 108.92 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.792 2.037 . . . . 10.0 110.831 -171.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.8 t -76.79 -174.77 3.17 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.336 1.054 . . . . 10.0 112.301 174.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 100.27 160.58 28.25 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 126.92 2.2 . . . . 10.0 113.795 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -151.17 135.26 9.53 Favored Pre-proline 0 CA--C 1.548 0.889 0 C-N-CA 126.044 1.738 . . . . 10.0 109.531 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.18 169.94 37.76 Favored 'Cis proline' 0 CA--C 1.539 0.76 0 CA-C-N 121.15 1.447 . . . . 10.0 112.373 -6.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 123.18 51.65 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 124.581 1.153 . . . . 10.0 111.278 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -70.88 161.57 45.61 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 122.501 2.134 . . . . 10.0 113.333 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 40.2 m-20 -65.66 170.56 5.02 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.826 1.25 . . . . 10.0 111.761 165.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 5.6 p -138.37 122.96 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.219 1.408 . . . . 10.0 111.471 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.0 m -137.36 106.25 5.94 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.818 1.647 . . . . 10.0 110.563 174.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.8 m95 -85.86 153.54 22.17 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 123.953 0.901 . . . . 10.0 113.223 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -142.19 159.0 43.1 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.979 2.112 . . . . 10.0 111.295 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -143.93 117.07 8.93 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 127.072 2.149 . . . . 10.0 110.281 175.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 54.07 18.86 1.85 Allowed 'General case' 0 CA--C 1.554 1.116 0 C-N-CA 126.375 1.87 . . . . 10.0 114.558 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.97 -9.35 46.86 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.422 1.963 . . . . 10.0 115.476 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -89.18 155.13 19.61 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.044 1.422 . . . . 10.0 110.166 171.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 17.6 p -69.34 155.24 40.75 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.801 0.84 . . . . 10.0 112.585 173.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 57.4 t -133.12 105.04 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.332 1.853 . . . . 10.0 108.766 173.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 95.4 mm-40 -72.62 159.59 33.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.498 0.719 . . . . 10.0 111.701 173.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.3 p -70.11 154.9 41.36 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.35 0.66 . . . . 10.0 111.67 166.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -154.15 168.95 24.78 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.404 1.482 . . . . 10.0 111.025 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -57.83 -34.55 69.8 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.792 -1.193 . . . . 10.0 112.658 168.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 72.3 mt -82.79 -15.16 52.77 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.556 1.142 . . . . 10.0 113.9 173.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -134.61 69.41 1.46 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.011 1.724 . . . . 10.0 111.324 -173.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -70.61 144.4 51.18 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.086 1.354 . . . . 10.0 111.666 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.3 mtt -141.14 103.36 4.43 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 126.835 2.054 . . . . 10.0 109.723 -174.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.75 162.03 37.57 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 C-N-CA 124.617 1.167 . . . . 10.0 112.66 -176.683 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 t -133.83 113.91 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.632 1.573 . . . . 10.0 109.698 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 66.8 m -69.04 144.46 54.03 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.47 0.708 . . . . 10.0 111.053 171.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.03 -17.1 56.24 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.487 1.515 . . . . 10.0 114.579 -176.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -74.44 -4.88 39.3 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 126.155 1.782 . . . . 10.0 114.107 173.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 92.17 38.35 5.71 Favored Glycine 0 CA--C 1.533 1.16 0 C-N-CA 125.139 1.352 . . . . 10.0 113.644 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 44.4 tp -125.68 102.54 7.38 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.424 1.489 . . . . 10.0 110.646 -177.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -78.25 145.26 35.56 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.009 0.924 . . . . 10.0 110.926 169.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 32.6 t -134.53 145.52 48.83 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.943 1.297 . . . . 10.0 111.985 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -130.63 120.53 24.1 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.434 2.694 . . . . 10.0 108.115 -178.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.4 152.33 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.605 1.162 . . . . 10.0 111.424 -170.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -125.96 108.84 11.79 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 127.273 2.229 . . . . 10.0 108.892 168.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -65.98 -38.45 88.56 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.323 -0.861 . . . . 10.0 112.715 175.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.2 p -150.28 86.82 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 126.098 1.759 . . . . 10.0 110.043 -178.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.5 p -66.64 139.6 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 O-C-N 121.3 -0.875 . . . . 10.0 111.827 -177.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -119.69 160.82 21.8 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.964 1.705 . . . . 10.0 112.069 176.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.29 -31.62 65.81 Favored 'General case' 0 CA--C 1.548 0.891 0 N-CA-C 113.709 1.003 . . . . 10.0 113.709 -176.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -65.3 -21.13 66.68 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.125 1.37 . . . . 10.0 113.891 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -77.66 -6.16 52.91 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.68 1.192 . . . . 10.0 113.591 178.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.2 147.79 52.82 Favored 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.874 -1.141 . . . . 10.0 112.695 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.76 -172.6 22.49 Favored Glycine 0 CA--C 1.532 1.155 0 C-N-CA 124.767 1.175 . . . . 10.0 114.894 177.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.92 109.83 18.43 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.981 1.712 . . . . 10.0 111.06 175.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -85.15 153.72 22.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.473 1.109 . . . . 10.0 112.213 171.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.17 159.34 42.42 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.172 0.989 . . . . 10.0 112.069 167.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -139.03 104.26 4.99 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.76 1.624 . . . . 10.0 110.827 -178.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.8 t -76.39 129.61 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.316 1.046 . . . . 10.0 109.692 171.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.68 117.91 20.16 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.668 1.987 . . . . 10.0 110.681 178.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -132.11 139.63 48.53 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.299 1.44 . . . . 10.0 112.017 -172.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 26.8 p30 -134.27 -177.98 4.83 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.903 1.281 . . . . 10.0 111.411 167.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -61.29 -11.22 8.91 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.778 1.77 . . . . 10.0 115.778 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.97 -19.78 12.23 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.409 1.484 . . . . 10.0 114.443 -178.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.44 -170.39 43.51 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 116.149 1.22 . . . . 10.0 116.149 178.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -136.8 144.17 43.56 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.968 2.107 . . . . 10.0 111.819 -170.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.68 157.1 47.2 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 126.482 1.913 . . . . 10.0 110.534 166.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -140.12 98.03 3.36 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.64 1.176 . . . . 10.0 110.206 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -75.35 156.97 34.96 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.107 0.963 . . . . 10.0 111.467 177.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 33.0 m -144.87 143.47 30.61 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.058 1.343 . . . . 10.0 111.348 -176.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.5 p -153.95 170.74 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 C-N-CA 126.215 1.806 . . . . 10.0 110.867 173.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 -131.15 146.81 52.48 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.756 1.222 . . . . 10.0 111.88 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.5 tp -131.76 119.41 21.25 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 126.057 1.743 . . . . 10.0 111.018 -178.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -104.35 83.02 2.01 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.79 1.636 . . . . 10.0 110.857 176.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.05 110.89 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 O-C-N 121.531 -0.731 . . . . 10.0 110.692 -179.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 67.4 mt -73.01 97.95 2.42 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.305 1.842 . . . . 10.0 109.87 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.5 147.0 46.78 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.644 1.177 . . . . 10.0 113.661 -173.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -89.25 -26.0 21.42 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 125.932 1.693 . . . . 10.0 113.782 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 . . . . . 0 C--O 1.252 1.236 0 C-N-CA 125.619 1.568 . . . . 10.0 114.619 177.411 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.583 0 N-CA-C 111.928 -0.469 . . . . 10.0 111.928 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.67 158.15 25.34 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.239 1.015 . . . . 10.0 112.961 176.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.67 176.78 10.69 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.235 1.814 . . . . 10.0 111.522 -177.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.91 172.44 45.38 Favored Glycine 0 CA--C 1.542 1.744 0 N-CA-C 117.5 1.76 . . . . 10.0 117.5 -176.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -69.11 159.52 53.56 Favored 'Trans proline' 0 CA--C 1.543 0.963 0 C-N-CA 123.761 2.974 . . . . 10.0 112.943 -173.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -70.23 166.07 29.41 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.144 2.562 . . . . 10.0 112.428 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 21.3 tpp180 -140.77 147.18 38.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.462 1.105 . . . . 10.0 112.436 -174.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -76.8 58.06 1.38 Allowed 'General case' 0 CA--C 1.55 0.977 0 C-N-CA 128.564 2.746 . . . . 10.0 112.409 -177.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.3 mm -60.64 -58.5 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.964 -1.085 . . . . 10.0 112.63 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -154.35 153.34 31.45 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 119.006 0.821 . . . . 10.0 113.172 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 17.8 m -131.05 155.57 81.37 Favored Pre-proline 0 N--CA 1.479 0.997 0 C-N-CA 127.371 2.269 . . . . 10.0 110.382 167.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -74.8 166.14 29.93 Favored 'Trans proline' 0 CA--C 1.542 0.921 0 C-N-CA 122.771 2.314 . . . . 10.0 111.499 168.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -73.05 176.45 5.77 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.446 -0.784 . . . . 10.0 111.194 163.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -59.18 152.83 19.62 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.911 -1.118 . . . . 10.0 112.128 171.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.7 mtp -132.46 157.19 45.24 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 125.526 1.531 . . . . 10.0 111.946 -172.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 76.4 p -145.93 136.79 24.43 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 125.26 1.424 . . . . 10.0 110.856 169.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 24.9 mm -138.4 133.08 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.581 1.552 . . . . 10.0 109.531 -170.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -63.85 131.12 46.8 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.639 1.175 . . . . 10.0 112.302 173.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -51.54 130.59 28.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.515 1.526 . . . . 10.0 113.305 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.4 -10.25 67.13 Favored Glycine 0 CA--C 1.537 1.426 0 C-N-CA 126.185 1.85 . . . . 10.0 115.175 178.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.3 mtp180 -72.3 161.33 30.99 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.037 1.418 . . . . 10.0 113.356 177.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -71.49 148.6 46.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.678 1.191 . . . . 10.0 110.637 156.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.8 t -147.06 154.62 41.39 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.941 1.296 . . . . 10.0 111.019 168.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -145.53 166.18 26.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.747 1.219 . . . . 10.0 112.547 165.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 49.5 mtt -133.07 166.9 21.35 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.471 1.908 . . . . 10.0 111.815 -176.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -134.39 117.65 16.56 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.082 1.753 . . . . 10.0 111.694 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -127.83 99.55 5.58 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.551 1.54 . . . . 10.0 111.358 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -66.41 123.31 19.64 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.862 0.865 . . . . 10.0 110.115 172.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 5.9 p -142.45 102.63 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.311 1.845 . . . . 10.0 110.684 -176.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.7 t -75.68 -177.25 3.63 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.003 0.921 . . . . 10.0 111.855 172.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 117.32 160.3 11.73 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 127.356 2.408 . . . . 10.0 113.319 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -149.47 128.38 6.15 Favored Pre-proline 0 CA--C 1.548 0.871 0 C-N-CA 124.797 1.239 . . . . 10.0 110.414 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -66.86 169.61 47.63 Favored 'Cis proline' 0 CA--C 1.54 0.809 0 CA-C-N 121.06 1.414 . . . . 10.0 112.507 -3.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.18 122.59 55.06 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.616 1.166 . . . . 10.0 111.429 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.57 151.39 64.42 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 122.55 2.167 . . . . 10.0 113.284 -173.098 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -72.99 145.66 46.54 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.337 1.055 . . . . 10.0 109.963 160.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.0 m -129.68 86.37 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.091 1.356 . . . . 10.0 112.103 -165.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 58.4 m -78.5 116.1 18.66 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.866 1.267 . . . . 10.0 111.506 177.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.1 m95 -90.27 155.77 18.76 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.704 1.001 . . . . 10.0 113.704 177.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.34 160.54 41.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.476 2.311 . . . . 10.0 111.495 -177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.9 tp -147.23 119.76 8.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.392 2.277 . . . . 10.0 110.024 174.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 54.9 15.0 1.01 Allowed 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 126.645 1.978 . . . . 10.0 115.145 179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.58 -13.23 35.8 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 126.631 2.063 . . . . 10.0 115.19 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -86.84 159.55 19.04 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 118.971 1.385 . . . . 10.0 110.833 169.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.7 p -73.21 159.15 33.91 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.098 0.959 . . . . 10.0 112.729 174.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 90.5 t -137.12 145.71 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 127.008 2.123 . . . . 10.0 108.775 171.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 80.4 mt-30 -128.1 163.21 25.13 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.295 1.438 . . . . 10.0 111.285 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.5 p -68.35 152.61 45.19 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.657 0.783 . . . . 10.0 112.613 176.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -152.17 168.18 26.16 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.978 1.711 . . . . 10.0 110.641 175.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.45 -35.12 67.53 Favored 'General case' 0 CA--C 1.544 0.741 0 O-C-N 120.906 -1.121 . . . . 10.0 112.76 169.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.0 mt -84.84 -12.99 52.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.608 1.163 . . . . 10.0 113.979 173.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.9 m80 -136.59 71.18 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.633 1.573 . . . . 10.0 111.453 -173.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -71.89 147.45 47.07 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.797 1.239 . . . . 10.0 111.898 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.6 mtt -141.54 107.28 5.11 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 126.846 2.058 . . . . 10.0 109.908 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.0 157.93 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.641 1.176 . . . . 10.0 112.398 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.1 t -133.81 113.93 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.893 1.677 . . . . 10.0 109.928 -177.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 68.7 m -70.38 151.27 45.4 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.954 0.902 . . . . 10.0 112.132 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -57.45 -32.18 66.67 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 125.766 1.627 . . . . 10.0 113.856 -175.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . 0.422 ' HA ' ' HE2' ' A' ' 303' ' ' LYS . 11.3 mmpt? -70.82 -3.39 18.71 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 126.174 1.79 . . . . 10.0 114.425 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.83 49.92 3.91 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 125.006 1.289 . . . . 10.0 112.897 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 65.1 tp -130.72 104.15 7.01 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.455 1.502 . . . . 10.0 110.469 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -83.7 125.9 32.35 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 125.145 1.378 . . . . 10.0 111.229 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.8 m -102.86 142.67 33.58 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.243 1.417 . . . . 10.0 111.739 169.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -130.55 126.07 35.84 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 127.469 2.308 . . . . 10.0 107.884 175.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 44.1 mt -122.1 152.68 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.237 1.415 . . . . 10.0 111.722 -167.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.93 109.98 10.93 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 128.059 2.544 . . . . 10.0 109.064 169.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.33 -38.87 85.59 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.02 -1.05 . . . . 10.0 113.069 177.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.04 88.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 125.723 1.609 . . . . 10.0 110.286 -178.059 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -70.66 141.81 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 O-C-N 121.235 -0.915 . . . . 10.0 112.313 -175.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -126.18 163.21 23.63 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 126.631 1.972 . . . . 10.0 111.958 177.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.1 -31.56 65.4 Favored 'General case' 0 CA--C 1.548 0.875 0 N-CA-C 113.899 1.074 . . . . 10.0 113.899 -177.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.5 m -68.28 -15.91 63.75 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 114.216 1.191 . . . . 10.0 114.216 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -82.83 -5.16 58.84 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.432 1.093 . . . . 10.0 113.308 177.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 150.22 48.84 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.933 -1.104 . . . . 10.0 113.143 178.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.17 -175.19 21.06 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.905 1.241 . . . . 10.0 115.279 174.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.12 98.05 7.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.801 1.64 . . . . 10.0 111.246 175.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -74.5 150.96 39.61 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 123.556 0.742 . . . . 10.0 111.479 167.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.01 161.9 38.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 123.966 0.906 . . . . 10.0 111.997 168.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 43.1 t -137.31 139.01 40.6 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.737 1.615 . . . . 10.0 110.487 176.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.9 t -117.17 104.7 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.289 1.835 . . . . 10.0 108.862 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -89.64 118.06 28.98 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 126.283 1.833 . . . . 10.0 110.881 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -129.84 132.61 46.53 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.085 1.354 . . . . 10.0 112.598 -176.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -129.44 -179.02 4.92 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.834 1.253 . . . . 10.0 111.513 166.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -61.64 -12.28 15.36 Favored 'General case' 0 N--CA 1.482 1.129 0 N-CA-C 115.726 1.75 . . . . 10.0 115.726 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.18 -20.03 12.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 125.383 1.473 . . . . 10.0 114.424 -178.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 172.92 -169.26 42.42 Favored Glycine 0 CA--C 1.534 1.232 0 N-CA-C 116.101 1.2 . . . . 10.0 116.101 178.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -134.19 143.8 48.09 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 126.939 2.095 . . . . 10.0 111.909 -171.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.25 165.92 25.0 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.281 1.833 . . . . 10.0 111.076 168.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 19.0 m -141.57 141.59 33.5 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.203 1.001 . . . . 10.0 111.569 -173.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -134.47 150.93 50.87 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.797 1.639 . . . . 10.0 110.556 -178.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -146.4 146.81 30.76 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 124.454 1.102 . . . . 10.0 111.786 -169.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.7 p -152.97 146.68 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 125.251 1.42 . . . . 10.0 112.026 170.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 9.2 tp-100 -100.14 127.47 46.39 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 125.667 1.587 . . . . 10.0 110.245 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -121.18 105.56 10.7 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.542 1.537 . . . . 10.0 111.261 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -93.62 85.79 4.99 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.268 1.427 . . . . 10.0 111.319 175.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.6 t -66.14 115.35 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 121.301 -0.874 . . . . 10.0 110.826 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.3 mt -78.91 100.0 7.04 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.437 1.895 . . . . 10.0 110.356 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.83 147.65 37.51 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 123.947 0.899 . . . . 10.0 112.821 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.56 -18.77 59.66 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 114.736 1.384 . . . . 10.0 114.736 -178.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.254 1.322 0 C-N-CA 126.527 1.931 . . . . 10.0 113.761 -178.844 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.536 0 N-CA-C 111.756 -0.538 . . . . 10.0 111.756 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.22 164.21 16.25 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 124.472 1.109 . . . . 10.0 113.036 176.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.9 ptt? -145.95 -178.89 6.35 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.025 1.73 . . . . 10.0 111.747 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.03 168.98 41.16 Favored Glycine 0 CA--C 1.54 1.63 0 N-CA-C 116.963 1.545 . . . . 10.0 116.963 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.98 161.66 45.35 Favored 'Trans proline' 0 CA--C 1.543 0.935 0 C-N-CA 123.751 2.967 . . . . 10.0 112.943 -174.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -65.39 133.59 35.44 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.351 2.701 . . . . 10.0 111.324 171.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -130.64 134.66 47.14 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 126.698 1.999 . . . . 10.0 110.654 -176.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -48.87 120.39 3.82 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 127.09 2.156 . . . . 10.0 112.58 173.587 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 49.7 mm -113.85 -59.29 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.232 1.013 . . . . 10.0 110.413 171.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.5 tt0 -150.47 136.04 18.12 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.013 0.925 . . . . 10.0 111.531 177.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 21.9 m -117.88 149.75 45.89 Favored Pre-proline 0 N--CA 1.474 0.749 0 C-N-CA 125.367 1.467 . . . . 10.0 109.579 167.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -72.78 155.96 53.38 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 122.485 2.123 . . . . 10.0 111.92 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -69.98 168.35 15.58 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.74 0.816 . . . . 10.0 111.091 166.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.21 152.19 21.22 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 121.211 -0.931 . . . . 10.0 112.334 173.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 86.1 mtp -127.05 152.44 47.26 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.222 1.409 . . . . 10.0 111.87 -167.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 p -144.15 104.94 4.18 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.265 1.426 . . . . 10.0 111.094 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 39.9 mm -122.6 130.95 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 125.401 1.481 . . . . 10.0 110.405 -166.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -65.15 129.97 41.64 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.51 1.124 . . . . 10.0 112.518 175.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -52.57 123.5 11.27 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 125.656 1.582 . . . . 10.0 113.132 -176.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 101.45 -10.25 57.76 Favored Glycine 0 CA--C 1.534 1.269 0 C-N-CA 125.975 1.75 . . . . 10.0 115.551 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -70.77 160.64 32.33 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-N 119.248 1.524 . . . . 10.0 113.086 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -73.43 147.73 43.93 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.663 1.185 . . . . 10.0 110.571 159.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 7.1 t -153.4 168.26 26.69 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.075 0.95 . . . . 10.0 112.607 169.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.1 ptm85 -145.61 166.68 25.05 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.95 1.7 . . . . 10.0 112.82 167.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.3 mtt -121.06 159.82 24.9 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 126.964 2.106 . . . . 10.0 111.241 173.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -140.27 93.21 2.6 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.076 1.35 . . . . 10.0 111.961 -166.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -114.07 106.9 14.94 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.733 1.613 . . . . 10.0 111.651 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -85.88 129.73 34.75 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.027 -1.045 . . . . 10.0 111.513 176.521 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.6 p -132.63 153.68 38.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 126.072 1.749 . . . . 10.0 110.351 170.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 58.4 m -127.24 126.67 43.13 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.766 1.226 . . . . 10.0 110.889 172.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.1 168.01 40.66 Favored Glycine 0 CA--C 1.534 1.28 0 C-N-CA 126.615 2.055 . . . . 10.0 111.236 175.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.9 tp -146.56 131.39 8.9 Favored Pre-proline 0 CA--C 1.546 0.825 0 C-N-CA 124.474 1.11 . . . . 10.0 110.73 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.13 170.59 45.23 Favored 'Cis proline' 0 CA--C 1.541 0.825 0 CA-C-N 120.414 1.184 . . . . 10.0 112.665 -3.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.13 122.05 45.59 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 124.662 1.185 . . . . 10.0 111.29 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -73.82 164.31 34.98 Favored 'Trans proline' 0 CA--C 1.539 0.765 0 C-N-CA 122.572 2.181 . . . . 10.0 113.845 -170.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -61.58 165.77 4.7 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.114 1.766 . . . . 10.0 111.961 165.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.2 p -139.23 113.6 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.097 1.359 . . . . 10.0 111.455 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 75.4 m -128.92 147.61 50.85 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.945 1.698 . . . . 10.0 110.821 173.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -128.44 153.29 47.27 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.355 1.062 . . . . 10.0 113.545 -174.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -143.3 162.65 35.13 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 127.324 2.25 . . . . 10.0 111.227 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.5 tp -147.86 123.59 10.54 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 126.905 2.082 . . . . 10.0 110.012 176.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 55.02 10.15 0.37 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.739 2.016 . . . . 10.0 116.049 176.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.01 -5.09 25.58 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.08 1.8 . . . . 10.0 115.607 -177.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -105.58 161.65 14.18 Favored 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 119.176 1.488 . . . . 10.0 111.922 171.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.9 p -70.08 154.94 41.31 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.427 1.091 . . . . 10.0 112.791 176.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.33 101.76 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.791 2.036 . . . . 10.0 108.401 170.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -74.3 157.58 35.54 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.529 0.731 . . . . 10.0 111.319 172.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 30.2 p -70.61 149.5 47.0 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.691 0.796 . . . . 10.0 112.388 172.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -152.29 179.54 8.45 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.419 1.487 . . . . 10.0 111.063 167.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -57.24 -28.66 63.12 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.425 1.269 . . . . 10.0 114.425 -177.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 48.7 mt -92.41 -11.82 33.83 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.272 1.429 . . . . 10.0 113.391 176.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -134.25 70.91 1.45 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.397 1.879 . . . . 10.0 111.153 -174.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -71.87 143.32 49.44 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.171 1.388 . . . . 10.0 111.052 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -138.9 106.47 5.58 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 126.318 1.847 . . . . 10.0 110.455 -172.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.92 171.79 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.315 1.446 . . . . 10.0 112.229 -177.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -135.55 134.23 51.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.807 1.643 . . . . 10.0 109.275 174.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 24.9 p -67.95 172.14 5.89 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.838 1.051 . . . . 10.0 113.838 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -59.37 -20.3 53.68 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.237 1.415 . . . . 10.0 113.436 170.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -117.43 5.64 12.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.278 1.831 . . . . 10.0 114.243 -171.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.78 15.71 36.02 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 124.623 1.106 . . . . 10.0 115.777 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 28.4 tp -80.13 98.0 7.11 Favored 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 118.864 1.332 . . . . 10.0 110.3 171.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -63.5 132.24 50.68 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.926 0.89 . . . . 10.0 110.002 166.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -129.71 126.26 37.84 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 126.33 1.852 . . . . 10.0 111.167 -171.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -126.21 123.35 37.99 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 127.043 2.137 . . . . 10.0 108.027 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 50.9 mt -114.54 153.55 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 125.177 1.391 . . . . 10.0 110.968 -171.275 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -127.78 109.39 11.59 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 127.353 2.261 . . . . 10.0 108.897 170.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -68.14 -41.66 81.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.188 -0.945 . . . . 10.0 112.606 174.587 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.83 90.2 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.764 1.625 . . . . 10.0 110.388 -176.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -69.89 151.91 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 O-C-N 121.31 -0.869 . . . . 10.0 112.898 -175.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 86.7 mmt-85 -132.31 159.83 38.0 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 127.019 2.128 . . . . 10.0 111.836 174.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.84 -30.83 64.17 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.386 1.074 . . . . 10.0 113.721 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.9 t -62.99 -23.46 67.46 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.966 1.306 . . . . 10.0 113.646 174.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -78.6 -8.46 58.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.556 1.142 . . . . 10.0 113.64 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 152.58 42.84 Favored 'General case' 0 CA--C 1.547 0.839 0 CA-C-N 119.543 1.065 . . . . 10.0 113.406 -179.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.27 -170.88 22.42 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.928 1.252 . . . . 10.0 114.891 176.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.62 97.67 7.99 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.939 1.696 . . . . 10.0 111.454 176.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -71.55 150.41 44.78 Favored 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 123.948 0.899 . . . . 10.0 111.793 168.271 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.31 158.08 44.36 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.799 0.84 . . . . 10.0 112.406 168.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.8 t -130.62 141.9 50.44 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 127.162 2.185 . . . . 10.0 109.601 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 28.6 t -124.66 131.74 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.255 1.422 . . . . 10.0 109.489 177.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.43 124.03 40.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.189 1.795 . . . . 10.0 110.705 -177.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 1.9 mppt? -129.04 135.94 49.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.241 1.416 . . . . 10.0 111.602 -176.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -134.77 179.39 6.33 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.269 1.028 . . . . 10.0 111.534 163.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 14.9 ptp180 -62.62 -11.08 14.67 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 115.551 1.685 . . . . 10.0 115.551 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.17 -18.6 13.96 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.507 1.523 . . . . 10.0 114.167 178.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 169.04 -171.1 42.85 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-N 119.854 1.206 . . . . 10.0 115.849 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -135.26 147.09 49.16 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.586 1.955 . . . . 10.0 111.835 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.94 159.08 42.99 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.882 1.673 . . . . 10.0 111.861 170.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 86.9 m -138.75 138.26 37.48 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.76 1.624 . . . . 10.0 110.49 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -131.69 156.06 46.55 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.002 1.721 . . . . 10.0 111.25 -175.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -143.93 147.03 33.4 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.427 1.091 . . . . 10.0 112.392 -170.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 10.1 p -150.98 158.93 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 C-N-CA 126.201 1.8 . . . . 10.0 111.277 168.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.6 tt0 -109.16 135.1 50.83 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.848 1.259 . . . . 10.0 111.538 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.4 tp -119.09 110.16 16.75 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.349 1.86 . . . . 10.0 110.639 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -96.5 83.98 3.61 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 125.825 1.65 . . . . 10.0 111.017 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -65.02 112.28 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 121.405 -0.809 . . . . 10.0 110.649 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.0 mt -74.11 101.37 3.9 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.169 1.788 . . . . 10.0 109.862 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.61 153.61 23.27 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.436 1.094 . . . . 10.0 113.895 -174.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -71.65 -26.39 62.52 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 126.086 1.754 . . . . 10.0 113.444 179.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 C--O 1.254 1.301 0 C-N-CA 126.811 2.044 . . . . 10.0 113.933 -179.002 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.505 0 N-CA-C 111.395 -0.682 . . . . 10.0 111.395 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.81 165.81 12.21 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.407 1.083 . . . . 10.0 112.92 175.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 22.9 ptt? -145.09 -179.42 6.61 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.943 1.697 . . . . 10.0 111.765 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.55 169.9 42.15 Favored Glycine 0 CA--C 1.54 1.64 0 N-CA-C 116.881 1.512 . . . . 10.0 116.881 178.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -69.03 159.97 51.8 Favored 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 123.614 2.876 . . . . 10.0 112.511 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -67.91 158.85 55.49 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 122.631 2.22 . . . . 10.0 111.794 171.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 41.6 ttt-85 -142.31 150.69 41.14 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.008 1.323 . . . . 10.0 111.538 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 8.9 m-30 -63.84 133.92 54.27 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.073 0.949 . . . . 10.0 110.161 162.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 32.0 mm -130.83 -59.64 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.095 1.358 . . . . 10.0 109.547 173.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -152.51 141.67 21.38 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.739 1.216 . . . . 10.0 111.21 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 26.6 m -127.5 152.77 77.03 Favored Pre-proline 0 N--CA 1.476 0.853 0 C-N-CA 125.736 1.614 . . . . 10.0 110.522 170.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.74 152.8 59.04 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 122.676 2.251 . . . . 10.0 111.553 171.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -72.76 174.17 8.04 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 123.904 0.882 . . . . 10.0 111.833 164.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -60.45 152.99 24.23 Favored 'General case' 0 CA--C 1.547 0.829 0 O-C-N 121.178 -0.951 . . . . 10.0 112.303 175.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.5 mtp -131.02 158.24 40.86 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 125.121 1.368 . . . . 10.0 112.292 -171.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 46.9 p -143.36 120.43 11.41 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.537 1.535 . . . . 10.0 110.49 172.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.5 mm -129.91 134.46 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.475 1.51 . . . . 10.0 109.796 -169.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.54 130.02 43.22 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.275 1.43 . . . . 10.0 112.39 175.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -51.47 127.21 19.41 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.227 1.411 . . . . 10.0 112.618 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.73 -10.61 60.81 Favored Glycine 0 CA--C 1.537 1.412 0 C-N-CA 126.125 1.821 . . . . 10.0 115.196 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -74.65 160.78 30.37 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 119.28 1.54 . . . . 10.0 113.302 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -74.61 142.65 44.59 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.63 1.172 . . . . 10.0 110.044 155.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.7 p -150.75 170.47 19.15 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 123.575 0.75 . . . . 10.0 112.254 163.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -146.61 162.77 37.72 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.156 1.382 . . . . 10.0 112.669 177.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -137.2 139.73 41.27 Favored 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 127.508 2.323 . . . . 10.0 109.151 176.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -134.22 124.05 25.33 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.048 0.939 . . . . 10.0 111.453 -171.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -123.82 110.11 14.48 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 126.517 1.927 . . . . 10.0 110.678 -168.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -72.14 119.63 16.6 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.6 0.76 . . . . 10.0 110.002 173.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.9 p -137.94 110.18 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 126.762 2.025 . . . . 10.0 110.3 -175.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 5.6 t -75.81 -170.88 1.44 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.378 1.071 . . . . 10.0 112.441 176.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 103.64 164.25 25.23 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 126.886 2.184 . . . . 10.0 114.039 176.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.8 tp -150.8 133.53 8.46 Favored Pre-proline 0 CA--C 1.548 0.895 0 C-N-CA 125.433 1.493 . . . . 10.0 110.335 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -67.02 168.79 51.76 Favored 'Cis proline' 0 CA--C 1.539 0.729 0 CA-C-N 120.783 1.315 . . . . 10.0 112.528 -3.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.03 124.76 60.78 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.418 1.087 . . . . 10.0 110.846 177.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 155.35 64.46 Favored 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 122.434 2.089 . . . . 10.0 113.375 -170.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -72.8 114.24 10.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.458 1.503 . . . . 10.0 109.327 161.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 48.1 t -106.53 131.34 56.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.682 1.193 . . . . 10.0 111.289 -175.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.5 m -129.44 156.06 44.7 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 126.073 1.749 . . . . 10.0 111.405 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 63.4 m95 -124.88 156.4 37.97 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.85 1.26 . . . . 10.0 113.194 -176.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -144.4 159.78 42.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 127.119 2.168 . . . . 10.0 111.098 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.8 tp -145.74 119.21 9.05 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 126.887 2.075 . . . . 10.0 110.118 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 54.47 15.69 1.09 Allowed 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.449 1.9 . . . . 10.0 115.019 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.55 -11.87 39.16 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.663 2.078 . . . . 10.0 115.254 -177.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -87.43 158.03 19.08 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.948 1.374 . . . . 10.0 111.125 171.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.1 p -71.54 153.37 42.22 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.395 1.078 . . . . 10.0 112.674 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 53.9 t -132.76 100.85 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.367 1.867 . . . . 10.0 108.715 172.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 59.2 mt-30 -73.23 160.77 31.4 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.554 0.742 . . . . 10.0 111.359 171.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.2 p -68.49 155.67 39.46 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.383 0.673 . . . . 10.0 112.012 168.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -153.07 168.91 24.3 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.484 1.513 . . . . 10.0 110.917 177.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -56.9 -35.37 68.89 Favored 'General case' 0 CA--C 1.545 0.775 0 O-C-N 120.942 -1.098 . . . . 10.0 112.779 169.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.7 mt -84.48 -14.19 49.86 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.48 1.112 . . . . 10.0 113.9 173.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -133.62 70.27 1.46 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.837 1.655 . . . . 10.0 111.264 -174.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -71.29 144.09 50.11 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.834 1.254 . . . . 10.0 111.518 -176.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -141.54 106.06 4.86 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.654 1.982 . . . . 10.0 109.811 -175.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.01 164.99 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.643 1.177 . . . . 10.0 112.37 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 62.3 t -131.58 116.05 30.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 125.992 1.717 . . . . 10.0 109.63 178.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -72.54 143.51 48.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.369 0.667 . . . . 10.0 111.105 170.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.18 -20.33 40.21 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 115.308 1.596 . . . . 10.0 115.308 -174.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -75.45 -5.18 43.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.574 1.55 . . . . 10.0 113.867 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 93.64 50.75 2.28 Favored Glycine 0 CA--C 1.531 1.064 0 C-N-CA 125.436 1.493 . . . . 10.0 112.855 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 17.9 tp -136.46 106.17 6.2 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.332 1.453 . . . . 10.0 110.511 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -76.51 144.41 39.79 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.582 0.353 . . . . 10.0 110.864 168.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.5 m -130.62 114.76 15.82 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 126.427 1.891 . . . . 10.0 110.603 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -108.59 121.06 44.2 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 127.656 2.383 . . . . 10.0 108.715 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 71.3 mt -121.57 152.17 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.514 1.126 . . . . 10.0 111.304 -168.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.74 110.73 12.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.532 2.333 . . . . 10.0 109.43 171.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -66.11 -39.95 90.33 Favored 'General case' 0 N--CA 1.474 0.749 0 O-C-N 121.285 -0.884 . . . . 10.0 113.038 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -151.22 90.22 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.747 1.619 . . . . 10.0 110.277 -178.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.3 p -69.98 140.96 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 O-C-N 121.287 -0.883 . . . . 10.0 111.995 -177.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.3 mmt180 -124.22 161.81 24.98 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.421 1.888 . . . . 10.0 112.043 177.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.74 -33.89 64.68 Favored 'General case' 0 CA--C 1.546 0.82 0 N-CA-C 113.434 0.902 . . . . 10.0 113.434 -178.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.4 m -65.24 -17.68 64.69 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.355 1.462 . . . . 10.0 114.512 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -82.53 -5.47 58.76 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.685 1.194 . . . . 10.0 113.228 177.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.98 151.98 45.59 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.084 -1.01 . . . . 10.0 113.067 178.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 134.78 -171.27 22.44 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.746 1.165 . . . . 10.0 114.801 175.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.91 103.87 14.35 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.972 1.709 . . . . 10.0 111.055 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -78.15 152.02 32.98 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.009 0.924 . . . . 10.0 111.839 169.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -139.04 156.34 47.27 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.068 0.947 . . . . 10.0 111.687 168.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.0 t -134.06 136.74 44.2 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.525 1.93 . . . . 10.0 109.472 -175.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 67.8 t -128.25 126.53 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.488 1.515 . . . . 10.0 109.143 -178.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.83 117.4 23.29 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.258 1.823 . . . . 10.0 110.77 -174.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 23.0 mtpp -124.49 133.71 53.26 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.482 1.513 . . . . 10.0 111.536 -174.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 14.4 p30 -131.43 178.81 6.44 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.145 0.978 . . . . 10.0 111.7 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -63.57 -10.04 16.37 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 115.636 1.717 . . . . 10.0 115.636 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.12 -20.33 12.73 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.645 1.578 . . . . 10.0 114.246 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.05 -169.2 42.21 Favored Glycine 0 CA--C 1.535 1.291 0 CA-C-N 119.788 1.176 . . . . 10.0 115.769 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -138.54 147.09 42.69 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.357 1.863 . . . . 10.0 112.013 -173.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.66 153.61 50.86 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.033 1.733 . . . . 10.0 111.242 169.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.7 m -136.67 140.07 42.46 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.566 1.546 . . . . 10.0 110.646 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -133.55 159.28 40.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.966 1.706 . . . . 10.0 111.247 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 27.6 m -143.43 144.14 31.9 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 124.949 1.3 . . . . 10.0 111.341 -174.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.39 161.4 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.938 1.695 . . . . 10.0 110.563 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.8 tt0 -123.72 138.44 54.52 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 124.484 1.114 . . . . 10.0 111.196 176.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.3 tp -125.24 108.94 12.25 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.035 1.734 . . . . 10.0 110.711 -178.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -93.8 83.15 4.36 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.432 1.493 . . . . 10.0 110.682 174.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.34 114.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 O-C-N 121.452 -0.78 . . . . 10.0 110.418 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.9 mt -75.25 94.09 2.95 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.193 1.797 . . . . 10.0 110.015 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.99 151.54 34.81 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.43 1.092 . . . . 10.0 112.98 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -65.45 -52.21 54.73 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.127 1.371 . . . . 10.0 112.228 177.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.253 1.284 0 C-N-CA 125.985 1.714 . . . . 10.0 113.079 177.14 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 N-CA-C 111.855 -0.498 . . . . 10.0 111.855 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -62.33 107.33 0.89 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.343 1.457 . . . . 10.0 112.733 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.97 162.6 18.94 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 125.169 1.387 . . . . 10.0 112.785 176.082 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 179.86 170.85 42.07 Favored Glycine 0 CA--C 1.542 1.772 0 O-C-N 121.296 -0.877 . . . . 10.0 115.244 -176.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.14 162.82 41.29 Favored 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 123.816 3.011 . . . . 10.0 113.528 -170.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -65.71 139.09 56.38 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.02 2.48 . . . . 10.0 111.006 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 53.1 ttt85 -128.78 151.64 49.35 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.457 1.503 . . . . 10.0 112.617 -174.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -76.44 88.72 3.21 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.041 2.137 . . . . 10.0 111.708 177.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 28.2 mm -82.92 -58.78 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 O-C-N 121.605 -0.684 . . . . 10.0 110.264 171.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 24.8 tt0 -154.29 146.62 23.89 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.735 1.214 . . . . 10.0 111.776 175.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.79 152.29 74.86 Favored Pre-proline 0 N--CA 1.477 0.881 0 C-N-CA 126.452 1.901 . . . . 10.0 110.004 169.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.83 157.45 35.12 Favored 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 122.567 2.178 . . . . 10.0 112.247 -178.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -73.88 168.15 20.02 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.833 0.853 . . . . 10.0 111.326 166.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -60.14 158.14 11.85 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 121.419 -0.8 . . . . 10.0 112.801 176.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -128.47 152.75 47.88 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.714 1.606 . . . . 10.0 111.742 -171.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 39.5 p -141.77 116.85 9.98 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 125.385 1.474 . . . . 10.0 110.416 170.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.9 mm -129.3 129.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.29 1.436 . . . . 10.0 109.995 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -60.66 127.17 30.35 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.173 1.389 . . . . 10.0 112.12 173.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -53.22 134.38 39.2 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.202 1.401 . . . . 10.0 113.161 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.85 -12.02 67.55 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.346 1.927 . . . . 10.0 114.79 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -74.24 161.56 29.81 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 118.972 1.386 . . . . 10.0 113.268 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -75.9 141.16 42.4 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.885 1.274 . . . . 10.0 110.276 156.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.79 172.03 15.29 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.678 0.791 . . . . 10.0 112.065 161.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.3 ptm180 -152.43 170.21 20.68 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.145 1.378 . . . . 10.0 112.923 174.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.9 mtt -121.8 164.7 17.03 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 126.587 1.955 . . . . 10.0 112.526 -177.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -138.23 103.42 4.92 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 126.353 1.861 . . . . 10.0 111.738 -178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -115.37 109.61 18.15 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.5 1.52 . . . . 10.0 111.178 179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -80.03 74.72 6.79 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 121.302 -0.874 . . . . 10.0 111.496 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 7.4 p -79.84 128.14 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.913 1.285 . . . . 10.0 109.945 163.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 68.6 m -135.28 115.35 13.19 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.787 1.235 . . . . 10.0 111.343 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -158.41 169.85 34.99 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 126.695 2.093 . . . . 10.0 111.55 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 21.8 tp -142.14 120.04 7.47 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.504 1.122 . . . . 10.0 110.449 -177.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -68.05 167.54 63.18 Favored 'Cis proline' 0 CA--C 1.54 0.79 0 CA-C-N 121.018 1.399 . . . . 10.0 112.906 0.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 124.39 62.23 Favored Pre-proline 0 CA--C 1.549 0.908 0 C-N-CA 124.791 1.236 . . . . 10.0 111.189 179.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.49 151.33 59.02 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.41 2.073 . . . . 10.0 113.82 -169.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -69.94 130.45 42.26 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.611 1.564 . . . . 10.0 109.543 159.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.3 m -124.54 134.74 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.891 1.276 . . . . 10.0 112.253 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 56.6 m -136.47 114.56 11.48 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.673 1.589 . . . . 10.0 111.418 -173.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -87.44 151.98 22.61 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 114.016 1.117 . . . . 10.0 114.016 -178.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -141.61 160.57 39.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.975 2.51 . . . . 10.0 111.017 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.2 tp -146.97 120.92 9.34 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.541 2.337 . . . . 10.0 109.833 176.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 54.93 14.71 0.97 Allowed 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.494 1.918 . . . . 10.0 115.341 178.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.28 -7.31 34.76 Favored Glycine 0 CA--C 1.539 1.582 0 C-N-CA 126.351 1.929 . . . . 10.0 115.487 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -99.55 159.75 14.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.587 1.555 . . . . 10.0 110.921 171.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.9 p -71.69 158.99 35.17 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.12 0.968 . . . . 10.0 112.788 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 39.0 t -135.71 102.47 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.984 1.714 . . . . 10.0 109.354 173.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.9 mt-30 -70.18 155.21 40.96 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.239 0.615 . . . . 10.0 111.251 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 67.6 p -69.63 160.23 31.96 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 123.562 0.745 . . . . 10.0 112.164 170.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -152.66 169.66 22.16 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.383 1.473 . . . . 10.0 111.024 178.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -56.9 -35.01 68.47 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 120.867 -1.146 . . . . 10.0 112.749 168.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 77.1 mt -82.65 -14.08 55.33 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.506 1.122 . . . . 10.0 113.889 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -135.25 69.53 1.44 Allowed 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.782 1.633 . . . . 10.0 111.501 -173.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 77.9 mttt -71.34 134.22 46.56 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.037 1.335 . . . . 10.0 110.547 -179.008 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 60.4 mtt -131.75 101.04 5.3 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 126.22 1.808 . . . . 10.0 109.524 -174.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.19 159.15 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 124.839 1.256 . . . . 10.0 112.562 -170.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.53 167.9 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 126.007 1.723 . . . . 10.0 111.992 -177.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 34.2 t -131.14 147.39 52.6 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 125.545 1.538 . . . . 10.0 112.128 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -57.82 -20.37 35.44 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.831 1.652 . . . . 10.0 113.87 168.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -78.0 -1.36 31.74 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.788 1.635 . . . . 10.0 114.355 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 79.87 60.94 2.34 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 124.677 1.132 . . . . 10.0 111.935 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 42.9 tp -150.97 148.53 28.5 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.96 1.704 . . . . 10.0 110.862 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -132.84 129.24 38.21 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.897 2.079 . . . . 10.0 110.097 174.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.1 m -108.81 147.1 32.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.475 1.51 . . . . 10.0 112.146 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.91 108.57 9.48 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 126.623 1.969 . . . . 10.0 108.333 171.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -89.89 151.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 125.268 1.427 . . . . 10.0 110.329 -178.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -130.61 99.69 5.06 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.94 2.096 . . . . 10.0 108.38 167.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -62.4 -38.4 89.49 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 113.225 0.824 . . . . 10.0 113.225 -176.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.8 p -149.65 87.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 125.897 1.679 . . . . 10.0 110.133 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.1 p -70.07 139.53 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 121.347 -0.846 . . . . 10.0 112.029 -176.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 7.4 mmm180 -128.42 161.68 28.92 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.466 1.907 . . . . 10.0 111.26 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -52.21 -35.95 50.78 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 114.195 1.183 . . . . 10.0 114.195 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 28.2 m -64.7 -17.72 64.36 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.242 1.417 . . . . 10.0 114.673 176.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -82.52 -5.92 59.02 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.74 1.216 . . . . 10.0 113.473 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 151.01 47.6 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.988 -1.07 . . . . 10.0 113.187 179.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.49 -172.63 22.4 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.872 1.225 . . . . 10.0 115.069 175.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.72 102.54 13.07 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.075 1.75 . . . . 10.0 111.538 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -79.67 149.02 31.37 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 124.291 1.037 . . . . 10.0 111.932 171.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.9 159.26 43.18 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.906 0.882 . . . . 10.0 112.271 170.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 49.8 t -137.68 118.2 13.87 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 125.139 1.375 . . . . 10.0 111.391 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 42.3 t -87.75 124.85 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 125.169 1.388 . . . . 10.0 109.268 172.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -117.65 128.16 54.65 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.456 1.903 . . . . 10.0 111.075 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.0 mtmt -133.83 130.12 37.47 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 126.116 1.767 . . . . 10.0 112.159 -167.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -136.4 -179.56 5.75 Favored 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 118.879 0.763 . . . . 10.0 112.305 162.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -59.33 -14.68 12.48 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 115.823 1.786 . . . . 10.0 115.823 -177.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.6 -12.28 15.0 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.452 1.501 . . . . 10.0 114.357 -178.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 162.98 -172.39 38.99 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-N 119.443 1.02 . . . . 10.0 115.457 177.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -134.6 147.76 50.28 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.239 1.816 . . . . 10.0 111.57 -173.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.08 163.26 30.74 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.537 1.935 . . . . 10.0 110.785 169.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 96.4 m -144.29 124.28 13.57 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.514 1.126 . . . . 10.0 110.649 177.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -113.54 155.5 25.27 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.523 1.529 . . . . 10.0 111.17 -176.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.5 m -141.77 148.51 39.05 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.621 1.168 . . . . 10.0 112.41 -171.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.79 171.01 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 127.024 2.13 . . . . 10.0 110.603 168.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -128.78 140.63 51.62 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.924 1.29 . . . . 10.0 111.12 172.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.3 tp -125.41 111.81 15.56 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.4 1.88 . . . . 10.0 110.642 -178.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -97.38 85.85 3.75 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.8 1.64 . . . . 10.0 110.864 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.5 t -67.08 112.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.364 -0.835 . . . . 10.0 110.599 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.51 94.16 3.66 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 126.037 1.735 . . . . 10.0 110.1 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.43 147.87 39.45 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 124.519 1.127 . . . . 10.0 112.764 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -72.55 -47.85 44.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.601 0.761 . . . . 10.0 112.387 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 C--O 1.254 1.305 0 C-N-CA 126.087 1.755 . . . . 10.0 113.622 -179.798 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.55 0 N-CA-C 111.888 -0.485 . . . . 10.0 111.888 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.49 163.96 14.89 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.403 1.081 . . . . 10.0 113.014 175.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.25 171.75 13.88 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 126.278 1.831 . . . . 10.0 111.21 179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.44 175.86 47.66 Favored Glycine 0 CA--C 1.541 1.69 0 N-CA-C 116.932 1.533 . . . . 10.0 116.932 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.66 162.97 38.84 Favored 'Trans proline' 0 CA--C 1.544 0.991 0 C-N-CA 123.756 2.97 . . . . 10.0 113.31 -172.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -69.73 168.26 22.02 Favored 'Trans proline' 0 CA--C 1.541 0.867 0 C-N-CA 123.249 2.632 . . . . 10.0 112.361 171.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 58.2 ttp85 -134.44 156.42 48.6 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.322 1.449 . . . . 10.0 112.22 -174.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -93.94 64.6 3.4 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 126.816 2.047 . . . . 10.0 111.086 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.48 -66.08 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.095 -1.003 . . . . 10.0 112.679 -170.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -155.24 165.03 37.94 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.156 0.799 . . . . 10.0 113.156 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.0 m -132.92 161.99 60.32 Favored Pre-proline 0 N--CA 1.476 0.829 0 C-N-CA 127.871 2.468 . . . . 10.0 110.492 170.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.67 164.02 32.86 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.832 2.355 . . . . 10.0 111.228 164.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -72.59 169.43 16.55 Favored 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.251 -0.906 . . . . 10.0 112.523 169.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.31 148.79 40.09 Favored 'General case' 0 CA--C 1.546 0.789 0 O-C-N 121.346 -0.846 . . . . 10.0 112.652 173.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 75.8 mtp -130.81 154.07 48.42 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.882 1.273 . . . . 10.0 112.48 -170.117 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 64.6 m -140.48 101.03 4.01 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.302 1.841 . . . . 10.0 110.107 -176.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 37.6 mm -117.8 134.31 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 124.528 1.131 . . . . 10.0 111.292 -166.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -64.11 130.06 42.46 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.816 1.246 . . . . 10.0 112.445 173.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -53.24 129.8 32.64 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.112 1.365 . . . . 10.0 112.925 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.74 -11.5 62.73 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 126.305 1.907 . . . . 10.0 115.041 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -75.72 161.18 29.28 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.001 1.401 . . . . 10.0 113.276 177.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 65.5 t80 -70.9 149.22 46.96 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.665 1.186 . . . . 10.0 110.71 157.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 10.7 t -150.39 160.43 43.75 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.755 1.222 . . . . 10.0 111.903 168.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 -151.65 167.41 28.23 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.342 1.457 . . . . 10.0 112.883 167.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.1 mtt -132.91 167.03 20.98 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 126.646 1.978 . . . . 10.0 112.119 -176.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -134.55 108.35 8.03 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.258 1.823 . . . . 10.0 111.775 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -117.67 112.17 20.14 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.448 1.499 . . . . 10.0 111.42 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -71.96 108.5 5.24 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.4 1.08 . . . . 10.0 110.31 174.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 18.0 t -117.59 149.32 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.684 1.594 . . . . 10.0 109.819 177.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.4 t -148.15 -177.58 5.82 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.254 1.422 . . . . 10.0 111.112 175.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 122.77 162.14 11.44 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 127.65 2.548 . . . . 10.0 111.795 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.1 tp -144.61 122.73 6.68 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-O 118.083 -0.96 . . . . 10.0 110.571 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -66.56 167.89 53.29 Favored 'Cis proline' 0 CA--C 1.539 0.765 0 CA-C-N 120.689 1.282 . . . . 10.0 112.627 -1.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -57.24 126.02 72.72 Favored Pre-proline 0 CA--C 1.549 0.935 0 C-N-CA 124.454 1.102 . . . . 10.0 111.291 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.51 149.9 62.79 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.406 2.071 . . . . 10.0 113.321 -173.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -74.66 151.05 39.33 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.61 1.164 . . . . 10.0 109.918 159.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 59.1 t -131.56 138.46 52.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.963 0.905 . . . . 10.0 112.125 -169.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 63.2 m -132.73 115.27 15.14 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 126.767 2.027 . . . . 10.0 110.61 177.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 53.4 m95 -86.44 158.83 19.5 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 122.001 0.905 . . . . 10.0 112.85 176.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -144.69 159.88 42.11 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 127.063 2.145 . . . . 10.0 111.235 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 52.6 tp -145.65 118.12 8.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 127.146 2.178 . . . . 10.0 110.062 175.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.1 m-20 54.87 14.95 0.99 Allowed 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 126.479 1.912 . . . . 10.0 115.092 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.82 -14.02 34.78 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 126.747 2.118 . . . . 10.0 115.165 -177.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.1 mtp180 -83.41 155.53 23.42 Favored 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 118.981 1.39 . . . . 10.0 110.929 169.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.7 p -71.46 155.14 40.94 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.27 1.028 . . . . 10.0 112.602 173.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 59.5 t -136.63 135.96 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 126.678 1.991 . . . . 10.0 108.976 172.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -119.09 164.01 16.17 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 125.267 1.427 . . . . 10.0 111.344 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 98.1 p -66.89 152.76 45.05 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.655 0.741 . . . . 10.0 112.441 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -151.95 167.96 26.71 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.827 1.651 . . . . 10.0 110.656 176.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.65 -34.92 67.78 Favored 'General case' 0 CA--C 1.545 0.772 0 O-C-N 120.97 -1.081 . . . . 10.0 112.832 169.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.4 mt -85.39 -13.55 49.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.55 1.14 . . . . 10.0 114.001 174.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.3 m80 -136.08 70.35 1.42 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.658 1.583 . . . . 10.0 111.184 -174.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -69.91 145.28 52.06 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.713 1.205 . . . . 10.0 111.636 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.4 mtt -139.41 101.74 4.31 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.785 2.034 . . . . 10.0 109.736 -176.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.37 162.24 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.851 1.26 . . . . 10.0 111.818 -178.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 13.8 p -136.83 134.61 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 124.631 1.172 . . . . 10.0 111.269 -179.119 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 40.7 t -65.21 159.89 22.65 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.923 1.289 . . . . 10.0 112.505 177.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -52.19 -33.15 39.53 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.538 1.535 . . . . 10.0 111.965 164.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -81.72 -3.63 54.19 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.405 1.882 . . . . 10.0 113.735 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.25 -3.48 82.23 Favored Glycine 0 CA--C 1.538 1.494 0 C-N-CA 125.75 1.643 . . . . 10.0 115.468 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 48.2 tp -67.97 107.59 2.74 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.846 1.259 . . . . 10.0 111.165 174.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 3.6 t60 -84.86 124.57 31.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.781 1.632 . . . . 10.0 111.514 178.488 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 58.8 m -97.74 134.1 41.37 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.638 1.575 . . . . 10.0 111.793 171.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -123.07 123.55 41.1 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 127.154 2.182 . . . . 10.0 107.94 171.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 47.4 mt -121.79 153.63 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 125.124 1.37 . . . . 10.0 111.517 -166.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -132.18 108.23 9.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 128.044 2.538 . . . . 10.0 109.224 172.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -66.73 -38.79 87.37 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.846 -1.159 . . . . 10.0 112.914 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.5 p -151.78 89.51 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.684 1.593 . . . . 10.0 110.441 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.35 140.56 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 121.212 -0.93 . . . . 10.0 111.883 -178.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -129.34 162.3 28.3 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 126.385 1.874 . . . . 10.0 111.267 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -53.11 -35.11 59.28 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.128 1.158 . . . . 10.0 114.128 -175.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.4 m -65.09 -17.83 64.79 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.32 1.448 . . . . 10.0 114.644 176.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -82.9 -7.0 59.7 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.754 1.222 . . . . 10.0 113.518 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.97 147.9 52.64 Favored 'General case' 0 CA--C 1.546 0.8 0 O-C-N 121.096 -1.003 . . . . 10.0 113.218 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.74 -171.99 24.19 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.507 1.051 . . . . 10.0 115.448 173.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.69 104.15 11.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.846 1.658 . . . . 10.0 110.893 173.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -80.79 151.1 28.93 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.985 0.914 . . . . 10.0 111.751 170.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.93 161.19 38.42 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.093 0.957 . . . . 10.0 112.132 168.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 29.6 t -141.49 104.79 4.64 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.549 1.94 . . . . 10.0 109.766 -172.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.69 131.1 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.576 1.15 . . . . 10.0 109.386 174.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -125.15 126.15 44.81 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.304 1.842 . . . . 10.0 110.721 -179.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -134.35 135.42 42.69 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.479 1.512 . . . . 10.0 112.435 -169.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -130.04 -178.2 4.63 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.577 1.151 . . . . 10.0 111.712 166.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -59.88 -12.41 7.55 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 115.841 1.793 . . . . 10.0 115.841 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.7 -14.31 12.02 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.448 1.499 . . . . 10.0 114.589 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.32 -170.3 42.88 Favored Glycine 0 CA--C 1.533 1.19 0 CA-C-N 119.978 1.263 . . . . 10.0 116.165 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -134.74 144.35 47.67 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.104 2.162 . . . . 10.0 111.674 -172.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.98 163.13 31.44 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.039 1.735 . . . . 10.0 111.043 168.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 35.0 m -142.26 140.44 32.24 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.16 0.984 . . . . 10.0 111.492 -175.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -126.93 156.69 41.09 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 126.097 1.759 . . . . 10.0 110.841 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 26.8 m -145.3 146.62 31.71 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 124.761 1.224 . . . . 10.0 111.682 -171.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.1 p -151.59 161.65 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 125.894 1.678 . . . . 10.0 110.848 169.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 40.2 tt0 -116.75 128.52 55.39 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.583 1.153 . . . . 10.0 110.466 170.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.9 tp -118.55 104.15 10.39 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 126.003 1.721 . . . . 10.0 109.831 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -77.99 138.74 38.99 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.23 0.612 . . . . 10.0 110.108 163.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 27.8 t -117.01 105.16 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.051 0.94 . . . . 10.0 109.157 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 65.8 mt -67.62 97.71 0.63 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.535 1.934 . . . . 10.0 109.869 179.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.52 155.31 22.35 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.382 1.073 . . . . 10.0 112.683 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 23.0 ttpt -122.57 15.23 10.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.216 1.406 . . . . 10.0 113.93 -171.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 . . . . . 0 C--O 1.255 1.382 0 C-N-CA 126.155 1.782 . . . . 10.0 114.496 169.72 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 N-CA-C 111.896 -0.481 . . . . 10.0 111.896 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.36 157.27 26.7 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 124.277 1.031 . . . . 10.0 112.824 176.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.7 176.98 10.51 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.089 1.755 . . . . 10.0 111.799 -177.039 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.54 171.76 44.46 Favored Glycine 0 CA--C 1.542 1.732 0 N-CA-C 117.135 1.614 . . . . 10.0 117.135 -176.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.95 162.22 43.4 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.771 2.981 . . . . 10.0 113.101 -173.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -66.86 150.84 83.12 Favored 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 122.784 2.322 . . . . 10.0 111.064 168.419 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 64.2 ttt-85 -138.54 153.74 48.73 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.317 1.447 . . . . 10.0 111.62 -177.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.95 117.2 9.5 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.614 1.166 . . . . 10.0 111.052 169.29 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.32 -57.78 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 125.102 1.361 . . . . 10.0 110.368 176.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -149.53 137.15 20.17 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.847 1.259 . . . . 10.0 111.547 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.9 m -131.96 153.82 81.52 Favored Pre-proline 0 N--CA 1.474 0.736 0 C-N-CA 126.488 1.915 . . . . 10.0 110.028 170.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -74.75 162.91 36.8 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 122.627 2.218 . . . . 10.0 111.433 171.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.13 179.92 2.61 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.629 0.772 . . . . 10.0 110.738 161.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -58.11 142.68 46.32 Favored 'General case' 0 CA--C 1.546 0.82 0 O-C-N 120.506 -1.372 . . . . 10.0 111.156 166.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 89.9 mtp -122.53 157.33 32.27 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 125.484 1.513 . . . . 10.0 111.937 -172.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 57.8 p -144.38 129.62 18.73 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.295 1.438 . . . . 10.0 110.691 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.9 mm -134.51 133.97 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.7 1.6 . . . . 10.0 109.288 -170.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -63.94 130.83 45.67 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.616 1.166 . . . . 10.0 112.171 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -52.28 126.69 19.74 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.01 1.324 . . . . 10.0 112.509 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.0 61.46 Favored Glycine 0 CA--C 1.537 1.423 0 C-N-CA 125.842 1.687 . . . . 10.0 115.22 179.033 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -72.72 160.59 31.96 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.379 1.59 . . . . 10.0 113.105 175.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -72.67 149.38 43.9 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 124.488 1.115 . . . . 10.0 110.513 157.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 34.6 t -148.78 157.0 43.13 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.461 1.104 . . . . 10.0 111.272 167.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -144.73 154.47 42.77 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.003 1.321 . . . . 10.0 111.503 164.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.3 mtt -125.61 113.25 17.14 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 125.718 1.607 . . . . 10.0 111.107 -173.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -69.65 127.53 33.27 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.426 1.49 . . . . 10.0 112.766 174.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -137.97 93.82 2.81 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 125.105 1.362 . . . . 10.0 110.976 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -67.38 121.25 15.34 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.551 0.741 . . . . 10.0 110.124 174.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.8 p -135.17 115.59 18.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 126.859 2.064 . . . . 10.0 110.189 -173.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 66.2 m -126.98 107.25 9.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.892 1.277 . . . . 10.0 111.59 -173.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -156.15 167.58 33.38 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 127.166 2.317 . . . . 10.0 110.927 169.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -142.14 125.58 9.63 Favored Pre-proline 0 CA--C 1.547 0.839 0 C-N-CA 124.417 1.087 . . . . 10.0 110.686 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -66.06 168.06 49.72 Favored 'Cis proline' 0 CA--C 1.539 0.763 0 CA-C-N 120.622 1.258 . . . . 10.0 112.453 -2.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.57 123.45 57.07 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 124.348 1.059 . . . . 10.0 111.264 -179.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.83 149.21 66.14 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.428 2.085 . . . . 10.0 112.999 -172.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -72.1 139.19 48.27 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.263 1.025 . . . . 10.0 109.535 161.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.36 142.05 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.266 1.027 . . . . 10.0 113.136 -172.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.7 m -141.39 115.34 9.2 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 125.841 1.657 . . . . 10.0 111.195 -176.355 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 71.1 m95 -84.07 151.22 25.08 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 122.2 1.0 . . . . 10.0 113.43 176.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -141.3 161.3 38.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 128.249 2.619 . . . . 10.0 110.776 -179.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.1 tp -147.09 119.78 8.59 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.431 2.292 . . . . 10.0 110.041 176.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 55.02 15.29 1.14 Allowed 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 126.581 1.952 . . . . 10.0 115.045 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 107.33 -12.53 40.01 Favored Glycine 0 CA--C 1.539 1.564 0 C-N-CA 126.607 2.051 . . . . 10.0 115.104 -177.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -87.67 158.33 18.86 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 119.008 1.404 . . . . 10.0 110.824 170.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 21.8 p -71.25 158.32 36.59 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.99 0.916 . . . . 10.0 112.345 173.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 40.1 t -134.62 100.82 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.844 1.658 . . . . 10.0 108.779 171.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -71.43 156.22 39.72 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.346 0.658 . . . . 10.0 110.693 170.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 57.0 p -70.08 151.96 44.9 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 121.559 -0.713 . . . . 10.0 111.908 170.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -152.74 -177.49 6.29 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.051 1.34 . . . . 10.0 111.949 171.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -60.3 -22.75 63.54 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 114.64 1.348 . . . . 10.0 114.64 -177.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 52.9 mt -104.19 -26.19 12.63 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.866 1.666 . . . . 10.0 112.67 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -110.9 74.14 0.86 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 126.416 1.886 . . . . 10.0 111.052 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 92.2 mttt -77.21 146.31 37.07 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.691 1.196 . . . . 10.0 111.175 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 66.1 mtt -145.34 102.51 3.73 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 126.06 1.744 . . . . 10.0 110.281 -170.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.91 163.25 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 124.505 1.122 . . . . 10.0 112.468 178.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 54.7 t -121.38 112.58 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.536 1.934 . . . . 10.0 109.266 174.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 74.7 m -69.25 151.51 46.18 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.76 0.824 . . . . 10.0 111.552 173.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -57.96 -19.68 32.2 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 115.346 1.61 . . . . 10.0 115.346 -174.366 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -75.97 -4.0 38.72 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.763 1.625 . . . . 10.0 113.994 178.104 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 86.09 48.92 4.43 Favored Glycine 0 CA--C 1.531 1.071 0 C-N-CA 125.161 1.363 . . . . 10.0 112.139 -175.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 51.5 tp -136.82 103.56 5.22 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.571 1.549 . . . . 10.0 110.642 -171.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 23.7 t60 -70.45 147.27 49.64 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 122.032 -0.418 . . . . 10.0 110.46 166.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 5.5 t -135.94 99.53 4.18 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.016 1.326 . . . . 10.0 111.204 176.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -81.86 120.28 24.99 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.485 1.514 . . . . 10.0 108.884 173.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 42.6 mt -115.55 151.6 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 125.125 1.37 . . . . 10.0 111.514 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -129.25 108.04 10.02 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.954 2.502 . . . . 10.0 109.258 170.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -63.94 -42.0 97.47 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.194 -0.942 . . . . 10.0 112.845 175.015 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.47 90.88 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.863 1.665 . . . . 10.0 110.121 -179.226 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.7 140.89 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.296 -0.878 . . . . 10.0 112.212 -176.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 26.1 mmt180 -120.86 160.76 22.77 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.454 1.901 . . . . 10.0 112.057 176.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.86 -30.81 66.1 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 113.617 0.969 . . . . 10.0 113.617 -177.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.6 p -67.85 -15.62 63.71 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.921 1.689 . . . . 10.0 114.788 173.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -83.05 -5.08 58.97 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.599 1.16 . . . . 10.0 113.486 176.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.66 151.75 44.07 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.012 -1.055 . . . . 10.0 113.063 177.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.31 -173.07 22.67 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.915 1.245 . . . . 10.0 114.837 176.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -87.6 101.28 13.48 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.9 1.68 . . . . 10.0 111.274 176.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -78.37 151.78 32.65 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 124.295 1.038 . . . . 10.0 111.972 169.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.8 157.31 43.93 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.246 1.018 . . . . 10.0 112.109 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 48.6 t -134.97 104.89 6.14 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.645 1.578 . . . . 10.0 110.925 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 91.1 t -71.42 134.53 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 123.916 0.886 . . . . 10.0 109.131 168.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -133.51 119.46 19.56 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.756 2.023 . . . . 10.0 110.27 179.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.3 mtpt -134.4 136.06 43.05 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.79 1.236 . . . . 10.0 113.018 -170.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 24.9 p30 -132.51 -178.36 4.89 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.061 1.344 . . . . 10.0 111.547 167.093 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.1 ptm180 -60.97 -14.84 25.45 Favored 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 115.482 1.66 . . . . 10.0 115.482 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.03 -19.65 13.66 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.443 1.497 . . . . 10.0 114.208 -177.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.28 -169.98 42.63 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 116.142 1.217 . . . . 10.0 116.142 177.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -134.54 144.64 48.12 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 127.262 2.225 . . . . 10.0 111.664 -170.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -137.88 159.91 40.71 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 126.214 1.806 . . . . 10.0 110.794 167.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 32.8 m -140.35 101.14 4.05 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 124.457 1.103 . . . . 10.0 110.733 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -77.66 155.56 31.3 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.777 1.231 . . . . 10.0 111.254 175.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 28.3 m -146.98 146.35 30.05 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.728 1.211 . . . . 10.0 112.057 -174.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.3 p -154.3 145.99 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 125.819 1.648 . . . . 10.0 111.934 170.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -100.45 135.46 41.85 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.611 1.165 . . . . 10.0 110.929 170.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.1 tp -122.39 112.4 18.04 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.98 1.712 . . . . 10.0 111.026 177.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -100.0 85.22 3.01 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.942 1.697 . . . . 10.0 110.834 175.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.4 t -64.94 114.49 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.954 0.902 . . . . 10.0 110.684 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.6 mt -75.81 99.78 4.55 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.154 1.781 . . . . 10.0 110.042 179.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.01 148.41 40.26 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.304 1.042 . . . . 10.0 113.525 -175.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -144.43 83.15 1.71 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.759 2.023 . . . . 10.0 110.385 176.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 . . . . . 0 C--O 1.254 1.298 0 C-N-CA 125.668 1.587 . . . . 10.0 114.397 176.169 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.568 0 N-CA-C 111.853 -0.499 . . . . 10.0 111.853 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.26 162.06 18.13 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.332 1.053 . . . . 10.0 112.94 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.9 174.17 12.13 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 126.096 1.758 . . . . 10.0 111.648 -178.267 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.81 172.96 45.65 Favored Glycine 0 CA--C 1.542 1.757 0 N-CA-C 116.792 1.477 . . . . 10.0 116.792 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.36 161.72 44.75 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.569 2.846 . . . . 10.0 113.161 -172.358 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -67.05 158.78 55.17 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.861 2.374 . . . . 10.0 111.32 168.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.7 tpt85 -135.1 151.44 50.72 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.007 1.323 . . . . 10.0 111.772 -174.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -79.01 65.4 4.17 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 127.251 2.22 . . . . 10.0 111.812 -176.356 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 39.8 mm -63.16 -62.35 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 O-C-N 121.225 -0.922 . . . . 10.0 112.635 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -153.16 149.67 28.27 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.822 0.849 . . . . 10.0 112.59 -178.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.2 m -134.44 151.11 75.56 Favored Pre-proline 0 N--CA 1.477 0.925 0 C-N-CA 126.405 1.882 . . . . 10.0 110.558 167.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -74.65 159.77 42.06 Favored 'Trans proline' 0 CA--C 1.542 0.916 0 C-N-CA 123.049 2.499 . . . . 10.0 111.596 168.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -77.24 172.61 13.0 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 123.942 0.897 . . . . 10.0 111.542 167.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -49.61 108.86 0.23 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.416 1.486 . . . . 10.0 113.594 178.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 95.3 mtp -82.41 155.66 24.56 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.349 1.46 . . . . 10.0 112.008 -177.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 71.2 p -140.36 131.81 26.91 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.964 1.306 . . . . 10.0 111.023 170.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 32.2 mm -137.08 129.46 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.385 1.474 . . . . 10.0 109.94 -170.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -62.26 127.61 32.17 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.785 1.234 . . . . 10.0 112.169 172.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -52.82 135.02 36.59 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.289 1.435 . . . . 10.0 113.171 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 95.12 -11.27 69.45 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.046 1.784 . . . . 10.0 114.952 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 28.9 mtp-105 -77.63 162.73 26.82 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 118.989 1.394 . . . . 10.0 113.162 177.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -71.71 151.98 43.17 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.884 1.273 . . . . 10.0 110.763 158.327 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 36.0 t -148.41 156.83 42.98 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.496 1.118 . . . . 10.0 111.474 167.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -135.76 139.98 43.97 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 125.516 1.526 . . . . 10.0 110.858 162.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 43.9 mtt -100.77 155.39 17.94 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.801 1.641 . . . . 10.0 109.818 167.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -139.57 118.32 12.37 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.157 1.383 . . . . 10.0 110.984 -170.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -130.52 106.84 8.78 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 125.992 1.717 . . . . 10.0 111.952 -170.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -65.93 127.64 32.84 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.902 0.881 . . . . 10.0 110.52 173.126 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.1 125.34 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.642 1.577 . . . . 10.0 110.769 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 69.4 m -133.21 115.3 14.84 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.674 1.19 . . . . 10.0 111.907 -173.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -161.69 169.76 37.23 Favored Glycine 0 CA--C 1.536 1.393 0 C-N-CA 127.161 2.315 . . . . 10.0 111.381 172.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -143.7 125.3 8.24 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.09 0.956 . . . . 10.0 111.194 -178.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -66.01 167.64 51.14 Favored 'Cis proline' 0 CA--C 1.539 0.744 0 CA-C-N 120.866 1.345 . . . . 10.0 112.476 -2.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.11 122.32 47.31 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.404 1.081 . . . . 10.0 111.231 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -69.34 148.59 68.16 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.42 2.08 . . . . 10.0 112.922 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -72.06 145.73 48.06 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.143 0.977 . . . . 10.0 109.736 161.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.98 139.72 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.556 1.142 . . . . 10.0 112.575 -172.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 73.2 m -136.81 142.12 42.91 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 126.024 1.729 . . . . 10.0 110.672 177.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -111.86 158.05 19.88 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.474 1.11 . . . . 10.0 113.278 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -145.69 159.57 42.96 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 127.256 2.222 . . . . 10.0 111.329 -174.15 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.4 tp -147.19 119.52 8.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.054 2.142 . . . . 10.0 110.0 175.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 55.26 14.05 0.98 Allowed 'General case' 0 CA--C 1.554 1.106 0 C-N-CA 126.537 1.935 . . . . 10.0 115.376 179.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.17 -12.22 31.4 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.564 2.031 . . . . 10.0 115.182 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -89.9 160.68 16.32 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 118.924 1.362 . . . . 10.0 110.978 169.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.5 p -73.99 158.92 33.48 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.369 1.067 . . . . 10.0 112.752 175.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 87.6 t -136.82 104.98 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 127.097 2.159 . . . . 10.0 108.623 173.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -79.68 161.54 25.77 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.417 0.687 . . . . 10.0 111.131 170.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.9 p -70.27 148.02 49.03 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.564 0.746 . . . . 10.0 112.211 171.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -152.61 -179.93 8.04 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 125.365 1.466 . . . . 10.0 111.328 168.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -57.97 -27.53 63.53 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.698 1.37 . . . . 10.0 114.698 -176.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 57.2 mt -93.11 -13.97 27.84 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.23 1.412 . . . . 10.0 113.084 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -131.97 68.82 1.49 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.545 1.938 . . . . 10.0 111.204 -172.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -72.9 146.61 46.02 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.092 1.357 . . . . 10.0 111.321 -179.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -139.2 110.35 6.89 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 126.547 1.939 . . . . 10.0 110.278 -172.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.26 162.78 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 125.079 1.351 . . . . 10.0 112.212 -177.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.4 t -129.8 104.09 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.518 1.527 . . . . 10.0 109.491 177.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 70.8 m -73.05 166.32 23.33 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 125.063 1.345 . . . . 10.0 112.804 177.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.07 158.52 6.73 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.292 1.437 . . . . 10.0 112.323 175.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt 64.8 9.64 5.45 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 127.392 2.277 . . . . 10.0 114.782 -172.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.2 62.74 1.86 Allowed Glycine 0 CA--C 1.53 1.027 0 C-N-CA 125.178 1.371 . . . . 10.0 113.491 173.235 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 43.2 tp -131.03 99.86 5.04 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.027 1.331 . . . . 10.0 111.09 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -76.68 133.95 39.39 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.923 0.889 . . . . 10.0 110.739 172.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 49.4 m -121.01 141.23 50.92 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.574 1.55 . . . . 10.0 111.434 178.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -133.2 115.78 15.43 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 126.788 2.035 . . . . 10.0 108.641 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 49.5 mt -105.35 154.36 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 124.83 1.252 . . . . 10.0 111.836 -168.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -130.4 107.51 9.3 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.496 2.318 . . . . 10.0 109.019 167.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 -63.77 -42.83 97.72 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.256 -0.902 . . . . 10.0 113.049 178.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 3.5 p -151.66 91.91 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 125.845 1.658 . . . . 10.0 110.233 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.0 p -74.63 142.47 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 O-C-N 121.368 -0.833 . . . . 10.0 112.123 -177.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -129.02 163.26 25.77 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 126.408 1.883 . . . . 10.0 111.394 177.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.5 -31.72 62.28 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.393 1.257 . . . . 10.0 114.393 -174.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 74.0 m -67.75 -16.31 64.06 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 114.166 1.173 . . . . 10.0 114.166 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -83.87 -5.98 59.33 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.732 1.213 . . . . 10.0 113.48 178.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.04 151.69 42.31 Favored 'General case' 0 CA--C 1.547 0.859 0 O-C-N 120.985 -1.072 . . . . 10.0 113.1 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 140.11 -174.0 22.68 Favored Glycine 0 CA--C 1.533 1.161 0 C-N-CA 124.317 0.96 . . . . 10.0 114.993 176.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 98.53 9.24 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.888 1.675 . . . . 10.0 111.367 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -76.37 146.92 38.41 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.016 0.926 . . . . 10.0 111.386 168.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.4 160.32 41.25 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.595 0.758 . . . . 10.0 112.425 169.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.0 t -133.39 142.28 48.29 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.091 2.156 . . . . 10.0 109.841 176.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 58.1 t -122.29 124.5 71.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.536 1.534 . . . . 10.0 108.72 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -115.39 124.48 51.3 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.374 1.87 . . . . 10.0 110.451 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -134.16 134.95 42.74 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.01 1.324 . . . . 10.0 112.543 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -130.87 -178.24 4.72 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 124.624 1.17 . . . . 10.0 111.55 166.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 -60.14 -12.61 8.92 Favored 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 115.804 1.779 . . . . 10.0 115.804 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.45 -16.19 13.38 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.381 1.472 . . . . 10.0 114.525 -178.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.78 -168.83 40.92 Favored Glycine 0 CA--C 1.533 1.217 0 CA-C-N 119.884 1.22 . . . . 10.0 116.124 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -134.11 145.78 49.65 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 127.117 2.167 . . . . 10.0 111.878 -170.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.75 161.02 37.12 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.133 1.773 . . . . 10.0 111.205 168.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 60.8 m -137.11 141.92 42.3 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.084 1.354 . . . . 10.0 110.966 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -135.98 137.04 40.86 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.595 1.558 . . . . 10.0 110.056 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 35.5 m -141.65 143.7 33.76 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.797 0.839 . . . . 10.0 112.049 -167.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 12.6 p -152.36 142.51 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 125.279 1.431 . . . . 10.0 111.947 171.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -90.34 136.25 33.17 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.996 0.918 . . . . 10.0 110.751 168.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.6 tp -118.82 104.22 10.36 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.879 1.672 . . . . 10.0 110.909 178.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -84.63 88.3 7.33 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.036 1.334 . . . . 10.0 110.846 170.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.78 108.04 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.228 -0.92 . . . . 10.0 109.84 174.055 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 63.9 mt -73.96 97.03 2.74 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.072 1.749 . . . . 10.0 109.852 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.27 152.69 28.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.65 1.18 . . . . 10.0 113.754 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 63.1 tttp -108.64 -39.29 5.42 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.971 2.108 . . . . 10.0 111.976 177.093 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 . . . . . 0 C--O 1.253 1.239 0 C-N-CA 125.137 1.375 . . . . 10.0 113.239 172.256 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.578 0 N-CA-C 111.905 -0.478 . . . . 10.0 111.905 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.94 166.05 14.31 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.637 1.175 . . . . 10.0 113.238 176.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 23.7 ptt? -148.1 177.42 9.39 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 126.169 1.788 . . . . 10.0 111.662 178.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -175.63 167.79 39.85 Favored Glycine 0 CA--C 1.541 1.702 0 N-CA-C 116.706 1.442 . . . . 10.0 116.706 178.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -67.92 162.77 38.34 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 123.907 3.071 . . . . 10.0 113.228 -173.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -63.99 139.13 66.02 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.963 2.442 . . . . 10.0 110.795 172.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 76.4 ttt-85 -139.41 141.41 37.52 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.39 1.076 . . . . 10.0 113.568 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -59.19 118.88 6.4 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.352 2.261 . . . . 10.0 111.912 171.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.6 -52.75 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.262 1.025 . . . . 10.0 110.001 165.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 40.1 tt0 -150.57 134.86 17.06 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.649 1.18 . . . . 10.0 111.145 176.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 31.7 m -119.35 152.78 53.12 Favored Pre-proline 0 N--CA 1.475 0.791 0 C-N-CA 126.0 1.72 . . . . 10.0 109.266 168.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -75.73 163.77 33.17 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 122.599 2.2 . . . . 10.0 112.211 -177.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.52 170.77 14.47 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.484 -0.76 . . . . 10.0 110.79 163.091 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 13.6 p30 -61.18 157.69 15.58 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.167 -0.958 . . . . 10.0 111.867 169.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 93.8 mtp -127.2 151.92 48.05 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.592 1.557 . . . . 10.0 111.664 -170.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -143.67 84.64 1.8 Allowed 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.304 1.442 . . . . 10.0 111.183 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 40.4 mm -102.41 136.56 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.304 1.441 . . . . 10.0 110.593 -170.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -66.92 129.15 38.96 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.441 1.096 . . . . 10.0 112.414 175.126 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -53.92 128.09 28.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.169 1.388 . . . . 10.0 112.704 178.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 104.7 -13.19 50.38 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 126.564 2.031 . . . . 10.0 114.651 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.6 mtp85 -77.43 161.86 27.65 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 118.775 1.288 . . . . 10.0 113.577 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -75.32 144.08 42.58 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.683 1.193 . . . . 10.0 110.433 155.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.72 172.36 16.23 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 123.686 0.794 . . . . 10.0 112.394 159.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -147.18 168.3 22.01 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.397 1.479 . . . . 10.0 112.516 173.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 45.8 mtt -118.03 165.88 13.2 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 126.508 1.923 . . . . 10.0 111.7 176.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -142.62 107.95 5.02 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.586 1.555 . . . . 10.0 112.448 -171.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -125.7 101.44 6.88 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 126.489 1.916 . . . . 10.0 111.128 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -76.59 111.2 11.82 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 121.118 -0.989 . . . . 10.0 109.685 172.113 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 3.1 p -123.76 102.16 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 125.666 1.586 . . . . 10.0 110.481 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 12.3 t -73.76 173.08 10.35 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.725 0.81 . . . . 10.0 111.357 171.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 124.16 162.89 11.56 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 127.076 2.274 . . . . 10.0 112.431 -176.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.6 tp -152.52 130.84 6.28 Favored Pre-proline 0 CA--C 1.547 0.835 0 C-N-CA 124.393 1.077 . . . . 10.0 110.828 -177.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -67.89 169.25 54.77 Favored 'Cis proline' 0 CA--C 1.539 0.762 0 CA-C-N 120.891 1.354 . . . . 10.0 112.735 -2.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.04 122.19 46.05 Favored Pre-proline 0 CA--C 1.549 0.917 0 C-N-CA 124.658 1.183 . . . . 10.0 111.038 178.043 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.1 151.0 61.0 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 122.483 2.122 . . . . 10.0 113.295 -170.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 150.45 47.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.158 0.983 . . . . 10.0 109.531 157.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 p -138.48 143.85 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 113.269 0.84 . . . . 10.0 113.269 -174.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 21.6 m -127.12 151.7 48.3 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 126.901 2.081 . . . . 10.0 110.353 173.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 34.9 m95 -125.51 157.59 36.65 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.282 1.033 . . . . 10.0 112.865 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 74.9 m-85 -147.16 160.13 42.8 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 126.309 1.844 . . . . 10.0 111.553 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.8 tp -148.45 124.77 10.88 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 127.38 2.272 . . . . 10.0 110.121 176.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 53.42 14.18 0.53 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.845 2.058 . . . . 10.0 116.202 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.2 0.49 25.23 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.732 1.634 . . . . 10.0 115.962 -179.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 10.4 ptp85 -122.21 166.55 14.44 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 125.769 1.628 . . . . 10.0 112.319 173.352 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 20.1 p -71.58 158.85 35.47 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.835 1.254 . . . . 10.0 113.674 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 97.1 t -136.84 142.52 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 128.069 2.547 . . . . 10.0 108.299 171.037 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 67.2 mt-30 -128.93 163.67 24.8 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.151 1.38 . . . . 10.0 111.344 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 52.9 p -66.67 148.54 51.77 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.616 0.766 . . . . 10.0 112.383 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -152.44 167.27 29.3 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.727 1.611 . . . . 10.0 110.824 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -56.63 -34.93 67.75 Favored 'General case' 0 CA--C 1.546 0.796 0 O-C-N 121.005 -1.06 . . . . 10.0 112.963 170.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 82.9 mt -84.84 -14.74 47.04 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.527 1.131 . . . . 10.0 113.902 174.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.83 70.52 1.41 Allowed 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.546 1.538 . . . . 10.0 111.371 -172.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.57 147.7 48.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.591 1.156 . . . . 10.0 111.517 -176.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.6 mtt -134.36 107.09 7.42 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 126.927 2.091 . . . . 10.0 109.467 -177.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.31 161.32 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.735 1.214 . . . . 10.0 112.429 -176.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 19.7 t -135.75 120.19 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 125.882 1.673 . . . . 10.0 109.509 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 22.6 t -64.33 160.32 19.12 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.439 1.096 . . . . 10.0 112.341 175.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -51.8 -35.48 44.32 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.781 1.633 . . . . 10.0 112.579 173.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 44.8 mmtm -82.15 -0.7 46.09 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.022 1.729 . . . . 10.0 114.704 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.52 8.65 65.65 Favored Glycine 0 CA--C 1.538 1.479 0 C-N-CA 124.987 1.28 . . . . 10.0 115.345 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 50.3 tp -76.7 102.01 6.03 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.71 1.204 . . . . 10.0 110.699 171.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -78.29 144.21 36.33 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.36 1.064 . . . . 10.0 111.085 168.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 17.2 m -135.37 155.14 51.07 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.174 1.39 . . . . 10.0 112.833 173.194 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.05 116.09 15.07 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 128.122 2.569 . . . . 10.0 107.949 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -98.61 154.79 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.405 1.482 . . . . 10.0 111.26 -171.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -130.6 104.91 7.48 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.127 2.171 . . . . 10.0 108.831 164.156 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.8 mm-40 -64.0 -37.09 86.15 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.287 -0.883 . . . . 10.0 113.023 178.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.0 p -150.61 91.66 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 125.816 1.646 . . . . 10.0 110.3 177.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.29 139.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 121.3 -0.875 . . . . 10.0 112.194 -176.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -125.9 161.05 28.33 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 126.853 2.061 . . . . 10.0 111.112 176.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.37 -29.64 64.21 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.716 1.206 . . . . 10.0 113.74 -177.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 39.5 p -67.08 -17.07 64.72 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 125.477 1.511 . . . . 10.0 114.597 173.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -82.27 -6.49 59.27 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.7 1.2 . . . . 10.0 113.256 174.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.56 152.45 45.25 Favored 'General case' 0 CA--C 1.546 0.806 0 O-C-N 120.912 -1.117 . . . . 10.0 113.403 -178.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 133.14 -170.21 22.3 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.79 1.186 . . . . 10.0 115.147 174.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.66 105.64 16.37 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 126.052 1.741 . . . . 10.0 111.197 177.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -81.38 153.75 26.81 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.378 1.071 . . . . 10.0 111.769 169.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.01 159.09 42.96 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.016 0.927 . . . . 10.0 112.006 167.436 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 37.6 t -138.81 127.19 22.96 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 127.052 2.141 . . . . 10.0 109.248 -173.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.8 t -122.68 113.09 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.26 1.424 . . . . 10.0 109.49 -175.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -108.44 135.17 50.18 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.64 1.576 . . . . 10.0 111.231 -177.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.28 133.71 37.25 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.735 1.614 . . . . 10.0 111.763 -171.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -135.1 179.99 5.98 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 124.148 0.979 . . . . 10.0 111.99 166.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -61.32 -9.37 5.1 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 115.83 1.789 . . . . 10.0 115.83 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.84 -12.62 13.29 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 125.823 1.649 . . . . 10.0 114.332 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 165.77 -170.49 40.59 Favored Glycine 0 CA--C 1.535 1.343 0 CA-C-N 120.02 1.282 . . . . 10.0 115.949 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -135.43 147.56 49.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.858 2.063 . . . . 10.0 111.487 -176.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -141.06 158.36 44.04 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.629 1.572 . . . . 10.0 111.93 172.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 85.4 m -136.71 130.59 32.29 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.096 1.358 . . . . 10.0 111.148 -176.354 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -123.87 156.35 36.4 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.496 1.918 . . . . 10.0 110.815 -178.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 29.2 m -142.85 145.6 33.3 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 124.463 1.105 . . . . 10.0 111.559 -169.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.0 p -151.59 159.1 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 125.894 1.678 . . . . 10.0 110.85 172.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -121.83 137.17 54.88 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.808 1.243 . . . . 10.0 111.015 176.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 64.2 tp -124.65 105.3 9.22 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 126.359 1.864 . . . . 10.0 110.277 -178.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -93.97 80.35 4.12 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.676 1.59 . . . . 10.0 110.809 176.342 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -62.3 115.27 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.701 0.8 . . . . 10.0 110.95 -178.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.1 mt -76.03 97.38 4.02 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.702 1.601 . . . . 10.0 109.792 178.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.76 149.3 36.09 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 124.731 1.212 . . . . 10.0 113.962 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -95.81 -42.41 8.35 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 127.465 2.306 . . . . 10.0 111.336 174.014 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--O 1.253 1.289 0 C-N-CA 125.685 1.594 . . . . 10.0 113.298 174.503 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.546 0 N-CA-C 111.718 -0.553 . . . . 10.0 111.718 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.48 158.05 24.99 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 124.178 0.991 . . . . 10.0 112.928 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.68 175.09 11.88 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.243 1.817 . . . . 10.0 111.272 -178.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.41 172.89 45.86 Favored Glycine 0 CA--C 1.542 1.737 0 N-CA-C 117.092 1.597 . . . . 10.0 117.092 -176.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -68.77 160.42 49.68 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.679 2.919 . . . . 10.0 113.045 -173.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -70.92 167.56 25.59 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.231 2.62 . . . . 10.0 112.58 173.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -135.42 156.75 48.41 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.223 1.409 . . . . 10.0 112.703 -171.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -96.94 74.37 2.62 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.161 2.185 . . . . 10.0 110.695 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 3.5 mp -76.05 -71.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.134 -0.979 . . . . 10.0 112.322 -173.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -152.13 143.47 23.34 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.983 0.913 . . . . 10.0 112.281 -174.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.91 152.55 54.1 Favored Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 126.295 1.838 . . . . 10.0 110.57 172.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -74.29 160.84 41.57 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.768 2.312 . . . . 10.0 111.348 172.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -72.16 165.7 23.83 Favored 'General case' 0 CA--C 1.543 0.711 0 O-C-N 121.452 -0.78 . . . . 10.0 111.551 169.217 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -62.19 158.05 17.87 Favored 'General case' 0 CA--C 1.546 0.792 0 O-C-N 121.453 -0.779 . . . . 10.0 112.433 174.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 46.5 mtm -130.15 162.32 29.13 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.318 1.047 . . . . 10.0 112.912 -178.013 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -139.83 96.37 3.06 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.862 2.065 . . . . 10.0 110.482 178.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.1 mm -112.74 133.29 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 124.594 1.158 . . . . 10.0 111.214 -166.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -60.15 126.93 29.42 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.439 1.496 . . . . 10.0 112.456 172.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -55.18 127.13 27.76 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.273 1.029 . . . . 10.0 112.18 -178.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 100.92 -10.43 58.67 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 126.004 1.764 . . . . 10.0 114.955 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -73.93 161.19 30.37 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 119.362 1.581 . . . . 10.0 113.333 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -75.98 140.32 41.96 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.328 1.451 . . . . 10.0 110.264 157.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.5 p -151.48 166.3 31.54 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.702 0.801 . . . . 10.0 112.598 165.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.6 ptm85 -141.69 168.0 20.81 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.88 1.272 . . . . 10.0 113.744 175.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 52.3 mtt -131.76 160.29 35.97 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 127.317 2.247 . . . . 10.0 111.01 175.231 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -140.96 103.52 4.49 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.442 1.497 . . . . 10.0 111.932 -168.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 -113.85 121.59 44.47 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.849 1.66 . . . . 10.0 111.677 -176.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 30.7 mtpp -77.48 127.35 32.37 Favored 'General case' 0 N--CA 1.478 0.955 0 O-C-N 121.382 -0.824 . . . . 10.0 110.887 173.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 11.7 p -138.96 145.12 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.596 1.558 . . . . 10.0 111.053 -179.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.9 t -142.99 -176.06 4.76 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.63 1.572 . . . . 10.0 110.886 178.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 118.42 164.49 13.0 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 127.519 2.485 . . . . 10.0 112.005 -172.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.5 tp -147.27 129.08 7.44 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 123.975 0.91 . . . . 10.0 110.785 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.4 169.15 47.01 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 CA-C-N 120.784 1.316 . . . . 10.0 112.373 -3.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.68 123.76 53.23 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 124.498 1.119 . . . . 10.0 111.102 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -69.33 150.44 70.82 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.398 2.065 . . . . 10.0 113.049 -172.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -70.4 140.71 52.14 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.129 0.972 . . . . 10.0 109.456 159.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.0 m -129.01 137.9 55.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.323 1.049 . . . . 10.0 112.521 -170.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 72.2 m -132.92 152.8 51.85 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.165 1.786 . . . . 10.0 110.861 177.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -128.15 152.86 47.52 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.85 1.26 . . . . 10.0 112.765 -175.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -145.48 158.32 43.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 126.08 1.752 . . . . 10.0 111.68 -171.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 57.8 tp -148.16 123.33 10.17 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 127.187 2.195 . . . . 10.0 109.875 177.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 54.22 11.0 0.34 Allowed 'General case' 0 CA--C 1.556 1.192 0 N-CA-C 116.571 2.063 . . . . 10.0 116.571 173.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 116.05 -0.64 21.11 Favored Glycine 0 CA--C 1.54 1.608 0 C-N-CA 125.802 1.668 . . . . 10.0 115.875 -178.239 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -119.41 166.45 13.05 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 125.865 1.666 . . . . 10.0 112.108 172.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 24.1 p -72.49 161.17 31.15 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.756 1.222 . . . . 10.0 113.131 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.92 91.97 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.878 2.071 . . . . 10.0 108.703 173.207 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -69.31 145.34 53.11 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 123.254 0.622 . . . . 10.0 110.661 171.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 44.1 p -73.77 153.93 39.79 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 123.453 0.701 . . . . 10.0 112.542 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -156.69 -172.91 4.24 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.527 1.931 . . . . 10.0 111.676 175.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -61.55 -17.76 56.3 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.984 1.475 . . . . 10.0 114.984 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.4 mt -113.26 -18.84 11.98 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 126.285 1.834 . . . . 10.0 113.423 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 49.9 m80 -121.0 93.38 4.01 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.947 2.099 . . . . 10.0 109.923 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.9 mttt -106.7 121.33 44.14 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.444 1.098 . . . . 10.0 110.79 -169.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -128.71 100.57 5.77 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.258 1.423 . . . . 10.0 110.375 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.18 161.65 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 125.888 1.675 . . . . 10.0 111.934 -174.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.93 167.04 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 125.686 1.594 . . . . 10.0 112.12 -178.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.8 t -133.85 149.55 51.36 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.648 1.579 . . . . 10.0 112.046 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -58.86 -19.54 42.81 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.904 1.682 . . . . 10.0 114.156 175.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -76.74 -2.23 31.97 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 125.622 1.569 . . . . 10.0 114.142 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 84.0 46.27 6.0 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.816 1.198 . . . . 10.0 112.703 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 11.6 tp -137.94 150.59 47.18 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.257 1.423 . . . . 10.0 111.265 -174.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -130.81 123.84 29.99 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.767 2.027 . . . . 10.0 109.893 174.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 48.3 m -94.49 156.02 16.66 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.339 1.056 . . . . 10.0 112.506 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.92 116.46 15.62 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.368 1.867 . . . . 10.0 107.205 162.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.36 133.86 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.819 1.248 . . . . 10.0 110.636 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -109.69 108.77 19.28 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.975 2.11 . . . . 10.0 108.916 171.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -64.19 -37.74 88.54 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 121.489 -0.757 . . . . 10.0 112.817 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.4 p -151.07 89.45 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.154 1.782 . . . . 10.0 109.918 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -66.32 138.29 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 O-C-N 121.232 -0.918 . . . . 10.0 111.742 -178.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.7 mmt180 -121.32 160.35 24.16 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 126.021 1.728 . . . . 10.0 112.208 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.97 -34.37 65.65 Favored 'General case' 0 CA--C 1.546 0.81 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -176.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 19.9 m -65.51 -16.47 63.7 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.498 1.519 . . . . 10.0 114.555 175.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -82.18 -7.48 59.62 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.649 1.179 . . . . 10.0 113.311 179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.52 147.33 53.03 Favored 'General case' 0 CA--C 1.546 0.815 0 O-C-N 121.185 -0.947 . . . . 10.0 112.926 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.94 -170.79 23.02 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 124.512 1.053 . . . . 10.0 115.347 175.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.97 107.03 15.28 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.994 1.718 . . . . 10.0 111.326 177.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -83.3 151.13 25.73 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.386 1.075 . . . . 10.0 111.776 170.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.27 160.38 40.59 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 10.0 112.309 169.115 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -133.02 145.84 51.2 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 126.416 1.886 . . . . 10.0 110.027 175.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 66.6 t -127.73 129.15 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 125.624 1.569 . . . . 10.0 108.882 175.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -122.4 120.79 35.0 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.574 1.95 . . . . 10.0 110.469 -175.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.0 mtpp -131.56 134.48 46.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.305 1.442 . . . . 10.0 112.11 -171.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -130.63 -178.23 4.69 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.472 1.109 . . . . 10.0 111.645 168.182 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -60.03 -11.3 5.53 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 115.788 1.773 . . . . 10.0 115.788 -179.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -114.97 -18.48 11.24 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.417 1.487 . . . . 10.0 114.654 -177.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 174.53 -170.13 43.2 Favored Glycine 0 CA--C 1.534 1.22 0 CA-C-N 120.034 1.288 . . . . 10.0 116.314 179.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -135.12 143.6 46.66 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.172 2.189 . . . . 10.0 111.764 -172.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.75 160.18 38.99 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.167 1.787 . . . . 10.0 111.173 168.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 90.4 m -138.89 145.26 39.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 125.229 1.412 . . . . 10.0 110.871 -175.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -136.48 152.92 51.08 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.33 1.452 . . . . 10.0 111.102 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.8 m -145.16 145.88 31.55 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.567 1.147 . . . . 10.0 111.762 -172.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -152.79 171.82 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 126.36 1.864 . . . . 10.0 110.734 171.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -128.53 142.98 50.9 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.755 1.222 . . . . 10.0 111.404 173.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 62.0 tp -127.36 109.13 11.47 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.04 1.736 . . . . 10.0 110.128 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -78.88 141.89 37.27 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.935 -0.478 . . . . 10.0 110.035 160.091 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 40.0 t -120.5 106.53 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.458 1.103 . . . . 10.0 108.752 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.5 mt -69.37 96.78 0.9 Allowed 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.222 1.809 . . . . 10.0 109.288 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.67 154.33 29.63 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.954 1.302 . . . . 10.0 114.259 -167.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 31.4 ttmt -130.81 -25.62 2.29 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 127.223 2.209 . . . . 10.0 113.28 -176.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 . . . . . 0 C--O 1.253 1.278 0 C-N-CA 125.346 1.458 . . . . 10.0 113.208 169.263 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 N-CA-C 111.7 -0.56 . . . . 10.0 111.7 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.58 167.6 10.66 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 124.443 1.097 . . . . 10.0 112.998 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -141.32 179.86 6.53 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 126.052 1.741 . . . . 10.0 111.864 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 178.87 170.89 41.47 Favored Glycine 0 CA--C 1.541 1.663 0 N-CA-C 116.773 1.469 . . . . 10.0 116.773 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.85 161.19 46.89 Favored 'Trans proline' 0 CA--C 1.543 0.947 0 C-N-CA 123.838 3.025 . . . . 10.0 112.934 -174.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -65.85 145.0 79.27 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 123.017 2.478 . . . . 10.0 111.228 169.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -136.28 147.82 47.68 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.569 1.548 . . . . 10.0 112.384 -175.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -61.22 110.07 1.29 Allowed 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.814 2.046 . . . . 10.0 111.502 171.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 46.9 mm -105.46 -63.8 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.995 0.918 . . . . 10.0 110.285 172.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -153.36 101.88 2.55 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.311 1.044 . . . . 10.0 111.456 176.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 25.3 m -72.27 150.07 91.84 Favored Pre-proline 0 N--CA 1.476 0.834 0 C-N-CA 123.019 0.528 . . . . 10.0 110.22 161.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -75.72 161.0 37.25 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 122.859 2.373 . . . . 10.0 112.089 177.179 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -73.2 166.66 22.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 123.912 0.885 . . . . 10.0 111.517 168.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -62.01 157.79 17.93 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 121.34 -0.85 . . . . 10.0 112.644 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.0 mtp -132.6 153.41 51.06 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.349 1.459 . . . . 10.0 112.118 -166.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 16.9 p -147.27 100.95 3.34 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.8 1.64 . . . . 10.0 110.947 178.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 38.3 mm -117.32 138.95 46.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.044 1.337 . . . . 10.0 110.911 -167.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -67.75 132.18 46.95 Favored 'General case' 0 CA--C 1.543 0.688 0 O-C-N 121.359 -0.838 . . . . 10.0 112.311 176.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 -54.63 119.49 5.37 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.564 1.545 . . . . 10.0 112.132 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 108.52 -10.8 35.83 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 126.216 1.865 . . . . 10.0 115.191 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -74.01 162.31 29.17 Favored 'General case' 0 N--CA 1.479 0.985 0 CA-C-N 119.224 1.512 . . . . 10.0 113.577 178.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -73.97 147.18 43.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.565 1.146 . . . . 10.0 110.558 158.37 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 4.3 t -153.72 173.29 16.03 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.212 1.005 . . . . 10.0 112.541 167.373 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -148.57 166.83 27.07 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 126.039 1.736 . . . . 10.0 112.436 166.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.0 mtt -118.15 157.41 26.97 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.617 1.967 . . . . 10.0 111.333 172.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -140.02 95.01 2.83 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.275 1.43 . . . . 10.0 111.579 -167.054 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -113.1 100.74 8.83 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.426 1.49 . . . . 10.0 111.609 -175.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -73.4 128.97 36.98 Favored 'General case' 0 N--CA 1.477 0.889 0 O-C-N 121.356 -0.84 . . . . 10.0 111.311 175.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 4.4 p -146.99 138.52 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.632 1.973 . . . . 10.0 110.501 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 70.4 m -125.68 126.33 44.49 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.641 1.176 . . . . 10.0 111.596 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -172.02 169.02 42.16 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 127.12 2.295 . . . . 10.0 111.338 175.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 14.6 tp -146.69 131.36 8.81 Favored Pre-proline 0 CA--C 1.548 0.901 0 C-N-CA 124.47 1.108 . . . . 10.0 111.105 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -66.91 169.86 46.94 Favored 'Cis proline' 0 CA--C 1.54 0.797 0 CA-C-N 120.533 1.226 . . . . 10.0 112.546 -3.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.17 120.78 32.36 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 124.605 1.162 . . . . 10.0 111.255 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.41 161.49 45.39 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 122.585 2.19 . . . . 10.0 113.221 -172.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -63.85 163.05 12.51 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.844 1.258 . . . . 10.0 111.692 166.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 6.4 p -139.31 114.97 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.139 1.375 . . . . 10.0 111.525 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 53.2 m -137.1 158.91 43.38 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.948 1.699 . . . . 10.0 110.876 171.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -133.94 160.86 36.42 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.576 1.151 . . . . 10.0 113.604 -170.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -143.5 161.64 37.92 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.872 2.069 . . . . 10.0 111.529 -177.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.7 tp -146.12 119.26 8.85 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 127.027 2.131 . . . . 10.0 110.188 176.052 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.4 m-20 54.78 16.65 1.48 Allowed 'General case' 0 CA--C 1.554 1.132 0 C-N-CA 126.469 1.908 . . . . 10.0 114.964 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.37 -11.86 47.51 Favored Glycine 0 CA--C 1.538 1.531 0 C-N-CA 126.52 2.01 . . . . 10.0 115.164 -177.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -86.17 156.34 20.37 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 118.932 1.366 . . . . 10.0 110.976 170.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.4 p -70.88 154.14 42.09 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.345 1.058 . . . . 10.0 112.51 173.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.5 t -132.89 107.38 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.099 1.76 . . . . 10.0 108.78 173.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -78.68 163.47 25.41 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.027 0.931 . . . . 10.0 111.37 171.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 59.7 p -72.59 157.13 38.15 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.709 0.803 . . . . 10.0 112.615 173.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -146.95 171.09 15.77 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 126.538 1.935 . . . . 10.0 110.322 170.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -59.97 -31.54 69.99 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.039 -1.038 . . . . 10.0 112.292 167.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 80.2 mt -81.95 -17.2 47.86 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.191 1.396 . . . . 10.0 113.949 173.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.2 m80 -136.28 69.77 1.42 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.985 1.714 . . . . 10.0 110.895 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -68.07 142.72 55.76 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.952 1.301 . . . . 10.0 111.005 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 68.3 mtt -133.63 102.49 5.51 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 126.494 1.917 . . . . 10.0 110.049 -175.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.84 171.54 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.371 1.468 . . . . 10.0 111.874 -176.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 23.8 m -131.45 134.55 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 125.021 1.328 . . . . 10.0 110.983 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 23.7 t -77.53 151.0 34.75 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.272 0.629 . . . . 10.0 111.91 173.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -60.74 -20.88 62.26 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.835 1.254 . . . . 10.0 113.224 168.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -75.96 -5.37 45.9 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.718 1.607 . . . . 10.0 113.86 173.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 82.9 56.54 2.72 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.792 1.186 . . . . 10.0 112.571 -177.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.5 tp -133.58 105.51 6.91 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.619 1.567 . . . . 10.0 110.629 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 9.3 m170 -65.79 129.08 38.52 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.45 0.7 . . . . 10.0 110.101 166.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 66.2 m -125.1 131.56 53.27 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.899 1.679 . . . . 10.0 111.681 -173.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -134.17 115.87 14.71 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 126.657 1.983 . . . . 10.0 108.927 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.94 154.36 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 125.187 1.395 . . . . 10.0 110.696 -174.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -127.08 102.8 7.12 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.032 2.133 . . . . 10.0 108.952 164.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 76.9 mm-40 -65.67 -36.01 82.42 Favored 'General case' 0 N--CA 1.476 0.83 0 O-C-N 121.044 -1.035 . . . . 10.0 112.675 176.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.2 p -151.58 90.23 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 126.188 1.795 . . . . 10.0 110.012 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.82 131.52 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 O-C-N 121.199 -0.938 . . . . 10.0 111.392 -179.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -110.8 161.07 16.16 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.508 1.523 . . . . 10.0 111.555 177.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.43 -34.45 66.83 Favored 'General case' 0 CA--C 1.546 0.808 0 N-CA-C 113.355 0.872 . . . . 10.0 113.355 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 23.5 m -66.44 -16.59 64.22 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.522 1.529 . . . . 10.0 114.57 176.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -81.32 -7.92 59.65 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.302 1.041 . . . . 10.0 113.469 179.022 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -63.12 148.14 48.8 Favored 'General case' 0 CA--C 1.548 0.88 0 CA-C-N 119.428 1.013 . . . . 10.0 113.099 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.24 -172.65 25.26 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.655 1.121 . . . . 10.0 115.079 176.121 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -81.34 101.92 10.11 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.834 1.654 . . . . 10.0 111.02 174.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -78.83 151.51 31.84 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 124.119 0.968 . . . . 10.0 111.886 171.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.47 161.47 37.97 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.667 0.787 . . . . 10.0 112.179 168.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.1 t -135.28 149.98 49.92 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 126.627 1.971 . . . . 10.0 110.079 177.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 12.4 p -124.05 141.47 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.898 1.279 . . . . 10.0 110.844 174.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -130.11 120.63 24.93 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.686 1.994 . . . . 10.0 110.095 -178.054 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -135.11 132.89 38.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 125.176 1.39 . . . . 10.0 111.672 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 29.2 p30 -134.03 -179.58 5.64 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.744 1.218 . . . . 10.0 111.332 166.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -61.97 -11.78 15.15 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 115.576 1.695 . . . . 10.0 115.576 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.18 -15.28 14.9 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.552 1.541 . . . . 10.0 114.246 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.46 -167.94 37.9 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.839 1.2 . . . . 10.0 116.023 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.85 146.48 47.5 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.84 2.056 . . . . 10.0 112.221 -170.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.79 157.01 46.01 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.317 1.847 . . . . 10.0 111.294 167.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.4 m -139.56 135.35 33.3 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.487 1.515 . . . . 10.0 110.069 -179.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -128.43 156.19 43.58 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.47 1.508 . . . . 10.0 111.791 -173.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.9 m -142.39 147.42 36.19 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 124.632 1.173 . . . . 10.0 112.139 -171.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.11 165.9 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 126.484 1.914 . . . . 10.0 110.852 168.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -119.25 131.75 55.83 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.981 1.313 . . . . 10.0 110.827 173.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 58.5 tp -120.44 108.62 14.33 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 126.206 1.802 . . . . 10.0 110.253 177.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -78.66 146.18 34.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 121.951 -0.468 . . . . 10.0 110.569 160.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.1 t -124.84 104.91 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 124.287 1.035 . . . . 10.0 109.152 174.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.95 98.98 1.7 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.674 1.989 . . . . 10.0 110.253 -175.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -57.64 128.9 39.4 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.878 1.271 . . . . 10.0 112.47 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 14.4 ttmm -73.98 -20.01 60.48 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 125.083 1.353 . . . . 10.0 113.402 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 . . . . . 0 C--O 1.254 1.304 0 C-N-CA 127.407 2.283 . . . . 10.0 113.998 179.062 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.567 0 N-CA-C 111.885 -0.486 . . . . 10.0 111.885 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -64.03 155.81 30.03 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 124.162 0.985 . . . . 10.0 112.91 177.072 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.43 174.45 13.85 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.31 1.844 . . . . 10.0 111.478 -176.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -173.86 172.63 45.42 Favored Glycine 0 CA--C 1.543 1.833 0 N-CA-C 116.978 1.551 . . . . 10.0 116.978 -175.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -68.13 159.45 53.05 Favored 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.628 2.886 . . . . 10.0 113.021 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -69.17 162.38 42.03 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.044 2.496 . . . . 10.0 112.152 175.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.14 162.73 31.3 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.753 1.221 . . . . 10.0 113.561 -171.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -106.55 83.8 1.92 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.654 1.982 . . . . 10.0 110.76 -171.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.4 mm -83.04 -67.94 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.526 0.73 . . . . 10.0 111.7 -173.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 23.0 tt0 -155.59 148.8 24.68 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 124.386 1.074 . . . . 10.0 111.955 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 20.8 m -126.02 150.75 70.22 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 125.724 1.61 . . . . 10.0 110.654 172.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -74.63 159.39 42.63 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 123.016 2.478 . . . . 10.0 111.861 174.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -75.6 167.43 21.9 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.745 0.818 . . . . 10.0 112.344 168.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -59.7 152.14 23.36 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.688 0.795 . . . . 10.0 113.027 175.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 58.4 mtm -130.16 160.74 32.87 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.207 1.003 . . . . 10.0 112.908 -176.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 35.2 p -138.04 108.21 6.42 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 126.2 1.8 . . . . 10.0 110.642 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.7 mm -123.93 132.41 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 125.267 1.427 . . . . 10.0 110.409 -165.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -63.49 133.69 54.33 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.44 1.096 . . . . 10.0 112.456 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -52.51 132.46 35.2 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.465 1.506 . . . . 10.0 112.981 -179.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 91.4 -9.24 77.83 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.782 1.658 . . . . 10.0 115.394 177.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.44 160.72 32.25 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.206 1.503 . . . . 10.0 113.201 176.527 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 57.8 t80 -71.96 145.87 48.12 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.836 1.254 . . . . 10.0 110.488 158.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.8 t -150.44 163.48 38.29 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.454 1.102 . . . . 10.0 111.686 170.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.6 ptm85 -144.64 166.82 24.09 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.256 1.422 . . . . 10.0 112.769 169.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 50.0 mtt -130.87 159.14 38.26 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.956 2.102 . . . . 10.0 110.84 173.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -138.15 95.03 2.95 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 125.486 1.514 . . . . 10.0 111.34 -167.531 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -108.89 103.36 12.4 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 125.794 1.638 . . . . 10.0 111.103 -175.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -68.01 137.37 55.03 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 121.188 -0.945 . . . . 10.0 110.54 174.309 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.09 155.29 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.508 1.523 . . . . 10.0 111.396 -173.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -142.63 170.45 15.68 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.136 1.375 . . . . 10.0 110.992 171.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 137.71 160.47 8.54 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 127.613 2.53 . . . . 10.0 112.573 -176.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.7 tp -150.46 127.01 5.23 Favored Pre-proline 0 CA--C 1.547 0.846 0 C-N-CA 124.396 1.079 . . . . 10.0 110.711 178.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -66.78 169.13 49.01 Favored 'Cis proline' 0 CA--C 1.538 0.709 0 CA-C-N 121.346 1.517 . . . . 10.0 112.31 -2.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.58 121.11 36.66 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.708 1.203 . . . . 10.0 111.335 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -70.36 160.23 50.24 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 122.538 2.158 . . . . 10.0 113.274 -173.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -66.7 169.65 7.55 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 125.481 1.512 . . . . 10.0 111.736 169.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.5 p -133.33 115.71 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 125.708 1.603 . . . . 10.0 111.624 -175.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.9 m -133.84 99.16 4.37 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.515 1.526 . . . . 10.0 110.622 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 59.0 m95 -84.38 156.06 22.01 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 121.873 0.844 . . . . 10.0 112.798 175.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -143.0 159.58 41.97 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.126 2.17 . . . . 10.0 111.208 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -146.35 118.35 8.23 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.956 2.102 . . . . 10.0 109.892 176.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.2 m-20 55.4 12.26 0.71 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.578 1.951 . . . . 10.0 115.487 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 113.48 -13.05 23.25 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 126.662 2.077 . . . . 10.0 115.343 -178.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -91.14 161.77 14.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 125.233 1.413 . . . . 10.0 110.923 170.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 70.5 p -70.92 160.5 32.73 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.61 0.719 . . . . 10.0 112.34 174.67 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 98.5 t -129.85 113.43 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 126.53 1.932 . . . . 10.0 107.308 166.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -107.59 139.0 42.79 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 125.014 1.326 . . . . 10.0 109.832 -174.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 51.1 p -63.6 144.5 56.96 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.283 0.846 . . . . 10.0 113.283 -174.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -154.21 -177.77 6.66 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.9 1.68 . . . . 10.0 111.342 172.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -58.95 -18.84 37.4 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.227 1.411 . . . . 10.0 114.721 -177.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.7 mt -107.44 -11.42 15.52 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.74 1.616 . . . . 10.0 113.205 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -130.21 70.85 1.44 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.973 2.109 . . . . 10.0 110.285 -175.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 89.6 mttt -80.12 144.54 32.99 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.897 1.279 . . . . 10.0 111.706 -173.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.2 mtt -141.65 107.37 5.1 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.418 1.887 . . . . 10.0 110.535 -171.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.85 164.62 25.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.781 1.232 . . . . 10.0 112.232 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 22.1 t -133.69 116.37 24.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 125.334 1.453 . . . . 10.0 110.012 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 44.6 t -65.37 143.98 57.39 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.097 0.959 . . . . 10.0 111.755 173.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -59.26 -18.88 41.17 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.926 1.29 . . . . 10.0 113.888 173.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -77.11 -3.7 40.67 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.005 1.722 . . . . 10.0 114.014 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 88.33 45.94 4.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.971 1.272 . . . . 10.0 113.414 178.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 55.5 tp -135.18 105.6 6.38 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 125.293 1.437 . . . . 10.0 111.005 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -77.34 116.4 17.92 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.501 1.121 . . . . 10.0 110.984 171.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 69.9 m -93.33 137.14 32.93 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 125.495 1.518 . . . . 10.0 111.672 171.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.37 124.84 31.2 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.13 2.172 . . . . 10.0 107.639 174.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 4.4 mp -123.37 147.71 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.518 1.127 . . . . 10.0 111.536 -170.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -121.45 107.39 12.41 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 127.707 2.403 . . . . 10.0 109.175 170.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.4 mm-40 -66.68 -37.3 84.47 Favored 'General case' 0 N--CA 1.474 0.775 0 O-C-N 121.076 -1.015 . . . . 10.0 112.924 177.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.15 90.89 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 125.865 1.666 . . . . 10.0 110.284 -178.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 5.7 p -69.45 147.28 12.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 O-C-N 121.175 -0.953 . . . . 10.0 112.305 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -136.27 156.5 48.58 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.722 1.609 . . . . 10.0 112.721 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.54 -34.91 71.54 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.679 1.192 . . . . 10.0 113.663 -177.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.4 m -64.63 -13.08 52.1 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.453 1.501 . . . . 10.0 114.389 176.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -108.8 8.09 26.53 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.255 1.822 . . . . 10.0 113.009 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.38 158.0 30.41 Favored 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.94 -1.1 . . . . 10.0 112.616 168.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.37 -167.55 21.91 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.549 1.071 . . . . 10.0 115.134 173.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -80.63 103.25 10.35 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.174 1.79 . . . . 10.0 111.544 178.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -80.72 150.26 29.39 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.711 1.205 . . . . 10.0 111.919 171.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 162.96 35.0 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.113 0.965 . . . . 10.0 112.066 168.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 41.8 t -140.38 127.51 20.96 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.653 1.581 . . . . 10.0 110.768 176.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 89.7 t -102.55 132.78 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 125.666 1.586 . . . . 10.0 109.401 173.22 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.47 117.55 22.33 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.527 1.931 . . . . 10.0 110.659 -178.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -131.05 139.5 49.93 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.249 1.42 . . . . 10.0 112.056 -172.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -132.92 -177.87 4.7 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.8 1.24 . . . . 10.0 111.355 167.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -61.72 -8.8 5.1 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 115.888 1.81 . . . . 10.0 115.888 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -116.36 -17.44 10.72 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.587 1.555 . . . . 10.0 114.736 -178.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 175.4 -170.36 43.37 Favored Glycine 0 CA--C 1.534 1.232 0 CA-C-N 120.0 1.273 . . . . 10.0 116.257 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -136.58 141.99 43.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.222 2.209 . . . . 10.0 111.68 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.5 158.56 44.14 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.209 1.804 . . . . 10.0 110.953 168.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -143.52 141.32 30.69 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 124.517 1.127 . . . . 10.0 111.072 -175.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -132.4 154.2 50.04 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.694 1.598 . . . . 10.0 111.349 -176.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.0 m -145.39 145.3 31.1 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 124.672 1.189 . . . . 10.0 112.003 -171.036 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 7.7 p -154.0 172.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 C-N-CA 126.572 1.949 . . . . 10.0 110.984 172.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 39.5 tt0 -130.1 143.13 50.62 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 120.665 -1.272 . . . . 10.0 111.557 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 55.9 tp -129.39 106.58 8.88 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.088 1.755 . . . . 10.0 111.14 -177.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -91.96 85.62 5.61 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.815 1.646 . . . . 10.0 111.307 177.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 20.9 t -70.15 110.06 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.256 -0.902 . . . . 10.0 110.997 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 73.8 mt -75.47 98.74 4.0 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 126.454 1.902 . . . . 10.0 110.503 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.73 144.48 52.2 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.255 1.022 . . . . 10.0 112.743 178.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -75.15 -25.05 58.08 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 113.525 0.935 . . . . 10.0 113.525 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.253 1.27 0 C-N-CA 126.934 2.094 . . . . 10.0 112.678 -177.482 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.541 0 N-CA-C 112.08 -0.408 . . . . 10.0 112.08 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.35 162.44 17.58 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.364 1.066 . . . . 10.0 112.931 175.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.83 -179.24 6.46 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 125.816 1.646 . . . . 10.0 112.177 -175.076 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -173.89 171.19 44.32 Favored Glycine 0 CA--C 1.541 1.659 0 N-CA-C 116.731 1.453 . . . . 10.0 116.731 -177.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -69.65 158.95 55.29 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.463 2.775 . . . . 10.0 113.08 -172.514 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -69.04 164.59 33.25 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.146 2.564 . . . . 10.0 111.52 168.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -141.12 155.32 46.13 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.717 1.207 . . . . 10.0 112.0 -174.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -74.6 102.66 4.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.19 2.196 . . . . 10.0 111.452 178.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . 0.489 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.2 OUTLIER -115.0 -176.69 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 126.026 1.73 . . . . 10.0 110.483 175.76 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.489 ' H ' HG22 ' A' ' 253' ' ' ILE . 0.0 OUTLIER -46.35 102.43 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 128.458 2.703 . . . . 10.0 115.024 -175.033 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.91 151.59 92.99 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 124.385 1.074 . . . . 10.0 111.061 158.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.4 162.65 33.29 Favored 'Trans proline' 0 CA--C 1.541 0.852 0 C-N-CA 123.023 2.482 . . . . 10.0 111.269 170.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -73.3 159.97 32.56 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 121.36 -0.838 . . . . 10.0 111.478 170.395 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -59.45 129.93 44.42 Favored 'General case' 0 CA--C 1.544 0.739 0 O-C-N 121.564 -0.71 . . . . 10.0 111.529 175.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 31.1 mtm -100.09 155.04 17.95 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.928 0.891 . . . . 10.0 112.162 -174.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 23.6 p -134.81 105.76 6.59 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.852 1.661 . . . . 10.0 110.269 175.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 31.0 mm -125.44 127.06 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.12 1.368 . . . . 10.0 110.206 -164.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -62.91 134.3 56.0 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.157 0.983 . . . . 10.0 112.189 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -53.03 130.16 33.02 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.813 1.245 . . . . 10.0 112.751 -178.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 92.74 -8.87 76.4 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 125.9 1.714 . . . . 10.0 115.284 177.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -70.15 160.29 32.35 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 119.272 1.536 . . . . 10.0 113.004 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 43.8 t80 -76.95 139.62 40.21 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.818 1.247 . . . . 10.0 110.222 156.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.6 p -149.32 169.71 20.18 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.754 0.822 . . . . 10.0 111.892 162.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 35.5 ptt-85 -145.27 137.78 25.96 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.217 1.007 . . . . 10.0 112.525 172.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 57.2 mtt -87.47 159.31 18.71 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.888 1.275 . . . . 10.0 110.906 169.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -136.7 132.29 34.69 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.014 1.326 . . . . 10.0 112.025 173.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -134.43 113.92 12.36 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 126.715 2.006 . . . . 10.0 109.645 -176.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.71 146.69 53.53 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 121.067 -1.021 . . . . 10.0 110.206 171.178 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.7 p -149.21 156.51 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 125.063 1.345 . . . . 10.0 111.492 -174.016 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.1 t -144.53 -176.62 5.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.712 1.605 . . . . 10.0 111.668 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 104.92 162.77 23.98 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.125 2.297 . . . . 10.0 113.54 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.2 tp -148.74 131.05 7.7 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 125.234 1.414 . . . . 10.0 110.48 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -67.33 170.97 44.65 Favored 'Cis proline' 0 CA--C 1.54 0.778 0 CA-C-N 120.917 1.363 . . . . 10.0 112.615 -3.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.01 120.96 32.83 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.022 1.329 . . . . 10.0 111.437 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.53 152.42 59.86 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 122.481 2.121 . . . . 10.0 113.466 -171.273 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -72.31 141.6 48.84 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.81 1.244 . . . . 10.0 109.899 160.316 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 3.1 m -128.15 89.23 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.699 1.199 . . . . 10.0 112.233 -166.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 67.5 m -74.93 115.76 14.9 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.762 1.225 . . . . 10.0 111.251 175.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -96.89 148.77 22.61 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.475 1.11 . . . . 10.0 113.349 177.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 83.1 m-85 -143.21 160.19 40.92 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 126.562 1.945 . . . . 10.0 112.427 -174.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.2 tp -147.13 120.78 9.17 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.721 2.408 . . . . 10.0 109.799 174.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 54.93 15.1 1.05 Allowed 'General case' 0 CA--C 1.556 1.192 0 C-N-CA 126.584 1.954 . . . . 10.0 115.43 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 106.82 -11.01 41.53 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.207 1.86 . . . . 10.0 115.176 -177.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -90.55 159.81 16.28 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.207 1.403 . . . . 10.0 110.677 169.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 25.2 p -74.28 160.49 31.03 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.018 0.927 . . . . 10.0 112.6 174.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 41.2 t -135.54 104.77 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.979 1.712 . . . . 10.0 109.563 174.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -70.32 148.88 47.95 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.135 0.574 . . . . 10.0 111.209 170.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 34.7 p -73.55 149.5 42.15 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.497 0.719 . . . . 10.0 111.611 166.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -155.04 -177.67 6.7 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.171 1.388 . . . . 10.0 111.977 172.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -59.29 -19.95 50.38 Favored 'General case' 0 CA--C 1.547 0.829 0 N-CA-C 114.81 1.411 . . . . 10.0 114.81 -177.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 71.7 mt -105.16 -9.35 17.8 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.501 1.52 . . . . 10.0 113.112 175.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 66.3 m80 -132.95 65.91 1.58 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 127.22 2.208 . . . . 10.0 110.261 -174.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -76.42 130.74 38.45 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.771 1.229 . . . . 10.0 110.668 -174.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 62.3 mtt -129.32 103.1 6.73 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.241 1.817 . . . . 10.0 109.776 -174.23 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.32 163.46 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.703 1.201 . . . . 10.0 112.763 -172.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 30.4 m -124.01 166.75 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 126.308 1.843 . . . . 10.0 111.649 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 35.6 t -136.88 149.04 47.43 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.487 1.515 . . . . 10.0 112.365 -178.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -58.72 -19.59 41.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.895 1.678 . . . . 10.0 114.075 174.291 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.2 mmtt -75.06 -2.17 26.23 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.565 1.546 . . . . 10.0 113.949 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.86 41.7 7.08 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.008 1.29 . . . . 10.0 112.903 -178.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 14.2 tp -133.51 150.02 51.7 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.276 1.43 . . . . 10.0 111.641 -175.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.9 t60 -132.93 137.78 46.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.02 2.528 . . . . 10.0 108.952 173.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 50.9 m -131.72 153.1 50.38 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.812 0.845 . . . . 10.0 112.471 -175.684 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.91 102.18 5.95 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.151 1.78 . . . . 10.0 109.059 178.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -86.68 142.32 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 124.841 1.256 . . . . 10.0 109.35 179.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -120.62 104.68 10.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.608 1.963 . . . . 10.0 108.459 167.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -64.85 -39.73 94.03 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 112.957 0.725 . . . . 10.0 112.957 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.4 p -151.16 85.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 125.969 1.708 . . . . 10.0 110.111 -178.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.3 p -67.54 142.9 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 O-C-N 121.255 -0.903 . . . . 10.0 112.327 -176.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -124.77 161.07 27.23 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.286 1.834 . . . . 10.0 112.255 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.12 -30.87 64.76 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 113.839 1.051 . . . . 10.0 113.839 -176.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.7 p -67.53 -16.34 64.14 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 125.658 1.583 . . . . 10.0 114.803 173.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -82.18 -7.63 59.63 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.635 1.174 . . . . 10.0 113.433 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.94 151.61 45.35 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.136 -0.977 . . . . 10.0 113.021 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.96 -170.97 21.11 Favored Glycine 0 CA--C 1.532 1.141 0 C-N-CA 124.664 1.126 . . . . 10.0 114.935 176.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.41 104.08 14.12 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.067 1.747 . . . . 10.0 111.724 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -78.97 150.39 32.03 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.377 1.071 . . . . 10.0 112.016 170.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -145.43 160.28 41.82 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 123.778 0.831 . . . . 10.0 112.427 169.097 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.35 142.36 43.8 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.747 1.619 . . . . 10.0 110.414 174.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 39.2 t -123.14 104.92 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.798 1.639 . . . . 10.0 109.102 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.75 120.54 27.28 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 126.277 1.831 . . . . 10.0 110.835 177.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -126.64 135.45 51.21 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 125.21 1.404 . . . . 10.0 111.9 -178.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -133.85 -179.16 5.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.05 0.94 . . . . 10.0 111.744 164.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.7 ptp180 -60.53 -12.58 10.27 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 115.797 1.777 . . . . 10.0 115.797 -179.249 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.44 -17.99 13.33 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 125.521 1.528 . . . . 10.0 114.356 -178.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 170.44 -169.72 42.5 Favored Glycine 0 CA--C 1.535 1.298 0 CA-C-N 119.846 1.203 . . . . 10.0 115.809 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -137.94 145.6 42.22 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.352 1.861 . . . . 10.0 111.958 -173.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -140.18 162.34 35.5 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.072 1.749 . . . . 10.0 111.385 170.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 64.2 m -135.83 145.94 46.96 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.316 1.046 . . . . 10.0 111.736 -171.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -136.2 149.52 48.6 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 126.391 1.876 . . . . 10.0 110.63 -177.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 24.2 m -146.42 145.2 30.16 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.597 1.159 . . . . 10.0 111.79 -172.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.8 p -152.4 172.78 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 126.042 1.737 . . . . 10.0 110.856 168.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 49.4 tt0 -126.62 147.16 49.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.17 1.388 . . . . 10.0 111.334 172.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 63.6 tp -127.86 113.0 15.34 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 126.09 1.756 . . . . 10.0 111.024 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -92.88 91.57 7.49 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.584 1.554 . . . . 10.0 110.606 171.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 19.4 t -74.62 106.84 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 O-C-N 121.158 -0.964 . . . . 10.0 110.157 175.495 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.1 mt -76.64 97.95 4.57 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.846 1.658 . . . . 10.0 110.5 -179.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.33 57.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.077 0.951 . . . . 10.0 112.542 177.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -69.88 -42.6 73.24 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 124.058 0.943 . . . . 10.0 112.964 -178.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.253 1.25 0 C-N-CA 128.296 2.638 . . . . 10.0 114.253 -175.067 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.532 0 N-CA-C 111.652 -0.579 . . . . 10.0 111.652 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.6 159.15 25.35 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.286 1.034 . . . . 10.0 113.044 177.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -150.29 176.99 10.38 Favored 'General case' 0 CA--C 1.549 0.938 0 C-N-CA 126.314 1.846 . . . . 10.0 111.513 -178.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.62 170.57 43.38 Favored Glycine 0 CA--C 1.542 1.763 0 N-CA-C 116.947 1.539 . . . . 10.0 116.947 -178.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -69.13 158.11 59.03 Favored 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 123.402 2.735 . . . . 10.0 112.85 -173.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.4 143.12 62.37 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.756 2.304 . . . . 10.0 110.766 169.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 38.1 ttp-105 -111.02 152.59 26.67 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.472 1.509 . . . . 10.0 111.429 179.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -77.64 75.63 4.18 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 126.32 1.848 . . . . 10.0 111.712 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . 0.531 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.7 OUTLIER -75.15 177.45 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.034 0 C-N-CA 124.739 1.216 . . . . 10.0 111.312 175.969 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.531 ' H ' HG22 ' A' ' 253' ' ' ILE . 32.9 tt0 -49.94 113.01 0.75 Allowed 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.79 2.436 . . . . 10.0 114.439 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 23.6 m -76.41 154.13 83.95 Favored Pre-proline 0 N--CA 1.477 0.905 0 C-N-CA 125.008 1.323 . . . . 10.0 111.19 159.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -76.45 167.53 25.48 Favored 'Trans proline' 0 CA--C 1.543 0.956 0 C-N-CA 123.265 2.644 . . . . 10.0 111.779 171.259 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.39 167.31 20.77 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.334 -0.854 . . . . 10.0 111.66 166.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.4 p-10 -61.88 160.15 12.66 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.345 -0.847 . . . . 10.0 112.767 174.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 91.5 mtp -127.74 154.02 45.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 125.8 1.64 . . . . 10.0 111.793 -171.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 59.1 p -144.23 120.17 10.65 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 125.061 1.344 . . . . 10.0 110.367 166.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.0 mm -129.02 130.2 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.16 1.384 . . . . 10.0 109.89 -166.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -60.28 126.22 26.66 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.895 1.278 . . . . 10.0 112.238 173.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -52.33 130.71 31.78 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.48 1.512 . . . . 10.0 113.222 -177.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.33 -10.73 67.34 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.077 1.798 . . . . 10.0 115.106 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -71.69 162.06 30.03 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.144 1.472 . . . . 10.0 113.395 176.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -74.03 139.45 44.73 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.494 1.118 . . . . 10.0 110.466 155.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 29.3 p -148.78 172.66 14.27 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.596 0.758 . . . . 10.0 112.255 159.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -151.77 175.46 12.4 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 126.029 1.732 . . . . 10.0 112.1 175.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 54.7 mtt -129.14 162.32 28.04 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 126.042 1.737 . . . . 10.0 112.078 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -136.6 108.94 7.31 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.758 1.623 . . . . 10.0 111.525 -177.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -124.71 113.38 17.9 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.482 1.513 . . . . 10.0 111.155 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -67.48 146.38 54.03 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.542 -0.724 . . . . 10.0 111.099 173.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 9.3 p -149.21 139.8 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 125.444 1.498 . . . . 10.0 111.551 177.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 24.6 m -142.21 115.11 8.69 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.985 1.314 . . . . 10.0 111.19 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . -174.32 166.79 38.9 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 127.086 2.279 . . . . 10.0 111.723 174.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 15.9 tp -148.44 129.81 7.23 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.311 1.045 . . . . 10.0 111.242 -178.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -67.13 169.57 49.18 Favored 'Cis proline' 0 CA--C 1.539 0.739 0 CA-C-N 121.022 1.401 . . . . 10.0 112.686 -2.055 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.83 120.66 34.67 Favored Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 124.845 1.258 . . . . 10.0 111.478 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.51 159.85 50.14 Favored 'Trans proline' 0 CA--C 1.54 0.775 0 C-N-CA 122.593 2.196 . . . . 10.0 113.45 -173.31 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -66.86 167.49 11.41 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.514 1.526 . . . . 10.0 111.748 167.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.72 107.02 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 125.708 1.603 . . . . 10.0 110.48 -171.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.0 m -124.62 99.53 6.22 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.418 1.487 . . . . 10.0 111.339 179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -81.82 151.83 27.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.051 0.94 . . . . 10.0 113.093 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -140.72 160.24 40.47 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.155 2.182 . . . . 10.0 111.416 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.9 tp -146.56 116.73 7.37 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 127.257 2.223 . . . . 10.0 110.128 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 55.76 12.46 0.85 Allowed 'General case' 0 CA--C 1.556 1.179 0 C-N-CA 126.503 1.921 . . . . 10.0 115.234 -179.556 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 110.25 -14.76 30.69 Favored Glycine 0 CA--C 1.54 1.611 0 C-N-CA 126.778 2.132 . . . . 10.0 114.959 -176.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -80.9 158.09 25.41 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.996 1.318 . . . . 10.0 110.524 168.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 65.8 p -74.4 162.93 28.37 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.408 0.683 . . . . 10.0 111.855 170.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 16.7 t -136.01 137.43 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.378 1.471 . . . . 10.0 109.44 171.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 25.6 mp0 -107.9 156.53 19.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.321 1.449 . . . . 10.0 111.032 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 63.7 p -71.14 155.68 40.47 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.757 0.823 . . . . 10.0 112.316 173.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -153.48 168.91 24.53 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 125.476 1.51 . . . . 10.0 110.92 177.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.66 -35.69 70.89 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 120.832 -1.168 . . . . 10.0 112.655 169.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 76.7 mt -81.2 -15.45 55.65 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.527 1.131 . . . . 10.0 113.803 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -135.28 70.41 1.43 Allowed 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.723 1.609 . . . . 10.0 111.561 -173.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -69.12 136.56 52.41 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.776 1.23 . . . . 10.0 110.478 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 55.6 mtt -134.06 102.46 5.41 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 126.477 1.911 . . . . 10.0 109.357 -173.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.57 162.51 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 125.02 1.328 . . . . 10.0 112.985 -169.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 17.7 t -132.42 113.02 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 126.964 2.106 . . . . 10.0 109.538 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 36.3 t -68.93 146.41 52.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 124.545 1.138 . . . . 10.0 111.937 173.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -59.0 -19.59 45.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.803 1.241 . . . . 10.0 113.89 172.084 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -77.7 -3.29 40.37 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.381 1.472 . . . . 10.0 113.99 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.94 49.36 4.31 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.942 1.258 . . . . 10.0 113.014 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -144.74 121.39 11.14 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 125.863 1.665 . . . . 10.0 109.496 -175.034 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -114.14 157.22 22.9 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.424 0.898 . . . . 10.0 113.424 173.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.4 m -143.36 158.58 43.52 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.766 1.226 . . . . 10.0 113.291 -169.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.96 104.96 7.43 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.962 2.105 . . . . 10.0 108.549 171.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.7 mp -79.4 151.01 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.445 1.098 . . . . 10.0 109.736 177.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -131.6 98.84 4.61 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 126.69 1.996 . . . . 10.0 108.195 167.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -62.85 -36.2 82.47 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 113.088 0.773 . . . . 10.0 113.088 -178.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.34 83.93 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.142 1.777 . . . . 10.0 109.747 178.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.5 p -66.5 141.45 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 121.246 -0.909 . . . . 10.0 112.014 -175.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 10.6 mmt180 -127.33 160.91 29.92 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.028 1.731 . . . . 10.0 112.503 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -54.9 -33.24 61.86 Favored 'General case' 0 CA--C 1.547 0.865 0 N-CA-C 114.131 1.16 . . . . 10.0 114.131 -177.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 73.6 m -68.62 -15.62 63.59 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.328 1.233 . . . . 10.0 114.328 175.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -81.47 -6.79 59.31 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.386 1.074 . . . . 10.0 113.236 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.06 149.69 49.43 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 120.931 -1.106 . . . . 10.0 113.017 179.014 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 138.75 -173.87 22.36 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.812 1.196 . . . . 10.0 114.976 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -85.21 103.16 13.92 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.069 1.748 . . . . 10.0 111.297 176.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 62.7 m-85 -81.04 151.5 28.36 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.0 0.92 . . . . 10.0 112.11 172.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.17 164.86 29.47 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.223 1.009 . . . . 10.0 112.283 168.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 34.0 t -140.83 117.26 10.77 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.64 1.576 . . . . 10.0 110.643 175.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 84.8 t -88.3 132.16 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.834 1.253 . . . . 10.0 109.373 170.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -126.58 119.7 27.75 Favored 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 126.459 1.904 . . . . 10.0 110.876 -177.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -131.76 137.11 48.05 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 125.408 1.483 . . . . 10.0 112.32 -170.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.5 p30 -132.53 -177.24 4.39 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.806 1.243 . . . . 10.0 111.572 166.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -59.83 -15.78 23.51 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 115.652 1.723 . . . . 10.0 115.652 -179.28 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -107.97 -20.65 13.11 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.262 1.425 . . . . 10.0 114.192 -176.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.15 -169.7 42.84 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 116.104 1.201 . . . . 10.0 116.104 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -134.67 143.33 47.18 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 127.041 2.136 . . . . 10.0 111.647 -172.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -135.93 164.28 28.33 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 126.013 1.725 . . . . 10.0 111.153 166.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.5 m -140.75 140.22 34.78 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.479 1.111 . . . . 10.0 110.931 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -124.92 153.09 43.21 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.212 1.805 . . . . 10.0 110.437 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 16.1 m -148.41 146.25 28.38 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 124.197 0.999 . . . . 10.0 112.274 -169.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 8.2 p -151.36 171.74 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.538 1.935 . . . . 10.0 110.601 171.102 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -130.95 140.03 50.11 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.841 1.256 . . . . 10.0 110.758 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 65.9 tp -126.2 110.58 13.62 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.321 1.849 . . . . 10.0 110.695 -176.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -97.64 82.56 3.08 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.682 1.593 . . . . 10.0 110.86 175.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.3 t -64.3 114.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.897 0.879 . . . . 10.0 110.779 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 78.3 mt -78.35 93.33 4.66 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 126.279 1.831 . . . . 10.0 110.366 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -63.11 156.59 24.59 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.893 1.277 . . . . 10.0 113.486 -179.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -131.83 -18.12 2.74 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 115.645 1.721 . . . . 10.0 115.645 178.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 124.127 0.971 . . . . 10.0 112.55 166.528 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.58 0 N-CA-C 111.799 -0.521 . . . . 10.0 111.799 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -63.41 153.53 34.96 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.201 1.0 . . . . 10.0 112.714 176.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.74 174.94 12.92 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 126.278 1.831 . . . . 10.0 111.449 -177.101 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.52 171.14 43.39 Favored Glycine 0 CA--C 1.541 1.717 0 N-CA-C 117.063 1.585 . . . . 10.0 117.063 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -73.79 162.84 38.58 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.023 3.149 . . . . 10.0 113.578 -171.088 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -67.56 161.15 44.78 Favored 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 123.116 2.544 . . . . 10.0 112.094 169.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 50.6 ttp180 -144.7 155.55 43.63 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 124.911 1.284 . . . . 10.0 112.649 -173.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -75.15 83.02 2.34 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.915 2.086 . . . . 10.0 111.831 176.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 31.3 mm -79.12 -66.33 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 O-C-N 121.543 -0.723 . . . . 10.0 110.778 177.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -156.24 145.84 20.92 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 124.833 1.253 . . . . 10.0 111.347 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.7 m -127.5 150.93 74.18 Favored Pre-proline 0 N--CA 1.477 0.882 0 C-N-CA 125.77 1.628 . . . . 10.0 110.331 171.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_endo -73.38 158.08 48.73 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.817 2.345 . . . . 10.0 112.198 176.108 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -73.81 170.69 14.8 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.928 0.891 . . . . 10.0 111.275 165.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -59.96 155.18 17.21 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.258 -0.901 . . . . 10.0 112.577 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.4 mtp -132.72 159.45 39.65 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.435 1.494 . . . . 10.0 112.341 -171.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 58.2 p -142.54 128.0 18.96 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 125.657 1.583 . . . . 10.0 110.288 168.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 30.9 mm -133.73 132.04 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 125.306 1.442 . . . . 10.0 109.826 -169.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -61.79 128.86 38.23 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.12 1.368 . . . . 10.0 112.347 173.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.32 132.94 29.34 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 125.717 1.607 . . . . 10.0 113.268 -177.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.62 -9.18 78.41 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 125.767 1.651 . . . . 10.0 115.277 177.318 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.5 mtp85 -70.22 160.25 32.51 Favored 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 119.185 1.492 . . . . 10.0 113.112 175.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 48.9 t80 -73.26 138.82 45.76 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.203 1.001 . . . . 10.0 110.267 154.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 30.7 p -151.28 172.39 15.95 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.797 0.839 . . . . 10.0 112.103 162.278 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -148.43 171.95 15.23 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.857 1.263 . . . . 10.0 113.005 173.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 55.2 mtt -132.08 154.93 48.94 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 127.72 2.408 . . . . 10.0 110.105 176.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -134.98 102.09 5.1 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.655 1.582 . . . . 10.0 112.041 -170.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -107.95 106.68 17.04 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 125.651 1.581 . . . . 10.0 110.126 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -65.54 131.9 47.54 Favored 'General case' 0 N--CA 1.474 0.773 0 O-C-N 121.348 -0.845 . . . . 10.0 109.978 172.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 12.9 p -137.16 155.95 33.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 125.771 1.628 . . . . 10.0 111.051 -171.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.4 t -142.84 -170.83 3.32 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.464 1.506 . . . . 10.0 111.737 -176.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 93.86 165.44 37.0 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 126.717 2.103 . . . . 10.0 113.301 -176.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 17.2 tp -146.81 130.98 8.55 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 125.818 1.647 . . . . 10.0 109.363 178.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -67.11 169.95 47.65 Favored 'Cis proline' 0 CA--C 1.541 0.847 0 CA-C-N 120.788 1.317 . . . . 10.0 112.635 -3.215 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.0 123.54 54.06 Favored Pre-proline 0 CA--C 1.55 0.952 0 C-N-CA 124.832 1.253 . . . . 10.0 111.209 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.4 150.6 58.53 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 122.324 2.016 . . . . 10.0 114.081 -168.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -68.99 117.28 10.44 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.09 1.756 . . . . 10.0 109.485 160.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -114.71 86.74 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.654 1.582 . . . . 10.0 111.917 -169.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.8 m -72.3 157.48 37.61 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.913 0.885 . . . . 10.0 111.742 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 62.0 m95 -131.24 155.33 47.3 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.914 1.286 . . . . 10.0 112.828 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -146.29 159.52 43.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.435 1.894 . . . . 10.0 111.488 -175.049 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 56.4 tp -147.59 121.58 9.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.15 2.18 . . . . 10.0 110.047 176.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 54.18 17.35 1.44 Allowed 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 126.466 1.906 . . . . 10.0 115.241 178.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.46 -7.09 42.57 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 126.181 1.848 . . . . 10.0 115.416 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.8 mtt85 -98.2 161.45 13.7 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.458 1.503 . . . . 10.0 111.219 171.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.7 p -71.56 156.74 39.07 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.535 1.134 . . . . 10.0 113.003 176.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 80.5 t -134.33 141.84 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 127.101 2.16 . . . . 10.0 108.551 170.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -126.18 161.9 26.62 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.228 1.411 . . . . 10.0 111.354 -177.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 55.6 p -68.36 150.14 48.54 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.548 0.739 . . . . 10.0 112.304 174.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -152.68 167.68 28.14 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.826 1.65 . . . . 10.0 110.723 176.72 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -56.34 -34.53 66.66 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 121.003 -1.06 . . . . 10.0 112.883 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 73.3 mt -86.39 -12.94 47.8 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.671 1.188 . . . . 10.0 113.91 174.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 46.9 m80 -136.39 71.02 1.41 Allowed 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.579 1.551 . . . . 10.0 111.271 -173.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.9 mttt -71.55 144.83 49.42 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.684 1.194 . . . . 10.0 111.574 -176.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 64.6 mtt -137.75 104.93 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.897 2.079 . . . . 10.0 109.602 -176.016 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.3 157.14 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 124.175 0.99 . . . . 10.0 112.616 -177.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.58 108.17 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 126.54 1.936 . . . . 10.0 110.752 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 41.7 t -64.8 142.17 58.52 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.75 0.82 . . . . 10.0 111.573 174.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -60.11 -18.44 47.29 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.752 1.221 . . . . 10.0 113.705 172.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -77.51 -3.6 41.38 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.935 1.694 . . . . 10.0 113.849 173.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.0 45.64 4.73 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.155 1.359 . . . . 10.0 113.694 177.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.4 108.28 8.07 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 125.306 1.443 . . . . 10.0 110.478 -177.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.4 t60 -83.31 108.68 16.68 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.141 0.977 . . . . 10.0 111.155 170.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 23.8 m -85.02 136.18 33.7 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.52 1.128 . . . . 10.0 111.585 169.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -128.56 119.33 24.59 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 127.096 2.158 . . . . 10.0 107.918 174.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.6 mt -116.68 152.4 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.762 1.225 . . . . 10.0 111.576 -166.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -129.4 107.97 9.92 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.5 2.32 . . . . 10.0 109.187 169.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.04 -37.99 85.06 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.219 -0.925 . . . . 10.0 112.961 176.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.3 p -151.88 83.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.68 1.592 . . . . 10.0 110.353 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.4 p -68.48 143.9 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 O-C-N 121.178 -0.951 . . . . 10.0 112.291 -176.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -126.13 163.33 23.34 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 126.222 1.809 . . . . 10.0 112.276 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.3 -30.8 65.05 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.715 1.006 . . . . 10.0 113.715 -178.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.9 p -67.96 -16.63 64.14 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 125.673 1.589 . . . . 10.0 114.707 173.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -82.73 -5.97 59.16 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 124.691 1.196 . . . . 10.0 113.354 175.437 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -66.33 152.09 45.73 Favored 'General case' 0 CA--C 1.547 0.837 0 O-C-N 121.035 -1.041 . . . . 10.0 113.082 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.77 -170.56 22.01 Favored Glycine 0 CA--C 1.532 1.142 0 C-N-CA 124.881 1.229 . . . . 10.0 114.937 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.0 104.56 14.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.025 1.73 . . . . 10.0 111.402 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -80.06 153.11 28.99 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.415 1.086 . . . . 10.0 112.029 170.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -142.93 159.9 41.35 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.947 0.899 . . . . 10.0 112.207 167.26 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.3 t -132.51 145.15 50.93 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.346 1.858 . . . . 10.0 110.031 176.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 45.3 t -130.14 102.1 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.119 1.368 . . . . 10.0 109.812 -179.657 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -85.46 125.41 33.01 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 126.649 1.98 . . . . 10.0 111.245 176.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 22.7 mtmt -131.63 131.72 43.43 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.181 1.792 . . . . 10.0 111.996 -175.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 21.5 p30 -137.15 -179.1 5.51 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 123.461 0.704 . . . . 10.0 112.078 162.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.1 ptp180 -59.6 -14.41 13.36 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 115.763 1.764 . . . . 10.0 115.763 -177.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -108.3 -15.08 14.56 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.207 1.403 . . . . 10.0 114.402 -178.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.34 -173.5 42.48 Favored Glycine 0 CA--C 1.533 1.207 0 CA-C-N 119.587 1.085 . . . . 10.0 115.709 178.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -134.86 146.99 49.76 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 126.515 1.926 . . . . 10.0 111.455 -174.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.25 155.94 48.16 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.795 1.638 . . . . 10.0 111.12 170.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.7 m -135.36 131.45 36.37 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.769 1.228 . . . . 10.0 110.753 -173.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -126.17 157.25 38.63 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.364 1.466 . . . . 10.0 111.219 -176.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 20.5 m -146.13 146.34 30.83 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.37 1.068 . . . . 10.0 111.931 -169.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.4 p -152.32 165.81 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 C-N-CA 126.245 1.818 . . . . 10.0 110.629 170.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -126.29 139.17 53.52 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.82 1.248 . . . . 10.0 110.956 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 54.5 tp -126.74 113.12 16.23 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.979 1.712 . . . . 10.0 110.969 -177.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -98.9 85.21 3.23 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.638 1.575 . . . . 10.0 110.964 175.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.0 t -66.96 114.23 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.899 0.88 . . . . 10.0 110.82 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 71.4 mt -78.33 98.29 5.9 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.387 1.875 . . . . 10.0 110.516 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -64.62 158.43 24.42 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 124.354 1.061 . . . . 10.0 113.577 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -130.97 17.25 5.11 Favored 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 125.85 1.66 . . . . 10.0 114.85 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? . . . . . 0 C--O 1.253 1.272 0 C-N-CA 126.526 1.93 . . . . 10.0 114.874 173.277 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.545 0 N-CA-C 111.722 -0.551 . . . . 10.0 111.722 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.96 162.47 19.18 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.394 1.078 . . . . 10.0 113.064 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.6 174.58 11.3 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 126.407 1.883 . . . . 10.0 111.399 179.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.92 176.12 47.86 Favored Glycine 0 CA--C 1.541 1.695 0 N-CA-C 117.03 1.572 . . . . 10.0 117.03 -176.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -67.04 157.19 62.91 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 123.361 2.707 . . . . 10.0 112.633 -173.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.01 159.99 51.71 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.619 2.212 . . . . 10.0 112.218 176.503 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 9.3 mpt_? -112.35 169.05 9.15 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.752 1.621 . . . . 10.0 112.989 -172.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -108.7 97.55 7.18 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.798 2.039 . . . . 10.0 109.417 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . 0.512 HG22 ' H ' ' A' ' 254' ' ' GLN . 1.1 mp -115.37 171.41 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 126.245 1.818 . . . . 10.0 109.868 -174.133 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.512 ' H ' HG22 ' A' ' 253' ' ' ILE . 6.5 tm0? -44.34 122.08 2.85 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.692 2.397 . . . . 10.0 114.655 -173.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 33.7 m -107.69 158.86 32.29 Favored Pre-proline 0 N--CA 1.476 0.867 0 C-N-CA 127.508 2.323 . . . . 10.0 110.461 172.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -73.6 159.0 46.78 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 122.456 2.104 . . . . 10.0 111.697 173.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -71.41 172.5 9.34 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 123.71 0.804 . . . . 10.0 111.125 165.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.3 p30 -59.0 151.62 21.67 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 121.109 -0.994 . . . . 10.0 112.067 173.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.8 mtp -134.11 158.18 44.28 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.184 1.394 . . . . 10.0 111.961 -171.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 61.3 p -141.86 131.28 23.74 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 125.483 1.513 . . . . 10.0 110.823 173.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 28.3 mm -136.57 133.82 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.54 1.536 . . . . 10.0 109.557 -169.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -65.11 131.33 46.25 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.408 1.083 . . . . 10.0 112.428 175.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -51.61 123.44 9.99 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.607 1.563 . . . . 10.0 113.045 -179.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 102.9 -10.39 55.63 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 126.285 1.898 . . . . 10.0 115.106 178.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 76.7 mtp180 -72.94 160.93 31.34 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 119.127 1.464 . . . . 10.0 113.398 177.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -72.3 148.94 44.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.866 1.266 . . . . 10.0 110.632 157.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 45.4 t -149.48 156.05 41.38 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 124.763 1.225 . . . . 10.0 111.087 169.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -146.35 163.14 36.52 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.605 1.162 . . . . 10.0 112.675 165.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 59.0 mtt -137.51 121.72 18.04 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.784 1.634 . . . . 10.0 111.661 -173.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 26.1 m-20 -80.73 117.9 21.8 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 126.363 1.865 . . . . 10.0 112.353 175.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -128.13 105.46 8.39 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 125.373 1.469 . . . . 10.0 111.448 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -65.78 131.73 47.02 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 121.253 -0.904 . . . . 10.0 111.131 175.328 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.39 133.2 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.157 1.783 . . . . 10.0 110.73 -177.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 9.5 t -146.86 157.15 43.58 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.599 1.159 . . . . 10.0 111.536 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 149.13 165.52 12.37 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 128.178 2.799 . . . . 10.0 111.332 -173.671 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.0 tp -146.69 125.33 6.31 Favored Pre-proline 0 CA--C 1.546 0.816 0 CA-C-O 118.106 -0.949 . . . . 10.0 111.137 179.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -66.46 167.87 52.77 Favored 'Cis proline' 0 CA--C 1.538 0.708 0 CA-C-N 120.937 1.37 . . . . 10.0 112.669 -1.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.17 121.46 41.9 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.787 1.235 . . . . 10.0 111.341 -178.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -70.52 153.56 65.33 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 122.474 2.116 . . . . 10.0 113.196 -172.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -74.54 141.87 44.79 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.378 1.071 . . . . 10.0 109.55 159.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 47.8 t -130.94 131.7 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.262 1.025 . . . . 10.0 111.475 -170.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 69.1 m -131.73 156.7 45.46 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.865 1.666 . . . . 10.0 111.966 177.189 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -123.56 155.45 37.6 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.214 1.405 . . . . 10.0 113.177 -177.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -145.01 160.74 40.89 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 127.142 2.177 . . . . 10.0 111.572 -173.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.7 tp -145.64 118.08 8.5 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 127.346 2.258 . . . . 10.0 109.905 176.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 54.72 16.24 1.33 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 126.318 1.847 . . . . 10.0 114.793 -179.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 105.96 -12.65 45.41 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.689 2.09 . . . . 10.0 115.24 -177.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.6 mtt85 -84.99 158.11 20.59 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 125.088 1.355 . . . . 10.0 110.698 170.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.4 p -72.1 157.11 38.38 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.882 0.873 . . . . 10.0 112.611 174.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 55.0 t -133.86 93.29 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 126.446 1.898 . . . . 10.0 108.74 173.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 60.8 mt-30 -68.51 155.09 40.61 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.615 0.766 . . . . 10.0 111.223 172.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.2 p -71.12 155.94 40.18 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-O 121.832 0.825 . . . . 10.0 112.327 171.525 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -155.07 170.16 22.44 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 126.68 1.992 . . . . 10.0 110.668 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.95 -34.5 65.72 Favored 'General case' 0 CA--C 1.546 0.805 0 O-C-N 120.568 -1.333 . . . . 10.0 112.828 169.12 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 66.8 mt -86.08 -13.25 47.87 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.755 1.222 . . . . 10.0 114.289 176.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -138.56 91.84 2.58 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.509 1.524 . . . . 10.0 111.122 -173.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 81.4 mttt -95.66 145.06 25.56 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.466 1.106 . . . . 10.0 111.494 -174.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -139.74 104.01 4.8 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 127.031 2.133 . . . . 10.0 109.621 -178.037 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.58 162.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.119 1.368 . . . . 10.0 111.728 177.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.13 133.68 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 126.147 1.779 . . . . 10.0 109.664 176.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 60.3 p -66.22 170.59 5.64 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.265 1.026 . . . . 10.0 113.561 176.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -68.99 -4.44 16.81 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.455 1.102 . . . . 10.0 113.886 166.65 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -109.07 -3.64 17.23 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 126.488 1.915 . . . . 10.0 114.134 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 87.55 40.75 6.7 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 124.509 1.052 . . . . 10.0 114.048 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 41.7 tp -124.52 106.81 10.45 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.313 1.445 . . . . 10.0 110.395 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 13.7 t60 -72.75 142.81 48.14 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.633 0.773 . . . . 10.0 111.19 173.122 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 55.1 m -123.55 97.06 5.22 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 126.865 2.066 . . . . 10.0 110.552 175.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -83.03 123.06 29.11 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 125.112 1.365 . . . . 10.0 108.662 169.161 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 37.1 mt -124.94 149.26 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 125.129 1.371 . . . . 10.0 111.705 -169.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -127.1 113.85 16.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 128.362 2.665 . . . . 10.0 109.481 171.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -69.21 -41.52 76.97 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.033 -1.042 . . . . 10.0 112.913 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.57 88.91 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 125.72 1.608 . . . . 10.0 110.345 -176.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.7 p -70.59 141.49 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.219 -0.925 . . . . 10.0 112.252 -176.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -123.18 162.54 22.34 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.556 1.942 . . . . 10.0 112.045 176.282 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.69 -34.41 65.04 Favored 'General case' 0 CA--C 1.547 0.848 0 N-CA-C 113.463 0.912 . . . . 10.0 113.463 -178.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 24.9 m -64.59 -17.71 64.22 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 125.386 1.474 . . . . 10.0 114.508 175.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -83.46 -6.16 59.37 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.637 1.175 . . . . 10.0 113.383 178.398 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -64.84 151.21 46.06 Favored 'General case' 0 CA--C 1.548 0.866 0 O-C-N 121.057 -1.027 . . . . 10.0 112.986 178.357 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.51 -171.55 22.87 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 124.746 1.165 . . . . 10.0 114.881 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.78 101.33 11.52 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 125.858 1.663 . . . . 10.0 111.314 176.334 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -75.96 148.65 37.99 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.807 0.843 . . . . 10.0 111.661 169.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -140.83 156.84 46.05 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.852 0.861 . . . . 10.0 112.074 170.282 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 45.2 t -132.18 140.56 48.78 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 126.865 2.066 . . . . 10.0 109.411 -179.056 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 61.2 t -130.6 125.41 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 125.147 1.379 . . . . 10.0 109.311 -178.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -118.55 125.02 48.92 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.149 1.78 . . . . 10.0 110.542 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -133.03 133.27 42.84 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 125.568 1.547 . . . . 10.0 112.215 -170.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -131.06 -177.74 4.52 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 124.693 1.197 . . . . 10.0 111.737 168.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.9 ptm180 -59.52 -14.82 14.41 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 115.702 1.742 . . . . 10.0 115.702 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -110.96 -17.88 13.19 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.524 1.53 . . . . 10.0 114.331 -176.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.75 -169.22 42.32 Favored Glycine 0 CA--C 1.534 1.243 0 N-CA-C 116.175 1.23 . . . . 10.0 116.175 178.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -133.65 144.42 49.19 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 127.331 2.252 . . . . 10.0 111.498 -173.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -134.94 157.71 46.19 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.009 1.724 . . . . 10.0 111.278 170.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 62.1 m -137.88 145.06 41.7 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.996 1.318 . . . . 10.0 111.408 -173.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -136.63 152.89 50.93 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.191 1.796 . . . . 10.0 110.478 -179.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 22.6 m -145.36 147.35 32.19 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.042 0.937 . . . . 10.0 112.252 -170.649 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.5 p -151.98 160.87 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 C-N-CA 126.308 1.843 . . . . 10.0 111.039 169.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.2 tt0 -116.96 134.96 54.09 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 124.972 1.309 . . . . 10.0 110.912 173.103 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 57.8 tp -121.02 111.21 17.2 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.022 1.729 . . . . 10.0 110.875 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -97.32 85.88 3.77 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 125.777 1.631 . . . . 10.0 110.968 175.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 22.1 t -67.04 112.97 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.764 0.826 . . . . 10.0 110.736 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 69.0 mt -76.03 99.53 4.63 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 126.214 1.806 . . . . 10.0 110.101 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.94 150.44 33.3 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.109 0.964 . . . . 10.0 112.976 -179.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -77.17 -12.82 59.99 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 114.802 1.408 . . . . 10.0 114.802 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 29.8 mm-40 . . . . . 0 C--O 1.253 1.253 0 C-N-CA 126.888 2.075 . . . . 10.0 113.824 179.304 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.505 0 N-CA-C 111.118 -0.793 . . . . 10.0 111.118 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.16 165.68 10.92 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.372 1.069 . . . . 10.0 112.93 174.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -143.0 172.95 12.0 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 125.99 1.716 . . . . 10.0 111.752 -177.194 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.77 173.76 46.31 Favored Glycine 0 CA--C 1.542 1.779 0 N-CA-C 116.849 1.5 . . . . 10.0 116.849 -175.994 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -69.84 159.58 52.83 Favored 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 123.661 2.907 . . . . 10.0 113.366 -171.714 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -69.45 164.82 32.77 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.32 2.68 . . . . 10.0 111.787 169.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.6 ttt180 -143.4 158.02 43.98 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.4 1.08 . . . . 10.0 112.366 -173.233 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -82.77 69.7 9.61 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.681 1.992 . . . . 10.0 112.516 -171.258 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . 0.566 HG22 ' H ' ' A' ' 254' ' ' GLN . 2.7 mm -77.88 175.34 0.76 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.231 0 C-N-CA 124.338 1.055 . . . . 10.0 110.865 175.624 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.566 ' H ' HG22 ' A' ' 253' ' ' ILE . 47.4 tt0 -48.72 115.42 1.25 Allowed 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 128.302 2.641 . . . . 10.0 115.259 -173.651 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 27.7 m -78.4 153.7 79.1 Favored Pre-proline 0 N--CA 1.479 0.999 0 C-N-CA 124.927 1.291 . . . . 10.0 111.552 162.439 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -76.31 166.85 26.87 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 123.267 2.645 . . . . 10.0 111.714 169.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -74.42 164.91 26.03 Favored 'General case' 0 N--CA 1.475 0.786 0 O-C-N 121.311 -0.868 . . . . 10.0 111.887 169.097 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -63.46 162.22 12.98 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.601 0.76 . . . . 10.0 112.634 172.625 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 44.6 mtm -134.11 161.43 34.9 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.373 1.069 . . . . 10.0 113.228 -178.234 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 13.7 p -140.15 90.14 2.35 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.887 2.075 . . . . 10.0 110.477 177.411 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 41.7 mm -103.87 138.23 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 124.697 1.199 . . . . 10.0 111.184 -166.797 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -68.83 130.06 41.71 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.108 0.963 . . . . 10.0 112.355 174.613 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -53.23 125.79 18.78 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.448 1.499 . . . . 10.0 112.824 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.95 -8.74 61.38 Favored Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.185 1.85 . . . . 10.0 115.115 -179.234 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 77.7 mtp85 -74.35 159.79 31.91 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 119.489 1.644 . . . . 10.0 113.102 175.103 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -76.75 141.01 40.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.453 1.101 . . . . 10.0 110.207 156.368 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 31.1 p -150.22 173.61 13.74 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.733 0.813 . . . . 10.0 112.353 162.436 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.5 ptm85 -145.95 167.89 22.21 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 125.682 1.593 . . . . 10.0 112.356 175.342 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 47.1 mtt -126.48 159.78 32.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.531 1.933 . . . . 10.0 110.772 172.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -137.43 96.87 3.34 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.448 1.499 . . . . 10.0 111.504 -167.862 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -110.13 111.39 22.71 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 125.678 1.591 . . . . 10.0 111.126 -177.037 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 90.7 mttt -66.38 147.35 53.43 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 121.111 -0.993 . . . . 10.0 110.272 169.438 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -150.78 159.95 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.232 1.413 . . . . 10.0 111.458 -175.669 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.3 t -143.53 -176.88 5.13 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.648 1.579 . . . . 10.0 111.854 178.102 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.22 161.43 23.53 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.251 2.358 . . . . 10.0 113.481 -178.161 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.9 tp -149.7 130.87 7.25 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 125.124 1.37 . . . . 10.0 110.282 179.823 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -66.0 168.97 45.62 Favored 'Cis proline' 0 CA--C 1.539 0.742 0 CA-C-N 121.194 1.462 . . . . 10.0 112.56 -2.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.92 121.54 41.15 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 124.783 1.233 . . . . 10.0 111.403 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.21 151.49 66.55 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 122.517 2.144 . . . . 10.0 113.102 -173.152 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -71.68 143.57 49.66 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.157 0.983 . . . . 10.0 109.783 160.357 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.64 87.53 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 125.081 1.353 . . . . 10.0 111.83 -166.073 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 62.5 m -77.08 113.72 15.12 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.549 1.14 . . . . 10.0 111.177 176.318 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -91.17 153.12 20.26 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.19 0.996 . . . . 10.0 113.186 176.481 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -144.11 159.92 41.79 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.658 1.983 . . . . 10.0 111.995 -176.512 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.2 tp -146.02 119.25 8.9 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 127.511 2.325 . . . . 10.0 110.022 176.236 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 54.9 14.14 0.86 Allowed 'General case' 0 CA--C 1.555 1.148 0 C-N-CA 126.419 1.887 . . . . 10.0 115.309 179.221 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.44 -12.19 36.27 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.602 2.049 . . . . 10.0 115.165 -177.345 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.8 mtp180 -87.95 158.07 18.77 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.974 1.387 . . . . 10.0 110.976 170.097 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.6 p -71.6 156.78 39.01 Favored 'General case' 0 N--CA 1.477 0.916 0 C-N-CA 124.357 1.063 . . . . 10.0 112.656 173.627 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 60.7 t -133.85 105.94 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 126.373 1.869 . . . . 10.0 108.866 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 63.0 mt-30 -74.31 159.36 32.52 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.458 0.703 . . . . 10.0 111.394 171.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 61.0 p -69.07 155.92 39.54 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.514 0.726 . . . . 10.0 112.036 169.647 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -153.13 168.55 25.56 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 125.26 1.424 . . . . 10.0 110.891 175.634 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -57.23 -35.98 70.36 Favored 'General case' 0 CA--C 1.546 0.797 0 O-C-N 120.857 -1.152 . . . . 10.0 112.548 168.692 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 75.9 mt -80.19 -17.79 51.4 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 124.537 1.135 . . . . 10.0 113.804 173.886 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -134.46 70.51 1.45 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.18 1.792 . . . . 10.0 111.205 -172.186 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -73.16 142.43 47.43 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.4 1.48 . . . . 10.0 111.046 -173.199 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.8 mtt -136.48 98.7 3.89 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 126.249 1.82 . . . . 10.0 110.074 -174.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.09 159.86 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.363 1.465 . . . . 10.0 111.636 -177.034 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.38 122.57 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.753 1.221 . . . . 10.0 111.504 -177.85 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 67.6 m -69.63 148.6 49.12 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.508 1.123 . . . . 10.0 112.016 177.293 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 19.4 tp10 -55.8 -34.78 65.62 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.656 1.583 . . . . 10.0 113.396 -177.663 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -78.41 0.38 25.95 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 126.082 1.753 . . . . 10.0 114.574 179.369 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.49 50.23 1.88 Allowed Glycine 0 CA--C 1.532 1.133 0 C-N-CA 124.833 1.206 . . . . 10.0 114.841 170.19 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 54.4 tp -133.51 106.5 7.48 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 125.155 1.382 . . . . 10.0 111.056 176.696 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -86.45 118.37 25.84 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.954 1.701 . . . . 10.0 111.365 177.484 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 70.7 m -91.71 144.93 25.01 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.903 1.681 . . . . 10.0 112.224 173.658 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -138.21 115.73 11.26 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 126.439 1.896 . . . . 10.0 108.669 173.569 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 154.19 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 C-N-CA 125.36 1.464 . . . . 10.0 111.42 -170.832 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -131.74 108.36 9.41 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 127.007 2.123 . . . . 10.0 109.599 163.565 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 36.5 mm-40 -65.06 -45.32 85.82 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 113.898 1.073 . . . . 10.0 113.898 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.61 70.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 CA-C-O 122.614 1.197 . . . . 10.0 111.344 -172.506 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.96 142.23 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.025 1.33 . . . . 10.0 113.502 -170.0 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.2 mmt-85 -120.64 162.07 20.29 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 126.5 1.92 . . . . 10.0 112.323 177.04 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.11 -31.32 61.15 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.265 1.026 . . . . 10.0 113.613 177.239 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 43.2 p -67.8 -17.12 64.42 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.539 1.536 . . . . 10.0 114.806 174.287 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -83.31 -7.39 59.59 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.54 1.136 . . . . 10.0 113.409 175.823 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.68 149.68 49.71 Favored 'General case' 0 CA--C 1.547 0.85 0 O-C-N 120.958 -1.089 . . . . 10.0 112.988 179.38 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 141.1 -173.44 23.27 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.806 1.193 . . . . 10.0 115.076 176.077 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.9 106.53 14.8 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.855 1.662 . . . . 10.0 111.094 175.063 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -84.01 150.43 25.62 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 124.347 1.059 . . . . 10.0 111.921 172.902 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.56 162.18 37.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.946 0.898 . . . . 10.0 112.268 170.516 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.3 t -139.01 140.42 38.15 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 125.581 1.552 . . . . 10.0 110.487 175.065 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 43.6 t -121.38 104.38 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.837 1.655 . . . . 10.0 109.07 179.395 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -86.3 122.0 29.67 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.278 1.831 . . . . 10.0 111.078 178.396 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -132.35 132.58 43.04 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.421 1.488 . . . . 10.0 112.224 -177.184 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.2 p30 -130.97 -177.95 4.6 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.488 1.115 . . . . 10.0 111.646 167.085 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.8 ptp180 -59.47 -12.71 6.71 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 115.922 1.823 . . . . 10.0 115.922 -179.37 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -113.52 -16.82 12.34 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 125.382 1.473 . . . . 10.0 114.557 -177.048 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 171.17 -169.27 42.34 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 120.022 1.283 . . . . 10.0 116.224 178.876 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -135.96 144.06 45.2 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.093 2.157 . . . . 10.0 111.997 -172.311 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -139.78 161.96 36.3 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.111 1.764 . . . . 10.0 111.151 168.587 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -137.65 144.17 41.74 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.319 1.048 . . . . 10.0 111.599 -172.31 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -134.52 152.38 51.75 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 126.189 1.796 . . . . 10.0 110.86 -178.214 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 15.4 m -147.85 146.18 29.0 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.525 1.13 . . . . 10.0 111.942 -173.027 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 9.9 p -153.45 174.21 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 126.49 1.916 . . . . 10.0 110.781 171.838 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -129.63 144.31 51.22 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.689 1.196 . . . . 10.0 111.51 172.773 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 60.0 tp -128.77 109.12 11.02 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.304 1.842 . . . . 10.0 109.997 179.386 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -79.4 147.0 32.51 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 121.938 -0.477 . . . . 10.0 110.029 158.406 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 30.1 t -128.43 106.83 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.124 0.97 . . . . 10.0 109.344 175.352 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.8 101.99 2.24 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.282 1.833 . . . . 10.0 109.659 -178.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.96 151.99 24.8 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 124.191 0.996 . . . . 10.0 113.22 -175.75 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 29.0 tptp -66.54 -40.91 89.32 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.857 1.263 . . . . 10.0 113.018 -178.042 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 . . . . . 0 C--O 1.253 1.243 0 C-N-CA 125.928 1.691 . . . . 10.0 113.09 176.731 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.501 0 N-CA-C 111.619 -0.592 . . . . 10.0 111.619 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -66.39 162.82 19.59 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.338 1.055 . . . . 10.0 113.161 176.898 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.94 173.25 12.6 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.4 1.88 . . . . 10.0 111.136 178.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -178.97 173.93 46.09 Favored Glycine 0 CA--C 1.541 1.695 0 N-CA-C 117.225 1.65 . . . . 10.0 117.225 -175.296 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -71.9 162.93 40.44 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 123.945 3.096 . . . . 10.0 113.483 -171.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -66.88 156.23 67.11 Favored 'Trans proline' 0 CA--C 1.54 0.776 0 C-N-CA 122.933 2.422 . . . . 10.0 112.021 170.888 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 47.2 ttt85 -146.43 150.48 35.71 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.554 1.142 . . . . 10.0 112.568 -173.374 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -77.59 82.49 4.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.058 2.143 . . . . 10.0 111.65 178.098 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 43.0 mm -74.89 -56.94 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.613 -0.679 . . . . 10.0 110.502 173.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -154.9 143.49 20.61 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.819 1.248 . . . . 10.0 111.44 176.711 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 18.0 m -131.39 151.84 79.48 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 126.053 1.741 . . . . 10.0 110.112 171.068 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.01 154.9 47.9 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.929 2.419 . . . . 10.0 112.132 175.736 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -75.63 171.15 14.81 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.353 1.061 . . . . 10.0 112.318 167.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -62.5 153.3 32.08 Favored 'General case' 0 CA--C 1.545 0.782 0 O-C-N 121.269 -0.894 . . . . 10.0 112.607 176.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 73.8 mtp -133.16 157.45 45.31 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.042 1.337 . . . . 10.0 112.408 -169.701 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.1 p -141.27 112.79 7.56 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.524 1.53 . . . . 10.0 111.036 178.755 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 33.2 mm -129.94 128.3 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 125.049 1.339 . . . . 10.0 110.949 -164.68 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -60.37 131.5 50.98 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.083 1.353 . . . . 10.0 112.661 173.864 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -54.44 136.2 44.52 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 124.886 1.275 . . . . 10.0 113.001 -177.768 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 90.76 -6.7 81.95 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.649 1.595 . . . . 10.0 115.312 177.683 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -71.87 158.31 36.28 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 118.944 1.372 . . . . 10.0 112.892 175.783 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -70.65 143.37 51.43 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.316 1.046 . . . . 10.0 109.968 155.1 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 11.6 t -147.62 165.58 29.96 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 124.245 1.018 . . . . 10.0 111.634 172.7 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -148.04 159.06 44.3 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.721 1.208 . . . . 10.0 112.868 168.544 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 58.3 mtt -130.1 151.12 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 126.678 1.991 . . . . 10.0 109.431 170.405 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -143.41 125.6 15.49 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.254 1.021 . . . . 10.0 111.442 -173.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -121.72 156.72 32.5 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.55 2.34 . . . . 10.0 110.196 -175.634 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -114.11 104.06 11.75 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.773 1.229 . . . . 10.0 110.198 175.836 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 43.8 t -109.38 99.15 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 126.462 1.905 . . . . 10.0 110.021 -170.316 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 7.5 t -73.44 -175.24 1.89 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.093 0.957 . . . . 10.0 112.527 174.106 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 109.79 155.88 15.91 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 127.312 2.386 . . . . 10.0 113.592 176.379 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 19.2 tp -147.48 125.31 5.92 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.531 . . . . 10.0 109.664 178.513 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.47 169.05 47.71 Favored 'Cis proline' 0 CA--C 1.541 0.834 0 CA-C-N 120.8 1.322 . . . . 10.0 112.567 -2.602 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.36 68.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 C-N-CA 124.205 1.002 . . . . 10.0 111.387 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -69.81 150.68 68.24 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.476 2.117 . . . . 10.0 113.14 -173.57 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -69.65 142.03 53.51 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.032 1.333 . . . . 10.0 110.431 165.113 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 55.9 t -117.16 126.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.723 1.609 . . . . 10.0 111.269 -167.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 74.3 m -134.31 106.47 7.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.635 1.574 . . . . 10.0 111.004 175.337 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -82.25 153.59 25.82 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.913 0.885 . . . . 10.0 113.044 176.064 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -142.86 160.44 40.33 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 127.286 2.235 . . . . 10.0 111.378 179.718 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 53.1 tp -146.4 119.08 8.57 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 127.223 2.209 . . . . 10.0 109.974 175.196 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 54.76 17.15 1.64 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 126.442 1.897 . . . . 10.0 115.014 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 104.94 -12.87 49.63 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.518 2.009 . . . . 10.0 115.117 -178.236 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.7 mtt85 -84.94 155.72 21.52 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.923 1.362 . . . . 10.0 110.78 169.077 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 16.5 p -69.84 157.67 36.96 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.02 0.928 . . . . 10.0 112.52 173.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 81.9 t -132.34 143.39 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.667 1.987 . . . . 10.0 108.875 172.442 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -132.85 155.3 49.24 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.629 1.572 . . . . 10.0 110.541 178.481 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.0 p -72.43 149.09 44.55 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 123.67 0.788 . . . . 10.0 112.851 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -154.62 -173.11 4.44 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.529 1.932 . . . . 10.0 111.322 175.312 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -60.53 -18.72 53.97 Favored 'General case' 0 CA--C 1.549 0.932 0 N-CA-C 114.84 1.422 . . . . 10.0 114.84 -178.693 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 59.9 mt -113.64 -16.82 12.27 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.556 1.943 . . . . 10.0 113.541 -179.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -122.25 98.34 5.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 126.798 2.039 . . . . 10.0 110.339 -178.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.96 109.77 19.41 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 124.536 1.134 . . . . 10.0 110.857 -168.384 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 5.1 mpp? -116.31 110.22 18.44 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.992 1.717 . . . . 10.0 110.718 -175.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.09 161.46 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.975 1.71 . . . . 10.0 112.096 -172.642 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.1 t -131.22 118.57 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 125.568 1.547 . . . . 10.0 110.238 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 14.5 t -67.55 163.18 21.74 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 124.793 1.237 . . . . 10.0 112.551 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -57.53 -30.52 65.24 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.635 1.574 . . . . 10.0 113.139 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 11.3 mmpt? -86.02 0.11 54.18 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.922 1.689 . . . . 10.0 114.604 178.356 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 89.01 6.36 71.98 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 124.896 1.236 . . . . 10.0 114.894 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -67.54 105.67 1.92 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.579 1.152 . . . . 10.0 109.453 170.329 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.0 t60 -95.8 114.44 26.17 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.612 1.565 . . . . 10.0 111.061 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 41.2 m -101.57 151.02 22.48 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.847 1.259 . . . . 10.0 112.477 -179.782 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -135.81 103.24 5.33 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.439 2.296 . . . . 10.0 108.368 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.32 139.65 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.57 1.148 . . . . 10.0 110.263 -179.524 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -115.14 105.61 13.12 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 127.922 2.489 . . . . 10.0 109.152 171.444 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -64.61 -40.4 95.43 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 120.995 -1.066 . . . . 10.0 113.339 -179.789 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.3 p -152.04 93.22 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 C-N-CA 125.635 1.574 . . . . 10.0 110.402 179.951 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.88 142.47 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 O-C-N 121.354 -0.842 . . . . 10.0 112.118 -177.548 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -123.08 160.21 26.88 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.145 1.778 . . . . 10.0 112.038 175.393 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -56.74 -31.87 64.98 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.989 1.107 . . . . 10.0 113.989 -175.2 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.2 t -65.9 -20.85 66.36 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.005 1.322 . . . . 10.0 113.958 175.582 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -78.41 -4.22 47.16 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.908 1.283 . . . . 10.0 113.685 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.78 155.3 36.61 Favored 'General case' 0 CA--C 1.547 0.84 0 N-CA-C 113.669 0.988 . . . . 10.0 113.669 178.362 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.6 -167.52 17.96 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.933 1.254 . . . . 10.0 114.909 174.312 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -84.05 105.3 14.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.91 1.684 . . . . 10.0 111.686 179.463 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 64.6 m-85 -79.58 151.15 30.81 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.311 1.044 . . . . 10.0 111.576 168.633 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.68 159.96 41.54 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.837 0.855 . . . . 10.0 112.226 169.084 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 52.6 t -137.49 103.95 5.21 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.806 1.642 . . . . 10.0 110.596 -179.501 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 90.0 t -74.95 130.03 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.432 1.093 . . . . 10.0 109.402 170.093 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -127.93 118.76 24.19 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.7 2.0 . . . . 10.0 110.259 178.825 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.9 mtpp -131.76 133.48 44.81 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.969 1.307 . . . . 10.0 112.553 -173.112 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 19.5 p30 -131.55 -178.91 5.07 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.497 1.119 . . . . 10.0 111.73 167.182 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 18.2 ptp180 -60.63 -11.84 8.45 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 115.798 1.777 . . . . 10.0 115.798 -179.101 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -112.1 -15.11 13.32 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.296 1.438 . . . . 10.0 114.547 -178.378 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 167.21 -169.57 41.06 Favored Glycine 0 CA--C 1.534 1.256 0 N-CA-C 116.025 1.17 . . . . 10.0 116.025 177.479 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -135.83 145.79 46.83 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.917 2.087 . . . . 10.0 112.002 -169.383 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -136.91 158.98 43.21 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.393 1.877 . . . . 10.0 110.632 166.017 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.9 m -140.03 100.23 3.87 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.781 1.232 . . . . 10.0 110.414 176.697 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -79.78 154.67 28.32 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.604 1.162 . . . . 10.0 111.187 177.289 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 32.0 m -144.64 145.41 31.74 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 124.456 1.102 . . . . 10.0 111.748 -172.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.92 165.77 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 126.324 1.85 . . . . 10.0 110.559 171.86 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -128.84 140.44 51.7 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.729 1.211 . . . . 10.0 111.549 177.255 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 53.1 tp -128.63 110.45 12.24 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.02 1.728 . . . . 10.0 111.951 -176.905 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 37.7 m-20 -87.78 89.88 8.16 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 125.155 1.382 . . . . 10.0 110.843 169.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.2 t -70.58 106.33 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.031 -1.043 . . . . 10.0 109.614 174.131 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.3 mt -72.56 97.91 2.21 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.116 1.766 . . . . 10.0 109.873 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -60.48 145.73 47.33 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 124.522 1.129 . . . . 10.0 113.399 -175.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -93.47 -14.4 26.75 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 114.907 1.447 . . . . 10.0 114.907 179.012 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 . . . . . 0 C--O 1.253 1.243 0 C-N-CA 125.987 1.715 . . . . 10.0 113.454 177.615 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.522 0 N-CA-C 111.541 -0.624 . . . . 10.0 111.541 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.97 160.9 22.56 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.287 1.035 . . . . 10.0 113.118 176.995 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -148.6 175.34 11.26 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 126.402 1.881 . . . . 10.0 111.386 -179.89 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.78 173.21 45.87 Favored Glycine 0 CA--C 1.543 1.795 0 N-CA-C 117.332 1.693 . . . . 10.0 117.332 -175.296 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.09 160.96 47.75 Favored 'Trans proline' 0 CA--C 1.543 0.941 0 C-N-CA 123.88 3.053 . . . . 10.0 113.258 -172.275 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.55 158.2 58.66 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.961 2.441 . . . . 10.0 112.337 173.667 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -145.18 161.44 39.51 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 125.018 1.327 . . . . 10.0 113.556 -171.533 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -83.45 98.84 9.73 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.022 1.729 . . . . 10.0 111.869 -178.602 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 36.5 mm -90.64 -68.27 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 123.445 0.698 . . . . 10.0 110.723 177.01 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 37.2 tt0 -155.49 143.78 20.16 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.306 1.042 . . . . 10.0 111.679 177.104 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 28.1 m -126.07 153.77 74.05 Favored Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 125.85 1.66 . . . . 10.0 110.659 171.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -70.65 155.03 63.83 Favored 'Trans proline' 0 CA--C 1.542 0.876 0 C-N-CA 122.61 2.207 . . . . 10.0 111.834 171.594 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -72.95 174.3 8.02 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.006 0.922 . . . . 10.0 111.311 166.405 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -59.03 152.24 20.39 Favored 'General case' 0 CA--C 1.548 0.886 0 O-C-N 121.051 -1.031 . . . . 10.0 112.371 174.671 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 85.0 mtp -134.87 159.3 41.85 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 125.59 1.556 . . . . 10.0 111.887 -171.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 67.2 p -142.12 134.25 27.55 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 125.11 1.364 . . . . 10.0 111.242 172.258 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 27.8 mm -139.41 132.83 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 125.62 1.568 . . . . 10.0 109.629 -170.197 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -63.44 132.63 52.02 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.624 1.169 . . . . 10.0 112.4 173.741 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -52.58 128.12 25.07 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.697 1.199 . . . . 10.0 112.786 -179.311 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 98.21 -9.29 63.13 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 126.017 1.77 . . . . 10.0 115.298 178.412 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -74.47 162.14 29.11 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 119.227 1.514 . . . . 10.0 113.342 176.668 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -72.75 150.97 42.38 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.199 1.4 . . . . 10.0 110.725 159.159 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 48.9 t -149.97 156.4 41.65 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.663 1.185 . . . . 10.0 111.437 170.425 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 8.5 ptm85 -140.87 164.62 29.75 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.558 1.143 . . . . 10.0 112.99 163.372 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.4 mtt -131.73 161.03 33.79 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 126.801 2.04 . . . . 10.0 111.142 176.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -137.12 94.25 2.93 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.131 1.372 . . . . 10.0 111.612 -167.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 41.7 m-85 -104.04 116.27 31.94 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 125.313 1.445 . . . . 10.0 110.831 -178.881 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -78.68 131.14 36.52 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 121.406 -0.809 . . . . 10.0 110.141 172.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 56.9 t -133.25 148.82 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.135 1.774 . . . . 10.0 110.192 -174.107 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 8.0 t -136.82 -174.32 3.69 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.542 1.537 . . . . 10.0 111.474 173.77 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 110.06 162.0 18.78 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 127.401 2.429 . . . . 10.0 112.549 -173.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.4 tp -148.04 128.78 6.94 Favored Pre-proline 0 CA--C 1.546 0.826 0 C-N-CA 124.661 1.184 . . . . 10.0 110.591 -179.587 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -66.56 170.01 44.55 Favored 'Cis proline' 0 CA--C 1.54 0.783 0 CA-C-N 120.786 1.316 . . . . 10.0 112.453 -4.225 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.55 123.42 56.8 Favored Pre-proline 0 CA--C 1.549 0.939 0 C-N-CA 124.512 1.125 . . . . 10.0 111.375 179.572 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.55 151.09 64.35 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.543 2.162 . . . . 10.0 113.168 -173.371 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -72.96 146.55 45.97 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.248 1.019 . . . . 10.0 109.831 160.158 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.8 m -130.97 135.98 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 124.662 1.185 . . . . 10.0 112.541 -170.23 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 64.1 m -135.51 119.3 17.25 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.234 1.814 . . . . 10.0 111.037 -178.834 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . 0.402 ' CD1' ' HG2' ' A' ' 298' ' ' MET . 62.2 m95 -91.02 156.22 18.11 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.598 0.962 . . . . 10.0 113.598 -179.43 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -143.45 160.25 40.93 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.796 2.438 . . . . 10.0 111.1 -176.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 54.6 tp -146.18 117.72 8.03 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 127.189 2.196 . . . . 10.0 109.997 176.237 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 55.54 13.33 0.94 Allowed 'General case' 0 CA--C 1.555 1.145 0 C-N-CA 126.467 1.907 . . . . 10.0 115.208 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 109.83 -14.62 31.82 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 126.731 2.11 . . . . 10.0 115.02 -177.313 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -82.09 157.42 24.1 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 118.9 1.35 . . . . 10.0 110.687 168.896 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 22.8 p -72.91 158.25 35.85 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.936 0.894 . . . . 10.0 112.339 172.358 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 48.6 t -133.98 90.83 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 126.278 1.831 . . . . 10.0 108.898 172.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -68.77 143.48 54.63 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.254 0.622 . . . . 10.0 110.412 169.815 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 27.3 p -69.39 149.53 48.28 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.374 0.67 . . . . 10.0 112.163 173.098 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -154.18 -172.68 4.3 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.186 1.794 . . . . 10.0 111.983 178.103 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.09 -18.34 46.26 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 114.774 1.398 . . . . 10.0 114.774 -178.472 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 63.8 mt -113.12 -15.07 12.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.915 1.686 . . . . 10.0 113.531 179.479 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -126.43 96.81 4.81 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.82 2.048 . . . . 10.0 109.755 -177.206 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -110.61 126.17 54.19 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.25 1.02 . . . . 10.0 111.207 -168.323 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . 0.402 ' HG2' ' CD1' ' A' ' 283' ' ' TRP . 1.8 mpt? -128.89 109.06 10.93 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.427 1.891 . . . . 10.0 110.033 -173.044 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.22 164.83 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 125.615 1.566 . . . . 10.0 111.858 -178.172 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 37.5 t -125.6 106.82 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 125.513 1.525 . . . . 10.0 109.688 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 75.7 m -74.31 164.93 26.01 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.525 1.13 . . . . 10.0 112.536 176.515 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -57.12 156.61 6.93 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.945 1.298 . . . . 10.0 112.018 173.199 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 29.0 mmmt 64.68 6.47 3.26 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 127.392 2.277 . . . . 10.0 114.642 -170.431 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 83.77 55.68 2.78 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.307 1.432 . . . . 10.0 114.041 171.854 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.31 101.36 7.92 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.892 1.277 . . . . 10.0 110.11 177.16 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -79.64 112.55 17.01 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.91 1.284 . . . . 10.0 111.197 174.733 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.8 m -83.34 146.78 28.31 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 124.753 1.221 . . . . 10.0 112.197 172.146 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.82 120.1 24.44 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.401 1.88 . . . . 10.0 107.088 161.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 58.7 mt -121.31 139.06 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.494 1.518 . . . . 10.0 110.453 -174.166 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -120.42 110.74 16.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 127.584 2.354 . . . . 10.0 109.522 176.746 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.83 -42.89 85.07 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 121.343 -0.848 . . . . 10.0 113.202 179.465 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 5.7 p -151.0 89.42 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.806 1.642 . . . . 10.0 110.161 -177.361 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 6.6 p -70.37 140.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.284 -0.885 . . . . 10.0 112.203 -176.239 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -119.93 160.79 22.03 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.358 1.863 . . . . 10.0 112.157 176.717 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -57.11 -32.56 66.46 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 113.726 1.01 . . . . 10.0 113.726 -177.45 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.4 t -65.13 -21.75 66.84 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.106 1.362 . . . . 10.0 113.776 175.209 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -79.48 -5.32 54.55 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.779 1.231 . . . . 10.0 113.611 -179.832 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.65 152.17 44.81 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.168 -0.957 . . . . 10.0 113.236 178.624 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.59 -168.98 22.53 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.633 1.111 . . . . 10.0 115.043 174.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -82.67 103.03 11.88 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.909 1.684 . . . . 10.0 111.551 177.856 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 -78.82 149.7 32.48 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.037 0.935 . . . . 10.0 111.678 169.714 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -144.94 160.93 40.55 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 123.901 0.881 . . . . 10.0 112.265 170.413 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.5 t -136.45 120.53 17.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.543 1.537 . . . . 10.0 110.858 177.12 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 59.1 t -92.36 126.39 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.757 1.223 . . . . 10.0 108.996 171.204 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -119.27 126.11 50.7 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 126.428 1.891 . . . . 10.0 110.747 -178.957 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -134.47 133.33 40.31 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 125.259 1.423 . . . . 10.0 112.516 -170.698 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 22.7 p30 -130.55 -179.1 5.08 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.741 1.216 . . . . 10.0 111.533 166.535 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -60.89 -12.77 12.14 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 115.618 1.71 . . . . 10.0 115.618 -179.465 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -109.44 -17.63 13.73 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.521 1.528 . . . . 10.0 114.392 -178.282 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 168.64 -169.2 41.55 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 115.972 1.149 . . . . 10.0 115.972 177.931 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -133.77 146.56 50.84 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.986 2.114 . . . . 10.0 111.745 -172.088 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.2 160.1 40.31 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.317 1.847 . . . . 10.0 110.974 169.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.3 m -136.33 130.56 33.06 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.722 1.209 . . . . 10.0 111.379 177.759 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -113.65 153.65 28.56 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 126.204 1.801 . . . . 10.0 110.659 177.81 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 23.7 m -143.09 148.19 36.25 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.598 1.159 . . . . 10.0 112.37 -173.13 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.41 169.15 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 C-N-CA 126.994 2.117 . . . . 10.0 110.763 169.468 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 52.4 tt0 -128.04 137.04 52.03 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.196 1.399 . . . . 10.0 111.088 174.271 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.5 tp -125.65 107.14 10.28 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.958 1.703 . . . . 10.0 111.077 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -88.96 87.47 7.23 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.259 1.424 . . . . 10.0 110.869 172.773 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 21.6 t -67.36 112.35 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.242 -0.911 . . . . 10.0 110.061 175.45 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 62.6 mt -75.3 94.65 3.05 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 126.104 1.762 . . . . 10.0 109.875 -179.747 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -63.43 151.72 40.28 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.765 1.226 . . . . 10.0 113.53 -175.769 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -68.89 -43.31 75.55 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 125.427 1.491 . . . . 10.0 112.022 171.516 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 38.6 mm-40 . . . . . 0 C--O 1.254 1.311 0 C-N-CA 126.768 2.027 . . . . 10.0 113.612 -179.481 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.513 0 N-CA-C 111.782 -0.527 . . . . 10.0 111.782 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.3 160.95 20.56 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.281 1.032 . . . . 10.0 112.997 176.341 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.54 176.41 10.08 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 126.12 1.768 . . . . 10.0 111.707 -179.009 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -177.01 173.14 46.07 Favored Glycine 0 CA--C 1.541 1.706 0 N-CA-C 117.037 1.575 . . . . 10.0 117.037 -176.935 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -69.18 160.72 48.74 Favored 'Trans proline' 0 CA--C 1.544 0.991 0 C-N-CA 123.521 2.814 . . . . 10.0 113.134 -173.316 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -68.07 167.67 21.14 Favored 'Trans proline' 0 CA--C 1.54 0.823 0 C-N-CA 123.303 2.668 . . . . 10.0 111.634 169.191 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 2.1 tpt180 -139.42 175.22 9.75 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.664 1.186 . . . . 10.0 112.803 -172.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -103.92 95.48 6.04 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 126.394 1.878 . . . . 10.0 110.326 -175.643 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . 0.549 HG22 ' H ' ' A' ' 254' ' ' GLN . 0.4 OUTLIER -115.61 -179.28 1.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.99 0 C-N-CA 126.298 1.839 . . . . 10.0 109.779 -179.655 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.549 ' H ' HG22 ' A' ' 253' ' ' ILE . 41.8 tt0 -46.15 123.37 4.61 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.507 2.323 . . . . 10.0 115.026 -166.535 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 19.1 m -106.84 153.83 40.56 Favored Pre-proline 0 N--CA 1.474 0.769 0 C-N-CA 126.425 1.89 . . . . 10.0 110.365 167.944 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.25 158.49 44.94 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.759 2.306 . . . . 10.0 111.705 169.902 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -66.29 172.4 3.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 124.606 1.162 . . . . 10.0 111.841 167.342 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -60.32 153.72 21.93 Favored 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.99 -1.068 . . . . 10.0 111.857 170.311 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 84.8 mtp -133.01 155.9 48.33 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.994 1.318 . . . . 10.0 112.179 -169.647 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 47.6 p -141.81 122.86 14.6 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 125.505 1.522 . . . . 10.0 110.903 175.091 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 29.5 mm -134.18 132.38 55.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.546 1.538 . . . . 10.0 109.901 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -63.99 129.12 38.78 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.235 1.014 . . . . 10.0 112.101 174.113 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -54.31 131.82 42.6 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.201 1.4 . . . . 10.0 112.683 -177.736 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 96.76 -10.11 66.34 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 126.042 1.782 . . . . 10.0 115.07 179.11 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 78.3 mtp85 -71.47 160.98 31.76 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 119.005 1.402 . . . . 10.0 113.061 175.91 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -71.18 145.8 49.49 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 124.014 0.926 . . . . 10.0 110.368 155.684 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 16.6 t -147.45 163.79 35.4 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.7 1.2 . . . . 10.0 111.405 168.612 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -143.85 157.52 44.31 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.589 1.556 . . . . 10.0 111.806 167.706 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 53.2 mtt -129.22 150.42 50.61 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 127.117 2.167 . . . . 10.0 109.187 171.454 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -142.12 126.08 17.23 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.317 1.047 . . . . 10.0 111.479 -169.85 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -130.86 123.69 29.59 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 126.745 2.018 . . . . 10.0 111.151 -168.718 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -70.27 130.81 43.02 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 121.493 -0.754 . . . . 10.0 110.301 171.472 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.77 149.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 126.109 1.763 . . . . 10.0 111.138 -175.592 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 6.1 t -147.24 -174.08 4.42 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 125.144 1.377 . . . . 10.0 112.113 -176.572 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 105.18 162.47 23.7 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 127.319 2.39 . . . . 10.0 112.864 -174.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -146.48 128.07 7.48 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.874 1.27 . . . . 10.0 110.567 -179.698 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -66.7 169.4 47.55 Favored 'Cis proline' 0 CA--C 1.539 0.743 0 CA-C-N 120.88 1.35 . . . . 10.0 112.658 -2.149 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -55.72 122.77 48.04 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.752 1.221 . . . . 10.0 111.575 -178.463 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -71.11 159.95 50.66 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 122.597 2.198 . . . . 10.0 113.359 -174.292 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.7 168.94 10.36 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.799 1.24 . . . . 10.0 111.851 166.426 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 71.5 t -130.24 123.76 56.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.691 1.597 . . . . 10.0 110.397 -178.366 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 68.2 m -134.82 150.35 50.49 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.68 1.592 . . . . 10.0 110.661 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 47.6 m95 -130.06 157.82 41.34 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 124.884 1.274 . . . . 10.0 112.593 179.151 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -143.91 159.19 43.0 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.674 1.99 . . . . 10.0 111.413 -177.292 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 55.1 tp -144.99 118.24 8.95 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 127.128 2.171 . . . . 10.0 109.943 175.844 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 54.91 14.79 0.97 Allowed 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 126.508 1.923 . . . . 10.0 115.177 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 108.8 -13.23 35.06 Favored Glycine 0 CA--C 1.539 1.556 0 C-N-CA 126.709 2.1 . . . . 10.0 115.182 -178.061 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 83.9 mtp180 -85.89 157.11 20.26 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.971 1.385 . . . . 10.0 110.961 170.134 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 15.6 p -71.41 155.25 40.84 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.358 1.063 . . . . 10.0 112.765 174.432 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 61.1 t -134.0 102.65 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.729 2.012 . . . . 10.0 108.597 172.834 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -74.61 161.4 29.75 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.463 0.705 . . . . 10.0 111.4 172.547 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 58.4 p -67.99 154.41 41.68 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.363 0.665 . . . . 10.0 111.785 168.163 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -153.6 168.68 25.4 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.144 1.377 . . . . 10.0 111.03 177.799 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.8 -35.18 68.43 Favored 'General case' 0 CA--C 1.544 0.749 0 O-C-N 120.933 -1.105 . . . . 10.0 112.696 168.84 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 69.8 mt -82.83 -14.25 54.69 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.553 1.141 . . . . 10.0 113.916 173.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 43.4 m80 -136.16 69.91 1.42 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 125.954 1.701 . . . . 10.0 111.216 -173.427 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 80.3 mttt -70.53 143.02 51.77 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.786 1.235 . . . . 10.0 111.134 -177.671 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 67.5 mtt -136.85 103.58 5.22 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.649 1.98 . . . . 10.0 109.718 -174.695 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.45 158.99 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.823 1.249 . . . . 10.0 112.18 -175.389 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 21.6 t -134.5 111.42 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 125.31 1.444 . . . . 10.0 110.035 -178.614 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 58.6 m -66.53 145.83 55.19 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.904 0.882 . . . . 10.0 111.401 173.269 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -62.47 -17.52 59.71 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.526 1.53 . . . . 10.0 114.622 -176.237 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -75.36 -4.82 41.51 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.058 1.743 . . . . 10.0 114.108 173.621 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 90.82 47.38 3.68 Favored Glycine 0 CA--C 1.532 1.098 0 C-N-CA 125.134 1.35 . . . . 10.0 113.219 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.94 105.71 6.51 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.085 1.354 . . . . 10.0 110.224 -176.129 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -85.45 124.94 32.61 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.073 1.349 . . . . 10.0 111.447 174.751 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 38.0 m -109.0 142.94 38.95 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.398 1.479 . . . . 10.0 111.915 175.695 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -132.79 115.85 15.83 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 127.538 2.335 . . . . 10.0 108.887 -178.306 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 1.8 mp -103.73 153.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.785 1.234 . . . . 10.0 111.44 -171.402 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -128.49 103.65 7.25 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.398 2.279 . . . . 10.0 109.05 164.663 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 74.1 mm-40 -65.34 -38.96 91.73 Favored 'General case' 0 N--CA 1.475 0.825 0 O-C-N 120.872 -1.143 . . . . 10.0 113.072 178.738 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.56 87.71 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.838 1.655 . . . . 10.0 110.245 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.58 137.39 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 O-C-N 121.241 -0.912 . . . . 10.0 111.928 -177.555 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 24.0 mmt180 -117.34 161.15 19.99 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.091 1.757 . . . . 10.0 112.094 176.57 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -55.91 -34.12 65.29 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.515 0.931 . . . . 10.0 113.515 -177.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 20.0 m -65.37 -16.6 63.77 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 125.515 1.526 . . . . 10.0 114.565 175.468 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -81.95 -5.33 58.21 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.695 1.198 . . . . 10.0 113.348 178.33 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.49 151.44 46.37 Favored 'General case' 0 CA--C 1.547 0.841 0 O-C-N 121.025 -1.047 . . . . 10.0 112.773 175.908 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.96 -171.89 21.59 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 124.97 1.271 . . . . 10.0 114.846 176.892 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.01 105.74 14.25 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.891 1.676 . . . . 10.0 111.252 176.518 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -80.6 152.7 28.42 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.206 1.002 . . . . 10.0 111.963 169.479 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.92 44.52 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.905 0.882 . . . . 10.0 111.933 166.231 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 51.3 t -130.66 143.61 50.86 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 126.666 1.987 . . . . 10.0 109.789 177.018 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 99.0 t -126.38 129.66 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 125.57 1.548 . . . . 10.0 109.673 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -123.58 118.81 28.18 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.404 1.881 . . . . 10.0 110.433 -178.529 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -131.95 138.23 48.24 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 125.373 1.469 . . . . 10.0 111.822 -173.467 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -134.14 -177.48 4.6 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.936 1.295 . . . . 10.0 111.358 168.174 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -60.91 -11.63 8.56 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 115.727 1.751 . . . . 10.0 115.727 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -111.49 -19.82 12.42 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 125.569 1.548 . . . . 10.0 114.503 -178.107 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 173.4 -168.92 41.99 Favored Glycine 0 CA--C 1.534 1.252 0 N-CA-C 116.371 1.308 . . . . 10.0 116.371 178.984 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -135.71 142.41 45.05 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.29 2.236 . . . . 10.0 111.683 -172.059 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.05 162.53 33.9 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.052 1.741 . . . . 10.0 111.309 169.011 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 39.3 m -141.4 146.09 36.14 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.023 1.329 . . . . 10.0 110.753 -172.511 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -133.45 154.22 50.97 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.349 1.46 . . . . 10.0 110.774 177.263 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.7 m -144.27 144.71 31.62 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.489 1.116 . . . . 10.0 111.615 -171.491 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 13.8 p -153.23 164.02 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 126.126 1.77 . . . . 10.0 110.698 172.414 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -125.17 138.71 54.14 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 124.79 1.236 . . . . 10.0 111.13 174.888 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 52.9 tp -124.61 120.04 30.77 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 125.997 1.719 . . . . 10.0 111.068 -177.829 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -105.69 86.24 2.36 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.064 1.746 . . . . 10.0 110.723 176.694 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 23.8 t -67.47 109.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 123.992 0.917 . . . . 10.0 110.607 -179.581 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 66.1 mt -72.98 103.11 3.66 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 126.324 1.85 . . . . 10.0 109.853 178.798 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -59.48 140.26 56.38 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 113.887 1.069 . . . . 10.0 113.887 -172.069 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -101.05 -32.33 10.66 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 127.304 2.241 . . . . 10.0 111.755 173.563 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 . . . . . 0 C--O 1.254 1.313 0 C-N-CA 126.109 1.764 . . . . 10.0 113.38 174.174 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' -4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.547 0 N-CA-C 111.944 -0.462 . . . . 10.0 111.944 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' -3' ' ' ALA . . . . . . . . . . . . . . . -65.5 162.92 16.98 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.4 1.08 . . . . 10.0 112.933 175.881 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 24.2 ptt? -147.97 -179.16 6.7 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.897 1.679 . . . . 10.0 111.913 -178.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.79 169.27 41.64 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.83 1.492 . . . . 10.0 116.83 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 249' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -72.56 162.85 40.22 Favored 'Trans proline' 0 CA--C 1.544 1.007 0 C-N-CA 123.83 3.02 . . . . 10.0 113.077 -175.106 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 250' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.54 160.49 49.1 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 123.146 2.564 . . . . 10.0 112.083 171.013 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.27 168.96 23.69 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.266 1.426 . . . . 10.0 112.539 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -72.98 146.47 45.98 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 125.517 1.527 . . . . 10.0 111.988 173.269 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 253' ' ' ILE . . . . . . . . . . . . . 4.2 mp -136.4 -64.08 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 125.699 1.6 . . . . 10.0 109.054 168.539 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 43.3 tt0 -151.7 138.39 18.8 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.716 1.606 . . . . 10.0 110.521 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 255' ' ' VAL . . . . . . . . . . . . . 34.6 m -133.37 151.99 78.5 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.773 1.629 . . . . 10.0 110.404 173.688 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 256' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.24 148.03 67.56 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 122.652 2.234 . . . . 10.0 112.348 175.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 257' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -74.53 176.5 6.79 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.489 1.115 . . . . 10.0 111.253 166.273 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 258' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -54.37 122.86 11.32 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.04 -1.037 . . . . 10.0 112.508 176.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 259' ' ' MET . . . . . . . . . . . . . 88.6 mtp -101.31 159.02 15.62 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.01 1.724 . . . . 10.0 111.872 -177.2 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 p -146.82 115.28 6.71 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.178 1.391 . . . . 10.0 111.259 177.708 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 261' ' ' ILE . . . . . . . . . . . . . 34.0 mm -127.01 134.22 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.595 1.558 . . . . 10.0 110.166 -169.221 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 262' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -63.98 131.85 48.89 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.683 1.193 . . . . 10.0 112.666 176.202 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 263' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -52.74 121.54 7.4 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.758 1.623 . . . . 10.0 112.962 -178.941 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 264' ' ' GLY . . . . . . . . . . . . . . . 103.81 -9.31 51.56 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 126.2 1.857 . . . . 10.0 115.106 177.829 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 265' ' ' ARG . . . . . . . . . . . . . 75.8 mtp180 -72.05 159.51 34.07 Favored 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 119.173 1.486 . . . . 10.0 113.398 177.449 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 266' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -72.55 147.7 45.67 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.54 1.136 . . . . 10.0 110.412 156.513 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 267' ' ' CYS . . . . . . . . . . . . . 15.0 t -149.49 162.82 39.39 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.329 1.052 . . . . 10.0 111.941 170.199 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 10.0 ptm85 -143.08 164.26 30.59 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.67 1.588 . . . . 10.0 112.107 165.541 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 269' ' ' MET . . . . . . . . . . . . . 56.0 mtt -126.11 159.97 31.42 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 126.802 2.041 . . . . 10.0 110.654 173.883 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 270' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -136.72 89.95 2.5 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.416 1.486 . . . . 10.0 111.025 -169.369 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 271' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -100.72 106.06 17.46 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.24 1.416 . . . . 10.0 111.029 -178.329 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 272' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -67.05 133.07 49.17 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 121.62 -0.675 . . . . 10.0 110.117 171.17 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 10.7 p -143.71 146.43 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 125.467 1.507 . . . . 10.0 111.392 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 274' ' ' SER . . . . . . . . . . . . . 93.6 p -128.6 -165.7 1.54 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.974 1.71 . . . . 10.0 112.733 -174.687 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 98.99 163.45 29.88 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 126.298 1.904 . . . . 10.0 112.813 -178.264 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 276' ' ' LEU . . . . . . . . . . . . . 16.1 tp -142.68 127.09 9.83 Favored Pre-proline 0 CA--C 1.546 0.797 0 C-N-CA 125.507 1.523 . . . . 10.0 109.555 177.781 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 277' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -66.26 169.16 46.24 Favored 'Cis proline' 0 CA--C 1.54 0.825 0 CA-C-N 120.312 1.147 . . . . 10.0 112.584 -4.193 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . . . . . . . . . . . -56.77 125.96 70.01 Favored Pre-proline 0 CA--C 1.549 0.927 0 C-N-CA 124.386 1.075 . . . . 10.0 111.046 178.479 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 279' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.63 148.53 59.67 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 122.284 1.989 . . . . 10.0 113.834 -169.155 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 280' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -67.43 132.83 48.42 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.384 1.474 . . . . 10.0 109.561 158.43 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 281' ' ' VAL . . . . . . . . . . . . . 11.1 m -124.0 138.64 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.514 1.126 . . . . 10.0 112.155 -173.276 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 282' ' ' SER . . . . . . . . . . . . . 48.1 m -135.25 154.08 51.7 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.975 1.71 . . . . 10.0 110.755 178.221 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 283' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -124.93 153.21 43.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.536 1.135 . . . . 10.0 113.389 -176.469 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 79.3 m-85 -145.1 160.29 41.64 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.088 2.155 . . . . 10.0 111.15 -172.372 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 285' ' ' LEU . . . . . . . . . . . . . 58.3 tp -149.87 122.34 8.5 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 126.695 1.998 . . . . 10.0 110.332 178.171 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 286' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 54.98 6.97 0.14 Allowed 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 126.995 2.118 . . . . 10.0 116.595 174.864 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 287' ' ' GLY . . . . . . . . . . . . . . . 121.21 -6.18 10.92 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 126.2 1.857 . . . . 10.0 115.725 -177.189 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 11.0 ptm180 -108.09 165.44 11.47 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 119.254 1.527 . . . . 10.0 112.227 171.637 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 289' ' ' THR . . . . . . . . . . . . . 19.8 p -72.47 158.1 36.37 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.861 1.264 . . . . 10.0 112.437 172.302 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 290' ' ' VAL . . . . . . . . . . . . . 44.4 t -131.09 101.72 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 126.076 1.751 . . . . 10.0 108.372 171.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 291' ' ' GLN . . . . . . . . . . . . . 11.5 mp0 -67.04 149.95 49.9 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.573 1.149 . . . . 10.0 111.295 176.818 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 292' ' ' SER . . . . . . . . . . . . . 25.4 p -65.54 138.98 58.42 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.45 0.7 . . . . 10.0 110.922 167.698 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 293' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -146.8 167.96 22.58 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.721 1.208 . . . . 10.0 111.819 -176.479 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 294' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -56.79 -35.07 68.29 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 121.162 -0.961 . . . . 10.0 113.105 171.023 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 70.4 mt -85.76 -15.17 42.96 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.996 1.11 . . . . 10.0 113.996 174.834 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 296' ' ' HIS . . . . . . . . . . . . . 44.5 m80 -135.72 73.03 1.45 Allowed 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.975 1.71 . . . . 10.0 111.088 -174.35 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -73.02 143.66 47.46 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 125.144 1.377 . . . . 10.0 111.329 -178.173 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 298' ' ' MET . . . . . . . . . . . . . 58.8 mtt -142.44 105.25 4.54 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.864 1.666 . . . . 10.0 110.214 -172.338 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 299' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.92 144.77 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.161 0.984 . . . . 10.0 112.46 -178.667 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 48.0 t -95.16 100.52 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 125.154 1.382 . . . . 10.0 108.757 175.484 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 301' ' ' SER . . . . . . . . . . . . . 15.2 m -64.3 168.76 5.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 126.693 1.997 . . . . 10.0 112.741 176.307 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 302' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -62.01 165.45 5.54 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.541 1.136 . . . . 10.0 113.793 174.705 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 303' ' ' LYS . . . . . . . . . . . . . 96.6 mttt 56.76 20.69 5.31 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 126.874 2.07 . . . . 10.0 115.794 173.129 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 85.42 53.83 2.98 Favored Glycine 0 CA--C 1.533 1.179 0 C-N-CA 124.816 1.198 . . . . 10.0 114.131 173.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 305' ' ' LEU . . . . . . . . . . . . . 52.0 tp -137.16 146.56 45.11 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.726 1.61 . . . . 10.0 110.517 179.505 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 306' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -126.84 115.72 19.76 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.997 1.319 . . . . 10.0 111.359 -179.784 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 307' ' ' SER . . . . . . . . . . . . . 74.0 m -80.83 129.19 34.4 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.834 1.654 . . . . 10.0 111.819 172.366 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 308' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -128.35 119.43 25.04 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 127.088 2.155 . . . . 10.0 107.645 170.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 309' ' ' ILE . . . . . . . . . . . . . 54.4 mt -119.68 154.06 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.808 1.243 . . . . 10.0 111.662 -164.464 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 310' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -131.57 108.65 9.69 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 127.848 2.459 . . . . 10.0 109.35 173.468 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -66.36 -43.21 86.65 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 120.985 -1.072 . . . . 10.0 113.031 177.432 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 312' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.71 89.12 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.791 1.637 . . . . 10.0 110.16 -177.685 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 8.8 p -70.09 139.48 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.353 -0.842 . . . . 10.0 112.26 -176.322 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 314' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -121.91 163.53 19.1 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.312 1.845 . . . . 10.0 112.045 175.408 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -58.06 -30.33 66.1 Favored 'General case' 0 CA--C 1.548 0.872 0 N-CA-C 113.574 0.953 . . . . 10.0 113.574 -178.686 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 37.7 p -67.82 -16.9 64.32 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.657 1.583 . . . . 10.0 114.681 173.648 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 317' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -83.66 -5.63 59.23 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.633 1.173 . . . . 10.0 113.356 175.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 318' ' ' ALA . . . . . . . . . . . . . . . -65.83 154.43 39.16 Favored 'General case' 0 CA--C 1.546 0.798 0 O-C-N 121.027 -1.046 . . . . 10.0 113.352 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 132.01 -169.72 21.99 Favored Glycine 0 CA--C 1.532 1.123 0 C-N-CA 124.67 1.128 . . . . 10.0 115.043 174.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -83.81 100.19 10.79 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.966 1.706 . . . . 10.0 111.392 177.626 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 321' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -75.11 151.57 38.6 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.214 1.006 . . . . 10.0 111.679 167.432 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 322' ' ' ALA . . . . . . . . . . . . . . . -143.36 159.01 43.15 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.94 0.896 . . . . 10.0 112.157 168.71 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 323' ' ' CYS . . . . . . . . . . . . . 42.2 t -130.69 144.47 51.46 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.545 1.938 . . . . 10.0 110.223 177.272 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . . . . . . . . . 57.3 t -126.57 116.11 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 125.49 1.516 . . . . 10.0 109.347 179.229 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 325' ' ' ALA . . . . . . . . . . . . . . . -106.3 126.58 52.41 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.452 1.901 . . . . 10.0 110.806 -178.255 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 326' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -132.47 127.58 35.58 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 126.439 1.896 . . . . 10.0 111.774 -168.058 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -134.33 177.73 7.53 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.864 0.757 . . . . 10.0 112.238 164.211 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 328' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 -62.47 -11.13 14.25 Favored 'General case' 0 N--CA 1.48 1.072 0 N-CA-C 115.536 1.68 . . . . 10.0 115.536 -178.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 329' ' ' ALA . . . . . . . . . . . . . . . -106.49 -15.37 14.81 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.569 1.548 . . . . 10.0 114.088 178.138 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 330' ' ' GLY . . . . . . . . . . . . . . . 163.18 -170.39 38.61 Favored Glycine 0 CA--C 1.536 1.369 0 CA-C-N 119.659 1.118 . . . . 10.0 115.423 176.365 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 331' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -134.06 149.59 51.15 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 126.059 1.744 . . . . 10.0 111.892 -172.775 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . . . . . . . . . . . -138.42 162.73 33.71 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.237 1.815 . . . . 10.0 111.501 171.144 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 30.1 m -140.28 135.97 32.81 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.938 1.295 . . . . 10.0 110.758 -175.7 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -129.72 154.02 47.58 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.669 1.588 . . . . 10.0 110.976 -178.059 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 335' ' ' THR . . . . . . . . . . . . . 25.6 m -144.84 145.61 31.7 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.236 1.014 . . . . 10.0 112.017 -169.421 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 336' ' ' VAL . . . . . . . . . . . . . 14.6 p -152.27 150.46 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 125.661 1.584 . . . . 10.0 111.696 170.46 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 337' ' ' GLN . . . . . . . . . . . . . 42.3 tt0 -100.91 139.2 36.94 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.531 1.133 . . . . 10.0 111.004 171.655 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 338' ' ' LEU . . . . . . . . . . . . . 51.9 tp -123.25 103.86 8.79 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.89 1.676 . . . . 10.0 110.566 175.898 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 339' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -90.73 82.9 5.71 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.63 1.572 . . . . 10.0 110.981 175.861 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 340' ' ' VAL . . . . . . . . . . . . . 25.9 t -63.69 112.82 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.844 0.858 . . . . 10.0 110.621 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 341' ' ' LEU . . . . . . . . . . . . . 72.7 mt -75.34 98.54 3.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.288 1.835 . . . . 10.0 110.184 -179.22 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -61.04 149.5 36.73 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 124.062 0.945 . . . . 10.0 112.72 179.351 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -80.84 -2.48 47.48 Favored 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.218 1.562 . . . . 10.0 115.218 -179.595 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 344' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 . . . . . 0 C--O 1.253 1.273 0 C-N-CA 126.826 2.05 . . . . 10.0 114.062 178.757 . . . . . . . . 0 0 . 1 stop_ save_